<!DOCTYPE html>
<html lang="en">
  <head>
    <title>US20200368173A1 - Nucleic acid-containing lipid nanoparticle 
        - Google Patents</title>

    <meta name="viewport" content="width=device-width, initial-scale=1">
    <meta charset="UTF-8">
    <meta name="referrer" content="origin-when-crossorigin">
    <link rel="canonical" href="https://patents.google.com/patent/US20200368173A1/en">
    <meta name="description" content="
     The present invention provides a nucleic acid-containing lipid nanoparticle comprising an analog of a fatty acid ester of glycerol, and a nucleic acid, wherein the analog is not hydrolyzable by a lipase. 
   
   ">
    <meta name="DC.type" content="patent">
    <meta name="DC.title" content="Nucleic acid-containing lipid nanoparticle 
       ">
    <meta name="DC.date" content="2018-08-06" scheme="dateSubmitted">
    <meta name="DC.description" content="
     The present invention provides a nucleic acid-containing lipid nanoparticle comprising an analog of a fatty acid ester of glycerol, and a nucleic acid, wherein the analog is not hydrolyzable by a lipase. 
   
   ">
    <meta name="citation_patent_application_number" content="US:16/636,177">
    <meta name="citation_pdf_url" content="https://patentimages.storage.googleapis.com/a7/b7/eb/7dc0dbec322559/US20200368173A1.pdf">
    <meta name="citation_patent_publication_number" content="US:20200368173:A1">
    <meta name="DC.date" content="2020-11-26">
    <meta name="DC.contributor" content="Kentaro Hatanaka" scheme="inventor">
    <meta name="DC.contributor" content="Michihiro MAEMOTO" scheme="inventor">
    <meta name="DC.contributor" content="Shintaro Hosoe" scheme="inventor">
    <meta name="DC.contributor" content="Kyowa Kirin Co Ltd" scheme="assignee">
    <meta name="DC.relation" content="US:20180353434:A1" scheme="references">
    <meta name="DC.relation" content="US:20170210698:A1" scheme="references">
    <meta name="citation_reference" content="Damase et al (Frontiers in Bioengineering and Biotech., Vol. 9, article 628137, pages 1-24 (2021)) (Year: 2021)" scheme="references">
    <meta name="citation_reference" content="Roberts et al (Nature Reviews: Drug Discovery, Vol. 19, pages 673-694 (2020)) (Year: 2020)" scheme="references">
    <meta name="citation_reference" content="Structures provided. (Year: 2017)" scheme="references">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Roboto:400,400italic,500,500italic,700">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Product+Sans">
    <link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Google+Sans:wght@400;500;700">

    <style>
      
      #gb { top: 15px; left: auto; right: 0; width: auto; min-width: 135px !important; }   
      body { transition: none; }
    </style>
    <script></script>

    <script>
      window.version = 'patent-search.search_20250707_RC00';

      function sendFeedback() {
        userfeedback.api.startFeedback({
          'productId': '713680',
          'bucket': 'patent-search-web',
          'productVersion': window.version,
        });
      }

      window.experiments = {};
      window.experiments.patentCountries = "ae,ag,al,am,ao,ap,ar,at,au,aw,az,ba,bb,bd,be,bf,bg,bh,bj,bn,bo,br,bw,bx,by,bz,ca,cf,cg,ch,ci,cl,cm,cn,co,cr,cs,cu,cy,cz,dd,de,dj,dk,dm,do,dz,ea,ec,ee,eg,em,ep,es,fi,fr,ga,gb,gc,gd,ge,gh,gm,gn,gq,gr,gt,gw,hk,hn,hr,hu,ib,id,ie,il,in,ir,is,it,jo,jp,ke,kg,kh,km,kn,kp,kr,kw,kz,la,lc,li,lk,lr,ls,lt,lu,lv,ly,ma,mc,md,me,mg,mk,ml,mn,mo,mr,mt,mw,mx,my,mz,na,ne,ng,ni,nl,no,nz,oa,om,pa,pe,pg,ph,pl,pt,py,qa,ro,rs,ru,rw,sa,sc,sd,se,sg,si,sk,sl,sm,sn,st,su,sv,sy,sz,td,tg,th,tj,tm,tn,tr,tt,tw,tz,ua,ug,us,uy,uz,vc,ve,vn,wo,yu,za,zm,zw";
      
      
      window.experiments.keywordWizard = true;
      
      
      
      window.experiments.definitions = true;
      window.experiments.plogs = true;

      window.Polymer = {
        dom: 'shady',
        lazyRegister: true,
      };
    </script>

    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/webcomponentsjs/webcomponents-lite.min.js"></script>
    <link rel="import" href="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.html">
  </head>
  <body unresolved>
    
    
    <script></script>
    <script src="//www.gstatic.com/patent-search/frontend/patent-search.search_20250707_RC00/scs/compiled_dir/search-app-vulcanized.js"></script>
    <search-app>
      
      

      <article class="result" itemscope itemtype="http://schema.org/ScholarlyArticle">
  <h1 itemprop="pageTitle">US20200368173A1 - Nucleic acid-containing lipid nanoparticle 
        - Google Patents</h1>
  <span itemprop="title">Nucleic acid-containing lipid nanoparticle 
       </span>

  <meta itemprop="type" content="patent">
  <a href="https://patentimages.storage.googleapis.com/a7/b7/eb/7dc0dbec322559/US20200368173A1.pdf" itemprop="pdfLink">Download PDF</a>
  <h2>Info</h2>

  <dl>
    <dt>Publication number</dt>
    <dd itemprop="publicationNumber">US20200368173A1</dd>
    <meta itemprop="numberWithoutCodes" content="20200368173">
    <meta itemprop="kindCode" content="A1">
    <meta itemprop="publicationDescription" content="Patent application publication">
    <span>US20200368173A1</span>
    <span>US16/636,177</span>
    <span>US201816636177A</span>
    <span>US2020368173A1</span>
    <span>US 20200368173 A1</span>
    <span>US20200368173 A1</span>
    <span>US 20200368173A1</span>
    <span>  </span>
    <span> </span>
    <span> </span>
    <span>US 201816636177 A</span>
    <span>US201816636177 A</span>
    <span>US 201816636177A</span>
    <span>US 2020368173 A1</span>
    <span>US2020368173 A1</span>
    <span>US 2020368173A1</span>

    <dt>Authority</dt>
    <dd itemprop="countryCode">US</dd>
    <dd itemprop="countryName">United States</dd>

    <dt>Prior art keywords</dt>
    <dd itemprop="priorArtKeywords" repeat>alkyl</dd>
    <dd itemprop="priorArtKeywords" repeat>same</dd>
    <dd itemprop="priorArtKeywords" repeat>different</dd>
    <dd itemprop="priorArtKeywords" repeat>optionally substituted</dd>
    <dd itemprop="priorArtKeywords" repeat>hydrogen atom</dd>

    <dt>Prior art date</dt>
    <dd><time itemprop="priorArtDate" datetime="2017-08-04">2017-08-04</time></dd>

    <dt>Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)</dt>
    <dd itemprop="legalStatusIfi" itemscope>
      <span itemprop="status">Granted</span>
    </dd>
  </dl>

  <dt>Application number</dt>
  <dd itemprop="applicationNumber">US16/636,177</dd>

  

  <dt>Other versions</dt>
  <dd itemprop="directAssociations" itemscope repeat>
    <a href="/patent/US11633365B2/en">
      <span itemprop="publicationNumber">US11633365B2</span>
      (<span itemprop="primaryLanguage">en</span>
    </a>
  </dd>

  <dt>Inventor</dt>
  <dd itemprop="inventor" repeat>Kentaro Hatanaka</dd>
  <dd itemprop="inventor" repeat>Michihiro MAEMOTO</dd>
  <dd itemprop="inventor" repeat>Shintaro Hosoe</dd>

  <dt>Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)</dt>
  <dd itemprop="assigneeCurrent" repeat>
    Kyowa Kirin Co Ltd
  </dd>

  <dt>Original Assignee</dt>
  <dd itemprop="assigneeOriginal" repeat>Kyowa Kirin Co Ltd</dd>

  <dt>Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)</dt>
  <dd><time itemprop="priorityDate" datetime="2017-08-04">2017-08-04</time></dd>

  <dt>Filing date</dt>
  <dd><time itemprop="filingDate" datetime="2018-08-06">2018-08-06</time></dd>

  <dt>Publication date</dt>
  <dd><time itemprop="publicationDate" datetime="2020-11-26">2020-11-26</time></dd>

  
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2018-08-06">2018-08-06</time>
    <span itemprop="title">Application filed by Kyowa Kirin Co Ltd</span>
    <span itemprop="type">filed</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    <span itemprop="assigneeSearch">Kyowa Kirin Co Ltd</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-03-16">2020-03-16</time>
    <span itemprop="title">Assigned to KYOWA KIRIN CO., LTD.</span>
    <span itemprop="type">reassignment</span>
    
    
    
    
    <span itemprop="assigneeSearch">KYOWA KIRIN CO., LTD.</span>
    <span itemprop="description" repeat>ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).</span>
    <span itemprop="description" repeat>Assignors: HOSOE, Shintaro, HATANAKA, KENTARO, MAEMOTO, Michihiro</span>
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2020-11-26">2020-11-26</time>
    <span itemprop="title">Publication of US20200368173A1</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US20200368173A1/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2023-04-25">2023-04-25</time>
    <span itemprop="title">Application granted</span>
    <span itemprop="type">granted</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2023-04-25">2023-04-25</time>
    <span itemprop="title">Publication of US11633365B2</span>
    <span itemprop="type">publication</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    <span itemprop="documentId">patent/US11633365B2/en</span>
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date">Status</time>
    <span itemprop="title">Active</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    <span itemprop="current" content="true" bool>Current</span>
    
    
    
  </dd>
  <dd itemprop="events" itemscope repeat>
    <time itemprop="date" datetime="2039-10-08">2039-10-08</time>
    <span itemprop="title">Adjusted expiration</span>
    <span itemprop="type">legal-status</span>
    <span itemprop="critical" content="true" bool>Critical</span>
    
    
    
    
  </dd>

  <h2>Links</h2>
  <ul>
    <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoLink">
          <a href="https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&p=1&u=/netahtml/PTO/srchnum.html&r=1&f=G&l=50&d=PG01&s1=20200368173.PGNR." itemprop="url" target="_blank"><span itemprop="text">USPTO</span></a>
        </li>
        
        <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoPatentCenterLink">
          <a href="https://patentcenter.uspto.gov/applications/16636177" itemprop="url" target="_blank"><span itemprop="text">USPTO PatentCenter</span></a>
        </li>
        <li itemprop="links" itemscope repeat>
          <meta itemprop="id" content="usptoAssignmentLink">
          <a href="https://assignment.uspto.gov/patent/index.html#/patent/search/resultFilter?searchInput=20200368173" itemprop="url" target="_blank"><span itemprop="text">USPTO Assignment</span></a>
        </li>

    <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="espacenetLink">
        <a href="https://worldwide.espacenet.com/publicationDetails/biblio?CC=US&amp;NR=2020368173A1&amp;KC=A1&amp;FT=D" itemprop="url" target="_blank"><span itemprop="text">Espacenet</span></a>
      </li>
      

    

    <li itemprop="links" itemscope repeat>
      <meta itemprop="id" content="globalDossierLink">
      <a href="https://globaldossier.uspto.gov/result/application/US/16636177/1" itemprop="url" target="_blank"><span itemprop="text">Global Dossier</span></a>
    </li>

    

      

      

      <li itemprop="links" itemscope repeat>
        <meta itemprop="id" content="stackexchangeLink">
        <a href="https://patents.stackexchange.com/questions/tagged/US20200368173" itemprop="url"><span itemprop="text">Discuss</span></a>
      </li>
      
  </ul>

  <ul itemprop="concept" itemscope>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">0</span>
      <span itemprop="name">[7*:0]SCCN([8*:0])C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[7*:0]SCCN([8*:0])C</span>
      <span itemprop="inchi_key"></span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">100</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VFPKIWATTACVJR-UHFFFAOYSA-N</span>
      <span itemprop="name">[H]CC(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[H]CC(=O)CN(C)C</span>
      <span itemprop="inchi_key">VFPKIWATTACVJR-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">10</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WQVAMFRPCWXWSS-UHFFFAOYSA-N</span>
      <span itemprop="name">[H]CC(=O)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[H]CC(=O)CCN(C)C</span>
      <span itemprop="inchi_key">WQVAMFRPCWXWSS-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">8</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GSFXTQVXDLCXRH-UHFFFAOYSA-N</span>
      <span itemprop="name">C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C2C(C)(C)[N&#43;](C)(C1(C)C)C2(C)C.CC(C)(C)[N&#43;](C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C2C(C)(C)[N&#43;](C)(C1(C)C)C2(C)C.CC(C)(C)[N&#43;](C)(C)C</span>
      <span itemprop="inchi_key">GSFXTQVXDLCXRH-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">4</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YHGQLBNLXWLPMP-UHFFFAOYSA-N</span>
      <span itemprop="name">[H]CS(=O)(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[H]CS(=O)(=O)CN(C)C</span>
      <span itemprop="inchi_key">YHGQLBNLXWLPMP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">4</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SPJZSTLXABSXII-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(C)(C)[N&#43;](C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)[N&#43;](C)(C)C</span>
      <span itemprop="inchi_key">SPJZSTLXABSXII-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">3</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BJQGYZPBZUUMTH-QMMMGPOBSA-M</span>
      <span itemprop="name">COP(=O)([O-])OC[C@H](COC(C)=O)OC(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">COP(=O)([O-])OC[C@H](COC(C)=O)OC(C)=O</span>
      <span itemprop="inchi_key">BJQGYZPBZUUMTH-QMMMGPOBSA-M</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">3</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IJNQKCZYVKVJLG-UHFFFAOYSA-N</span>
      <span itemprop="name">C.CC(C)(C)CC1C2C(C)(C)N(C1(C)C)C2(C)C.CN(C)C(C)(C)C.CN1C(C)(C)C(CC(C)(C)C)C1(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.CC(C)(C)CC1C2C(C)(C)N(C1(C)C)C2(C)C.CN(C)C(C)(C)C.CN1C(C)(C)C(CC(C)(C)C)C1(C)C</span>
      <span itemprop="inchi_key">IJNQKCZYVKVJLG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KXKVZYRAOJGSLG-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C2C(C)(C)[N&#43;](C)(C1(C)C)C2(C)C.CC(C)(C)[N&#43;](C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C2C(C)(C)[N&#43;](C)(C1(C)C)C2(C)C.CC(C)(C)[N&#43;](C)(C)C</span>
      <span itemprop="inchi_key">KXKVZYRAOJGSLG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QGSWDUITWWBPAJ-ZJNSTNPOSA-N</span>
      <span itemprop="name">CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CCN(C)(C)C.CCC(O)CC(C)C.CCCC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CCN(C)(C)C.CCC(O)CC(C)C.CCCC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="inchi_key">QGSWDUITWWBPAJ-ZJNSTNPOSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MCQSBHKPNJFHAY-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CO)(CCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CO)(CCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C</span>
      <span itemprop="inchi_key">MCQSBHKPNJFHAY-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QDNMNPIKMDQXBS-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCCCN(CCCCCCCCCC/C=C\C/C=C\CCCCC)C(=O)OCC1CCCN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCCCN(CCCCCCCCCC/C=C\C/C=C\CCCCC)C(=O)OCC1CCCN(C)C1</span>
      <span itemprop="inchi_key">QDNMNPIKMDQXBS-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IPNWAZQQBOIRFL-LTEAFHAISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">IPNWAZQQBOIRFL-LTEAFHAISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DDTUMACRVFWPKZ-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCCCOCCNCCOCCCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCCCOCCNCCOCCCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">DDTUMACRVFWPKZ-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QEXHJSLJVZCWMB-YVFFZHSKSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)CCN(C)C</span>
      <span itemprop="inchi_key">QEXHJSLJVZCWMB-YVFFZHSKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FGTBWKIAVQTMJJ-YVFFZHSKSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)OCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)OCCN(C)C</span>
      <span itemprop="inchi_key">FGTBWKIAVQTMJJ-YVFFZHSKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CKSWQTZGVCQCOX-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="inchi_key">CKSWQTZGVCQCOX-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FCLXKZXFTVSOJC-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC1(COCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC1(COCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">FCLXKZXFTVSOJC-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GZMKRIMQARSOMK-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCSCCNCCSCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCSCCNCCSCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">GZMKRIMQARSOMK-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SDLKJIMFLWBCHA-GJVMBIMVSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCO[C@@H]1CN(C)C[C@H]1OCCCCCCCC/C=C\CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCO[C@@H]1CN(C)C[C@H]1OCCCCCCCC/C=C\CCCCCC</span>
      <span itemprop="inchi_key">SDLKJIMFLWBCHA-GJVMBIMVSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DKDLSHOXNBKIES-WRBBJXAJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(CC)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(CC)C1</span>
      <span itemprop="inchi_key">DKDLSHOXNBKIES-WRBBJXAJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DBZHKXHZJXKSHK-CLFAGFIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCSCCNCCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCSCCNCCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">DBZHKXHZJXKSHK-CLFAGFIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LYVCKXIOCZNKRV-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCCCCCCCC)C(=O)CSCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCC(=O)OCCN(CCOC(=O)CCCCCCCCCCCCC)C(=O)CSCCN(C)C</span>
      <span itemprop="inchi_key">LYVCKXIOCZNKRV-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DQLJRWJDWPEJRE-UHFFFAOYSA-N</span>
      <span itemprop="name">[H]CC(=O)OCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[H]CC(=O)OCN(C)C</span>
      <span itemprop="inchi_key">DQLJRWJDWPEJRE-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">2</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BMMABKNLLROTRD-NOVAYXTLSA-M</span>
      <span itemprop="name">C.C.C.C.C.C.CC(=O)OC[C@@H](CO)OC(C)=O.CC(C)=O.CC(C)=O.CC1(C)OC[C@@H](CO)O1.CCCl(=N)(CC)(CC)P(=O)(Cl)Cl.CC[C@@H](O)CO.CC[C@@H]1COC(C)(C)O1.CC[C@H](COC(C)=O)OC(C)=O.CO.COP(=O)([O-])OC[C@H](COC(C)=O)OC(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.C.C.C.C.C.CC(=O)OC[C@@H](CO)OC(C)=O.CC(C)=O.CC(C)=O.CC1(C)OC[C@@H](CO)O1.CCCl(=N)(CC)(CC)P(=O)(Cl)Cl.CC[C@@H](O)CO.CC[C@@H]1COC(C)(C)O1.CC[C@H](COC(C)=O)OC(C)=O.CO.COP(=O)([O-])OC[C@H](COC(C)=O)OC(C)=O</span>
      <span itemprop="inchi_key">BMMABKNLLROTRD-NOVAYXTLSA-M</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NOHYEDZNOWXTIB-UHFFFAOYSA-M</span>
      <span itemprop="name">C.C.C.C.C.CC(=O)Cl.CC1(C)OCC(CO)O1.CCC.CCC(C)CC.CCC(C)COP(=O)([O-])OC.CCC(O)CO.CCC1COC(C)(C)O1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.C.C.C.C.CC(=O)Cl.CC1(C)OCC(CO)O1.CCC.CCC(C)CC.CCC(C)COP(=O)([O-])OC.CCC(O)CO.CCC1COC(C)(C)O1</span>
      <span itemprop="inchi_key">NOHYEDZNOWXTIB-UHFFFAOYSA-M</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IUEVNAACCVGXAA-FTDIPSKDSA-M</span>
      <span itemprop="name">C.C.CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CCN.CC(C)CCN(C)(C)C.CCC(C)COP(=O)([O-])OC.CCC(O)CC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.C.CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CCN.CC(C)CCN(C)(C)C.CCC(C)COP(=O)([O-])OC.CCC(O)CC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="inchi_key">IUEVNAACCVGXAA-FTDIPSKDSA-M</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RKXJPDVDTSWBBX-DVYALXSZSA-N</span>
      <span itemprop="name">C.C.CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CCN.CC(C)CCN(C)(C)C.CCC(O)CC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.C.CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CCN.CC(C)CCN(C)(C)C.CCC(O)CC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="inchi_key">RKXJPDVDTSWBBX-DVYALXSZSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ADSCWHOHPZDHBU-UHFFFAOYSA-N</span>
      <span itemprop="name">C.C.CCC(COC)COC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.C.CCC(COC)COC</span>
      <span itemprop="inchi_key">ADSCWHOHPZDHBU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NBNGNEFHBGAOIF-UHFFFAOYSA-N</span>
      <span itemprop="name">C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C</span>
      <span itemprop="inchi_key">NBNGNEFHBGAOIF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GWLBTQMZNYGTPT-UHFFFAOYSA-N</span>
      <span itemprop="name">C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C2C(C)(C)[N&#43;](C)(C1(C)C)C2(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.CC(C)(C)CC1C(C)(C)[N&#43;](C)(C)C1(C)C.CC(C)(C)CC1C2C(C)(C)[N&#43;](C)(C1(C)C)C2(C)C</span>
      <span itemprop="inchi_key">GWLBTQMZNYGTPT-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UETSOZSOSJYKHU-UHFFFAOYSA-N</span>
      <span itemprop="name">C.CC(C)(C)CC1C2C(C)(C)N(C1(C)C)C2(C)C.CN1C(C)(C)C(CC(C)(C)C)C1(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.CC(C)(C)CC1C2C(C)(C)N(C1(C)C)C2(C)C.CN1C(C)(C)C(CC(C)(C)C)C1(C)C</span>
      <span itemprop="inchi_key">UETSOZSOSJYKHU-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RTGIYTDXRQMBIF-UHFFFAOYSA-N</span>
      <span itemprop="name">C.[H]CC1C(C)(C)N(C)C1(C)C.[H]CC1C2C(C)(C)N(C1(C)C)C2(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C.[H]CC1C(C)(C)N(C)C1(C)C.[H]CC1C2C(C)(C)N(C1(C)C)C2(C)C</span>
      <span itemprop="inchi_key">RTGIYTDXRQMBIF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UJXPDAXMYRQUBG-GAYWYDNTSA-N</span>
      <span itemprop="name">C1=CC=NC=C1.CC1=CC=C(S(=O)(=O)[O-])C=C1.CCCCCCCCCCCCCCCCCC(=O)Cl.CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](CO)OC(=O)CCCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COCC1=CC=CC=C1)OC(=O)CCCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)([O-])OCC[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC.C[N&#43;](C)(C)CCO.C[Pd].OC[C@H](O)COCC1=CC=CC=C1.[HH]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C1=CC=NC=C1.CC1=CC=C(S(=O)(=O)[O-])C=C1.CCCCCCCCCCCCCCCCCC(=O)Cl.CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](CO)OC(=O)CCCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COCC1=CC=CC=C1)OC(=O)CCCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)([O-])OCC[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC.C[N&#43;](C)(C)CCO.C[Pd].OC[C@H](O)COCC1=CC=CC=C1.[HH]</span>
      <span itemprop="inchi_key">UJXPDAXMYRQUBG-GAYWYDNTSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IYEFXEKKCLUMPM-ZGMREHQJSA-N</span>
      <span itemprop="name">C=CCCCCCCCOC(=O)CCCCCCCCC(C)(C)C.CCCCC/C=C\C/C=C\CCCCCCCCC(C)(C)C.CCCCCC/C=C\COC(=O)CCCCCCCCC(C)(C)C.CCCCCCCC/C=C\CCCCCCCCC(C)(C)C.CCCCCCCCCOC(=O)CCCCCCCCC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">C=CCCCCCCCOC(=O)CCCCCCCCC(C)(C)C.CCCCC/C=C\C/C=C\CCCCCCCCC(C)(C)C.CCCCCC/C=C\COC(=O)CCCCCCCCC(C)(C)C.CCCCCCCC/C=C\CCCCCCCCC(C)(C)C.CCCCCCCCCOC(=O)CCCCCCCCC(C)(C)C</span>
      <span itemprop="inchi_key">IYEFXEKKCLUMPM-ZGMREHQJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ITBDBDNPFJBXJC-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(C)(C)C(=O)OC1CCC[N&#43;]1(C)C.CC(C)(C)C(=O)OC1CCN(C)(C)C1.CC(C)(C)C(=O)OC1CCN(C)(C)CC1.CC(C)(C)C(=O)OC1CN2(C)CCC1CC2</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)(C)C(=O)OC1CCC[N&#43;]1(C)C.CC(C)(C)C(=O)OC1CCN(C)(C)C1.CC(C)(C)C(=O)OC1CCN(C)(C)CC1.CC(C)(C)C(=O)OC1CN2(C)CCC1CC2</span>
      <span itemprop="inchi_key">ITBDBDNPFJBXJC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GSMGCAYDFNPNOA-IXSARBFQSA-N</span>
      <span itemprop="name">CC(C)C1C(O)C(C)C(O)C(O)C1O.CCC(O)CC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)C1C(O)C(C)C(O)C(O)C1O.CCC(O)CC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="inchi_key">GSMGCAYDFNPNOA-IXSARBFQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AUHNCSIYXBIWTJ-AQFWRPTESA-M</span>
      <span itemprop="name">CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CC(O)CO.CC(C)CCN(C)(C)C.CCC(C)COP(=O)([O-])OC.CCCC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CC(O)CO.CC(C)CCN(C)(C)C.CCC(C)COP(=O)([O-])OC.CCCC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="inchi_key">AUHNCSIYXBIWTJ-AQFWRPTESA-M</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VEUAGJIBOLTOEX-ZJNSTNPOSA-N</span>
      <span itemprop="name">CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CC(O)CO.CC(C)CCN(C)(C)C.CCCC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CC(O)CO.CC(C)CCN(C)(C)C.CCCC(C)C.[H][C@](N)(CC(C)C)C(C)=O</span>
      <span itemprop="inchi_key">VEUAGJIBOLTOEX-ZJNSTNPOSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VGAXWCRDRXTPRV-USRYLFPTSA-L</span>
      <span itemprop="name">CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CCN(C)(C)C.CCC(C)COP(=O)([O-])OC.CCC(O)CC(C)C.CCCC(C)C.[H][C@](C)(CC(C)C)C(=O)[O-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)C1C(O)C(O)C(O)C(O)C1O.CC(C)CCN(C)(C)C.CCC(C)COP(=O)([O-])OC.CCC(O)CC(C)C.CCCC(C)C.[H][C@](C)(CC(C)C)C(=O)[O-]</span>
      <span itemprop="inchi_key">VGAXWCRDRXTPRV-USRYLFPTSA-L</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XNVVXWODVJMJHC-UHFFFAOYSA-N</span>
      <span itemprop="name">CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OCC(COC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C)(COC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)CCCC(C)CCCC(C)CCCC(C)CC(=O)OCC(COC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C)(COC(=O)CC(C)CCCC(C)CCCC(C)CCCC(C)C)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">XNVVXWODVJMJHC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UBIFGDVFNGMPQP-USWFNJDKSA-N</span>
      <span itemprop="name">CC(C)[C@H]1C(O)C(O)[C@H](O)C(O)[C@@H]1O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC(C)[C@H]1C(O)C(O)[C@H](O)C(O)[C@@H]1O</span>
      <span itemprop="inchi_key">UBIFGDVFNGMPQP-USWFNJDKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GGKHHICPJKUUIJ-UHFFFAOYSA-N</span>
      <span itemprop="name">CC.CC.CC(C)C.N.N</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC.CC.CC(C)C.N.N</span>
      <span itemprop="inchi_key">GGKHHICPJKUUIJ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PMFVZBCZDOIHHQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CC.CC.CC.CC.CC(C)(C)C.CC(C)C.[NH4&#43;].[NH4&#43;].[NH4&#43;]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CC.CC.CC.CC.CC(C)(C)C.CC(C)C.[NH4&#43;].[NH4&#43;].[NH4&#43;]</span>
      <span itemprop="inchi_key">PMFVZBCZDOIHHQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VMIQFGQCSQCPRW-JFJOQQEJSA-N</span>
      <span itemprop="name">CCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCC)(COC(=O)CCCCCCC/C=C\CCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCC)(COC(=O)CCCCCCC/C=C\CCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">VMIQFGQCSQCPRW-JFJOQQEJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IIPZAKVPHMZWBO-JFJOQQEJSA-N</span>
      <span itemprop="name">CCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCC)(COC(=O)CCCCCCC/C=C\CCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCC)(COC(=O)CCCCCCC/C=C\CCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">IIPZAKVPHMZWBO-JFJOQQEJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HRMZMHCYLONXDM-JFJOQQEJSA-N</span>
      <span itemprop="name">CCCC/C=C\CCCCCCCCOC(=O)CCOCC(COCCC(=O)OCCCCCCCC/C=C\CCCC)(COCCC(=O)OCCCCCCCC/C=C\CCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCCCCCCCOC(=O)CCOCC(COCCC(=O)OCCCCCCCC/C=C\CCCC)(COCCC(=O)OCCCCCCCC/C=C\CCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">HRMZMHCYLONXDM-JFJOQQEJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IKOBULXUUASFSE-JFJOQQEJSA-N</span>
      <span itemprop="name">CCCC/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\CCCC)(COCCCCCCCC/C=C\CCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\CCCC)(COCCCCCCCC/C=C\CCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">IKOBULXUUASFSE-JFJOQQEJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BVCLAFFNLAJWDA-XSYHWHKQSA-N</span>
      <span itemprop="name">CCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="inchi_key">BVCLAFFNLAJWDA-XSYHWHKQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">STPWSNIGLSBNGX-MIMPSMLTSA-N</span>
      <span itemprop="name">CCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCC)CN(C)C1</span>
      <span itemprop="inchi_key">STPWSNIGLSBNGX-MIMPSMLTSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GEHJJRMMNWLKPK-HWAYABPNSA-N</span>
      <span itemprop="name">CCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCC)CNC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCC)CNC1</span>
      <span itemprop="inchi_key">GEHJJRMMNWLKPK-HWAYABPNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SYVCULRFYJMNTF-MOKVCOEPSA-O</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC(=O)NC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COC(=O)CCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC(=O)NC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COC(=O)CCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">SYVCULRFYJMNTF-MOKVCOEPSA-O</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HCAJCMUKLZSPFT-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(CN(C)C)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">HCAJCMUKLZSPFT-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NLUKNIBSKDFXRO-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CC(=O)CCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">NLUKNIBSKDFXRO-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CSXMMTQMGBOLNR-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CC(=O)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CC(=O)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">CSXMMTQMGBOLNR-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IBDBMKDFXLPYKR-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">IBDBMKDFXLPYKR-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KWZHBVFQDLRUME-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">KWZHBVFQDLRUME-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HNMOAPYINKOXRO-IXQWNJBLSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC[N&#43;](C)(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OCC[N&#43;](C)(CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC)CCOC(=O)CCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="inchi_key">HNMOAPYINKOXRO-IXQWNJBLSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UPJLUFOWASBONR-KMTCDGPVSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@@H]1CN(C)C[C@H]1COC(=O)CCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@@H]1CN(C)C[C@H]1COC(=O)CCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">UPJLUFOWASBONR-KMTCDGPVSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NQXSVRYXYBFEMX-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(=CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(=CCCN(C)C)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">NQXSVRYXYBFEMX-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MMNOLHXKWRIUSJ-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)(CCC(=O)OCCC[N&#43;](C)(C)C)COC(=O)CCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)(CCC(=O)OCCC[N&#43;](C)(C)C)COC(=O)CCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="inchi_key">MMNOLHXKWRIUSJ-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RZXMQWJZVSHVCN-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">RZXMQWJZVSHVCN-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YTLKPWSRNRNHSY-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="inchi_key">YTLKPWSRNRNHSY-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PRFMJJJHANAIMD-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)NC(=O)CN(C)C</span>
      <span itemprop="inchi_key">PRFMJJJHANAIMD-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NRLNQCOGCKAESA-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">NRLNQCOGCKAESA-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BOMJQUFXHKVCOZ-CWJLHRMTSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="inchi_key">BOMJQUFXHKVCOZ-CWJLHRMTSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SUHMLXPLRNAJGZ-PNIKFMEDSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)CCN(C)C(=O)CCCCCCCCCCCCCCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)CCN(C)C(=O)CCCCCCCCCCCCCCCCC.[Cl-]</span>
      <span itemprop="inchi_key">SUHMLXPLRNAJGZ-PNIKFMEDSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KZIQWSQXCKPZBG-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(CO)(CCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(CO)(CCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="inchi_key">KZIQWSQXCKPZBG-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WOEJWSMPOQRQOX-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">WOEJWSMPOQRQOX-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BKOCTDIPPAIJON-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(O)C(CCCCCCCC/C=C\C/C=C\CCCCC)(CCCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(O)C(CCCCCCCC/C=C\C/C=C\CCCCC)(CCCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">BKOCTDIPPAIJON-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YJPNSOJCNDNRJQ-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCC[N&#43;](C)(C)C)C(O)(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC(OC(=O)CCC[N&#43;](C)(C)C)C(O)(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="inchi_key">YJPNSOJCNDNRJQ-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XZZSNBNXYUGQQZ-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)CN(C(=O)OCCCN(C)C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)CN(C(=O)OCCCN(C)C)C1</span>
      <span itemprop="inchi_key">XZZSNBNXYUGQQZ-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VCAPOSNTDGEWSI-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">VCAPOSNTDGEWSI-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RQHZGTCLPKRLLA-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)CN(CCCO)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)CN(CCCO)C1</span>
      <span itemprop="inchi_key">RQHZGTCLPKRLLA-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ITKKJJPJJIIAFQ-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)CN(CCO)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)CN(CCO)C1</span>
      <span itemprop="inchi_key">ITKKJJPJJIIAFQ-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LRFJOIPOPUJUMI-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)OCC(CCN(C)C)O1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCC1(CCCCCCCC/C=C\C/C=C\CCCCC)OCC(CCN(C)C)O1</span>
      <span itemprop="inchi_key">LRFJOIPOPUJUMI-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HQJMKPUDVGJNDE-LTEAFHAISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCCCNCCOCCCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCCCNCCOCCCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">HQJMKPUDVGJNDE-LTEAFHAISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RECILYIJTXFXGE-NCLNRZQNSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCCCOC[C@@H]1CN(C)C[C@H]1COCCCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCCCOC[C@@H]1CN(C)C[C@H]1COCCCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">RECILYIJTXFXGE-NCLNRZQNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VIBZCANAMJWLMP-LQHNYHSCSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCCCO[C@@H]1CNC[C@H]1OCCCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCCCO[C@@H]1CNC[C@H]1OCCCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">VIBZCANAMJWLMP-LQHNYHSCSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LLCRQFZLLSKLBP-IXQWNJBLSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCCC[N&#43;](C)(CCCCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCCC[N&#43;](C)(CCCCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="inchi_key">LLCRQFZLLSKLBP-IXQWNJBLSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZUVNJQGVJAFACY-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(C)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(C)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">ZUVNJQGVJAFACY-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DHYJTCXEPURSOH-ATEMJZPOSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(C)CCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(C)CCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">DHYJTCXEPURSOH-ATEMJZPOSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KHIPLWGPZRCXSS-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)OCCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)OCCCCN(C)C</span>
      <span itemprop="inchi_key">KHIPLWGPZRCXSS-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UZFKMJMIEVMXFK-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)OCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)OCCCN(C)C</span>
      <span itemprop="inchi_key">UZFKMJMIEVMXFK-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RLKRWTFFLXLQLM-FLDLJHRZSA-O</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)[C@H](CCCC[N&#43;](C)(C)C)NC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)[C@H](CCCC[N&#43;](C)(C)C)NC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="inchi_key">RLKRWTFFLXLQLM-FLDLJHRZSA-O</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SGQSGJUTBKNKIB-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCO)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCO)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">SGQSGJUTBKNKIB-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LGYCGTNBOXLEQA-LTEAFHAISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCO)CCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCO)CCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">LGYCGTNBOXLEQA-LTEAFHAISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MZJZGZYKDHIBNY-LTEAFHAISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCO)CCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCCO)CCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">MZJZGZYKDHIBNY-LTEAFHAISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XKRJBBWVUHGXTP-CWJLHRMTSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCC[N&#43;](C)(C)CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)CCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCC[N&#43;](C)(C)CCCCCCCC/C=C\C/C=C\CCCCC)C(=O)CCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="inchi_key">XKRJBBWVUHGXTP-CWJLHRMTSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VHFVFEIQUCUIOM-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCO)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">VHFVFEIQUCUIOM-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PTFDZXXDNHVUOO-YVFFZHSKSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCOCCCCCCCC/C=C\CCCCCCCC)C(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCOCCCCCCCC/C=C\CCCCCCCC)C(=O)CN(C)C</span>
      <span itemprop="inchi_key">PTFDZXXDNHVUOO-YVFFZHSKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KWADACVSLNULOG-YVFFZHSKSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)CN(C)C</span>
      <span itemprop="inchi_key">KWADACVSLNULOG-YVFFZHSKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PNDZMPMBZCVZBS-IBEJZQOGSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)CN(CC)CC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)CN(CC)CC</span>
      <span itemprop="inchi_key">PNDZMPMBZCVZBS-IBEJZQOGSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZXWWVWYZLYJYCX-YVFFZHSKSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)OCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)OCCCN(C)C</span>
      <span itemprop="inchi_key">ZXWWVWYZLYJYCX-YVFFZHSKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CYQSTMDWBKDJRN-YVFFZHSKSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)SCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)C(=O)SCCN(C)C</span>
      <span itemprop="inchi_key">CYQSTMDWBKDJRN-YVFFZHSKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WSOZKQIBNYOGQM-YVFFZHSKSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)S(=O)(=O)CCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCN(CCSCCCCCCCC/C=C\CCCCCCCC)S(=O)(=O)CCN(C)C</span>
      <span itemprop="inchi_key">WSOZKQIBNYOGQM-YVFFZHSKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SFPJCZDLNJKIQD-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">SFPJCZDLNJKIQD-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HIMRVZSLVSNKQQ-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNCCCOCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNCCCOCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">HIMRVZSLVSNKQQ-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DNLPRYBHMUFJTG-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">DNLPRYBHMUFJTG-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KFWJRSYIDHBFKA-PNBIJBBKSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\CCCCCC</span>
      <span itemprop="inchi_key">KFWJRSYIDHBFKA-PNBIJBBKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DPXUQAONLLWKDS-LTEAFHAISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">DPXUQAONLLWKDS-LTEAFHAISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HYUGWCKWIPPILN-RQOIEFAZSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">HYUGWCKWIPPILN-RQOIEFAZSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XHLSQVMDDRMXJP-LTEAFHAISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNCCOCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">XHLSQVMDDRMXJP-LTEAFHAISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YEHYMRZRGGXSNB-LTEAFHAISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCNCCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCNCCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">YEHYMRZRGGXSNB-LTEAFHAISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PEXGZOLLBWAXNH-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOC(=O)C(CCCCCCCC/C=C\C/C=C\CCCCC)(CCCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOC(=O)C(CCCCCCCC/C=C\C/C=C\CCCCC)(CCCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">PEXGZOLLBWAXNH-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JCOLFEHCAYKQMN-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOC(=O)CCOCC(COCCC(=O)OCCCCCCCC/C=C\C/C=C\CCCCC)(COCCC(=O)OCCCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOC(=O)CCOCC(COCCC(=O)OCCCCCCCC/C=C\C/C=C\CCCCC)(COCCC(=O)OCCCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">JCOLFEHCAYKQMN-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JJHZEMWRIYPBOK-ZPPAUJSGSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(C)(COCCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(C)(COCCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="inchi_key">JJHZEMWRIYPBOK-ZPPAUJSGSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XUTBOPULPGCUJW-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(C)(COCCCCCCCC/C=C\C/C=C\CCCCC)NC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(C)(COCCCCCCCC/C=C\C/C=C\CCCCC)NC</span>
      <span itemprop="inchi_key">XUTBOPULPGCUJW-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NFQBIAXADRDUGK-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">NFQBIAXADRDUGK-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OCQRNKJCMCQWPB-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN1CCCC1)OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CN1CCCC1)OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">OCQRNKJCMCQWPB-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JVPCRRBCIFQOEG-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CO)(COCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CO)(COCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C</span>
      <span itemprop="inchi_key">JVPCRRBCIFQOEG-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SBIIXADGZNPZFF-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CO)(COCCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(CO)(COCCCCCCCC/C=C\C/C=C\CCCCC)N(C)C</span>
      <span itemprop="inchi_key">SBIIXADGZNPZFF-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">YUMAEUWIUVYYPY-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\C/C=C\CCCCC)(COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">YUMAEUWIUVYYPY-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NZHIQHWWLLHHHT-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\C/C=C\CCCCC)(COCCCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\C/C=C\CCCCC)(COCCCCCCCC/C=C\C/C=C\CCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">NZHIQHWWLLHHHT-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KHRMZGFYOYJEOX-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\C/C=C\CCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\C/C=C\CCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="inchi_key">KHRMZGFYOYJEOX-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RHNSHOKPUGRDBW-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">RHNSHOKPUGRDBW-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BCFLOENOUVYVAO-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCCC1(CCOCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCCC1(CCOCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">BCFLOENOUVYVAO-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WQKIASNYROSNGC-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCCCC1(CCCOCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCCCC1(CCCOCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">WQKIASNYROSNGC-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NRUKBFFXNJSWOW-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCCN(C)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCCN(C)CCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">NRUKBFFXNJSWOW-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RMSBHXYHAMKGEU-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCCN(C)CCOCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCCN(C)CCOCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">RMSBHXYHAMKGEU-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SMFNOBBHYGDJRP-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOCCNCCOCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOCCNCCOCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">SMFNOBBHYGDJRP-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AMWYVYNJINSEAX-MOKVCOEPSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCOC[N&#43;](COCCCCCCCC/C=C\C/C=C\CCCCC)(COCCCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCOC[N&#43;](COCCCCCCCC/C=C\C/C=C\CCCCC)(COCCCCCCCC/C=C\C/C=C\CCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">AMWYVYNJINSEAX-MOKVCOEPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PXYLQBIBHOENSG-NBZSJQJNSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCO[C@@H]1CN(C(=O)OCCCN(C)C)C[C@H]1OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCO[C@@H]1CN(C(=O)OCCCN(C)C)C[C@H]1OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">PXYLQBIBHOENSG-NBZSJQJNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DNPBLNKOGLNHOY-PZYNCWBWSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCO[C@@H]1CN(CC(O)CO)C[C@H]1OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCO[C@@H]1CN(CC(O)CO)C[C@H]1OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">DNPBLNKOGLNHOY-PZYNCWBWSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WYTXNJWGKPSAOO-QYCRHRGJSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\C/C=C\CCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">WYTXNJWGKPSAOO-QYCRHRGJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JBBHAUZKHVFCEU-MAZCIEHSSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\C/C=C\CCCCC)CNC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\C/C=C\CCCCC)CNC1</span>
      <span itemprop="inchi_key">JBBHAUZKHVFCEU-MAZCIEHSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KIXMWXAIJCEJLY-YVFFZHSKSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="inchi_key">KIXMWXAIJCEJLY-YVFFZHSKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NNTXTNIHGUGHEE-KWXKLSQISA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCCSCCN(CCSCCCCCCCC/C=C\C/C=C\CCCCC)C(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCCSCCN(CCSCCCCCCCC/C=C\C/C=C\CCCCC)C(=O)CN(C)C</span>
      <span itemprop="inchi_key">NNTXTNIHGUGHEE-KWXKLSQISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MCZDUQMUXFYSCZ-IXQWNJBLSA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC[N&#43;](C)(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC[N&#43;](C)(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="inchi_key">MCZDUQMUXFYSCZ-IXQWNJBLSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HXJLTORYNOXKHJ-BBWANDEASA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC[N&#43;](CCCO)(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC[N&#43;](CCCO)(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="inchi_key">HXJLTORYNOXKHJ-BBWANDEASA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SCYMWXDIVTURKR-BBWANDEASA-N</span>
      <span itemprop="name">CCCCC/C=C\C/C=C\CCCCCCCC[N&#43;](CCO)(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCC/C=C\C/C=C\CCCCCCCC[N&#43;](CCO)(CCCCCCCC/C=C\C/C=C\CCCCC)CCCCCCCC/C=C\C/C=C\CCCCC.[Cl-]</span>
      <span itemprop="inchi_key">SCYMWXDIVTURKR-BBWANDEASA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IRXGRQYQTGTARF-DMGKHJLRSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">IRXGRQYQTGTARF-DMGKHJLRSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JITYDIPHHAIYAD-IQRFGFHNSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCCCSCC1(CSCCCCCCCCCC/C=C\CCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCCCSCC1(CSCCCCCCCCCC/C=C\CCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="inchi_key">JITYDIPHHAIYAD-IQRFGFHNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RWUFIWUSTDGGMK-RYOQUFEFSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCCCSCC1(CSCCCCCCCCCC/C=C\CCCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCCCSCC1(CSCCCCCCCCCC/C=C\CCCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">RWUFIWUSTDGGMK-RYOQUFEFSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QVBCPEITGDTYGK-VMNXYWKNSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCCCSCC1(CSCCCCCCCCCC/C=C\CCCCCC)CNC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCCCSCC1(CSCCCCCCCCCC/C=C\CCCCCC)CNC1</span>
      <span itemprop="inchi_key">QVBCPEITGDTYGK-VMNXYWKNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">INWSWCLRFKUZND-KXYOHKLBSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">INWSWCLRFKUZND-KXYOHKLBSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HIIAIOXNLLWFAY-DMGKHJLRSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCOC(=O)CCOCC(COCCC(=O)OCCCCCCCC/C=C\CCCCCC)(COCCC(=O)OCCCCCCCC/C=C\CCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCOC(=O)CCOCC(COCCC(=O)OCCCCCCCC/C=C\CCCCCC)(COCCC(=O)OCCCCCCCC/C=C\CCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">HIIAIOXNLLWFAY-DMGKHJLRSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CSPOKXXGRNJJHE-DMGKHJLRSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\CCCCCC)(COCCCCCCCC/C=C\CCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCOCC(COCCCCCCCC/C=C\CCCCCC)(COCCCCCCCC/C=C\CCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">CSPOKXXGRNJJHE-DMGKHJLRSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VNAYNYLMGVVNPX-RYOQUFEFSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCOCCN(C)CCOCCCCCCCC/C=C\CCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCOCCN(C)CCOCCCCCCCC/C=C\CCCCCC</span>
      <span itemprop="inchi_key">VNAYNYLMGVVNPX-RYOQUFEFSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AXTBKZCVFWOVGD-IQRFGFHNSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="inchi_key">AXTBKZCVFWOVGD-IQRFGFHNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FUEKCGFTSCQAJO-RYOQUFEFSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">FUEKCGFTSCQAJO-RYOQUFEFSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XISCIXSFZKTVHZ-VMNXYWKNSA-N</span>
      <span itemprop="name">CCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCC)CNC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCC)CNC1</span>
      <span itemprop="inchi_key">XISCIXSFZKTVHZ-VMNXYWKNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DGNMJYUPWDTKJB-ZDSKVHJSSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCCCCC(CCCCCCCC(=O)OC/C=C\CCCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCCCCC(CCCCCCCC(=O)OC/C=C\CCCCCC)OC(=O)CCCN(C)C</span>
      <span itemprop="inchi_key">DGNMJYUPWDTKJB-ZDSKVHJSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RGAIHNZNCGOCLA-ZDSKVHJSSA-N</span>
      <span itemprop="name">CCCCCC/C=C\COC(=O)CCCCCCCN(CCCCCCCC(=O)OC/C=C\CCCCCC)C(=O)SCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC/C=C\COC(=O)CCCCCCCN(CCCCCCCC(=O)OC/C=C\CCCCCC)C(=O)SCCN(C)C</span>
      <span itemprop="inchi_key">RGAIHNZNCGOCLA-ZDSKVHJSSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">AHHFBEDHVJRORF-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCC1CC1CC1CC1CCCCCCCC(C)(C)C.CCCCCC1CC1CC1CC1CCCCCCCCC(C)(C)C.CCCCCCC1CC1CCCCCCCCC(C)(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCC1CC1CC1CC1CCCCCCCC(C)(C)C.CCCCCC1CC1CC1CC1CCCCCCCCC(C)(C)C.CCCCCCC1CC1CCCCCCCCC(C)(C)C</span>
      <span itemprop="inchi_key">AHHFBEDHVJRORF-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GPCJWRSBPIKVTP-PGEUSFDPSA-N</span>
      <span itemprop="name">CCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">GPCJWRSBPIKVTP-PGEUSFDPSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UTPMGYQOWDDCJV-XNQILKFJSA-O</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCC(=O)NCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCC(=O)NCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">UTPMGYQOWDDCJV-XNQILKFJSA-O</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CPPFPNMSJGYWHZ-XNQILKFJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(CC[N&#43;](C)(C)C)(COC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(CC[N&#43;](C)(C)C)(COC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="inchi_key">CPPFPNMSJGYWHZ-XNQILKFJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GRFJLSGMLQDOPH-XNQILKFJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">GRFJLSGMLQDOPH-XNQILKFJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GSMCPMNSWFLCPI-XNQILKFJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCC/C=C\CCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">GSMCPMNSWFLCPI-XNQILKFJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KYSLKBKVDGVGCP-ZUELCTOOSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCC/C=C\CCCCCCCC)(COC(=O)CCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">KYSLKBKVDGVGCP-ZUELCTOOSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KUSSPUKMCMGBBU-RQZHXJHFSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">KUSSPUKMCMGBBU-RQZHXJHFSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RWFPHSMMIKTBQD-UWDAMKIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCC(=O)OCC[N&#43;](C)(CCOC(=O)CCCCCCC/C=C\CCCCCCCC)CCOC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCC(=O)OCC[N&#43;](C)(CCOC(=O)CCCCCCC/C=C\CCCCCCCC)CCOC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="inchi_key">RWFPHSMMIKTBQD-UWDAMKIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WCAJOHJLBOYJHC-XNQILKFJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCC(CCC[N&#43;](C)(C)C)(COC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCC(CCC[N&#43;](C)(C)C)(COC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="inchi_key">WCAJOHJLBOYJHC-XNQILKFJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZFBZHJYCNLRYDF-XNQILKFJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCC(CC[N&#43;](C)(C)C)(COC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCC(CC[N&#43;](C)(C)C)(COC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="inchi_key">ZFBZHJYCNLRYDF-XNQILKFJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UUZBALLXPWIBDK-WRBBJXAJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCN(CCCCCCCC/C=C\CCCCCCCC)C(=O)OCCCN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCN(CCCCCCCC/C=C\CCCCCCCC)C(=O)OCCCN(C)C</span>
      <span itemprop="inchi_key">UUZBALLXPWIBDK-WRBBJXAJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KGGMQGNIHKULJB-CLFAGFIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCN(CCCO)CCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCN(CCCO)CCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">KGGMQGNIHKULJB-CLFAGFIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QJWLXRCSILVSPL-CLFAGFIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCN(CCO)CCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCN(CCO)CCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">QJWLXRCSILVSPL-CLFAGFIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XFKJUZZZRJZWDQ-CLFAGFIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">XFKJUZZZRJZWDQ-CLFAGFIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MLIBZKIQWADIBJ-ZIADKAODSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOC(=O)C(CCC(=O)OC(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOC(=O)C(CCC(=O)OC(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">MLIBZKIQWADIBJ-ZIADKAODSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OMVUIFQKBSIMKD-WRBBJXAJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="inchi_key">OMVUIFQKBSIMKD-WRBBJXAJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HNSZUTGOICHZEY-AUYXYSRISA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">HNSZUTGOICHZEY-AUYXYSRISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">KJXNZIUOPXXIQE-CLFAGFIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\CCCCCCCC)CNC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCC1(CSCCCCCCCC/C=C\CCCCCCCC)CNC1</span>
      <span itemprop="inchi_key">KJXNZIUOPXXIQE-CLFAGFIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ATYNEPKJEBVTEQ-WRBBJXAJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCCN(CCOCCCCCCCC/C=C\CCCCCCCC)C(=O)CN(C)C</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCCN(CCOCCCCCCCC/C=C\CCCCCCCC)C(=O)CN(C)C</span>
      <span itemprop="inchi_key">ATYNEPKJEBVTEQ-WRBBJXAJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UHWVIVRBTWBYQX-XZIBJWJKSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCCN(CCOCCCCCCCC/C=C\CCCCCCCC)C(=O)[C@@H](N)CO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCCN(CCOCCCCCCCC/C=C\CCCCCCCC)C(=O)[C@@H](N)CO</span>
      <span itemprop="inchi_key">UHWVIVRBTWBYQX-XZIBJWJKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FKYXEGAFFCFFNK-CLFAGFIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCCN(CCOCCCCCCCC/C=C\CCCCCCCC)CC(O)CO</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCCN(CCOCCCCCCCC/C=C\CCCCCCCC)CC(O)CO</span>
      <span itemprop="inchi_key">FKYXEGAFFCFFNK-CLFAGFIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GZZWNTSNZSONEK-CLFAGFIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCCN(CCOCCCCCCCC/C=C\CCCCCCCC)CCC(N)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCCN(CCOCCCCCCCC/C=C\CCCCCCCC)CCC(N)=O</span>
      <span itemprop="inchi_key">GZZWNTSNZSONEK-CLFAGFIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QLNYDGRHOBULPB-ZCXUNETKSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCCNCCCCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCCNCCCCCCCCCCCCCC</span>
      <span itemprop="inchi_key">QLNYDGRHOBULPB-ZCXUNETKSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DDXRUGYCLJQGHI-ZZEZOPTASA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCCNCCCCCCCCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCCNCCCCCCCCCCCCCCCCCC</span>
      <span itemprop="inchi_key">DDXRUGYCLJQGHI-ZZEZOPTASA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FKLGDFVGDJWXBW-CLFAGFIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOCCNCCOCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">FKLGDFVGDJWXBW-CLFAGFIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GBGQNKMJZGPTSD-FLJPJEBUSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCOC[C@@H]1CN(C)C[C@H]1COCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCOC[C@@H]1CN(C)C[C@H]1COCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">GBGQNKMJZGPTSD-FLJPJEBUSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SUHZVXMMTSDLJZ-WRBBJXAJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C(=O)CN(C)C)C1</span>
      <span itemprop="inchi_key">SUHZVXMMTSDLJZ-WRBBJXAJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XHVWWVOGKDDJMZ-AUYXYSRISA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(C)C1</span>
      <span itemprop="inchi_key">XHVWWVOGKDDJMZ-AUYXYSRISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VCWSHGFRKRMMMX-WRBBJXAJSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(CCC)C1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CN(CCC)C1</span>
      <span itemprop="inchi_key">VCWSHGFRKRMMMX-WRBBJXAJSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">HBHLPLPHALFAKU-CLFAGFIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CNC1</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCSCC1(CSCCCCCCCC/C=C\CCCCCCCC)CNC1</span>
      <span itemprop="inchi_key">HBHLPLPHALFAKU-CLFAGFIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">XUNFXTTYVIXDIZ-AUYXYSRISA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCCSCCN(C)CCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCCSCCN(C)CCSCCCCCCCC/C=C\CCCCCCCC</span>
      <span itemprop="inchi_key">XUNFXTTYVIXDIZ-AUYXYSRISA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SAPYQCCVWXFBRG-UWDAMKIQSA-N</span>
      <span itemprop="name">CCCCCCCC/C=C\CCCCCCCC[N&#43;](C)(CCCCCCCC/C=C\CCCCCCCC)CCCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCC/C=C\CCCCCCCC[N&#43;](C)(CCCCCCCC/C=C\CCCCCCCC)CCCCCCCC/C=C\CCCCCCCC.[Cl-]</span>
      <span itemprop="inchi_key">SAPYQCCVWXFBRG-UWDAMKIQSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">MKBLJUJPIQUZPC-DSOYXUETSA-N</span>
      <span itemprop="name">CCCCCCCCCCC/C=C\CCCCCOCCN(C)CCOCCCCC/C=C\CCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCC/C=C\CCCCCOCCN(C)CCOCCCCC/C=C\CCCCCCCCCCC</span>
      <span itemprop="inchi_key">MKBLJUJPIQUZPC-DSOYXUETSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VYYPZHBSYFKSII-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">VYYPZHBSYFKSII-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QUCHGXSZSBUXMT-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)CC(=O)CCC(=O)OC1C[N&#43;]2(C)CCC1CC2.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)CC(=O)CCC(=O)OC1C[N&#43;]2(C)CCC1CC2.[Cl-]</span>
      <span itemprop="inchi_key">QUCHGXSZSBUXMT-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GYJBWHZGIRGOOG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)CC(=O)CCC(=O)OCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)CC(=O)CCC(=O)OCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">GYJBWHZGIRGOOG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BOFUSPFAKIEIII-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)CN(C)CCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)CN(C)CCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">BOFUSPFAKIEIII-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QRZKCZPMOUMPGI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">QRZKCZPMOUMPGI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">GIDMBTMIYSECGO-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">GIDMBTMIYSECGO-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">PEJPPAMBKRQKFI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCC(CCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCC(CCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">PEJPPAMBKRQKFI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZLOWCVVDTYFFIY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCC(CCCCCCCCCCCCCC)OC(=O)CCC(C(=O)OCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCC(CCCCCCCCCCCCCC)OC(=O)CCC(C(=O)OCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">ZLOWCVVDTYFFIY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UELLHNLBVKGUMR-UHFFFAOYSA-O</span>
      <span itemprop="name">CCCCCCCCCCCCCCCC(=O)OC.CCCCCCCCCCCCCCNC(=O)OC.CCCCCCCCCCCCCCNC(=O)OCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCC(=O)OC.CCCCCCCCCCCCCCNC(=O)OC.CCCCCCCCCCCCCCNC(=O)OCC[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">UELLHNLBVKGUMR-UHFFFAOYSA-O</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZSNXXMXXKJPQRG-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">ZSNXXMXXKJPQRG-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ODOFAXHTWNJUMN-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">ODOFAXHTWNJUMN-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BIWFIOHYAKQYHR-JKKMMKAFSA-K</span>
      <span itemprop="name">CCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)([O-])OCCN(C)(C)C)OC(=O)CCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)([O-])OCCN(C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCCN(C)(C)C)OCCCCCCCCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)([O-])OCCN(C)(C)C)OC(=O)CCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COP(=O)([O-])OCCN(C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC.CCCCCCCCCCCCCCCCCCOC[C@H](COP(=O)([O-])OCCN(C)(C)C)OCCCCCCCCCCCCCCCCCC</span>
      <span itemprop="inchi_key">BIWFIOHYAKQYHR-JKKMMKAFSA-K</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QLDVQPOTYDRRLA-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCC(CCCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCC(CCCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">QLDVQPOTYDRRLA-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VXTAWVOPOFQVTC-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCC(=O)OCC(CCCCCCCCCCCCCC)(CCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCC(=O)OCC(CCCCCCCCCCCCCC)(CCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">VXTAWVOPOFQVTC-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FFGHOCRLFVIJGZ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">FFGHOCRLFVIJGZ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UVFNYQIQRVLXTQ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">UVFNYQIQRVLXTQ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">OWBXBJOWVIQESP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">OWBXBJOWVIQESP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">SDRPXVDCTOSCGV-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">SDRPXVDCTOSCGV-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">FCAOMWABQXOMRI-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">FCAOMWABQXOMRI-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">ZGNMONIQQLBTMT-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">ZGNMONIQQLBTMT-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">UDGKEMIDIONSRW-GOSXZHBCSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)[C@@H](C(O)C[N&#43;](C)(C)C)C[C@H]1O.CCCCCCCCCCCCCCCCCC=O.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCC(=O)O[C@@H]1[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)[C@@H](C(O)C[N&#43;](C)(C)C)C[C@H]1O.CCCCCCCCCCCCCCCCCC=O.[Cl-]</span>
      <span itemprop="inchi_key">UDGKEMIDIONSRW-GOSXZHBCSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">DGSYLIAGFULHRY-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCC)(COC(=O)CCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">DGSYLIAGFULHRY-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">IZBDQRFRSMTPGP-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCCCC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">IZBDQRFRSMTPGP-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">NLBDJORITLMJRG-UHFFFAOYSA-O</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCCNC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCCNC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">NLBDJORITLMJRG-UHFFFAOYSA-O</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">WELGQKQHQWFABB-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCCCOC(=O)C(CCC(=O)OC(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCCCOC(=O)C(CCC(=O)OC(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">WELGQKQHQWFABB-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QFZUQPKNQANIDK-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCCCOC(=O)C(CCC(=O)OC(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCCCOC(=O)C(CCC(=O)OC(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">QFZUQPKNQANIDK-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">LGDDQRCHUGXNJE-UHFFFAOYSA-O</span>
      <span itemprop="name">CCCCCCCCCCCCCCNC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCNC(=O)OCC(COC(=O)CCCCCCCCCCCCC)(COC(=O)CCCCCCCCCCCCC)C[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">LGDDQRCHUGXNJE-UHFFFAOYSA-O</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JMIGNGARRUCWHJ-UHFFFAOYSA-N</span>
      <span itemprop="name">CCCCCCCCCCCCCCOC(=O)C(CCC(=O)OC(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">CCCCCCCCCCCCCCOC(=O)C(CCC(=O)OC(CCCCCCCCCCCCCC)CCCCCCCCCCCCCC)[N&#43;](C)(C)C.[Cl-]</span>
      <span itemprop="inchi_key">JMIGNGARRUCWHJ-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BJQGYZPBZUUMTH-MRVPVSSYSA-M</span>
      <span itemprop="name">COP(=O)([O-])OC[C@@H](COC(C)=O)OC(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">COP(=O)([O-])OC[C@@H](COC(C)=O)OC(C)=O</span>
      <span itemprop="inchi_key">BJQGYZPBZUUMTH-MRVPVSSYSA-M</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RHNYQTXANOEWDJ-ZHSLIVISSA-N</span>
      <span itemprop="name">OC1C(O)[C@H](O)[C@H](O)C(O)[C@@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@H]1O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">OC1C(O)[C@H](O)[C@H](O)C(O)[C@@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@H]1O.OC1C(O)[C@H](O)[C@H](O)C(O)[C@H]1O</span>
      <span itemprop="inchi_key">RHNYQTXANOEWDJ-ZHSLIVISSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">RZDGJWMWTPDBFL-HJMMCELGSA-N</span>
      <span itemprop="name">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCC)OC[C@H](OC(=O)CCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCC)OC[C@H](OC(=O)CCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCC</span>
      <span itemprop="inchi_key">RZDGJWMWTPDBFL-HJMMCELGSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">VJZGTAVYENCLAE-MSWBOWAZSA-N</span>
      <span itemprop="name">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCCCC)OC[C@H](OC(=O)CCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCCCC)OC[C@H](OC(=O)CCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCC</span>
      <span itemprop="inchi_key">VJZGTAVYENCLAE-MSWBOWAZSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">QSGUTMHJMIOAHC-RKODNJJYSA-N</span>
      <span itemprop="name">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCCCCCC)OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCCCCCC)OC[C@H](OC(=O)CCCCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCCCC</span>
      <span itemprop="inchi_key">QSGUTMHJMIOAHC-RKODNJJYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">BDWUUTOOIWKXJG-WNFOEZSOSA-N</span>
      <span itemprop="name">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC)OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OC(=O)CCCCCCCCCCCCCCCCC)OC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC</span>
      <span itemprop="inchi_key">BDWUUTOOIWKXJG-WNFOEZSOSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">JQTCJDIRHADEHS-KICACRSNSA-N</span>
      <span itemprop="name">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC)OC[C@H](OCCCCCCCC/C=C\C/C=C\CCCCC)[C@H]1OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[Cl-].[H][C@]1([C@@H](C[N&#43;](C)(C)C)OCCCCCCCC/C=C\C/C=C\CCCCC)OC[C@H](OCCCCCCCC/C=C\C/C=C\CCCCC)[C@H]1OCCCCCCCC/C=C\C/C=C\CCCCC</span>
      <span itemprop="inchi_key">JQTCJDIRHADEHS-KICACRSNSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
    <li itemprop="match" itemscope repeat>
      <span itemprop="id">CSCPPACGZOOCGX-UHFFFAOYSA-N</span>
      <span itemprop="name">[H]CC(C)=O</span>
      <span itemprop="domain">Chemical compound</span>
      <span itemprop="svg_large"></span>
      <span itemprop="svg_small"></span>
      <span itemprop="smiles">[H]CC(C)=O</span>
      <span itemprop="inchi_key">CSCPPACGZOOCGX-UHFFFAOYSA-N</span>
      <span itemprop="similarity">0.000</span>
      <span itemprop="sections" repeat>description</span>
      <span itemprop="count">1</span>
    </li>
  </ul>

  <section>
    <h2>Images</h2>
    <ul>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/06/e2/aa/3cab0702c7339a/US20200368173A1-20201126-D00001.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/31/fe/40/fb8b3717aedf6d/US20200368173A1-20201126-D00001.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="1">
            <meta itemprop="label" content="Step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="275">
              <meta itemprop="top" content="1051">
              <meta itemprop="right" content="325">
              <meta itemprop="bottom" content="1100">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="100">
            <meta itemprop="label" content="Grignard reagents">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="46">
              <meta itemprop="top" content="283">
              <meta itemprop="right" content="144">
              <meta itemprop="bottom" content="329">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="100">
            <meta itemprop="label" content="Grignard reagents">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="50">
              <meta itemprop="top" content="1682">
              <meta itemprop="right" content="147">
              <meta itemprop="bottom" content="1725">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="120">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="46">
              <meta itemprop="top" content="147">
              <meta itemprop="right" content="143">
              <meta itemprop="bottom" content="188">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="120">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="50">
              <meta itemprop="top" content="1545">
              <meta itemprop="right" content="146">
              <meta itemprop="bottom" content="1589">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="13">
            <meta itemprop="label" content="Experimental Chemistry">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="298">
              <meta itemprop="top" content="2445">
              <meta itemprop="right" content="366">
              <meta itemprop="bottom" content="2513">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="14">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="588">
              <meta itemprop="top" content="2442">
              <meta itemprop="right" content="660">
              <meta itemprop="bottom" content="2515">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="19">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="879">
              <meta itemprop="top" content="2440">
              <meta itemprop="right" content="952">
              <meta itemprop="bottom" content="2513">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="2">
            <meta itemprop="label" content="step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="486">
              <meta itemprop="top" content="1050">
              <meta itemprop="right" content="535">
              <meta itemprop="bottom" content="1099">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="20">
            <meta itemprop="label" content="Experimental Chemistry">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="78">
              <meta itemprop="top" content="833">
              <meta itemprop="right" content="143">
              <meta itemprop="bottom" content="876">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="20">
            <meta itemprop="label" content="Experimental Chemistry">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="82">
              <meta itemprop="top" content="2228">
              <meta itemprop="right" content="146">
              <meta itemprop="bottom" content="2269">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="20">
            <meta itemprop="label" content="Experimental Chemistry">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1169">
              <meta itemprop="top" content="2440">
              <meta itemprop="right" content="1246">
              <meta itemprop="bottom" content="2517">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="21">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1462">
              <meta itemprop="top" content="2442">
              <meta itemprop="right" content="1536">
              <meta itemprop="bottom" content="2517">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="3">
            <meta itemprop="label" content="Step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="695">
              <meta itemprop="top" content="1050">
              <meta itemprop="right" content="742">
              <meta itemprop="bottom" content="1097">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="40">
            <meta itemprop="label" content="Preparation">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="78">
              <meta itemprop="top" content="694">
              <meta itemprop="right" content="143">
              <meta itemprop="bottom" content="738">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="40">
            <meta itemprop="label" content="Preparation">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="81">
              <meta itemprop="top" content="2090">
              <meta itemprop="right" content="145">
              <meta itemprop="bottom" content="2133">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="60">
            <meta itemprop="label" content="castor oil">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="78">
              <meta itemprop="top" content="558">
              <meta itemprop="right" content="145">
              <meta itemprop="bottom" content="601">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="60">
            <meta itemprop="label" content="castor oil">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="83">
              <meta itemprop="top" content="1955">
              <meta itemprop="right" content="148">
              <meta itemprop="bottom" content="1997">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="7">
            <meta itemprop="label" content="preparation">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="903">
              <meta itemprop="top" content="1050">
              <meta itemprop="right" content="953">
              <meta itemprop="bottom" content="1099">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="8">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1114">
              <meta itemprop="top" content="1050">
              <meta itemprop="right" content="1164">
              <meta itemprop="bottom" content="1099">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="80">
            <meta itemprop="label" content="polysorbate">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="80">
              <meta itemprop="top" content="1815">
              <meta itemprop="right" content="148">
              <meta itemprop="bottom" content="1864">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="80">
            <meta itemprop="label" content="polysorbate">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="77">
              <meta itemprop="top" content="422">
              <meta itemprop="right" content="146">
              <meta itemprop="bottom" content="465">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="0">
            <meta itemprop="id" content="9">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1319">
              <meta itemprop="top" content="1041">
              <meta itemprop="right" content="1380">
              <meta itemprop="bottom" content="1102">
            </span>
          </li>
        </ul>
      </li>
      <li itemprop="images" itemscope repeat>
        <img itemprop="thumbnail" src="https://patentimages.storage.googleapis.com/ff/c5/a2/359072ccb364ff/US20200368173A1-20201126-D00002.png">
        <meta itemprop="full" content="https://patentimages.storage.googleapis.com/06/4e/88/c451dfb2f80fd4/US20200368173A1-20201126-D00002.png">
        <ul>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="100">
            <meta itemprop="label" content="Grignard reagents">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="50">
              <meta itemprop="top" content="385">
              <meta itemprop="right" content="145">
              <meta itemprop="bottom" content="427">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="120">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="50">
              <meta itemprop="top" content="269">
              <meta itemprop="right" content="148">
              <meta itemprop="bottom" content="312">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="140">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="50">
              <meta itemprop="top" content="150">
              <meta itemprop="right" content="145">
              <meta itemprop="bottom" content="194">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="20">
            <meta itemprop="label" content="Experimental Chemistry">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="80">
              <meta itemprop="top" content="854">
              <meta itemprop="right" content="148">
              <meta itemprop="bottom" content="896">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="21">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1462">
              <meta itemprop="top" content="1050">
              <meta itemprop="right" content="1536">
              <meta itemprop="bottom" content="1124">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="37">
            <meta itemprop="label" content="preparations">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="294">
              <meta itemprop="top" content="1048">
              <meta itemprop="right" content="371">
              <meta itemprop="bottom" content="1124">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="38">
            <meta itemprop="label" content="Preparation">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="583">
              <meta itemprop="top" content="1046">
              <meta itemprop="right" content="661">
              <meta itemprop="bottom" content="1124">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="40">
            <meta itemprop="label" content="Preparation">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="80">
              <meta itemprop="top" content="735">
              <meta itemprop="right" content="148">
              <meta itemprop="bottom" content="780">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="43">
            <meta itemprop="label" content="step">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="877">
              <meta itemprop="top" content="1049">
              <meta itemprop="right" content="950">
              <meta itemprop="bottom" content="1122">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="44">
            <meta itemprop="label" content="compound">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="1170">
              <meta itemprop="top" content="1049">
              <meta itemprop="right" content="1242">
              <meta itemprop="bottom" content="1121">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="60">
            <meta itemprop="label" content="castor oil">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="81">
              <meta itemprop="top" content="619">
              <meta itemprop="right" content="147">
              <meta itemprop="bottom" content="662">
            </span>
          </li>
          <li itemprop="callouts" itemscope repeat>
            <meta itemprop="figurePage" content="1">
            <meta itemprop="id" content="80">
            <meta itemprop="label" content="polysorbate">
            <span itemprop="bounds" itemscope>
              <meta itemprop="left" content="81">
              <meta itemprop="top" content="502">
              <meta itemprop="right" content="145">
              <meta itemprop="bottom" content="545">
            </span>
          </li>
        </ul>
      </li>
    </ul>
  </section>

  <section>
    <h2>Classifications</h2>
    <ul>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C333/00</span>&mdash;<span itemprop="Description">Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C333/02</span>&mdash;<span itemprop="Description">Monothiocarbamic acids; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C333/04</span>&mdash;<span itemprop="Description">Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/48</span>&mdash;<span itemprop="Description">Preparations in capsules, e.g. of gelatin, of chocolate</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/50</span>&mdash;<span itemprop="Description">Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/51</span>&mdash;<span itemprop="Description">Nanocapsules; Nanoparticles</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5107</span>&mdash;<span itemprop="Description">Excipients; Inactive ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/5123</span>&mdash;<span itemprop="Description">Organic compounds, e.g. fats, sugars</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="FirstCode" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/00</span>&mdash;<span itemprop="Description">Medicinal preparations containing organic active ingredients</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/70</span>&mdash;<span itemprop="Description">Carbohydrates; Sugars; Derivatives thereof</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/7088</span>&mdash;<span itemprop="Description">Compounds having three or more nucleosides or nucleotides</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K31/713</span>&mdash;<span itemprop="Description">Double-stranded nucleic acids or oligonucleotides</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/08</span>&mdash;<span itemprop="Description">Solutions</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/10</span>&mdash;<span itemprop="Description">Dispersions; Emulsions</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/127</span>&mdash;<span itemprop="Description">Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K</span>&mdash;<span itemprop="Description">PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/00</span>&mdash;<span itemprop="Description">Medicinal preparations characterised by special physical form</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/10</span>&mdash;<span itemprop="Description">Dispersions; Emulsions</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/127</span>&mdash;<span itemprop="Description">Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1271</span>&mdash;<span itemprop="Description">Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61K9/1272</span>&mdash;<span itemprop="Description">Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P29/00</span>&mdash;<span itemprop="Description">Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A</span>&mdash;<span itemprop="Description">HUMAN NECESSITIES</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61</span>&mdash;<span itemprop="Description">MEDICAL OR VETERINARY SCIENCE; HYGIENE</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P</span>&mdash;<span itemprop="Description">SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">A61P35/00</span>&mdash;<span itemprop="Description">Antineoplastic agents</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/00</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/23</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/24</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/25</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/00</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/23</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/39</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/40</span>&mdash;<span itemprop="Description">Y being a hydrogen or a carbon atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/41</span>&mdash;<span itemprop="Description">Y being a hydrogen or an acyclic carbon atom</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C</span>&mdash;<span itemprop="Description">ACYCLIC OR CARBOCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/00</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/23</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/46</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07C323/49</span>&mdash;<span itemprop="Description">Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having at least one of the nitrogen atoms, not being part of nitro or nitroso groups, further bound to other hetero atoms to sulfur atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D205/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D205/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D205/04</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/04</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/04</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/08</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/02</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/04</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/10</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D207/12</span>&mdash;<span itemprop="Description">Oxygen or sulfur atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D211/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D211/04</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D211/06</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D211/08</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D211/18</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D211/20</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D211/22</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07</span>&mdash;<span itemprop="Description">ORGANIC CHEMISTRY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D</span>&mdash;<span itemprop="Description">HETEROCYCLIC COMPOUNDS</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D317/00</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D317/08</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D317/10</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D317/14</span>&mdash;<span itemprop="Description">Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C07D317/28</span>&mdash;<span itemprop="Description">Radicals substituted by nitrogen atoms</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/00</span>&mdash;<span itemprop="Description">Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/09</span>&mdash;<span itemprop="Description">Recombinant DNA-technology</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/11</span>&mdash;<span itemprop="Description">DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/113</span>&mdash;<span itemprop="Description">Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/00</span>&mdash;<span itemprop="Description">Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/09</span>&mdash;<span itemprop="Description">Recombinant DNA-technology</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/87</span>&mdash;<span itemprop="Description">Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N15/88</span>&mdash;<span itemprop="Description">Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
      <li>
        <ul itemprop="classifications" itemscope repeat>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C</span>&mdash;<span itemprop="Description">CHEMISTRY; METALLURGY</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12</span>&mdash;<span itemprop="Description">BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N</span>&mdash;<span itemprop="Description">MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/00</span>&mdash;<span itemprop="Description">Structure or type of the nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/10</span>&mdash;<span itemprop="Description">Type of nucleic acid</span>
            <meta itemprop="IsCPC" content="true">
          </li>
          <li itemprop="classifications" itemscope repeat>
            <span itemprop="Code">C12N2310/14</span>&mdash;<span itemprop="Description">Type of nucleic acid interfering nucleic acids [NA]</span>
            <meta itemprop="Leaf" content="true"><meta itemprop="Additional" content="true"><meta itemprop="IsCPC" content="true">
          </li>
        </ul>
      </li>
    </ul>
  </section>

  

  

  <section>
    <h2>Definitions</h2>
    <ul>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to a nucleic acid-containing lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0001">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acids</span>
        <span itemprop="definition">such as plasmid DNA (pDNA), antisense oligodeoxynucleic acid (ODN) and short interfering RNA (siRNA) to target cells in vivo.</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">pDNA</span>
        <span itemprop="definition">plasmid DNA</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">ODN</span>
        <span itemprop="definition">antisense oligodeoxynucleic acid</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">siRNA</span>
        <span itemprop="definition">short interfering RNA</span>
        <meta itemprop="num_attr" content="0002">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Patent Literature 1 and Non Patent Literature 1</span>
        <span itemprop="definition">have reported, as a method for producing a liposome containing a nucleic acid or the like, for example, a method for producing a liposome containing siRNA by dissolving a dried cationic lipid, an aqueous sodium citrate solution of siRNA and a neutral lipid, and a polyethylene glycolated phospholipid in HEPES [N-(2-hydroxyethyl)piperazine-N-(2-ethanesulfonic acid)] buffered saline (hereinafter, referred to as HBS) and ethanol, adding the resulting solution to diethyl ether to form a water-in-oil (W/O) emulsion, then mixing the solution, and treating the solution by a reverse-phase evaporation method.</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">HBS</span>
        <span itemprop="definition">HEPES [N-(2-hydroxyethyl)piperazine-N-(2-ethanesulfonic acid)] buffered saline</span>
        <meta itemprop="num_attr" content="0003">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Patent Literature 2 and Non Patent Literature 2</span>
        <span itemprop="definition">have reported a method for producing a liposome containing ODN by dissolving ODN in an aqueous citric acid solution of pH 3.8, adding a solution of a lipid in ethanol to the solution, decreasing the ethanol concentration to 20 v/v % to prepare a liposome containing ODN, filtering the solution through a sizing membrane, removing an excess of ethanol by dialysis, and then further dialyzing the sample at pH 7.5 to remove ODN attached to the liposome surface.</span>
        <meta itemprop="num_attr" content="0004">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Patent Literature 3</span>
        <span itemprop="definition">has reported, for example, a method for producing a liposome containing pDNA by mixing a solution containing pDNA dissolved in an aqueous citric acid solution with a solution containing a lipid dissolved in ethanol using a T-shaped mixer, decreasing the ethanol concentration to 45 v/v %, then further adding thereto a citrate buffer solution so that the ethanol concentration is decreased to 20 v/v % to prepare a liposome containing pDNA, removing residual pDNA through an anion-exchange resin, and removing an excess of ethanol by ultrafiltration.</span>
        <meta itemprop="num_attr" content="0005">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Patent Literature 4</span>
        <span itemprop="definition">has reported a method for producing a liposome containing pDNA by complexing pDNA with a cationic lipid as micelle in an organic solvent containing water, further adding a lipid thereto, and then removing the organic solvent by dialysis.</span>
        <meta itemprop="num_attr" content="0006">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Patent Literature 5</span>
        <span itemprop="definition">has reported a method for producing a liposome containing pDNA by complexing pDNA with a cationic lipid as micelle in an aqueous solution of a surfactant, further adding a lipid thereto, and then removing the surfactant by dialysis.</span>
        <meta itemprop="num_attr" content="0007">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Non Patent Literature 3</span>
        <span itemprop="definition">has reported that in a test using lipid nanoparticles containing doxorubicin, the contents are efficiently released by hydrolyzing an ester bond at position sn-2 of phospholipid with phospholipase A2 (hereinafter, also referred to as PLA2).</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PPA2</span>
        <span itemprop="definition">phospholipase A2</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the drug</span>
        <span itemprop="definition">is a low-molecular drug, the reduced stability of the particles facilitates smoothly releasing the drug so that the drug exhibits activity.</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Nanoparticles containing the nucleic acid mentioned above</span>
        <span itemprop="definition">generally employ a lipid served as a substrate of PLA2. Thus, it has been difficult to prepare a lipid particle having high stability.</span>
        <meta itemprop="num_attr" content="0008">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Patent Literature 6</span>
        <span itemprop="definition">discloses that 1,2-di-O-hexadecyl-sn-glycero-3-phosphocholine is used in a composition for the oral administration and transport of bioactive drugs, and states that such a composition is stable against acids. However, the literature does not state that this composition was used for nucleic acid transport.</span>
        <meta itemprop="num_attr" content="0009">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">An object of the present invention</span>
        <span itemprop="definition">is to provide a nucleic acid-containing lipid nanoparticle that is useful as a medicament and is more stable than conventional particles.</span>
        <meta itemprop="num_attr" content="0018">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">relates to the following:</span>
        <meta itemprop="num_attr" content="0019">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">comprising</span>
        <meta itemprop="num_attr" content="0020">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">according to [1] or [2], wherein the lipase is phospholipase A2.</span>
        <meta itemprop="num_attr" content="0024">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">according to any one of [1] to [3], wherein the analog of the fatty acid ester of glycerol is a lipid represented by the following formula (1) or (2):</span>
        <meta itemprop="num_attr" content="0025">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 1 and Rx 2</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl;</span>
        <meta itemprop="num_attr" content="0026">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 3</span>
        <span itemprop="definition">is a negative charge, a hydrogen atom, or any of the following groups:</span>
        <meta itemprop="num_attr" content="0027">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 4</span>
        <span itemprop="definition">is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl or Rx 41 -CO;</span>
        <meta itemprop="num_attr" content="0028">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 41</span>
        <span itemprop="definition">is optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl;</span>
        <meta itemprop="num_attr" content="0029">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 5</span>
        <span itemprop="definition">is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0030">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 6</span>
        <span itemprop="definition">is a negative charge, a hydrogen atom, or any of the following groups:</span>
        <meta itemprop="num_attr" content="0031">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">according to any one of [1] to [4], wherein a content of the analog of the fatty acid ester of glycerol is 0.001-fold molar amount or more with respect to the molar number of total lipid.</span>
        <meta itemprop="num_attr" content="0032">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">according to any one of [1] to [5], further comprising a cationic lipid.</span>
        <meta itemprop="num_attr" content="0033">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">wherein the cationic lipid is lipid A represented by at least one of formulas (I), (II), (III), (IV), (V) and (V) given below, and/or lipid B represented by at least one of formulas (CL-I), (CL-II), (CL-III), (CL-IV), (CL-V), (CL-VI), (CL-VII), (CL-VIII), (CL-IX), (CL-X), (CL-XI), (CL-XII), (CL-XIII), (CL-XIV), (CL-XV), (CL-XVI), (CL-XVII), (CL-XVIII) and (CL-XIX) given below (wherein the formulas (I), (II), (III), (IV), (V) and (V) are represented by structures described in Description of Embodiments mentioned later, and the formulas (CL-I), (CL-II), (CL-III), (V) are represented</span>
        <meta itemprop="num_attr" content="0034">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">according to any one of [1] to [8], further comprising a lipid derivative or a fatty acid derivative of a water-soluble polymer.</span>
        <meta itemprop="num_attr" content="0036">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">wherein the water-soluble polymer moiety of the lipid derivative or the fatty acid derivative of the water-soluble polymer is selected from the group consisting of polyethylene glycol, polyglycerin, polyethyleneimine, polyvinyl alcohol, polyacrylic acid and polyacrylamide.</span>
        <meta itemprop="num_attr" content="0037">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">according to any one of [1] to [10], further comprising a neutral lipid.</span>
        <meta itemprop="num_attr" content="0038">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">according to [11], wherein the neutral lipid is selected from the group consisting of phospholipid, sterol, glyceroglycolipid, sphingoglycolipid and sphingoid.</span>
        <meta itemprop="num_attr" content="0039">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">RNAi</span>
        <span itemprop="definition">RNA interference</span>
        <meta itemprop="num_attr" content="0040">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">according to [13], wherein the target gene is a gene related to tumor or inflammation.</span>
        <meta itemprop="num_attr" content="0041">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method for stabilizing a nucleic acid-containing lipid nanoparticle using an analog of a fatty acid ester of glycerol, wherein the analog is not hydrolyzable by a lipase</span>
        <span itemprop="definition">may be the analog referred in any of [1] to [5]</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">may be the nucleic acid-containing lipid nanoparticle according to any of [1] to [14].</span>
        <meta itemprop="num_attr" content="0042">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method for the introduction into the cell</span>
        <span itemprop="definition">is a method of introduction into the cell by intravenous administration or subcutaneous administration.</span>
        <meta itemprop="num_attr" content="0046">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a method for treating a cancer or an inflammatory disease</span>
        <span itemprop="definition">comprising administering the nucleic acid-containing lipid nanoparticle according to any one of [1] to [14] to a mammal.</span>
        <meta itemprop="num_attr" content="0047">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a medicament</span>
        <span itemprop="definition">comprising the nucleic acid-containing lipid nanoparticle according to any one of [1] to [14].</span>
        <meta itemprop="num_attr" content="0049">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a therapeutic agent for a cancer or an inflammatory disease</span>
        <span itemprop="definition">comprising the nucleic acid-containing lipid nanoparticle according to any one of [1] to [14].</span>
        <meta itemprop="num_attr" content="0051">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 137 and R 138</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, C8-24 alkenylthioethyl, or C8-C24 alkynylthioethyl; and</span>
        <meta itemprop="num_attr" content="0054">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 135</span>
        <span itemprop="definition">is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (C):</span>
        <meta itemprop="num_attr" content="0055">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 136 and X 137</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X 136 and X 137 optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 132</span>
        <span itemprop="definition">is S or O; and</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 115</span>
        <span itemprop="definition">is an integer from 2 to 4, formula (D):</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 138 and X 139</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X 138 and X 139 optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p 116 is an integer from 1 to 4, or formula (E):</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 140 and X 141</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X 140 and X 141 optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p 117 is an integer from 1 to 4.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 139 and R 140</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0057">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 133</span>
        <span itemprop="definition">is S or O</span>
        <meta itemprop="num_attr" content="0058">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 142</span>
        <span itemprop="definition">is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (F):</span>
        <meta itemprop="num_attr" content="0059">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 143 and X 144</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X 143 and X 144 optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 134</span>
        <span itemprop="definition">is S or O; and</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 118</span>
        <span itemprop="definition">is an integer from 2 to 4, or formula (G):</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 145 and X 146</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X 145 and X 146 optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p 119 is an integer from 1 to 4.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the present invention</span>
        <span itemprop="definition">can provide a nucleic acid-containing lipid nanoparticle that is useful as a medicament and is more stable than conventional particles.</span>
        <meta itemprop="num_attr" content="0060">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 1</span>
        <span itemprop="definition">shows a graph showing the amount of lipids remaining in each preparation.</span>
        <meta itemprop="num_attr" content="0061">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ordinate of the graph</span>
        <span itemprop="definition">depicts the amount of lipids remaining (%) with that in a PLA2-untreated group defined as 1.</span>
        <meta itemprop="num_attr" content="0061">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the abscissa</span>
        <span itemprop="definition">depicts each preparation.</span>
        <meta itemprop="num_attr" content="0061">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 2</span>
        <span itemprop="definition">shows a graph showing the amount of lipids remaining in each preparation.</span>
        <meta itemprop="num_attr" content="0062">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ordinate of the graph</span>
        <span itemprop="definition">depicts the amount of lipids remaining (%) with that in a PLA2-untreated group defined as 1.</span>
        <meta itemprop="num_attr" content="0062">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the abscissa</span>
        <span itemprop="definition">depicts each preparation.</span>
        <meta itemprop="num_attr" content="0062">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">FIG. 3</span>
        <span itemprop="definition">shows a graph showing the amount of lipids remaining in each preparation.</span>
        <meta itemprop="num_attr" content="0063">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the ordinate of the graph</span>
        <span itemprop="definition">depicts the amount of lipids remaining (%) with that in a PLA2-untreated group defined as 1.</span>
        <meta itemprop="num_attr" content="0063">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the abscissa</span>
        <span itemprop="definition">depicts each preparation.</span>
        <meta itemprop="num_attr" content="0063">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-containing lipid nanoparticle of the present invention</span>
        <span itemprop="definition">comprises an analog of a fatty acid ester of glycerol, and a nucleic acid.</span>
        <meta itemprop="num_attr" content="0065">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the analog</span>
        <span itemprop="definition">is not hydrolyzable by a lipase.</span>
        <meta itemprop="num_attr" content="0065">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-containing lipid nanoparticle of the present invention</span>
        <span itemprop="definition">can be stably present even if contacted with a lipase, because the lipid in the particle resists degradation.</span>
        <meta itemprop="num_attr" content="0066">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a lipid having a fatty acid ester structure of glycerol</span>
        <span itemprop="definition">(hereinafter, also referred to as a natural glycerol lipid)</span>
        <meta itemprop="num_attr" content="0067">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">at least one hydroxy group of glycerol, and a fatty acid</span>
        <span itemprop="definition">form an ester bond. This ester bond is hydrolyzed by the action of a lipase.</span>
        <meta itemprop="num_attr" content="0067">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the analog of the fatty acid ester of glycerol according to the present invention</span>
        <span itemprop="definition">is a lipid having a structure modified from a partial structure in the natural glycerol lipid, and is not hydrolyzable by a lipase.</span>
        <meta itemprop="num_attr" content="0068">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the phrase not hydrolyzable by a lipase</span>
        <span itemprop="definition">means that when the nucleic acid-containing lipid nanoparticle of the present invention is contacted with a lipase, usually 30% or more, preferably 50% or more, more preferably 70% or more, further preferably 90% or more, still further preferably 99% or more, is not degraded with respect to the total amount of the analog of the fatty acid ester of glycerol present in the nucleic acid-containing lipid nanoparticle.</span>
        <meta itemprop="num_attr" content="0069">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the bringing into contact the analog with the lipase</span>
        <span itemprop="definition">is performed under conditions of usually 30 to 45 C., preferably 35 to 42 C., more preferably 37 C., and usually 0 minutes to 48 hours, preferably 1 minute to 36 hours, more preferably 1 minute to 24 hours.</span>
        <meta itemprop="num_attr" content="0070">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the analog of the fatty acid ester of glycerol according to the present invention</span>
        <span itemprop="definition">is preferably structurally modified in the range of preferably 10 angstroms (angstrom: 10   10 m) or less, more preferably 8 angstroms or less, further preferably 6 angstroms or less, from the carbon atom at position sn-2 of a glycerol skeleton in a natural glycerol lipid represented by formula (NL1) given below.</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the structural modification</span>
        <span itemprop="definition">is in the range of 10 angstroms or less from the carbon atom at position sn-2, the nucleic acid-containing lipid nanoparticle tends to resist the hydrolytic effect of a lipase and is thus stabilized.</span>
        <meta itemprop="num_attr" content="0071">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lower limit value of the structural modification range</span>
        <span itemprop="definition">is not particularly limited as long as the lower limit value is 0 angstroms or more.</span>
        <meta itemprop="num_attr" content="0072">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the range of 0 angstroms from the carbon atom at position sn-2</span>
        <span itemprop="definition">refers to the carbon atom at position sn-2.</span>
        <meta itemprop="num_attr" content="0072">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the structural modification</span>
        <span itemprop="definition">means that a structure near the glycerol skeleton of the natural glycerol lipid is changed, and is not particularly limited as long as the structural modification reduces interaction with an active site of a lipase.</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">include: the inversion of the asymmetric center of the natural glycerol lipid, i.e., the conversion of an L form to a D form; the replacement of the ester bond between the glycerol skeleton and the fatty acid with a bond such as an ether bond (O), a thioether bond (S), an amino bond (N(R p ) (wherein R p is a hydrogen atom or an organic group) or an amide bond (NHCO); the replacement of hydrogen at any one or more of positions sn-1, sn-2 and sn-3 with an organic group; and the introduction of an organic group to position   ,   ,    or    of an acyl group mentioned later.</span>
        <meta itemprop="num_attr" content="0073">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the organic group</span>
        <span itemprop="definition">examples include hydroxy, alkoxy, alkoxycarbonyl, nitro, cyano, fluoro, chloro and bromo.</span>
        <meta itemprop="num_attr" content="0074">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl moiety in alkoxy and alkoxycarbonyl</span>
        <span itemprop="definition">is a C1-C4 alkyl such as methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl or cyclopropylmethyl.</span>
        <meta itemprop="num_attr" content="0074">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a and b</span>
        <span itemprop="definition">are each independently an acyl group given below, and c is an acyl group, a phosphoric acid group, a sugar or the like.</span>
        <meta itemprop="num_attr" content="0075">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a and c</span>
        <span itemprop="definition">are acyl groups, these acyl groups differ in the number of carbon atoms, structure, etc. and are not the same.</span>
        <meta itemprop="num_attr" content="0075">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rxx in the acyl group</span>
        <span itemprop="definition">include optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl and C7-C23 alkynyl.</span>
        <meta itemprop="num_attr" content="0076">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the analog of the fatty acid ester of glycerol according to the present invention</span>
        <span itemprop="definition">i.e., the analog of the natural glycerol lipid represented by formula (NL1), is preferably a glycerophospholipid analog.</span>
        <meta itemprop="num_attr" content="0077">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the glycerophospholipid</span>
        <span itemprop="definition">can be represented by, for example, the following formula (NL2), and the glycerophospholipid analog is a structurally modified form of the lipid represented by the following formula (NL2):</span>
        <meta itemprop="num_attr" content="0078">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rxx 1 and Rxx 2</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl.</span>
        <meta itemprop="num_attr" content="0079">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rxx 3</span>
        <span itemprop="definition">include a hydrogen atom, and the following groups:</span>
        <meta itemprop="num_attr" content="0079">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the linear or branched C7-C23 alkyl in formulas (NL1) and (NL2)</span>
        <span itemprop="definition">include heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl.</span>
        <meta itemprop="num_attr" content="0080">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C7-C23 alkenyl in formulas (NL1) and (NL2)</span>
        <span itemprop="definition">can be linear or branched C7-C23 alkenyl containing one to three double bonds.</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dieny</span>
        <meta itemprop="num_attr" content="0081">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C7-C23 alkynyl in formulas (NL1) and (NL2)</span>
        <span itemprop="definition">can be linear or branched C8-24 alkynyl containing one to three triple bonds.</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptade</span>
        <meta itemprop="num_attr" content="0082">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the substituent for the optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl in formulas (NL1) and (NL2)</span>
        <span itemprop="definition">include hydroxy, alkoxy, alkoxycarbonyl, nitro, cyano, fluoro, chloro and bromo.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl moiety in alkoxy and alkoxycarbonyl</span>
        <span itemprop="definition">is C1-C4 alkyl such as methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl or cyclopropylmethyl.</span>
        <meta itemprop="num_attr" content="0083">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the glycerophospholipid represented by formula (NL2)</span>
        <span itemprop="definition">include, but are not limited to, natural or synthetic phospholipids such as phosphatidylcholines (PCs) (specifically, soybean phosphatidylcholine, egg phosphatidylcholine (EPC), distearoyl phosphatidylcholine, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), dipalmitoyl phosphatidylcholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), palmitoyl oleoyl phosphatidylcholine (POPC), dimyristoyl phosphatidylcholine (DMPC), dioleoyl phosphatidylcholine (DOPC), etc.), phosphatidylethanolamines (specifically distearoyl phosphatidylethanolamine (DSPE), dipalmitoyl phosphatidylethanol</span>
        <meta itemprop="num_attr" content="0084">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipase according to the present invention</span>
        <span itemprop="definition">is not particularly limited as long as the enzyme hydrolyzes the fatty acid ester contained in the natural glycerol lipid represented by formula (NL1).</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the lipase</span>
        <span itemprop="definition">include phospholipase.</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the phospholipase</span>
        <span itemprop="definition">specifically include phospholipase A1, phospholipase A2, phospholipase B, lysophospholipase, phospholipase C and phospholipase D.</span>
        <meta itemprop="num_attr" content="0085">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the analog of the fatty acid ester of glycerol according to the present invention</span>
        <span itemprop="definition">is preferably an analog of a fatty acid ester of glycerol, and the analog is not hydrolyzable by phospholipase A2.</span>
        <meta itemprop="num_attr" content="0086">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the glycerophospholipid analog</span>
        <span itemprop="definition">has a structure modified from a partial structure of the glycerophospholipid represented by formula (NL2) described above.</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the glycerophospholipid analog</span>
        <span itemprop="definition">is preferably a lipid represented by the following formula (1) or (2):</span>
        <meta itemprop="num_attr" content="0087">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 1 and Rx 2</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl;</span>
        <meta itemprop="num_attr" content="0089">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 3</span>
        <span itemprop="definition">is a negative charge, a hydrogen atom, or any of the following groups:</span>
        <meta itemprop="num_attr" content="0090">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 4</span>
        <span itemprop="definition">is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl or Rx 41 -CO;</span>
        <meta itemprop="num_attr" content="0092">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 41</span>
        <span itemprop="definition">is optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl;</span>
        <meta itemprop="num_attr" content="0093">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 5</span>
        <span itemprop="definition">is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0094">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 6</span>
        <span itemprop="definition">is a negative charge, a hydrogen atom, or any of the following groups:</span>
        <meta itemprop="num_attr" content="0095">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the linear or branched C7-C23 alkyl, C1-C23 alkenyl and C7-C23 alkenyl in formulas (1) and (2)</span>
        <span itemprop="definition">can include the same as those listed about C7-C23 alkyl, C7-C23 alkenyl and C7-C23 alkenyl in formula (NL2).</span>
        <meta itemprop="num_attr" content="0096">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">linear or branched C8-C24 alkyl</span>
        <span itemprop="definition">examples include heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl.</span>
        <meta itemprop="num_attr" content="0097">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C8-C24 alkenyl</span>
        <span itemprop="definition">can be linear or branched C8-24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octade</span>
        <meta itemprop="num_attr" content="0098">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C8-C24 alkynyl</span>
        <span itemprop="definition">can be linear or branched C8-24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-ynyl and oct</span>
        <meta itemprop="num_attr" content="0099">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the substituent for the optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C7-C23 alkyl, C7-C23 alkenyl and C7-C23 alkynyl in formulas (1) and (2)</span>
        <span itemprop="definition">include hydroxy, alkoxy, alkoxycarbonyl, nitro, cyano, fluoro, chloro and bromo.</span>
        <meta itemprop="num_attr" content="0100">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in alkoxy and alkoxycarbonyl</span>
        <span itemprop="definition">is C1-C4 alkyl such as methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl or cyclopropylmethyl.</span>
        <meta itemprop="num_attr" content="0100">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the analog of the fatty acid ester of glycerol according to the present invention</span>
        <span itemprop="definition">may be a salt.</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the salt</span>
        <span itemprop="definition">is not particularly limited as long as the salt is pharmaceutically acceptable.</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of Rx 3 and Rx 6 in formulas (1) and (2)</span>
        <span itemprop="definition">is a hydrogen atom,</span>
        <meta itemprop="num_attr" content="0101">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a salt of an alkali metal such as sodium or potassium, or ammonium salt</span>
        <span itemprop="definition">is preferred.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each of Rx 3 and Rx 6</span>
        <span itemprop="definition">may be a negative charge.</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the negative charge represented by Rx 3 or Rx 6</span>
        <span itemprop="definition">means that hydrogen corresponding to Rx 3 or Rx 6 is deprotonated.</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the negative charge</span>
        <span itemprop="definition">means that a phosphoric acid ester group in formulas (1) and (2) may be PO 4 2 .</span>
        <meta itemprop="num_attr" content="0102">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by formula (2)</span>
        <span itemprop="definition">may be a single substance of any one optical isomer as to asymmetric carbon having a configuration that is not shown herein, or may be a mixture containing such optical isomers at an arbitrary ratio.</span>
        <meta itemprop="num_attr" content="0103">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an inositol skeleton in Rxx 3 , Rx 3 and Rx 6 in formula (NL2) and formulas (1) and (2)</span>
        <span itemprop="definition">is derived from any inositol given below.</span>
        <meta itemprop="num_attr" content="0104">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a hydroxy group to form a bond to phosphoric acid</span>
        <span itemprop="definition">is not particularly limited.</span>
        <meta itemprop="num_attr" content="0104">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the inositol skeleton</span>
        <span itemprop="definition">is preferably represented by the following formula:</span>
        <meta itemprop="num_attr" content="0105">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C7-C23 alkyl, the C7-C23 alkenyl, the C7-C23 alkynyl, the C8-C24 alkyl, the C8-C24 alkenyl and the C8-C24 alkynyl in formulas (1) and (2)</span>
        <span itemprop="definition">can include the same as those listed about their respective groups in formulas (NL1) and (NL2).</span>
        <meta itemprop="num_attr" content="0106">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Preferred examples thereof</span>
        <span itemprop="definition">can include the same as those listed about the respective groups in formulas (NL1) and (NL2).</span>
        <meta itemprop="num_attr" content="0106">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the analog of the fatty acid ester of glycerol in the nucleic acid-containing nanoparticle of the present invention</span>
        <span itemprop="definition">can specifically include the following compounds:</span>
        <meta itemprop="num_attr" content="0108">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the analog of the fatty acid ester of glycerol according to the present invention</span>
        <span itemprop="definition">may be a commercially available product or may be synthesized by use of an organic synthesis approach.</span>
        <meta itemprop="num_attr" content="0109">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by formula (1)</span>
        <span itemprop="definition">can be produced, for example, as follows, though the production method is not particularly limited.</span>
        <meta itemprop="num_attr" content="0110">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 1 , Rx 2 and Rx 3</span>
        <span itemprop="definition">are as defined in Rx 1 , Rx 2 and Rx 3 in formula (1).</span>
        <meta itemprop="num_attr" content="0111">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diol X3</span>
        <span itemprop="definition">may be obtained as a commercially available product such as (S)-3-(benzyloxy)propane-1,2-diol. Subsequently, diol X3 is reacted with an acid chloride represented by Rx 1 -COCl, Rx 2 -COCl or the like to obtain compound X4.</span>
        <meta itemprop="num_attr" content="0112">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the protective group (PG group)</span>
        <span itemprop="definition">is removed, and the resulting hydroxy group can be reacted with phosphorus(V) oxychloride in the presence of a base such as triethylamine and further reacted with a compound represented by Rx 3 -OH to obtain the lipid represented by formula (1).</span>
        <meta itemprop="num_attr" content="0112">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction for the conversion of diol X3 to compound X4</span>
        <span itemprop="definition">may be performed by protecting any of a primary alcohol and a secondary alcohol with a protective group.</span>
        <meta itemprop="num_attr" content="0113">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the protective group for use in the synthesis of the lipid represented by formula (1)</span>
        <span itemprop="definition">can be selected on the basis of reaction conditions or a substrate with reference to, for example, Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999).</span>
        <meta itemprop="num_attr" content="0114">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by formula (2)</span>
        <span itemprop="definition">can be produced, for example, as follows, though the production method is not particularly limited.</span>
        <meta itemprop="num_attr" content="0115">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 0</span>
        <span itemprop="definition">represents optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl</span>
        <meta itemprop="num_attr" content="0116">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X</span>
        <span itemprop="definition">represents a halogen atom such as chlorine, bromine or iodine, OMs, or OTs</span>
        <meta itemprop="num_attr" content="0116">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Rx 4 , Rx 5 , Rx 6 and Rx 41</span>
        <span itemprop="definition">are as defined in Rx 4 , Rx 5 , Rx 6 and Rx 41 in formula (2).</span>
        <meta itemprop="num_attr" content="0116">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a hydroxy group of acetal X6 known in the art which is obtained from a sugar such as mannitol</span>
        <span itemprop="definition">is protected with a protective group (PG group), and an isopropylidene group is hydrolyzed to prepare diol X8.</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diol X8</span>
        <span itemprop="definition">can be reacted with an electrophile represented by, for example, Rx 0 -CH 2 X (reaction conditions of Williamson etherification can be referred to and applied thereto) to obtain diether X9.</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">diol X8</span>
        <span itemprop="definition">can be reacted with an acid chloride represented by Rx 42 -COCl or the like and subsequently reacted with an electrophile represented by RX 0 CH 2 X to obtain compound X9.</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the protective group (PG group)</span>
        <span itemprop="definition">is removed, and the resulting hydroxy group can be reacted with phosphorus(V) oxychloride in the presence of a base such as triethylamine and further reacted with a compound represented by Rx 3 -OH to obtain the lipid represented by formula (2).</span>
        <meta itemprop="num_attr" content="0117">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the reaction for the conversion of diol X3 to compound X4</span>
        <span itemprop="definition">may be performed by protecting any of a primary alcohol and a secondary alcohol with a protective group.</span>
        <meta itemprop="num_attr" content="0118">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the protective group for use in the synthesis of the lipid represented by formula (2)</span>
        <span itemprop="definition">can be selected on the basis of reaction conditions or a substrate with reference to, for example, Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999).</span>
        <meta itemprop="num_attr" content="0119">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-containing lipid nanoparticle of the present invention</span>
        <span itemprop="definition">preferably further comprises a cationic lipid.</span>
        <meta itemprop="num_attr" content="0120">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid</span>
        <span itemprop="definition">is not particularly limited as long as the cationic lipid is an amphipathic molecule having a lipophilic region containing one or more optionally substituted hydrocarbon groups, and a cationic hydrophilic region containing at least one primary amino group, secondary amino group, tertiary amino group and/or quaternary ammonium group.</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">can include a lipid having a hydrophilic unit having one quaternary ammonium group and optionally substituted three independent hydrocarbon groups (lipid A), and a lipid having a hydrophilic unit having optionally substituted one amino group or one quaternary ammonium group and a hydrophobic unit having optionally substituted two independent hydrocarbon groups (lipid B).</span>
        <meta itemprop="num_attr" content="0121">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">is prepared using the lipid having a hydrophilic unit having one quaternary ammonium group and optionally substituted three independent hydrocarbon groups (lipid A) with a lipid derivative or a fatty acid derivative of a water-soluble polymer, and a nucleic acid.</span>
        <meta itemprop="num_attr" content="0122">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid A</span>
        <span itemprop="definition">three independent hydrocarbon groups</span>
        <meta itemprop="num_attr" content="0122">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the obtained nucleic acid-containing lipid nanoparticle</span>
        <span itemprop="definition">can have much better physicochemical stability and physiological activity.</span>
        <meta itemprop="num_attr" content="0122">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid having a hydrophilic unit having one quaternary ammonium group and optionally substituted three independent hydrocarbon groups</span>
        <span itemprop="definition">is not particularly limited as long as the lipid is a molecule intramolecularly having one quaternary ammonium group as a hydrophilic unit and having optionally substituted three independent hydrocarbon groups.</span>
        <meta itemprop="num_attr" content="0123">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid A</span>
        <span itemprop="definition">is represented by, for example, any of structural formulas (A) to (C) given below.</span>
        <meta itemprop="num_attr" content="0123">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrophilic unit</span>
        <span itemprop="definition">represents a hydrophilic unit having one quaternary ammonium group</span>
        <meta itemprop="num_attr" content="0123">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the three hydrophobic units</span>
        <span itemprop="definition">represent optionally substituted three independent hydrocarbon groups.</span>
        <meta itemprop="num_attr" content="0123">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the optionally substituted chain and/or cyclic hydrocarbon group constituting the hydrophilic unit</span>
        <span itemprop="definition">can be any group composed of carbon and hydrogen atoms and is preferably a group having 1 to 10 carbon atoms, more preferably a group having 1 to 6 carbon atoms, further preferably a group having 1 to 3 carbon atoms.</span>
        <meta itemprop="num_attr" content="0124">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrophilic unit</span>
        <span itemprop="definition">may have one or more ethers, esters, amides or the like via a carbon atom in the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting this hydrophilic unit. Examples of the substituent for the optionally substituted chain and/or cyclic hydrocarbon group, etc.</span>
        <meta itemprop="num_attr" content="0125">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">carbamate</span>
        <span itemprop="definition">include carbamate, amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro, and bromo.</span>
        <meta itemprop="num_attr" content="0125">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrocarbon group constituting the hydrophobic unit</span>
        <span itemprop="definition">can be any group consisting of 8 to 24 carbon atoms and hydrogen atoms.</span>
        <meta itemprop="num_attr" content="0126">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hydrocarbon groups</span>
        <span itemprop="definition">can be classified from the viewpoint of topology. Examples thereof include linear hydrocarbon groups, branched hydrocarbon groups and cyclic hydrocarbon groups (e.g., a cholesteryl group). A linear or branched hydrocarbon group is preferred. Also, hydrocarbon groups can be classified on the basis of the presence or absence of an unsaturated bond (double bond or triple bond). Hydrocarbon groups having an unsaturated bond can also be classified on the basis of the presence or absence of aromaticity.</span>
        <meta itemprop="num_attr" content="0126">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a hydrocarbon group having only a saturated bond (alkyl) or a hydrocarbon group having an unsaturated bond and lacking aromaticity (e.g., alkenyl or alkynyl)</span>
        <span itemprop="definition">is preferred.</span>
        <meta itemprop="num_attr" content="0126">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrocarbon group in lipid A</span>
        <span itemprop="definition">is preferably linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl.</span>
        <meta itemprop="num_attr" content="0126">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each hydrocarbon group constituting the hydrophobic unit</span>
        <span itemprop="definition">may be bonded directly to the quaternary ammonium group of the hydrophilic unit, or may be bonded to the quaternary ammonium group via an ether, ester or amide bond, etc. and the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting the hydrophilic unit.</span>
        <meta itemprop="num_attr" content="0127">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrocarbon groups constituting two or three hydrophobic units</span>
        <span itemprop="definition">may be bonded via a carbon atom, and this carbon atom may be bonded either directly to the quaternary ammonium group of the hydrophilic unit or to the quaternary ammonium group via an ether, ester or amide bond, etc. and the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting the hydrophilic unit.</span>
        <meta itemprop="num_attr" content="0127">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid A</span>
        <span itemprop="definition">can include lipids represented by the following formulas (I) to (IV), (V) and (V):</span>
        <meta itemprop="num_attr" content="0128">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 to R 3</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0129">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1 to L 3</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 1 (CY 1 Y 2 ) p1  or Z 2 (CY 3 Y 4 ) p2 Z 3 (CY 5 Y 6 ) p3  wherein Y 1 to Y 6 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 1 to Z 3 are the same or different and are each O, NY 7A , COO, OCO, CONY 7B , NY 7C CO or NY 7D COO wherein Y 7A to Y 7D are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; and p 1 to p 3 are the same or different and are each an integer from 1 to 5;</span>
        <meta itemprop="num_attr" content="0130">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 1</span>
        <span itemprop="definition">is optionally substituted C1-C4 alkyl</span>
        <meta itemprop="num_attr" content="0131">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 1</span>
        <span itemprop="definition">is a pharmaceutically acceptable anion</span>
        <meta itemprop="num_attr" content="0132">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 to R 6</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0133">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 4 to L 6</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 4 (CY 8 Y 9 ) p4  or Z 5 (CY 10 Y 11 ) p5 Z 6 (CY 12 Y 13 ) p6  wherein Y 8 to Y 13 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 4 to Z 6 are the same or different and are each O, NY 14A , COO, OCO, CONY 14B , NY 14C CO or NY 14D COO wherein Y 14A to Y 14D are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p 4 is an integer from 0 to 5; p 5 is an integer from 1 to 5; and p 6 is an integer from 0 to 5;</span>
        <meta itemprop="num_attr" content="0134">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 7</span>
        <span itemprop="definition">is absent, or (CY 15 Y 16 ) p7 , (CY 17 Y 18 ) p8 Z 7 (CY 19 Y 20 ) p9  or (CY 21 Y 22 ) p10 Z 8 (CY 23 Y 24 ) p11 Z 9 (CY 25 Y 26 ) p12  wherein Y 15 to Y 26 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 7 to Z 9 are the same or different and are each O, NY 27A , COO, OCO, CONY 27B , NY 27C CO or NY 27D COO wherein Y 27A to Y 27D are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p 7 is an</span>
        <meta itemprop="num_attr" content="0135">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 2 and X 3</span>
        <span itemprop="definition">are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 4</span>
        <span itemprop="definition">is optionally substituted C1-C4 alkyl;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 5 and X 6</span>
        <span itemprop="definition">are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 7</span>
        <span itemprop="definition">is optionally substituted C1-C4 alkyl;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 28 to Y 37</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 10 and Z 11</span>
        <span itemprop="definition">are the same or different and are each O, NY 38A , COO, OCO, CONY 38B , NY 38C CO or NY 38D COO wherein</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 2</span>
        <span itemprop="definition">is a pharmaceutically acceptable anion</span>
        <meta itemprop="num_attr" content="0137">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7 to R 9</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0138">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 8 to L 10</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 12 (CY 39 Y 40 ) p18  or Z 13 (CY 41 Y 42 ) p19 Z 14 (CY 43 Y 44 ) p20  wherein Y 39 to Y 44 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 12 to Z 14 are the same or different and are each O, NY 45A , COO, OCO, CONY 45B , NY 45C CO, NY 45D COO or CO wherein Y 45A to Y 45D are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p 18 is an integer from 0 to 5; p 19 is an integer from 1 to 5; and p 20 is an integer from</span>
        <meta itemprop="num_attr" content="0139">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 11</span>
        <span itemprop="definition">is absent, or (CY 46 Y 47 ) p21 , (CY 48 Y 49 ) p22 Z 15 (CY 50 Y 51 ) p23  or (CY 52 Y 53 ) p24 Z 16 (CY 54 Y 55 ) p25 Z 17 (CY 56 Y 57 ) p26  wherein Y 46 to Y 57 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 15 to Z 17 are the same or different and are each O, NY 58A , COO, OCO, CONY 58B , NY 58C CO, NY 58D COO or CO wherein Y 58A to Y 58D are the same or different and are each a hydrogen atom or optionally substituted C</span>
        <meta itemprop="num_attr" content="0140">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 12</span>
        <span itemprop="definition">is absent, or (CY 59 Y 60 ) p27 , (CY 61 Y 62 ) p28 Z 18 (CY 63 Y 64 ) p29  or (CY 65 Y 66 ) p30 Z 19 (CY 67 Y 68 ) p31 Z 20 (CY 69 Y 70 ) p32  wherein Y 59 to Y 70 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 18 to Z 20 are the same or different and are each O, NY 71A , COO, OCO, CONY 71B , NY 71C CO, NY 71D COO or CO wherein Y 71A to Y 71D are the same or different and are each a hydrogen</span>
        <meta itemprop="num_attr" content="0141">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">J 1 and J 2</span>
        <span itemprop="definition">are the same or different and are each CY 72 or N wherein Y 72 is a hydrogen atom, hydroxy, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, or optionally substituted C1-C4 acyloxy;</span>
        <meta itemprop="num_attr" content="0142">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 8 and X 9</span>
        <span itemprop="definition">are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 10</span>
        <span itemprop="definition">is optionally substituted C1-C4 alkyl;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 11 and X 12</span>
        <span itemprop="definition">are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 13</span>
        <span itemprop="definition">is optionally substituted C1-C4 alkyl;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 73 to Y 82</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 21 and Z 22</span>
        <span itemprop="definition">are the same or different and are each O, NY 83A , COO, OCO, CONY 83B , NY 83C CO or NY 83D CO</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 3</span>
        <span itemprop="definition">is a pharmaceutically acceptable anion</span>
        <meta itemprop="num_attr" content="0144">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 10 to R 12</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0145">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 13</span>
        <span itemprop="definition">is absent, or Z 23 (CY 84 Y 85 ) p38  or Z 24 (CY 86 Y 87 ) p39 Z 25 (CY 88 Y 89 ) p40  wherein Y 84 to Y 89 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 23 to Z 25 are the same or different and are each O, NY 90A , COO, OCO, CONY 90B , NY 90C CO or NY 90D COO wherein Y 90A to Y 90D are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; and p 38 to p 40 are the same or different and are each an integer from 1 to 5;</span>
        <meta itemprop="num_attr" content="0146">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 14 and L 15</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 26 (CY 91 Y 92 ) p41  or Z 27 (CY 93 Y 94 ) p42 Z 28 (CY 95 Y 96 ) p43  wherein Y 91 to Y 96 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 26 to Z 28 are the same or different and are each O, NY 97A , COO, OCO, CONY 97B , NY 97C CO, NY 97D COO or CO wherein Y 97A to Y 97D are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p 41 is an integer from 0 to 5; p 42 is an integer from</span>
        <meta itemprop="num_attr" content="0147">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 16</span>
        <span itemprop="definition">is absent, or (CY 98 Y 99 ) p44 , (CY 100 Y 101 ) p45 Z 29 (CY 102 Y 103 ) p46  or (CY 104 Y 105 ) p47 Z 30 (CY 106 Y 107 ) p48 Z 31 (CY 108 Y 109 ) p49  wherein Y 98 to Y 109 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 29 to Z 31 are the same or different and are each O, NY 110A , COO, OCO, CONY 110B , NY 110C CO, NY 110D COO or CO wherein Y 110A to Y 110D are the same or different and are each a hydrogen atom or optionally</span>
        <meta itemprop="num_attr" content="0148">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">J 3</span>
        <span itemprop="definition">is CY 111 or N wherein Y 111 is a hydrogen atom, hydroxy, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, or optionally substituted C1-C4 acyloxy;</span>
        <meta itemprop="num_attr" content="0149">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 14 and X 15</span>
        <span itemprop="definition">are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom;</span>
        <meta itemprop="num_attr" content="0150">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 4</span>
        <span itemprop="definition">is a pharmaceutically acceptable anion</span>
        <meta itemprop="num_attr" content="0151">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 13 to R 18</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 112 to Y 115</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom, hydroxy or optionally substituted C1-C4 alkyl;</span>
        <meta itemprop="num_attr" content="0152">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 17 to L 19 and L 22 to L 24</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 32 (CY 116 Y 117 ) p51  or Z 33 (CY 118 Y 119 ) p52 Z 34 (CY 120 Y 121 ) p53  wherein Y 116 to Y 121 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 32 to Z 34 are the same or different and are each O, NY 122A , COO, OCO, CONY 122B , NY 122C CO, NY 122D COO or CO wherein Y 122A to Y 122D are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p 51 is an integer from 0 to 5;</span>
        <meta itemprop="num_attr" content="0153">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 20 and L 25</span>
        <span itemprop="definition">are the same or different and are each absent, or (CY 123 Y 124 ) p54 , (CY 125 Y 126 ) p55 Z 35 (CY 127 Y 128 ) p56  or (CY 129 Y 130 ) p57 Z 36 (CY 131 Y 132 ) p58 Z 37 (CY 133 Y 134 ) p59  wherein Y 123 to Y 134 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 35 to Z 37 are the same or different and are each O, NY 135A , COO, OCO, CONY 135B , NY 135C CO, NY 135D COO or CO wherein Y 135A to Y 1</span>
        <meta itemprop="num_attr" content="0154">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 21 and L 26</span>
        <span itemprop="definition">are the same or different and are each absent, or (CY 136 Y 137 ) p60 , (CY 138 Y 139 ) p61 Z 38 (CY 140 Y 141 ) p62  or (CY 142 Y 143 ) p63 Z 39 (CY 144 Y 145 ) p64 Z 40 (CY 146 Y 147 ) p65  wherein Y 136 to Y 147 are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z 38 to Z 40 are the same or different and are each O, NY 148A , COO, OCO, CONY 148B , NR 148C CO, NY 148D COO or CO wherein Y 148A to Y</span>
        <meta itemprop="num_attr" content="0155">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B 3 and B 4</span>
        <span itemprop="definition">are the same or different and are each</span>
        <meta itemprop="num_attr" content="0156">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 16 and X 17</span>
        <span itemprop="definition">are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 18</span>
        <span itemprop="definition">is optionally substituted C1-C4 alkyl</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 19 and X 20</span>
        <span itemprop="definition">are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 21</span>
        <span itemprop="definition">is optionally substituted C1-C4 alkyl</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 149 to Y 158</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 41 and Z 42</span>
        <span itemprop="definition">are the same or different and are each O, NY 159A , COO, OCO, CONY 159B , NY 159C CO or NY 159D COO wherein</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 5 and A 6</span>
        <span itemprop="definition">are the same or different and are each a pharmaceutically acceptable anion.</span>
        <meta itemprop="num_attr" content="0157">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">linear or branched C8-C24 alkyl</span>
        <span itemprop="definition">examples include octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl, preferably nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexa</span>
        <meta itemprop="num_attr" content="0160">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">linear or branched C9-C18 alkyl</span>
        <span itemprop="definition">examples include nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl and 6,10,14-trimethylpentadecan-2-yl, preferably nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl, more preferably undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl and hexadecyl.</span>
        <meta itemprop="num_attr" content="0161">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C8-C24 alkenyl</span>
        <span itemprop="definition">can be linear or branched C8-24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octade</span>
        <meta itemprop="num_attr" content="0162">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the linear or branched C15-C20 alkenyl</span>
        <span itemprop="definition">include (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octadeca-9,12-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (9Z,12Z,15Z)-oc</span>
        <meta itemprop="num_attr" content="0163">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a group having a cyclopropane ring formed by adding formally a methylene biradical to a double bond of the optionally substituted linear or branched C8-C24 alkenyl</span>
        <span itemprop="definition">is also included in the C8-C24 alkenyl.</span>
        <meta itemprop="num_attr" content="0164">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">include groups having the following cyclopropane rings corresponding to (Z)-hexadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl and (8Z,11Z)-heptadeca-8,11-dienyl:</span>
        <meta itemprop="num_attr" content="0164">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C8-C24 alkynyl</span>
        <span itemprop="definition">can be linear or branched C8-24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-ynyl and oct</span>
        <meta itemprop="num_attr" content="0165">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C4 alkyl</span>
        <span itemprop="definition">include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl and cyclopropylmethyl, preferably methyl and ethyl, more preferably methyl.</span>
        <meta itemprop="num_attr" content="0166">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl moiety in the optionally substituted C1-C4 alkoxy</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0167">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the substituent for the optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl</span>
        <span itemprop="definition">include hydroxy, alkoxy, alkoxycarbonyl, nitro, cyano, fluoro, chloro and bromo.</span>
        <meta itemprop="num_attr" content="0168">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl moiety in alkoxy and alkoxycarbonyl</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0168">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">substituent for the optionally substituted C1-C4 alkyl</span>
        <span itemprop="definition">include amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo.</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two alkyl moieties in dialkylamino and dialkylcarbamoyl</span>
        <span itemprop="definition">may be the same as or different from each other.</span>
        <meta itemprop="num_attr" content="0169">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of the pyrrolidin-2-yl, the pyrrolidin-3-yl, the piperidin-2-yl, the piperidin-3-yl, the piperidin-4-yl, the morpholin-2-yl and the morpholin-3-yl</span>
        <span itemprop="definition">includes a group formed by adding C1-C3 alkyl such as methyl or ethyl to a nitrogen atom in a ring.</span>
        <meta itemprop="num_attr" content="0170">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C3 alkyl</span>
        <span itemprop="definition">include methyl, ethyl, propyl, isopropyl and cyclopropyl, preferably methyl and ethyl, more preferably methyl.</span>
        <meta itemprop="num_attr" content="0171">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C4-C6 hetero ring together formed by X 2 and X 3 with the adjacent nitrogen atom</span>
        <span itemprop="definition">include pyrrolidine, piperidine, morpholine and azepane, preferably pyrrolidine and piperidine.</span>
        <meta itemprop="num_attr" content="0172">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the substituent for the optionally substituted C4-C6 hetero ring together formed by X 2 and X 3 with the adjacent nitrogen atom</span>
        <span itemprop="definition">include optionally substituted C1-C4 alkyl (as defined above), amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo</span>
        <meta itemprop="num_attr" content="0172">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0172">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two alkyl moieties in dialkylamino and dialkylcarbamoyl</span>
        <span itemprop="definition">may be the same as or different from each other.</span>
        <meta itemprop="num_attr" content="0172">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X 5 and X 6 with the adjacent nitrogen atom</span>
        <span itemprop="definition">are each as defined above.</span>
        <meta itemprop="num_attr" content="0173">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X 8 and X 9 with the adjacent nitrogen atom</span>
        <span itemprop="definition">are each as defined above.</span>
        <meta itemprop="num_attr" content="0174">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X 11 and X 12 with the adjacent nitrogen atom</span>
        <span itemprop="definition">are each as defined above.</span>
        <meta itemprop="num_attr" content="0175">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X 14 and X 15 with the adjacent nitrogen atom</span>
        <span itemprop="definition">are each as defined above.</span>
        <meta itemprop="num_attr" content="0176">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X 16 and X 17 with the adjacent nitrogen atom</span>
        <span itemprop="definition">are each as defined above.</span>
        <meta itemprop="num_attr" content="0177">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X 19 and X 20 with the adjacent nitrogen atom</span>
        <span itemprop="definition">are each as defined above.</span>
        <meta itemprop="num_attr" content="0178">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acyl in the C1-C4 acyloxy</span>
        <span itemprop="definition">examples include formyl, acetyl, propanoyl, 2-methylpropanoyl, cyclopropanoyl and butanoyl, preferably acetyl.</span>
        <meta itemprop="num_attr" content="0179">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">substituent for the optionally substituted C1-C4 acyloxy</span>
        <span itemprop="definition">include amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two alkyl moieties in dialkylamino and dialkylcarbamoyl</span>
        <span itemprop="definition">may be the same as or different from each other.</span>
        <meta itemprop="num_attr" content="0180">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the quaternary ammonium group</span>
        <span itemprop="definition">means a group having a nitrogen atom having four covalent bonds to four carbon atoms. Unlike a hydrogen atom added to primary to tertiary amines, the quaternary ammonium group always has a positive charge irrespective of ambient pH.</span>
        <meta itemprop="num_attr" content="0181">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the pharmaceutically acceptable anion</span>
        <span itemprop="definition">include, but are not limited to: inorganic ions such as chloride ions, bromide ions, iodide ions, nitrate ions, sulfate ions and phosphate ions; and organic acid ions such as acetate ions, oxalate ions, maleate ions, fumarate ions, citrate ions, benzoate ions and methanesulfonate ions.</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">inorganic ions</span>
        <span itemprop="definition">such as chloride ions, bromide ions, iodide ions, nitrate ions, sulfate ions and phosphate ions</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">organic acid ions</span>
        <span itemprop="definition">such as acetate ions, oxalate ions, maleate ions, fumarate ions, citrate ions, benzoate ions and methanesulfonate ions.</span>
        <meta itemprop="num_attr" content="0182">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 1 to R 3</span>
        <span itemprop="definition">are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C8-C24 alkyl or C8-C24 alkenyl, further preferably the same linear or branched C15-C20 alkenyl or the same linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0183">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1 to L 3</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 1 (CY 1 Y 2 ) p1  or Z 2 (CY 3 Y 4 ) p2 Z 3 (CY 5 Y 6 ) p3 , preferably Z 1 (CY 1 Y 2 ) p2 .</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 1 to Y 6</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 1 to Z 3</span>
        <span itemprop="definition">are the same or different and are each O, NY 7A , COO, OCO, CONY 7B , NY 7C CO or NY 7D COO, preferably O, COO, OCO, CONY 7B  or NY 7C CO.</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 7A to Y 7D</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 1 to p 3</span>
        <span itemprop="definition">are the same or different and are each an integer from 1 to 5, preferably 1 or 2.</span>
        <meta itemprop="num_attr" content="0184">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1 to L 3</span>
        <span itemprop="definition">are preferably the same or different and are each O(CY 1 Y 2 ) p1 , COO(CY 1 Y 2 ) p1 , OCO(CY 1 Y 2 ) p1 , CONY 73 (CY 1 Y 2 ) p1  or NY 7C CO(CY 1 Y 2 ) p1 , more preferably are the same or different and are each COO(CY 1 Y 2 ) p2  or OCO(CY 1 Y 2 ) p1 , further preferably are the same and COO(CH 2 ) 2 .</span>
        <meta itemprop="num_attr" content="0185">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1 to L 3</span>
        <span itemprop="definition">are the same or different and are each COO(CY 1 Y 2 ) p1  or OCO(CY 1 Y 2 ) p1 , and R 1 to R 3 are the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0186">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1 to L 3</span>
        <span itemprop="definition">When at least one of L 1 to L 3 is absent, or O(CY 1 Y 2 ) p1 , OCO(CY 1 Y 2 ) p1  or NY 7C CO(CY 1 Y 2 ) p1 , R 1 to R 3 bonded to the positively charged nitrogen atom (N &#43; ), O(CY 1 Y 2 ) p1 , OCO(CY 1 Y 2 ) p1  or NR 6 CO(CY 1 Y 2 ) p2  are the same or different and are each more preferably octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9</span>
        <meta itemprop="num_attr" content="0187">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 1 to L 3</span>
        <span itemprop="definition">When at least one of L 1 to L 3 is COO(CY 1 Y 2 ) p2  or CONY 7B (CY 2 Y 2 ) p1 , R 1 to R 3 bonded to COO(CY 1 Y 2 ) p1  or CONY 7B (CY 1 Y 2 ) p1  are the same or different and are each more preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-en</span>
        <meta itemprop="num_attr" content="0188">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 1</span>
        <span itemprop="definition">is preferably methyl, hydroxypropyl or hydroxyethyl, more preferably methyl.</span>
        <meta itemprop="num_attr" content="0189">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4 to R 6</span>
        <span itemprop="definition">are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C8-C24 alkyl or C8-C24 alkenyl, further preferably the same linear or branched C15-C20 alkenyl or the same linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0190">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 4 to L 6</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 4 (CY 8 Y 9 ) p4  or Z 5 (CY 10 Y 11 ) p5 Z 6 (CY 12 Y 13 ) p6 , preferably Z 4 (CY 8 Y 9 ) p4  or Z 5 (CY 10 Y 11 ) p5 Z 6 (CY 12 Y 13 ) p6 , more preferably Z 4 (CY 8 Y 9 ) p4 .</span>
        <meta itemprop="num_attr" content="0191">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 8 to Y 13</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0191">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 4 to Z 6</span>
        <span itemprop="definition">are the same or different and are each O, NY 14A , COO, OCO, CONY 14B , NY 14C CO or NY 14D COO, preferably O, COO, OCO, CONY 14B  or NY 14C CO.</span>
        <meta itemprop="num_attr" content="0191">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 27A to Y 27D</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl, p 4 is an integer from 0 to 5. p 5 is an integer from 1 to 5. p 6 is an integer from 0 to 5. All of p 4 to p 6 are preferably 1 or 2.</span>
        <meta itemprop="num_attr" content="0191">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 4 to L 6</span>
        <span itemprop="definition">are preferably the same or different and are each O(CY 8 Y 9 ) p4 , COO(CY 8 Y 9 ) p4 , OCO(CY 8 Y 9 ) p4 , CONY 14B (CY 8 Y 9 ) p4 , NY 14C CO(CY 8 Y 9 ) p4 , NY 14D CO-Q-(CY 8 Y 9 ) p4  or OCO(CY 10 Y 11 ) p5 Z 6 (CY 12 Y 13 ) p6 , more preferably are the same or different and are each COO(CY 8 Y 9 ) p4 , OCO(CY 8 Y 9 ) p4  or OCO(CY 10 Y 11 ) p5 O(</span>
        <meta itemprop="num_attr" content="0192">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 4 to L 6</span>
        <span itemprop="definition">are the same or different and are each COO(CY 8 Y 9 ) p4 , OCO(CY 8 Y 9 ) p4 , or OCO(CY 10 Y 11 ) p5 O(CY 12 Y 13 ) p6 , and R 4 to R 6 are the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0193">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 4 to L 6</span>
        <span itemprop="definition">When at least one of L 4 to L 6 is absent, or O(CY 8 Y 9 ) p4 , OCO(CY 8 Y 9 ) p4 , NY 14C CO(CY 8 Y 9 ) p4 , NY 14D COO or OCO(CY 10 Y 11 ) p5 (CY 12 Y 13 ) p6 , R 7 to R 9 bonded to the carbon atom adjacent to L 7 , O(CY 8 Y 9 ) p4 , OCO(CY 8 Y 9 ) p4 , NY 14C CO(CY 8 Y 9 ) p4 , NY 14D COO or OCO(CY 10 Y 11 ) p5 Z 6 (CY 12 Y 13 ) p6  are the</span>
        <meta itemprop="num_attr" content="0194">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 4 to L 6</span>
        <span itemprop="definition">When at least one of L 4 to L 6 is COO(CY 8 Y 9 ) p4  or CONY 14B (CY 8 Y 9 ) p4 , R 4 to R 6 bonded to COO(CY 8 Y 9 ) p4  or CONY 14B (CY 8 Y 9 ) p4  are the same or different and are each preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-eny</span>
        <meta itemprop="num_attr" content="0195">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 7</span>
        <span itemprop="definition">is preferably absent, or (CY 15 Y 16 ) p7 , (CY 17 Y 18 ) p8 OCO(CY 19 Y 20 ) p9  or (CY 17 Y 18 ) p8 NY 27C CO(CY 19 Y 20 ) p9 , more preferably absent, or (CY 15 Y 16 ) p7 .</span>
        <meta itemprop="num_attr" content="0196">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B 1</span>
        <span itemprop="definition">is preferably absent, or (CY 15 Y 16 ) p7 .</span>
        <meta itemprop="num_attr" content="0196">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 7</span>
        <span itemprop="definition">is (CY 15 Y 16 ) p7 </span>
        <meta itemprop="num_attr" content="0197">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 7</span>
        <span itemprop="definition">is preferably 1 to 3, more preferably 1 or 2, further preferably 1.</span>
        <meta itemprop="num_attr" content="0197">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each of Y 15 and Y 16</span>
        <span itemprop="definition">is preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0197">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B 1</span>
        <span itemprop="definition">is preferably N &#43; (CH 3 ) 3 .</span>
        <meta itemprop="num_attr" content="0197">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 7</span>
        <span itemprop="definition">is (CY 17 Y 18 ) p8 OCO(CY 19 Y 20 ) p9  or (CY 17 Y 18 ) p8 NY 27C CO(CY 19 Y 20 ) p9 </span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 8</span>
        <span itemprop="definition">is 0 to 3</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 9</span>
        <span itemprop="definition">is 1 to 3. More preferably, p 8 is 0 to 1, and p 9 is 1 to 3.</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of Y 17 to Y 20</span>
        <span itemprop="definition">is a hydrogen atom</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 27C</span>
        <span itemprop="definition">is a hydrogen atom or methyl.</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B 1</span>
        <span itemprop="definition">is preferably N &#43; (CH 3 ) 3 .</span>
        <meta itemprop="num_attr" content="0198">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 2 and X 3</span>
        <span itemprop="definition">are the same or different and are each methyl or ethyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom. More preferably, X 2 and X 3 are the same and methyl, or together form pyrrolidine or piperidine with the adjacent nitrogen atom. Further preferably, X 2 and X 3 are the same and methyl.</span>
        <meta itemprop="num_attr" content="0199">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 4</span>
        <span itemprop="definition">is preferably methyl, ethyl, hydroxypropyl, hydroxyethyl or the like, more preferably methyl.</span>
        <meta itemprop="num_attr" content="0200">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 2 and X 3</span>
        <span itemprop="definition">are the same or different and are each methyl or ethyl, and X 4 is methyl, ethyl, hydroxypropyl, hydroxyethyl or the like. Each of X 2 to X 4 is more preferably methyl.</span>
        <meta itemprop="num_attr" content="0201">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B 1</span>
        <span itemprop="definition">is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl</span>
        <meta itemprop="num_attr" content="0202">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 7</span>
        <span itemprop="definition">is absent, or (CY 15 Y 16 ) p7 , (CY 17 Y 18 ) p8 OCO(CY 19 Y 20 ) p9  or (CY 17 Y 18 ) p8 NY 27C CO(CY 19 Y 20 ) p9 .</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B 1</span>
        <span itemprop="definition">is</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 7</span>
        <span itemprop="definition">is absent, or NHCO(CH 2 ) p9 , OCO(CH 2 ) p9 , CH 2 NHCO(CH 2 ) p9  or CH 2 OCO(CH 2 ) p9 .</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 7</span>
        <span itemprop="definition">is preferably linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0203">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 8 and R 9</span>
        <span itemprop="definition">are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0203">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 8</span>
        <span itemprop="definition">is absent, or Z 12 (CY 39 Y 40 ) p19  or Z 13 (CY 41 Y 42 ) p19 Z 14 (CY 43 Y 44 ) p20 , preferably absent or Z 12 (CY 39 Y 40 ) p19 .</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 9 and L 10</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 12 (CY 39 Y 40 ) p18  or Z 13 (CY 41 Y 42 ) p19 Z 14 (CY 43 Y 44 ) p20 , preferably are the same or different and are each absent or Z 12 (CY 39 Y 40 ) p18 .</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 39 to Y 44</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 12 to Z 14</span>
        <span itemprop="definition">are the same or different and are each O, NY 45A , COO, OCO, CONY 453 , NY 45C CO, NY 45D COO or CO, preferably COO, OCO, CONY 45B , NY 45C CO or CO.</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 45A to Y 45D</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl, p 18 is an integer from 0 to 5, preferably 0 or 1. p 19 is an integer from 1 to 5, preferably 1 or 2. p 20 is an integer from 0 to 5, preferably 0 or 1.</span>
        <meta itemprop="num_attr" content="0204">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one of L 8 to L 10</span>
        <span itemprop="definition">is COO(CY 39 Y 40 ) p18  or OCO(CY 39 Y 40 ) p18 , or two or more of L 8 to L 10 are the same or different and are each COO(CY 39 Y 40 ) p18 or OCO(CY 39 Y 40 ) p18 , and each of R 7 to R 9 is linear C15-C20 alkenyl or C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 8 and R 9</span>
        <span itemprop="definition">are preferably the same.</span>
        <meta itemprop="num_attr" content="0205">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 8</span>
        <span itemprop="definition">is preferably absent, or COO(CY 39 Y 40 ) p18 , OCO(CY 39 Y 40 ) p18 , CONY 45B (CY 39 Y 40 ) p18  or NY 45C CO(CY 39 Y 40 ) p18 , more preferably absent, or COO(CY 39 Y 40 ) p18 , OCO(CY 39 Y 40 ) p28  or CONY 45B (CY 39 Y 40 ) p28 , further preferably absent, or COO(CH 2 ) p18 , OCO(CH 2 ) p18  or CONH(CH 2 ) p18 .</span>
        <meta itemprop="num_attr" content="0206">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 9 and L 10</span>
        <span itemprop="definition">are preferably the same or different and are each absent, or COO(CY 39 Y 40 ) p18 , OCO(CY 39 Y 40 ) p18 , CONY 45B (CY 39 Y 40 ) p18  or NY 45C CO(CY 39 Y 40 ) p18 , more preferably are the same or different and are each absent, or COO(CY 39 Y 40 ) p18  or OCO(CY 39 Y 40 ) p18 , further preferably are the same or different and are each absent or COO(CH 2 ) p18 , most preferably are the same and absent or COO(CH 2 ) p18 .</span>
        <meta itemprop="num_attr" content="0207">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">one of L 8 to L 10</span>
        <span itemprop="definition">is absent, or COO(CY 39 Y 40 ) p18 , OCO(CY 39 Y 40 ) p18 , CONY 45b (CY 39 Y 40 ) p18  or NY 45C CO(CY 39 Y 40 ) p18 , or two or more of L 8 to L 10 are the same or different and are each absent, or COO(CY 39 Y 40 ) p18 , OCO(CY 39 Y 40 ) p18 , CONY 45b (CY 39 Y 40 ) p18  or NY 45C CO(CY 39 Y 40 ) p18 , and each of R 7 to R 9 is preferably linear C15-C20 alkenyl or C9-C18 alkyl. R 8 and R 9 are preferably the same.</span>
        <meta itemprop="num_attr" content="0208">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 8 to L 10</span>
        <span itemprop="definition">When at least one of L 8 to L 10 is absent, or O(CY 39 Y 40 ) p18 , OCO(CY 39 Y 40 ) p18 , NY 45C CO(CY 39 Y 40 ) p18  or NY 45D COO(CY 39 Y 40 ) p18 , R 7 to R 9 bonded to J 1 or J 2 , O(CY 39 Y 40 ) p18 , OCO(CY 39 Y 40 ) p18 , NY 45C CO(CY 39 Y 40 ) p18  or NY 45D COO(CY 39 Y 40 ) p18  are the same or different and are each preferably octyl, decyl, dodecyl, tetradecyl, hexadecyl, oct</span>
        <meta itemprop="num_attr" content="0209">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 8 to L 10</span>
        <span itemprop="definition">When at least one of L 8 to L 10 is COO(CY 39 Y 40 ) p18 , CONY 45B (CY 39 Y 40 ) p18  or CO(CY 39 Y 40 ) p18 , R 7 to R 9 bonded to COO(CY 39 Y 40 ) p18 , CONY 45B (CY 39 Y 40 ) p18  or CO(CY 39 Y 40 ) p18 are the same or different and are each preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8</span>
        <meta itemprop="num_attr" content="0210">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 11</span>
        <span itemprop="definition">is absent, or (CY 46 Y 47 ) p21 , (CY 48 Y 49 ) p22 Z 15 (CY 50 Y 51 ) p23  or (CY 52 Y 53 ) p24 Z 16 (CY 54 Y 55 ) p25 Z 17 (CY 56 Y 57 ) p26 , preferably absent, or (CY 46 Y 47 ) p21  or (CY 48 Y 49 ) p22 Z 15 (CY 50 Y 51 ) p23 .</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 46 to Y 57</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 15 to Z 17</span>
        <span itemprop="definition">are the same or different and are each O, NY 58A , COO, OCO, CONY 58B , NY 58C CO, NY 58D COO or CO, preferably COO, OCO, CONY 58B , NY 58C CO or CO, more preferably OCO or NY 58C CO.</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 21</span>
        <span itemprop="definition">is an integer from 1 to 5, preferably 1 to 3.</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 22</span>
        <span itemprop="definition">is an integer from 0 to 5, preferably 0 to 3.</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 23</span>
        <span itemprop="definition">is an integer from 1 to 5, preferably 1 or 2.</span>
        <meta itemprop="num_attr" content="0211">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 11</span>
        <span itemprop="definition">is preferably absent, or (CY 46 Y 47 ) p21 , (CY 48 Y 49 ) p22 OCO(CY 50 Y 51 ) p23 , or (CY 48 Y 49 ) p22 NY 58C CO(CY 50 Y 51 ) p23 , more preferably absent or (CY 46 Y 47 ) p21 , further preferably absent or (CH 2 ) p2 .</span>
        <meta itemprop="num_attr" content="0212">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 12</span>
        <span itemprop="definition">is preferably absent or (CY 59 Y 60 ) p27 , more preferably absent or (CH 2 ) p27 , further preferably absent or CH 2  or (CH 2 ) 2 .</span>
        <meta itemprop="num_attr" content="0213">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">J 1 and J 2</span>
        <span itemprop="definition">are the same or different and are each CY 72 or N.</span>
        <meta itemprop="num_attr" content="0214">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">J 1 and J 2</span>
        <span itemprop="definition">are the same or different and are each CH, C(OH) or N.</span>
        <meta itemprop="num_attr" content="0214">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">J 1</span>
        <span itemprop="definition">is preferably CH.</span>
        <meta itemprop="num_attr" content="0215">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 9 and L 10</span>
        <span itemprop="definition">are absent; L 12 is CO(CH 2 ) p29 ; J 1 is CH; and J 2 is N.</span>
        <meta itemprop="num_attr" content="0216">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 8</span>
        <span itemprop="definition">is CONY 45B (CH 2 ) p18 , and L 11 is absent or (CH 2 ) p22 .</span>
        <meta itemprop="num_attr" content="0216">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 9 and L 10</span>
        <span itemprop="definition">are absent; L 12 is OCO(CH 2 ) p18 ; and each of J 1 and J 2 is CH.</span>
        <meta itemprop="num_attr" content="0217">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 8</span>
        <span itemprop="definition">is OCO(CH 2 ) p18 , and L 11 is absent.</span>
        <meta itemprop="num_attr" content="0217">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B 2</span>
        <span itemprop="definition">is preferably</span>
        <meta itemprop="num_attr" content="0218">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 8 to X 10</span>
        <span itemprop="definition">are as defined above in X 2 to X 4 , respectively.</span>
        <meta itemprop="num_attr" content="0219">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 10</span>
        <span itemprop="definition">is preferably linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably linear C15-C20 alkenyl or linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0220">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 11 and R 12</span>
        <span itemprop="definition">are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0220">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 13</span>
        <span itemprop="definition">is absent, or Z 23 (CY 84 Y 85 ) p38  or Z 24 (CY 86 Y 87 ) p39 Z 25 (CY 88 Y 89 ) p40 , preferably absent, or Z 23 (CY 84 Y 85 ) p38 .</span>
        <meta itemprop="num_attr" content="0221">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 84 to Y 89</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0221">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 23 to Z 25</span>
        <span itemprop="definition">are the same or different and are each O, NY 90A , COO, OCO, CONY 903 , NY 90C CO or NY 90D COO, preferably COO, OCO, CONY 90B  or NY 90C CO, more preferably CONY 90B .</span>
        <meta itemprop="num_attr" content="0221">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 90A to Y 90D</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl, p 38 to p 40 are the same or different and are each an integer from 1 to 5, preferably 1 or 2.</span>
        <meta itemprop="num_attr" content="0221">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 13</span>
        <span itemprop="definition">is preferably absent, or COO(CY 84 Y 85 ) p38 , OCO(CY 84 Y 85 ) p38 , CONY 90B (CY 84 Y 85 ) p38 , or NY 90C CO(CY 84 Y 85 ) p38 , more preferably absent, or COO(CH 2 ) p38 , OCO(CH 2 ) p38  or CONCH 3 (CH 2 ) p38 , further preferably absent, or CONCH 3 (CH 2 ) p38 .</span>
        <meta itemprop="num_attr" content="0222">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 14 and L 15</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 26 (CY 91 Y 92 ) p41  or Z 27 (CY 93 Y 94 ) p42 Z 28 (CY 95 Y 96 ) p43 , preferably absent, or Z 26 (CY 91 Y 92 ) p41 .</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 91 to Y 96</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Z 26 to Z 28</span>
        <span itemprop="definition">are the same or different and are each O, NY 97A , COO, OCO, CONY 97B , NY 97C CO, NY 97D COO or CO, preferably COO, OCO, CONY 97B , NY 97C CO, or CO.</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 97A to Y 97D</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 41</span>
        <span itemprop="definition">is an integer from 0 to 5, preferably 0 to 2.</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 42</span>
        <span itemprop="definition">is an integer from 1 to 5, preferably 1 or 2.</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 43</span>
        <span itemprop="definition">is an integer from 0 to 5, preferably 0 to 2.</span>
        <meta itemprop="num_attr" content="0223">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 14 and L 15</span>
        <span itemprop="definition">are preferably the same or different and are each absent, or COO(CY 91 Y 92 ) p41 , OCO(CY 91 Y 92 ) p41 , CONY 97B (CY 91 Y 92 ) p41 , NY 97C CO(CY 91 Y 92 ) p41  or CO(CY 91 Y 92 ) p41 , more preferably are the same or different and are each absent, or COO(CY 91 Y 92 ) p41 , OCO(CY 91 Y 92 ) p41  or CO(CY 91 Y 92 ) p41 , further preferably are the same or different and are each absent, or COO(CH 2 ) p41 , OCO(CH 2 )</span>
        <meta itemprop="num_attr" content="0224">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 13</span>
        <span itemprop="definition">is COO(CY 84 Y 85 ) p38 , OCO(CY 84 Y 85 ) p38  or CONY 90B (CY 84 Y 85 ) p38 ; one of L 14 and L 15 is COO(CY 91 Y 92 ) p41  or OCO(CY 91 Y 92 ) p41 ; L 13 is COO(CY 84 Y 85 ) p38 , OCO(CY 84 Y 85 ) p38  or CONY 89B (CY 84 Y 85 ) p38 , and one of L 14 and L 15 is COO(CY 91 Y 92 ) p41  or OCO(CY 91 Y 92 ) p41 ; L 14</span>
        <meta itemprop="num_attr" content="0225">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 10</span>
        <span itemprop="definition">is preferably octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octade</span>
        <meta itemprop="num_attr" content="0226">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 10</span>
        <span itemprop="definition">is more preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (Z)-nonadec-10-enyl,</span>
        <meta itemprop="num_attr" content="0227">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 14 and L 15</span>
        <span itemprop="definition">When at least one of L 14 and L 15 is COO(CY 91 Y 92 ) p41  or CONY 97B (CY 91 Y 92 ) p41 , R 11 and R 12 bonded to COO(CY 91 Y 92 ) p41  or CONY 97B (CY 91 Y 92 ) p41  are the same or different and are each more preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-hept</span>
        <meta itemprop="num_attr" content="0229">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 16</span>
        <span itemprop="definition">is absent, or (CY 98 Y 99 ) p44 , (CY 100 Y 101 ) p45 Z 29 (CY 102 Y 103 ) p46  or (CY 104 Y 105 ) p47 Z 30 (CY 106 Y 107 ) p48 Z 31 (CY 108 Y 109 ) p49 , preferably absent, or (CY 98 Y 99 ) p44  or (CY 100 Y 101 ) p45 Z 29 (CY 102 Y 103 ) p46 , more preferably absent, or (CY 98 Y 99 ) p44 , (CY 100 Y 101 ) p45 OCO(CY 102 Y 103 ) p46 , (CY 100 Y 101 ) p45 NY 109C CO(CY</span>
        <meta itemprop="num_attr" content="0230">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">J 3</span>
        <span itemprop="definition">is CY 111 or N, preferably CH or N.</span>
        <meta itemprop="num_attr" content="0231">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 14</span>
        <span itemprop="definition">is absent; L 15 is CO; and L 16 is absent, or (CY 98 Y 99 ) p44 , or L 14 is absent; L 15 is absent; and L 16 is CO(CY 102 Y 103 ) p46 .</span>
        <meta itemprop="num_attr" content="0231">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 14 and X 15</span>
        <span itemprop="definition">are as defined above in X 2 and X 3 , respectively.</span>
        <meta itemprop="num_attr" content="0232">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 13</span>
        <span itemprop="definition">is preferably linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably linear C15-C20 alkenyl or linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 14 and R 15</span>
        <span itemprop="definition">are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or linear C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0233">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 17 to L 19</span>
        <span itemprop="definition">are the same or different and are each absent, or Z 32 (CY 116 Y 117 ) p51  or Z 33 (CY 118 Y 119 ) p52 Z 34 (CY 120 Y 121 ) p53 , preferably Z 32 (CY 116 Y 117 ) p51 , more preferably O(CY 116 Y 117 ) p51  or COO(CY 116 Y 117 ) p51 , further preferably O or COO.</span>
        <meta itemprop="num_attr" content="0234">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 17 to L 19</span>
        <span itemprop="definition">are the same or different and are each O or COO, and each of R 13 to R 15 is linear C15-C20 alkenyl or C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0235">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 17 to L 19</span>
        <span itemprop="definition">are the same and O or COO, and R 13 to R 15 are the same and linear C15-C20 alkenyl or C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0235">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 17 to L 19</span>
        <span itemprop="definition">When at least one of L 17 to L 19 is absent, or O(CY 116 Y 117 ) p51 , OCO(CY 116 Y 117 ) p51 , NY 122C CO(CY 116 Y 117 ) p51  or NY 122D COO(CY 116 Y 117 ) p51 , R 13 to R 15 bonded to carbon adjacent to the furanose ring or L 20 , O(CY 116 Y 117 ) p51 , OCO(CY 116 Y 117 ) p51 , NY 122C CO(CY 116 Y 117 ) p51  or NY 122D COO(CY 116 Y 117 ) p51  are the same or different and are each preferably octyl, decyl,</span>
        <meta itemprop="num_attr" content="0236">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 17 to L 19</span>
        <span itemprop="definition">When at least one of L 17 to L 19 is COO(CY 116 Y 117 ) p51 , CONY 122B (CY 116 Y 117 ) p51  or CO(CY 116 Y 117 ) p51 , R 13 to R 15 bonded to COO(CY 116 Y 117 ) p51 , CONY 122B (CY 116 Y 117 ) p51  or CO(CY 116 Y 117 ) p51  are the same or different and are each preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptade</span>
        <meta itemprop="num_attr" content="0237">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 20</span>
        <span itemprop="definition">is absent, or (CY 123 Y 124 ) p54 , (CY 125 Y 126 ) p55 Z 35 (CY 127 Y 128 ) p56  or (CY 129 Y 130 ) p57 Z 36 (CY 131 Y 132 ) p58 Z 37 (CY 133 Y 134 ) p59 , preferably (CY 123 Y 124 ) p54 , more preferably (CH 2 ) p54 , further preferably CH 2 .</span>
        <meta itemprop="num_attr" content="0238">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 21</span>
        <span itemprop="definition">is absent, or (CY 136 Y 137 ) p60 , (CY 138 Y 139 ) p61 Z 38 (CY 140 Y 141 ) p62  or (CY 142 Y 143 ) p63 Z 39 (CY 144 Y 145 ) p64 Z 40 (CY 146 Y 147 ) p65 , preferably absent or (CY 136 Y 137 ) p60 , more preferably absent or (CH 2 ) p60 , further preferably absent.</span>
        <meta itemprop="num_attr" content="0239">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y 112 and Y 113</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom, hydroxy or optionally substituted C1-C4 alkyl, preferably are the same or different and are each a hydrogen atom or hydroxy, more preferably are the same and a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0241">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 16 to R 18 , L 22 to L 26 , B 4 , Y 114 to Y 115 and A 6</span>
        <span itemprop="definition">are as defined in R 13 to R 15 , L 17 to L 21 , B 3 , Y 112 to Y 113 and A 5 , respectively.</span>
        <meta itemprop="num_attr" content="0242">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 17 to L 19</span>
        <span itemprop="definition">are the same or different and are each O or COO, and each of R 13 to R 15 is linear C15-C20 alkenyl or C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 17 to L 19</span>
        <span itemprop="definition">are the same or different and are each O or COO; each of R 13 to R 15 is linear C15-C20 alkenyl or C9-C18 alkyl; L 17 and L 21 are absent; and Y 113 is a hydrogen atom or hydroxy.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">formula (V)</span>
        <span itemprop="definition">four substituents on the furan ring are preferably added on different carbon atoms, respectively, on the furan ring.</span>
        <meta itemprop="num_attr" content="0244">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Formula (V)</span>
        <span itemprop="definition">is more preferably</span>
        <meta itemprop="num_attr" content="0244">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 22 to L 24</span>
        <span itemprop="definition">are the same or different and are each O or COO, and each of R 16 to R 18 is linear C15-C20 alkenyl or C9-C18 alkyl.</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 22 to L 24</span>
        <span itemprop="definition">are the same or different and are each O or COO; each of R 16 to R 18 is linear C15-C20 alkenyl or C9-C18 alkyl; L 22 and L 26 are absent; and Y 114 is a hydrogen atom or hydroxy.</span>
        <meta itemprop="num_attr" content="0245">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N &#43;</span>
        <span itemprop="definition">is bonded to carbon adjacent to each of Z 10 , Z 21 and Z 41 .</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-containing lipid nanoparticle of the present invention</span>
        <span itemprop="definition">preferably comprises a lipid represented by formula (II) as lipid A.</span>
        <meta itemprop="num_attr" content="0247">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the nucleic acid-containing lipid nanoparticle of the present invention</span>
        <span itemprop="definition">may comprise a cationic lipid other than the lipid having a hydrophilic unit having one quaternary ammonium group and optionally substituted three independent hydrocarbon groups (lipid A).</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid other than lipid A used in the present invention</span>
        <span itemprop="definition">is not particularly limited as long as the cationic lipid is an amphipathic molecule having a lipophilic region containing one or more optionally substituted hydrocarbon groups, and a cationic hydrophilic region containing at least one primary amino group, secondary amino group, tertiary amino group and/or quaternary ammonium group (except for lipid A).</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid other than lipid A</span>
        <span itemprop="definition">is preferably a lipid having a hydrophilic unit having optionally substituted one amino group or one quaternary ammonium group and a hydrophobic unit having optionally substituted two independent hydrocarbon groups (lipid B).</span>
        <meta itemprop="num_attr" content="0248">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid having, in the same molecule, a hydrophilic unit having optionally substituted one amino group or one quaternary ammonium group and a hydrophobic unit having optionally substituted two independent hydrocarbon groups</span>
        <span itemprop="definition">is not particularly limited as long as the lipid is a molecule intramolecularly having optionally substituted one amino group or one quaternary ammonium group as a hydrophilic unit, and having optionally substituted two independent hydrocarbon groups.</span>
        <meta itemprop="num_attr" content="0249">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid B</span>
        <span itemprop="definition">is represented by, for example, any of structural formulas (D) and (E) given below.</span>
        <meta itemprop="num_attr" content="0249">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydrophilic unit</span>
        <span itemprop="definition">represents a hydrophilic unit having optionally substituted one amino group or one quaternary ammonium group</span>
        <meta itemprop="num_attr" content="0250">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">hydrophobic unit</span>
        <span itemprop="definition">represents an optionally substituted independent hydrocarbon group</span>
        <meta itemprop="num_attr" content="0250">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the optionally substituted chain and/or cyclic hydrocarbon group constituting the hydrophilic unit</span>
        <span itemprop="definition">can be any group composed of carbon and hydrogen atoms and is preferably a group having 1 to 10 carbon atoms, more preferably a group having 1 to 6 carbon atoms, further preferably a group having 1 to 3 carbon atoms.</span>
        <meta itemprop="num_attr" content="0253">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrophilic unit</span>
        <span itemprop="definition">may have one or more ethers, esters, amides or the like via a carbon atom in the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting this hydrophilic unit. Examples of the substituent for the optionally substituted chain and/or cyclic hydrocarbon group, etc.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">carbamate</span>
        <span itemprop="definition">include carbamate, amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro, and bromo.</span>
        <meta itemprop="num_attr" content="0254">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrocarbon group constituting the hydrophobic unit</span>
        <span itemprop="definition">can be any group consisting of 8 to 24 carbon atoms and hydrogen atoms.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hydrocarbon groups</span>
        <span itemprop="definition">can be classified from the viewpoint of topology. Examples thereof include linear hydrocarbon groups, branched hydrocarbon groups and cyclic hydrocarbon groups (e.g., a cholesteryl group). A linear or branched hydrocarbon group is preferred. Also, hydrocarbon groups can be classified on the basis of the presence or absence of an unsaturated bond (double bond or triple bond). Hydrocarbon groups having an unsaturated bond can also be classified on the basis of the presence or absence of aromaticity.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrocarbon group</span>
        <span itemprop="definition">is preferably a hydrocarbon group having only a saturated bond (alkyl) or a hydrocarbon group having an unsaturated bond and lacking aromaticity (e.g., alkenyl or alkynyl).</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrocarbon group in lipid A</span>
        <span itemprop="definition">is preferably linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl.</span>
        <meta itemprop="num_attr" content="0255">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each hydrocarbon group constituting the hydrophobic unit</span>
        <span itemprop="definition">may be bonded directly to the amino group or the quaternary ammonium group of the hydrophilic unit, or may be bonded to the amino group or the quaternary ammonium group via an ether, ester or amide bond, etc. and the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting the hydrophilic unit.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrocarbon groups constituting two hydrophobic units</span>
        <span itemprop="definition">may be bonded via a carbon atom, and this carbon atom may be bonded either directly to the amino group or the quaternary ammonium group of the hydrophilic unit or to the amino group or the quaternary ammonium group via an ether, ester or amide bond, etc. and the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting the hydrophilic unit.</span>
        <meta itemprop="num_attr" content="0256">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the cationic lipid in the nucleic acid-containing lipid nanoparticle of the present invention</span>
        <span itemprop="definition">may be lipid A alone or lipid B alone and preferably comprises both lipid A and lipid B.</span>
        <meta itemprop="num_attr" content="0257">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">cationic lipid other than lipid A used in the present invention</span>
        <span itemprop="definition">examples include cationic lipids described in WO 2013/089151, WO 2011/136368, WO 2014/007398, WO 2010/042877 and WO 2010/054401.</span>
        <meta itemprop="num_attr" content="0258">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid B used in the present invention</span>
        <span itemprop="definition">can include lipids represented by the following formulas (CL-I) to (CL-XIX):</span>
        <meta itemprop="num_attr" content="0259">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 101 and R 102</span>
        <span itemprop="definition">are the same or different and are each linear or branched C10-C24 alkyl, C10-C24 alkenyl or C10-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0260">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 101 and L 102</span>
        <span itemprop="definition">are each a hydrogen atom, or together form a single bond or C1-C3 alkylene;</span>
        <meta itemprop="num_attr" content="0261">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 103</span>
        <span itemprop="definition">is a single bond, CO or COO;</span>
        <meta itemprop="num_attr" content="0262">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 103 and R 104</span>
        <span itemprop="definition">are the same or different and are each linear or branched C12-C24 alkyl, C12-C24 alkenyl or C12-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0267">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 101 and p 102</span>
        <span itemprop="definition">are the same or different and are each an integer from 0 to 3;</span>
        <meta itemprop="num_attr" content="0268">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 106 and L 107</span>
        <span itemprop="definition">are each a hydrogen atom, or together form a single bond or C2-C8 alkylene;</span>
        <meta itemprop="num_attr" content="0269">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 104 and L 105</span>
        <span itemprop="definition">are the same or different and are each O, COO or OCO;</span>
        <meta itemprop="num_attr" content="0270">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 108</span>
        <span itemprop="definition">is a single bond, CO or COO;</span>
        <meta itemprop="num_attr" content="0271">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105</span>
        <span itemprop="definition">is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 106</span>
        <span itemprop="definition">is linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl or C8-C24 alkynyloxypropyl;</span>
        <meta itemprop="num_attr" content="0276">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 103 and X 104</span>
        <span itemprop="definition">are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene, or X 103 forms C2-C8 alkylene together with L 111 ;</span>
        <meta itemprop="num_attr" content="0277">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 111</span>
        <span itemprop="definition">is a hydrogen atom, C1-C6 alkyl, C3-C6 alkenyl, amino, monoalkylamino, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl, or forms C2-C8 alkylene together with X 103 ;</span>
        <meta itemprop="num_attr" content="0278">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 109</span>
        <span itemprop="definition">is C1-C6 alkylene</span>
        <meta itemprop="num_attr" content="0279">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 110</span>
        <span itemprop="definition">is a single bond, or C1-C6 alkylene, provided that the sum of the numbers of carbon atoms of L 109 and L 110 is 7 or less; when L 111 is a hydrogen atom, L 110 is a single bond; and when L 111 forms C2-C6 alkylene together with X 103 , L 110 is a single bond, or methylene or ethylene,</span>
        <meta itemprop="num_attr" content="0280">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 107</span>
        <span itemprop="definition">is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0281">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 108</span>
        <span itemprop="definition">is linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl, C8-C24 alkynyloxypropyl, C8-C24 alkyloxyethoxyethyl, C8-C24 alkenyloxyethoxyethyl or C8-C24 alkynyloxyethoxyethyl;</span>
        <meta itemprop="num_attr" content="0282">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 105</span>
        <span itemprop="definition">is a hydrogen atom, optionally substituted C1-C4 alkyl or CO(CH 2 ) n NY1Y2;</span>
        <meta itemprop="num_attr" content="0283">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">an integer from 1 to 4.</span>
        <meta itemprop="num_attr" content="0284">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y1 and Y2</span>
        <span itemprop="definition">are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene,</span>
        <meta itemprop="num_attr" content="0285">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 109</span>
        <span itemprop="definition">is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0286">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 110</span>
        <span itemprop="definition">is linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl or C8-C24 alkynyloxypropyl;</span>
        <meta itemprop="num_attr" content="0287">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 112</span>
        <span itemprop="definition">is C1-C3 alkylene</span>
        <meta itemprop="num_attr" content="0288">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 105 </span>
        <span itemprop="definition">is a hydrogen atom or C1-C3 alkyl</span>
        <meta itemprop="num_attr" content="0289">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 111 and R 112</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0290">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 106 and X 107</span>
        <span itemprop="definition">are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene;</span>
        <meta itemprop="num_attr" content="0291">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 103 , p 104 and p 105</span>
        <span itemprop="definition">are the same or different and are each 0 or 1, provided that p 103 , p 104 and p 105 are not 0 at the same time;</span>
        <meta itemprop="num_attr" content="0292">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 113 and L 114</span>
        <span itemprop="definition">are the same or different and are each 0, S or NH,</span>
        <meta itemprop="num_attr" content="0293">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 113 and R 114</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0294">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 115</span>
        <span itemprop="definition">is a hydrogen atom, hydroxy, optionally substituted C1-C4 alkyl, C1-C4 alkoxy or C1-C4 acyloxy;</span>
        <meta itemprop="num_attr" content="0295">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 109 and X 110</span>
        <span itemprop="definition">are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene;</span>
        <meta itemprop="num_attr" content="0296">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 115</span>
        <span itemprop="definition">is COO, OCO, NHCO or CONH;</span>
        <meta itemprop="num_attr" content="0297">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 106</span>
        <span itemprop="definition">is an integer from 0 to 3.</span>
        <meta itemprop="num_attr" content="0298">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 107</span>
        <span itemprop="definition">is an integer from 1 to 4,</span>
        <meta itemprop="num_attr" content="0299">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 116 and R 117</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C7-C20 alkyloxy C1-C3 alkyl, C7-C20 alkenyloxy C1-C3 alkyl or C7-C20 alkynyloxy C1-C3 alkyl, or</span>
        <meta itemprop="num_attr" content="0300">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the biodegradable group thus integrated</span>
        <span itemprop="definition">is C(O)O or OC(O)</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the group having the biodegradable group present at the terminal</span>
        <span itemprop="definition">is C(O)OC1-C4 alkyl or OC(O)C1-C4 alkyl;</span>
        <meta itemprop="num_attr" content="0302">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">B 100</span>
        <span itemprop="definition">is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, C1-C3 dialkylamino C2-C4 alkyl, formula (A):</span>
        <meta itemprop="num_attr" content="0303">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 111 and X 112</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X 111 and X 112 optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p 110 is an integer from 2 to 6, or formula (B):</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 113 and X 114</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X 113 and X 114 optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p 111 is an integer from 1 to 6;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 108</span>
        <span itemprop="definition">is an integer from 0 to 4;</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 109</span>
        <span itemprop="definition">is an integer from 1 to 4, provided that when p 108 is 0, p 109 is not 1;</span>
        <meta itemprop="num_attr" content="0304">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 116</span>
        <span itemprop="definition">is the same or different on each carbon to which it is bonded and is a hydrogen atom or C1-C3 alkyl</span>
        <meta itemprop="num_attr" content="0305">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 117</span>
        <span itemprop="definition">is the same or different on each carbon to which it is bonded and is a hydrogen atom or C1-C3 alkyl</span>
        <meta itemprop="num_attr" content="0306">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 115 and X 116</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1-C3 alkyl</span>
        <meta itemprop="num_attr" content="0307">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 118 and L 119</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkylene or C8-C24 alkenylene;</span>
        <meta itemprop="num_attr" content="0308">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 101 and M 102</span>
        <span itemprop="definition">are the same or different and are each selected from the group consisting of C  C, OC(O), C(O)O, SC(O), C(O)S, OC(S), C(S)O, SS, C(R)  N, N  C(R), C(R)  NO, ON  C(R), N(R)C(O), C(O)N(R), N(R)C(S), C(S)N(R), N(R)C(O)N(R), N(R)C(O)O, OC(O)N(R) and OC(O)O;</span>
        <meta itemprop="num_attr" content="0309">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R and R</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1-C3 alkyl</span>
        <meta itemprop="num_attr" content="0310">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 and R 119</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C1-C16 alkyl or C2-C16 alkenyl,</span>
        <meta itemprop="num_attr" content="0311">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 117 and X 118</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom, optionally substituted C1-C6 alkyl, heterocyclyl or polyamine, or X 117 and X 118 optionally form, together with the nitrogen to which they are bonded, a 4- to 7-membered monocyclic hetero ring optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen; and</span>
        <meta itemprop="num_attr" content="0312">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 120 and R 121</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C4-C24 alkyl or C4-C24 alkenyl,</span>
        <meta itemprop="num_attr" content="0313">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 119 and X 120</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom, optionally substituted linear or branched C1-C20 alkyl, C1-C20 alkenyl, C1-C20 alkynyl or C6-C20 acyl;</span>
        <meta itemprop="num_attr" content="0314">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 122 and R 123</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C1-C30 alkyl, C2-C30 alkenyl or C2-C30 alkynyl; and</span>
        <meta itemprop="num_attr" content="0315">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 112 , p 113 and p 114</span>
        <span itemprop="definition">are the same or different and are each 0, or an arbitrary positive integer</span>
        <meta itemprop="num_attr" content="0316">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 121 and X 122</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom, C1-C6 alkyl, cycloalkyl or cycloalkenyl, or X 121 and X 122 optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 120 and L 121</span>
        <span itemprop="definition">are the same or different and are each O, OC(O) or (O)CO;</span>
        <meta itemprop="num_attr" content="0317">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 124 and R 125</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl or C8-C24 alkenyl,</span>
        <meta itemprop="num_attr" content="0318">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 126 and R 127</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 heteroalkyl, C8-C24 heteroalkenyl or C8-C24 heteroalkynyl;</span>
        <meta itemprop="num_attr" content="0319">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 123</span>
        <span itemprop="definition">is a hydrogen atom or optionally substituted C1-C6 alkyl</span>
        <meta itemprop="num_attr" content="0320">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 124</span>
        <span itemprop="definition">is C1-C6 alkyl, substituted C1-C6 alkyl which is substituted with NR 4a R 4b , or optionally substituted C3-C7 heterocyclyl;</span>
        <meta itemprop="num_attr" content="0321">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 4a and R 4b</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom, C(  NH)NH 2 or optionally substituted C1-C6 alkyl, or R 4a and R 4b optionally form optionally substituted C3-C7 heterocyclyl together with the nitrogen atom to which they are bonded;</span>
        <meta itemprop="num_attr" content="0322">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 123 and X 124</span>
        <span itemprop="definition">optionally form optionally substituted C3-C7 heterocyclyl together with the nitrogen atom to which they are bonded,</span>
        <meta itemprop="num_attr" content="0323">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 123 and X 124</span>
        <span itemprop="definition">do not form imidazolyl, benzimidazolyl, or succinimidyl, and only one primary amine is allowed to be present on any one of X 123 and X 124 , or any primary amine is not present on any one of X 123 and X 124 , and neither X 123 nor X 124 is substituted amide;</span>
        <meta itemprop="num_attr" content="0324">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 126 and R 127</span>
        <span itemprop="definition">are C11 alkyl or C15 alkyl, X 123 is not a hydrogen atom;</span>
        <meta itemprop="num_attr" content="0325">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 126 and R 127</span>
        <span itemprop="definition">are C16 alkyl or C17 alkyl, R 126 and R 127 are not substituted with OH;</span>
        <meta itemprop="num_attr" content="0326">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 126 and R 127</span>
        <span itemprop="definition">are C18 alkyl, X 124 is not substituted with optionally substituted imidazolyl,</span>
        <meta itemprop="num_attr" content="0328">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 125 and X 126</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom, optionally substituted C1-C6 alkyl, heterocyclyl or polyamine, or X 125 and X 126 optionally form, together with the nitrogen to which they are bonded, a 4- to 7-membered monocyclic hetero ring optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen;</span>
        <meta itemprop="num_attr" content="0329">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 130</span>
        <span itemprop="definition">is a hydrogen atom or C1-C6 alkyl</span>
        <meta itemprop="num_attr" content="0330">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 128 and R 129</span>
        <span itemprop="definition">are the same or different and are each optionally substituted linear or branched C4-C24 alkyl or C4-C24 alkenyl;</span>
        <meta itemprop="num_attr" content="0331">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Y3 and Y4</span>
        <span itemprop="definition">are the same or different and are each an oxygen atom or CH 2 ;</span>
        <meta itemprop="num_attr" content="0332">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p115</span>
        <span itemprop="definition">is an integer of 0 to 2</span>
        <meta itemprop="num_attr" content="0333">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 127 and X 128</span>
        <span itemprop="definition">are the same or different and are each C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl, or</span>
        <meta itemprop="num_attr" content="0334">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 127 and X 128</span>
        <span itemprop="definition">form, together with the nitrogen atom to which they are bonded, a hetero ring having one or two nitrogen atoms;</span>
        <meta itemprop="num_attr" content="0335">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 122</span>
        <span itemprop="definition">is C(O)O, OC(O), C(O)N(X 130 ), N(X 130 )C(O), OC(O)O, OC(O)N(X 130 ), N(X 130 )C(O)N(X 130 ), or N(X 130 )C(O)O;</span>
        <meta itemprop="num_attr" content="0336">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each X 130 present</span>
        <span itemprop="definition">is independently a hydrogen atom or C1-C3 alkyl</span>
        <meta itemprop="num_attr" content="0337">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a</span>
        <span itemprop="definition">is 1, 2, 3, 4, 5, or 6;</span>
        <meta itemprop="num_attr" content="0338">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">b</span>
        <span itemprop="definition">0, 1, 2, or 3;</span>
        <meta itemprop="num_attr" content="0339">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 129</span>
        <span itemprop="definition">is absent, or hydrogen or C1-C3 alkyl</span>
        <meta itemprop="num_attr" content="0340">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 131 and R 132</span>
        <span itemprop="definition">are the same or different and are each alkyl having 12 to 24 carbon atoms, alkenyl having 12 to 24 carbon atoms, or alkoxy having 12 to 24 carbon atoms, which has one or more biodegradable groups; the biodegradable groups are each independently integrated in the alkyl group having 12 to 24 carbon atoms, the alkenyl group having 12 to 24 carbon atoms, or the alkoxy group having 12 to 24 carbon atoms, or present at a terminal of the alkyl group having 12 to 24 carbon atoms, the alkenyl group having 12 to 24 carbon atoms, or the alkoxy group having 12 to 24 carbon atoms, wherein</span>
        <meta itemprop="num_attr" content="0341">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the biodegradable group thus integrated</span>
        <span itemprop="definition">is C(O)O, OC(O), C(O)N(X 130 ), or N(X 130 ) C(O)</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the group having the biodegradable group present at the terminal</span>
        <span itemprop="definition">is C(O)OC1-C4 alkyl, OC(O)C1-C4 alkyl, C(O)N(X 130 )C1-C4 alkyl, or N(X 130 )C(O)C1-C4 alkyl</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 131 and R 132</span>
        <span itemprop="definition">each have at least four carbon atoms between the biodegradable group and the asterisked (*) tertiary carbon atom</span>
        <meta itemprop="num_attr" content="0342">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 133 and R 134</span>
        <span itemprop="definition">are the same or different and are each linear or branched C1-C9 alkyl, C2-C11 alkenyl or C2-C11 alkynyl;</span>
        <meta itemprop="num_attr" content="0343">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 123 and L 124</span>
        <span itemprop="definition">are the same or different and are each linear C5-C18 alkylene or linear C5-C18 alkenylene, or forms a hetero ring with N to which they are bonded;</span>
        <meta itemprop="num_attr" content="0344">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 125</span>
        <span itemprop="definition">is a single bond or COO</span>
        <meta itemprop="num_attr" content="0345">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 127</span>
        <span itemprop="definition">is S or O</span>
        <meta itemprop="num_attr" content="0347">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 126</span>
        <span itemprop="definition">is a single bond or linear or branched C1-C6 alkylene, or forms a hetero ring with N to which they are bonded via C(O);</span>
        <meta itemprop="num_attr" content="0348">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 128</span>
        <span itemprop="definition">is linear or branched C1-C6 alkylene</span>
        <meta itemprop="num_attr" content="0349">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 131 and X 132</span>
        <span itemprop="definition">are the same or different and are each hydrogen or linear or branched C1-C6 alkyl</span>
        <meta itemprop="num_attr" content="0350">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 131</span>
        <span itemprop="definition">is C2-C4 alkylene or CH 2 SCH 2 CH 2 ;</span>
        <meta itemprop="num_attr" content="0351">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 129 and L 130</span>
        <span itemprop="definition">are the same or different and are each C1-C6 alkyl</span>
        <meta itemprop="num_attr" content="0352">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 135 and R 136</span>
        <span itemprop="definition">are the same or different and are each C10-C30 alkyl or C10-C30 alkenyl;</span>
        <meta itemprop="num_attr" content="0353">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 133 and X 134</span>
        <span itemprop="definition">are the same or different and are each hydrogen, C1-C6 alkyl or CH 2 CH 2 OH,</span>
        <meta itemprop="num_attr" content="0354">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 137 and R 138</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, C8-24 alkenylthioethyl, or C8-C24 alkynylthioethyl;</span>
        <meta itemprop="num_attr" content="0355">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 135</span>
        <span itemprop="definition">is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (C):</span>
        <meta itemprop="num_attr" content="0356">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 136 and X 137</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X 136 and X 137 optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 132</span>
        <span itemprop="definition">is S or O; and</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 115</span>
        <span itemprop="definition">is an integer from 2 to 4, formula (D):</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 138 and X 139</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X 138 and X 139 optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p 116 is an integer from 1 to 4, or formula (E):</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 140 and X 141</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X 140 and X 141 optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p 117 is an integer from 1 to 4, and formula (CL-XIX)</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 139 and R 140</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</span>
        <meta itemprop="num_attr" content="0357">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 133</span>
        <span itemprop="definition">is S or O</span>
        <meta itemprop="num_attr" content="0358">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 142</span>
        <span itemprop="definition">is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (F):</span>
        <meta itemprop="num_attr" content="0359">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 143 and X 144</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X 143 and X 144 optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 134</span>
        <span itemprop="definition">is S or O; and</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 118</span>
        <span itemprop="definition">is an integer from 2 to 4, or formula (G):</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 145 and X 146</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X 145 and X 146 optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p 119 is an integer from 1 to 4.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">One aspect of the present invention</span>
        <span itemprop="definition">provides a compound represented by formula (CL-XVIII) or (CL-XIX), or a pharmaceutically acceptable salt thereof.</span>
        <meta itemprop="num_attr" content="0360">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a hydrogen ion</span>
        <span itemprop="definition">may be coordinated on a lone pair of electrons on the nitrogen atom in the structure.</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the hydrogen ion</span>
        <span itemprop="definition">may form a salt with a pharmaceutically acceptable anion.</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound represented by formula (CL-XVIII) or (CL-XIX), or the pharmaceutically acceptable salt thereof</span>
        <span itemprop="definition">also encompasses a cationic lipid in which a hydrogen ion may be coordinated on a lone pair of electrons on the nitrogen atom in the structure.</span>
        <meta itemprop="num_attr" content="0361">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">examples of the pharmaceutically acceptable anion</span>
        <span itemprop="definition">include: inorganic ions such as chloride ions, bromide ions, nitrate ions, sulfate ions and phosphate ions; and organic acid ions such as acetate ions, oxalate ions, maleate ions, fumarate ions, citrate ions, benzoate ions and methanesulfonate ions.</span>
        <meta itemprop="num_attr" content="0362">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">inorganic ions</span>
        <span itemprop="definition">such as chloride ions, bromide ions, nitrate ions, sulfate ions and phosphate ions</span>
        <meta itemprop="num_attr" content="0362">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">organic acid ions</span>
        <span itemprop="definition">such as acetate ions, oxalate ions, maleate ions, fumarate ions, citrate ions, benzoate ions and methanesulfonate ions.</span>
        <meta itemprop="num_attr" content="0362">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the pharmaceutically acceptable salt of the compound represented by formula (CL-XVIII) or (CL-XIX) of the present invention</span>
        <span itemprop="definition">include hydrochloride, bromate, nitrate, sulfate, phosphate, acetate, oxalate, maleate, fumarate, citrate, benzoate and methanesulfonate.</span>
        <meta itemprop="num_attr" content="0363">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Some compounds represented by formula (CL-XVIII) or (CL-XIX) of the present invention</span>
        <span itemprop="definition">may have stereoisomers such as geometric isomers and optical isomers, tautomers, or the like.</span>
        <meta itemprop="num_attr" content="0364">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (I) of the present invention</span>
        <span itemprop="definition">encompasses all possible isomers including them, and mixtures thereof.</span>
        <meta itemprop="num_attr" content="0364">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">atoms in formula (CL-XVIII) or (CL-XIX) of the present invention</span>
        <span itemprop="definition">may be replaced with their corresponding isotopic atoms.</span>
        <meta itemprop="num_attr" content="0365">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound represented by formula (CL-XVIII) or (CL-XIX)</span>
        <span itemprop="definition">also encompasses such a compound containing isotopic atoms replaced therefor.</span>
        <meta itemprop="num_attr" content="0365">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">some or all of the hydrogen atoms in compound (I)</span>
        <span itemprop="definition">may each be a hydrogen atom having an atomic weight of 2 (deuterium atom).</span>
        <meta itemprop="num_attr" content="0365">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound derived from formula (CL-XVIII) or (CL-XIX) of the present invention by the replacement of some or all of the atoms with their corresponding isotopic atoms</span>
        <span itemprop="definition">can be produced in the same way as in each production method described above by using commercially available building blocks.</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound derived from formula (CL-XVIII) or (CL-XIX) by the replacement of some or all of the hydrogen atoms with deuterium atoms</span>
        <span itemprop="definition">can also be produced by use of, for example, a method which involves deuterating an alcohol, a carboxylic acid, or the like using an iridium complex as a catalyst and heavy water as a deuterium source [see J. Am. Chem. Soc., Vol. 124, No. 10, 2092 (2002)].</span>
        <meta itemprop="num_attr" content="0366">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">examples of the linear or branched C10-C24 alkyl</span>
        <span itemprop="definition">include decyl, undecyl, dodecyl, tridecyl, 6,10-dimethylundec-2-yl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, icosyl, henicosyl, docosyl, tricosyl and tetracosyl, preferably decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl, more preferably tridecyl, tetradecyl, pentadecyl, hexadecyl, heptade</span>
        <meta itemprop="num_attr" content="0367">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C10-C24 alkenyl</span>
        <span itemprop="definition">can be linear or branched C10-C24 alkenyl containing one to three double bonds. Examples thereof include (Z)-dodec-7-enyl, (Z)-tetradec-7-enyl, (Z)-tetradec-9-enyl, (Z)-hexadec-4-enyl, (Z)-hexadec-7-enyl, (E)-hexadec-7-enyl, (Z)-hexadec-9-enyl, (7Z,10Z)-hexadeca-7,10-dienyl, (7Z,10Z,13Z)-hexadeca-7,10,13-trienyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (9Z,12Z)-octadeca-9,</span>
        <meta itemprop="num_attr" content="0368">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C10-C24 alkynyl</span>
        <span itemprop="definition">can be linear or branched C10-C24 alkynyl containing one to three triple bonds.</span>
        <meta itemprop="num_attr" content="0369">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">include dec-9-ynyl, dodec-4-ynyl, dodec-11-ynyl, tetradec-5-ynyl, tetradec-6-ynyl, hexadec-7-ynyl, hexadeca-3,5-diynyl, hexadeca-5,7-diynyl and octadec-9-ynyl, preferably hexadec-7-ynyl and octadec-9-ynyl, more preferably octadec-9-ynyl.</span>
        <meta itemprop="num_attr" content="0369">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 101 and R 103</span>
        <span itemprop="definition">are preferably the same linear or branched C10-C24 alkyl, C10-C24 alkenyl or C10-C24 alkynyl, more preferably the same linear or branched C10-C24 alkyl or C10-C24 alkenyl, further preferably the same linear C10-C24 alkenyl.</span>
        <meta itemprop="num_attr" content="0370">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C3 alkylene</span>
        <span itemprop="definition">include methylene, ethylene and propylene, preferably methylene and ethylene, more preferably methylene.</span>
        <meta itemprop="num_attr" content="0371">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C6 alkyl</span>
        <span itemprop="definition">include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, cyclopropylmethyl, pentyl, isopentyl, sec-pentyl, neopentyl, tert-pentyl, cyclopentyl, hexyl and cyclohexyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, sec-pentyl, tert-pentyl, neopentyl and hexyl, more preferably methyl, ethyl and propyl.</span>
        <meta itemprop="num_attr" content="0372">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C3-C6 alkenyl</span>
        <span itemprop="definition">include allyl, 1-propenyl, butenyl, pentenyl and hexenyl, preferably allyl.</span>
        <meta itemprop="num_attr" content="0373">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each of the monoalkylamino and the dialkylamino</span>
        <span itemprop="definition">can be amino substituted with one or two same or different C1-C6 alkyl (as defined above) groups, or C1-C6 alkyl (as defined above) substituted with amino, methylamino, ethylamino, dimethylamino, diethylamino, pyrrolidinyl, piperidyl or morpholinyl.</span>
        <meta itemprop="num_attr" content="0374">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">include methylamino, ethylamino, propylamine, butylamino, pentylamino, hexylamino, dimethylamino, diethylamino, ethylmethylamino, methylpropylamino, butylmethylamino, methylpentylamino, hexylmethylamino, aminoethylamino, aminopropylamino, (aminoethyl)methylamino and bis(aminoethyl)amino, preferably methylamino, ethylamino, dimethylamino, diethylamino, aminopropylamino and bis(aminoethyl)amino, more preferably methylamino and dimethylamino.</span>
        <meta itemprop="num_attr" content="0374">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the trialkylammonio</span>
        <span itemprop="definition">can be ammonio substituted by three same or different C1-C6 alkyl (as defined above) groups, or C1-C6 alkyl (as defined above) substituted with amino, methylamino, ethylamino, dimethylamino, diethylamino, pyrrolidinyl, piperidyl or morpholinyl.</span>
        <meta itemprop="num_attr" content="0375">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">include trimethylammonio, ethyldimethylammonio, diethylmethylammonio, triethylammonio, tripropylammonio, tributylammonio, tripentylammonio, trihexylammonio, tris(aminoethyl)ammonio, (aminoethyl)dimethylammonio and bis(aminoethyl)methylammonio, preferably trimethylammonio, triethylammonio, tris(aminoethyl)ammonio, (aminoethyl)dimethylammonio and bis(aminoethyl)methylammonio, more preferably trimethylammonio.</span>
        <meta itemprop="num_attr" content="0375">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the trialkylammonio</span>
        <span itemprop="definition">may form a salt with a pharmaceutically acceptable anion (as defined above).</span>
        <meta itemprop="num_attr" content="0376">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkoxy</span>
        <span itemprop="definition">can be hydroxy substituted with C1-C6 alkyl (as defined above) or C1-C6 alkyl (as defined above) substituted with amino, methylamino, ethylamino, dimethylamino, diethylamino, pyrrolidinyl, piperidyl or morpholinyl.</span>
        <meta itemprop="num_attr" content="0377">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">include methoxy, ethoxy, propyloxy, butyloxy, pentyloxy, hexyloxy, aminoethoxy and methylaminoethoxy, preferably methoxy, ethoxy, aminoethoxy and methylaminoethoxy, more preferably methoxy.</span>
        <meta itemprop="num_attr" content="0377">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each of the monoalkylcarbamoyl and the dialkylcarbamoyl</span>
        <span itemprop="definition">can be carbamoyl substituted with one or two same or different C1-C6 alkyl (as defined above) groups, or C1-C6 alkyl (as defined above) substituted with amino, methylamino, ethylamino, dimethylamino, diethylamino, pyrrolidinyl, piperidyl or morpholinyl.</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples thereof</span>
        <span itemprop="definition">include methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, butylcarbamoyl, pentylcarbamoyl, hexylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, methylpropylcarbamoyl, butylmethylcarbamoyl, methylpentylcarbamoyl, hexylmethylcarbamoyl, aminoethylcarbamoyl, aminopropylcarbamoyl, (aminoethyl)methylcarbamoyl and bis(aminoethyl)carbamoyl, preferably methylcarbamoyl, ethylcarbamoyl and dimethylcarbamoyl, more preferably methylcarbamoyl and dimethylcarb</span>
        <meta itemprop="num_attr" content="0378">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each of L 101 and L 102</span>
        <span itemprop="definition">is more preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0379">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 101 and R 102</span>
        <span itemprop="definition">are the same or different and are each preferably dodecyl, tetradecyl, (Z)-dodec-7-enyl, (Z)-tetradec-7-enyl, (Z)-hexadec-4-enyl, (Z)-hexadec-7-enyl, (E)-hexadec-7-enyl, (Z)-hexadec-9-enyl, (7Z,10Z)-hexadeca-7,10-dienyl, (7Z,10Z,13Z)-hexadeca-7,10,13-trienyl, (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, more preferably (Z)-tetradec-7-enyl, (Z)-hexadec-7-enyl</span>
        <meta itemprop="num_attr" content="0379">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 101</span>
        <span itemprop="definition">is more preferably a hydrogen atom, methyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, further preferably a hydrogen atom, methyl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, hydroxy and carbamoyl, still further preferably a hydrogen atom, methyl or the like.</span>
        <meta itemprop="num_attr" content="0380">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 101 and R 102</span>
        <span itemprop="definition">are the same or different and are each preferably tetradecyl, hexadecyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, or (11Z,14Z)-icosa-11,14-dienyl, more preferably (Z)-octadec-9-enyl or (9Z,12Z)</span>
        <meta itemprop="num_attr" content="0381">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 101</span>
        <span itemprop="definition">is more preferably a hydrogen atom, methyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, further preferably a hydrogen atom, methyl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, hydroxy and carbamoyl, most preferably a hydrogen atom, methyl or the like.</span>
        <meta itemprop="num_attr" content="0382">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 103</span>
        <span itemprop="definition">is CO or COO, preferably CO.</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 101</span>
        <span itemprop="definition">is preferably aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 1,4-diaminobutyl, 1,5-diaminopentyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl or the like, more preferably 1,2-diaminoethyl, 1,3-diaminopropyl, 1,4-diaminobutyl or 1,5-diaminopentyl.</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 101 and R 102</span>
        <span itemprop="definition">are the same or different and are each preferably tetradecyl, hexadecyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl or (11Z,14Z)-icosa-11,14-dienyl, more preferably (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, further preferably are the same</span>
        <meta itemprop="num_attr" content="0383">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 103</span>
        <span itemprop="definition">is more preferably a single bond.</span>
        <meta itemprop="num_attr" content="0384">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 101</span>
        <span itemprop="definition">is more preferably a hydrogen atom, methyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, or the like, further preferably a hydrogen atom, methyl, hydroxymethyl, 2-hydroxyethyl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 2-hydroxy-3-methoxypropyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl</span>
        <meta itemprop="num_attr" content="0385">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 101</span>
        <span itemprop="definition">is pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, and at least one of the substituents is amino, monoalkylamino, dialkylamino, trialkylammonio, pyrrolidinyl, piperidyl, morpholinyl or the like.</span>
        <meta itemprop="num_attr" content="0386">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 3</span>
        <span itemprop="definition">is further preferably aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 3-aminopropyl, 1,4-diaminobutyl, 4-aminobutyl, 1,5-diaminopentyl, 5-aminopentyl, (N,N-dimethylamino)methyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 1-hydroxy-2-aminoethyl, 1-amino-2-hydroxyethyl or the like, most preferably 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 3-aminopropyl, 1,4-diaminobutyl, 4-aminobutyl, 1,5-diaminopentyl, 5-aminopentyl or the like.</span>
        <meta itemprop="num_attr" content="0386">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 103</span>
        <span itemprop="definition">is a single bond</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 101</span>
        <span itemprop="definition">is a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 101 and R 102</span>
        <span itemprop="definition">are the same or different and are each preferably dodecyl, tetradecyl, (Z)-dodec-7-enyl, (Z)-tetradec-7-enyl, (Z)-hexadec-4-enyl, (Z)-hexadec-7-enyl, (E)-hexadec-7-enyl, (Z)-hexadec-9-enyl, (7Z,10Z)-hexadeca-7,10-dienyl, (7Z,10Z,13Z)-hexadeca-7,10,13-trienyl, (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, more preferably are the same or different and are each (Z)-te</span>
        <meta itemprop="num_attr" content="0387">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 103</span>
        <span itemprop="definition">is a single bond</span>
        <meta itemprop="num_attr" content="0388">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 101</span>
        <span itemprop="definition">is methyl.</span>
        <meta itemprop="num_attr" content="0388">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 101 and R 102</span>
        <span itemprop="definition">are the same or different and are each preferably dodecyl, tetradecyl, (Z)-dodec-7-enyl, (Z)-tetradec-7-enyl, (Z)-hexadec-4-enyl, (Z)-hexadec-7-enyl, (E)-hexadec-7-enyl, (Z)-hexadec-9-enyl, (7Z,10Z)-hexadeca-7,10-dienyl, (7Z,10Z,13Z)-hexadeca-7,10,13-trienyl, (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, more preferably are the same or different and are each (Z)-tetradec-7</span>
        <meta itemprop="num_attr" content="0388">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">examples of the linear or branched C12-C24 alkyl</span>
        <span itemprop="definition">include dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl, preferably dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadec</span>
        <meta itemprop="num_attr" content="0389">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C12-C24 alkenyl</span>
        <span itemprop="definition">can be linear or branched C12-C24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-oct</span>
        <meta itemprop="num_attr" content="0390">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C12-C24 alkynyl</span>
        <span itemprop="definition">can be linear or branched C12-C24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-ynyl and o</span>
        <meta itemprop="num_attr" content="0391">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the monoalkylamino, the dialkylamino, the trialkylammonio, the alkoxy, the monoalkylcarbamoyl and the dialkylcarbamoyl</span>
        <span itemprop="definition">are each as defined above in formula (CL-I).</span>
        <meta itemprop="num_attr" content="0393">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 103 and R 104</span>
        <span itemprop="definition">are preferably the same linear or branched C12-C24 alkyl, C12-C24 alkenyl or C12-C24 alkynyl, more preferably the same linear or branched C12-C24 alkyl or C12-C24 alkenyl.</span>
        <meta itemprop="num_attr" content="0394">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 104 and L 105</span>
        <span itemprop="definition">are more preferably the same and O, COO or OCO.</span>
        <meta itemprop="num_attr" content="0395">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 103 and R 104</span>
        <span itemprop="definition">are the same or different and are each more preferably dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-ico</span>
        <meta itemprop="num_attr" content="0396">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of R 103 and R 104</span>
        <span itemprop="definition">is more preferably tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (Z)-nonadec-10-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icos</span>
        <meta itemprop="num_attr" content="0397">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 101 and p 102</span>
        <span itemprop="definition">are more preferably 0 or 1 at the same time.</span>
        <meta itemprop="num_attr" content="0398">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 106 and L 107</span>
        <span itemprop="definition">more preferably together form a single bond or C1-C3 alkylene.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 102</span>
        <span itemprop="definition">is more preferably a hydrogen atom, methyl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, further preferably a hydrogen atom, methyl, or C1-C6 alkyl,</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in monoalkylamino, dialkylamino, trialkylammonio, alkoxy, monoalkylcarbamoyl and dialkylcarbamoyl</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two or three alkyl moieties in dialkylamino, trialkylammonio and dialkylcarbamoyl</span>
        <span itemprop="definition">are the same as or different from each other.</span>
        <meta itemprop="num_attr" content="0399">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 108</span>
        <span itemprop="definition">is CO or COO, preferably CO.</span>
        <meta itemprop="num_attr" content="0400">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 101 and p 102</span>
        <span itemprop="definition">are the same or different and are each preferably 1 to 3.</span>
        <meta itemprop="num_attr" content="0401">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 102</span>
        <span itemprop="definition">is preferably a hydrogen atom, methyl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, more preferably a hydrogen atom, methyl or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, trialkylammonio, hydroxy</span>
        <meta itemprop="num_attr" content="0402">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in monoalkylamino, dialkylamino, trialkylammonio, alkoxy, monoalkylcarbamoyl and dialkylcarbamoyl</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0402">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two or three alkyl moieties in dialkylamino, trialkylammonio, and dialkylcarbamoyl</span>
        <span itemprop="definition">are the same as or different from each other.</span>
        <meta itemprop="num_attr" content="0402">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 108</span>
        <span itemprop="definition">is preferably a single bond.</span>
        <meta itemprop="num_attr" content="0403">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of L 104 and L 105</span>
        <span itemprop="definition">is preferably O.</span>
        <meta itemprop="num_attr" content="0403">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 102</span>
        <span itemprop="definition">is preferably a hydrogen atom, methyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, or the like, more preferably a hydrogen atom, methyl, hydroxymethyl, 2-hydroxyethyl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 2-hydroxy-3-methoxypropyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl,</span>
        <meta itemprop="num_attr" content="0404">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in monoalkylamino, dialkylamino, trialkylammonio, alkoxy, monoalkylcarbamoyl and dialkylcarbamoyl</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0404">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two or three alkyl moieties in dialkylamino, trialkylammonio, and dialkylcarbamoyl</span>
        <span itemprop="definition">are the same as or different from each other.</span>
        <meta itemprop="num_attr" content="0404">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 104 and L 105</span>
        <span itemprop="definition">are more preferably O.</span>
        <meta itemprop="num_attr" content="0405">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 108</span>
        <span itemprop="definition">is a single bond and X 102 is a hydrogen atom</span>
        <meta itemprop="num_attr" content="0405">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 104 and L 105</span>
        <span itemprop="definition">are preferably the same and COO or OCO, more preferably COO.</span>
        <meta itemprop="num_attr" content="0405">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 104 and L 105</span>
        <span itemprop="definition">are preferably the same and COO or OCO, more preferably COO.</span>
        <meta itemprop="num_attr" content="0406">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 102</span>
        <span itemprop="definition">is preferably pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, and at least one of the substituents is preferably amino, monoalkylamino, dialkylamino, trialkylammonio, pyrrolidinyl, piperidyl or morpholinyl.</span>
        <meta itemprop="num_attr" content="0407">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 102</span>
        <span itemprop="definition">is more preferably aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 3-aminopropyl, 1,4-diaminobutyl, 4-aminobutyl, 1,5-diaminopentyl, 5-aminopentyl, (N,N-dimethylamino)methyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 1-amino-2-hydroxyethyl or the like, further preferably aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 3-aminopropyl, 1,4-diaminobutyl, 4-aminobutyl, 1,5-diaminopentyl, 5-aminopentyl or the like.</span>
        <meta itemprop="num_attr" content="0407">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in monoalkylamino, dialkylamino, trialkylammonio, alkoxy, monoalkylcarbamoyl and dialkylcarbamoyl</span>
        <span itemprop="definition">is as defined in the C1-C6 alkyl.</span>
        <meta itemprop="num_attr" content="0407">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two or three alkyl moieties in dialkylamino, trialkylammonio and dialkylcarbamoyl</span>
        <span itemprop="definition">are the same as or different from each other.</span>
        <meta itemprop="num_attr" content="0407">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 104 and L 105</span>
        <span itemprop="definition">are preferably the same and COO or OCO, more preferably COO.</span>
        <meta itemprop="num_attr" content="0408">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">examples of the alkyl moiety in C8-C24 alkyloxyethyl and C8-C24 alkyloxypropyl</span>
        <span itemprop="definition">include those listed about the linear or branched C8-C24 alkyl.</span>
        <meta itemprop="num_attr" content="0410">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkynyl moiety in alkynyloxyethyl and alkynyloxypropyl</span>
        <span itemprop="definition">examples include those listed about the linear or branched C8-C24 alkynyl.</span>
        <meta itemprop="num_attr" content="0411">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105 and R 106</span>
        <span itemprop="definition">are preferably the same or different and are each linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably are the same or different and are each linear or branched C8-C24 alkenyl, further preferably are the same or different and are each linear C8-C24 alkenyl. Also, R 105 and R 106 are more preferably the same. In this case, linear or branched C12-C24 alkyl, C12-C24 alkenyl or C12-C24 alkynyl is preferred, and linear C12-C24 alkenyl is more preferred.</span>
        <meta itemprop="num_attr" content="0412">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C12-C24 alkyl, C12-C24 alkenyl and C12-C24 alkynyl</span>
        <span itemprop="definition">are each as defined above in formula (CL-II).</span>
        <meta itemprop="num_attr" content="0412">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105 and R 106</span>
        <span itemprop="definition">are preferably the same or different and are each linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably are the same or different and are each linear or branched C8-C24 alkenyl, further preferably are the same or different and are each linear C8-C24 alkenyl. Also, R 105 and R 106 are more preferably the same. In this, case, linear or branched C15-C20 alkyl, C15-C20 alkenyl or C15-C20 alkynyl is preferred, and linear C15-C20 alkenyl is more preferred.</span>
        <meta itemprop="num_attr" content="0413">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C15-C20 alkyl, C15-C20 alkenyl and C15-C20 alkynyl</span>
        <span itemprop="definition">are each as defined above in formulas (I) to (IV), and the same groups as those described therein are preferred.</span>
        <meta itemprop="num_attr" content="0413">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105 and R 106</span>
        <span itemprop="definition">are different, preferably, R 105 is linear or branched C15-C20 alkyl, C15-C20 alkenyl or C15-C20 alkynyl, and R 106 is linear or branched C8-C12 alkyl.</span>
        <meta itemprop="num_attr" content="0414">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">examples of the linear or branched C8-C12 alkyl</span>
        <span itemprop="definition">include octyl, nonyl, decyl, undecyl and dodecyl, preferably octyl, decyl and dodecyl.</span>
        <meta itemprop="num_attr" content="0414">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105</span>
        <span itemprop="definition">is linear C15-C20 alkenyl</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 106</span>
        <span itemprop="definition">is linear C8-C12 alkyl.</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105</span>
        <span itemprop="definition">is (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 106</span>
        <span itemprop="definition">is octyl, decyl or dodecyl.</span>
        <meta itemprop="num_attr" content="0415">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105 and R 106</span>
        <span itemprop="definition">are different, also preferably, R 105 is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, and R 106 is C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl or C8-C24 alkynyloxypropyl.</span>
        <meta itemprop="num_attr" content="0416">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105</span>
        <span itemprop="definition">is linear C8-C24 alkenyl</span>
        <meta itemprop="num_attr" content="0416">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 106</span>
        <span itemprop="definition">is C8-C24 alkenyloxyethyl.</span>
        <meta itemprop="num_attr" content="0416">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105</span>
        <span itemprop="definition">is (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl or (11Z,14Z)-icosa-11,14-dienyl</span>
        <meta itemprop="num_attr" content="0416">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 106</span>
        <span itemprop="definition">is (Z)-octadec-9-enyloxyethyl, (9Z,12Z)-octadeca-9,12-dienyloxyethyl or (11Z,14Z)-icosa-11,14-dienyloxyethyl.</span>
        <meta itemprop="num_attr" content="0416">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105</span>
        <span itemprop="definition">is (9Z,12Z)-octadeca-9,12-dienyl</span>
        <meta itemprop="num_attr" content="0416">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 106</span>
        <span itemprop="definition">is (9Z,12Z)-octadeca-9,12-dienyloxyethyl.</span>
        <meta itemprop="num_attr" content="0416">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105 and R 106</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkyl or C8-C24 alkenyl</span>
        <meta itemprop="num_attr" content="0417">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 105 and R 106</span>
        <span itemprop="definition">are preferably the same or different and are each tetradecyl, hexadecyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl or (Z)-doco</span>
        <meta itemprop="num_attr" content="0417">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 107</span>
        <span itemprop="definition">is as defined above in R 105 , and R 107 is preferably the same group as in R 105 .</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 108</span>
        <span itemprop="definition">is preferably linear C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl, C8-C24 alkynyloxypropyl, C8-C24 alkyloxyethoxyethyl, C8-C24 alkenyloxyethoxyethyl or C8-C24 alkynyloxyethoxyethyl, more preferably linear C8-C24 alkyloxyethyl, C8-C24 alkenyloxyethyl or C8-C24 alkynyloxyethyl.</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 107</span>
        <span itemprop="definition">is linear C15-C20 alkenyl</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 108</span>
        <span itemprop="definition">is</span>
        <meta itemprop="num_attr" content="0418">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 109 and R 110</span>
        <span itemprop="definition">are as defined above in R 105 and R 106 , respectively, and preferably the same groups as in R 109 and R 110 described above.</span>
        <meta itemprop="num_attr" content="0419">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 109 and R 110</span>
        <span itemprop="definition">are preferably the same linear or branched C15-C20 alkyl, C15-C20 alkenyl or C15-C20 alkynyl, more preferably are the same and (9Z,12Z)-octadeca-9,12-dienyl.</span>
        <meta itemprop="num_attr" content="0419">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C3 alkyl represented by X 103 and X 104</span>
        <span itemprop="definition">include methyl, ethyl, propyl, isopropyl and cyclopropyl, preferably methyl and ethyl, more preferably methyl.</span>
        <meta itemprop="num_attr" content="0420">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C2-C8 alkylene together formed by X 103 and X 104</span>
        <span itemprop="definition">include ethylene, propylene, butylene, pentylene, hexylene, heptylene and octylene, preferably butylene, pentylene and hexylene, more preferably hexylene.</span>
        <meta itemprop="num_attr" content="0421">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C2-C8 alkylene formed by X 103 together with L 111</span>
        <span itemprop="definition">include ethylene, propylene, butylene, pentylene, hexylene, heptylene and octylene, preferably propylene, butylene and pentylene, more preferably propylene and butylene, further preferably propylene.</span>
        <meta itemprop="num_attr" content="0422">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 103 and X 104</span>
        <span itemprop="definition">are the same or different and are each methyl or ethyl, or together form butylene, pentylene or hexylene, or X 103 forms ethylene, propylene or butylene together with L 111 .</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 103 and X 104</span>
        <span itemprop="definition">are the same or different and are each methyl or ethyl, or together form butylene, pentylene or hexylene.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 103</span>
        <span itemprop="definition">forms ethylene, propylene or butylene together with L 111</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 104</span>
        <span itemprop="definition">is methyl or ethyl.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 103 and X 104</span>
        <span itemprop="definition">are the same and methyl, or together form hexylene.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 103</span>
        <span itemprop="definition">forms propylene or butylene together with L 111</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 104</span>
        <span itemprop="definition">is methyl.</span>
        <meta itemprop="num_attr" content="0423">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the C1-C6 alkyl, the C3-C6 alkenyl, the monoalkylamino, the alkoxy, the monoalkylcarbamoyl and the di alkyl carbamoyl represented by L 111</span>
        <span itemprop="definition">are each as defined above in formula (CL-I).</span>
        <meta itemprop="num_attr" content="0424">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 111</span>
        <span itemprop="definition">is a hydrogen atom, C1-C6 alkyl, amino, monoalkylamino, hydroxy, alkoxy or C1-C6 alkyl substituted with one to three same or different substituents selected from amino, monoalkylamino, hydroxy and alkoxy, or forms C2-C6 alkylene together with X 103 . More preferably, L 111 is a hydrogen atom, methyl, amino, methylamino, hydroxy, methoxy or methyl substituted with one to three same or different substituents selected from amino and hydroxy, or forms ethylene, propylene or butylene together with X 103 .</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 111</span>
        <span itemprop="definition">is a hydrogen atom, C1-C3 alkyl, or hydroxy, or forms propylene or butylene together with X 103 . Most preferably, L 111 is a hydrogen atom or forms propylene together with X 103 .</span>
        <meta itemprop="num_attr" content="0425">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C6 alkylene represented by L 109 and L 110</span>
        <span itemprop="definition">include methylene, ethylene, propylene, butylene, pentylene and hexylene, preferably methylene and ethylene.</span>
        <meta itemprop="num_attr" content="0426">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 109</span>
        <span itemprop="definition">is preferably methylene, ethylene, propylene or the like, more preferably methylene, ethylene or the like.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 110</span>
        <span itemprop="definition">is preferably a single bond, methylene, ethylene or the like, more preferably a single bond, methylene or the like.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the sum of the numbers of carbon atoms of L 109 and L 110</span>
        <span itemprop="definition">is preferably 1 to 3, more preferably 2.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 103 and X 104</span>
        <span itemprop="definition">are the same or different and are each methyl, ethyl or the like, and L 111 is a hydrogen atom, methyl, amino, methylamino, hydroxy, methoxy or methyl substituted with one to three same or different substituents selected from amino and hydroxy, or the like; X 103 and X 104 together form pentylene, hexylene, heptylene or the like, and L 111 is a hydrogen atom, methyl, amino, methylamino, hydroxy, methoxy or methyl substituted with one to three same or different substituents selected from amino and hydroxy, or the like; or X 103 forms propylene, butylene, pentylene or the like together with L 111 , and X 104 is methyl, ethyl or the like.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each of X 103 and X 104</span>
        <span itemprop="definition">is methyl, and L 111 is a hydrogen atom; X 103 and X 104 together form pentylene or hexylene, and L 111 is a hydrogen atom; or X 103 forms propylene together with L 111 , and X 104 is methyl or the like.</span>
        <meta itemprop="num_attr" content="0427">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C4 alkyl represented by X 105</span>
        <span itemprop="definition">include methyl, ethyl, propyl, isopropyl, butyl and cyclobutyl, preferably methyl.</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 105</span>
        <span itemprop="definition">is further preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0428">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">examples of the C1-C3 alkyl represented by X 105 </span>
        <span itemprop="definition">include methyl, ethyl, propyl, isopropyl and cyclopropyl, preferably methyl, ethyl and isopropyl, more preferably methyl and ethyl.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 105 </span>
        <span itemprop="definition">is further preferably a hydrogen atom, methyl or the like, most preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0429">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C3 alkylene represented by L 112</span>
        <span itemprop="definition">include methylene, ethylene and propylene, preferably methylene and ethylene.</span>
        <meta itemprop="num_attr" content="0430">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C4 alkyl in the optionally substituted C1-C4 alkyl represented by R 115 in formula (CL-VII)</span>
        <span itemprop="definition">include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl and cyclopropylmethyl, preferably methyl and ethyl, more preferably methyl.</span>
        <meta itemprop="num_attr" content="0432">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl moiety in the optionally substituted C1-C4 alkoxy</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0433">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">substituent for the optionally substituted C1-C4 alkyl</span>
        <span itemprop="definition">include amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two alkyl moieties in dialkylamino and dialkylcarbamoyl</span>
        <span itemprop="definition">may be the same as or different from each other.</span>
        <meta itemprop="num_attr" content="0434">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">acyl in the optionally substituted C1-C4 acyloxy</span>
        <span itemprop="definition">examples include formyl, acetyl, propanoyl, 2-methylpropanoyl, cyclopropanoyl and butanoyl, preferably acetyl.</span>
        <meta itemprop="num_attr" content="0435">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">substituent for the optionally substituted C1-C4 acyloxy</span>
        <span itemprop="definition">include amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo.</span>
        <meta itemprop="num_attr" content="0436">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl</span>
        <span itemprop="definition">is as defined in the C1-C4 alkyl.</span>
        <meta itemprop="num_attr" content="0436">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Two alkyl moieties in dialkylamino and dialkylcarbamoyl</span>
        <span itemprop="definition">may be the same as or different from each other.</span>
        <meta itemprop="num_attr" content="0436">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 111 and R 112</span>
        <span itemprop="definition">are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C8-C24 alkyl or C8-C24 alkenyl.</span>
        <meta itemprop="num_attr" content="0437">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 111 and R 112</span>
        <span itemprop="definition">are preferably the same or different and are each octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, 3,7</span>
        <meta itemprop="num_attr" content="0438">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 106 and X 107</span>
        <span itemprop="definition">are preferably the same or different and are each methyl or ethyl, more preferably are the same and methyl.</span>
        <meta itemprop="num_attr" content="0439">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C2-C8 alkylene together formed by X 106 and X 107</span>
        <span itemprop="definition">include ethylene, propylene, butylene, pentylene, hexylene, heptylene and octylene, preferably butylene, pentylene and hexylene, more preferably butylene and pentylene.</span>
        <meta itemprop="num_attr" content="0440">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 106 and X 107</span>
        <span itemprop="definition">are the same and methyl, or together form butylene, pentylene or hexylene.</span>
        <meta itemprop="num_attr" content="0441">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 103 and p 104</span>
        <span itemprop="definition">are preferably 0 at the same time, and p 105 is preferably 1.</span>
        <meta itemprop="num_attr" content="0442">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 113 and L 114</span>
        <span itemprop="definition">are preferably 0 at the same time.</span>
        <meta itemprop="num_attr" content="0443">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 113 and R 114</span>
        <span itemprop="definition">are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C8-C24 alkyl or C8-C24 alkenyl.</span>
        <meta itemprop="num_attr" content="0444">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the C1-C3 alkyl and the C2-C8 alkylene represented by X 109 and X 110</span>
        <span itemprop="definition">are each as defined above in formula (CL-VI).</span>
        <meta itemprop="num_attr" content="0445">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 115</span>
        <span itemprop="definition">is preferably a hydrogen atom, hydroxy, methyl, methoxy or the like, more preferably a hydrogen atom, hydroxy or the like, further preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0446">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 115</span>
        <span itemprop="definition">is preferably OCO or NHCO.</span>
        <meta itemprop="num_attr" content="0447">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 106</span>
        <span itemprop="definition">is 0 or 1</span>
        <meta itemprop="num_attr" content="0447">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 107</span>
        <span itemprop="definition">is an integer from 1 to 3. More preferably, p 106 is 0, and p 107 is 1 or 3.</span>
        <meta itemprop="num_attr" content="0447">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 115</span>
        <span itemprop="definition">is COO</span>
        <meta itemprop="num_attr" content="0448">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 106</span>
        <span itemprop="definition">is 0, and p 107 is an integer from 2 to 4. More preferably, p 106 is 0, and p 107 is 3.</span>
        <meta itemprop="num_attr" content="0448">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 115</span>
        <span itemprop="definition">is CONH</span>
        <meta itemprop="num_attr" content="0449">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">p 106</span>
        <span itemprop="definition">is 0, and p 107 is an integer from 2 to 4. More preferably, p 106 is 0, and p 107 is 3.</span>
        <meta itemprop="num_attr" content="0449">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each group in formulas (CL-VIII) to (CL-XIX)</span>
        <span itemprop="definition">may be as defined in formulas (I) to (V), or may be as defined in formulas (CL-I) to (CL-VIII).</span>
        <meta itemprop="num_attr" content="0450">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 137 and R 138</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, C8-24 alkenylthioethyl or C8-C24 alkynylthioethyl.</span>
        <meta itemprop="num_attr" content="0451">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the linear or branched C8-C24 alkyl represented by R 137 and R 138</span>
        <span itemprop="definition">include heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl.</span>
        <meta itemprop="num_attr" content="0452">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C8-C24 alkenyl represented by R 137 and R 138</span>
        <span itemprop="definition">can be linear or branched C8-24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,</span>
        <meta itemprop="num_attr" content="0453">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C8-C24 alkynyl represented by R 137 and R 138</span>
        <span itemprop="definition">can be linear or branched C8-24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-</span>
        <meta itemprop="num_attr" content="0454">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C8-C24 alkyl, the C8-24 alkenyl and the C8-C24 alkynyl contained in the C8-C24 alkylthioethyl, the C8-24 alkenylthioethyl and the C8-C24 alkynylthioethyl represented by R 137 and R 138</span>
        <span itemprop="definition">can include the same groups as those of the aforementioned C8-C24 alkyl, C8-24 alkenyl and C8-C24 alkynyl, respectively.</span>
        <meta itemprop="num_attr" content="0455">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C3 alkyl represented by X 135</span>
        <span itemprop="definition">include methyl, ethyl, n-propyl and isopropyl.</span>
        <meta itemprop="num_attr" content="0456">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the hydroxy C2-C4 alkyl represented by X 135</span>
        <span itemprop="definition">include hydroxyethyl, hydroxypropyl and hydroxybutyl.</span>
        <meta itemprop="num_attr" content="0457">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the position of substitution with the hydroxy group</span>
        <span itemprop="definition">is arbitrary.</span>
        <meta itemprop="num_attr" content="0457">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1 to C3 alkyl represented by X 136 , X 137 , X 138 , X 139 , X 140 and X 141</span>
        <span itemprop="definition">include methyl, ethyl, n-propyl and isopropyl.</span>
        <meta itemprop="num_attr" content="0458">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C3-C6 nitrogen-containing hetero ring that may be formed by X 136 and X 137 , X 138 and X 139 , or X 140 and X 141</span>
        <span itemprop="definition">include pyrrolidine, piperidine, morpholine and azepane.</span>
        <meta itemprop="num_attr" content="0459">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 139 and R 140 in formula (CL-XIX)</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl.</span>
        <meta itemprop="num_attr" content="0460">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the linear or branched C8-C24 alkyl represented by R 139 and R 140</span>
        <span itemprop="definition">include heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl.</span>
        <meta itemprop="num_attr" content="0461">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C8-C24 alkenyl represented by R 139 and R 140</span>
        <span itemprop="definition">can be linear or branched C8-24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12</span>
        <meta itemprop="num_attr" content="0462">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the linear or branched C8-C24 alkynyl represented by R 139 and R 140</span>
        <span itemprop="definition">can be linear or branched C8-24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-y</span>
        <meta itemprop="num_attr" content="0463">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1-C3 alkyl represented by X 146</span>
        <span itemprop="definition">include methyl, ethyl, n-propyl and isopropyl.</span>
        <meta itemprop="num_attr" content="0464">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the hydroxy C2-C4 alkyl represented by X 146</span>
        <span itemprop="definition">include hydroxyethyl, hydroxypropyl and hydroxybutyl.</span>
        <meta itemprop="num_attr" content="0465">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the position of substitution with the hydroxy group</span>
        <span itemprop="definition">is arbitrary.</span>
        <meta itemprop="num_attr" content="0465">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C1 to C3 alkyl represented by X 143 , X 144 , X 145 and X 146</span>
        <span itemprop="definition">include methyl, ethyl, n-propyl and isopropyl.</span>
        <meta itemprop="num_attr" content="0466">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the C3-C6 nitrogen-containing hetero ring that may be formed by X 143 and X 144 , or X 145 and X 146</span>
        <span itemprop="definition">include pyrrolidine, piperidine, morpholine and azepane.</span>
        <meta itemprop="num_attr" content="0467">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each group in formula (CL-VIII)</span>
        <span itemprop="definition">may be a preferred form of the corresponding group described in WO 2016/002753; each group in formula (CL-X) may be a preferred form of the corresponding group described in WO 2009/129385; each group in formula (CL-XI) may be a preferred form of the corresponding group described in WO 2013/149140; each group in formula (CL-XII) may be a preferred form of the corresponding group described in WO 2009/129395; each group in formula (CL-XIII) may be a preferred form of the corresponding group described in WO 2013/059496; each group in formula (CL-XIV) may be a preferred form of the corresponding group described in WO 2011/149733; each group in formula (CL-XV) may be a preferred form of the corresponding group described in WO 2011/153493; each group in formula (CL-XVI) may be a preferred form of the corresponding group described in WO 2015/074085; and each group in formula (CL-XVI</span>
        <meta itemprop="num_attr" content="0468">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 118 and L 119 in formula (CL-IX)</span>
        <span itemprop="definition">are the same or different and are each preferably linear or branched C8-C24 alkylene or C8-C24 alkenylene, more preferably linear or branched C8-C20 alkylene or C8-C20 alkenylene.</span>
        <meta itemprop="num_attr" content="0469">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the C1-C6 alkyl, the heterocyclyl or the polyamine of X 117 and X 118 in formula (CL-X)</span>
        <span itemprop="definition">may be substituted with one to three substituents selected from a halogen atom, R, OR, SR, ON, CO 2 R and CONR 2 .</span>
        <meta itemprop="num_attr" content="0470">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 4- to 7-membered monocyclic hetero ring</span>
        <span itemprop="definition">optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen, the monocyclic hetero ring may be substituted with one to three substituents selected from a halogen atom, R, OR, SR, ON, CO 2 R and CONR 2 .</span>
        <meta itemprop="num_attr" content="0471">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is a hydrogen atom or C1-C6 alkyl, and the C1-C6 alkyl represented by R may be substituted with a halogen atom or OH.</span>
        <meta itemprop="num_attr" content="0472">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 120 and R 121 in formula (CL-X)</span>
        <span itemprop="definition">are the same or different and are each preferably linear or branched C4-C24 alkyl or C4-C24 alkenyl, more preferably linear or branched C4-C20 alkyl or C4-C20 alkenyl.</span>
        <meta itemprop="num_attr" content="0473">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the C4-C24 alkyl or the C4-C24 alkenyl</span>
        <span itemprop="definition">may be substituted with one or more substituents selected from a halogen atom, R, OR, SR, CN, CO 2 R and CONR 2 .</span>
        <meta itemprop="num_attr" content="0474">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is a hydrogen atom or C1-C6 alkyl, and the C1-C6 alkyl represented by R may be substituted with a halogen atom or OH.</span>
        <meta itemprop="num_attr" content="0475">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a structure other than the carbonyl group in the C6-C20 acyl</span>
        <span itemprop="definition">can be C5-C19 alkyl, C5-C19 alkenyl or C5-C19 alkynyl.</span>
        <meta itemprop="num_attr" content="0476">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 124 and R 125 in formula (CL-XII)</span>
        <span itemprop="definition">are the same or different and are each preferably linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably linear or branched C14-C20 alkyl or C14-C20 alkenyl.</span>
        <meta itemprop="num_attr" content="0477">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the C1-C6 alkyl, the heterocyclyl or the polyamine of X 125 and X 126 in formula (CL-XIV)</span>
        <span itemprop="definition">may be substituted with one to three substituents selected from a halogen atom, R, OR, SR, CN, CO 2 R and CONR 2 .</span>
        <meta itemprop="num_attr" content="0478">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a 4- to 7-membered monocyclic hetero ring</span>
        <span itemprop="definition">optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen, the monocyclic hetero ring may be substituted with one to three substituents selected from a halogen atom, R, OR, SR, CN, CO 2 R and CONR 2 .</span>
        <meta itemprop="num_attr" content="0479">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is a hydrogen atom or C1-C6 alkyl, and the C1-C6 alkyl represented by R may be substituted with a halogen atom or OH.</span>
        <meta itemprop="num_attr" content="0480">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 128 and R 129 in formula (CL-XIV)</span>
        <span itemprop="definition">are the same or different and are each preferably linear or branched C4-C24 alkyl or C4-C24 alkenyl, more preferably linear or branched C4-C20 alkyl or C4-C20 alkenyl.</span>
        <meta itemprop="num_attr" content="0481">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the C4-C24 alkyl or the C4-C24 alkenyl</span>
        <span itemprop="definition">may be substituted with one or more substituents selected from a halogen atom, R, OR, SR, CN, CO 2 R and CONR 2 .</span>
        <meta itemprop="num_attr" content="0482">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R</span>
        <span itemprop="definition">is a hydrogen atom or C1-C6 alkyl, and the C1-C6 alkyl represented by R may be substituted with a halogen atom or OH.</span>
        <meta itemprop="num_attr" content="0483">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 137 and R 138 in formula (CL-XVIII)</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, 08-24 alkenylthioethyl or C8-C24 alkynylthioethyl, preferably are the same or different and are each linear C8-C24 alkenyl.</span>
        <meta itemprop="num_attr" content="0484">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 135</span>
        <span itemprop="definition">is a hydrogen atom, C1-C3 alkyl, or hydroxy C2-C4 alkyl, formula (C), formula (D) or formula (E), preferably a hydrogen atom or formula (C) or formula (D), more preferably a hydrogen atom or formula (E), further preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0485">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 139 and R 140 in formula (CL-XIX)</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, preferably are the same or different and are each linear C8-C24 alkenyl.</span>
        <meta itemprop="num_attr" content="0486">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 133</span>
        <span itemprop="definition">is S or O, preferably S.</span>
        <meta itemprop="num_attr" content="0487">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X 142</span>
        <span itemprop="definition">is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (F) or formula (G), preferably C1-C3 alkyl, further preferably methyl.</span>
        <meta itemprop="num_attr" content="0488">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Lipid B in the nucleic acid-containing lipid nanoparticle of the present invention</span>
        <span itemprop="definition">is preferably a lipid represented by formula (CL-I) or a lipid represented by formula (CL-II), more preferably a lipid represented by formula (CL-I).</span>
        <meta itemprop="num_attr" content="0489">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid B used in the present invention</span>
        <span itemprop="definition">will be shown below in Tables 1 to 15, though lipid B used in the present invention is not limited thereto.</span>
        <meta itemprop="num_attr" content="0490">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">lipid A used in the present invention</span>
        <span itemprop="definition">methods for producing lipid A used in the present invention will be described.</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the desired compounds</span>
        <span itemprop="definition">can be obtained by use of introduction and removal methods of protective groups commonly used in organic synthetic chemistry [e.g., methods described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999)] or the like. If necessary, the order of reaction steps including substituent introduction or the like may be changed.</span>
        <meta itemprop="num_attr" content="0491">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (I)</span>
        <span itemprop="definition">can be obtained by any method of synthesis route 1 or 2 given below, a method equivalent to the method, or the like.</span>
        <meta itemprop="num_attr" content="0493">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (I)</span>
        <span itemprop="definition">can be obtained from ammonia according to synthesis route 1.</span>
        <meta itemprop="num_attr" content="0494">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Ms</span>
        <span itemprop="definition">represents a methanesulfonyl group</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 2</span>
        <span itemprop="definition">can be obtained by reacting ammonia with compound 1 in a solvent (e.g., polar solvents such as tetrahydrofuran and methanol) at a high temperature (e.g., 80 C. or higher).</span>
        <meta itemprop="num_attr" content="0495">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., polar solvents such as tetrahydrofuran and methanol</span>
        <meta itemprop="num_attr" content="0495">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 4</span>
        <span itemprop="definition">is obtained by reacting compound 2 with compound 3 in the presence of a base (e.g., inorganic bases such as sodium hydroxide) at a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0496">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., inorganic bases such as sodium hydroxide</span>
        <meta itemprop="num_attr" content="0496">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a high temperature</span>
        <span itemprop="definition">e.g., 100 C. or higher.</span>
        <meta itemprop="num_attr" content="0496">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a high-boiling solvent</span>
        <span itemprop="definition">e.g., polar solvents such as ethylene glycol</span>
        <meta itemprop="num_attr" content="0496">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 6</span>
        <span itemprop="definition">is obtained by reacting compound 4 with compound 5 in the presence of a base (e.g., inorganic bases such as sodium hydroxide) at a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., inorganic bases such as sodium hydroxide</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a high temperature</span>
        <span itemprop="definition">e.g., 100 C. or higher.</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a high-boiling solvent</span>
        <span itemprop="definition">e.g., polar solvents such as ethylene glycol</span>
        <meta itemprop="num_attr" content="0497">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each of these three heating reactions</span>
        <span itemprop="definition">may suitably employ a microwave reaction apparatus.</span>
        <meta itemprop="num_attr" content="0498">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a halide</span>
        <span itemprop="definition">such as bromide or iodide corresponding to compound 1, compound 3 or compound 5 may be used instead of the compound.</span>
        <meta itemprop="num_attr" content="0498">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (I)</span>
        <span itemprop="definition">is obtained by reacting compound 6 with compound 7 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0500">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as chloroform</span>
        <meta itemprop="num_attr" content="0500">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 1 of compound (I)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (I) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0500">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each compound such as compound 1, compound 3, compound 5 and compound 7, etc. for use in the reactions</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fifth Series of Experimental Chemistry 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0501">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compound 1</span>
        <span itemprop="definition">may be obtained by treating corresponding R 1 -L 1 -OH with mesyl anhydride or mesyl chloride.</span>
        <meta itemprop="num_attr" content="0502">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound R 1 -L 1 -OH wherein L 1 is Z 1 (CY 1 Y 2 ) p2  (wherein each group is as defined above)</span>
        <span itemprop="definition">can be obtained by subjecting any one of R 1 OMs, R 1 OH, R 1 NY 7A H (wherein Y 7A is as defined above) and R 1 CO 2 H and any one of HO(CY 7 Y 2 ) p1 OPRO 1 , MsO(CY 7 Y 2 ) p1 OPRO 1 , HO 2 C(CY 2 Y 2 ) p1 OPRO 1 and HNY 7A (CY 2 Y 2 ) p1 OPRO 1 (wherein PRO 1 is a silyl-based protective group (e.g., triethylsilyl (TES), tert-butyldimethylsilyl (TBS) and tert-butyldiphenyl</span>
        <meta itemprop="num_attr" content="0503">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compound R 1 -L 1 -OH</span>
        <span itemprop="definition">wherein L 1 is Z 2 (CY 3 Y 4 ) p2 Z 3 (CY 5 Y 6 ) p3  (wherein each group is as defined above) can also be obtained by the application of reaction known in the art one to several times using a reaction substrate appropriate for the desired compound.</span>
        <meta itemprop="num_attr" content="0504">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (Ia)</span>
        <span itemprop="definition">can be obtained from compound 8 according to synthesis route 2.</span>
        <meta itemprop="num_attr" content="0506">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 1 to M 3</span>
        <span itemprop="definition">are the same or different and are each (CY 1 Y 2 ) p1  or (CY 3 Y 4 ) p2 Z 3 (CY 5 Y 6 ) p3  (wherein each group is as defined above); and the other groups are each as defined above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 10</span>
        <span itemprop="definition">is obtained by treating compound 8 and compound 9 with a base (e.g., organic bases such as triethylamine), a condensing agent (e.g., condensing agents such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate) and an activator (activators such as N,N-dimethylaminopyridine) in a solvent (e.g., halogen-based solvents such as chloroform).</span>
        <meta itemprop="num_attr" content="0507">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., organic bases such as triethylamine</span>
        <meta itemprop="num_attr" content="0507">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a condensing agent</span>
        <span itemprop="definition">e.g., condensing agents such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and O-(7-aza</span>
        <meta itemprop="num_attr" content="0507">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 12</span>
        <span itemprop="definition">is obtained by esterifying compound 10 and compound 11 in the same way as above.</span>
        <meta itemprop="num_attr" content="0508">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 14</span>
        <span itemprop="definition">is obtained by esterifying compound 12 and compound 13 in the same way as above.</span>
        <meta itemprop="num_attr" content="0509">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (Ia)</span>
        <span itemprop="definition">is obtained by reacting compound 14 with compound 15 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as chloroform</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 1 of compound (Ia)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (Ia) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0511">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each compound such as compound 8, compound 9, compound 11, compound 14 and compound 15, etc. for use in the reaction</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fifth Series of Experimental Chemistry 14, Synthesis of Organic Compound II, 5th edition, p. 1, Maruzen Co., Ltd. (2005) or The Fourth Series of Experimental Chemistry 22, Synthesis of Organic Compound IV, 4th edition, p. 1, Maruzen Co., Ltd. (1992)) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0512">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (II)</span>
        <span itemprop="definition">can be obtained by any method of synthesis routes 3 to 16 shown below, a method equivalent to the method, or the like.</span>
        <meta itemprop="num_attr" content="0513">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIa)</span>
        <span itemprop="definition">can be obtained from compound 15 according to synthesis route 3.</span>
        <meta itemprop="num_attr" content="0514">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 7</span>
        <span itemprop="definition">is absent, and M 4 is (CY 8 Y 9 ) p4 ; M 7 is absent, and M 4 is (CY 10 Y 11 ) p5 Z 6 (CY 12 Y 13 ) p6 ; or M 7 is Z 5 (CY 10 Y 11 ) p5 , and M 4 is (CY 12 Y 13 ) p6  (wherein each group is as defined above); M 8 is absent, and M 5 is (CY 8 Y 9 ) p4 ; M 8 is absent, and M 5 is (CY 10 Y 11 ) p5 Z 6 (CY 12 Y 13 ) p6 ; or M 8 is Z 5 (CY 10 Y 11 ) p5 , and M 5 is (CY 12 Y 13 ) p6 ; M 9 is absent, and M 6 is (CY 8 Y 9 ) p4 </span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 22</span>
        <span itemprop="definition">is obtained by reacting compound 16 with compound 17, compound 19 and compound 21 in order by the application of the same reaction conditions as in the esterification reaction of compound 8 with compound 9 in synthesis route 2.</span>
        <meta itemprop="num_attr" content="0515">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIa)</span>
        <span itemprop="definition">is obtained by reacting compound 22 with compound 23 by the application of the same conditions as the reaction conditions for the synthesis of compound (Ia) through the reaction of compound 14 with compound 15 in synthesis route 2.</span>
        <meta itemprop="num_attr" content="0516">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 2 of compound (IIa)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IIa) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0516">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each compound such as compound 16, compound 17, compound 19, compound 21 and compound 23, etc. for use in the reaction</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fifth Series of Experimental Chemistry 14, Synthesis of Organic Compound II, 5th edition, p. 1, Maruzen Co., Ltd. (2005) or The Fourth Series of Experimental Chemistry 22, Synthesis of Organic Compound IV, 4th edition, p. 1, Maruzen Co., Ltd. (1992)) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0517">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 16</span>
        <span itemprop="definition">can also be obtained by any method of synthesis routes 11 to 15 mentioned later.</span>
        <meta itemprop="num_attr" content="0518">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 17 wherein M 7 is Z 5 (CY 10 Y 11 ) p5 </span>
        <span itemprop="definition">can be obtained by subjecting any one of R 4 OMs, R 4 OH, R 4 NY 14A H (wherein Y 14A is as defined above) and R 4 CO 2 H and any one of HO(CY 10 Y 11 ) p5 COOPRO 2 , MsO(CY 10 Y 11 ) p5 COOPRO 2 , HO 2 C(CY 10 Y 11 ) p5 COOPRO 2 and HNY 14A (CY 10 Y 11 ) p5    COOPRO 2 (wherein PRO 2 is a protective group for carboxylic acid (e.g., methyl, tert-butyl and benzyl)) to any reaction of etherification (e.g., using a strong base such as sodium hydride), amination (e.g.</span>
        <meta itemprop="num_attr" content="0519">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">synthesis route 3</span>
        <span itemprop="definition">the introduction of X 4 may be performed first. Specifically, first, compound 23 may be allowed to act on compound 16, followed by the esterification of compounds 17, 19 and 21 in order to obtain compound (IIa).</span>
        <meta itemprop="num_attr" content="0521">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIb)</span>
        <span itemprop="definition">can be obtained from compound 16 according to synthesis route 4.</span>
        <meta itemprop="num_attr" content="0522">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 25</span>
        <span itemprop="definition">can be obtained by reacting compound 16 with compound 24 in the presence of a base (e.g., inorganic bases such as sodium hydride) in a solvent (e.g., aprotic solvents such as tetrahydrofuran and toluene) at a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0523">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., inorganic bases such as sodium hydride</span>
        <meta itemprop="num_attr" content="0523">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., aprotic solvents such as tetrahydrofuran and toluene</span>
        <meta itemprop="num_attr" content="0523">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 27</span>
        <span itemprop="definition">is obtained by etherifying compound 25 and compound 26 in the same way as above.</span>
        <meta itemprop="num_attr" content="0524">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 29</span>
        <span itemprop="definition">is obtained by etherifying compound 27 and compound 28 in the same way as above.</span>
        <meta itemprop="num_attr" content="0525">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each of these three heating reactions</span>
        <span itemprop="definition">may suitably employ a microwave reaction apparatus.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">bromide, iodide or the like corresponding to compound 24, compound 26 and compound 28</span>
        <span itemprop="definition">may be used instead of the compound.</span>
        <meta itemprop="num_attr" content="0526">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 27 wherein R 4 -M 7 and R 5 -M 8 are the same</span>
        <span itemprop="definition">is also obtained from compound 16 using excessive compound 24.</span>
        <meta itemprop="num_attr" content="0527">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 29 wherein R 5 -M 8 and R 6 -M 9 are the same</span>
        <span itemprop="definition">is also obtained from compound 25 using excessive compound 26.</span>
        <meta itemprop="num_attr" content="0527">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 29 wherein R 4 -M 7 , R 5 -M 8 and R 6 -M 9 are the same</span>
        <span itemprop="definition">is also obtained from compound 16 using more excessive compound 24.</span>
        <meta itemprop="num_attr" content="0527">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIb)</span>
        <span itemprop="definition">is obtained by reacting compound 29 with compound 23 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0528">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as chloroform</span>
        <meta itemprop="num_attr" content="0528">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 2 of compound (IIb)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (lib) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0528">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each compound such as compound 16, compound 24, compound 26, compound 28 and compound 23, etc. for use in the reaction</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fifth Series of Experimental Chemistry 14, Synthesis of Organic Compound II, 5th edition, p. 1, Maruzen Co., Ltd. (2005) or The Fifth Series of Experimental Chemistry 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0529">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compound 24</span>
        <span itemprop="definition">may be obtained by treating corresponding R 4 -M 7 -OH with mesyl anhydride or mesyl chloride.</span>
        <meta itemprop="num_attr" content="0530">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound R 4 -M 7 -OH wherein M 7 is Z 5 (CY 10 Y 11 ) p5 </span>
        <span itemprop="definition">can be obtained by subjecting any one of R 4 OMs, R 4 OH, R 4 NY 14A H (wherein Y 14A is as defined above) and R 4 CO 2 H and any one of HO(CY 10 Y 11 ) p5 OPRO 1 , MsO(CY 10 Y 11 ) p5 OPRO 1 , HO 2 C(CY 10 Y 11 ) p5 OPRO 1 and HNY 14A (CY 10 Y 11 ) p5 OPRO 1 (wherein each group is as defined above) to any reaction of etherification, amination, esterification and amidation, followed by deprotection.</span>
        <meta itemprop="num_attr" content="0531">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compound (IIe)</span>
        <span itemprop="definition">can be obtained from compound 25 obtained in synthesis route 4 by appropriately combining the reactions such as esterification in synthesis route 3.</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compound (IId)</span>
        <span itemprop="definition">can be obtained from compound 27 obtained in synthesis route 4 by appropriately combining the reactions such as esterification in synthesis route 3.</span>
        <meta itemprop="num_attr" content="0533">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIe)</span>
        <span itemprop="definition">can be obtained from compound 30 according to synthesis route 6.</span>
        <meta itemprop="num_attr" content="0534">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 10 , M 11 and M 12</span>
        <span itemprop="definition">are each independently 0 or NY 14A ; and the other groups are each as defined above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 33</span>
        <span itemprop="definition">is obtained through the esterification or amidation reaction of compound 30 with compound 17, compound 19 and compound 21 in order.</span>
        <meta itemprop="num_attr" content="0535">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIe)</span>
        <span itemprop="definition">is obtained by reacting compound 33 with compound 23 by the application of the same conditions as the reaction conditions for the synthesis of compound (Ia) through the reaction of compound 14 with compound 15 in synthesis route 2.</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 2 of compound (lie)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IIe) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0536">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 30</span>
        <span itemprop="definition">can also be obtained by any method of synthesis routes 11 to 15 mentioned later.</span>
        <meta itemprop="num_attr" content="0537">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIf)</span>
        <span itemprop="definition">can be obtained from compound 34 according to synthesis route 7.</span>
        <meta itemprop="num_attr" content="0538">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 35</span>
        <span itemprop="definition">is obtained by protecting compound 34 with an appropriate protective group.</span>
        <meta itemprop="num_attr" content="0539">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 36</span>
        <span itemprop="definition">is obtained by reacting compound 35 with compound 23 by the application of the same conditions as the reaction conditions for the synthesis of compound (la) through the reaction of compound 14 with compound 15 in synthesis route 2, followed by deprotection under appropriate conditions.</span>
        <meta itemprop="num_attr" content="0540">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIf)</span>
        <span itemprop="definition">is obtained by the esterification or amidation reaction of compound 36 with compound 37, compound 39 and compound 41 in order.</span>
        <meta itemprop="num_attr" content="0541">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 2 of compound (IIf)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IIf) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0541">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each of compounds 34, 35 and 36</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0542">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 37 wherein M 10 is NY 14A</span>
        <span itemprop="definition">can also be obtained by reacting R 4 -M 7 -OMs (compound 24) with Y 14A NH 2 .</span>
        <meta itemprop="num_attr" content="0543">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compound (IIf)</span>
        <span itemprop="definition">can also be obtained by performing the esterification or amidation of compound 24 with compounds 37, 39 and 41 in order, and finally introducing X 4 by the action of compound 23.</span>
        <meta itemprop="num_attr" content="0545">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIg)</span>
        <span itemprop="definition">can be obtained from ethyl cyanoacetate according to synthesis route 9.</span>
        <meta itemprop="num_attr" content="0546">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Et</span>
        <span itemprop="definition">represents an ethyl group</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LAH</span>
        <span itemprop="definition">is lithium aluminum hydride</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the other groups</span>
        <span itemprop="definition">are each as defined above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 42</span>
        <span itemprop="definition">can be obtained by reacting ethyl cyanoacetate with compound 24 in the presence of a base (e.g., inorganic bases such as sodium hydride) and, in some cases, an additive (e.g., additives such as tetrabutylammonium iodide) in a solvent (e.g., aprotic solvents such as tetrahydrofuran) at a high temperature (e.g., 60 C. or higher).</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., inorganic bases such as sodium hydride</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an additive</span>
        <span itemprop="definition">e.g., additives such as tetrabutylammonium iodide</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., aprotic solvents such as tetrahydrofuran</span>
        <meta itemprop="num_attr" content="0547">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 43</span>
        <span itemprop="definition">can be obtained by reacting compound 42 with compound 26 in the presence of a base (e.g., inorganic bases such as sodium hydride) and, in some cases, an additive (e.g., additives such as tetrabutylammonium iodide) in a solvent (e.g., aprotic solvents such as tetrahydrofuran) at a high temperature (e.g., 60 C. or higher).</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., inorganic bases such as sodium hydride</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an additive</span>
        <span itemprop="definition">e.g., additives such as tetrabutylammonium iodide</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., aprotic solvents such as tetrahydrofuran</span>
        <meta itemprop="num_attr" content="0548">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 43 wherein R 4 and R 5 are the same</span>
        <span itemprop="definition">can also be obtained from ethyl cyanoacetate using excessive compound 24.</span>
        <meta itemprop="num_attr" content="0549">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 44</span>
        <span itemprop="definition">can be obtained by reducing compound 43 with excessive lithium aluminum hydride (LAH) in a solvent (e.g., aprotic solvents such as tetrahydrofuran).</span>
        <meta itemprop="num_attr" content="0550">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LAH</span>
        <span itemprop="definition">lithium aluminum hydride</span>
        <meta itemprop="num_attr" content="0550">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 47</span>
        <span itemprop="definition">can be obtained by allowing compound 45, compound 46 and compound 23 in order to act on compound 44 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform).</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as chloroform.</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 47 wherein X 2 , X 3 and X 4 are the same</span>
        <span itemprop="definition">can also be obtained from compound 44 using excessive compound 45.</span>
        <meta itemprop="num_attr" content="0551">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIg)</span>
        <span itemprop="definition">is obtained by reacting compound 47 with compound 21 by the application of the same reaction conditions as in the esterification reaction of compound 8 with compound 9 in synthesis route 2.</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 2 of compound (IIg)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IIg) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0552">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIh)</span>
        <span itemprop="definition">can be obtained from dimethyl malonate according to synthesis route 10.</span>
        <meta itemprop="num_attr" content="0554">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Me</span>
        <span itemprop="definition">represents a methyl group</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LAH</span>
        <span itemprop="definition">is lithium aluminum hydride</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the other groups</span>
        <span itemprop="definition">are each as defined above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 48</span>
        <span itemprop="definition">can be obtained by reacting dimethyl malonate with compound 24 in the presence of a base (e.g., inorganic bases such as cesium carbonate) and, in some cases, an additive (e.g., additives such as tetrabutylammonium iodide) in a solvent (e.g., aprotic solvents such as acetonitrile) under heating (e.g., 50 C.).</span>
        <meta itemprop="num_attr" content="0555">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., inorganic bases such as cesium carbonate</span>
        <meta itemprop="num_attr" content="0555">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an additive</span>
        <span itemprop="definition">e.g., additives such as tetrabutylammonium iodide</span>
        <meta itemprop="num_attr" content="0555">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">solvent</span>
        <span itemprop="definition">e.g., aprotic solvents such as acetonitrile</span>
        <meta itemprop="num_attr" content="0555">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 50</span>
        <span itemprop="definition">can be obtained by reacting compound 48 with compound 49 in the presence of acetic anhydride and a base (e.g., inorganic bases such as sodium hydride) in a solvent (e.g., aprotic solvents such as acetonitrile).</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., inorganic bases such as sodium hydride</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., aprotic solvents such as acetonitrile</span>
        <meta itemprop="num_attr" content="0556">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 51</span>
        <span itemprop="definition">can be obtained by reducing compound 50 with excessive lithium aluminum hydride (LAH) in a solvent (e.g., aprotic solvents such as tetrahydrofuran).</span>
        <meta itemprop="num_attr" content="0557">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">LAH</span>
        <span itemprop="definition">lithium aluminum hydride</span>
        <meta itemprop="num_attr" content="0557">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 52</span>
        <span itemprop="definition">is obtained by reacting compound 51 with compound 19 and compound 21 by the application of the same reaction conditions as in the esterification of compound 8 and compound 9 in synthesis route 2.</span>
        <meta itemprop="num_attr" content="0558">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIh)</span>
        <span itemprop="definition">is obtained by reacting compound 52 with compound 53 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as chloroform</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 2 of compound (IIh)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IIh) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0559">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 49</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in Helvetica Chimica Acta, Vol. 92, No. 8, p. 1644-1656, 2009) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0560">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 54</span>
        <span itemprop="definition">can be obtained by protecting hydroxy of compound 53.</span>
        <meta itemprop="num_attr" content="0562">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 53</span>
        <span itemprop="definition">can be obtained as a commercially available product.</span>
        <meta itemprop="num_attr" content="0563">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 55</span>
        <span itemprop="definition">can be obtained by allowing compound 45 and compound 46 to act on compound 54.</span>
        <meta itemprop="num_attr" content="0564">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 56</span>
        <span itemprop="definition">can be obtained by deprotecting compound 55.</span>
        <meta itemprop="num_attr" content="0565">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hal</span>
        <span itemprop="definition">is a halogen atom such as chlorine, bromine or iodine; and the other groups are each as defined above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 58</span>
        <span itemprop="definition">can be obtained by protecting hydroxy of compound 57.</span>
        <meta itemprop="num_attr" content="0567">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 57</span>
        <span itemprop="definition">can be obtained as a commercially available product.</span>
        <meta itemprop="num_attr" content="0568">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 59</span>
        <span itemprop="definition">can be obtained by allowing a halogenation reagent (e.g., chlorine, bromine, iodine and iodine chloride) to act on compound 58.</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a halogenation reagent</span>
        <span itemprop="definition">e.g., chlorine, bromine, iodine and iodine chloride</span>
        <meta itemprop="num_attr" content="0569">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 60</span>
        <span itemprop="definition">is obtained by reacting compound 59 with ammonia.</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 61</span>
        <span itemprop="definition">is obtained by allowing compound 45 to act on compound 60.</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 63</span>
        <span itemprop="definition">is obtained by allowing compound 46 to act on compound 61.</span>
        <meta itemprop="num_attr" content="0570">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compound 63</span>
        <span itemprop="definition">may be obtained by reacting compound 59 with compound 62.</span>
        <meta itemprop="num_attr" content="0571">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 63</span>
        <span itemprop="definition">is obtained by deprotecting compound 62.</span>
        <meta itemprop="num_attr" content="0572">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 64</span>
        <span itemprop="definition">is obtained by oxidizing compound 58 with an appropriate oxidizing agent (e.g., potassium permanganate and Jones reagent).</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an appropriate oxidizing agent</span>
        <span itemprop="definition">e.g., potassium permanganate and Jones reagent.</span>
        <meta itemprop="num_attr" content="0573">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 66</span>
        <span itemprop="definition">is obtained by allowing a cyanide (e.g., sodium cyanide, potassium cyanide and lithium cyanide) to act on compound 59.</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a cyanide</span>
        <span itemprop="definition">e.g., sodium cyanide, potassium cyanide and lithium cyanide</span>
        <meta itemprop="num_attr" content="0575">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 67</span>
        <span itemprop="definition">is obtained by reducing compound 66 with lithium aluminum hydride or the like.</span>
        <meta itemprop="num_attr" content="0576">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 68</span>
        <span itemprop="definition">is obtained by allowing compound 45 to act on compound 67.</span>
        <meta itemprop="num_attr" content="0577">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 69</span>
        <span itemprop="definition">is obtained by allowing compound 46 to act on compound 68.</span>
        <meta itemprop="num_attr" content="0577">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 70</span>
        <span itemprop="definition">is obtained by deprotecting compound 69.</span>
        <meta itemprop="num_attr" content="0578">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 71</span>
        <span itemprop="definition">is obtained by hydrolyzing compound 66 with a base (e.g., sodium hydroxide).</span>
        <meta itemprop="num_attr" content="0579">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., sodium hydroxide</span>
        <meta itemprop="num_attr" content="0579">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 72</span>
        <span itemprop="definition">is obtained by reducing compound 71 with a reducing agent (e.g., borane).</span>
        <meta itemprop="num_attr" content="0580">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a reducing agent</span>
        <span itemprop="definition">e.g., borane</span>
        <meta itemprop="num_attr" content="0580">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 73</span>
        <span itemprop="definition">can be obtained by allowing a halogenation reagent (e.g., chlorine, bromine, iodine and iodine chloride) to act on compound 72.</span>
        <meta itemprop="num_attr" content="0581">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a halogenation reagent</span>
        <span itemprop="definition">e.g., chlorine, bromine, iodine and iodine chloride</span>
        <meta itemprop="num_attr" content="0581">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a compound having a further extended alkylene chain between each functional group (amino group, monoalkylamino group, dialkylamino group, carboxylic acid, hydroxy and halogen) and quaternary carbon of compounds 67, 68, 69, 71, 72 and 73</span>
        <span itemprop="definition">can be obtained by performing a series of reactions from compound 59 in synthesis route 13 for compound 73. Also, the alkylene chain between each functional group and quaternary carbon can be freely extended by repeating this operation.</span>
        <meta itemprop="num_attr" content="0582">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 76</span>
        <span itemprop="definition">can be synthesized according to synthesis route 14.</span>
        <meta itemprop="num_attr" content="0583">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 13</span>
        <span itemprop="definition">is (CH 2 ) p201 ;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 15</span>
        <span itemprop="definition">is (CH 2 ) p202  wherein each of p 201 and p 202 is an integer from 1 to 5;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 14</span>
        <span itemprop="definition">is O, COO or NY 27A ;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">PRO 4</span>
        <span itemprop="definition">represents any of protective group PRO 1 for hydroxy, protective group PRO 2 for carboxylic acid and protective group PRO 3 for amine (e.g., carbamate-based protective groups such as tert-butoxycarbonyl, and benzyl) according to M 14 .</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 74</span>
        <span itemprop="definition">is obtained by any method described in synthesis routes 11 to 13, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0584">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 75</span>
        <span itemprop="definition">is obtained by appropriately protecting and deprotecting compound 74.</span>
        <meta itemprop="num_attr" content="0585">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 76</span>
        <span itemprop="definition">is obtained by any method described in synthesis routes 11 to 13, or a method equivalent thereto with compound 75 as a starting material.</span>
        <meta itemprop="num_attr" content="0586">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compounds 77 to 79</span>
        <span itemprop="definition">can be obtained by performing protection and deprotection, and a method equivalent to synthesis route 14 in order with compound 76 as a starting material.</span>
        <meta itemprop="num_attr" content="0587">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 16 and M 17</span>
        <span itemprop="definition">each represent (CH 2 ) p203  and (CH 2 ) p204  wherein each of p 203 and p 204 is an integer from 1 to 5; and the other groups are each as defined above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Ar</span>
        <span itemprop="definition">is a p-nitrophenyl group</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Hal</span>
        <span itemprop="definition">is a halogen atom such as chlorine, bromine or iodine</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the other groups</span>
        <span itemprop="definition">are each as defined above</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">when p13 is 0, N</span>
        <span itemprop="definition">is directly bonded to the carbon atom adjacent to Z 10 .</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 82</span>
        <span itemprop="definition">is obtained by condensing compound 80 and compound 81 through esterification, followed by deprotection.</span>
        <meta itemprop="num_attr" content="0589">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 84</span>
        <span itemprop="definition">is obtained by condensing compound 83 and compound 81 through amidation, followed by deprotection.</span>
        <meta itemprop="num_attr" content="0590">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 87</span>
        <span itemprop="definition">is obtained by condensing compound 85 and compound 86 through esterification, followed by deprotection.</span>
        <meta itemprop="num_attr" content="0591">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 89</span>
        <span itemprop="definition">is obtained by condensing compound 85 and compound 88 through amidation, followed by deprotection.</span>
        <meta itemprop="num_attr" content="0592">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 92</span>
        <span itemprop="definition">is obtained by subjecting compound 90 and compound 91 to nucleophilic substitution reaction, followed by deprotection.</span>
        <meta itemprop="num_attr" content="0593">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 95</span>
        <span itemprop="definition">is obtained by subjecting compound 93 and compound 94 to transesterification reaction, followed by deprotection.</span>
        <meta itemprop="num_attr" content="0594">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compounds 80, 83, 85, 90 and 93</span>
        <span itemprop="definition">can be obtained by synthesis routes 12 to 15 or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0595">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each of compounds 81, 86, 88, 91 and 94 wherein M 18 is (CY 19 Y 20 ) p9 </span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by the conversion of a functional group of a commercially available product according to a conventional method.</span>
        <meta itemprop="num_attr" content="0596">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 37</span>
        <span itemprop="definition">is OH, CO 2 H or NY 38 (provided that Y 38 is a hydrogen atom or optionally substituted C1-C4 alkyl) with each corresponding appropriate fragment through etherification, amination, esterification, amidation or the like.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (III)</span>
        <span itemprop="definition">can be obtained by any method of synthesis routes 17 to 21 given below, a method equivalent to the method, or the like.</span>
        <meta itemprop="num_attr" content="0599">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIIa)</span>
        <span itemprop="definition">can be obtained from compound 96 according to synthesis route 17.</span>
        <meta itemprop="num_attr" content="0600">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIIa)</span>
        <span itemprop="definition">is obtained by reacting compound 96 with compound 97 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0601">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as chloroform</span>
        <meta itemprop="num_attr" content="0601">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 3 of compound (IIIa)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IIIa) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0601">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 96</span>
        <span itemprop="definition">can be obtained by a method described in Examples or a method equivalent thereto, or by a method described in the literature (U.S. Patent Application Publication No. 2012/0172411) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0602">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each compound such as compound 97, etc. for use in the reaction</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0603">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIIb)</span>
        <span itemprop="definition">can be obtained from ethyl glyoxylate according to synthesis route 18.</span>
        <meta itemprop="num_attr" content="0604">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 19</span>
        <span itemprop="definition">is (CY 50 Y 51 ) p23  or (CY 54 Y 55 ) p25 Z 17 (CY 56 Y 57 ) p26  (wherein each group is as defined above); b 2 is</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">N</span>
        <span itemprop="definition">is directly bonded to the carbon atom adjacent to Z 21 .</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 101</span>
        <span itemprop="definition">is obtained by reacting ethyl glyoxylate with Grignard reagents 98, 99 and 100 in order in a solvent (e.g., ether-based solvents such as tetrahydrofuran).</span>
        <meta itemprop="num_attr" content="0605">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., ether-based solvents such as tetrahydrofuran.</span>
        <meta itemprop="num_attr" content="0605">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 101 wherein R 7 , R 8 and R 9 are the same</span>
        <span itemprop="definition">is also obtained by allowing excessive compound 98 to act on ethyl glyoxylate.</span>
        <meta itemprop="num_attr" content="0605">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 103</span>
        <span itemprop="definition">is obtained by treating compound 101 and compound 102 with a base (e.g., organic bases such as triethylamine), a condensing agent (e.g., condensing agents such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and an activator (activators such as N,N-dimethylaminopyridine) in a solvent (e.g., halogen-based solvents such as chloroform).</span>
        <meta itemprop="num_attr" content="0606">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., organic bases such as triethylamine</span>
        <meta itemprop="num_attr" content="0606">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a condensing agent</span>
        <span itemprop="definition">e.g., condensing agents such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride</span>
        <meta itemprop="num_attr" content="0606">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an activator</span>
        <span itemprop="definition">activators such as N,N-dimethylaminopyridine</span>
        <meta itemprop="num_attr" content="0606">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as chloroform</span>
        <meta itemprop="num_attr" content="0606">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIIb)</span>
        <span itemprop="definition">is obtained by reacting compound 103 with compound 97, 104 or 105 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0607">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as chloroform</span>
        <meta itemprop="num_attr" content="0607">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 3 of compound (IIIb)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IIIb) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0607">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 98</span>
        <span itemprop="definition">is obtained by allowing a mesylation reagent (mesyl anhydride or mesyl chloride, etc.), a bromide (magnesium bromide or lithium bromide, etc.), and metal magnesium in order to act on R 7 OH (which is a commercially available product or is obtained by a method described in Examples or a method equivalent thereto).</span>
        <meta itemprop="num_attr" content="0608">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a mesylation reagent</span>
        <span itemprop="definition">mesyl anhydride or mesyl chloride, etc.</span>
        <meta itemprop="num_attr" content="0608">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a bromide</span>
        <span itemprop="definition">magnesium bromide or lithium bromide, etc.</span>
        <meta itemprop="num_attr" content="0608">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">metal magnesium</span>
        <span itemprop="definition">which is a commercially available product or is obtained by a method described in Examples or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0608">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compounds 108, 109 and 112</span>
        <span itemprop="definition">can be obtained from ammonia, ethyl formate and compound 99, respectively according to synthesis route 19.</span>
        <meta itemprop="num_attr" content="0611">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 21</span>
        <span itemprop="definition">is OH, M 22 is HOCO, and M 25 is OCO;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 21</span>
        <span itemprop="definition">is NY 45C H, M 22 is HOCO, and M 25 is NY 45C CO;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 21</span>
        <span itemprop="definition">is COOH, M 22 is HO, and M 25 is COO; or</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 21</span>
        <span itemprop="definition">is COOH, M 22 is HNY 14B , and M 25 is CONY 14B ;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 20</span>
        <span itemprop="definition">is absent, and M 23 is (CY 39 Y 40 ) p18 ;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 20</span>
        <span itemprop="definition">is absent, and M 23 is (CY 41 Y 42 ) p19 Z 14 (CY 43 Y 44 ) p20 ; or</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 20</span>
        <span itemprop="definition">is Z 13 (CY 41 Y 42 ) p19 , and M 23 is (CY 43 Y 44 ) p20 ;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 24</span>
        <span itemprop="definition">is </span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 108</span>
        <span itemprop="definition">is obtained by reacting ammonia with compound 106 and compound 107 by the application of the same reaction conditions as those for the synthesis of compound 4 from ammonia in synthesis route 1.</span>
        <meta itemprop="num_attr" content="0612">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 109</span>
        <span itemprop="definition">is obtained by reacting ethyl formate with compound 99 and compound 100 by the application of the same reaction conditions as those for the synthesis of compound 101 from ethyl glyoxylate in synthesis route 18.</span>
        <meta itemprop="num_attr" content="0613">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 112</span>
        <span itemprop="definition">can be obtained by condensing compound 110 and compound 111 through esterification or amidation, followed by deprotection.</span>
        <meta itemprop="num_attr" content="0614">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 111</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fourth Series of Experimental Chemistry 20, Synthesis of Organic Compound II, 4th edition, p. 187, Maruzen Co., Ltd. (1992)) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0617">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compounds (IIIc) and (IIId)</span>
        <span itemprop="definition">can be obtained from compounds 108 and 112, and compounds 109 and 112, respectively, according to synthesis route 20.</span>
        <meta itemprop="num_attr" content="0618">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIIc)</span>
        <span itemprop="definition">is obtained by condensing compounds 108 and 112 through amidation, and then allowing compound 114, 115, or 116 to act on the condensate.</span>
        <meta itemprop="num_attr" content="0619">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IIId)</span>
        <span itemprop="definition">is obtained by condensing compounds 109 and 112 through esterification, and then allowing compound 114, 115, or 116 to act on the condensate.</span>
        <meta itemprop="num_attr" content="0620">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 3 of compound (IIIc) or (IIId)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IIIc) or (IIId) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0621">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IV)</span>
        <span itemprop="definition">can be obtained by any method of synthesis routes 11 and 12 given below, a method equivalent to the method, or the like.</span>
        <meta itemprop="num_attr" content="0623">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 127</span>
        <span itemprop="definition">can be obtained according to synthesis route 21.</span>
        <meta itemprop="num_attr" content="0624">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 26 and M 27</span>
        <span itemprop="definition">are the same or different and are each (CY 91 Y 92 ) p41 ;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 28 and M 29</span>
        <span itemprop="definition">are the same or different and are each OCO(CY 91 Y 92 ) p41  or COO(CY 91 Y 92 ) p41 ;</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 30 and M 31</span>
        <span itemprop="definition">are the same or different and are each absent, or OCO(CY 91 Y 92 ) p41  or COO(CY 91 Y 92 ) p41 ; and the other groups are each as defined above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 121</span>
        <span itemprop="definition">can be obtained by condensing compound 118 with compound 119 and compound 120 in order through esterification reaction, or condensing compound 122 with compound 123 and compound 124 in order through esterification reaction.</span>
        <meta itemprop="num_attr" content="0625">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 125</span>
        <span itemprop="definition">can be obtained by allowing a deprotection reagent (e.g., deprotection reagents such as tetra-n-butylammonium fluoride) to act on compound 121 in a solvent (e.g., ether-based solvents such as tetrahydrofuran), or subjecting ethyl formate to addition reaction with compound 126 and compound 127 in order in a solvent (e.g., ether-based solvents such as tetrahydrofuran).</span>
        <meta itemprop="num_attr" content="0626">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a deprotection reagent</span>
        <span itemprop="definition">e.g., deprotection reagents such as tetra-n-butylammonium fluoride</span>
        <meta itemprop="num_attr" content="0626">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., ether-based solvents such as tetrahydrofuran</span>
        <meta itemprop="num_attr" content="0626">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., ether-based solvents such as tetrahydrofuran</span>
        <meta itemprop="num_attr" content="0626">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 128</span>
        <span itemprop="definition">can be obtained by allowing an oxidizing agent (e.g., organic oxidizing agents such as Dess-Martin reagent, and inorganic oxidizing agents such as pyridinium chlorochromate) to act on compound 125 in a solvent (e.g., aprotic solvents such as chloroform).</span>
        <meta itemprop="num_attr" content="0627">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an oxidizing agent</span>
        <span itemprop="definition">e.g., organic oxidizing agents such as Dess-Martin reagent, and inorganic oxidizing agents such as pyridinium chlorochromate</span>
        <meta itemprop="num_attr" content="0627">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., aprotic solvents such as chloroform</span>
        <meta itemprop="num_attr" content="0627">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each compound such as compound 118, compound 119, compound 120, compound 122, compound 123, compound 124, compound 126 and compound 127, etc. for use in the reaction</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., The Fourth Series of Experimental Chemistry 22, Synthesis of Organic Compound IV, 4th edition, p. 1, Maruzen Co., Ltd. (1992), The Fourth Series of Experimental Chemistry 20, Synthesis of Organic Compound II, 4th edition, p. 1, Maruzen Co., Ltd. (1992), and The Fourth Series of Experimental Chemistry 25, Synthesis of Organic Compound VII, 4th edition, p. 59, Maruzen Co., Ltd. (1991)) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0628">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a literature</span>
        <span itemprop="definition">e.g., The Fourth Series of Experimental Chemistry 22, Synthesis of Organic Compound IV, 4th edition, p. 1, Maruzen Co., Ltd. (1992), The Fourth Series of</span>
        <meta itemprop="num_attr" content="0628">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IVa)</span>
        <span itemprop="definition">can be obtained from compound 128 according to synthesis route 22.</span>
        <meta itemprop="num_attr" content="0629">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 130</span>
        <span itemprop="definition">can be obtained by reacting compound 128 with compound 129 in the presence of a reducing agent (e.g., hydride compounds such as sodium borohydride and triacetoxyborohydride) and, in some cases, an additive (e.g., acids such as acetic acid) in a solvent (e.g., halogen-based solvents such as 1,2-dichloroethane).</span>
        <meta itemprop="num_attr" content="0630">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a reducing agent</span>
        <span itemprop="definition">e.g., hydride compounds such as sodium borohydride and triacetoxyborohydride</span>
        <meta itemprop="num_attr" content="0630">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">an additive</span>
        <span itemprop="definition">e.g., acids such as acetic acid</span>
        <meta itemprop="num_attr" content="0630">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as 1,2-dichloroethane</span>
        <meta itemprop="num_attr" content="0630">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 132</span>
        <span itemprop="definition">is obtained by reacting compound 130 with compound 131 in the presence of a base (e.g., inorganic bases such as sodium hydroxide) at a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0631">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a base</span>
        <span itemprop="definition">e.g., inorganic bases such as sodium hydroxide</span>
        <meta itemprop="num_attr" content="0631">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a high temperature</span>
        <span itemprop="definition">e.g. 100 C. or higher.</span>
        <meta itemprop="num_attr" content="0631">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">such as ethylene glycol may be used in some cases.</span>
        <meta itemprop="num_attr" content="0631">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IVa)</span>
        <span itemprop="definition">is obtained by reacting compound 132 with compound 133 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher).</span>
        <meta itemprop="num_attr" content="0632">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">a solvent</span>
        <span itemprop="definition">e.g., halogen-based solvents such as chloroform</span>
        <meta itemprop="num_attr" content="0632">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 4 of compound (IVa)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IVa) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0632">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each compound such as compound 129, compound 131 and compound 133, etc. for use in the reaction</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in WO 2010/042877, WO 2010/054401, or The Fifth Series of Experimental Chemistry 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0633">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IVb)</span>
        <span itemprop="definition">can be obtained according to synthesis route 23.</span>
        <meta itemprop="num_attr" content="0634">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 32</span>
        <span itemprop="definition">is absent, or Z 27 (CY 93 Y 94 ) p42 ; Ns represents an o-nitrobenzenesulfonyl group; and the other groups are each as defined above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 136</span>
        <span itemprop="definition">is obtained by reacting compound 134, compound 135, triphenylphosphine, and diethyl azodicarboxylate, and then removing Ns from the obtained condensate by the action of thiol (e.g., dodecane-1-thiol and thiophenol).</span>
        <meta itemprop="num_attr" content="0635">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">thiol</span>
        <span itemprop="definition">e.g., dodecane-1-thiol and thiophenol</span>
        <meta itemprop="num_attr" content="0635">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 138</span>
        <span itemprop="definition">is obtained by amidating compounds 136 and 137.</span>
        <meta itemprop="num_attr" content="0636">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IVb)</span>
        <span itemprop="definition">is obtained by allowing compound 139 to act on compound 138.</span>
        <meta itemprop="num_attr" content="0637">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 4 of compound (IVb)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (IVb) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0637">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 134</span>
        <span itemprop="definition">is obtained by allowing o-nitrobenzenesulfonyl chloride to act on R 11 -L 14 -NH 2 .</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 11 -L 14 -NH 2</span>
        <span itemprop="definition">can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fourth Series of Experimental Chemistry 20, Synthesis of Organic Compound II, 4th edition, p. 279, Maruzen Co., Ltd. (1992)) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0638">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Each compound such as compounds 135, 137 and 139, etc. for use in the reaction</span>
        <span itemprop="definition">is obtained by any of the methods mentioned above.</span>
        <meta itemprop="num_attr" content="0639">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (Va)</span>
        <span itemprop="definition">can be obtained according to synthesis route 24.</span>
        <meta itemprop="num_attr" content="0640">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">DMTr</span>
        <span itemprop="definition">represents a 2,2-dimethoxytrityl group</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 33</span>
        <span itemprop="definition">represents (CY 123 R 124 ) p54 , (CY 125 Y 126 ) p55 Z 35 (CY 127 R 128 ) p56  or (CY 129 R 130 ) p57 Z 36 (CY 131 Y 132 ) p58 Z 37 (CY 133 Y 134 ) p59 </span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 34 , M 35 and M 36</span>
        <span itemprop="definition">are each independently O or COO; and the other groups are each as defined above.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 141</span>
        <span itemprop="definition">is obtained by allowing 2,2-dimethoxytrityl chloride to act on compound 140.</span>
        <meta itemprop="num_attr" content="0641">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 142</span>
        <span itemprop="definition">is obtained by etherifying or esterifying compound 141 at 3 stages.</span>
        <meta itemprop="num_attr" content="0642">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 143</span>
        <span itemprop="definition">is obtained by treating compound 142 with an acid.</span>
        <meta itemprop="num_attr" content="0643">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 144</span>
        <span itemprop="definition">is obtained by activating compound 143 with a halogenation reagent, followed by treatment with a corresponding amine compound.</span>
        <meta itemprop="num_attr" content="0644">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (Va)</span>
        <span itemprop="definition">is obtained by allowing compound 145 to act on compound 144.</span>
        <meta itemprop="num_attr" content="0645">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Anion A 5 of compound (Va)</span>
        <span itemprop="definition">may be converted to another anion, for example, by treating the compound (Va) with an appropriate anion-exchange resin.</span>
        <meta itemprop="num_attr" content="0645">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 140</span>
        <span itemprop="definition">can be obtained as a commercially available product, as a natural product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Organic Chemistry of Sugars, Daniel E. Levy, et al. ed., Taylor &amp; Francis Group, 2005) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0646">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (Va)</span>
        <span itemprop="definition">can be obtained in the same way as in synthesis route 25 with compound 146 as a starting material.</span>
        <meta itemprop="num_attr" content="0647">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound 146</span>
        <span itemprop="definition">can be obtained as a commercially available product, as a natural product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Organic Chemistry of Sugars, Daniel E. Levy, et al. ed., Taylor &amp; Francis Group, 2005) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0648">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compounds (I) to (V)</span>
        <span itemprop="definition">can be obtained by any method of synthesis routes 1 to 25 described above, or an appropriate combination of methods equivalent to these methods, or the like.</span>
        <meta itemprop="num_attr" content="0649">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by compound (CL-I)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2013/089151, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0650">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by compound (CL-II)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2011/136368, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0651">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipids represented by compound (CL-III), compound (CL-IV) and compound (CL-V)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2014/007398, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0652">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by compound (CL-VI)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2010/042877, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0653">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (CL-VII)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2010/054401, a method described in WO 2013/059496, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0654">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (CL-VIII)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2016/002753, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0655">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (CL-IX)</span>
        <span itemprop="definition">can be obtained by a method described below, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0656">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the desired compounds</span>
        <span itemprop="definition">can be produced by use of introduction and removal methods of protective groups commonly used in organic synthetic chemistry [e.g., methods described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999)] or the like. If necessary, the order of reaction steps including substituent introduction or the like may be changed.</span>
        <meta itemprop="num_attr" content="0657">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 , R 119 , M 101 , M 102 , L 118 and L 119</span>
        <span itemprop="definition">are each as defined above;</span>
        <meta itemprop="num_attr" content="0660">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">X in IX-IIIa and X in IX-IIIb</span>
        <span itemprop="definition">are the same or different and are each a leaving group such as a chlorine atom, a bromine atom, an iodine atom, trifluoromethanesulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy or p-toluenesulfonyloxy;</span>
        <meta itemprop="num_attr" content="0660">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 141</span>
        <span itemprop="definition">is a hydrogen atom, methyl or ethyl; and</span>
        <meta itemprop="num_attr" content="0660">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 142</span>
        <span itemprop="definition">is a hydrogen atom or methyl, or R 141 and R 142 form a cyclopropyl ring together with the adjacent carbon (provided that when R 141 is a hydrogen atom or ethyl, R 142 is not methyl.</span>
        <meta itemprop="num_attr" content="0660">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IIa)</span>
        <span itemprop="definition">can be produced by reacting compound (IX-IIIa) with 2-amino-2-methyl-1,3-propanediol at a temperature between room temperature and 200 C. for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a base without a solvent or in a solvent.</span>
        <meta itemprop="num_attr" content="0662">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (CL-IXa)</span>
        <span itemprop="definition">can be produced by reacting compound (IX-IIa) with compound (IX-IIIb) at a temperature between room temperature and 200 C. for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a base without a solvent or in a solvent.</span>
        <meta itemprop="num_attr" content="0662">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">solvent</span>
        <span itemprop="definition">examples include dichloromethane, 1,2-dichloroethane, toluene, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane and pyridine. These solvents can be used alone or as a mixture.</span>
        <meta itemprop="num_attr" content="0663">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the base</span>
        <span itemprop="definition">include sodium methoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide, lithium hexamethyldisilazane, sodium hexamethyldisilazane and n-butyllithium.</span>
        <meta itemprop="num_attr" content="0664">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IIIa) and compound (IX-IIIb)</span>
        <span itemprop="definition">can each be obtained as a commercially available product or by a method known in the art (e.g., The Fifth Series of Experimental Chemistry 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0665">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compound (CL-IXa)</span>
        <span itemprop="definition">can be obtained by using 2 equivalents or more of compound (IX-IIIa) in step 26.</span>
        <meta itemprop="num_attr" content="0666">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">2-Amino-2-methyl-1,3-propanediol</span>
        <span itemprop="definition">can be obtained as a commercially available product.</span>
        <meta itemprop="num_attr" content="0667">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Step 28</span>
        <span itemprop="definition">Compound (CL-IXb) can be produced by reacting compound (CL-IXa) with 2 to 20 equivalents of compound (IX-IV) at a temperature between   20 C. and 150 C. for 5 minutes to 72 hours in the presence of preferably 1 equivalent to a large excess of a reducing agent and, if necessary, preferably 1 to 10 equivalents of an acid, in a solvent.</span>
        <meta itemprop="num_attr" content="0668">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the solvent</span>
        <span itemprop="definition">include methanol, ethanol, tert-butyl alcohol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, ti-methylpyrrolidone and water. These solvents are used alone or as a mixture.</span>
        <meta itemprop="num_attr" content="0669">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the reducing agent</span>
        <span itemprop="definition">include sodium triacetoxyborohydride and sodium cyanoborohydride.</span>
        <meta itemprop="num_attr" content="0670">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the acid</span>
        <span itemprop="definition">include hydrochloric acid and acetic acid.</span>
        <meta itemprop="num_attr" content="0671">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IV)</span>
        <span itemprop="definition">can be obtained as a commercially available product.</span>
        <meta itemprop="num_attr" content="0672">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 , R 119 , M 101 , M 102 , L 118 , L 119 , R 141 , R 142 and X</span>
        <span itemprop="definition">are each as defined above; R 143 is as defined in X 115 ; and PC represents a protective group.</span>
        <meta itemprop="num_attr" content="0675">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IIb)</span>
        <span itemprop="definition">can be produced by protecting compound (CL-IXa) by a protective group commonly used in organic synthetic chemistry [e.g., protective groups described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc.].</span>
        <meta itemprop="num_attr" content="0677">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IIc)</span>
        <span itemprop="definition">can be produced by reacting compound (IX-IIb) with compound (IX-IIIc) at a temperature between   20 C. and 150 C. for 5 minutes to 72 hours in the presence of 1 to 10 equivalents of a base without a solvent or in a solvent.</span>
        <meta itemprop="num_attr" content="0679">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">solvent</span>
        <span itemprop="definition">examples include dichloromethane, 1,2-dichloroethane, toluene, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, pyridine, N,N-dimethylformamide and N,N-dimethylacetamide. These solvents can be used alone or as a mixture.</span>
        <meta itemprop="num_attr" content="0680">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the base</span>
        <span itemprop="definition">include sodium methoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide, lithium hexamethyldisilazane, sodium hexamethyldisilazane, n-butyllithium, potassium carbonate, cesium carbonate and triethylamine.</span>
        <meta itemprop="num_attr" content="0681">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IIIc)</span>
        <span itemprop="definition">can be obtained as a commercially available product.</span>
        <meta itemprop="num_attr" content="0682">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (CL-IXc)</span>
        <span itemprop="definition">is obtained by removing the protective group PG on compound (IX-IIc) by an appropriate method.</span>
        <meta itemprop="num_attr" content="0684">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods for removing protective groups commonly used in organic synthetic chemistry</span>
        <span itemprop="definition">e.g., removal methods described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999)] can be used as the protective group removal method.</span>
        <meta itemprop="num_attr" content="0684">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the compound of interest</span>
        <span itemprop="definition">can thereby be produced.</span>
        <meta itemprop="num_attr" content="0684">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (CL-IXd)</span>
        <span itemprop="definition">can be produced by reacting compound (CL-IXc) with 1 to 10 equivalents of compound (IX-IV) at a temperature between   20 C. and 150 C. for 5 minutes to 72 hours in the presence of preferably 1 equivalent to a large excess of a reducing agent and, if necessary, preferably 1 to 10 equivalents of an acid in a solvent.</span>
        <meta itemprop="num_attr" content="0686">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the solvent, the reducing agent and the acid</span>
        <span itemprop="definition">include those listed in step 28.</span>
        <meta itemprop="num_attr" content="0687">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 , R 119 , M 101 , M 102 , L 118 , L 119 , R 141 , R 142 , R 143 and PG</span>
        <span itemprop="definition">are each as defined above; and each of B and B is linear or branched C1-C16 alkyl or C2-C16 alkenyl.</span>
        <meta itemprop="num_attr" content="0690">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IId)</span>
        <span itemprop="definition">can be produced by reacting compound (IX-IIc) with an oxidizing agent at a temperature between   20 C. and 150 C. for 5 minutes to 72 hours in a solvent.</span>
        <meta itemprop="num_attr" content="0692">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oxidizing agent</span>
        <span itemprop="definition">examples include ozone, osmium tetroxide/sodium periodate and osmium tetroxide/lead tetraacetate.</span>
        <meta itemprop="num_attr" content="0693">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the solvent</span>
        <span itemprop="definition">include those listed in step 28.</span>
        <meta itemprop="num_attr" content="0694">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IIc)</span>
        <span itemprop="definition">can be produced by the method described in Production Method 2.</span>
        <meta itemprop="num_attr" content="0695">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IIe)</span>
        <span itemprop="definition">can be produced by reacting compound (IX-IId) with an oxidizing agent at a temperature between   20 C. and 150 C. for 5 minutes to 72 hours in a solvent.</span>
        <meta itemprop="num_attr" content="0697">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">oxidizing agent</span>
        <span itemprop="definition">examples include Jones reagent, pyridinium dichromate, ruthenium tetroxide and sodium chlorite.</span>
        <meta itemprop="num_attr" content="0698">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the solvent</span>
        <span itemprop="definition">include tert-butyl alcohol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetone, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl pyrrolidone and water.</span>
        <meta itemprop="num_attr" content="0699">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">These solvents</span>
        <span itemprop="definition">can be used alone or as a mixture.</span>
        <meta itemprop="num_attr" content="0699">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IIf)</span>
        <span itemprop="definition">can be produced by reacting compound (IX-IIe) with compound (IX-Va) at a temperature between room temperature and 200 C. for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a condensing agent and 1 to 10 equivalents of a base without a solvent or in a solvent.</span>
        <meta itemprop="num_attr" content="0701">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (IX-IIc)</span>
        <span itemprop="definition">can be produced by reacting compound (IX-IIf) with compound (IX-Vb) at a temperature between room temperature and 200 C. for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a condensing agent and 1 to 10 equivalents of a base without a solvent or in a solvent.</span>
        <meta itemprop="num_attr" content="0701">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the solvent</span>
        <span itemprop="definition">include dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl pyrrolidone and pyridine. These solvents can be used alone or as a mixture.</span>
        <meta itemprop="num_attr" content="0702">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">condensing agent</span>
        <span itemprop="definition">examples include 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N,N-dicyclohexylcarbodiimide, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride n hydrate, 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate and O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate.</span>
        <meta itemprop="num_attr" content="0703">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the base</span>
        <span itemprop="definition">include potassium carbonate, cesium carbonate, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine and pyridine.</span>
        <meta itemprop="num_attr" content="0704">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compound (IX-Va) and compound (IX-Vb)</span>
        <span itemprop="definition">can be obtained as a commercially available product.</span>
        <meta itemprop="num_attr" content="0705">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (CL-IXc)</span>
        <span itemprop="definition">is obtained by removing the protective group PC on compound (IX-IIc) by appropriate methods.</span>
        <meta itemprop="num_attr" content="0708">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Methods for removing protective groups commonly used in organic synthetic chemistry</span>
        <span itemprop="definition">e.g., removal methods described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999) or the like] can be used as the protective group removal methods, and thus, the compound of interest can be produced.</span>
        <meta itemprop="num_attr" content="0708">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Compound (CL-IXd)</span>
        <span itemprop="definition">can be produced by reacting compound (CL-IXc) with 1 to 10 equivalents of compound (IX-IV) at a temperature between   20 C. and 150 C. for 5 minutes to 72 hours in the presence of preferably 1 equivalent to a large excess of a reducing agent and, if necessary, preferably 1 to 10 equivalents of an acid in a solvent.</span>
        <meta itemprop="num_attr" content="0710">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the solvent and the acid</span>
        <span itemprop="definition">include those listed in step 28.</span>
        <meta itemprop="num_attr" content="0711">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">compounds other than compounds (CL-IXa) to (CL-IXd) described above</span>
        <span itemprop="definition">can be produced according to the production methods described above or by the application of general production methods commonly used in organic synthetic chemistry, by adopting starting materials, reagents, or the like suitable for the structures of the compounds of interest.</span>
        <meta itemprop="num_attr" content="0712">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">each intermediate and the desired compounds in the production methods described above</span>
        <span itemprop="definition">can each be isolated and purified by separation and purification methods commonly used in organic synthetic chemistry, for example, filtration, extraction, washing, drying, concentration, recrystallization, various chromatography techniques, or the like. Alternatively, each intermediate may be subjected to the next reaction without being particularly purified.</span>
        <meta itemprop="num_attr" content="0713">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 115 and R 116</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1-C3 alkyl.</span>
        <meta itemprop="num_attr" content="0714">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 115 and R 116</span>
        <span itemprop="definition">are the same or different and are each preferably a hydrogen atom, methyl, ethyl or propyl, more preferably a hydrogen atom or methyl.</span>
        <meta itemprop="num_attr" content="0715">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the combination (R 115 ,R 116 )</span>
        <span itemprop="definition">is preferably (a hydrogen atom,a hydrogen atom), (a hydrogen atom,methyl) or (methyl,methyl), more preferably (a hydrogen atom,methyl) or (methyl,methyl).</span>
        <meta itemprop="num_attr" content="0716">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 118 and L 119</span>
        <span itemprop="definition">are the same or different and are each linear or branched C8-C24 alkylene or C8-C24 alkenylene.</span>
        <meta itemprop="num_attr" content="0717">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkylene</span>
        <span itemprop="definition">is preferably linear C8-C24 alkylene, more preferably linear C8-C20 alkylene, further preferably linear C8-C12 alkylene.</span>
        <meta itemprop="num_attr" content="0718">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 118 and L 119</span>
        <span itemprop="definition">are the same or different and are each preferably octylene, nonylene, undecylene, tridecylene or pentadecylene, more preferably octylene, nonylene or undecylene.</span>
        <meta itemprop="num_attr" content="0719">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkenylene</span>
        <span itemprop="definition">is preferably linear C8-C24 alkenylene, more preferably linear C10-C20 alkenylene, further preferably linear C10-C12 alkenylene.</span>
        <meta itemprop="num_attr" content="0720">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 118 and L 119</span>
        <span itemprop="definition">are the same or different and are each preferably (Z)-undec-9-enylene, (Z)-tridec-11-enylene, (Z)-tetradec-9-enylene, (Z)-hexadec-9-enylene, (Z)-octadec-9-enylene, (Z)-octadec-11-enylene or (9Z,12Z)-octadeca-9,12-dienylene.</span>
        <meta itemprop="num_attr" content="0721">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">L 118 and L 119</span>
        <span itemprop="definition">are preferably the same.</span>
        <meta itemprop="num_attr" content="0722">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 101 and M 102</span>
        <span itemprop="definition">are the same or different and are each C  C, OC(O)C(O)O, SC(O)C(O)S, OC(S), C(S)O, SS, C(R)  N, N  C(R), C(R)  NO, ON  C(R), N(R)C(O)C(O)N(R)N(R)C(S)C(S)N(R), N(R)C(O)N(R), N(R 3 )C(O)O, OC(O)N(R) or OC(O)O.</span>
        <meta itemprop="num_attr" content="0723">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 101 and M 102</span>
        <span itemprop="definition">are the same or different and are each preferably C  C, OC(O), C(O)O, C(O)(NR), N(R)C(O), N(R)C(O), N(R)C(O)N(R), N(R)C(O)O, OC(O)N(R) or OC(O)O, more preferably C  C, OC(O) or C(O)O.</span>
        <meta itemprop="num_attr" content="0724">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Bonds in the structures of M 101 and M 102</span>
        <span itemprop="definition">mean a structure of R 118 OC(O)-L 118 when OC(O) is taken as an example.</span>
        <meta itemprop="num_attr" content="0725">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">M 101 and M 102</span>
        <span itemprop="definition">are preferably the same.</span>
        <meta itemprop="num_attr" content="0726">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R and R in M 101 and M 102</span>
        <span itemprop="definition">are the same or different and are each a hydrogen atom or C1-C3 alkyl.</span>
        <meta itemprop="num_attr" content="0727">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R and R</span>
        <span itemprop="definition">is preferably a hydrogen atom, methyl, ethyl or propyl, more preferably a hydrogen atom or methyl, further preferably a hydrogen atom.</span>
        <meta itemprop="num_attr" content="0728">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 and R 119</span>
        <span itemprop="definition">are the same or different and are each linear or branched C1-C16 alkyl or C2-C16 alkenyl.</span>
        <meta itemprop="num_attr" content="0729">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 and R 119</span>
        <span itemprop="definition">are the same or different and are each alkyl</span>
        <meta itemprop="num_attr" content="0730">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkyl</span>
        <span itemprop="definition">is preferably linear C1-C16 alkyl, more preferably linear C2-C9 alkyl.</span>
        <meta itemprop="num_attr" content="0730">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 and R 119</span>
        <span itemprop="definition">are the same or different and are each preferably pentyl, octyl, nonyl, decyl or dodecyl.</span>
        <meta itemprop="num_attr" content="0731">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the alkenyl</span>
        <span itemprop="definition">is preferably linear C2-C16 alkenyl, more preferably linear C3-C9 alkenyl.</span>
        <meta itemprop="num_attr" content="0732">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 and R 119</span>
        <span itemprop="definition">are the same or different and are each preferably (Z)-hept-2-ene, (Z)-oct-2-ene, (Z)-non-2-ene, (Z)-non-3-ene, non-8-ene, (Z)-dodec-2-ene or (Z)-tridec-2-ene.</span>
        <meta itemprop="num_attr" content="0733">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 and R 119</span>
        <span itemprop="definition">are preferably the same.</span>
        <meta itemprop="num_attr" content="0734">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 -M 101 -L 118 and R 119 -M 102 -L 119</span>
        <span itemprop="definition">are the same or different, R 118 and R 119 , M 101 and M 102 , or L 118 and L 119 may be a combination selected from the structures described about each group.</span>
        <meta itemprop="num_attr" content="0735">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 -M 101 -L 118 and R 119 -M 102 -L 119</span>
        <span itemprop="definition">are preferably the same.</span>
        <meta itemprop="num_attr" content="0736">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 -M 101 -L 118 and R 119 -M 102 -L 119</span>
        <span itemprop="definition">are the same or different and are each preferably selected from the group consisting of (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl and (Z)-docos-13-enyl, more preferably selected from the group consisting of (Z)-hexadec-9-enyl, (Z)-octadec-9-enyl</span>
        <meta itemprop="num_attr" content="0737">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">R 118 -M 101 -L 118 and R 119 -M 102 -L 119</span>
        <span itemprop="definition">are the same or different and are each preferably any of the following structures (1) to (5), more preferably are the same and any of the following structures (1) to (5):</span>
        <meta itemprop="num_attr" content="0738">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">n</span>
        <span itemprop="definition">is an integer from 1 to 4.</span>
        <meta itemprop="num_attr" content="0000">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by compound (CL-X)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2009/129385, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0739">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by compound (CL-XI)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2013/1491401, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0740">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by compound (CL-XII)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2009/129395, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0741">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by compound (CL-XIII)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2013/059496, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0742">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by compound (CL-XIV)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2011/149733, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0743">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by formula (CL-XV)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2011/153493, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0744">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by formula (CL-XVI)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2015/074085, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0745">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by formula (CL-XVII)</span>
        <span itemprop="definition">can be obtained by a method described in WO 2012/170952, or a method equivalent thereto.</span>
        <meta itemprop="num_attr" content="0746">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">the lipid represented by formula (CL-XVIII)</span>
        <span itemprop="definition">can be synthesized according to methods given below.</span>
        <meta itemprop="num_attr" content="0747">
      </li>
      <li itemprop="definitions" itemscope repeat>
        <span itemprop="subject">Examples of the method for synthesizing the lipid represented by formula (CL-XVIII)</span>
        <span itemprop="definition">include Synthesis Method I for formula (CL-XVIII) and Synthesis Method II for formula (CL-XVIII) given below.</span>
        <meta itemprop="num_attr" content="0748">
      </li>
    </ul>
  </section>

  <section>
    <h2>Landscapes</h2>
    <ul>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Organic Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Life Sciences &amp; Earth Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Health &amp; Medical Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Genetics &amp; Genomics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Veterinary Medicine</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Animal Behavior &amp; Ethology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmacology &amp; Pharmacy</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Public Health</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biomedical Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Bioinformatics &amp; Cheminformatics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Molecular Biology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Epidemiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Engineering &amp; Computer Science</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Wood Science &amp; Technology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Zoology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Physics &amp; Mathematics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biophysics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Biochemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Plant Pathology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Microbiology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Nuclear Medicine, Radiotherapy &amp; Molecular Imaging</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Chemical Kinetics &amp; Catalysis</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">General Chemical &amp; Material Sciences</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Dispersion Chemistry</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Nanotechnology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Optics &amp; Photonics</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pain &amp; Pain Management</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Rheumatology</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Pharmaceuticals Containing Other Organic And Inorganic Compounds</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicinal Preparation</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Medicines That Contain Protein Lipid Enzymes And Other Medicines</span>
        (<span itemprop="type">AREA</span>)
      </li>
      <li itemprop="landscapes" itemscope repeat>
        <span itemprop="name">Organic Low-Molecular-Weight Compounds And Preparation Thereof</span>
        (<span itemprop="type">AREA</span>)
      </li>
    </ul>
  </section>


  <section itemprop="abstract" itemscope>
    <h2>Abstract</h2>
    
    <div itemprop="content" html><abstract mxw-id="PA425171550" lang="EN" source="national office" load-source="docdb">
    <div class="abstract">The present invention provides a nucleic acid-containing lipid nanoparticle comprising an analog of a fatty acid ester of glycerol, and a nucleic acid, wherein the analog is not hydrolyzable by a lipase.</div>
  </abstract>
  </div>
  </section>

  <section itemprop="description" itemscope>
    <h2>Description</h2>
    
    <div itemprop="content" html><ul mxw-id="PDES280553781" lang="EN" load-source="patent-office" class="description">
    
    <heading id="h-0001">TECHNICAL FIELD</heading>
    <li> <para-num num="[0001]"> </para-num> <div id="p-0002" num="0001" class="description-line">The present invention relates to a nucleic acid-containing lipid nanoparticle.</div>
    </li> <heading id="h-0002">BACKGROUND ART</heading>
    <li> <para-num num="[0002]"> </para-num> <div id="p-0003" num="0002" class="description-line">In order to achieve gene therapy, carriers have been developed for efficiently delivering nucleic acids such as plasmid DNA (pDNA), antisense oligodeoxynucleic acid (ODN) and short interfering RNA (siRNA) to target cells in vivo. A method which involves allowing lipid particles to contain nucleic acids in order to protect the nucleic acids from in vivo nucleases and the like, and administering the complexes is known as an approach thereof.</div>
    </li> <li> <para-num num="[0003]"> </para-num> <div id="p-0004" num="0003" class="description-line"> <figure-callout id="1" label="Patent Literature" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Patent Literature</figure-callout> 1 and <figure-callout id="1" label="Non Patent Literature" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Non Patent Literature</figure-callout> 1 have reported, as a method for producing a liposome containing a nucleic acid or the like, for example, a method for producing a liposome containing siRNA by dissolving a dried cationic lipid, an aqueous sodium citrate solution of siRNA and a neutral lipid, and a polyethylene glycolated phospholipid in HEPES [N-(2-hydroxyethyl)piperazine-N-(2-ethanesulfonic acid)] buffered saline (hereinafter, referred to as HBS) and ethanol, adding the resulting solution to diethyl ether to form a water-in-oil (W/O) emulsion, then mixing the solution, and treating the solution by a reverse-phase evaporation method.</div>
    </li> <li> <para-num num="[0004]"> </para-num> <div id="p-0005" num="0004" class="description-line"> <figure-callout id="2" label="Patent Literature" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Patent Literature</figure-callout> 2 and <figure-callout id="2" label="Non Patent Literature" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Non Patent Literature</figure-callout> 2 have reported a method for producing a liposome containing ODN by dissolving ODN in an aqueous citric acid solution of pH 3.8, adding a solution of a lipid in ethanol to the solution, decreasing the ethanol concentration to 20 v/v % to prepare a liposome containing ODN, filtering the solution through a sizing membrane, removing an excess of ethanol by dialysis, and then further dialyzing the sample at pH 7.5 to remove ODN attached to the liposome surface.</div>
    </li> <li> <para-num num="[0005]"> </para-num> <div id="p-0006" num="0005" class="description-line"> <figure-callout id="3" label="Patent Literature" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Patent Literature</figure-callout> 3 has reported, for example, a method for producing a liposome containing pDNA by mixing a solution containing pDNA dissolved in an aqueous citric acid solution with a solution containing a lipid dissolved in ethanol using a T-shaped mixer, decreasing the ethanol concentration to 45 v/v %, then further adding thereto a citrate buffer solution so that the ethanol concentration is decreased to 20 v/v % to prepare a liposome containing pDNA, removing residual pDNA through an anion-exchange resin, and removing an excess of ethanol by ultrafiltration.</div>
    </li> <li> <para-num num="[0006]"> </para-num> <div id="p-0007" num="0006" class="description-line">Patent Literature 4 has reported a method for producing a liposome containing pDNA by complexing pDNA with a cationic lipid as micelle in an organic solvent containing water, further adding a lipid thereto, and then removing the organic solvent by dialysis.</div>
    </li> <li> <para-num num="[0007]"> </para-num> <div id="p-0008" num="0007" class="description-line">Patent Literature 5 has reported a method for producing a liposome containing pDNA by complexing pDNA with a cationic lipid as micelle in an aqueous solution of a surfactant, further adding a lipid thereto, and then removing the surfactant by dialysis.</div>
    </li> <li> <para-num num="[0008]"> </para-num> <div id="p-0009" num="0008" class="description-line">Meanwhile, Non <figure-callout id="3" label="Patent Literature" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Patent Literature</figure-callout> 3 has reported that in a test using lipid nanoparticles containing doxorubicin, the contents are efficiently released by hydrolyzing an ester bond at position sn-2 of phospholipid with phospholipase A2 (hereinafter, also referred to as PLA2). This means that when phospholipid, a constituent of the lipid nanoparticles, is metabolized with phospholipase A2 in vivo, the stability of the particles carrying a drug is reduced. When the drug is a low-molecular drug, the reduced stability of the particles facilitates smoothly releasing the drug so that the drug exhibits activity. On the other hand, when the contents are a nucleic acid, the nucleic acid is poorly taken up into cells even after release and is enzymatically degraded, leading to the disappearance of its activity. Nanoparticles containing the nucleic acid mentioned above generally employ a lipid served as a substrate of PLA2. Thus, it has been difficult to prepare a lipid particle having high stability.</div>
    </li> <li> <para-num num="[0009]"> </para-num> <div id="p-0010" num="0009" class="description-line">Patent Literature 6 discloses that 1,2-di-O-hexadecyl-sn-glycero-3-phosphocholine is used in a composition for the oral administration and transport of bioactive drugs, and states that such a composition is stable against acids. However, the literature does not state that this composition was used for nucleic acid transport.</div>
    </li> <heading id="h-0003">CITATION LIST</heading>
    <heading id="h-0004">Patent Literature</heading>
    <li> <div id="p-0011" num="0000" class="description-line">
      </div> </li> <ul>
        <li id="ul0001-0001" num="0010">Patent Literature 1: U.S. Patent Application Publication No. 2013/0149374</li>
        <li id="ul0001-0002" num="0011">Patent Literature 2: Japanese Unexamined Patent Application Publication (Translation of PCT Application) No. 2002-501511</li>
        <li id="ul0001-0003" num="0012">Patent Literature 3: WO 2004/002453</li>
        <li id="ul0001-0004" num="0013">Patent Literature 4: WO 96/40964</li>
        <li id="ul0001-0005" num="0014">Patent Literature 5: U.S. Patent Application Publication No. 2010/0041152</li>
        <li id="ul0001-0006" num="0015">Patent Literature 6: WO 2014/143806</li>
      </ul>
    
    <heading id="h-0005">Non Patent Literature</heading>
    <li> <div id="p-0012" num="0000" class="description-line">
      </div> </li> <ul>
        <li id="ul0002-0001" num="0016">Non Patent Literature 1: Biochimica et Biophysica Acta, 2012, Vol. 1818, p. 1633-1641</li>
        <li id="ul0002-0002" num="0017">Non Patent Literature 2: Biochimica et Biophysica Acta, 2001, Vol. 1510, p. 152-166</li>
      </ul>
    
    <heading id="h-0006">SUMMARY OF INVENTION</heading>
    <heading id="h-0007">Technical Problem</heading>
    <li> <para-num num="[0018]"> </para-num> <div id="p-0013" num="0018" class="description-line">An object of the present invention is to provide a nucleic acid-containing lipid nanoparticle that is useful as a medicament and is more stable than conventional particles.</div>
    </li> <heading id="h-0008">Solution to Problem</heading>
    <li> <para-num num="[0019]"> </para-num> <div id="p-0014" num="0019" class="description-line">The present invention relates to the following:</div>
    </li> <li> <div id="p-0015" num="0000" class="description-line">[1]</div>
    </li> <li> <para-num num="[0020]"> </para-num> <div id="p-0016" num="0020" class="description-line">A nucleic acid-containing lipid nanoparticle comprising</div>
    </li> <li> <para-num num="[0021]"> </para-num> <div id="p-0017" num="0021" class="description-line">an analog of a fatty acid ester of glycerol, and</div>
    </li> <li> <para-num num="[0022]"> </para-num> <div id="p-0018" num="0022" class="description-line">a nucleic acid,</div>
    </li> <li> <div id="p-0019" num="0000" class="description-line">wherein the analog is not hydrolyzable by a lipase.
<br/>
[2]
</div>
    </li> <li> <para-num num="[0023]"> </para-num> <div id="p-0020" num="0023" class="description-line">The nucleic acid-containing lipid nanoparticle according to [1], wherein the analog of the fatty acid ester of glycerol is an analog of a glycerophospholipid.</div>
    </li> <li> <div id="p-0021" num="0000" class="description-line">[3]</div>
    </li> <li> <para-num num="[0024]"> </para-num> <div id="p-0022" num="0024" class="description-line">The nucleic acid-containing lipid nanoparticle according to [1] or [2], wherein the lipase is phospholipase A2.</div>
    </li> <li> <div id="p-0023" num="0000" class="description-line">[4]</div>
    </li> <li> <para-num num="[0025]"> </para-num> <div id="p-0024" num="0025" class="description-line">The nucleic acid-containing lipid nanoparticle according to any one of [1] to [3], wherein the analog of the fatty acid ester of glycerol is a lipid represented by the following formula (1) or (2):</div>
    </li> <li> <div id="p-0025" num="0000" class="description-line">
      <chemistry id="CHEM-US-00001" num="00001">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2b/fc/26/884b85cc0d4759/US20200368173A1-20201126-C00001.png"><img id="EMI-C00001" he="26.50mm" wi="64.77mm" file="US20200368173A1-20201126-C00001.TIF" alt="Figure US20200368173A1-20201126-C00001" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="259" height="106" alt="Figure US20200368173A1-20201126-C00001" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2b/fc/26/884b85cc0d4759/US20200368173A1-20201126-C00001.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00001" attachment-type="cdx" file="US20200368173A1-20201126-C00001.CDX"> </attachment>
          <attachment idref="CHEM-US-00001" attachment-type="mol" file="US20200368173A1-20201126-C00001.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0026" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0026]"> </para-num> <div id="p-0027" num="0026" class="description-line">Rx<sup>1 </sup>and Rx<sup>2 </sup>are the same or different and are each optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl; and</div>
    </li> <li> <para-num num="[0027]"> </para-num> <div id="p-0028" num="0027" class="description-line">Rx<sup>3 </sup>is a negative charge, a hydrogen atom, or any of the following groups:</div>
    </li> <li> <div id="p-0029" num="0000" class="description-line">
      <chemistry id="CHEM-US-00002" num="00002">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/39/b6/93/6193640643f3b0/US20200368173A1-20201126-C00002.png"><img id="EMI-C00002" he="91.78mm" wi="73.66mm" file="US20200368173A1-20201126-C00002.TIF" alt="Figure US20200368173A1-20201126-C00002" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="295" height="367" alt="Figure US20200368173A1-20201126-C00002" class="patent-full-image" src="https://patentimages.storage.googleapis.com/39/b6/93/6193640643f3b0/US20200368173A1-20201126-C00002.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00002" attachment-type="cdx" file="US20200368173A1-20201126-C00002.CDX"> </attachment>
          <attachment idref="CHEM-US-00002" attachment-type="mol" file="US20200368173A1-20201126-C00002.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0030" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0028]"> </para-num> <div id="p-0031" num="0028" class="description-line">Rx<sup>4 </sup>is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl or Rx<sup>41</sup>-CO;</div>
    </li> <li> <para-num num="[0029]"> </para-num> <div id="p-0032" num="0029" class="description-line">Rx<sup>41 </sup>is optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl;</div>
    </li> <li> <para-num num="[0030]"> </para-num> <div id="p-0033" num="0030" class="description-line">Rx<sup>5 </sup>is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl; and</div>
    </li> <li> <para-num num="[0031]"> </para-num> <div id="p-0034" num="0031" class="description-line">Rx<sup>6 </sup>is a negative charge, a hydrogen atom, or any of the following groups:</div>
    </li> <li> <div id="p-0035" num="0000" class="description-line">
      <chemistry id="CHEM-US-00003" num="00003">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/24/00/73/925c4c64dff42d/US20200368173A1-20201126-C00003.png"><img id="EMI-C00003" he="54.53mm" wi="70.70mm" file="US20200368173A1-20201126-C00003.TIF" alt="Figure US20200368173A1-20201126-C00003" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="283" height="218" alt="Figure US20200368173A1-20201126-C00003" class="patent-full-image" src="https://patentimages.storage.googleapis.com/24/00/73/925c4c64dff42d/US20200368173A1-20201126-C00003.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00003" attachment-type="cdx" file="US20200368173A1-20201126-C00003.CDX"> </attachment>
          <attachment idref="CHEM-US-00003" attachment-type="mol" file="US20200368173A1-20201126-C00003.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0036" num="0000" class="description-line">[5]</div>
    </li> <li> <para-num num="[0032]"> </para-num> <div id="p-0037" num="0032" class="description-line">The nucleic acid-containing lipid nanoparticle according to any one of [1] to [4], wherein a content of the analog of the fatty acid ester of glycerol is 0.001-fold molar amount or more with respect to the molar number of total lipid.</div>
    </li> <li> <div id="p-0038" num="0000" class="description-line">[6]</div>
    </li> <li> <para-num num="[0033]"> </para-num> <div id="p-0039" num="0033" class="description-line">The nucleic acid-containing lipid nanoparticle according to any one of [1] to [5], further comprising a cationic lipid.</div>
    </li> <li> <div id="p-0040" num="0000" class="description-line">[7]</div>
    </li> <li> <para-num num="[0034]"> </para-num> <div id="p-0041" num="0034" class="description-line">The nucleic acid-containing lipid nanoparticle according to [6], wherein the cationic lipid is lipid A represented by at least one of formulas (I), (II), (III), (IV), (V) and (V) given below, and/or lipid B represented by at least one of formulas (CL-I), (CL-II), (CL-III), (CL-IV), (CL-V), (CL-VI), (CL-VII), (CL-VIII), (CL-IX), (CL-X), (CL-XI), (CL-XII), (CL-XIII), (CL-XIV), (CL-XV), (CL-XVI), (CL-XVII), (CL-XVIII) and (CL-XIX) given below (wherein the formulas (I), (II), (III), (IV), (V) and (V) are represented by structures described in Description of Embodiments mentioned later, and the formulas (CL-I), (CL-II), (CL-III), (CL-IV), (CL-V), (CL-VI), (CL-VII), (CL-VIII), (CL-IX), (CL-X), (CL-XI), (CL-XII), (CL-XIII), (CL-XIV), (CL-XV), (CL-XVI), (CL-XVII), (CL-XVIII) and (CL-XIX) are represented by structures described in Description of Embodiments mentioned later; the same holds true for the description below).</div>
    </li> <li> <div id="p-0042" num="0000" class="description-line">[8]</div>
    </li> <li> <para-num num="[0035]"> </para-num> <div id="p-0043" num="0035" class="description-line">The nucleic acid-containing lipid nanoparticle according to [7], wherein the cationic lipid is the lipid B.</div>
    </li> <li> <div id="p-0044" num="0000" class="description-line">[9]</div>
    </li> <li> <para-num num="[0036]"> </para-num> <div id="p-0045" num="0036" class="description-line">The nucleic acid-containing lipid nanoparticle according to any one of [1] to [8], further comprising a lipid derivative or a fatty acid derivative of a water-soluble polymer.</div>
    </li> <li> <div id="p-0046" num="0000" class="description-line">[10]</div>
    </li> <li> <para-num num="[0037]"> </para-num> <div id="p-0047" num="0037" class="description-line">The nucleic acid-containing lipid nanoparticle according to [9], wherein the water-soluble polymer moiety of the lipid derivative or the fatty acid derivative of the water-soluble polymer is selected from the group consisting of polyethylene glycol, polyglycerin, polyethyleneimine, polyvinyl alcohol, polyacrylic acid and polyacrylamide.</div>
    </li> <li> <div id="p-0048" num="0000" class="description-line">[11]</div>
    </li> <li> <para-num num="[0038]"> </para-num> <div id="p-0049" num="0038" class="description-line">The nucleic acid-containing lipid nanoparticle according to any one of [1] to [10], further comprising a neutral lipid.</div>
    </li> <li> <div id="p-0050" num="0000" class="description-line">[12]</div>
    </li> <li> <para-num num="[0039]"> </para-num> <div id="p-0051" num="0039" class="description-line">The nucleic acid-containing lipid nanoparticle according to [11], wherein the neutral lipid is selected from the group consisting of phospholipid, sterol, glyceroglycolipid, sphingoglycolipid and sphingoid.</div>
    </li> <li> <div id="p-0052" num="0000" class="description-line">[13]</div>
    </li> <li> <para-num num="[0040]"> </para-num> <div id="p-0053" num="0040" class="description-line">The nucleic acid-containing lipid nanoparticle according to any one of [1] to [12], wherein the nucleic acid is a nucleic acid having a silencing effect on a target gene through the use of RNA interference (RNAi).</div>
    </li> <li> <div id="p-0054" num="0000" class="description-line">[14]</div>
    </li> <li> <para-num num="[0041]"> </para-num> <div id="p-0055" num="0041" class="description-line">The nucleic acid-containing lipid nanoparticle according to [13], wherein the target gene is a gene related to tumor or inflammation.</div>
    </li> <li> <div id="p-0056" num="0000" class="description-line">[15]</div>
    </li> <li> <para-num num="[0042]"> </para-num> <div id="p-0057" num="0042" class="description-line">A method for stabilizing a nucleic acid-containing lipid nanoparticle using an analog of a fatty acid ester of glycerol, wherein the analog is not hydrolyzable by a lipase. Here, the analog may be the analog referred in any of [1] to [5], and the nucleic acid-containing lipid nanoparticle may be the nucleic acid-containing lipid nanoparticle according to any of [1] to [14].</div>
    </li> <li> <div id="p-0058" num="0000" class="description-line">[16]</div>
    </li> <li> <para-num num="[0043]"> </para-num> <div id="p-0059" num="0043" class="description-line">A method for introducing a nucleic acid into a cell using the nucleic acid-containing lipid nanoparticle according to any one of [1] to [14].</div>
    </li> <li> <div id="p-0060" num="0000" class="description-line">[17]</div>
    </li> <li> <para-num num="[0044]"> </para-num> <div id="p-0061" num="0044" class="description-line">The method according to [16], wherein the cell is a cell residing at a mammalian tumor or inflammation site.</div>
    </li> <li> <div id="p-0062" num="0000" class="description-line">[18]</div>
    </li> <li> <para-num num="[0045]"> </para-num> <div id="p-0063" num="0045" class="description-line">The method according to [16] or [17], wherein the cell is a cell residing in the mammalian liver, stomach, lung, kidney, pancreas or spleen.</div>
    </li> <li> <div id="p-0064" num="0000" class="description-line">[19]</div>
    </li> <li> <para-num num="[0046]"> </para-num> <div id="p-0065" num="0046" class="description-line">The method according to any one of [16] to [18], wherein a method for the introduction into the cell is a method of introduction into the cell by intravenous administration or subcutaneous administration.</div>
    </li> <li> <div id="p-0066" num="0000" class="description-line">[20]</div>
    </li> <li> <para-num num="[0047]"> </para-num> <div id="p-0067" num="0047" class="description-line">A method for treating a cancer or an inflammatory disease, comprising administering the nucleic acid-containing lipid nanoparticle according to any one of [1] to [14] to a mammal.</div>
    </li> <li> <div id="p-0068" num="0000" class="description-line">[21]</div>
    </li> <li> <para-num num="[0048]"> </para-num> <div id="p-0069" num="0048" class="description-line">The method for treating method according to [20], wherein the administration is intravenous administration or subcutaneous administration.</div>
    </li> <li> <div id="p-0070" num="0000" class="description-line">[22]</div>
    </li> <li> <para-num num="[0049]"> </para-num> <div id="p-0071" num="0049" class="description-line">A medicament comprising the nucleic acid-containing lipid nanoparticle according to any one of [1] to [14].</div>
    </li> <li> <div id="p-0072" num="0000" class="description-line">[23]</div>
    </li> <li> <para-num num="[0050]"> </para-num> <div id="p-0073" num="0050" class="description-line">The medicament according to [22], wherein the medicament is intended for intravenous administration or subcutaneous administration.</div>
    </li> <li> <div id="p-0074" num="0000" class="description-line">[24]</div>
    </li> <li> <para-num num="[0051]"> </para-num> <div id="p-0075" num="0051" class="description-line">A therapeutic agent for a cancer or an inflammatory disease comprising the nucleic acid-containing lipid nanoparticle according to any one of [1] to [14].</div>
    </li> <li> <div id="p-0076" num="0000" class="description-line">[25]</div>
    </li> <li> <para-num num="[0052]"> </para-num> <div id="p-0077" num="0052" class="description-line">The therapeutic agent according to [24], wherein the therapeutic agent is intended for intravenous administration or subcutaneous administration.</div>
    </li> <li> <div id="p-0078" num="0000" class="description-line">[26]</div>
    </li> <li> <para-num num="[0053]"> </para-num> <div id="p-0079" num="0053" class="description-line">A compound represented by formula (CL-XVIII), or a pharmaceutically acceptable salt thereof (the cationic lipid):</div>
    </li> <li> <div id="p-0080" num="0000" class="description-line">
      <chemistry id="CHEM-US-00004" num="00004">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a9/f3/38/7c25dc0adf8511/US20200368173A1-20201126-C00004.png"><img id="EMI-C00004" he="13.55mm" wi="59.44mm" file="US20200368173A1-20201126-C00004.TIF" alt="Figure US20200368173A1-20201126-C00004" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="238" height="54" alt="Figure US20200368173A1-20201126-C00004" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a9/f3/38/7c25dc0adf8511/US20200368173A1-20201126-C00004.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00004" attachment-type="cdx" file="US20200368173A1-20201126-C00004.CDX"> </attachment>
          <attachment idref="CHEM-US-00004" attachment-type="mol" file="US20200368173A1-20201126-C00004.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0081" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0054]"> </para-num> <div id="p-0082" num="0054" class="description-line">R<sup>137 </sup>and R<sup>138 </sup>are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, C8-24 alkenylthioethyl, or C8-C24 alkynylthioethyl; and</div>
    </li> <li> <para-num num="[0055]"> </para-num> <div id="p-0083" num="0055" class="description-line">X<sup>135 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (C):</div>
    </li> <li> <div id="p-0084" num="0000" class="description-line">
      <chemistry id="CHEM-US-00005" num="00005">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/44/4c/2059b8482f037e/US20200368173A1-20201126-C00005.png"><img id="EMI-C00005" he="18.03mm" wi="55.12mm" file="US20200368173A1-20201126-C00005.TIF" alt="Figure US20200368173A1-20201126-C00005" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="220" height="72" alt="Figure US20200368173A1-20201126-C00005" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cc/44/4c/2059b8482f037e/US20200368173A1-20201126-C00005.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00005" attachment-type="cdx" file="US20200368173A1-20201126-C00005.CDX"> </attachment>
          <attachment idref="CHEM-US-00005" attachment-type="mol" file="US20200368173A1-20201126-C00005.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0085" num="0000" class="description-line">wherein X<sup>136 </sup>and X<sup>137 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>136 </sup>and X<sup>137 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; L<sup>132 </sup>is S or O; and p<sup>115 </sup>is an integer from 2 to 4,
<br/>
formula (D):
</div>
    </li> <li> <div id="p-0086" num="0000" class="description-line">
      <chemistry id="CHEM-US-00006" num="00006">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/aa/a4/f8/acfe2dfc47e8f3/US20200368173A1-20201126-C00006.png"><img id="EMI-C00006" he="14.22mm" wi="51.65mm" file="US20200368173A1-20201126-C00006.TIF" alt="Figure US20200368173A1-20201126-C00006" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="57" alt="Figure US20200368173A1-20201126-C00006" class="patent-full-image" src="https://patentimages.storage.googleapis.com/aa/a4/f8/acfe2dfc47e8f3/US20200368173A1-20201126-C00006.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00006" attachment-type="cdx" file="US20200368173A1-20201126-C00006.CDX"> </attachment>
          <attachment idref="CHEM-US-00006" attachment-type="mol" file="US20200368173A1-20201126-C00006.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0087" num="0000" class="description-line">wherein X<sup>138 </sup>and X<sup>139 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>138 </sup>and X<sup>139 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>116 </sup>is an integer from 1 to 4,
<br/>
or formula (E):
</div>
    </li> <li> <div id="p-0088" num="0000" class="description-line">
      <chemistry id="CHEM-US-00007" num="00007">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/58/21/6d/d95c970c0ef01e/US20200368173A1-20201126-C00007.png"><img id="EMI-C00007" he="14.22mm" wi="51.56mm" file="US20200368173A1-20201126-C00007.TIF" alt="Figure US20200368173A1-20201126-C00007" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="206" height="57" alt="Figure US20200368173A1-20201126-C00007" class="patent-full-image" src="https://patentimages.storage.googleapis.com/58/21/6d/d95c970c0ef01e/US20200368173A1-20201126-C00007.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00007" attachment-type="cdx" file="US20200368173A1-20201126-C00007.CDX"> </attachment>
          <attachment idref="CHEM-US-00007" attachment-type="mol" file="US20200368173A1-20201126-C00007.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0089" num="0000" class="description-line">wherein X<sup>140 </sup>and X<sup>141 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>140 </sup>and X<sup>141 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>117 </sup>is an integer from 1 to 4.
<br/>
[27]
</div>
    </li> <li> <para-num num="[0056]"> </para-num> <div id="p-0090" num="0056" class="description-line">A compound represented by formula (CL-XIX), or a pharmaceutically acceptable salt thereof (the cationic lipid):</div>
    </li> <li> <div id="p-0091" num="0000" class="description-line">
      <chemistry id="CHEM-US-00008" num="00008">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b8/9b/96/407588719f8ede/US20200368173A1-20201126-C00008.png"><img id="EMI-C00008" he="16.85mm" wi="60.54mm" file="US20200368173A1-20201126-C00008.TIF" alt="Figure US20200368173A1-20201126-C00008" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="242" height="67" alt="Figure US20200368173A1-20201126-C00008" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b8/9b/96/407588719f8ede/US20200368173A1-20201126-C00008.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00008" attachment-type="cdx" file="US20200368173A1-20201126-C00008.CDX"> </attachment>
          <attachment idref="CHEM-US-00008" attachment-type="mol" file="US20200368173A1-20201126-C00008.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0092" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0057]"> </para-num> <div id="p-0093" num="0057" class="description-line">R<sup>139 </sup>and R<sup>140 </sup>are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0058]"> </para-num> <div id="p-0094" num="0058" class="description-line">L<sup>133 </sup>is S or O; and</div>
    </li> <li> <para-num num="[0059]"> </para-num> <div id="p-0095" num="0059" class="description-line">X<sup>142 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (F):</div>
    </li> <li> <div id="p-0096" num="0000" class="description-line">
      <chemistry id="CHEM-US-00009" num="00009">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5d/6f/31/2e79c789494b25/US20200368173A1-20201126-C00009.png"><img id="EMI-C00009" he="18.03mm" wi="54.95mm" file="US20200368173A1-20201126-C00009.TIF" alt="Figure US20200368173A1-20201126-C00009" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="220" height="72" alt="Figure US20200368173A1-20201126-C00009" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5d/6f/31/2e79c789494b25/US20200368173A1-20201126-C00009.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00009" attachment-type="cdx" file="US20200368173A1-20201126-C00009.CDX"> </attachment>
          <attachment idref="CHEM-US-00009" attachment-type="mol" file="US20200368173A1-20201126-C00009.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0097" num="0000" class="description-line">wherein X<sup>143 </sup>and X<sup>144 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>143 </sup>and X<sup>144 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; L<sup>134 </sup>is S or O; and p<sup>118 </sup>is an integer from 2 to 4,
<br/>
or formula (G):
</div>
    </li> <li> <div id="p-0098" num="0000" class="description-line">
      <chemistry id="CHEM-US-00010" num="00010">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b2/9c/0c/41ae5b8897492d/US20200368173A1-20201126-C00010.png"><img id="EMI-C00010" he="14.82mm" wi="51.73mm" file="US20200368173A1-20201126-C00010.TIF" alt="Figure US20200368173A1-20201126-C00010" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="59" alt="Figure US20200368173A1-20201126-C00010" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b2/9c/0c/41ae5b8897492d/US20200368173A1-20201126-C00010.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00010" attachment-type="cdx" file="US20200368173A1-20201126-C00010.CDX"> </attachment>
          <attachment idref="CHEM-US-00010" attachment-type="mol" file="US20200368173A1-20201126-C00010.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0099" num="0000" class="description-line">wherein X<sup>145 </sup>and X<sup>146 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>145 </sup>and X<sup>146 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>119 </sup>is an integer from 1 to 4.</div>
    </li> <heading id="h-0009">Advantageous Effects of Invention</heading>
    <li> <para-num num="[0060]"> </para-num> <div id="p-0100" num="0060" class="description-line">The present invention can provide a nucleic acid-containing lipid nanoparticle that is useful as a medicament and is more stable than conventional particles.</div>
    
    
    </li> <description-of-drawings>
      <heading id="h-0010">BRIEF DESCRIPTION OF DRAWINGS</heading>
      <li> <para-num num="[0061]"> </para-num> <div id="p-0101" num="0061" class="description-line"> <figref idrefs="DRAWINGS">FIG. 1</figref> shows a graph showing the amount of lipids remaining in each preparation. The ordinate of the graph depicts the amount of lipids remaining (%) with that in a PLA2-untreated group defined as 1. The abscissa depicts each preparation.</div>
      </li> <li> <para-num num="[0062]"> </para-num> <div id="p-0102" num="0062" class="description-line"> <figref idrefs="DRAWINGS">FIG. 2</figref> shows a graph showing the amount of lipids remaining in each preparation. The ordinate of the graph depicts the amount of lipids remaining (%) with that in a PLA2-untreated group defined as 1. The abscissa depicts each preparation.</div>
      </li> <li> <para-num num="[0063]"> </para-num> <div id="p-0103" num="0063" class="description-line"> <figref idrefs="DRAWINGS">FIG. 3</figref> shows a graph showing the amount of lipids remaining in each preparation. The ordinate of the graph depicts the amount of lipids remaining (%) with that in a PLA2-untreated group defined as 1. The abscissa depicts each preparation.</div>
    </li> </description-of-drawings>
    
    
    <heading id="h-0011">DESCRIPTION OF EMBODIMENTS</heading>
    <li> <para-num num="[0064]"> </para-num> <div id="p-0104" num="0064" class="description-line">Hereinafter, the mode for carrying out the present invention will be described in detail. The embodiments described below do not limit the present invention.</div>
    </li> <li> <para-num num="[0065]"> </para-num> <div id="p-0105" num="0065" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention comprises an analog of a fatty acid ester of glycerol, and a nucleic acid. The analog is not hydrolyzable by a lipase.</div>
    </li> <li> <para-num num="[0066]"> </para-num> <div id="p-0106" num="0066" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention can be stably present even if contacted with a lipase, because the lipid in the particle resists degradation.</div>
    </li> <li> <para-num num="[0067]"> </para-num> <div id="p-0107" num="0067" class="description-line">In a lipid having a fatty acid ester structure of glycerol (hereinafter, also referred to as a natural glycerol lipid), at least one hydroxy group of glycerol, and a fatty acid form an ester bond. This ester bond is hydrolyzed by the action of a lipase.</div>
    </li> <li> <para-num num="[0068]"> </para-num> <div id="p-0108" num="0068" class="description-line">The analog of the fatty acid ester of glycerol according to the present invention is a lipid having a structure modified from a partial structure in the natural glycerol lipid, and is not hydrolyzable by a lipase.</div>
    </li> <li> <para-num num="[0069]"> </para-num> <div id="p-0109" num="0069" class="description-line">In the present invention, the phrase not hydrolyzable by a lipase means that when the nucleic acid-containing lipid nanoparticle of the present invention is contacted with a lipase, usually 30% or more, preferably 50% or more, more preferably 70% or more, further preferably 90% or more, still further preferably 99% or more, is not degraded with respect to the total amount of the analog of the fatty acid ester of glycerol present in the nucleic acid-containing lipid nanoparticle.</div>
    </li> <li> <para-num num="[0070]"> </para-num> <div id="p-0110" num="0070" class="description-line">The bringing into contact the analog with the lipase is performed under conditions of usually 30 to 45 C., preferably 35 to 42 C., more preferably 37 C., and usually 0 minutes to 48 hours, preferably 1 minute to 36 hours, more preferably 1 minute to 24 hours.</div>
    </li> <li> <para-num num="[0071]"> </para-num> <div id="p-0111" num="0071" class="description-line">The analog of the fatty acid ester of glycerol according to the present invention is preferably structurally modified in the range of preferably 10 angstroms (angstrom: 10<sup>10 </sup>m) or less, more preferably 8 angstroms or less, further preferably 6 angstroms or less, from the carbon atom at position sn-2 of a glycerol skeleton in a natural glycerol lipid represented by formula (NL1) given below. When the structural modification is in the range of 10 angstroms or less from the carbon atom at position sn-2, the nucleic acid-containing lipid nanoparticle tends to resist the hydrolytic effect of a lipase and is thus stabilized.</div>
    </li> <li> <para-num num="[0072]"> </para-num> <div id="p-0112" num="0072" class="description-line">The lower limit value of the structural modification range is not particularly limited as long as the lower limit value is 0 angstroms or more. The range of 0 angstroms from the carbon atom at position sn-2 refers to the carbon atom at position sn-2.</div>
    </li> <li> <para-num num="[0073]"> </para-num> <div id="p-0113" num="0073" class="description-line">In this context, the structural modification means that a structure near the glycerol skeleton of the natural glycerol lipid is changed, and is not particularly limited as long as the structural modification reduces interaction with an active site of a lipase. Examples thereof include: the inversion of the asymmetric center of the natural glycerol lipid, i.e., the conversion of an L form to a D form; the replacement of the ester bond between the glycerol skeleton and the fatty acid with a bond such as an ether bond (O), a thioether bond (S), an amino bond (N(R<sup>p</sup>) (wherein R<sup>p </sup>is a hydrogen atom or an organic group) or an amide bond (NHCO); the replacement of hydrogen at any one or more of positions sn-1, sn-2 and sn-3 with an organic group; and the introduction of an organic group to position , ,  or  of an acyl group mentioned later.</div>
    </li> <li> <para-num num="[0074]"> </para-num> <div id="p-0114" num="0074" class="description-line">Examples of the organic group include hydroxy, alkoxy, alkoxycarbonyl, nitro, cyano, fluoro, chloro and bromo. Among these substituents, the alkyl moiety in alkoxy and alkoxycarbonyl is a C1-C4 alkyl such as methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl or cyclopropylmethyl.</div>
    </li> <li> <div id="p-0115" num="0000" class="description-line">
      <chemistry id="CHEM-US-00011" num="00011">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4f/a7/76/ca2154a5f54533/US20200368173A1-20201126-C00011.png"><img id="EMI-C00011" he="23.79mm" wi="60.88mm" file="US20200368173A1-20201126-C00011.TIF" alt="Figure US20200368173A1-20201126-C00011" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="244" height="95" alt="Figure US20200368173A1-20201126-C00011" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4f/a7/76/ca2154a5f54533/US20200368173A1-20201126-C00011.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00011" attachment-type="cdx" file="US20200368173A1-20201126-C00011.CDX"> </attachment>
          <attachment idref="CHEM-US-00011" attachment-type="mol" file="US20200368173A1-20201126-C00011.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0075]"> </para-num> <div id="p-0116" num="0075" class="description-line">a and b are each independently an acyl group given below, and c is an acyl group, a phosphoric acid group, a sugar or the like. However, when both a and c are acyl groups, these acyl groups differ in the number of carbon atoms, structure, etc. and are not the same.</div>
    </li> <li> <div id="p-0117" num="0000" class="description-line">
      <chemistry id="CHEM-US-00012" num="00012">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c4/6a/aa/aee1767f55edf4/US20200368173A1-20201126-C00012.png"><img id="EMI-C00012" he="14.39mm" wi="14.48mm" file="US20200368173A1-20201126-C00012.TIF" alt="Figure US20200368173A1-20201126-C00012" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="58" height="58" alt="Figure US20200368173A1-20201126-C00012" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c4/6a/aa/aee1767f55edf4/US20200368173A1-20201126-C00012.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00012" attachment-type="cdx" file="US20200368173A1-20201126-C00012.CDX"> </attachment>
          <attachment idref="CHEM-US-00012" attachment-type="mol" file="US20200368173A1-20201126-C00012.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0076]"> </para-num> <div id="p-0118" num="0076" class="description-line">Examples of Rxx in the acyl group include optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl and C7-C23 alkynyl.</div>
    </li> <li> <para-num num="[0077]"> </para-num> <div id="p-0119" num="0077" class="description-line">The analog of the fatty acid ester of glycerol according to the present invention, i.e., the analog of the natural glycerol lipid represented by formula (NL1), is preferably a glycerophospholipid analog.</div>
    </li> <li> <para-num num="[0078]"> </para-num> <div id="p-0120" num="0078" class="description-line">The glycerophospholipid can be represented by, for example, the following formula (NL2), and the glycerophospholipid analog is a structurally modified form of the lipid represented by the following formula (NL2):</div>
    </li> <li> <div id="p-0121" num="0000" class="description-line">
      <chemistry id="CHEM-US-00013" num="00013">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/48/eb/3a/3c8fd2915c0871/US20200368173A1-20201126-C00013.png"><img id="EMI-C00013" he="29.21mm" wi="67.73mm" file="US20200368173A1-20201126-C00013.TIF" alt="Figure US20200368173A1-20201126-C00013" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="271" height="117" alt="Figure US20200368173A1-20201126-C00013" class="patent-full-image" src="https://patentimages.storage.googleapis.com/48/eb/3a/3c8fd2915c0871/US20200368173A1-20201126-C00013.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00013" attachment-type="cdx" file="US20200368173A1-20201126-C00013.CDX"> </attachment>
          <attachment idref="CHEM-US-00013" attachment-type="mol" file="US20200368173A1-20201126-C00013.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0079]"> </para-num> <div id="p-0122" num="0079" class="description-line">In formula (NL2), Rxx<sup>1 </sup>and Rxx<sup>2 </sup>are the same or different and are each optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl. Examples of Rxx<sup>3 </sup>include a hydrogen atom, and the following groups:</div>
    </li> <li> <div id="p-0123" num="0000" class="description-line">
      <chemistry id="CHEM-US-00014" num="00014">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e1/03/82/a9184ca7963739/US20200368173A1-20201126-C00014.png"><img id="EMI-C00014" he="50.80mm" wi="74.17mm" file="US20200368173A1-20201126-C00014.TIF" alt="Figure US20200368173A1-20201126-C00014" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="297" height="203" alt="Figure US20200368173A1-20201126-C00014" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e1/03/82/a9184ca7963739/US20200368173A1-20201126-C00014.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00014" attachment-type="cdx" file="US20200368173A1-20201126-C00014.CDX"> </attachment>
          <attachment idref="CHEM-US-00014" attachment-type="mol" file="US20200368173A1-20201126-C00014.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0080]"> </para-num> <div id="p-0124" num="0080" class="description-line">Examples of the linear or branched C7-C23 alkyl in formulas (NL1) and (NL2) include heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl.</div>
    </li> <li> <para-num num="[0081]"> </para-num> <div id="p-0125" num="0081" class="description-line">The linear or branched C7-C23 alkenyl in formulas (NL1) and (NL2) can be linear or branched C7-C23 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octadeca-9,12-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-nonadec-10-enyl, (Z)-icos-11-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 2,6,10,14-tetramethylpentadec-1-enyl and 3,7,11,15-tetramethylhexadec-2-enyl, preferably (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl, more preferably (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0082]"> </para-num> <div id="p-0126" num="0082" class="description-line">The linear or branched C7-C23 alkynyl in formulas (NL1) and (NL2) can be linear or branched C8-24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-ynyl and octadec-9-ynyl.</div>
    </li> <li> <para-num num="[0083]"> </para-num> <div id="p-0127" num="0083" class="description-line">Examples of the substituent for the optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl in formulas (NL1) and (NL2) include hydroxy, alkoxy, alkoxycarbonyl, nitro, cyano, fluoro, chloro and bromo. Among these substituents, the alkyl moiety in alkoxy and alkoxycarbonyl is C1-C4 alkyl such as methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl or cyclopropylmethyl.</div>
    </li> <li> <para-num num="[0084]"> </para-num> <div id="p-0128" num="0084" class="description-line">Examples of the glycerophospholipid represented by formula (NL2) include, but are not limited to, natural or synthetic phospholipids such as phosphatidylcholines (PCs) (specifically, soybean phosphatidylcholine, egg phosphatidylcholine (EPC), distearoyl phosphatidylcholine, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), dipalmitoyl phosphatidylcholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), palmitoyl oleoyl phosphatidylcholine (POPC), dimyristoyl phosphatidylcholine (DMPC), dioleoyl phosphatidylcholine (DOPC), etc.), phosphatidylethanolamines (specifically distearoyl phosphatidylethanolamine (DSPE), dipalmitoyl phosphatidylethanolamine (DPPE), dioleoyl phosphatidylethanolamine (DOPE), dimyristoyl phospoethanolamine (DMPE), 16-0-monomethyl PE, 16-0-dimethyl PE, 18-1-trans PE, palmitoyl oleoyl-phosphatidylethanolamine (POPE), 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), etc.), glycerophospholipids (specifically, phosphatidylserine, phosphatidic acid, phosphatidylglycerol, phosphatidylinositol, palmitoyl oleoyl phosphatidylglycerol (POPG), lysophosphatidylcholine, etc.), sphingophospholipids (specifically, sphingomyelin, ceramide phosphoethanolamine, ceramide phosphoglycerol, ceramide phosphoglycerophosphoric acid, etc.), glycerophosphonolipids, sphingophosphonolipids, natural lecithins (specifically, egg lecithin, soybean lecithin, etc.) and hydrogenated phospholipids (specifically, hydrogenated soybean phosphatidylcholine, etc.).</div>
    </li> <li> <para-num num="[0085]"> </para-num> <div id="p-0129" num="0085" class="description-line">The lipase according to the present invention is not particularly limited as long as the enzyme hydrolyzes the fatty acid ester contained in the natural glycerol lipid represented by formula (NL1). Examples of the lipase include phospholipase. Examples of the phospholipase specifically include phospholipase A1, phospholipase A2, phospholipase B, lysophospholipase, phospholipase C and phospholipase D.</div>
    </li> <li> <para-num num="[0086]"> </para-num> <div id="p-0130" num="0086" class="description-line">The analog of the fatty acid ester of glycerol according to the present invention is preferably an analog of a fatty acid ester of glycerol, and the analog is not hydrolyzable by phospholipase A2.</div>
    </li> <li> <para-num num="[0087]"> </para-num> <div id="p-0131" num="0087" class="description-line">The glycerophospholipid analog has a structure modified from a partial structure of the glycerophospholipid represented by formula (NL2) described above. Specifically, the glycerophospholipid analog is preferably a lipid represented by the following formula (1) or (2):</div>
    </li> <li> <div id="p-0132" num="0000" class="description-line">
      <chemistry id="CHEM-US-00015" num="00015">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4b/e8/71/9628d79acd6924/US20200368173A1-20201126-C00015.png"><img id="EMI-C00015" he="26.59mm" wi="64.85mm" file="US20200368173A1-20201126-C00015.TIF" alt="Figure US20200368173A1-20201126-C00015" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="259" height="106" alt="Figure US20200368173A1-20201126-C00015" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4b/e8/71/9628d79acd6924/US20200368173A1-20201126-C00015.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00015" attachment-type="cdx" file="US20200368173A1-20201126-C00015.CDX"> </attachment>
          <attachment idref="CHEM-US-00015" attachment-type="mol" file="US20200368173A1-20201126-C00015.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0088]"> </para-num> <div id="p-0133" num="0088" class="description-line">wherein</div>
    </li> <li> <para-num num="[0089]"> </para-num> <div id="p-0134" num="0089" class="description-line">Rx<sup>1 </sup>and Rx<sup>2 </sup>are the same or different and are each optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl; and</div>
    </li> <li> <para-num num="[0090]"> </para-num> <div id="p-0135" num="0090" class="description-line">Rx<sup>3 </sup>is a negative charge, a hydrogen atom, or any of the following groups:</div>
    </li> <li> <div id="p-0136" num="0000" class="description-line">
      <chemistry id="CHEM-US-00016" num="00016">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2a/5f/fa/3cc1e9ca976f86/US20200368173A1-20201126-C00016.png"><img id="EMI-C00016" he="126.49mm" wi="59.69mm" file="US20200368173A1-20201126-C00016.TIF" alt="Figure US20200368173A1-20201126-C00016" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="239" height="506" alt="Figure US20200368173A1-20201126-C00016" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2a/5f/fa/3cc1e9ca976f86/US20200368173A1-20201126-C00016.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00016" attachment-type="cdx" file="US20200368173A1-20201126-C00016.CDX"> </attachment>
          <attachment idref="CHEM-US-00016" attachment-type="mol" file="US20200368173A1-20201126-C00016.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0091]"> </para-num> <div id="p-0137" num="0091" class="description-line">wherein</div>
    </li> <li> <para-num num="[0092]"> </para-num> <div id="p-0138" num="0092" class="description-line">Rx<sup>4 </sup>is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl or Rx<sup>41</sup>-CO;</div>
    </li> <li> <para-num num="[0093]"> </para-num> <div id="p-0139" num="0093" class="description-line">Rx<sup>41 </sup>is optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl;</div>
    </li> <li> <para-num num="[0094]"> </para-num> <div id="p-0140" num="0094" class="description-line">Rx<sup>5 </sup>is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl; and</div>
    </li> <li> <para-num num="[0095]"> </para-num> <div id="p-0141" num="0095" class="description-line">Rx<sup>6 </sup>is a negative charge, a hydrogen atom, or any of the following groups:</div>
    </li> <li> <div id="p-0142" num="0000" class="description-line">
      <chemistry id="CHEM-US-00017" num="00017">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/90/23/9d/0d0f9ce6e671aa/US20200368173A1-20201126-C00017.png"><img id="EMI-C00017" he="50.80mm" wi="74.17mm" file="US20200368173A1-20201126-C00017.TIF" alt="Figure US20200368173A1-20201126-C00017" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="297" height="203" alt="Figure US20200368173A1-20201126-C00017" class="patent-full-image" src="https://patentimages.storage.googleapis.com/90/23/9d/0d0f9ce6e671aa/US20200368173A1-20201126-C00017.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00017" attachment-type="cdx" file="US20200368173A1-20201126-C00017.CDX"> </attachment>
          <attachment idref="CHEM-US-00017" attachment-type="mol" file="US20200368173A1-20201126-C00017.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0096]"> </para-num> <div id="p-0143" num="0096" class="description-line">Examples of the linear or branched C7-C23 alkyl, C1-C23 alkenyl and C7-C23 alkenyl in formulas (1) and (2) can include the same as those listed about C7-C23 alkyl, C7-C23 alkenyl and C7-C23 alkenyl in formula (NL2).</div>
    </li> <li> <para-num num="[0097]"> </para-num> <div id="p-0144" num="0097" class="description-line">Examples of the linear or branched C8-C24 alkyl include heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl.</div>
    </li> <li> <para-num num="[0098]"> </para-num> <div id="p-0145" num="0098" class="description-line">The linear or branched C8-C24 alkenyl can be linear or branched C8-24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octadeca-9,12-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-nonadec-10-enyl, (Z)-icos-11-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 2,6,10,14-tetramethylpentadec-1-enyl and 3,7,11,15-tetramethylhexadec-2-enyl, preferably (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl, more preferably (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0099]"> </para-num> <div id="p-0146" num="0099" class="description-line">The linear or branched C8-C24 alkynyl can be linear or branched C8-24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-ynyl and octadec-9-ynyl.</div>
    </li> <li> <para-num num="[0100]"> </para-num> <div id="p-0147" num="0100" class="description-line">Examples of the substituent for the optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C7-C23 alkyl, C7-C23 alkenyl and C7-C23 alkynyl in formulas (1) and (2) include hydroxy, alkoxy, alkoxycarbonyl, nitro, cyano, fluoro, chloro and bromo. Among these substituents, the alkyl moiety in alkoxy and alkoxycarbonyl is C1-C4 alkyl such as methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl or cyclopropylmethyl.</div>
    </li> <li> <para-num num="[0101]"> </para-num> <div id="p-0148" num="0101" class="description-line">The analog of the fatty acid ester of glycerol according to the present invention may be a salt. When the analog of the fatty acid ester of glycerol is a salt, the salt is not particularly limited as long as the salt is pharmaceutically acceptable. For example, when each of Rx<sup>3 </sup>and Rx<sup>6 </sup>in formulas (1) and (2) is a hydrogen atom,</div>
    </li> <li> <div id="p-0149" num="0000" class="description-line">
      <chemistry id="CHEM-US-00018" num="00018">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/12/d5/7f/460164ecef48a5/US20200368173A1-20201126-C00018.png"><img id="EMI-C00018" he="49.45mm" wi="53.93mm" file="US20200368173A1-20201126-C00018.TIF" alt="Figure US20200368173A1-20201126-C00018" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="216" height="198" alt="Figure US20200368173A1-20201126-C00018" class="patent-full-image" src="https://patentimages.storage.googleapis.com/12/d5/7f/460164ecef48a5/US20200368173A1-20201126-C00018.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00018" attachment-type="cdx" file="US20200368173A1-20201126-C00018.CDX"> </attachment>
          <attachment idref="CHEM-US-00018" attachment-type="mol" file="US20200368173A1-20201126-C00018.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0150" num="0000" class="description-line">a salt of an alkali metal such as sodium or potassium, or ammonium salt (NH<sub>4</sub> <sup>+</sup> salt) is preferred.</div>
    </li> <li> <para-num num="[0102]"> </para-num> <div id="p-0151" num="0102" class="description-line">Each of Rx<sup>3 </sup>and Rx<sup>6 </sup>may be a negative charge. The negative charge represented by Rx<sup>3 </sup>or Rx<sup>6 </sup>means that hydrogen corresponding to Rx<sup>3 </sup>or Rx<sup>6 </sup>is deprotonated. Specifically, the negative charge means that a phosphoric acid ester group in formulas (1) and (2) may be PO<sub>4</sub> <sup>2</sup>.</div>
    </li> <li> <para-num num="[0103]"> </para-num> <div id="p-0152" num="0103" class="description-line">The lipid represented by formula (2) may be a single substance of any one optical isomer as to asymmetric carbon having a configuration that is not shown herein, or may be a mixture containing such optical isomers at an arbitrary ratio.</div>
    </li> <li> <para-num num="[0104]"> </para-num> <div id="p-0153" num="0104" class="description-line">Specifically, an inositol skeleton in Rxx<sup>3</sup>, Rx<sup>3 </sup>and Rx<sup>6 </sup>in formula (NL2) and formulas (1) and (2) is derived from any inositol given below. In the following inositol structures, a hydroxy group to form a bond to phosphoric acid is not particularly limited.</div>
    </li> <li> <div id="p-0154" num="0000" class="description-line">
      <chemistry id="CHEM-US-00019" num="00019">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/73/d7/c3/c58cfa1477ba1c/US20200368173A1-20201126-C00019.png"><img id="EMI-C00019" he="102.02mm" wi="61.64mm" file="US20200368173A1-20201126-C00019.TIF" alt="Figure US20200368173A1-20201126-C00019" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="247" height="408" alt="Figure US20200368173A1-20201126-C00019" class="patent-full-image" src="https://patentimages.storage.googleapis.com/73/d7/c3/c58cfa1477ba1c/US20200368173A1-20201126-C00019.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00019" attachment-type="cdx" file="US20200368173A1-20201126-C00019.CDX"> </attachment>
          <attachment idref="CHEM-US-00019" attachment-type="mol" file="US20200368173A1-20201126-C00019.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0105]"> </para-num> <div id="p-0155" num="0105" class="description-line">When each of Rxx<sup>3</sup>, Rx<sup>3 </sup>and Rx<sup>6 </sup>is an inositol skeleton, the inositol skeleton is preferably represented by the following formula:</div>
    </li> <li> <div id="p-0156" num="0000" class="description-line">
      <chemistry id="CHEM-US-00020" num="00020">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5a/90/09/a585d1683440f5/US20200368173A1-20201126-C00020.png"><img id="EMI-C00020" he="13.63mm" wi="29.63mm" file="US20200368173A1-20201126-C00020.TIF" alt="Figure US20200368173A1-20201126-C00020" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="119" height="55" alt="Figure US20200368173A1-20201126-C00020" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5a/90/09/a585d1683440f5/US20200368173A1-20201126-C00020.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00020" attachment-type="cdx" file="US20200368173A1-20201126-C00020.CDX"> </attachment>
          <attachment idref="CHEM-US-00020" attachment-type="mol" file="US20200368173A1-20201126-C00020.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0106]"> </para-num> <div id="p-0157" num="0106" class="description-line">Examples of the C7-C23 alkyl, the C7-C23 alkenyl, the C7-C23 alkynyl, the C8-C24 alkyl, the C8-C24 alkenyl and the C8-C24 alkynyl in formulas (1) and (2) can include the same as those listed about their respective groups in formulas (NL1) and (NL2). Preferred examples thereof can include the same as those listed about the respective groups in formulas (NL1) and (NL2).</div>
    </li> <li> <para-num num="[0107]"> </para-num> <div id="p-0158" num="0107" class="description-line">The groups in each of formulas (1), (2), (NL1) and (NL2) may be arbitrarily combined as described about the respective groups or may be a combination of preferred groups.</div>
    </li> <li> <para-num num="[0108]"> </para-num> <div id="p-0159" num="0108" class="description-line">Examples of the analog of the fatty acid ester of glycerol in the nucleic acid-containing nanoparticle of the present invention can specifically include the following compounds:</div>
    </li> <li> <div id="p-0160" num="0000" class="description-line">
      <chemistry id="CHEM-US-00021" num="00021">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b8/95/4e/3a11cd3951d69b/US20200368173A1-20201126-C00021.png"><img id="EMI-C00021" he="124.71mm" wi="154.60mm" file="US20200368173A1-20201126-C00021.TIF" alt="Figure US20200368173A1-20201126-C00021" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="618" height="499" alt="Figure US20200368173A1-20201126-C00021" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b8/95/4e/3a11cd3951d69b/US20200368173A1-20201126-C00021.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00021" attachment-type="cdx" file="US20200368173A1-20201126-C00021.CDX"> </attachment>
          <attachment idref="CHEM-US-00021" attachment-type="mol" file="US20200368173A1-20201126-C00021.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0109]"> </para-num> <div id="p-0161" num="0109" class="description-line">The analog of the fatty acid ester of glycerol according to the present invention may be a commercially available product or may be synthesized by use of an organic synthesis approach.</div>
    </li> <li> <para-num num="[0110]"> </para-num> <div id="p-0162" num="0110" class="description-line">The lipid represented by formula (1) can be produced, for example, as follows, though the production method is not particularly limited.</div>
    </li> <li> <div id="p-0163" num="0000" class="description-line">
      <chemistry id="CHEM-US-00022" num="00022">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1e/7f/96/49c664f8be3022/US20200368173A1-20201126-C00022.png"><img id="EMI-C00022" he="185.00mm" wi="75.78mm" file="US20200368173A1-20201126-C00022.TIF" alt="Figure US20200368173A1-20201126-C00022" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="740" alt="Figure US20200368173A1-20201126-C00022" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1e/7f/96/49c664f8be3022/US20200368173A1-20201126-C00022.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00022" attachment-type="cdx" file="US20200368173A1-20201126-C00022.CDX"> </attachment>
          <attachment idref="CHEM-US-00022" attachment-type="mol" file="US20200368173A1-20201126-C00022.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0111]"> </para-num> <div id="p-0164" num="0111" class="description-line">wherein PG represents a protective group; and Rx<sup>1</sup>, Rx<sup>2 </sup>and Rx<sup>3 </sup>are as defined in Rx<sup>1</sup>, Rx<sup>2 </sup>and Rx<sup>3 </sup>in formula (1).</div>
    </li> <li> <para-num num="[0112]"> </para-num> <div id="p-0165" num="0112" class="description-line">Specifically, a hydroxy group of acetal X1 known in the art which is obtained from a sugar such as mannitol is protected with a protective group (PG group), and an isopropylidene group is hydrolyzed to prepare diol X3. Alternatively, diol X3 may be obtained as a commercially available product such as (S)-3-(benzyloxy)propane-1,2-diol. Subsequently, diol X3 is reacted with an acid chloride represented by Rx<sup>1</sup>-COCl, Rx<sup>2</sup>-COCl or the like to obtain compound X4. Further, the protective group (PG group) is removed, and the resulting hydroxy group can be reacted with phosphorus(V) oxychloride in the presence of a base such as triethylamine and further reacted with a compound represented by Rx<sup>3</sup>-OH to obtain the lipid represented by formula (1).</div>
    </li> <li> <para-num num="[0113]"> </para-num> <div id="p-0166" num="0113" class="description-line">The reaction for the conversion of diol X3 to compound X4 may be performed by protecting any of a primary alcohol and a secondary alcohol with a protective group.</div>
    </li> <li> <para-num num="[0114]"> </para-num> <div id="p-0167" num="0114" class="description-line">The protective group for use in the synthesis of the lipid represented by formula (1) can be selected on the basis of reaction conditions or a substrate with reference to, for example, Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999).</div>
    </li> <li> <para-num num="[0115]"> </para-num> <div id="p-0168" num="0115" class="description-line">The lipid represented by formula (2) can be produced, for example, as follows, though the production method is not particularly limited.</div>
    </li> <li> <div id="p-0169" num="0000" class="description-line">
      <chemistry id="CHEM-US-00023" num="00023">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e9/e7/85/360aef3eb2f28b/US20200368173A1-20201126-C00023.png"><img id="EMI-C00023" he="176.78mm" wi="75.78mm" file="US20200368173A1-20201126-C00023.TIF" alt="Figure US20200368173A1-20201126-C00023" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="707" alt="Figure US20200368173A1-20201126-C00023" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e9/e7/85/360aef3eb2f28b/US20200368173A1-20201126-C00023.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00023" attachment-type="cdx" file="US20200368173A1-20201126-C00023.CDX"> </attachment>
          <attachment idref="CHEM-US-00023" attachment-type="mol" file="US20200368173A1-20201126-C00023.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0116]"> </para-num> <div id="p-0170" num="0116" class="description-line">wherein PG represents a protective group; Rx<sup>0 </sup>represents optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl; X represents a halogen atom such as chlorine, bromine or iodine, OMs, or OTs; and Rx<sup>4</sup>, Rx<sup>5</sup>, Rx<sup>6 </sup>and Rx<sup>41 </sup>are as defined in Rx<sup>4</sup>, Rx<sup>5</sup>, Rx<sup>6 </sup>and Rx<sup>41 </sup>in formula (2).</div>
    </li> <li> <para-num num="[0117]"> </para-num> <div id="p-0171" num="0117" class="description-line">Specifically, a hydroxy group of acetal X6 known in the art which is obtained from a sugar such as mannitol is protected with a protective group (PG group), and an isopropylidene group is hydrolyzed to prepare diol X8. Subsequently, diol X8 can be reacted with an electrophile represented by, for example, Rx<sup>0</sup>-CH<sub>2</sub>X (reaction conditions of Williamson etherification can be referred to and applied thereto) to obtain diether X9. Alternatively, diol X8 can be reacted with an acid chloride represented by Rx<sup>42</sup>-COCl or the like and subsequently reacted with an electrophile represented by RX<sup>0</sup>CH<sub>2</sub>X to obtain compound X9. Further, the protective group (PG group) is removed, and the resulting hydroxy group can be reacted with phosphorus(V) oxychloride in the presence of a base such as triethylamine and further reacted with a compound represented by Rx<sup>3</sup>-OH to obtain the lipid represented by formula (2).</div>
    </li> <li> <para-num num="[0118]"> </para-num> <div id="p-0172" num="0118" class="description-line">The reaction for the conversion of diol X3 to compound X4 may be performed by protecting any of a primary alcohol and a secondary alcohol with a protective group.</div>
    </li> <li> <para-num num="[0119]"> </para-num> <div id="p-0173" num="0119" class="description-line">The protective group for use in the synthesis of the lipid represented by formula (2) can be selected on the basis of reaction conditions or a substrate with reference to, for example, Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999).</div>
    </li> <li> <para-num num="[0120]"> </para-num> <div id="p-0174" num="0120" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention preferably further comprises a cationic lipid.</div>
    </li> <li> <para-num num="[0121]"> </para-num> <div id="p-0175" num="0121" class="description-line">The cationic lipid is not particularly limited as long as the cationic lipid is an amphipathic molecule having a lipophilic region containing one or more optionally substituted hydrocarbon groups, and a cationic hydrophilic region containing at least one primary amino group, secondary amino group, tertiary amino group and/or quaternary ammonium group. Examples thereof can include a lipid having a hydrophilic unit having one quaternary ammonium group and optionally substituted three independent hydrocarbon groups (lipid A), and a lipid having a hydrophilic unit having optionally substituted one amino group or one quaternary ammonium group and a hydrophobic unit having optionally substituted two independent hydrocarbon groups (lipid B).</div>
    </li> <li> <para-num num="[0122]"> </para-num> <div id="p-0176" num="0122" class="description-line">In the present invention, the nucleic acid-containing lipid nanoparticle is prepared using the lipid having a hydrophilic unit having one quaternary ammonium group and optionally substituted three independent hydrocarbon groups (lipid A) with a lipid derivative or a fatty acid derivative of a water-soluble polymer, and a nucleic acid. The obtained nucleic acid-containing lipid nanoparticle can have much better physicochemical stability and physiological activity.</div>
    </li> <li> <para-num num="[0123]"> </para-num> <div id="p-0177" num="0123" class="description-line">In the present invention, the lipid having a hydrophilic unit having one quaternary ammonium group and optionally substituted three independent hydrocarbon groups (lipid A) is not particularly limited as long as the lipid is a molecule intramolecularly having one quaternary ammonium group as a hydrophilic unit and having optionally substituted three independent hydrocarbon groups. Lipid A is represented by, for example, any of structural formulas (A) to (C) given below. In structural formulas (A) to (C) given below, the hydrophilic unit represents a hydrophilic unit having one quaternary ammonium group, and the three hydrophobic units represent optionally substituted three independent hydrocarbon groups.</div>
    </li> <li> <para-num num="[0124]"> </para-num> <div id="p-0178" num="0124" class="description-line">Zero to three out of the four bonds of the quaternary ammonium group constituting the hydrophilic unit are attached to any 0 to 3 of the hydrocarbon groups constituting the hydrophobic unit, and the remaining bond(s) is attached to an optionally substituted chain and/or cyclic hydrocarbon group, etc. The optionally substituted chain and/or cyclic hydrocarbon group constituting the hydrophilic unit can be any group composed of carbon and hydrogen atoms and is preferably a group having 1 to 10 carbon atoms, more preferably a group having 1 to 6 carbon atoms, further preferably a group having 1 to 3 carbon atoms.</div>
    </li> <li> <para-num num="[0125]"> </para-num> <div id="p-0179" num="0125" class="description-line">The hydrophilic unit may have one or more ethers, esters, amides or the like via a carbon atom in the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting this hydrophilic unit. Examples of the substituent for the optionally substituted chain and/or cyclic hydrocarbon group, etc. include carbamate, amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro, and bromo.</div>
    </li> <li> <para-num num="[0126]"> </para-num> <div id="p-0180" num="0126" class="description-line">The hydrocarbon group constituting the hydrophobic unit can be any group consisting of 8 to 24 carbon atoms and hydrogen atoms. Hydrocarbon groups can be classified from the viewpoint of topology. Examples thereof include linear hydrocarbon groups, branched hydrocarbon groups and cyclic hydrocarbon groups (e.g., a cholesteryl group). A linear or branched hydrocarbon group is preferred. Also, hydrocarbon groups can be classified on the basis of the presence or absence of an unsaturated bond (double bond or triple bond). Hydrocarbon groups having an unsaturated bond can also be classified on the basis of the presence or absence of aromaticity. A hydrocarbon group having only a saturated bond (alkyl) or a hydrocarbon group having an unsaturated bond and lacking aromaticity (e.g., alkenyl or alkynyl) is preferred. The hydrocarbon group in lipid A is preferably linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl.</div>
    </li> <li> <para-num num="[0127]"> </para-num> <div id="p-0181" num="0127" class="description-line">Each hydrocarbon group constituting the hydrophobic unit may be bonded directly to the quaternary ammonium group of the hydrophilic unit, or may be bonded to the quaternary ammonium group via an ether, ester or amide bond, etc. and the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting the hydrophilic unit. As shown in structural formula (B) or (C), the hydrocarbon groups constituting two or three hydrophobic units may be bonded via a carbon atom, and this carbon atom may be bonded either directly to the quaternary ammonium group of the hydrophilic unit or to the quaternary ammonium group via an ether, ester or amide bond, etc. and the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting the hydrophilic unit.</div>
    </li> <li> <div id="p-0182" num="0000" class="description-line">
      <chemistry id="CHEM-US-00024" num="00024">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cf/c7/e8/1c43d24e53b454/US20200368173A1-20201126-C00024.png"><img id="EMI-C00024" he="135.72mm" wi="69.93mm" file="US20200368173A1-20201126-C00024.TIF" alt="Figure US20200368173A1-20201126-C00024" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="280" height="543" alt="Figure US20200368173A1-20201126-C00024" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cf/c7/e8/1c43d24e53b454/US20200368173A1-20201126-C00024.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00024" attachment-type="cdx" file="US20200368173A1-20201126-C00024.CDX"> </attachment>
          <attachment idref="CHEM-US-00024" attachment-type="mol" file="US20200368173A1-20201126-C00024.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0128]"> </para-num> <div id="p-0183" num="0128" class="description-line">Examples of lipid A can include lipids represented by the following formulas (I) to (IV), (V) and (V):</div>
    </li> <li> <div id="p-0184" num="0000" class="description-line">formula (I)</div>
    </li> <li> <div id="p-0185" num="0000" class="description-line">
      <chemistry id="CHEM-US-00025" num="00025">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/aa/7e/23/5864248fbb7313/US20200368173A1-20201126-C00025.png"><img id="EMI-C00025" he="16.43mm" wi="52.24mm" file="US20200368173A1-20201126-C00025.TIF" alt="Figure US20200368173A1-20201126-C00025" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="209" height="66" alt="Figure US20200368173A1-20201126-C00025" class="patent-full-image" src="https://patentimages.storage.googleapis.com/aa/7e/23/5864248fbb7313/US20200368173A1-20201126-C00025.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00025" attachment-type="cdx" file="US20200368173A1-20201126-C00025.CDX"> </attachment>
          <attachment idref="CHEM-US-00025" attachment-type="mol" file="US20200368173A1-20201126-C00025.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0186" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0129]"> </para-num> <div id="p-0187" num="0129" class="description-line">R<sup>1 </sup>to R<sup>3 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0130]"> </para-num> <div id="p-0188" num="0130" class="description-line">L<sup>1 </sup>to L<sup>3 </sup>are the same or different and are each absent, or Z<sup>1</sup>(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> or Z<sup>2</sup>(CY<sup>3</sup>Y<sup>4</sup>)<sub>p2</sub>Z<sup>3</sup>(CY<sup>5</sup>Y<sup>6</sup>)<sub>p3</sub> wherein Y<sup>1 </sup>to Y<sup>6 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>1 </sup>to Z<sup>3 </sup>are the same or different and are each O, NY<sup>7A</sup>, COO, OCO, CONY<sup>7B</sup>, NY<sup>7C</sup>CO or NY<sup>7D</sup>COO wherein Y<sup>7A </sup>to Y<sup>7D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; and p<sup>1 </sup>to p<sup>3 </sup>are the same or different and are each an integer from 1 to 5;</div>
    </li> <li> <para-num num="[0131]"> </para-num> <div id="p-0189" num="0131" class="description-line">X<sup>1 </sup>is optionally substituted C1-C4 alkyl; and</div>
    </li> <li> <para-num num="[0132]"> </para-num> <div id="p-0190" num="0132" class="description-line">A<sup>1 </sup>is a pharmaceutically acceptable anion,</div>
    </li> <li> <div id="p-0191" num="0000" class="description-line">formula (II)</div>
    </li> <li> <div id="p-0192" num="0000" class="description-line">
      <chemistry id="CHEM-US-00026" num="00026">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/08/30/07/71af648c3ea76b/US20200368173A1-20201126-C00026.png"><img id="EMI-C00026" he="20.49mm" wi="52.15mm" file="US20200368173A1-20201126-C00026.TIF" alt="Figure US20200368173A1-20201126-C00026" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="209" height="82" alt="Figure US20200368173A1-20201126-C00026" class="patent-full-image" src="https://patentimages.storage.googleapis.com/08/30/07/71af648c3ea76b/US20200368173A1-20201126-C00026.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00026" attachment-type="cdx" file="US20200368173A1-20201126-C00026.CDX"> </attachment>
          <attachment idref="CHEM-US-00026" attachment-type="mol" file="US20200368173A1-20201126-C00026.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0193" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0133]"> </para-num> <div id="p-0194" num="0133" class="description-line">R<sup>4 </sup>to R<sup>6 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0134]"> </para-num> <div id="p-0195" num="0134" class="description-line">L<sup>4 </sup>to L<sup>6 </sup>are the same or different and are each absent, or Z<sup>4</sup>(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub> or Z<sup>5</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>Z<sup>6</sup>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub> wherein Y<sup>8 </sup>to Y<sup>13 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>4 </sup>to Z<sup>6 </sup>are the same or different and are each O, NY<sup>14A</sup>, COO, OCO, CONY<sup>14B</sup>, NY<sup>14C</sup>CO or NY<sup>14D</sup>COO wherein Y<sup>14A </sup>to Y<sup>14D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>4 </sup>is an integer from 0 to 5; p<sup>5 </sup>is an integer from 1 to 5; and p<sup>6 </sup>is an integer from 0 to 5;</div>
    </li> <li> <para-num num="[0135]"> </para-num> <div id="p-0196" num="0135" class="description-line">L<sup>7 </sup>is absent, or (CY<sup>15</sup>Y<sup>16</sup>)<sub>p7</sub>, (CY<sup>17</sup>Y<sup>18</sup>)<sub>p8</sub>Z<sup>7</sup>(CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub> or (CY<sup>21</sup>Y<sup>22</sup>)<sub>p10</sub>Z<sup>8</sup>(CY<sup>23</sup>Y<sup>24</sup>)<sub>p11</sub>Z<sup>9</sup>(CY<sup>25</sup>Y<sup>26</sup>)<sub>p12</sub> wherein Y<sup>15 </sup>to Y<sup>26 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>7 </sup>to Z<sup>9 </sup>are the same or different and are each O, NY<sup>27A</sup>, COO, OCO, CONY<sup>27B</sup>, NY<sup>27C</sup>CO or NY<sup>27D</sup>COO wherein Y<sup>27A </sup>to Y<sup>27D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>7 </sup>is an integer from 1 to 5; p<sup>8 </sup>is an integer from 0 to 5; p<sup>9 </sup>is an integer from 1 to 5; p<sup>10 </sup>is an integer from 0 to 5; p<sup>11 </sup>is an integer from 1 to 5; and p<sup>12 </sup>is an integer from 1 to 5;</div>
    </li> <li> <para-num num="[0136]"> </para-num> <div id="p-0197" num="0136" class="description-line">B<sup>1 </sup>is</div>
    </li> <li> <div id="p-0198" num="0000" class="description-line">
      <chemistry id="CHEM-US-00027" num="00027">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3c/4e/41/6e229d6a294de8/US20200368173A1-20201126-C00027.png"><img id="EMI-C00027" he="64.43mm" wi="60.28mm" file="US20200368173A1-20201126-C00027.TIF" alt="Figure US20200368173A1-20201126-C00027" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="241" height="258" alt="Figure US20200368173A1-20201126-C00027" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3c/4e/41/6e229d6a294de8/US20200368173A1-20201126-C00027.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00027" attachment-type="cdx" file="US20200368173A1-20201126-C00027.CDX"> </attachment>
          <attachment idref="CHEM-US-00027" attachment-type="mol" file="US20200368173A1-20201126-C00027.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0199" num="0000" class="description-line">wherein X<sup>2 </sup>and X<sup>3 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>4 </sup>is optionally substituted C1-C4 alkyl; X<sup>5 </sup>and X<sup>6 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>7 </sup>is optionally substituted C1-C4 alkyl; Y<sup>28 </sup>to Y<sup>37 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>10 </sup>and Z<sup>11 </sup>are the same or different and are each O, NY<sup>38A</sup>, COO, OCO, CONY<sup>38B</sup>, NY<sup>38C</sup>CO or NY<sup>38D</sup>COO wherein Y<sup>38A </sup>to Y<sup>38D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>13 </sup>is an integer from 0 to 5; and p<sup>14 </sup>to p<sup>17 </sup>are the same or different and are each an integer from 1 to 5; and</div>
    </li> <li> <para-num num="[0137]"> </para-num> <div id="p-0200" num="0137" class="description-line">A<sup>2 </sup>is a pharmaceutically acceptable anion,</div>
    </li> <li> <div id="p-0201" num="0000" class="description-line">formula (III)</div>
    </li> <li> <div id="p-0202" num="0000" class="description-line">
      <chemistry id="CHEM-US-00028" num="00028">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/82/11/56/0b6ac35664a8a0/US20200368173A1-20201126-C00028.png"><img id="EMI-C00028" he="24.47mm" wi="57.07mm" file="US20200368173A1-20201126-C00028.TIF" alt="Figure US20200368173A1-20201126-C00028" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="228" height="98" alt="Figure US20200368173A1-20201126-C00028" class="patent-full-image" src="https://patentimages.storage.googleapis.com/82/11/56/0b6ac35664a8a0/US20200368173A1-20201126-C00028.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00028" attachment-type="cdx" file="US20200368173A1-20201126-C00028.CDX"> </attachment>
          <attachment idref="CHEM-US-00028" attachment-type="mol" file="US20200368173A1-20201126-C00028.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0203" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0138]"> </para-num> <div id="p-0204" num="0138" class="description-line">R<sup>7 </sup>to R<sup>9 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0139]"> </para-num> <div id="p-0205" num="0139" class="description-line">L<sup>8 </sup>to L<sup>10 </sup>are the same or different and are each absent, or Z<sup>12</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or Z<sup>13</sup>(CY<sup>41</sup>Y<sup>42</sup>)<sub>p19</sub>Z<sup>14</sup>(CY<sup>43</sup>Y<sup>44</sup>)<sub>p20</sub> wherein Y<sup>39 </sup>to Y<sup>44 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>12 </sup>to Z<sup>14 </sup>are the same or different and are each O, NY<sup>45A</sup>, COO, OCO, CONY<sup>45B</sup>, NY<sup>45C</sup>CO, NY<sup>45D</sup>COO or CO wherein Y<sup>45A </sup>to Y<sup>45D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>18 </sup>is an integer from 0 to 5; p<sup>19 </sup>is an integer from 1 to 5; and p<sup>20 </sup>is an integer from 0 to 5;</div>
    </li> <li> <para-num num="[0140]"> </para-num> <div id="p-0206" num="0140" class="description-line">L<sup>11 </sup>is absent, or (CY<sup>46</sup>Y<sup>47</sup>)<sub>p21</sub>, (CY<sup>48</sup>Y<sup>49</sup>)<sub>p22</sub>Z<sup>15</sup>(CY<sup>50</sup>Y<sup>51</sup>)<sub>p23</sub> or (CY<sup>52</sup>Y<sup>53</sup>)<sub>p24</sub>Z<sup>16</sup>(CY<sup>54</sup>Y<sup>55</sup>)<sub>p25</sub>Z<sup>17</sup>(CY<sup>56</sup>Y<sup>57</sup>)<sub>p26</sub> wherein Y<sup>46 </sup>to Y<sup>57 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>15 </sup>to Z<sup>17 </sup>are the same or different and are each O, NY<sup>58A</sup>, COO, OCO, CONY<sup>58B</sup>, NY<sup>58C</sup>CO, NY<sup>58D</sup>COO or CO wherein Y<sup>58A </sup>to Y<sup>58D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>21 </sup>is an integer from 1 to 5; p<sup>22 </sup>is an integer from 0 to 5; p<sup>23 </sup>is an integer from 1 to 5; p<sup>24 </sup>is an integer from 0 to 5; p<sup>25 </sup>is an integer from 1 to 5; and p<sup>26 </sup>is an integer from 1 to 5;</div>
    </li> <li> <para-num num="[0141]"> </para-num> <div id="p-0207" num="0141" class="description-line">L<sup>12 </sup>is absent, or (CY<sup>59</sup>Y<sup>60</sup>)<sub>p27</sub>, (CY<sup>61</sup>Y<sup>62</sup>)<sub>p28</sub>Z<sup>18</sup>(CY<sup>63</sup>Y<sup>64</sup>)<sub>p29</sub> or (CY<sup>65</sup>Y<sup>66</sup>)<sub>p30</sub>Z<sup>19</sup>(CY<sup>67</sup>Y<sup>68</sup>)<sub>p31</sub>Z<sup>20</sup>(CY<sup>69</sup>Y<sup>70</sup>)<sub>p32</sub> wherein Y<sup>59 </sup>to Y<sup>70 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>18 </sup>to Z<sup>20 </sup>are the same or different and are each O, NY<sup>71A</sup>, COO, OCO, CONY<sup>71B</sup>, NY<sup>71C</sup>CO, NY<sup>71D</sup>COO or CO wherein Y<sup>71A </sup>to Y<sup>71D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>27 </sup>is an integer from 1 to 5; p<sup>28 </sup>is an integer from 0 to 5; p<sup>29 </sup>is an integer from 0 to 5; p<sup>30 </sup>is an integer from 0 to 5; p<sup>31 </sup>is an integer from 1 to 5; and p<sup>32 </sup>is an integer from 0 to 5;</div>
    </li> <li> <para-num num="[0142]"> </para-num> <div id="p-0208" num="0142" class="description-line">J<sup>1 </sup>and J<sup>2 </sup>are the same or different and are each CY<sup>72 </sup>or N wherein Y<sup>72 </sup>is a hydrogen atom, hydroxy, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, or optionally substituted C1-C4 acyloxy;</div>
    </li> <li> <para-num num="[0143]"> </para-num> <div id="p-0209" num="0143" class="description-line">B<sup>2 </sup>is</div>
    </li> <li> <div id="p-0210" num="0000" class="description-line">
      <chemistry id="CHEM-US-00029" num="00029">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/44/9e/2a/19efc4dd685cec/US20200368173A1-20201126-C00029.png"><img id="EMI-C00029" he="64.43mm" wi="61.21mm" file="US20200368173A1-20201126-C00029.TIF" alt="Figure US20200368173A1-20201126-C00029" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="245" height="258" alt="Figure US20200368173A1-20201126-C00029" class="patent-full-image" src="https://patentimages.storage.googleapis.com/44/9e/2a/19efc4dd685cec/US20200368173A1-20201126-C00029.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00029" attachment-type="cdx" file="US20200368173A1-20201126-C00029.CDX"> </attachment>
          <attachment idref="CHEM-US-00029" attachment-type="mol" file="US20200368173A1-20201126-C00029.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0211" num="0000" class="description-line">wherein X<sup>8 </sup>and X<sup>9 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>10 </sup>is optionally substituted C1-C4 alkyl; X<sup>11 </sup>and X<sup>12 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>13 </sup>is optionally substituted C1-C4 alkyl; Y<sup>73 </sup>to Y<sup>82 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>21 </sup>and Z<sup>22 </sup>are the same or different and are each O, NY<sup>83A</sup>, COO, OCO, CONY<sup>83B</sup>, NY<sup>83C</sup>CO or NY<sup>83D</sup>COO wherein Y<sup>83A </sup>to Y<sup>83D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>33 </sup>is an integer from 0 to 5; and p<sup>34 </sup>to p<sup>37 </sup>are the same or different and are each an integer from 1 to 5; and</div>
    </li> <li> <para-num num="[0144]"> </para-num> <div id="p-0212" num="0144" class="description-line">A<sup>3 </sup>is a pharmaceutically acceptable anion,</div>
    </li> <li> <div id="p-0213" num="0000" class="description-line">formula (IV)</div>
    </li> <li> <div id="p-0214" num="0000" class="description-line">
      <chemistry id="CHEM-US-00030" num="00030">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b4/7c/4e/065ea5b7e9c2ef/US20200368173A1-20201126-C00030.png"><img id="EMI-C00030" he="21.08mm" wi="55.88mm" file="US20200368173A1-20201126-C00030.TIF" alt="Figure US20200368173A1-20201126-C00030" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="224" height="84" alt="Figure US20200368173A1-20201126-C00030" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b4/7c/4e/065ea5b7e9c2ef/US20200368173A1-20201126-C00030.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00030" attachment-type="cdx" file="US20200368173A1-20201126-C00030.CDX"> </attachment>
          <attachment idref="CHEM-US-00030" attachment-type="mol" file="US20200368173A1-20201126-C00030.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0215" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0145]"> </para-num> <div id="p-0216" num="0145" class="description-line">R<sup>10 </sup>to R<sup>12 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0146]"> </para-num> <div id="p-0217" num="0146" class="description-line">L<sup>13 </sup>is absent, or Z<sup>23</sup>(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub> or Z<sup>24</sup>(CY<sup>86</sup>Y<sup>87</sup>)<sub>p39</sub>Z<sup>25</sup>(CY<sup>88</sup>Y<sup>89</sup>)<sub>p40</sub> wherein Y<sup>84 </sup>to Y<sup>89 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>23 </sup>to Z<sup>25 </sup>are the same or different and are each O, NY<sup>90A</sup>, COO, OCO, CONY<sup>90B</sup>, NY<sup>90C</sup>CO or NY<sup>90D</sup>COO wherein Y<sup>90A </sup>to Y<sup>90D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; and p<sup>38 </sup>to p<sup>40 </sup>are the same or different and are each an integer from 1 to 5;</div>
    </li> <li> <para-num num="[0147]"> </para-num> <div id="p-0218" num="0147" class="description-line">L<sup>14 </sup>and L<sup>15 </sup>are the same or different and are each absent, or Z<sup>26</sup>(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or Z<sup>27</sup>(CY<sup>93</sup>Y<sup>94</sup>)<sub>p42</sub>Z<sup>28</sup>(CY<sup>95</sup>Y<sup>96</sup>)<sub>p43</sub> wherein Y<sup>91 </sup>to Y<sup>96 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>26 </sup>to Z<sup>28 </sup>are the same or different and are each O, NY<sup>97A</sup>, COO, OCO, CONY<sup>97B</sup>, NY<sup>97C</sup>CO, NY<sup>97D</sup>COO or CO wherein Y<sup>97A </sup>to Y<sup>97D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>41 </sup>is an integer from 0 to 5; p<sup>42 </sup>is an integer from 1 to 5; and p<sup>43 </sup>is an integer from 0 to 5;</div>
    </li> <li> <para-num num="[0148]"> </para-num> <div id="p-0219" num="0148" class="description-line">L<sup>16 </sup>is absent, or (CY<sup>98</sup>Y<sup>99</sup>)<sub>p44</sub>, (CY<sup>100</sup>Y<sup>101</sup>)<sub>p45</sub>Z<sup>29</sup>(CY<sup>102</sup>Y<sup>103</sup>)<sub>p46</sub> or (CY<sup>104</sup>Y<sup>105</sup>)<sub>p47</sub>Z<sup>30</sup>(CY<sup>106</sup>Y<sup>107</sup>)<sub>p48</sub>Z<sup>31</sup>(CY<sup>108</sup>Y<sup>109</sup>)<sub>p49</sub> wherein Y<sup>98 </sup>to Y<sup>109 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>29 </sup>to Z<sup>31 </sup>are the same or different and are each O, NY<sup>110A</sup>, COO, OCO, CONY<sup>110B</sup>, NY<sup>110C</sup>CO, NY<sup>110D</sup>COO or CO wherein Y<sup>110A </sup>to Y<sup>110D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>44 </sup>is an integer from 1 to 5; p<sup>45 </sup>is an integer from 0 to 5; p<sup>46 </sup>is an integer from 1 to 5; p<sup>47 </sup>is an integer from 0 to 5; p<sup>48 </sup>is an integer from 1 to 5; and p<sup>49 </sup>is an integer from 1 to 5;</div>
    </li> <li> <para-num num="[0149]"> </para-num> <div id="p-0220" num="0149" class="description-line">J<sup>3 </sup>is CY<sup>111 </sup>or N wherein Y<sup>111 </sup>is a hydrogen atom, hydroxy, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, or optionally substituted C1-C4 acyloxy;</div>
    </li> <li> <para-num num="[0150]"> </para-num> <div id="p-0221" num="0150" class="description-line">X<sup>14 </sup>and X<sup>15 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; and</div>
    </li> <li> <para-num num="[0151]"> </para-num> <div id="p-0222" num="0151" class="description-line">A<sup>4 </sup>is a pharmaceutically acceptable anion, and</div>
    </li> <li> <div id="p-0223" num="0000" class="description-line">formula (V) or formula (V)</div>
    </li> <li> <div id="p-0224" num="0000" class="description-line">
      <chemistry id="CHEM-US-00031" num="00031">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/03/ab/8a/f05cd08dc60484/US20200368173A1-20201126-C00031.png"><img id="EMI-C00031" he="65.11mm" wi="60.88mm" file="US20200368173A1-20201126-C00031.TIF" alt="Figure US20200368173A1-20201126-C00031" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="244" height="260" alt="Figure US20200368173A1-20201126-C00031" class="patent-full-image" src="https://patentimages.storage.googleapis.com/03/ab/8a/f05cd08dc60484/US20200368173A1-20201126-C00031.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00031" attachment-type="cdx" file="US20200368173A1-20201126-C00031.CDX"> </attachment>
          <attachment idref="CHEM-US-00031" attachment-type="mol" file="US20200368173A1-20201126-C00031.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0225" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0152]"> </para-num> <div id="p-0226" num="0152" class="description-line">R<sup>13 </sup>to R<sup>18 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl; Y<sup>112 </sup>to Y<sup>115 </sup>are the same or different and are each a hydrogen atom, hydroxy or optionally substituted C1-C4 alkyl;</div>
    </li> <li> <para-num num="[0153]"> </para-num> <div id="p-0227" num="0153" class="description-line">L<sup>17 </sup>to L<sup>19 </sup>and L<sup>22 </sup>to L<sup>24 </sup>are the same or different and are each absent, or Z<sup>32</sup>(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub> or Z<sup>33</sup>(CY<sup>118</sup>Y<sup>119</sup>)<sub>p52</sub>Z<sup>34</sup>(CY<sup>120</sup>Y<sup>121</sup>)<sub>p53</sub> wherein Y<sup>116 </sup>to Y<sup>121 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>32 </sup>to Z<sup>34 </sup>are the same or different and are each O, NY<sup>122A</sup>, COO, OCO, CONY<sup>122B</sup>, NY<sup>122C</sup>CO, NY<sup>122D</sup>COO or CO wherein Y<sup>122A </sup>to Y<sup>122D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>51 </sup>is an integer from 0 to 5; p<sup>52 </sup>is an integer from 1 to 5; and p<sup>53 </sup>is an integer from 0 to 5;</div>
    </li> <li> <para-num num="[0154]"> </para-num> <div id="p-0228" num="0154" class="description-line">L<sup>20 </sup>and L<sup>25 </sup>are the same or different and are each absent, or (CY<sup>123</sup>Y<sup>124</sup>)<sub>p54</sub>, (CY<sup>125</sup>Y<sup>126</sup>)<sub>p55</sub>Z<sup>35</sup>(CY<sup>127</sup>Y<sup>128</sup>)<sub>p56</sub> or (CY<sup>129</sup>Y<sup>130</sup>)<sub>p57</sub>Z<sup>36</sup>(CY<sup>131</sup>Y<sup>132</sup>)<sub>p58</sub>Z<sup>37</sup>(CY<sup>133</sup>Y<sup>134</sup>)<sub>p59</sub> wherein Y<sup>123 </sup>to Y<sup>134 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>35 </sup>to Z<sup>37 </sup>are the same or different and are each O, NY<sup>135A</sup>, COO, OCO, CONY<sup>135B</sup>, NY<sup>135C</sup>CO, NY<sup>135D</sup>COO or CO wherein Y<sup>135A </sup>to Y<sup>135D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>54 </sup>is an integer from 1 to 5; p<sup>55 </sup>is an integer from 0 to 5; p<sup>56 </sup>is an integer from 1 to 5; p<sup>57 </sup>is an integer from 0 to 5; p<sup>58 </sup>is an integer from 1 to 5; and p<sup>59 </sup>is an integer from 1 to 5;</div>
    </li> <li> <para-num num="[0155]"> </para-num> <div id="p-0229" num="0155" class="description-line">L<sup>21 </sup>and L<sup>26 </sup>are the same or different and are each absent, or (CY<sup>136</sup>Y<sup>137</sup>)<sub>p60</sub>, (CY<sup>138</sup>Y<sup>139</sup>)<sub>p61</sub>Z<sup>38</sup>(CY<sup>140</sup>Y<sup>141</sup>)<sub>p62</sub> or (CY<sup>142</sup>Y<sup>143</sup>)<sub>p63</sub>Z<sup>39</sup>(CY<sup>144</sup>Y<sup>145</sup>)<sub>p64</sub>Z<sup>40</sup>(CY<sup>146</sup>Y<sup>147</sup>)<sub>p65</sub> wherein Y<sup>136 </sup>to Y<sup>147 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>38 </sup>to Z<sup>40 </sup>are the same or different and are each O, NY<sup>148A</sup>, COO, OCO, CONY<sup>148B</sup>, NR<sup>148C</sup>CO, NY<sup>148D</sup>COO or CO wherein Y<sup>148A </sup>to Y<sup>148D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>60 </sup>is an integer from 1 to 5; p<sup>61 </sup>is an integer from 0 to 5; p<sup>62 </sup>is an integer from 0 to 5; p<sup>63 </sup>is an integer from 0 to 5; p<sup>64 </sup>is an integer from 1 to 5; and p<sup>65 </sup>is an integer from 0 to 5;</div>
    </li> <li> <para-num num="[0156]"> </para-num> <div id="p-0230" num="0156" class="description-line">B<sup>3 </sup>and B<sup>4 </sup>are the same or different and are each</div>
    </li> <li> <div id="p-0231" num="0000" class="description-line">
      <chemistry id="CHEM-US-00032" num="00032">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1c/76/96/f424cbcf023115/US20200368173A1-20201126-C00032.png"><img id="EMI-C00032" he="61.72mm" wi="60.62mm" file="US20200368173A1-20201126-C00032.TIF" alt="Figure US20200368173A1-20201126-C00032" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="242" height="247" alt="Figure US20200368173A1-20201126-C00032" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1c/76/96/f424cbcf023115/US20200368173A1-20201126-C00032.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00032" attachment-type="cdx" file="US20200368173A1-20201126-C00032.CDX"> </attachment>
          <attachment idref="CHEM-US-00032" attachment-type="mol" file="US20200368173A1-20201126-C00032.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0232" num="0000" class="description-line">wherein X<sup>16 </sup>and X<sup>17 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>18 </sup>is optionally substituted C1-C4 alkyl; X<sup>19 </sup>and X<sup>20 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>21 </sup>is optionally substituted C1-C4 alkyl; Y<sup>149 </sup>to Y<sup>158 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>41 </sup>and Z<sup>42 </sup>are the same or different and are each O, NY<sup>159A</sup>, COO, OCO, CONY<sup>159B</sup>, NY<sup>159C</sup>CO or NY<sup>159D</sup>COO wherein Y<sup>159A </sup>to Y<sup>159D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>66 </sup>is an integer from 0 to 5; and p<sup>67 </sup>to p<sup>70 </sup>are the same or different and are each an integer from 1 to 5; and</div>
    </li> <li> <para-num num="[0157]"> </para-num> <div id="p-0233" num="0157" class="description-line">A<sup>5 </sup>and A<sup>6 </sup>are the same or different and are each a pharmaceutically acceptable anion.</div>
    </li> <li> <para-num num="[0158]"> </para-num> <div id="p-0234" num="0158" class="description-line">Hereinafter, the compounds represented by formulas (I) to (IV), (V) and (V) are also referred to as compounds (I) to (IV), (V) and (V), respectively. The same holds true for compounds of other formula numbers.</div>
    </li> <li> <para-num num="[0159]"> </para-num> <div id="p-0235" num="0159" class="description-line">The definition of each group in formulas (I) to (V) will be described below.</div>
    </li> <li> <para-num num="[0160]"> </para-num> <div id="p-0236" num="0160" class="description-line">Examples of the linear or branched C8-C24 alkyl include octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl, preferably nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl, more preferably undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl and hexadecyl.</div>
    </li> <li> <para-num num="[0161]"> </para-num> <div id="p-0237" num="0161" class="description-line">Examples of the linear or branched C9-C18 alkyl include nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl and 6,10,14-trimethylpentadecan-2-yl, preferably nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl, more preferably undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl and hexadecyl.</div>
    </li> <li> <para-num num="[0162]"> </para-num> <div id="p-0238" num="0162" class="description-line">The linear or branched C8-C24 alkenyl can be linear or branched C8-24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octadeca-9,12-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-nonadec-10-enyl, (Z)-icos-11-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 2,6,10,14-tetramethylpentadec-1-enyl and 3,7,11,15-tetramethylhexadec-2-enyl, preferably (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl, more preferably (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0163]"> </para-num> <div id="p-0239" num="0163" class="description-line">Examples of the linear or branched C15-C20 alkenyl include (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octadeca-9,12-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-nonadec-10-enyl, (Z)-icos-11-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl and 3,7,11,15-tetramethylhexadec-2-enyl, preferably (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl, more preferably (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0164]"> </para-num> <div id="p-0240" num="0164" class="description-line">In the present invention, a group having a cyclopropane ring formed by adding formally a methylene biradical to a double bond of the optionally substituted linear or branched C8-C24 alkenyl is also included in the C8-C24 alkenyl. Examples thereof include groups having the following cyclopropane rings corresponding to (Z)-hexadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl and (8Z,11Z)-heptadeca-8,11-dienyl:</div>
    </li> <li> <div id="p-0241" num="0000" class="description-line">
      <chemistry id="CHEM-US-00033" num="00033">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dd/cf/ca/6a6cf3aa4d32cf/US20200368173A1-20201126-C00033.png"><img id="EMI-C00033" he="82.55mm" wi="74.08mm" file="US20200368173A1-20201126-C00033.TIF" alt="Figure US20200368173A1-20201126-C00033" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="296" height="330" alt="Figure US20200368173A1-20201126-C00033" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dd/cf/ca/6a6cf3aa4d32cf/US20200368173A1-20201126-C00033.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00033" attachment-type="cdx" file="US20200368173A1-20201126-C00033.CDX"> </attachment>
          <attachment idref="CHEM-US-00033" attachment-type="mol" file="US20200368173A1-20201126-C00033.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0165]"> </para-num> <div id="p-0242" num="0165" class="description-line">The linear or branched C8-C24 alkynyl can be linear or branched C8-24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-ynyl and octadec-9-ynyl.</div>
    </li> <li> <para-num num="[0166]"> </para-num> <div id="p-0243" num="0166" class="description-line">Examples of the C1-C4 alkyl include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl and cyclopropylmethyl, preferably methyl and ethyl, more preferably methyl.</div>
    </li> <li> <para-num num="[0167]"> </para-num> <div id="p-0244" num="0167" class="description-line">The alkyl moiety in the optionally substituted C1-C4 alkoxy is as defined in the C1-C4 alkyl.</div>
    </li> <li> <para-num num="[0168]"> </para-num> <div id="p-0245" num="0168" class="description-line">Examples of the substituent for the optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl include hydroxy, alkoxy, alkoxycarbonyl, nitro, cyano, fluoro, chloro and bromo. Among these substituents, the alkyl moiety in alkoxy and alkoxycarbonyl is as defined in the C1-C4 alkyl.</div>
    </li> <li> <para-num num="[0169]"> </para-num> <div id="p-0246" num="0169" class="description-line">Examples of the substituent for the optionally substituted C1-C4 alkyl include amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo. Among these substituents, the alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl is as defined in the C1-C4 alkyl. Two alkyl moieties in dialkylamino and dialkylcarbamoyl may be the same as or different from each other.</div>
    </li> <li> <para-num num="[0170]"> </para-num> <div id="p-0247" num="0170" class="description-line">In the present invention, each of the pyrrolidin-2-yl, the pyrrolidin-3-yl, the piperidin-2-yl, the piperidin-3-yl, the piperidin-4-yl, the morpholin-2-yl and the morpholin-3-yl includes a group formed by adding C1-C3 alkyl such as methyl or ethyl to a nitrogen atom in a ring.</div>
    </li> <li> <para-num num="[0171]"> </para-num> <div id="p-0248" num="0171" class="description-line">Examples of the C1-C3 alkyl include methyl, ethyl, propyl, isopropyl and cyclopropyl, preferably methyl and ethyl, more preferably methyl.</div>
    </li> <li> <para-num num="[0172]"> </para-num> <div id="p-0249" num="0172" class="description-line">Examples of the C4-C6 hetero ring together formed by X<sup>2 </sup>and X<sup>3 </sup>with the adjacent nitrogen atom include pyrrolidine, piperidine, morpholine and azepane, preferably pyrrolidine and piperidine. Examples of the substituent for the optionally substituted C4-C6 hetero ring together formed by X<sup>2 </sup>and X<sup>3 </sup>with the adjacent nitrogen atom include optionally substituted C1-C4 alkyl (as defined above), amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo. Among these substituents, the alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl is as defined in the C1-C4 alkyl. Two alkyl moieties in dialkylamino and dialkylcarbamoyl may be the same as or different from each other.</div>
    </li> <li> <para-num num="[0173]"> </para-num> <div id="p-0250" num="0173" class="description-line">The hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X<sup>5 </sup>and X<sup>6 </sup>with the adjacent nitrogen atom are each as defined above.</div>
    </li> <li> <para-num num="[0174]"> </para-num> <div id="p-0251" num="0174" class="description-line">The hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X<sup>8 </sup>and X<sup>9 </sup>with the adjacent nitrogen atom are each as defined above.</div>
    </li> <li> <para-num num="[0175]"> </para-num> <div id="p-0252" num="0175" class="description-line">The hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X<sup>11 </sup>and X<sup>12 </sup>with the adjacent nitrogen atom are each as defined above.</div>
    </li> <li> <para-num num="[0176]"> </para-num> <div id="p-0253" num="0176" class="description-line">The hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X<sup>14 </sup>and X<sup>15 </sup>with the adjacent nitrogen atom are each as defined above.</div>
    </li> <li> <para-num num="[0177]"> </para-num> <div id="p-0254" num="0177" class="description-line">The hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X<sup>16 </sup>and X<sup>17 </sup>with the adjacent nitrogen atom are each as defined above.</div>
    </li> <li> <para-num num="[0178]"> </para-num> <div id="p-0255" num="0178" class="description-line">The hetero ring moiety and the substituent moiety in the optionally substituted C4-C6 hetero ring together formed by X<sup>19 </sup>and X<sup>20 </sup>with the adjacent nitrogen atom are each as defined above.</div>
    </li> <li> <para-num num="[0179]"> </para-num> <div id="p-0256" num="0179" class="description-line">Examples of the acyl in the C1-C4 acyloxy include formyl, acetyl, propanoyl, 2-methylpropanoyl, cyclopropanoyl and butanoyl, preferably acetyl.</div>
    </li> <li> <para-num num="[0180]"> </para-num> <div id="p-0257" num="0180" class="description-line">Examples of the substituent for the optionally substituted C1-C4 acyloxy include amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo. Among these substituents, the alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl is as defined in the C1-C4 alkyl. Two alkyl moieties in dialkylamino and dialkylcarbamoyl may be the same as or different from each other.</div>
    </li> <li> <para-num num="[0181]"> </para-num> <div id="p-0258" num="0181" class="description-line">The quaternary ammonium group means a group having a nitrogen atom having four covalent bonds to four carbon atoms. Unlike a hydrogen atom added to primary to tertiary amines, the quaternary ammonium group always has a positive charge irrespective of ambient pH.</div>
    </li> <li> <para-num num="[0182]"> </para-num> <div id="p-0259" num="0182" class="description-line">Examples of the pharmaceutically acceptable anion include, but are not limited to: inorganic ions such as chloride ions, bromide ions, iodide ions, nitrate ions, sulfate ions and phosphate ions; and organic acid ions such as acetate ions, oxalate ions, maleate ions, fumarate ions, citrate ions, benzoate ions and methanesulfonate ions.</div>
    </li> <li> <para-num num="[0183]"> </para-num> <div id="p-0260" num="0183" class="description-line">In formula (I), R<sup>1 </sup>to R<sup>3 </sup>are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C8-C24 alkyl or C8-C24 alkenyl, further preferably the same linear or branched C15-C20 alkenyl or the same linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl.</div>
    </li> <li> <para-num num="[0184]"> </para-num> <div id="p-0261" num="0184" class="description-line">L<sup>1 </sup>to L<sup>3 </sup>are the same or different and are each absent, or Z<sup>1</sup>(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> or Z<sup>2</sup>(CY<sup>3</sup>Y<sup>4</sup>)<sub>p2</sub>Z<sup>3</sup>(CY<sup>5</sup>Y<sup>6</sup>)<sub>p3</sub>, preferably Z<sup>1</sup>(CY<sup>1</sup>Y<sup>2</sup>)<sub>p2</sub>. Y<sup>1 </sup>to Y<sup>6 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom. Z<sup>1 </sup>to Z<sup>3 </sup>are the same or different and are each O, NY<sup>7A</sup>, COO, OCO, CONY<sup>7B</sup>, NY<sup>7C</sup>CO or NY<sup>7D</sup>COO, preferably O, COO, OCO, CONY<sup>7B</sup> or NY<sup>7C</sup>CO. Y<sup>7A </sup>to Y<sup>7D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl, p<sup>1 </sup>to p<sup>3 </sup>are the same or different and are each an integer from 1 to 5, preferably 1 or 2.</div>
    </li> <li> <para-num num="[0185]"> </para-num> <div id="p-0262" num="0185" class="description-line">L<sup>1 </sup>to L<sup>3 </sup>are preferably the same or different and are each O(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub>, COO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub>, OCO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub>, CONY<sup>73</sup>(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> or NY<sup>7C</sup>CO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub>, more preferably are the same or different and are each COO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p2</sub> or OCO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub>, further preferably are the same and COO(CH<sub>2</sub>)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0186]"> </para-num> <div id="p-0263" num="0186" class="description-line">In formula (I), preferably, one or more of L<sup>1 </sup>to L<sup>3 </sup>are the same or different and are each COO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> or OCO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub>, and R<sup>1 </sup>to R<sup>3 </sup>are the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl.</div>
    </li> <li> <para-num num="[0187]"> </para-num> <div id="p-0264" num="0187" class="description-line">When at least one of L<sup>1 </sup>to L<sup>3 </sup>is absent, or O(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub>, OCO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> or NY<sup>7C</sup>CO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub>, R<sup>1 </sup>to R<sup>3 </sup>bonded to the positively charged nitrogen atom (N<sup>+</sup>), O(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub>, OCO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> or NR<sup>6</sup>CO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p2</sub> are the same or different and are each more preferably octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 3,7,11,15-tetramethylhexadec-2-enyl or the like, further preferably dodecyl, tetradecyl, hexadecyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl or the like.</div>
    </li> <li> <para-num num="[0188]"> </para-num> <div id="p-0265" num="0188" class="description-line">When at least one of L<sup>1 </sup>to L<sup>3 </sup>is COO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p2</sub> or CONY<sup>7B</sup>(CY<sup>2</sup>Y<sup>2</sup>)<sub>p1</sub>, R<sup>1 </sup>to R<sup>3 </sup>bonded to COO(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> or CONY<sup>7B</sup>(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> are the same or different and are each more preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (Z)-nonadec-10-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl, 2,6,10,14-tetramethylpentadec-1-enyl or the like, further preferably undecyl, tridecyl, pentadecyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (8Z,11Z)-heptadeca-8,11-dienyl or the like.</div>
    </li> <li> <para-num num="[0189]"> </para-num> <div id="p-0266" num="0189" class="description-line">X<sup>1 </sup>is preferably methyl, hydroxypropyl or hydroxyethyl, more preferably methyl.</div>
    </li> <li> <para-num num="[0190]"> </para-num> <div id="p-0267" num="0190" class="description-line">In formula (II), R<sup>4 </sup>to R<sup>6 </sup>are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C8-C24 alkyl or C8-C24 alkenyl, further preferably the same linear or branched C15-C20 alkenyl or the same linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl.</div>
    </li> <li> <para-num num="[0191]"> </para-num> <div id="p-0268" num="0191" class="description-line">L<sup>4 </sup>to L<sup>6 </sup>are the same or different and are each absent, or Z<sup>4</sup>(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub> or Z<sup>5</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>Z<sup>6</sup>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>, preferably Z<sup>4</sup>(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub> or Z<sup>5</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>Z<sup>6</sup>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>, more preferably Z<sup>4</sup>(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>. Y<sup>8 </sup>to Y<sup>13 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom. Z<sup>4 </sup>to Z<sup>6 </sup>are the same or different and are each O, NY<sup>14A</sup>, COO, OCO, CONY<sup>14B</sup>, NY<sup>14C</sup>CO or NY<sup>14D</sup>COO, preferably O, COO, OCO, CONY<sup>14B</sup> or NY<sup>14C</sup>CO. Y<sup>27A </sup>to Y<sup>27D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl, p<sup>4 </sup>is an integer from 0 to 5. p<sup>5 </sup>is an integer from 1 to 5. p<sup>6 </sup>is an integer from 0 to 5. All of p<sup>4 </sup>to p<sup>6 </sup>are preferably 1 or 2.</div>
    </li> <li> <para-num num="[0192]"> </para-num> <div id="p-0269" num="0192" class="description-line">L<sup>4 </sup>to L<sup>6 </sup>are preferably the same or different and are each O(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, COO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, OCO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, CONY<sup>14B</sup>(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, NY<sup>14C</sup>CO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, NY<sup>14D</sup>CO-Q-(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub> or OCO(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>Z<sup>6</sup>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>, more preferably are the same or different and are each COO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, OCO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub> or OCO(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>O(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>, further preferably are the same and COOCH<sub>2</sub>.</div>
    </li> <li> <para-num num="[0193]"> </para-num> <div id="p-0270" num="0193" class="description-line">In formula (II), preferably, one or more of L<sub>4 </sub>to L<sub>6 </sub>are the same or different and are each COO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, OCO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, or OCO(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>O(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>, and R<sup>4 </sup>to R<sup>6 </sup>are the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl.</div>
    </li> <li> <para-num num="[0194]"> </para-num> <div id="p-0271" num="0194" class="description-line">When at least one of L<sup>4 </sup>to L<sup>6 </sup>is absent, or O(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, OCO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, NY<sup>14C</sup>CO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, NY<sup>14D</sup>COO or OCO(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>, R<sup>7 </sup>to R<sup>9 </sup>bonded to the carbon atom adjacent to L<sup>7</sup>, O(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, OCO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, NY<sup>14C</sup>CO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, NY<sup>14D</sup>COO or OCO(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>Z<sup>6</sup>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub> are the same or different and are each preferably octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 3,7,11,15-tetramethylhexadec-2-enyl or the like, more preferably dodecyl, tetradecyl, hexadecyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl or the like.</div>
    </li> <li> <para-num num="[0195]"> </para-num> <div id="p-0272" num="0195" class="description-line">When at least one of L<sup>4 </sup>to L<sup>6 </sup>is COO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub> or CONY<sup>14B</sup>(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>, R<sup>4 </sup>to R<sup>6 </sup>bonded to COO(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub> or CONY<sup>14B</sup>(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub> are the same or different and are each preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (Z)-nonadec-10-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl, 2,6,10,14-tetramethylpentadec-1-enyl or the like, more preferably undecyl, tridecyl, pentadecyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (8Z,11Z)-heptadeca-8,11-dienyl or the like.</div>
    </li> <li> <para-num num="[0196]"> </para-num> <div id="p-0273" num="0196" class="description-line">L<sup>7 </sup>is preferably absent, or (CY<sup>15</sup>Y<sup>16</sup>)<sub>p7</sub>, (CY<sup>17</sup>Y<sup>18</sup>)<sub>p8</sub>OCO(CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub> or (CY<sup>17</sup>Y<sup>18</sup>)<sub>p8</sub>NY<sup>27C</sup>CO(CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub>, more preferably absent, or (CY<sup>15</sup>Y<sup>16</sup>)<sub>p7</sub>. In this case, B<sup>1 </sup>is preferably</div>
    </li> <li> <div id="p-0274" num="0000" class="description-line">
      <chemistry id="CHEM-US-00034" num="00034">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bf/96/73/1c0fd827ed36e3/US20200368173A1-20201126-C00034.png"><img id="EMI-C00034" he="13.89mm" wi="18.29mm" file="US20200368173A1-20201126-C00034.TIF" alt="Figure US20200368173A1-20201126-C00034" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="73" height="56" alt="Figure US20200368173A1-20201126-C00034" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bf/96/73/1c0fd827ed36e3/US20200368173A1-20201126-C00034.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00034" attachment-type="cdx" file="US20200368173A1-20201126-C00034.CDX"> </attachment>
          <attachment idref="CHEM-US-00034" attachment-type="mol" file="US20200368173A1-20201126-C00034.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0275" num="0000" class="description-line">more preferably N<sup>+</sup>(CH<sub>3</sub>)<sub>3</sub>.</div>
    </li> <li> <para-num num="[0197]"> </para-num> <div id="p-0276" num="0197" class="description-line">When L<sup>7 </sup>is (CY<sup>15</sup>Y<sup>16</sup>)<sub>p7</sub>, p<sup>7 </sup>is preferably 1 to 3, more preferably 1 or 2, further preferably 1. Each of Y<sup>15 </sup>and Y<sup>16 </sup>is preferably a hydrogen atom. B<sup>1 </sup>is preferably N<sup>+</sup>(CH<sub>3</sub>)<sub>3</sub>.</div>
    </li> <li> <para-num num="[0198]"> </para-num> <div id="p-0277" num="0198" class="description-line">When L<sup>7 </sup>is (CY<sup>17</sup>Y<sup>18</sup>)<sub>p8</sub>OCO(CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub> or (CY<sup>17</sup>Y<sup>18</sup>)<sub>p8</sub>NY<sup>27C</sup>CO(CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub>, preferably, p<sup>8 </sup>is 0 to 3, and p<sup>9 </sup>is 1 to 3. More preferably, p<sup>8 </sup>is 0 to 1, and p<sup>9 </sup>is 1 to 3. Preferably, each of Y<sup>17 </sup>to Y<sup>20 </sup>is a hydrogen atom, and Y<sup>27C </sup>is a hydrogen atom or methyl. B<sup>1 </sup>is preferably N<sup>+</sup>(CH<sub>3</sub>)<sub>3</sub>.</div>
    </li> <li> <para-num num="[0199]"> </para-num> <div id="p-0278" num="0199" class="description-line">Preferably, X<sup>2 </sup>and X<sup>3 </sup>are the same or different and are each methyl or ethyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom. More preferably, X<sup>2 </sup>and X<sup>3 </sup>are the same and methyl, or together form pyrrolidine or piperidine with the adjacent nitrogen atom. Further preferably, X<sup>2 </sup>and X<sup>3 </sup>are the same and methyl.</div>
    </li> <li> <para-num num="[0200]"> </para-num> <div id="p-0279" num="0200" class="description-line">X<sup>4 </sup>is preferably methyl, ethyl, hydroxypropyl, hydroxyethyl or the like, more preferably methyl.</div>
    </li> <li> <para-num num="[0201]"> </para-num> <div id="p-0280" num="0201" class="description-line">Preferably, X<sup>2 </sup>and X<sup>3 </sup>are the same or different and are each methyl or ethyl, and X<sup>4 </sup>is methyl, ethyl, hydroxypropyl, hydroxyethyl or the like. Each of X<sup>2 </sup>to X<sup>4 </sup>is more preferably methyl.</div>
    </li> <li> <para-num num="[0202]"> </para-num> <div id="p-0281" num="0202" class="description-line">In another preferred mode of the present invention, B<sup>1 </sup>is</div>
    </li> <li> <div id="p-0282" num="0000" class="description-line">
      <chemistry id="CHEM-US-00035" num="00035">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6d/8d/a6/1337bec08bf410/US20200368173A1-20201126-C00035.png"><img id="EMI-C00035" he="61.72mm" wi="39.37mm" file="US20200368173A1-20201126-C00035.TIF" alt="Figure US20200368173A1-20201126-C00035" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="157" height="247" alt="Figure US20200368173A1-20201126-C00035" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6d/8d/a6/1337bec08bf410/US20200368173A1-20201126-C00035.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00035" attachment-type="cdx" file="US20200368173A1-20201126-C00035.CDX"> </attachment>
          <attachment idref="CHEM-US-00035" attachment-type="mol" file="US20200368173A1-20201126-C00035.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0283" num="0000" class="description-line">and L<sup>7 </sup>is absent, or (CY<sup>15</sup>Y<sup>16</sup>)<sub>p7</sub>, (CY<sup>17</sup>Y<sup>18</sup>)<sub>p8</sub>OCO(CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub> or (CY<sup>17</sup>Y<sup>18</sup>)<sub>p8</sub>NY<sup>27C</sup>CO(CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub>. In this case, more preferably, B<sup>1 </sup>is</div>
    </li> <li> <div id="p-0284" num="0000" class="description-line">
      <chemistry id="CHEM-US-00036" num="00036">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/54/71/b9/c96af1239a8b04/US20200368173A1-20201126-C00036.png"><img id="EMI-C00036" he="77.47mm" wi="68.16mm" file="US20200368173A1-20201126-C00036.TIF" alt="Figure US20200368173A1-20201126-C00036" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="273" height="310" alt="Figure US20200368173A1-20201126-C00036" class="patent-full-image" src="https://patentimages.storage.googleapis.com/54/71/b9/c96af1239a8b04/US20200368173A1-20201126-C00036.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00036" attachment-type="cdx" file="US20200368173A1-20201126-C00036.CDX"> </attachment>
          <attachment idref="CHEM-US-00036" attachment-type="mol" file="US20200368173A1-20201126-C00036.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0285" num="0000" class="description-line">and L<sup>7 </sup>is absent, or NHCO(CH<sub>2</sub>)<sub>p9</sub>, OCO(CH<sub>2</sub>)<sub>p9</sub>, CH<sub>2</sub>NHCO(CH<sub>2</sub>)<sub>p9</sub> or CH<sub>2</sub>OCO(CH<sub>2</sub>)<sub>p9</sub>.</div>
    </li> <li> <para-num num="[0203]"> </para-num> <div id="p-0286" num="0203" class="description-line">In formula (III), R<sup>7 </sup>is preferably linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or the same linear C9-C18 alkyl. R<sup>8 </sup>and R<sup>9 </sup>are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or linear C9-C18 alkyl.</div>
    </li> <li> <para-num num="[0204]"> </para-num> <div id="p-0287" num="0204" class="description-line">L<sup>8 </sup>is absent, or Z<sup>12</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p19</sub> or Z<sup>13</sup>(CY<sup>41</sup>Y<sup>42</sup>)<sub>p19</sub>Z<sup>14</sup>(CY<sup>43</sup>Y<sup>44</sup>)<sub>p20</sub>, preferably absent or Z<sup>12</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p19</sub>. L<sup>9 </sup>and L<sup>10 </sup>are the same or different and are each absent, or Z<sup>12</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or Z<sup>13</sup>(CY<sup>41</sup>Y<sup>42</sup>)<sub>p19</sub>Z<sup>14</sup>(CY<sup>43</sup>Y<sup>44</sup>)<sub>p20</sub>, preferably are the same or different and are each absent or Z<sup>12</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>. Y<sup>39 </sup>to Y<sup>44 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom. Z<sup>12 </sup>to Z<sup>14 </sup>are the same or different and are each O, NY<sup>45A</sup>, COO, OCO, CONY<sup>453</sup>, NY<sup>45C</sup>CO, NY<sup>45D</sup>COO or CO, preferably COO, OCO, CONY<sup>45B</sup>, NY<sup>45C</sup>CO or CO. Y<sup>45A </sup>to Y<sup>45D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl, p<sup>18 </sup>is an integer from 0 to 5, preferably 0 or 1. p<sup>19 </sup>is an integer from 1 to 5, preferably 1 or 2. p<sup>20 </sup>is an integer from 0 to 5, preferably 0 or 1.</div>
    </li> <li> <para-num num="[0205]"> </para-num> <div id="p-0288" num="0205" class="description-line">Preferably, one of L<sup>8 </sup>to L<sup>10 </sup>is COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, or two or more of L<sup>8 </sup>to L<sup>10 </sup>are the same or different and are each COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18 </sub>or OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, and each of R<sup>7 </sup>to R<sup>9 </sup>is linear C15-C20 alkenyl or C9-C18 alkyl. R<sup>8 </sup>and R<sup>9 </sup>are preferably the same.</div>
    </li> <li> <para-num num="[0206]"> </para-num> <div id="p-0289" num="0206" class="description-line">L<sup>8 </sup>is preferably absent, or COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, CONY<sup>45B</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or NY<sup>45C</sup>CO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, more preferably absent, or COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p28</sub> or CONY<sup>45B</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p28</sub>, further preferably absent, or COO(CH<sub>2</sub>)<sub>p18</sub>, OCO(CH<sub>2</sub>)<sub>p18</sub> or CONH(CH<sub>2</sub>)<sub>p18</sub>.</div>
    </li> <li> <para-num num="[0207]"> </para-num> <div id="p-0290" num="0207" class="description-line">L<sup>9 </sup>and L<sup>10 </sup>are preferably the same or different and are each absent, or COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, CONY<sup>45B</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or NY<sup>45C</sup>CO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, more preferably are the same or different and are each absent, or COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, further preferably are the same or different and are each absent or COO(CH<sub>2</sub>)<sub>p18</sub>, most preferably are the same and absent or COO(CH<sub>2</sub>)<sub>p18</sub>.</div>
    </li> <li> <para-num num="[0208]"> </para-num> <div id="p-0291" num="0208" class="description-line">In formula (III), preferably, one of L<sup>8 </sup>to L<sup>10 </sup>is absent, or COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, CONY<sup>45b</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or NY<sup>45C</sup>CO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, or two or more of L<sup>8 </sup>to L<sup>10 </sup>are the same or different and are each absent, or COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, CONY<sup>45b</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or NY<sup>45C</sup>CO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, and each of R<sup>7 </sup>to R<sup>9 </sup>is preferably linear C15-C20 alkenyl or C9-C18 alkyl. R<sup>8 </sup>and R<sup>9 </sup>are preferably the same.</div>
    </li> <li> <para-num num="[0209]"> </para-num> <div id="p-0292" num="0209" class="description-line">When at least one of L<sup>8 </sup>to L<sup>10 </sup>is absent, or O(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, NY<sup>45C</sup>CO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or NY<sup>45D</sup>COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, R<sup>7 </sup>to R<sup>9 </sup>bonded to J<sup>1 </sup>or J<sup>2</sup>, O(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, OCO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, NY<sup>45C</sup>CO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or NY<sup>45D</sup>COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> are the same or different and are each preferably octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 3,7,11,15-tetramethylhexadec-2-enyl or the like, more preferably dodecyl, tetradecyl, hexadecyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl or the like.</div>
    </li> <li> <para-num num="[0210]"> </para-num> <div id="p-0293" num="0210" class="description-line">When at least one of L<sup>8 </sup>to L<sup>10 </sup>is COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, CONY<sup>45B</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or CO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, R<sup>7 </sup>to R<sup>9 </sup>bonded to COO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>, CONY<sup>45B</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or CO(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18 </sub>are the same or different and are each preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (Z)-nonadec-10-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl or 2,6,10,14-tetramethylpentadec-1-enyl, more preferably undecyl, tridecyl, pentadecyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (8Z,11Z)-heptadeca-8,11-dienyl or the like.</div>
    </li> <li> <para-num num="[0211]"> </para-num> <div id="p-0294" num="0211" class="description-line">L<sup>11 </sup>is absent, or (CY<sup>46</sup>Y<sup>47</sup>)<sub>p21</sub>, (CY<sup>48</sup>Y<sup>49</sup>)<sub>p22</sub>Z<sup>15</sup>(CY<sup>50</sup>Y<sup>51</sup>)<sub>p23</sub> or (CY<sup>52</sup>Y<sup>53</sup>)<sub>p24</sub>Z<sup>16</sup>(CY<sup>54</sup>Y<sup>55</sup>)<sub>p25</sub>Z<sup>17</sup>(CY<sup>56</sup>Y<sup>57</sup>)<sub>p26</sub>, preferably absent, or (CY<sup>46</sup>Y<sup>47</sup>)<sub>p21</sub> or (CY<sup>48</sup>Y<sup>49</sup>)<sub>p22</sub>Z<sup>15</sup>(CY<sup>50</sup>Y<sup>51</sup>)<sub>p23</sub>. Y<sup>46 </sup>to Y<sup>57 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom. Z<sup>15 </sup>to Z<sup>17 </sup>are the same or different and are each O, NY<sup>58A</sup>, COO, OCO, CONY<sup>58B</sup>, NY<sup>58C</sup>CO, NY<sup>58D</sup>COO or CO, preferably COO, OCO, CONY<sup>58B</sup>, NY<sup>58C</sup>CO or CO, more preferably OCO or NY<sup>58C</sup>CO. p<sup>21 </sup>is an integer from 1 to 5, preferably 1 to 3. p<sup>22 </sup>is an integer from 0 to 5, preferably 0 to 3. p<sup>23 </sup>is an integer from 1 to 5, preferably 1 or 2.</div>
    </li> <li> <para-num num="[0212]"> </para-num> <div id="p-0295" num="0212" class="description-line">L<sup>11 </sup>is preferably absent, or (CY<sup>46</sup>Y<sup>47</sup>)<sub>p21</sub>, (CY<sup>48</sup>Y<sup>49</sup>)<sub>p22</sub>OCO(CY<sup>50</sup>Y<sup>51</sup>)<sub>p23</sub>, or (CY<sup>48</sup>Y<sup>49</sup>)<sub>p22</sub>NY<sup>58C</sup>CO(CY<sup>50</sup>Y<sup>51</sup>)<sub>p23</sub>, more preferably absent or (CY<sup>46</sup>Y<sup>47</sup>)<sub>p21</sub>, further preferably absent or (CH<sub>2</sub>)<sub>p2</sub>.</div>
    </li> <li> <para-num num="[0213]"> </para-num> <div id="p-0296" num="0213" class="description-line">L<sup>12 </sup>is preferably absent or (CY<sup>59</sup>Y<sup>60</sup>)<sub>p27</sub>, more preferably absent or (CH<sub>2</sub>)<sub>p27</sub>, further preferably absent or CH<sub>2</sub> or (CH<sub>2</sub>)<sub>2</sub>.</div>
    </li> <li> <para-num num="[0214]"> </para-num> <div id="p-0297" num="0214" class="description-line">J<sup>1 </sup>and J<sup>2 </sup>are the same or different and are each CY<sup>72 </sup>or N. Preferably, J<sup>1 </sup>and J<sup>2 </sup>are the same or different and are each CH, C(OH) or N.</div>
    </li> <li> <para-num num="[0215]"> </para-num> <div id="p-0298" num="0215" class="description-line">When L<sup>11 </sup>is absent, J<sup>1 </sup>is preferably CH.</div>
    </li> <li> <para-num num="[0216]"> </para-num> <div id="p-0299" num="0216" class="description-line">In another preferred mode of the present invention, L<sup>9 </sup>and L<sup>10 </sup>are absent; L<sup>12 </sup>is CO(CH<sub>2</sub>)<sub>p29</sub>; J<sup>1 </sup>is CH; and J<sup>2 </sup>is N. In this case, preferably, L<sup>8 </sup>is CONY<sup>45B</sup>(CH<sub>2</sub>)<sub>p18</sub>, and L<sup>11 </sup>is absent or (CH<sub>2</sub>)<sub>p22</sub>.</div>
    </li> <li> <para-num num="[0217]"> </para-num> <div id="p-0300" num="0217" class="description-line">In an alternative preferred mode of the present invention, L<sup>9 </sup>and L<sup>10 </sup>are absent; L<sup>12 </sup>is OCO(CH<sub>2</sub>)<sub>p18</sub>; and each of J<sup>1 </sup>and J<sup>2 </sup>is CH. In this case, preferably, L<sup>8 </sup>is OCO(CH<sub>2</sub>)<sub>p18</sub>, and L<sup>11 </sup>is absent.</div>
    </li> <li> <para-num num="[0218]"> </para-num> <div id="p-0301" num="0218" class="description-line">B<sup>2 </sup>is preferably</div>
    </li> <li> <div id="p-0302" num="0000" class="description-line">
      <chemistry id="CHEM-US-00037" num="00037">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/98/c7/fbe5f20f859b7a/US20200368173A1-20201126-C00037.png"><img id="EMI-C00037" he="13.89mm" wi="18.29mm" file="US20200368173A1-20201126-C00037.TIF" alt="Figure US20200368173A1-20201126-C00037" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="73" height="56" alt="Figure US20200368173A1-20201126-C00037" class="patent-full-image" src="https://patentimages.storage.googleapis.com/78/98/c7/fbe5f20f859b7a/US20200368173A1-20201126-C00037.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00037" attachment-type="cdx" file="US20200368173A1-20201126-C00037.CDX"> </attachment>
          <attachment idref="CHEM-US-00037" attachment-type="mol" file="US20200368173A1-20201126-C00037.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0303" num="0000" class="description-line">more preferably N<sup>+</sup>(CH<sub>3</sub>)<sub>3</sub>.</div>
    </li> <li> <para-num num="[0219]"> </para-num> <div id="p-0304" num="0219" class="description-line">X<sup>8 </sup>to X<sup>10 </sup>are as defined above in X<sup>2 </sup>to X<sup>4</sup>, respectively.</div>
    </li> <li> <para-num num="[0220]"> </para-num> <div id="p-0305" num="0220" class="description-line">In formula (IV), R<sup>10 </sup>is preferably linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably linear C15-C20 alkenyl or linear C9-C18 alkyl. R<sup>11 </sup>and R<sup>12 </sup>are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or linear C9-C18 alkyl.</div>
    </li> <li> <para-num num="[0221]"> </para-num> <div id="p-0306" num="0221" class="description-line">L<sup>13 </sup>is absent, or Z<sup>23</sup>(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub> or Z<sup>24</sup>(CY<sup>86</sup>Y<sup>87</sup>)<sub>p39</sub>Z<sup>25</sup>(CY<sup>88</sup>Y<sup>89</sup>)<sub>p40</sub>, preferably absent, or Z<sup>23</sup>(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>. Y<sup>84 </sup>to Y<sup>89 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom. Z<sup>23 </sup>to Z<sup>25 </sup>are the same or different and are each O, NY<sup>90A</sup>, COO, OCO, CONY<sup>903</sup>, NY<sup>90C</sup>CO or NY<sup>90D</sup>COO, preferably COO, OCO, CONY<sup>90B</sup> or NY<sup>90C</sup>CO, more preferably CONY<sup>90B</sup>. Y<sup>90A </sup>to Y<sup>90D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl, p<sup>38 </sup>to p<sup>40 </sup>are the same or different and are each an integer from 1 to 5, preferably 1 or 2.</div>
    </li> <li> <para-num num="[0222]"> </para-num> <div id="p-0307" num="0222" class="description-line">L<sup>13 </sup>is preferably absent, or COO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, OCO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, CONY<sup>90B</sup>(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, or NY<sup>90C</sup>CO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, more preferably absent, or COO(CH<sub>2</sub>)<sub>p38</sub>, OCO(CH<sub>2</sub>)<sub>p38</sub> or CONCH<sub>3</sub>(CH<sub>2</sub>)<sub>p38</sub>, further preferably absent, or CONCH<sub>3</sub>(CH<sub>2</sub>)<sub>p38</sub>.</div>
    </li> <li> <para-num num="[0223]"> </para-num> <div id="p-0308" num="0223" class="description-line">L<sup>14 </sup>and L<sup>15 </sup>are the same or different and are each absent, or Z<sup>26</sup>(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or Z<sup>27</sup>(CY<sup>93</sup>Y<sup>94</sup>)<sub>p42</sub>Z<sup>28</sup>(CY<sup>95</sup>Y<sup>96</sup>)<sub>p43</sub>, preferably absent, or Z<sup>26</sup>(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>. Y<sup>91 </sup>to Y<sup>96 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom. Z<sup>26 </sup>to Z<sup>28 </sup>are the same or different and are each O, NY<sup>97A</sup>, COO, OCO, CONY<sup>97B</sup>, NY<sup>97C</sup>CO, NY<sup>97D</sup>COO or CO, preferably COO, OCO, CONY<sup>97B</sup>, NY<sup>97C</sup>CO, or CO. Y<sup>97A </sup>to Y<sup>97D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl, preferably a hydrogen atom or methyl, p<sup>41 </sup>is an integer from 0 to 5, preferably 0 to 2. p<sup>42 </sup>is an integer from 1 to 5, preferably 1 or 2. p<sup>43 </sup>is an integer from 0 to 5, preferably 0 to 2.</div>
    </li> <li> <para-num num="[0224]"> </para-num> <div id="p-0309" num="0224" class="description-line">L<sup>14 </sup>and L<sup>15 </sup>are preferably the same or different and are each absent, or COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, CONY<sup>97B</sup>(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, NY<sup>97C</sup>CO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or CO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, more preferably are the same or different and are each absent, or COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or CO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, further preferably are the same or different and are each absent, or COO(CH<sub>2</sub>)<sub>p41</sub>, OCO(CH<sub>2</sub>)<sub>p41</sub> or CO.</div>
    </li> <li> <para-num num="[0225]"> </para-num> <div id="p-0310" num="0225" class="description-line">In formula (IV), more preferably, L<sup>13 </sup>is COO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, OCO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub> or CONY<sup>90B</sup>(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>; one of L<sup>14 </sup>and L<sup>15 </sup>is COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>; L<sup>13 </sup>is COO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, OCO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub> or CONY<sup>89B</sup>(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, and one of L<sup>14 </sup>and L<sup>15 </sup>is COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>; L<sup>14 </sup>and L<sup>15 </sup>are the same or different and are each COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>; or L<sup>13 </sup>is COO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, OCO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub> or CONY<sup>89B</sup>(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, and L<sup>14 </sup>and L<sup>15 </sup>are the same or different and are each COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>; and each of R<sup>10 </sup>to R<sup>12 </sup>is linear or branched C15-C20 alkenyl or C9-C18 alkyl. R<sup>11 </sup>and R<sup>12 </sup>are preferably the same.</div>
    </li> <li> <para-num num="[0226]"> </para-num> <div id="p-0311" num="0226" class="description-line">When L<sup>13 </sup>is absent, or O(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, NY<sup>90A</sup>(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, OCO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, NY<sup>90C</sup>CO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub> or NY<sup>90D</sup>COO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, R<sup>10 </sup>is preferably octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl or 3,7,11,15-tetramethylhexadec-2-enyl, more preferably dodecyl, tetradecyl, hexadecyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0227]"> </para-num> <div id="p-0312" num="0227" class="description-line">When L<sup>13 </sup>is COO(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub> or CONY<sup>90B</sup>(CY<sup>84</sup>Y<sup>85</sup>)<sub>p38</sub>, R<sup>10 </sup>is more preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (Z)-nonadec-10-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl or 2,6,10,14-tetramethylpentadec-1-enyl, further preferably undecyl, tridecyl, pentadecyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl or (8Z,11Z)-heptadeca-8,11-dienyl.</div>
    </li> <li> <para-num num="[0228]"> </para-num> <div id="p-0313" num="0228" class="description-line">When at least one of L<sup>14 </sup>and L<sup>15 </sup>is absent, or O(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, NY<sup>97A</sup>(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, NY<sup>97C</sup>CO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or NY<sup>97D</sup>COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, R<sup>11 </sup>and R<sup>12 </sup>bonded to J<sup>3</sup>, O(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, NY<sup>97A</sup>(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, NY<sup>97C</sup>CO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or NY<sup>97D</sup>COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> are the same or different and are each more preferably octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl or 3,7,11,15-tetramethylhexadec-2-enyl, further preferably dodecyl, tetradecyl, hexadecyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0229]"> </para-num> <div id="p-0314" num="0229" class="description-line">When at least one of L<sup>14 </sup>and L<sup>15 </sup>is COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or CONY<sup>97B </sup>(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>, R<sup>11 </sup>and R<sup>12 </sup>bonded to COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or CONY<sup>97B </sup>(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> are the same or different and are each more preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (Z)-nonadec-10-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl or 2,6,10,14-tetramethylpentadec-1-enyl, further preferably undecyl, tridecyl, pentadecyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl or (8Z,11Z)-heptadeca-8,11-dienyl.</div>
    </li> <li> <para-num num="[0230]"> </para-num> <div id="p-0315" num="0230" class="description-line">L<sup>16 </sup>is absent, or (CY<sup>98</sup>Y<sup>99</sup>)<sub>p44</sub>, (CY<sup>100</sup>Y<sup>101</sup>)<sub>p45</sub>Z<sup>29</sup>(CY<sup>102</sup>Y<sup>103</sup>)<sub>p46</sub> or (CY<sup>104</sup>Y<sup>105</sup>)<sub>p47</sub>Z<sup>30</sup>(CY<sup>106</sup>Y<sup>107</sup>)<sub>p48</sub>Z<sup>31</sup>(CY<sup>108</sup>Y<sup>109</sup>)<sub>p49</sub>, preferably absent, or (CY<sup>98</sup>Y<sup>99</sup>)<sub>p44</sub> or (CY<sup>100</sup>Y<sup>101</sup>)<sub>p45</sub>Z<sup>29</sup>(CY<sup>102</sup>Y<sup>103</sup>)<sub>p46</sub>, more preferably absent, or (CY<sup>98</sup>Y<sup>99</sup>)<sub>p44</sub>, (CY<sup>100</sup>Y<sup>101</sup>)<sub>p45</sub>OCO(CY<sup>102</sup>Y<sup>103</sup>)<sub>p46</sub>, (CY<sup>100</sup>Y<sup>101</sup>)<sub>p45</sub>NY<sup>109C</sup>CO(CY<sup>102</sup>Y<sup>103</sup>)<sub>p46</sub> or CO(CY<sup>102</sup>Y<sup>103</sup>)<sub>p46</sub>, further preferably absent, or (CH<sub>2</sub>)<sub>p44</sub> or CO(CH<sub>2</sub>)<sub>p46</sub>.</div>
    </li> <li> <para-num num="[0231]"> </para-num> <div id="p-0316" num="0231" class="description-line">J<sup>3 </sup>is CY<sup>111 </sup>or N, preferably CH or N. When J<sup>3 </sup>is N, more preferably, L<sup>14 </sup>is absent; L<sup>15 </sup>is CO; and L<sup>16 </sup>is absent, or (CY<sup>98</sup>Y<sup>99</sup>)<sub>p44</sub>, or L<sup>14 </sup>is absent; L<sup>15 </sup>is absent; and L<sup>16 </sup>is CO(CY<sup>102</sup>Y<sup>103</sup>)<sub>p46</sub>.</div>
    </li> <li> <para-num num="[0232]"> </para-num> <div id="p-0317" num="0232" class="description-line">X<sup>14 </sup>and X<sup>15 </sup>are as defined above in X<sup>2 </sup>and X<sup>3</sup>, respectively.</div>
    </li> <li> <para-num num="[0233]"> </para-num> <div id="p-0318" num="0233" class="description-line">In formula (V), R<sup>13 </sup>is preferably linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably linear C15-C20 alkenyl or linear C9-C18 alkyl. R<sup>14 </sup>and R<sup>15 </sup>are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C15-C20 alkenyl or linear or branched C9-C18 alkyl, most preferably the same linear C15-C20 alkenyl or linear C9-C18 alkyl.</div>
    </li> <li> <para-num num="[0234]"> </para-num> <div id="p-0319" num="0234" class="description-line">L<sup>17 </sup>to L<sup>19 </sup>are the same or different and are each absent, or Z<sup>32</sup>(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub> or Z<sup>33</sup>(CY<sup>118</sup>Y<sup>119</sup>)<sub>p52</sub>Z<sup>34</sup>(CY<sup>120</sup>Y<sup>121</sup>)<sub>p53</sub>, preferably Z<sup>32</sup>(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, more preferably O(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub> or COO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, further preferably O or COO.</div>
    </li> <li> <para-num num="[0235]"> </para-num> <div id="p-0320" num="0235" class="description-line">In formula (V), preferably, L<sup>17 </sup>to L<sup>19 </sup>are the same or different and are each O or COO, and each of R<sup>13 </sup>to R<sup>15 </sup>is linear C15-C20 alkenyl or C9-C18 alkyl. In this case, preferably, L<sup>17 </sup>to L<sup>19 </sup>are the same and O or COO, and R<sup>13 </sup>to R<sup>15 </sup>are the same and linear C15-C20 alkenyl or C9-C18 alkyl.</div>
    </li> <li> <para-num num="[0236]"> </para-num> <div id="p-0321" num="0236" class="description-line">When at least one of L<sup>17 </sup>to L<sup>19 </sup>is absent, or O(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, OCO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, NY<sup>122C</sup>CO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub> or NY<sup>122D</sup>COO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, R<sup>13 </sup>to R<sup>15 </sup>bonded to carbon adjacent to the furanose ring or L<sup>20</sup>, O(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, OCO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, NY<sup>122C</sup>CO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub> or NY<sup>122D</sup>COO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub> are the same or different and are each preferably octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 3,7,11,15-tetramethylhexadec-2-enyl or the like, more preferably dodecyl, tetradecyl, hexadecyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl or the like.</div>
    </li> <li> <para-num num="[0237]"> </para-num> <div id="p-0322" num="0237" class="description-line">When at least one of L<sup>17 </sup>to L<sup>19 </sup>is COO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, CONY<sup>122B</sup>(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub> or CO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, R<sup>13 </sup>to R<sup>15 </sup>bonded to COO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub>, CONY<sup>122B</sup>(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub> or CO(CY<sup>116</sup>Y<sup>117</sup>)<sub>p51</sub> are the same or different and are each preferably nonyl, undecyl, tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (Z)-nonadec-10-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl or 2,6,10,14-tetramethylpentadec-1-enyl, more preferably undecyl, tridecyl, pentadecyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (8Z,11Z)-heptadeca-8,11-dienyl or the like.</div>
    </li> <li> <para-num num="[0238]"> </para-num> <div id="p-0323" num="0238" class="description-line">L<sup>20 </sup>is absent, or (CY<sup>123</sup>Y<sup>124</sup>)<sub>p54</sub>, (CY<sup>125</sup>Y<sup>126</sup>)<sub>p55</sub>Z<sup>35</sup>(CY<sup>127</sup>Y<sup>128</sup>)<sub>p56</sub> or (CY<sup>129</sup>Y<sup>130</sup>)<sub>p57</sub>Z<sup>36</sup>(CY<sup>131</sup>Y<sup>132</sup>)<sub>p58</sub>Z<sup>37</sup>(CY<sup>133</sup>Y<sup>134</sup>)<sub>p59</sub>, preferably (CY<sup>123</sup>Y<sup>124</sup>)<sub>p54</sub>, more preferably (CH<sub>2</sub>)<sub>p54</sub>, further preferably CH<sub>2</sub>.</div>
    </li> <li> <para-num num="[0239]"> </para-num> <div id="p-0324" num="0239" class="description-line">L<sup>21 </sup>is absent, or (CY<sup>136</sup>Y<sup>137</sup>)<sub>p60</sub>, (CY<sup>138</sup>Y<sup>139</sup>)<sub>p61</sub>Z<sup>38</sup>(CY<sup>140</sup>Y<sup>141</sup>)<sub>p62</sub> or (CY<sup>142</sup>Y<sup>143</sup>)<sub>p63</sub>Z<sup>39</sup>(CY<sup>144</sup>Y<sup>145</sup>)<sub>p64</sub>Z<sup>40</sup>(CY<sup>146</sup>Y<sup>147</sup>)<sub>p65</sub>, preferably absent or (CY<sup>136</sup>Y<sup>137</sup>)<sub>p60</sub>, more preferably absent or (CH<sub>2</sub>)<sub>p60</sub>, further preferably absent.</div>
    </li> <li> <para-num num="[0240]"> </para-num> <div id="p-0325" num="0240" class="description-line">B<sup>3 </sup>is preferably</div>
    </li> <li> <div id="p-0326" num="0000" class="description-line">
      <chemistry id="CHEM-US-00038" num="00038">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e5/37/57/98835772acb162/US20200368173A1-20201126-C00038.png"><img id="EMI-C00038" he="13.89mm" wi="19.22mm" file="US20200368173A1-20201126-C00038.TIF" alt="Figure US20200368173A1-20201126-C00038" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="77" height="56" alt="Figure US20200368173A1-20201126-C00038" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e5/37/57/98835772acb162/US20200368173A1-20201126-C00038.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00038" attachment-type="cdx" file="US20200368173A1-20201126-C00038.CDX"> </attachment>
          <attachment idref="CHEM-US-00038" attachment-type="mol" file="US20200368173A1-20201126-C00038.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0327" num="0000" class="description-line">more preferably N<sup>+</sup>(CH<sub>3</sub>)<sub>3</sub>.</div>
    </li> <li> <para-num num="[0241]"> </para-num> <div id="p-0328" num="0241" class="description-line">Y<sup>112 </sup>and Y<sup>113 </sup>are the same or different and are each a hydrogen atom, hydroxy or optionally substituted C1-C4 alkyl, preferably are the same or different and are each a hydrogen atom or hydroxy, more preferably are the same and a hydrogen atom.</div>
    </li> <li> <para-num num="[0242]"> </para-num> <div id="p-0329" num="0242" class="description-line">In formula (V), R<sup>16 </sup>to R<sup>18</sup>, L<sup>22 </sup>to L<sup>26</sup>, B<sup>4</sup>, Y<sup>114 </sup>to Y<sup>115 </sup>and A<sup>6 </sup>are as defined in R<sup>13 </sup>to R<sup>15</sup>, L<sup>17 </sup>to L<sup>21</sup>, B<sup>3</sup>, Y<sup>112 </sup>to Y<sup>113 </sup>and A<sup>5</sup>, respectively.</div>
    </li> <li> <para-num num="[0243]"> </para-num> <div id="p-0330" num="0243" class="description-line">In formula (V), when Y<sup>112 </sup>is a hydrogen atom, four substituents on the pyran ring are preferably added on different carbon atoms, respectively, on the pyran ring. Formula (V) is more preferably</div>
    </li> <li> <div id="p-0331" num="0000" class="description-line">
      <chemistry id="CHEM-US-00039" num="00039">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/90/8d/28/5e4b5a370ae596/US20200368173A1-20201126-C00039.png"><img id="EMI-C00039" he="27.69mm" wi="35.05mm" file="US20200368173A1-20201126-C00039.TIF" alt="Figure US20200368173A1-20201126-C00039" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="140" height="111" alt="Figure US20200368173A1-20201126-C00039" class="patent-full-image" src="https://patentimages.storage.googleapis.com/90/8d/28/5e4b5a370ae596/US20200368173A1-20201126-C00039.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00039" attachment-type="cdx" file="US20200368173A1-20201126-C00039.CDX"> </attachment>
          <attachment idref="CHEM-US-00039" attachment-type="mol" file="US20200368173A1-20201126-C00039.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0332" num="0000" class="description-line">In this case, further preferably, L<sup>17 </sup>to L<sup>19 </sup>are the same or different and are each O or COO, and each of R<sup>13 </sup>to R<sup>15 </sup>is linear C15-C20 alkenyl or C9-C18 alkyl. Most preferably, L<sup>17 </sup>to L<sup>19 </sup>are the same or different and are each O or COO; each of R<sup>13 </sup>to R<sup>15 </sup>is linear C15-C20 alkenyl or C9-C18 alkyl; L<sup>17 </sup>and L<sup>21 </sup>are absent; and Y<sup>113 </sup>is a hydrogen atom or hydroxy.</div>
    </li> <li> <para-num num="[0244]"> </para-num> <div id="p-0333" num="0244" class="description-line">In formula (V), four substituents on the furan ring are preferably added on different carbon atoms, respectively, on the furan ring. Formula (V) is more preferably</div>
    </li> <li> <div id="p-0334" num="0000" class="description-line">
      <chemistry id="CHEM-US-00040" num="00040">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/94/8c/67/a8ddf7a883cc33/US20200368173A1-20201126-C00040.png"><img id="EMI-C00040" he="26.50mm" wi="40.30mm" file="US20200368173A1-20201126-C00040.TIF" alt="Figure US20200368173A1-20201126-C00040" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="161" height="106" alt="Figure US20200368173A1-20201126-C00040" class="patent-full-image" src="https://patentimages.storage.googleapis.com/94/8c/67/a8ddf7a883cc33/US20200368173A1-20201126-C00040.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00040" attachment-type="cdx" file="US20200368173A1-20201126-C00040.CDX"> </attachment>
          <attachment idref="CHEM-US-00040" attachment-type="mol" file="US20200368173A1-20201126-C00040.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0245]"> </para-num> <div id="p-0335" num="0245" class="description-line">In this case, further preferably, L<sup>22 </sup>to L<sup>24 </sup>are the same or different and are each O or COO, and each of R<sup>16 </sup>to R<sup>18 </sup>is linear C15-C20 alkenyl or C9-C18 alkyl. Most preferably, L<sup>22 </sup>to L<sup>24 </sup>are the same or different and are each O or COO; each of R<sup>16 </sup>to R<sup>18 </sup>is linear C15-C20 alkenyl or C9-C18 alkyl; L<sup>22 </sup>and L<sup>26 </sup>are absent; and Y<sup>114 </sup>is a hydrogen atom or hydroxy.</div>
    </li> <li> <para-num num="[0246]"> </para-num> <div id="p-0336" num="0246" class="description-line">When p<sup>13</sup>, p<sup>33 </sup>and p<sup>66 </sup>are 0 in the definition of each of the formulas:</div>
    </li> <li> <div id="p-0337" num="0000" class="description-line">
      <chemistry id="CHEM-US-00041" num="00041">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/a3/d6/7f9965d436a4a6/US20200368173A1-20201126-C00041.png"><img id="EMI-C00041" he="53.26mm" wi="72.39mm" file="US20200368173A1-20201126-C00041.TIF" alt="Figure US20200368173A1-20201126-C00041" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="290" height="213" alt="Figure US20200368173A1-20201126-C00041" class="patent-full-image" src="https://patentimages.storage.googleapis.com/88/a3/d6/7f9965d436a4a6/US20200368173A1-20201126-C00041.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00041" attachment-type="cdx" file="US20200368173A1-20201126-C00041.CDX"> </attachment>
          <attachment idref="CHEM-US-00041" attachment-type="mol" file="US20200368173A1-20201126-C00041.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0338" num="0000" class="description-line">in the definition of formulas B<sup>1</sup>, B<sup>2</sup>, B<sup>3 </sup>and B<sup>4</sup>, N<sup>+</sup> is bonded to carbon adjacent to each of Z<sup>10</sup>, Z<sup>21 </sup>and Z<sup>41</sup>.</div>
    </li> <li> <para-num num="[0247]"> </para-num> <div id="p-0339" num="0247" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention preferably comprises a lipid represented by formula (II) as lipid A.</div>
    </li> <li> <para-num num="[0248]"> </para-num> <div id="p-0340" num="0248" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention may comprise a cationic lipid other than the lipid having a hydrophilic unit having one quaternary ammonium group and optionally substituted three independent hydrocarbon groups (lipid A). The cationic lipid other than lipid A used in the present invention is not particularly limited as long as the cationic lipid is an amphipathic molecule having a lipophilic region containing one or more optionally substituted hydrocarbon groups, and a cationic hydrophilic region containing at least one primary amino group, secondary amino group, tertiary amino group and/or quaternary ammonium group (except for lipid A). The cationic lipid other than lipid A is preferably a lipid having a hydrophilic unit having optionally substituted one amino group or one quaternary ammonium group and a hydrophobic unit having optionally substituted two independent hydrocarbon groups (lipid B).</div>
    </li> <li> <para-num num="[0249]"> </para-num> <div id="p-0341" num="0249" class="description-line">In the present invention, the lipid having, in the same molecule, a hydrophilic unit having optionally substituted one amino group or one quaternary ammonium group and a hydrophobic unit having optionally substituted two independent hydrocarbon groups (lipid B) is not particularly limited as long as the lipid is a molecule intramolecularly having optionally substituted one amino group or one quaternary ammonium group as a hydrophilic unit, and having optionally substituted two independent hydrocarbon groups. Lipid B is represented by, for example, any of structural formulas (D) and (E) given below.</div>
    </li> <li> <para-num num="[0250]"> </para-num> <div id="p-0342" num="0250" class="description-line">In structural formulas (D) and (E) given below, the hydrophilic unit represents a hydrophilic unit having optionally substituted one amino group or one quaternary ammonium group, and the hydrophobic unit represents an optionally substituted independent hydrocarbon group.</div>
    </li> <li> <para-num num="[0251]"> </para-num> <div id="p-0343" num="0251" class="description-line">Zero to two out of the three bonds of the amino group constituting the hydrophilic unit are attached to any 0 to 2 of the hydrocarbon groups constituting the hydrophobic unit, and the remaining bond(s) is attached to hydrogen or an optionally substituted chain and/or cyclic hydrocarbon group, etc.</div>
    </li> <li> <para-num num="[0252]"> </para-num> <div id="p-0344" num="0252" class="description-line">Zero to two out of the four bonds of the quaternary ammonium group constituting the hydrophilic unit are attached to any 0 to 2 of the hydrocarbon groups constituting the hydrophobic unit, and the remaining bonds are attached to hydrogen or an optionally substituted chain and/or cyclic hydrocarbon group, etc.</div>
    </li> <li> <para-num num="[0253]"> </para-num> <div id="p-0345" num="0253" class="description-line">The optionally substituted chain and/or cyclic hydrocarbon group constituting the hydrophilic unit can be any group composed of carbon and hydrogen atoms and is preferably a group having 1 to 10 carbon atoms, more preferably a group having 1 to 6 carbon atoms, further preferably a group having 1 to 3 carbon atoms.</div>
    </li> <li> <para-num num="[0254]"> </para-num> <div id="p-0346" num="0254" class="description-line">The hydrophilic unit may have one or more ethers, esters, amides or the like via a carbon atom in the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting this hydrophilic unit. Examples of the substituent for the optionally substituted chain and/or cyclic hydrocarbon group, etc. include carbamate, amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro, and bromo.</div>
    </li> <li> <para-num num="[0255]"> </para-num> <div id="p-0347" num="0255" class="description-line">The hydrocarbon group constituting the hydrophobic unit can be any group consisting of 8 to 24 carbon atoms and hydrogen atoms. Hydrocarbon groups can be classified from the viewpoint of topology. Examples thereof include linear hydrocarbon groups, branched hydrocarbon groups and cyclic hydrocarbon groups (e.g., a cholesteryl group). A linear or branched hydrocarbon group is preferred. Also, hydrocarbon groups can be classified on the basis of the presence or absence of an unsaturated bond (double bond or triple bond). Hydrocarbon groups having an unsaturated bond can also be classified on the basis of the presence or absence of aromaticity. The hydrocarbon group is preferably a hydrocarbon group having only a saturated bond (alkyl) or a hydrocarbon group having an unsaturated bond and lacking aromaticity (e.g., alkenyl or alkynyl). The hydrocarbon group in lipid A is preferably linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl.</div>
    </li> <li> <para-num num="[0256]"> </para-num> <div id="p-0348" num="0256" class="description-line">Each hydrocarbon group constituting the hydrophobic unit may be bonded directly to the amino group or the quaternary ammonium group of the hydrophilic unit, or may be bonded to the amino group or the quaternary ammonium group via an ether, ester or amide bond, etc. and the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting the hydrophilic unit. As shown in structural formula (E), the hydrocarbon groups constituting two hydrophobic units may be bonded via a carbon atom, and this carbon atom may be bonded either directly to the amino group or the quaternary ammonium group of the hydrophilic unit or to the amino group or the quaternary ammonium group via an ether, ester or amide bond, etc. and the optionally substituted chain and/or cyclic hydrocarbon group, etc. constituting the hydrophilic unit.</div>
    </li> <li> <div id="p-0349" num="0000" class="description-line">
      <chemistry id="CHEM-US-00042" num="00042">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8c/75/cd/1fd17b19e591cf/US20200368173A1-20201126-C00042.png"><img id="EMI-C00042" he="54.36mm" wi="68.41mm" file="US20200368173A1-20201126-C00042.TIF" alt="Figure US20200368173A1-20201126-C00042" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="274" height="217" alt="Figure US20200368173A1-20201126-C00042" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8c/75/cd/1fd17b19e591cf/US20200368173A1-20201126-C00042.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00042" attachment-type="cdx" file="US20200368173A1-20201126-C00042.CDX"> </attachment>
          <attachment idref="CHEM-US-00042" attachment-type="mol" file="US20200368173A1-20201126-C00042.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0257]"> </para-num> <div id="p-0350" num="0257" class="description-line">The cationic lipid in the nucleic acid-containing lipid nanoparticle of the present invention may be lipid A alone or lipid B alone and preferably comprises both lipid A and lipid B.</div>
    </li> <li> <para-num num="[0258]"> </para-num> <div id="p-0351" num="0258" class="description-line">Examples of the cationic lipid other than lipid A used in the present invention include cationic lipids described in WO 2013/089151, WO 2011/136368, WO 2014/007398, WO 2010/042877 and WO 2010/054401.</div>
    </li> <li> <para-num num="[0259]"> </para-num> <div id="p-0352" num="0259" class="description-line">Examples of lipid B used in the present invention can include lipids represented by the following formulas (CL-I) to (CL-XIX):</div>
    </li> <li> <div id="p-0353" num="0000" class="description-line">formula (CL-I)</div>
    </li> <li> <div id="p-0354" num="0000" class="description-line">
      <chemistry id="CHEM-US-00043" num="00043">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/45/a5/ebb0e65aae71b2/US20200368173A1-20201126-C00043.png"><img id="EMI-C00043" he="22.44mm" wi="57.74mm" file="US20200368173A1-20201126-C00043.TIF" alt="Figure US20200368173A1-20201126-C00043" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="231" height="90" alt="Figure US20200368173A1-20201126-C00043" class="patent-full-image" src="https://patentimages.storage.googleapis.com/97/45/a5/ebb0e65aae71b2/US20200368173A1-20201126-C00043.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00043" attachment-type="cdx" file="US20200368173A1-20201126-C00043.CDX"> </attachment>
          <attachment idref="CHEM-US-00043" attachment-type="mol" file="US20200368173A1-20201126-C00043.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0355" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0260]"> </para-num> <div id="p-0356" num="0260" class="description-line">R<sup>101 </sup>and R<sup>102 </sup>are the same or different and are each linear or branched C10-C24 alkyl, C10-C24 alkenyl or C10-C24 alkynyl;</div>
    </li> <li> <para-num num="[0261]"> </para-num> <div id="p-0357" num="0261" class="description-line">L<sup>101 </sup>and L<sup>102 </sup>are each a hydrogen atom, or together form a single bond or C1-C3 alkylene;</div>
    </li> <li> <para-num num="[0262]"> </para-num> <div id="p-0358" num="0262" class="description-line">L<sup>103 </sup>is a single bond, CO or COO;</div>
    </li> <li> <para-num num="[0263]"> </para-num> <div id="p-0359" num="0263" class="description-line">when L<sup>103 </sup>is a single bond,
</div> </li> <ul> <li id="ul0003-0001" num="0000"> <ul> <li id="ul0004-0001" num="0264">X<sup>101 </sup>is a hydrogen atom, C1-C6 alkyl, C3-C6 alkenyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl; and</li> </ul> </li> </ul>

    <li> <para-num num="[0265]"> </para-num> <div id="p-0360" num="0265" class="description-line">when L<sup>103 </sup>is CO or COO,
</div> </li> <ul> <li id="ul0005-0001" num="0000"> <ul> <li id="ul0006-0001" num="0266">X<sup>101 </sup>is pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, and at least one of the substituents is amino, monoalkylamino, dialkylamino, trialkylammonio, pyrrolidinyl, piperidyl or morpholinyl,
<br/>
formula (CL-II)
</li> </ul> </li> </ul>

    <li> <div id="p-0361" num="0000" class="description-line">
      <chemistry id="CHEM-US-00044" num="00044">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/95/36/b5/222a3eddeccf1e/US20200368173A1-20201126-C00044.png"><img id="EMI-C00044" he="25.15mm" wi="64.52mm" file="US20200368173A1-20201126-C00044.TIF" alt="Figure US20200368173A1-20201126-C00044" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="258" height="101" alt="Figure US20200368173A1-20201126-C00044" class="patent-full-image" src="https://patentimages.storage.googleapis.com/95/36/b5/222a3eddeccf1e/US20200368173A1-20201126-C00044.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00044" attachment-type="cdx" file="US20200368173A1-20201126-C00044.CDX"> </attachment>
          <attachment idref="CHEM-US-00044" attachment-type="mol" file="US20200368173A1-20201126-C00044.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0362" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0267]"> </para-num> <div id="p-0363" num="0267" class="description-line">R<sup>103 </sup>and R<sup>104 </sup>are the same or different and are each linear or branched C12-C24 alkyl, C12-C24 alkenyl or C12-C24 alkynyl;</div>
    </li> <li> <para-num num="[0268]"> </para-num> <div id="p-0364" num="0268" class="description-line">p<sup>101 </sup>and p<sup>102 </sup>are the same or different and are each an integer from 0 to 3;</div>
    </li> <li> <para-num num="[0269]"> </para-num> <div id="p-0365" num="0269" class="description-line">L<sup>106 </sup>and L<sup>107 </sup>are each a hydrogen atom, or together form a single bond or C2-C8 alkylene;</div>
    </li> <li> <para-num num="[0270]"> </para-num> <div id="p-0366" num="0270" class="description-line">L<sup>104 </sup>and L<sup>105 </sup>are the same or different and are each O, COO or OCO;</div>
    </li> <li> <para-num num="[0271]"> </para-num> <div id="p-0367" num="0271" class="description-line">L<sup>108 </sup>is a single bond, CO or COO;</div>
    </li> <li> <para-num num="[0272]"> </para-num> <div id="p-0368" num="0272" class="description-line">when L<sup>108 </sup>is a single bond,
</div> </li> <ul> <li id="ul0007-0001" num="0000"> <ul> <li id="ul0008-0001" num="0273">X<sup>102 </sup>is a hydrogen atom, C1-C6 alkyl, C3-C6 alkenyl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl; and</li> </ul> </li> </ul>

    <li> <para-num num="[0274]"> </para-num> <div id="p-0369" num="0274" class="description-line">when L<sup>108 </sup>is CO or COO,
</div> </li> <ul> <li id="ul0009-0001" num="0000"> <ul> <li id="ul0010-0001" num="0275">X<sup>102 </sup>is pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, and at least one of the substituents is amino, monoalkylamino, dialkylamino, trialkylammonio, pyrrolidinyl, piperidyl or morpholinyl,
<br/>
formula (CL-III)
</li> </ul> </li> </ul>

    <li> <div id="p-0370" num="0000" class="description-line">
      <chemistry id="CHEM-US-00045" num="00045">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/df/52/04/45c3382bf348b2/US20200368173A1-20201126-C00045.png"><img id="EMI-C00045" he="18.71mm" wi="64.60mm" file="US20200368173A1-20201126-C00045.TIF" alt="Figure US20200368173A1-20201126-C00045" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="258" height="75" alt="Figure US20200368173A1-20201126-C00045" class="patent-full-image" src="https://patentimages.storage.googleapis.com/df/52/04/45c3382bf348b2/US20200368173A1-20201126-C00045.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00045" attachment-type="cdx" file="US20200368173A1-20201126-C00045.CDX"> </attachment>
          <attachment idref="CHEM-US-00045" attachment-type="mol" file="US20200368173A1-20201126-C00045.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0371" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0276]"> </para-num> <div id="p-0372" num="0276" class="description-line">R<sup>105 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl; R<sup>106 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl or C8-C24 alkynyloxypropyl;</div>
    </li> <li> <para-num num="[0277]"> </para-num> <div id="p-0373" num="0277" class="description-line">X<sup>103 </sup>and X<sup>104 </sup>are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene, or X<sup>103 </sup>forms C2-C8 alkylene together with L<sup>111</sup>;</div>
    </li> <li> <para-num num="[0278]"> </para-num> <div id="p-0374" num="0278" class="description-line">L<sup>111 </sup>is a hydrogen atom, C1-C6 alkyl, C3-C6 alkenyl, amino, monoalkylamino, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl, or forms C2-C8 alkylene together with X<sup>103</sup>;</div>
    </li> <li> <para-num num="[0279]"> </para-num> <div id="p-0375" num="0279" class="description-line">L<sup>109 </sup>is C1-C6 alkylene;</div>
    </li> <li> <para-num num="[0280]"> </para-num> <div id="p-0376" num="0280" class="description-line">L<sup>110 </sup>is a single bond, or C1-C6 alkylene, provided that the sum of the numbers of carbon atoms of L<sup>109 </sup>and L<sup>110 </sup>is 7 or less; when L<sup>111 </sup>is a hydrogen atom, L<sup>110 </sup>is a single bond; and when L<sup>111 </sup>forms C2-C6 alkylene together with X<sup>103</sup>, L<sup>110 </sup>is a single bond, or methylene or ethylene,</div>
    </li> <li> <div id="p-0377" num="0000" class="description-line">formula (CL-IV)</div>
    </li> <li> <div id="p-0378" num="0000" class="description-line">
      <chemistry id="CHEM-US-00046" num="00046">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ec/5a/87/cd8f7b6822628d/US20200368173A1-20201126-C00046.png"><img id="EMI-C00046" he="11.43mm" wi="50.97mm" file="US20200368173A1-20201126-C00046.TIF" alt="Figure US20200368173A1-20201126-C00046" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="204" height="46" alt="Figure US20200368173A1-20201126-C00046" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ec/5a/87/cd8f7b6822628d/US20200368173A1-20201126-C00046.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00046" attachment-type="cdx" file="US20200368173A1-20201126-C00046.CDX"> </attachment>
          <attachment idref="CHEM-US-00046" attachment-type="mol" file="US20200368173A1-20201126-C00046.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0379" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0281]"> </para-num> <div id="p-0380" num="0281" class="description-line">R<sup>107 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0282]"> </para-num> <div id="p-0381" num="0282" class="description-line">R<sup>108 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl, C8-C24 alkynyloxypropyl, C8-C24 alkyloxyethoxyethyl, C8-C24 alkenyloxyethoxyethyl or C8-C24 alkynyloxyethoxyethyl;</div>
    </li> <li> <para-num num="[0283]"> </para-num> <div id="p-0382" num="0283" class="description-line">X<sup>105 </sup>is a hydrogen atom, optionally substituted C1-C4 alkyl or CO(CH<sub>2</sub>)<sub>n</sub>NY1Y2;</div>
    </li> <li> <para-num num="[0284]"> </para-num> <div id="p-0383" num="0284" class="description-line">n represents an integer from 1 to 4; and</div>
    </li> <li> <para-num num="[0285]"> </para-num> <div id="p-0384" num="0285" class="description-line">Y1 and Y2 are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene,</div>
    </li> <li> <div id="p-0385" num="0000" class="description-line">formula (CL-V)</div>
    </li> <li> <div id="p-0386" num="0000" class="description-line">
      <chemistry id="CHEM-US-00047" num="00047">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a9/52/03/95115d4bcbb883/US20200368173A1-20201126-C00047.png"><img id="EMI-C00047" he="11.26mm" wi="58.59mm" file="US20200368173A1-20201126-C00047.TIF" alt="Figure US20200368173A1-20201126-C00047" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="234" height="45" alt="Figure US20200368173A1-20201126-C00047" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a9/52/03/95115d4bcbb883/US20200368173A1-20201126-C00047.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00047" attachment-type="cdx" file="US20200368173A1-20201126-C00047.CDX"> </attachment>
          <attachment idref="CHEM-US-00047" attachment-type="mol" file="US20200368173A1-20201126-C00047.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0387" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0286]"> </para-num> <div id="p-0388" num="0286" class="description-line">R<sup>109 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0287]"> </para-num> <div id="p-0389" num="0287" class="description-line">R<sup>110 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl or C8-C24 alkynyloxypropyl;</div>
    </li> <li> <para-num num="[0288]"> </para-num> <div id="p-0390" num="0288" class="description-line">L<sup>112 </sup>is C1-C3 alkylene; and</div>
    </li> <li> <para-num num="[0289]"> </para-num> <div id="p-0391" num="0289" class="description-line">X<sup>105</sup> is a hydrogen atom or C1-C3 alkyl,</div>
    </li> <li> <div id="p-0392" num="0000" class="description-line">formula (CL-VI)</div>
    </li> <li> <div id="p-0393" num="0000" class="description-line">
      <chemistry id="CHEM-US-00048" num="00048">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d1/6a/a8/7ed1c7f1c856db/US20200368173A1-20201126-C00048.png"><img id="EMI-C00048" he="20.57mm" wi="61.13mm" file="US20200368173A1-20201126-C00048.TIF" alt="Figure US20200368173A1-20201126-C00048" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="245" height="82" alt="Figure US20200368173A1-20201126-C00048" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d1/6a/a8/7ed1c7f1c856db/US20200368173A1-20201126-C00048.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00048" attachment-type="cdx" file="US20200368173A1-20201126-C00048.CDX"> </attachment>
          <attachment idref="CHEM-US-00048" attachment-type="mol" file="US20200368173A1-20201126-C00048.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0394" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0290]"> </para-num> <div id="p-0395" num="0290" class="description-line">R<sup>111 </sup>and R<sup>112 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0291]"> </para-num> <div id="p-0396" num="0291" class="description-line">X<sup>106 </sup>and X<sup>107 </sup>are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene;</div>
    </li> <li> <para-num num="[0292]"> </para-num> <div id="p-0397" num="0292" class="description-line">p<sup>103</sup>, p<sup>104 </sup>and p<sup>105 </sup>are the same or different and are each 0 or 1, provided that p<sup>103</sup>, p<sup>104 </sup>and p<sup>105 </sup>are not 0 at the same time; and</div>
    </li> <li> <para-num num="[0293]"> </para-num> <div id="p-0398" num="0293" class="description-line">L<sup>113 </sup>and L<sup>114 </sup>are the same or different and are each 0, S or NH,</div>
    </li> <li> <div id="p-0399" num="0000" class="description-line">formula (CL-VII)</div>
    </li> <li> <div id="p-0400" num="0000" class="description-line">
      <chemistry id="CHEM-US-00049" num="00049">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/70/dc/89/15ec5cfccb85d2/US20200368173A1-20201126-C00049.png"><img id="EMI-C00049" he="14.56mm" wi="60.20mm" file="US20200368173A1-20201126-C00049.TIF" alt="Figure US20200368173A1-20201126-C00049" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="241" height="58" alt="Figure US20200368173A1-20201126-C00049" class="patent-full-image" src="https://patentimages.storage.googleapis.com/70/dc/89/15ec5cfccb85d2/US20200368173A1-20201126-C00049.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00049" attachment-type="cdx" file="US20200368173A1-20201126-C00049.CDX"> </attachment>
          <attachment idref="CHEM-US-00049" attachment-type="mol" file="US20200368173A1-20201126-C00049.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0401" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0294]"> </para-num> <div id="p-0402" num="0294" class="description-line">R<sup>113 </sup>and R<sup>114 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0295]"> </para-num> <div id="p-0403" num="0295" class="description-line">R<sup>115 </sup>is a hydrogen atom, hydroxy, optionally substituted C1-C4 alkyl, C1-C4 alkoxy or C1-C4 acyloxy;</div>
    </li> <li> <para-num num="[0296]"> </para-num> <div id="p-0404" num="0296" class="description-line">X<sup>109 </sup>and X<sup>110 </sup>are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene;</div>
    </li> <li> <para-num num="[0297]"> </para-num> <div id="p-0405" num="0297" class="description-line">L<sup>115 </sup>is COO, OCO, NHCO or CONH;</div>
    </li> <li> <para-num num="[0298]"> </para-num> <div id="p-0406" num="0298" class="description-line">p<sup>106 </sup>is an integer from 0 to 3; and</div>
    </li> <li> <para-num num="[0299]"> </para-num> <div id="p-0407" num="0299" class="description-line">p<sup>107 </sup>is an integer from 1 to 4,</div>
    </li> <li> <div id="p-0408" num="0000" class="description-line">formula (CL-VIII)</div>
    </li> <li> <div id="p-0409" num="0000" class="description-line">
      <chemistry id="CHEM-US-00050" num="00050">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/73/b3/8f/27e8833f01fec3/US20200368173A1-20201126-C00050.png"><img id="EMI-C00050" he="24.47mm" wi="55.12mm" file="US20200368173A1-20201126-C00050.TIF" alt="Figure US20200368173A1-20201126-C00050" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="220" height="98" alt="Figure US20200368173A1-20201126-C00050" class="patent-full-image" src="https://patentimages.storage.googleapis.com/73/b3/8f/27e8833f01fec3/US20200368173A1-20201126-C00050.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00050" attachment-type="cdx" file="US20200368173A1-20201126-C00050.CDX"> </attachment>
          <attachment idref="CHEM-US-00050" attachment-type="mol" file="US20200368173A1-20201126-C00050.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0410" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0300]"> </para-num> <div id="p-0411" num="0300" class="description-line">R<sup>116 </sup>and R<sup>117 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C7-C20 alkyloxy C1-C3 alkyl, C7-C20 alkenyloxy C1-C3 alkyl or C7-C20 alkynyloxy C1-C3 alkyl, or</div>
    </li> <li> <para-num num="[0301]"> </para-num> <div id="p-0412" num="0301" class="description-line">the C8-C24 alkyl, the C8-C24 alkenyl or the C8-C24 alkynyl in which a biodegradable group is integrated, or the C8-C24 alkyl group, the C8-C24 alkenyl group or the C8-C24 alkynyl group in which a biodegradable group is present at the terminal;</div>
    </li> <li> <para-num num="[0302]"> </para-num> <div id="p-0413" num="0302" class="description-line">the biodegradable group thus integrated is C(O)O or OC(O), and the group having the biodegradable group present at the terminal is C(O)OC1-C4 alkyl or OC(O)C1-C4 alkyl;</div>
    </li> <li> <para-num num="[0303]"> </para-num> <div id="p-0414" num="0303" class="description-line">B<sup>100 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, C1-C3 dialkylamino C2-C4 alkyl, formula (A):</div>
    </li> <li> <div id="p-0415" num="0000" class="description-line">
      <chemistry id="CHEM-US-00051" num="00051">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5a/37/7a/20922c20f771a1/US20200368173A1-20201126-C00051.png"><img id="EMI-C00051" he="18.63mm" wi="54.36mm" file="US20200368173A1-20201126-C00051.TIF" alt="Figure US20200368173A1-20201126-C00051" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="217" height="75" alt="Figure US20200368173A1-20201126-C00051" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5a/37/7a/20922c20f771a1/US20200368173A1-20201126-C00051.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00051" attachment-type="cdx" file="US20200368173A1-20201126-C00051.CDX"> </attachment>
          <attachment idref="CHEM-US-00051" attachment-type="mol" file="US20200368173A1-20201126-C00051.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0416" num="0000" class="description-line">wherein X<sup>111 </sup>and X<sup>112 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>111 </sup>and X<sup>112 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>110 </sup>is an integer from 2 to 6,
<br/>
or formula (B):
</div>
    </li> <li> <div id="p-0417" num="0000" class="description-line">
      <chemistry id="CHEM-US-00052" num="00052">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/14/3d/e2/8022c2c17745b3/US20200368173A1-20201126-C00052.png"><img id="EMI-C00052" he="14.48mm" wi="51.56mm" file="US20200368173A1-20201126-C00052.TIF" alt="Figure US20200368173A1-20201126-C00052" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="206" height="58" alt="Figure US20200368173A1-20201126-C00052" class="patent-full-image" src="https://patentimages.storage.googleapis.com/14/3d/e2/8022c2c17745b3/US20200368173A1-20201126-C00052.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00052" attachment-type="cdx" file="US20200368173A1-20201126-C00052.CDX"> </attachment>
          <attachment idref="CHEM-US-00052" attachment-type="mol" file="US20200368173A1-20201126-C00052.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0418" num="0000" class="description-line">wherein X<sup>113 </sup>and X<sup>114 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>113 </sup>and X<sup>114 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>111 </sup>is an integer from 1 to 6;</div>
    </li> <li> <para-num num="[0304]"> </para-num> <div id="p-0419" num="0304" class="description-line">p<sup>108 </sup>is an integer from 0 to 4; p<sup>109 </sup>is an integer from 1 to 4, provided that when p<sup>108 </sup>is 0, p<sup>109 </sup>is not 1;</div>
    </li> <li> <para-num num="[0305]"> </para-num> <div id="p-0420" num="0305" class="description-line">L<sup>116 </sup>is the same or different on each carbon to which it is bonded and is a hydrogen atom or C1-C3 alkyl; and</div>
    </li> <li> <para-num num="[0306]"> </para-num> <div id="p-0421" num="0306" class="description-line">L<sup>117 </sup>is the same or different on each carbon to which it is bonded and is a hydrogen atom or C1-C3 alkyl,</div>
    </li> <li> <div id="p-0422" num="0000" class="description-line">formula (CL-IX)</div>
    </li> <li> <div id="p-0423" num="0000" class="description-line">
      <chemistry id="CHEM-US-00053" num="00053">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6d/ce/a0/ac2a60044ad3d4/US20200368173A1-20201126-C00053.png"><img id="EMI-C00053" he="20.74mm" wi="63.92mm" file="US20200368173A1-20201126-C00053.TIF" alt="Figure US20200368173A1-20201126-C00053" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="256" height="83" alt="Figure US20200368173A1-20201126-C00053" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6d/ce/a0/ac2a60044ad3d4/US20200368173A1-20201126-C00053.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00053" attachment-type="cdx" file="US20200368173A1-20201126-C00053.CDX"> </attachment>
          <attachment idref="CHEM-US-00053" attachment-type="mol" file="US20200368173A1-20201126-C00053.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0424" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0307]"> </para-num> <div id="p-0425" num="0307" class="description-line">X<sup>115 </sup>and X<sup>116 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl;</div>
    </li> <li> <para-num num="[0308]"> </para-num> <div id="p-0426" num="0308" class="description-line">L<sup>118 </sup>and L<sup>119 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkylene or C8-C24 alkenylene;</div>
    </li> <li> <para-num num="[0309]"> </para-num> <div id="p-0427" num="0309" class="description-line">M<sup>101 </sup>and M<sup>102 </sup>are the same or different and are each selected from the group consisting of CC, OC(O), C(O)O, SC(O), C(O)S, OC(S), C(S)O, SS, C(R)N, NC(R), C(R)NO, ONC(R), N(R)C(O), C(O)N(R), N(R)C(S), C(S)N(R), N(R)C(O)N(R), N(R)C(O)O, OC(O)N(R) and OC(O)O;</div>
    </li> <li> <para-num num="[0310]"> </para-num> <div id="p-0428" num="0310" class="description-line">R and R are the same or different and are each a hydrogen atom or C1-C3 alkyl; and</div>
    </li> <li> <para-num num="[0311]"> </para-num> <div id="p-0429" num="0311" class="description-line">R<sup>118 </sup>and R<sup>119 </sup>are the same or different and are each optionally substituted linear or branched C1-C16 alkyl or C2-C16 alkenyl,</div>
    </li> <li> <div id="p-0430" num="0000" class="description-line">formula (CL-X)</div>
    </li> <li> <div id="p-0431" num="0000" class="description-line">
      <chemistry id="CHEM-US-00054" num="00054">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c4/a3/7c/a20693905d0512/US20200368173A1-20201126-C00054.png"><img id="EMI-C00054" he="21.67mm" wi="57.23mm" file="US20200368173A1-20201126-C00054.TIF" alt="Figure US20200368173A1-20201126-C00054" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="229" height="87" alt="Figure US20200368173A1-20201126-C00054" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c4/a3/7c/a20693905d0512/US20200368173A1-20201126-C00054.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00054" attachment-type="cdx" file="US20200368173A1-20201126-C00054.CDX"> </attachment>
          <attachment idref="CHEM-US-00054" attachment-type="mol" file="US20200368173A1-20201126-C00054.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0432" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0312]"> </para-num> <div id="p-0433" num="0312" class="description-line">X<sup>117 </sup>and X<sup>118 </sup>are the same or different and are each a hydrogen atom, optionally substituted C1-C6 alkyl, heterocyclyl or polyamine, or X<sup>117 </sup>and X<sup>118 </sup>optionally form, together with the nitrogen to which they are bonded, a 4- to 7-membered monocyclic hetero ring optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen; and</div>
    </li> <li> <para-num num="[0313]"> </para-num> <div id="p-0434" num="0313" class="description-line">R<sup>120 </sup>and R<sup>121 </sup>are the same or different and are each optionally substituted linear or branched C4-C24 alkyl or C4-C24 alkenyl,</div>
    </li> <li> <div id="p-0435" num="0000" class="description-line">formula (CL-XI)</div>
    </li> <li> <div id="p-0436" num="0000" class="description-line">
      <chemistry id="CHEM-US-00055" num="00055">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f1/2c/b8/7b995d2c74854a/US20200368173A1-20201126-C00055.png"><img id="EMI-C00055" he="18.54mm" wi="68.24mm" file="US20200368173A1-20201126-C00055.TIF" alt="Figure US20200368173A1-20201126-C00055" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="273" height="74" alt="Figure US20200368173A1-20201126-C00055" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f1/2c/b8/7b995d2c74854a/US20200368173A1-20201126-C00055.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00055" attachment-type="cdx" file="US20200368173A1-20201126-C00055.CDX"> </attachment>
          <attachment idref="CHEM-US-00055" attachment-type="mol" file="US20200368173A1-20201126-C00055.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0437" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0314]"> </para-num> <div id="p-0438" num="0314" class="description-line">X<sup>119 </sup>and X<sup>120 </sup>are the same or different and are each a hydrogen atom, optionally substituted linear or branched C1-C20 alkyl, C1-C20 alkenyl, C1-C20 alkynyl or C6-C20 acyl;</div>
    </li> <li> <para-num num="[0315]"> </para-num> <div id="p-0439" num="0315" class="description-line">R<sup>122 </sup>and R<sup>123 </sup>are the same or different and are each optionally substituted linear or branched C1-C30 alkyl, C2-C30 alkenyl or C2-C30 alkynyl; and</div>
    </li> <li> <para-num num="[0316]"> </para-num> <div id="p-0440" num="0316" class="description-line">p<sup>112</sup>, p<sup>113 </sup>and p<sup>114 </sup>are the same or different and are each 0, or an arbitrary positive integer,</div>
    </li> <li> <div id="p-0441" num="0000" class="description-line">formula (CL-XII)</div>
    </li> <li> <div id="p-0442" num="0000" class="description-line">
      <chemistry id="CHEM-US-00056" num="00056">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4a/24/b7/52cb9ec1aec7ef/US20200368173A1-20201126-C00056.png"><img id="EMI-C00056" he="16.43mm" wi="60.20mm" file="US20200368173A1-20201126-C00056.TIF" alt="Figure US20200368173A1-20201126-C00056" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="241" height="66" alt="Figure US20200368173A1-20201126-C00056" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4a/24/b7/52cb9ec1aec7ef/US20200368173A1-20201126-C00056.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00056" attachment-type="cdx" file="US20200368173A1-20201126-C00056.CDX"> </attachment>
          <attachment idref="CHEM-US-00056" attachment-type="mol" file="US20200368173A1-20201126-C00056.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0443" num="0000" class="description-line">wherein X<sup>121 </sup>and X<sup>122 </sup>are the same or different and are each a hydrogen atom, C1-C6 alkyl, cycloalkyl or cycloalkenyl, or X<sup>121 </sup>and X<sup>122 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded;</div>
    </li> <li> <para-num num="[0317]"> </para-num> <div id="p-0444" num="0317" class="description-line">L<sup>120 </sup>and L<sup>121 </sup>are the same or different and are each O, OC(O) or (O)CO; and</div>
    </li> <li> <para-num num="[0318]"> </para-num> <div id="p-0445" num="0318" class="description-line">R<sup>124 </sup>and R<sup>125 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl or C8-C24 alkenyl,</div>
    </li> <li> <div id="p-0446" num="0000" class="description-line">formula (CL-XIII)</div>
    </li> <li> <div id="p-0447" num="0000" class="description-line">
      <chemistry id="CHEM-US-00057" num="00057">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0f/70/dc/590b3b17f07d2e/US20200368173A1-20201126-C00057.png"><img id="EMI-C00057" he="15.75mm" wi="53.00mm" file="US20200368173A1-20201126-C00057.TIF" alt="Figure US20200368173A1-20201126-C00057" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="212" height="63" alt="Figure US20200368173A1-20201126-C00057" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0f/70/dc/590b3b17f07d2e/US20200368173A1-20201126-C00057.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00057" attachment-type="cdx" file="US20200368173A1-20201126-C00057.CDX"> </attachment>
          <attachment idref="CHEM-US-00057" attachment-type="mol" file="US20200368173A1-20201126-C00057.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0448" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0319]"> </para-num> <div id="p-0449" num="0319" class="description-line">R<sup>126 </sup>and R<sup>127 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 heteroalkyl, C8-C24 heteroalkenyl or C8-C24 heteroalkynyl;</div>
    </li> <li> <para-num num="[0320]"> </para-num> <div id="p-0450" num="0320" class="description-line">X<sup>123 </sup>is a hydrogen atom or optionally substituted C1-C6 alkyl;</div>
    </li> <li> <para-num num="[0321]"> </para-num> <div id="p-0451" num="0321" class="description-line">X<sup>124 </sup>is C1-C6 alkyl, substituted C1-C6 alkyl which is substituted with NR<sup>4a</sup>R<sup>4b</sup>, or optionally substituted C3-C7 heterocyclyl;</div>
    </li> <li> <para-num num="[0322]"> </para-num> <div id="p-0452" num="0322" class="description-line">R<sup>4a </sup>and R<sup>4b </sup>are the same or different and are each a hydrogen atom, C(NH)NH<sub>2 </sub>or optionally substituted C1-C6 alkyl, or R<sup>4a </sup>and R<sup>4b </sup>optionally form optionally substituted C3-C7 heterocyclyl together with the nitrogen atom to which they are bonded;</div>
    </li> <li> <para-num num="[0323]"> </para-num> <div id="p-0453" num="0323" class="description-line">X<sup>123 </sup>and X<sup>124 </sup>optionally form optionally substituted C3-C7 heterocyclyl together with the nitrogen atom to which they are bonded,</div>
    </li> <li> <para-num num="[0324]"> </para-num> <div id="p-0454" num="0324" class="description-line">provided that X<sup>123 </sup>and X<sup>124 </sup>do not form imidazolyl, benzimidazolyl, or succinimidyl, and only one primary amine is allowed to be present on any one of X<sup>123 </sup>and X<sup>124</sup>, or any primary amine is not present on any one of X<sup>123 </sup>and X<sup>124</sup>, and neither X<sup>123 </sup>nor X<sup>124 </sup>is substituted amide;</div>
    </li> <li> <para-num num="[0325]"> </para-num> <div id="p-0455" num="0325" class="description-line">when each of R<sup>126 </sup>and R<sup>127 </sup>is C11 alkyl or C15 alkyl, X<sup>123 </sup>is not a hydrogen atom;</div>
    </li> <li> <para-num num="[0326]"> </para-num> <div id="p-0456" num="0326" class="description-line">when each of R<sup>126 </sup>and R<sup>127 </sup>is C16 alkyl or C17 alkyl, R<sup>126 </sup>and R<sup>127 </sup>are not substituted with OH;</div>
    </li> <li> <para-num num="[0327]"> </para-num> <div id="p-0457" num="0327" class="description-line">when each of R<sup>126 </sup>and R<sup>127 </sup>is C17 alkyl, X<sup>123 </sup>and X<sup>124 </sup>are not substituted with OH; and</div>
    </li> <li> <para-num num="[0328]"> </para-num> <div id="p-0458" num="0328" class="description-line">when each of R<sup>126 </sup>and R<sup>127 </sup>is C18 alkyl, X<sup>124 </sup>is not substituted with optionally substituted imidazolyl,</div>
    </li> <li> <div id="p-0459" num="0000" class="description-line">formula (CL-XIV)</div>
    </li> <li> <div id="p-0460" num="0000" class="description-line">
      <chemistry id="CHEM-US-00058" num="00058">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4b/69/a8/59f87015ba466a/US20200368173A1-20201126-C00058.png"><img id="EMI-C00058" he="23.03mm" wi="60.54mm" file="US20200368173A1-20201126-C00058.TIF" alt="Figure US20200368173A1-20201126-C00058" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="242" height="92" alt="Figure US20200368173A1-20201126-C00058" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4b/69/a8/59f87015ba466a/US20200368173A1-20201126-C00058.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00058" attachment-type="cdx" file="US20200368173A1-20201126-C00058.CDX"> </attachment>
          <attachment idref="CHEM-US-00058" attachment-type="mol" file="US20200368173A1-20201126-C00058.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0461" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0329]"> </para-num> <div id="p-0462" num="0329" class="description-line">X<sup>125 </sup>and X<sup>126 </sup>are the same or different and are each a hydrogen atom, optionally substituted C1-C6 alkyl, heterocyclyl or polyamine, or X<sup>125 </sup>and X<sup>126 </sup>optionally form, together with the nitrogen to which they are bonded, a 4- to 7-membered monocyclic hetero ring optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen;</div>
    </li> <li> <para-num num="[0330]"> </para-num> <div id="p-0463" num="0330" class="description-line">R<sup>130 </sup>is a hydrogen atom or C1-C6 alkyl;</div>
    </li> <li> <para-num num="[0331]"> </para-num> <div id="p-0464" num="0331" class="description-line">R<sup>128 </sup>and R<sup>129 </sup>are the same or different and are each optionally substituted linear or branched C4-C24 alkyl or C4-C24 alkenyl;</div>
    </li> <li> <para-num num="[0332]"> </para-num> <div id="p-0465" num="0332" class="description-line">Y3 and Y4 are the same or different and are each an oxygen atom or CH<sub>2</sub>; and</div>
    </li> <li> <para-num num="[0333]"> </para-num> <div id="p-0466" num="0333" class="description-line">p115 is an integer of 0 to 2,</div>
    </li> <li> <div id="p-0467" num="0000" class="description-line">formula (CL-XV)</div>
    </li> <li> <div id="p-0468" num="0000" class="description-line">
      <chemistry id="CHEM-US-00059" num="00059">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/08/01/2c/c1466d9aa6d7aa/US20200368173A1-20201126-C00059.png"><img id="EMI-C00059" he="16.26mm" wi="60.62mm" file="US20200368173A1-20201126-C00059.TIF" alt="Figure US20200368173A1-20201126-C00059" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="242" height="65" alt="Figure US20200368173A1-20201126-C00059" class="patent-full-image" src="https://patentimages.storage.googleapis.com/08/01/2c/c1466d9aa6d7aa/US20200368173A1-20201126-C00059.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00059" attachment-type="cdx" file="US20200368173A1-20201126-C00059.CDX"> </attachment>
          <attachment idref="CHEM-US-00059" attachment-type="mol" file="US20200368173A1-20201126-C00059.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0469" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0334]"> </para-num> <div id="p-0470" num="0334" class="description-line">X<sup>127 </sup>and X<sup>128 </sup>are the same or different and are each C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl, or</div>
    </li> <li> <para-num num="[0335]"> </para-num> <div id="p-0471" num="0335" class="description-line">X<sup>127 </sup>and X<sup>128 </sup>form, together with the nitrogen atom to which they are bonded, a hetero ring having one or two nitrogen atoms;</div>
    </li> <li> <para-num num="[0336]"> </para-num> <div id="p-0472" num="0336" class="description-line">L<sup>122 </sup>is C(O)O, OC(O), C(O)N(X<sup>130</sup>), N(X<sup>130</sup>)C(O), OC(O)O, OC(O)N(X<sup>130</sup>), N(X<sup>130</sup>)C(O)N(X<sup>130</sup>), or N(X<sup>130</sup>)C(O)O;</div>
    </li> <li> <para-num num="[0337]"> </para-num> <div id="p-0473" num="0337" class="description-line">each X<sup>130 </sup>present is independently a hydrogen atom or C1-C3 alkyl;</div>
    </li> <li> <para-num num="[0338]"> </para-num> <div id="p-0474" num="0338" class="description-line">a is 1, 2, 3, 4, 5, or 6;</div>
    </li> <li> <para-num num="[0339]"> </para-num> <div id="p-0475" num="0339" class="description-line">b is 0, 1, 2, or 3;</div>
    </li> <li> <para-num num="[0340]"> </para-num> <div id="p-0476" num="0340" class="description-line">X<sup>129 </sup>is absent, or hydrogen or C1-C3 alkyl;</div>
    </li> <li> <para-num num="[0341]"> </para-num> <div id="p-0477" num="0341" class="description-line">R<sup>131 </sup>and R<sup>132 </sup>are the same or different and are each alkyl having 12 to 24 carbon atoms, alkenyl having 12 to 24 carbon atoms, or alkoxy having 12 to 24 carbon atoms, which has one or more biodegradable groups; the biodegradable groups are each independently integrated in the alkyl group having 12 to 24 carbon atoms, the alkenyl group having 12 to 24 carbon atoms, or the alkoxy group having 12 to 24 carbon atoms, or present at a terminal of the alkyl group having 12 to 24 carbon atoms, the alkenyl group having 12 to 24 carbon atoms, or the alkoxy group having 12 to 24 carbon atoms, wherein</div>
    </li> <li> <para-num num="[0342]"> </para-num> <div id="p-0478" num="0342" class="description-line">the biodegradable group thus integrated is C(O)O, OC(O), C(O)N(X<sup>130</sup>), or N(X<sup>130</sup>) C(O), and the group having the biodegradable group present at the terminal is C(O)OC1-C4 alkyl, OC(O)C1-C4 alkyl, C(O)N(X<sup>130</sup>)C1-C4 alkyl, or N(X<sup>130</sup>)C(O)C1-C4 alkyl; and R<sup>131 </sup>and R<sup>132 </sup>each have at least four carbon atoms between the biodegradable group and the asterisked (*) tertiary carbon atom,</div>
    </li> <li> <div id="p-0479" num="0000" class="description-line">formula (CL-XVI)</div>
    </li> <li> <div id="p-0480" num="0000" class="description-line">
      <chemistry id="CHEM-US-00060" num="00060">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0c/a3/31/0a118de29de571/US20200368173A1-20201126-C00060.png"><img id="EMI-C00060" he="32.85mm" wi="71.80mm" file="US20200368173A1-20201126-C00060.TIF" alt="Figure US20200368173A1-20201126-C00060" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="287" height="131" alt="Figure US20200368173A1-20201126-C00060" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0c/a3/31/0a118de29de571/US20200368173A1-20201126-C00060.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00060" attachment-type="cdx" file="US20200368173A1-20201126-C00060.CDX"> </attachment>
          <attachment idref="CHEM-US-00060" attachment-type="mol" file="US20200368173A1-20201126-C00060.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0481" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0343]"> </para-num> <div id="p-0482" num="0343" class="description-line">R<sup>133 </sup>and R<sup>134 </sup>are the same or different and are each linear or branched C1-C9 alkyl, C2-C11 alkenyl or C2-C11 alkynyl;</div>
    </li> <li> <para-num num="[0344]"> </para-num> <div id="p-0483" num="0344" class="description-line">L<sup>123 </sup>and L<sup>124 </sup>are the same or different and are each linear C5-C18 alkylene or linear C5-C18 alkenylene, or forms a hetero ring with N to which they are bonded;</div>
    </li> <li> <para-num num="[0345]"> </para-num> <div id="p-0484" num="0345" class="description-line">L<sup>125 </sup>is a single bond or COO, and
</div> </li> <ul> <li id="ul0011-0001" num="0000"> <ul> <li id="ul0012-0001" num="0346">when L<sup>125 </sup>is COO, -L<sup>124</sup>-COOR<sup>134 </sup>is formed;</li> </ul> </li> </ul>

    <li> <para-num num="[0347]"> </para-num> <div id="p-0485" num="0347" class="description-line">L<sup>127 </sup>is S or O;</div>
    </li> <li> <para-num num="[0348]"> </para-num> <div id="p-0486" num="0348" class="description-line">L<sup>126 </sup>is a single bond or linear or branched C1-C6 alkylene, or forms a hetero ring with N to which they are bonded via C(O);</div>
    </li> <li> <para-num num="[0349]"> </para-num> <div id="p-0487" num="0349" class="description-line">L<sup>128 </sup>is linear or branched C1-C6 alkylene; and</div>
    </li> <li> <para-num num="[0350]"> </para-num> <div id="p-0488" num="0350" class="description-line">X<sup>131 </sup>and X<sup>132 </sup>are the same or different and are each hydrogen or linear or branched C1-C6 alkyl,</div>
    </li> <li> <div id="p-0489" num="0000" class="description-line">formula (CL-XVII)</div>
    </li> <li> <div id="p-0490" num="0000" class="description-line">
      <chemistry id="CHEM-US-00061" num="00061">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/42/b0/882c5d163ac4ef/US20200368173A1-20201126-C00061.png"><img id="EMI-C00061" he="32.00mm" wi="66.29mm" file="US20200368173A1-20201126-C00061.TIF" alt="Figure US20200368173A1-20201126-C00061" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="265" height="128" alt="Figure US20200368173A1-20201126-C00061" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/42/b0/882c5d163ac4ef/US20200368173A1-20201126-C00061.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00061" attachment-type="cdx" file="US20200368173A1-20201126-C00061.CDX"> </attachment>
          <attachment idref="CHEM-US-00061" attachment-type="mol" file="US20200368173A1-20201126-C00061.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0491" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0351]"> </para-num> <div id="p-0492" num="0351" class="description-line">L<sup>131 </sup>is C2-C4 alkylene or CH<sub>2</sub>SCH<sub>2</sub>CH<sub>2</sub>;</div>
    </li> <li> <para-num num="[0352]"> </para-num> <div id="p-0493" num="0352" class="description-line">L<sup>129 </sup>and L<sup>130 </sup>are the same or different and are each C1-C6 alkyl;</div>
    </li> <li> <para-num num="[0353]"> </para-num> <div id="p-0494" num="0353" class="description-line">R<sup>135 </sup>and R<sup>136 </sup>are the same or different and are each C10-C30 alkyl or C10-C30 alkenyl; and</div>
    </li> <li> <para-num num="[0354]"> </para-num> <div id="p-0495" num="0354" class="description-line">X<sup>133 </sup>and X<sup>134 </sup>are the same or different and are each hydrogen, C1-C6 alkyl or CH<sub>2</sub>CH<sub>2</sub>OH,</div>
    </li> <li> <div id="p-0496" num="0000" class="description-line">formula (CL-XVIII)</div>
    </li> <li> <div id="p-0497" num="0000" class="description-line">
      <chemistry id="CHEM-US-00062" num="00062">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/f5/d0/801c2062aa6fcd/US20200368173A1-20201126-C00062.png"><img id="EMI-C00062" he="13.55mm" wi="59.35mm" file="US20200368173A1-20201126-C00062.TIF" alt="Figure US20200368173A1-20201126-C00062" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="237" height="54" alt="Figure US20200368173A1-20201126-C00062" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/f5/d0/801c2062aa6fcd/US20200368173A1-20201126-C00062.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00062" attachment-type="cdx" file="US20200368173A1-20201126-C00062.CDX"> </attachment>
          <attachment idref="CHEM-US-00062" attachment-type="mol" file="US20200368173A1-20201126-C00062.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0498" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0355]"> </para-num> <div id="p-0499" num="0355" class="description-line">R<sup>137 </sup>and R<sup>138 </sup>are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, C8-24 alkenylthioethyl, or C8-C24 alkynylthioethyl;</div>
    </li> <li> <para-num num="[0356]"> </para-num> <div id="p-0500" num="0356" class="description-line">X<sup>135 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (C):</div>
    </li> <li> <div id="p-0501" num="0000" class="description-line">
      <chemistry id="CHEM-US-00063" num="00063">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/03/62/af/acfa56c80cbe7e/US20200368173A1-20201126-C00063.png"><img id="EMI-C00063" he="17.53mm" wi="54.86mm" file="US20200368173A1-20201126-C00063.TIF" alt="Figure US20200368173A1-20201126-C00063" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="219" height="70" alt="Figure US20200368173A1-20201126-C00063" class="patent-full-image" src="https://patentimages.storage.googleapis.com/03/62/af/acfa56c80cbe7e/US20200368173A1-20201126-C00063.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00063" attachment-type="cdx" file="US20200368173A1-20201126-C00063.CDX"> </attachment>
          <attachment idref="CHEM-US-00063" attachment-type="mol" file="US20200368173A1-20201126-C00063.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0502" num="0000" class="description-line">wherein X<sup>136 </sup>and X<sup>137 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>136 </sup>and X<sup>137 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; L<sup>132 </sup>is S or O; and p<sup>115 </sup>is an integer from 2 to 4,
<br/>
formula (D):
</div>
    </li> <li> <div id="p-0503" num="0000" class="description-line">
      <chemistry id="CHEM-US-00064" num="00064">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/33/ca/881fa46515fefd/US20200368173A1-20201126-C00064.png"><img id="EMI-C00064" he="14.39mm" wi="51.65mm" file="US20200368173A1-20201126-C00064.TIF" alt="Figure US20200368173A1-20201126-C00064" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="58" alt="Figure US20200368173A1-20201126-C00064" class="patent-full-image" src="https://patentimages.storage.googleapis.com/78/33/ca/881fa46515fefd/US20200368173A1-20201126-C00064.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00064" attachment-type="cdx" file="US20200368173A1-20201126-C00064.CDX"> </attachment>
          <attachment idref="CHEM-US-00064" attachment-type="mol" file="US20200368173A1-20201126-C00064.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0504" num="0000" class="description-line">wherein X<sup>138 </sup>and X<sup>139 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>138 </sup>and X<sup>139 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>116 </sup>is an integer from 1 to 4,
<br/>
or formula (E):
</div>
    </li> <li> <div id="p-0505" num="0000" class="description-line">
      <chemistry id="CHEM-US-00065" num="00065">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1d/26/29/044983c058a8e2/US20200368173A1-20201126-C00065.png"><img id="EMI-C00065" he="14.39mm" wi="51.56mm" file="US20200368173A1-20201126-C00065.TIF" alt="Figure US20200368173A1-20201126-C00065" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="206" height="58" alt="Figure US20200368173A1-20201126-C00065" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1d/26/29/044983c058a8e2/US20200368173A1-20201126-C00065.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00065" attachment-type="cdx" file="US20200368173A1-20201126-C00065.CDX"> </attachment>
          <attachment idref="CHEM-US-00065" attachment-type="mol" file="US20200368173A1-20201126-C00065.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0506" num="0000" class="description-line">wherein X<sup>140 </sup>and X<sup>141 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>140 </sup>and X<sup>141 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>117 </sup>is an integer from 1 to 4, and
<br/>
formula (CL-XIX)
</div>
    </li> <li> <div id="p-0507" num="0000" class="description-line">
      <chemistry id="CHEM-US-00066" num="00066">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ca/b2/be/71d06093211ab2/US20200368173A1-20201126-C00066.png"><img id="EMI-C00066" he="16.76mm" wi="59.94mm" file="US20200368173A1-20201126-C00066.TIF" alt="Figure US20200368173A1-20201126-C00066" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="240" height="67" alt="Figure US20200368173A1-20201126-C00066" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ca/b2/be/71d06093211ab2/US20200368173A1-20201126-C00066.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00066" attachment-type="cdx" file="US20200368173A1-20201126-C00066.CDX"> </attachment>
          <attachment idref="CHEM-US-00066" attachment-type="mol" file="US20200368173A1-20201126-C00066.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0508" num="0000" class="description-line">wherein</div>
    </li> <li> <para-num num="[0357]"> </para-num> <div id="p-0509" num="0357" class="description-line">R<sup>139 </sup>and R<sup>140 </sup>are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
    </li> <li> <para-num num="[0358]"> </para-num> <div id="p-0510" num="0358" class="description-line">L<sup>133 </sup>is S or O; and</div>
    </li> <li> <para-num num="[0359]"> </para-num> <div id="p-0511" num="0359" class="description-line">X<sup>142 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (F):</div>
    </li> <li> <div id="p-0512" num="0000" class="description-line">
      <chemistry id="CHEM-US-00067" num="00067">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/99/27/52/519b8acb15ca26/US20200368173A1-20201126-C00067.png"><img id="EMI-C00067" he="18.37mm" wi="54.86mm" file="US20200368173A1-20201126-C00067.TIF" alt="Figure US20200368173A1-20201126-C00067" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="219" height="73" alt="Figure US20200368173A1-20201126-C00067" class="patent-full-image" src="https://patentimages.storage.googleapis.com/99/27/52/519b8acb15ca26/US20200368173A1-20201126-C00067.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00067" attachment-type="cdx" file="US20200368173A1-20201126-C00067.CDX"> </attachment>
          <attachment idref="CHEM-US-00067" attachment-type="mol" file="US20200368173A1-20201126-C00067.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0513" num="0000" class="description-line">wherein X<sup>143 </sup>and X<sup>144 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>143 </sup>and X<sup>144 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; L<sup>134 </sup>is S or O; and p<sup>118 </sup>is an integer from 2 to 4,
<br/>
or formula (G):
</div>
    </li> <li> <div id="p-0514" num="0000" class="description-line">
      <chemistry id="CHEM-US-00068" num="00068">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bf/a0/a0/ff4511a3e8b2cf/US20200368173A1-20201126-C00068.png"><img id="EMI-C00068" he="14.39mm" wi="51.65mm" file="US20200368173A1-20201126-C00068.TIF" alt="Figure US20200368173A1-20201126-C00068" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="58" alt="Figure US20200368173A1-20201126-C00068" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bf/a0/a0/ff4511a3e8b2cf/US20200368173A1-20201126-C00068.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00068" attachment-type="cdx" file="US20200368173A1-20201126-C00068.CDX"> </attachment>
          <attachment idref="CHEM-US-00068" attachment-type="mol" file="US20200368173A1-20201126-C00068.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0515" num="0000" class="description-line">wherein X<sup>145 </sup>and X<sup>146 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>145 </sup>and X<sup>146 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>119 </sup>is an integer from 1 to 4.</div>
    </li> <li> <para-num num="[0360]"> </para-num> <div id="p-0516" num="0360" class="description-line">One aspect of the present invention provides a compound represented by formula (CL-XVIII) or (CL-XIX), or a pharmaceutically acceptable salt thereof.</div>
    </li> <li> <para-num num="[0361]"> </para-num> <div id="p-0517" num="0361" class="description-line">In the compound represented by formula (CL-XVIII) or (CL-XIX) of the present invention, a hydrogen ion may be coordinated on a lone pair of electrons on the nitrogen atom in the structure. In this case, the hydrogen ion may form a salt with a pharmaceutically acceptable anion. In the present invention, the compound represented by formula (CL-XVIII) or (CL-XIX), or the pharmaceutically acceptable salt thereof also encompasses a cationic lipid in which a hydrogen ion may be coordinated on a lone pair of electrons on the nitrogen atom in the structure.</div>
    </li> <li> <para-num num="[0362]"> </para-num> <div id="p-0518" num="0362" class="description-line">In the present invention, examples of the pharmaceutically acceptable anion include: inorganic ions such as chloride ions, bromide ions, nitrate ions, sulfate ions and phosphate ions; and organic acid ions such as acetate ions, oxalate ions, maleate ions, fumarate ions, citrate ions, benzoate ions and methanesulfonate ions.</div>
    </li> <li> <para-num num="[0363]"> </para-num> <div id="p-0519" num="0363" class="description-line">Examples of the pharmaceutically acceptable salt of the compound represented by formula (CL-XVIII) or (CL-XIX) of the present invention include hydrochloride, bromate, nitrate, sulfate, phosphate, acetate, oxalate, maleate, fumarate, citrate, benzoate and methanesulfonate.</div>
    </li> <li> <para-num num="[0364]"> </para-num> <div id="p-0520" num="0364" class="description-line">Some compounds represented by formula (CL-XVIII) or (CL-XIX) of the present invention may have stereoisomers such as geometric isomers and optical isomers, tautomers, or the like. Compound (I) of the present invention encompasses all possible isomers including them, and mixtures thereof.</div>
    </li> <li> <para-num num="[0365]"> </para-num> <div id="p-0521" num="0365" class="description-line">Some or all of the atoms in formula (CL-XVIII) or (CL-XIX) of the present invention may be replaced with their corresponding isotopic atoms. The compound represented by formula (CL-XVIII) or (CL-XIX) also encompasses such a compound containing isotopic atoms replaced therefor. For example, some or all of the hydrogen atoms in compound (I) may each be a hydrogen atom having an atomic weight of 2 (deuterium atom).</div>
    </li> <li> <para-num num="[0366]"> </para-num> <div id="p-0522" num="0366" class="description-line">The compound derived from formula (CL-XVIII) or (CL-XIX) of the present invention by the replacement of some or all of the atoms with their corresponding isotopic atoms can be produced in the same way as in each production method described above by using commercially available building blocks. The compound derived from formula (CL-XVIII) or (CL-XIX) by the replacement of some or all of the hydrogen atoms with deuterium atoms can also be produced by use of, for example, a method which involves deuterating an alcohol, a carboxylic acid, or the like using an iridium complex as a catalyst and heavy water as a deuterium source [see J. Am. Chem. Soc., Vol. 124, No. 10, 2092 (2002)].</div>
    </li> <li> <para-num num="[0367]"> </para-num> <div id="p-0523" num="0367" class="description-line">In the definition of each group in formula (CL-I), examples of the linear or branched C10-C24 alkyl include decyl, undecyl, dodecyl, tridecyl, 6,10-dimethylundec-2-yl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, icosyl, henicosyl, docosyl, tricosyl and tetracosyl, preferably decyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl, more preferably tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl.</div>
    </li> <li> <para-num num="[0368]"> </para-num> <div id="p-0524" num="0368" class="description-line">The linear or branched C10-C24 alkenyl can be linear or branched C10-C24 alkenyl containing one to three double bonds. Examples thereof include (Z)-dodec-7-enyl, (Z)-tetradec-7-enyl, (Z)-tetradec-9-enyl, (Z)-hexadec-4-enyl, (Z)-hexadec-7-enyl, (E)-hexadec-7-enyl, (Z)-hexadec-9-enyl, (7Z,10Z)-hexadeca-7,10-dienyl, (7Z,10Z,13Z)-hexadeca-7,10,13-trienyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (Z)-octadec-11-enyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl and (11Z,14Z)-icosa-11,14-dienyl, preferably (Z)-dodec-7-enyl, (Z)-tetradec-7-enyl, (Z)-hexadec-4-enyl, (Z)-hexadec-7-enyl, (E)-hexadec-7-enyl, (Z)-hexadec-9-enyl, (7Z,10Z)-hexadeca-7,10-dienyl, (7Z,10Z,13Z)-hexadeca-7,10,13-trienyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl and (11Z,14Z)-icosa-11,14-dienyl, more preferably (7Z,10Z)-hexadeca-7,10-dienyl and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0369]"> </para-num> <div id="p-0525" num="0369" class="description-line">The linear or branched C10-C24 alkynyl can be linear or branched C10-C24 alkynyl containing one to three triple bonds. Examples thereof include dec-9-ynyl, dodec-4-ynyl, dodec-11-ynyl, tetradec-5-ynyl, tetradec-6-ynyl, hexadec-7-ynyl, hexadeca-3,5-diynyl, hexadeca-5,7-diynyl and octadec-9-ynyl, preferably hexadec-7-ynyl and octadec-9-ynyl, more preferably octadec-9-ynyl.</div>
    </li> <li> <para-num num="[0370]"> </para-num> <div id="p-0526" num="0370" class="description-line">In formula (CL-I), R<sup>101 </sup>and R<sup>103 </sup>are preferably the same linear or branched C10-C24 alkyl, C10-C24 alkenyl or C10-C24 alkynyl, more preferably the same linear or branched C10-C24 alkyl or C10-C24 alkenyl, further preferably the same linear C10-C24 alkenyl.</div>
    </li> <li> <para-num num="[0371]"> </para-num> <div id="p-0527" num="0371" class="description-line">Examples of the C1-C3 alkylene include methylene, ethylene and propylene, preferably methylene and ethylene, more preferably methylene.</div>
    </li> <li> <para-num num="[0372]"> </para-num> <div id="p-0528" num="0372" class="description-line">Examples of the C1-C6 alkyl include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl, cyclopropylmethyl, pentyl, isopentyl, sec-pentyl, neopentyl, tert-pentyl, cyclopentyl, hexyl and cyclohexyl, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, sec-pentyl, tert-pentyl, neopentyl and hexyl, more preferably methyl, ethyl and propyl.</div>
    </li> <li> <para-num num="[0373]"> </para-num> <div id="p-0529" num="0373" class="description-line">Examples of the C3-C6 alkenyl include allyl, 1-propenyl, butenyl, pentenyl and hexenyl, preferably allyl.</div>
    </li> <li> <para-num num="[0374]"> </para-num> <div id="p-0530" num="0374" class="description-line">Each of the monoalkylamino and the dialkylamino can be amino substituted with one or two same or different C1-C6 alkyl (as defined above) groups, or C1-C6 alkyl (as defined above) substituted with amino, methylamino, ethylamino, dimethylamino, diethylamino, pyrrolidinyl, piperidyl or morpholinyl. Examples thereof include methylamino, ethylamino, propylamine, butylamino, pentylamino, hexylamino, dimethylamino, diethylamino, ethylmethylamino, methylpropylamino, butylmethylamino, methylpentylamino, hexylmethylamino, aminoethylamino, aminopropylamino, (aminoethyl)methylamino and bis(aminoethyl)amino, preferably methylamino, ethylamino, dimethylamino, diethylamino, aminopropylamino and bis(aminoethyl)amino, more preferably methylamino and dimethylamino.</div>
    </li> <li> <para-num num="[0375]"> </para-num> <div id="p-0531" num="0375" class="description-line">The trialkylammonio can be ammonio substituted by three same or different C1-C6 alkyl (as defined above) groups, or C1-C6 alkyl (as defined above) substituted with amino, methylamino, ethylamino, dimethylamino, diethylamino, pyrrolidinyl, piperidyl or morpholinyl. Examples thereof include trimethylammonio, ethyldimethylammonio, diethylmethylammonio, triethylammonio, tripropylammonio, tributylammonio, tripentylammonio, trihexylammonio, tris(aminoethyl)ammonio, (aminoethyl)dimethylammonio and bis(aminoethyl)methylammonio, preferably trimethylammonio, triethylammonio, tris(aminoethyl)ammonio, (aminoethyl)dimethylammonio and bis(aminoethyl)methylammonio, more preferably trimethylammonio.</div>
    </li> <li> <para-num num="[0376]"> </para-num> <div id="p-0532" num="0376" class="description-line">In compound (CL-I), the trialkylammonio may form a salt with a pharmaceutically acceptable anion (as defined above).</div>
    </li> <li> <para-num num="[0377]"> </para-num> <div id="p-0533" num="0377" class="description-line">The alkoxy can be hydroxy substituted with C1-C6 alkyl (as defined above) or C1-C6 alkyl (as defined above) substituted with amino, methylamino, ethylamino, dimethylamino, diethylamino, pyrrolidinyl, piperidyl or morpholinyl. Examples thereof include methoxy, ethoxy, propyloxy, butyloxy, pentyloxy, hexyloxy, aminoethoxy and methylaminoethoxy, preferably methoxy, ethoxy, aminoethoxy and methylaminoethoxy, more preferably methoxy.</div>
    </li> <li> <para-num num="[0378]"> </para-num> <div id="p-0534" num="0378" class="description-line">Each of the monoalkylcarbamoyl and the dialkylcarbamoyl can be carbamoyl substituted with one or two same or different C1-C6 alkyl (as defined above) groups, or C1-C6 alkyl (as defined above) substituted with amino, methylamino, ethylamino, dimethylamino, diethylamino, pyrrolidinyl, piperidyl or morpholinyl. Examples thereof include methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl, butylcarbamoyl, pentylcarbamoyl, hexylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl, ethylmethylcarbamoyl, methylpropylcarbamoyl, butylmethylcarbamoyl, methylpentylcarbamoyl, hexylmethylcarbamoyl, aminoethylcarbamoyl, aminopropylcarbamoyl, (aminoethyl)methylcarbamoyl and bis(aminoethyl)carbamoyl, preferably methylcarbamoyl, ethylcarbamoyl and dimethylcarbamoyl, more preferably methylcarbamoyl and dimethylcarbamoyl.</div>
    </li> <li> <para-num num="[0379]"> </para-num> <div id="p-0535" num="0379" class="description-line">Each of L<sup>101 </sup>and L<sup>102 </sup>is more preferably a hydrogen atom. In this case, R<sup>101 </sup>and R<sup>102 </sup>are the same or different and are each preferably dodecyl, tetradecyl, (Z)-dodec-7-enyl, (Z)-tetradec-7-enyl, (Z)-hexadec-4-enyl, (Z)-hexadec-7-enyl, (E)-hexadec-7-enyl, (Z)-hexadec-9-enyl, (7Z,10Z)-hexadeca-7,10-dienyl, (7Z,10Z,13Z)-hexadeca-7,10,13-trienyl, (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, more preferably (Z)-tetradec-7-enyl, (Z)-hexadec-7-enyl, (7Z,10Z)-hexadeca-7,10-dienyl or (9Z,12Z)-octadeca-9,12-dienyl, further preferably are the same and (Z)-tetradec-7-enyl, (Z)-hexadec-7-enyl, (7Z,10Z)-hexadeca-7,10-dienyl or (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0380]"> </para-num> <div id="p-0536" num="0380" class="description-line">When each of L<sup>101 </sup>and L<sup>102 </sup>is a hydrogen atom, X<sup>101 </sup>is more preferably a hydrogen atom, methyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, further preferably a hydrogen atom, methyl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, hydroxy and carbamoyl, still further preferably a hydrogen atom, methyl or the like.</div>
    </li> <li> <para-num num="[0381]"> </para-num> <div id="p-0537" num="0381" class="description-line">When L<sup>101 </sup>and L<sup>102 </sup>together form a single bond or GI-GS alkylene, R<sup>101 </sup>and R<sup>102 </sup>are the same or different and are each preferably tetradecyl, hexadecyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, or (11Z,14Z)-icosa-11,14-dienyl, more preferably (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, further preferably are the same and (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0382]"> </para-num> <div id="p-0538" num="0382" class="description-line">When L<sup>101 </sup>and L<sup>102 </sup>together form a single bond or GI-GS alkylene, X<sup>101 </sup>is more preferably a hydrogen atom, methyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, further preferably a hydrogen atom, methyl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, hydroxy and carbamoyl, most preferably a hydrogen atom, methyl or the like.</div>
    </li> <li> <para-num num="[0383]"> </para-num> <div id="p-0539" num="0383" class="description-line">In another more preferred mode of the present invention, when L<sup>101 </sup>and L<sup>102 </sup>together form a single bond, L<sup>103 </sup>is CO or COO, preferably CO. In this case, X<sup>101 </sup>is preferably aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 1,4-diaminobutyl, 1,5-diaminopentyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl or the like, more preferably 1,2-diaminoethyl, 1,3-diaminopropyl, 1,4-diaminobutyl or 1,5-diaminopentyl. R<sup>101 </sup>and R<sup>102 </sup>are the same or different and are each preferably tetradecyl, hexadecyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl or (11Z,14Z)-icosa-11,14-dienyl, more preferably (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, further preferably are the same and (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0384]"> </para-num> <div id="p-0540" num="0384" class="description-line">L<sup>103 </sup>is more preferably a single bond.</div>
    </li> <li> <para-num num="[0385]"> </para-num> <div id="p-0541" num="0385" class="description-line">When L<sup>103 </sup>is a single bond, X<sup>101 </sup>is more preferably a hydrogen atom, methyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, or the like, further preferably a hydrogen atom, methyl, hydroxymethyl, 2-hydroxyethyl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 2-hydroxy-3-methoxypropyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-carbamoylethyl, 2-dimethylcarbamoylethyl, 1-methylpiperidin-4-yl or the like, most preferably a hydrogen atom or methyl.</div>
    </li> <li> <para-num num="[0386]"> </para-num> <div id="p-0542" num="0386" class="description-line">When L<sup>103 </sup>is CO or COO, more preferably, X<sup>101 </sup>is pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, and at least one of the substituents is amino, monoalkylamino, dialkylamino, trialkylammonio, pyrrolidinyl, piperidyl, morpholinyl or the like. R<sup>3 </sup>is further preferably aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 3-aminopropyl, 1,4-diaminobutyl, 4-aminobutyl, 1,5-diaminopentyl, 5-aminopentyl, (N,N-dimethylamino)methyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 1-hydroxy-2-aminoethyl, 1-amino-2-hydroxyethyl or the like, most preferably 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 3-aminopropyl, 1,4-diaminobutyl, 4-aminobutyl, 1,5-diaminopentyl, 5-aminopentyl or the like.</div>
    </li> <li> <para-num num="[0387]"> </para-num> <div id="p-0543" num="0387" class="description-line">In an alternative more preferred mode of the present invention, L<sup>103 </sup>is a single bond, and X<sup>101 </sup>is a hydrogen atom. In this case, R<sup>101 </sup>and R<sup>102 </sup>are the same or different and are each preferably dodecyl, tetradecyl, (Z)-dodec-7-enyl, (Z)-tetradec-7-enyl, (Z)-hexadec-4-enyl, (Z)-hexadec-7-enyl, (E)-hexadec-7-enyl, (Z)-hexadec-9-enyl, (7Z,10Z)-hexadeca-7,10-dienyl, (7Z,10Z,13Z)-hexadeca-7,10,13-trienyl, (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, more preferably are the same or different and are each (Z)-tetradec-7-enyl or (7Z,10Z)-hexadeca-7,10-dienyl, further preferably are the same and (Z)-tetradec-7-enyl, (Z)-hexadec-7-enyl or (7Z,10Z)-hexadeca-7,10-dienyl.</div>
    </li> <li> <para-num num="[0388]"> </para-num> <div id="p-0544" num="0388" class="description-line">In an alternative more preferred mode of the present invention, L<sup>103 </sup>is a single bond, and X<sup>101 </sup>is methyl. In this case, R<sup>101 </sup>and R<sup>102 </sup>are the same or different and are each preferably dodecyl, tetradecyl, (Z)-dodec-7-enyl, (Z)-tetradec-7-enyl, (Z)-hexadec-4-enyl, (Z)-hexadec-7-enyl, (E)-hexadec-7-enyl, (Z)-hexadec-9-enyl, (7Z,10Z)-hexadeca-7,10-dienyl, (7Z,10Z,13Z)-hexadeca-7,10,13-trienyl, (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, more preferably are the same or different and are each (Z)-tetradec-7-enyl, (7Z,10Z)-hexadeca-7,10-dienyl or (9Z,12Z)-octadeca-9,12-dienyl, further preferably are the same and (Z)-tetradec-7-enyl, (7Z,10Z)-hexadeca-7,10-dienyl or (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0389]"> </para-num> <div id="p-0545" num="0389" class="description-line">In the definition of each group in formula (CL-II), examples of the linear or branched C12-C24 alkyl include dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl, preferably dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl, nonadecyl and icosyl, more preferably dodecyl, tridecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl and octadecyl.</div>
    </li> <li> <para-num num="[0390]"> </para-num> <div id="p-0546" num="0390" class="description-line">The linear or branched C12-C24 alkenyl can be linear or branched C12-C24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octadeca-9,12-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-nonadec-10-enyl, (Z)-icos-11-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 2,6,10,14-tetramethylpentadec-1-enyl and 3,7,11,15-tetramethylhexadec-2-enyl, preferably (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl, more preferably (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0391]"> </para-num> <div id="p-0547" num="0391" class="description-line">The linear or branched C12-C24 alkynyl can be linear or branched C12-C24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-ynyl and octadec-9-ynyl.</div>
    </li> <li> <para-num num="[0392]"> </para-num> <div id="p-0548" num="0392" class="description-line">In the definition of each group in formula (CL-II), the C1-C3 alkylene, the C1-C6 alkyl and the C3-C6 alkenyl are each as defined above in formula (CL-I).</div>
    </li> <li> <para-num num="[0393]"> </para-num> <div id="p-0549" num="0393" class="description-line">The monoalkylamino, the dialkylamino, the trialkylammonio, the alkoxy, the monoalkylcarbamoyl and the dialkylcarbamoyl are each as defined above in formula (CL-I).</div>
    </li> <li> <para-num num="[0394]"> </para-num> <div id="p-0550" num="0394" class="description-line">R<sup>103 </sup>and R<sup>104 </sup>are preferably the same linear or branched C12-C24 alkyl, C12-C24 alkenyl or C12-C24 alkynyl, more preferably the same linear or branched C12-C24 alkyl or C12-C24 alkenyl.</div>
    </li> <li> <para-num num="[0395]"> </para-num> <div id="p-0551" num="0395" class="description-line">L<sup>104 </sup>and L<sup>105 </sup>are more preferably the same and O, COO or OCO.</div>
    </li> <li> <para-num num="[0396]"> </para-num> <div id="p-0552" num="0396" class="description-line">When at least one of L<sup>104 </sup>and L<sup>105 </sup>is O or OCO, R<sup>103 </sup>and R<sup>104 </sup>are the same or different and are each more preferably dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl or 3,7,11,15-tetramethylhexadec-2-enyl, further preferably tetradecyl, hexadecyl, octadecyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0397]"> </para-num> <div id="p-0553" num="0397" class="description-line">When at least one of L<sup>104 </sup>and L<sup>105 </sup>is COO, each of R<sup>103 </sup>and R<sup>104 </sup>is more preferably tridecyl, pentadecyl, heptadecyl, nonadecyl, henicosyl, tricosyl, (Z)-tridec-8-enyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl, (E)-heptadec-8-enyl, (Z)-heptadec-10-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (Z)-nonadec-10-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl or 2,6,10,14-tetramethylpentadec-1-enyl, further preferably tridecyl, pentadecyl, heptadecyl, (Z)-pentadec-8-enyl, (Z)-heptadec-5-enyl, (Z)-heptadec-8-enyl or (8Z,11Z)-heptadeca-8,11-dienyl.</div>
    </li> <li> <para-num num="[0398]"> </para-num> <div id="p-0554" num="0398" class="description-line">p<sup>101 </sup>and p<sup>102 </sup>are more preferably 0 or 1 at the same time.</div>
    </li> <li> <para-num num="[0399]"> </para-num> <div id="p-0555" num="0399" class="description-line">L<sup>106 </sup>and L<sup>107 </sup>more preferably together form a single bond or C1-C3 alkylene. When L<sup>106 </sup>and L<sup>107 </sup>together form a single bond or C1-C3 alkylene, X<sup>102 </sup>is more preferably a hydrogen atom, methyl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, further preferably a hydrogen atom, methyl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, trialkylammonio, hydroxy and carbamoyl, most preferably a hydrogen atom, methyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 1,4-diaminobutyl, 1,5-diaminopentyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl or 2-carbamoylethyl. Among these substituents, the alkyl moiety in monoalkylamino, dialkylamino, trialkylammonio, alkoxy, monoalkylcarbamoyl and dialkylcarbamoyl is as defined in the C1-C4 alkyl. Two or three alkyl moieties in dialkylamino, trialkylammonio and dialkylcarbamoyl are the same as or different from each other.</div>
    </li> <li> <para-num num="[0400]"> </para-num> <div id="p-0556" num="0400" class="description-line">When L<sup>106 </sup>and L<sup>107 </sup>together form a single bond, L<sup>108 </sup>is CO or COO, preferably CO.</div>
    </li> <li> <para-num num="[0401]"> </para-num> <div id="p-0557" num="0401" class="description-line">When L<sup>106 </sup>and L<sup>107 </sup>together form a single bond, p<sup>101 </sup>and p<sup>102 </sup>are the same or different and are each preferably 1 to 3.</div>
    </li> <li> <para-num num="[0402]"> </para-num> <div id="p-0558" num="0402" class="description-line">When each of L<sup>106 </sup>and L<sup>107 </sup>is a hydrogen atom, X<sup>102 </sup>is preferably a hydrogen atom, methyl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, more preferably a hydrogen atom, methyl or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, trialkylammonio, hydroxy and carbamoyl, further preferably a hydrogen atom, methyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 1,4-diaminobutyl, 1,5-diaminopentyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 2-carbamoylethyl or the like. Among these substituents, the alkyl moiety in monoalkylamino, dialkylamino, trialkylammonio, alkoxy, monoalkylcarbamoyl and dialkylcarbamoyl is as defined in the C1-C4 alkyl. Two or three alkyl moieties in dialkylamino, trialkylammonio, and dialkylcarbamoyl are the same as or different from each other.</div>
    </li> <li> <para-num num="[0403]"> </para-num> <div id="p-0559" num="0403" class="description-line">L<sup>108 </sup>is preferably a single bond. When L<sup>108 </sup>is a single bond, each of L<sup>104 </sup>and L<sup>105 </sup>is preferably O.</div>
    </li> <li> <para-num num="[0404]"> </para-num> <div id="p-0560" num="0404" class="description-line">When L<sup>108 </sup>is a single bond, X<sup>102 </sup>is preferably a hydrogen atom, methyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, or the like, more preferably a hydrogen atom, methyl, hydroxymethyl, 2-hydroxyethyl, 2,3-dihydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 2-hydroxy-3-methoxypropyl, aminomethyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 2-carbamoylethyl, 2-dimethylcarbamoylethyl, 1-methylpiperidin-4-yl or the like, further preferably a hydrogen atom, methyl, 2,3-dihydroxypropyl, 3-hydroxypropyl, 2-aminoethyl, 3-aminopropyl, 4-aminobutyl, 5-aminopentyl, 2-carbamoylethyl or the like. Among these substituents, the alkyl moiety in monoalkylamino, dialkylamino, trialkylammonio, alkoxy, monoalkylcarbamoyl and dialkylcarbamoyl is as defined in the C1-C4 alkyl. Two or three alkyl moieties in dialkylamino, trialkylammonio, and dialkylcarbamoyl are the same as or different from each other.</div>
    </li> <li> <para-num num="[0405]"> </para-num> <div id="p-0561" num="0405" class="description-line">Each of L<sup>104 </sup>and L<sup>105 </sup>is more preferably O. However, when L<sup>108 </sup>is a single bond and X<sup>102 </sup>is a hydrogen atom, L<sup>104 </sup>and L<sup>105 </sup>are preferably the same and COO or OCO, more preferably COO.</div>
    </li> <li> <para-num num="[0406]"> </para-num> <div id="p-0562" num="0406" class="description-line">When L<sup>108 </sup>is CO or COO, L<sup>104 </sup>and L<sup>105 </sup>are preferably the same and COO or OCO, more preferably COO.</div>
    </li> <li> <para-num num="[0407]"> </para-num> <div id="p-0563" num="0407" class="description-line">When L<sup>108 </sup>is CO or COO, X<sup>102 </sup>is preferably pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, and at least one of the substituents is preferably amino, monoalkylamino, dialkylamino, trialkylammonio, pyrrolidinyl, piperidyl or morpholinyl. X<sup>102 </sup>is more preferably aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 3-aminopropyl, 1,4-diaminobutyl, 4-aminobutyl, 1,5-diaminopentyl, 5-aminopentyl, (N,N-dimethylamino)methyl, 2-(N,N-dimethylamino)ethyl, 3-(N,N-dimethylamino)propyl, 1-amino-2-hydroxyethyl or the like, further preferably aminomethyl, 1,2-diaminoethyl, 2-aminoethyl, 1,3-diaminopropyl, 3-aminopropyl, 1,4-diaminobutyl, 4-aminobutyl, 1,5-diaminopentyl, 5-aminopentyl or the like. Among these substituents, the alkyl moiety in monoalkylamino, dialkylamino, trialkylammonio, alkoxy, monoalkylcarbamoyl and dialkylcarbamoyl is as defined in the C1-C6 alkyl. Two or three alkyl moieties in dialkylamino, trialkylammonio and dialkylcarbamoyl are the same as or different from each other.</div>
    </li> <li> <para-num num="[0408]"> </para-num> <div id="p-0564" num="0408" class="description-line">L<sup>104 </sup>and L<sup>105 </sup>are preferably the same and COO or OCO, more preferably COO.</div>
    </li> <li> <para-num num="[0409]"> </para-num> <div id="p-0565" num="0409" class="description-line">In the definition of each group in formulas (CL-III), (CL-IV) and (CL-V), the linear or branched C8-C24 alkyl, C8-C24 alkenyl and C8-C24 alkynyl are each as defined above in formulas (I) to (IV), and the same groups as those described therein are preferred.</div>
    </li> <li> <para-num num="[0410]"> </para-num> <div id="p-0566" num="0410" class="description-line">In the definition of each group in formulas (CL-III), (CL-IV) and (CL-V), examples of the alkyl moiety in C8-C24 alkyloxyethyl and C8-C24 alkyloxypropyl include those listed about the linear or branched C8-C24 alkyl.</div>
    </li> <li> <para-num num="[0411]"> </para-num> <div id="p-0567" num="0411" class="description-line">Examples of the alkynyl moiety in alkynyloxyethyl and alkynyloxypropyl include those listed about the linear or branched C8-C24 alkynyl.</div>
    </li> <li> <para-num num="[0412]"> </para-num> <div id="p-0568" num="0412" class="description-line">R<sup>105 </sup>and R<sup>106 </sup>are preferably the same or different and are each linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably are the same or different and are each linear or branched C8-C24 alkenyl, further preferably are the same or different and are each linear C8-C24 alkenyl. Also, R<sup>105 </sup>and R<sup>106 </sup>are more preferably the same. In this case, linear or branched C12-C24 alkyl, C12-C24 alkenyl or C12-C24 alkynyl is preferred, and linear C12-C24 alkenyl is more preferred. The linear or branched C12-C24 alkyl, C12-C24 alkenyl and C12-C24 alkynyl are each as defined above in formula (CL-II).</div>
    </li> <li> <para-num num="[0413]"> </para-num> <div id="p-0569" num="0413" class="description-line">R<sup>105 </sup>and R<sup>106 </sup>are preferably the same or different and are each linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably are the same or different and are each linear or branched C8-C24 alkenyl, further preferably are the same or different and are each linear C8-C24 alkenyl. Also, R<sup>105 </sup>and R<sup>106 </sup>are more preferably the same. In this, case, linear or branched C15-C20 alkyl, C15-C20 alkenyl or C15-C20 alkynyl is preferred, and linear C15-C20 alkenyl is more preferred. The linear or branched C15-C20 alkyl, C15-C20 alkenyl and C15-C20 alkynyl are each as defined above in formulas (I) to (IV), and the same groups as those described therein are preferred.</div>
    </li> <li> <para-num num="[0414]"> </para-num> <div id="p-0570" num="0414" class="description-line">When R<sup>105 </sup>and R<sup>106 </sup>are different, preferably, R<sup>105 </sup>is linear or branched C15-C20 alkyl, C15-C20 alkenyl or C15-C20 alkynyl, and R<sup>106 </sup>is linear or branched C8-C12 alkyl. In this context, examples of the linear or branched C8-C12 alkyl include octyl, nonyl, decyl, undecyl and dodecyl, preferably octyl, decyl and dodecyl.</div>
    </li> <li> <para-num num="[0415]"> </para-num> <div id="p-0571" num="0415" class="description-line">More preferably, R<sup>105 </sup>is linear C15-C20 alkenyl, and R<sup>106 </sup>is linear C8-C12 alkyl. Further preferably, R<sup>105 </sup>is (Z)-octadec-9-enyl or (9Z,12Z)-octadeca-9,12-dienyl, and R<sup>106 </sup>is octyl, decyl or dodecyl.</div>
    </li> <li> <para-num num="[0416]"> </para-num> <div id="p-0572" num="0416" class="description-line">When R<sup>105 </sup>and R<sup>106 </sup>are different, also preferably, R<sup>105 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, and R<sup>106 </sup>is C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl or C8-C24 alkynyloxypropyl. In this case, more preferably, R<sup>105 </sup>is linear C8-C24 alkenyl, and R<sup>106 </sup>is C8-C24 alkenyloxyethyl. Further preferably, R<sup>105 </sup>is (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl or (11Z,14Z)-icosa-11,14-dienyl, and R<sup>106 </sup>is (Z)-octadec-9-enyloxyethyl, (9Z,12Z)-octadeca-9,12-dienyloxyethyl or (11Z,14Z)-icosa-11,14-dienyloxyethyl. Most preferably, R<sup>105 </sup>is (9Z,12Z)-octadeca-9,12-dienyl, and R<sup>106 </sup>is (9Z,12Z)-octadeca-9,12-dienyloxyethyl.</div>
    </li> <li> <para-num num="[0417]"> </para-num> <div id="p-0573" num="0417" class="description-line">When R<sup>105 </sup>and R<sup>106 </sup>are the same or different and are each linear or branched C8-C24 alkyl or C8-C24 alkenyl, R<sup>105 </sup>and R<sup>106 </sup>are preferably the same or different and are each tetradecyl, hexadecyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl or (Z)-docos-13-enyl, more preferably are the same or different and are each hexadecyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (Z)-icos-11-enyl or (11Z,14Z)-icosa-11,14-dienyl, further preferably are the same or different and are each (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl or (11Z,14Z)-icosa-11,14-dienyl, most preferably are the same and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0418]"> </para-num> <div id="p-0574" num="0418" class="description-line">Preferably, R<sup>107 </sup>is as defined above in R<sup>105</sup>, and R<sup>107 </sup>is preferably the same group as in R<sup>105</sup>. R<sup>108 </sup>is preferably linear C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl, C8-C24 alkynyloxypropyl, C8-C24 alkyloxyethoxyethyl, C8-C24 alkenyloxyethoxyethyl or C8-C24 alkynyloxyethoxyethyl, more preferably linear C8-C24 alkyloxyethyl, C8-C24 alkenyloxyethyl or C8-C24 alkynyloxyethyl. Most preferably, R<sup>107 </sup>is linear C15-C20 alkenyl, and R<sup>108 </sup>is C8-C24 alkenyloxyethyl.</div>
    </li> <li> <para-num num="[0419]"> </para-num> <div id="p-0575" num="0419" class="description-line">Preferably, R<sup>109 </sup>and R<sup>110 </sup>are as defined above in R<sup>105 </sup>and R<sup>106</sup>, respectively, and preferably the same groups as in R<sup>109 </sup>and R<sup>110 </sup>described above. However, R<sup>109 </sup>and R<sup>110 </sup>are preferably the same linear or branched C15-C20 alkyl, C15-C20 alkenyl or C15-C20 alkynyl, more preferably are the same and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0420]"> </para-num> <div id="p-0576" num="0420" class="description-line">Examples of the C1-C3 alkyl represented by X<sup>103 </sup>and X<sup>104 </sup>include methyl, ethyl, propyl, isopropyl and cyclopropyl, preferably methyl and ethyl, more preferably methyl.</div>
    </li> <li> <para-num num="[0421]"> </para-num> <div id="p-0577" num="0421" class="description-line">Examples of the C2-C8 alkylene together formed by X<sup>103 </sup>and X<sup>104 </sup>include ethylene, propylene, butylene, pentylene, hexylene, heptylene and octylene, preferably butylene, pentylene and hexylene, more preferably hexylene.</div>
    </li> <li> <para-num num="[0422]"> </para-num> <div id="p-0578" num="0422" class="description-line">Examples of the C2-C8 alkylene formed by X<sup>103 </sup>together with L<sup>111 </sup>include ethylene, propylene, butylene, pentylene, hexylene, heptylene and octylene, preferably propylene, butylene and pentylene, more preferably propylene and butylene, further preferably propylene.</div>
    </li> <li> <para-num num="[0423]"> </para-num> <div id="p-0579" num="0423" class="description-line">Preferably, X<sup>103 </sup>and X<sup>104 </sup>are the same or different and are each methyl or ethyl, or together form butylene, pentylene or hexylene, or X<sup>103 </sup>forms ethylene, propylene or butylene together with L<sup>111</sup>. Preferably, X<sup>103 </sup>and X<sup>104 </sup>are the same or different and are each methyl or ethyl, or together form butylene, pentylene or hexylene. Also preferably, X<sup>103 </sup>forms ethylene, propylene or butylene together with L<sup>111</sup>, and X<sup>104 </sup>is methyl or ethyl. More preferably, X<sup>103 </sup>and X<sup>104 </sup>are the same and methyl, or together form hexylene. Also more preferably, X<sup>103 </sup>forms propylene or butylene together with L<sup>111</sup>, and X<sup>104 </sup>is methyl.</div>
    </li> <li> <para-num num="[0424]"> </para-num> <div id="p-0580" num="0424" class="description-line">The C1-C6 alkyl, the C3-C6 alkenyl, the monoalkylamino, the alkoxy, the monoalkylcarbamoyl and the di alkyl carbamoyl represented by L<sup>111 </sup>are each as defined above in formula (CL-I).</div>
    </li> <li> <para-num num="[0425]"> </para-num> <div id="p-0581" num="0425" class="description-line">Preferably, L<sup>111 </sup>is a hydrogen atom, C1-C6 alkyl, amino, monoalkylamino, hydroxy, alkoxy or C1-C6 alkyl substituted with one to three same or different substituents selected from amino, monoalkylamino, hydroxy and alkoxy, or forms C2-C6 alkylene together with X<sup>103</sup>. More preferably, L<sup>111 </sup>is a hydrogen atom, methyl, amino, methylamino, hydroxy, methoxy or methyl substituted with one to three same or different substituents selected from amino and hydroxy, or forms ethylene, propylene or butylene together with X<sup>103</sup>. Further preferably, L<sup>111 </sup>is a hydrogen atom, C1-C3 alkyl, or hydroxy, or forms propylene or butylene together with X<sup>103</sup>. Most preferably, L<sup>111 </sup>is a hydrogen atom or forms propylene together with X<sup>103</sup>.</div>
    </li> <li> <para-num num="[0426]"> </para-num> <div id="p-0582" num="0426" class="description-line">Examples of the C1-C6 alkylene represented by L<sup>109 </sup>and L<sup>110 </sup>include methylene, ethylene, propylene, butylene, pentylene and hexylene, preferably methylene and ethylene.</div>
    </li> <li> <para-num num="[0427]"> </para-num> <div id="p-0583" num="0427" class="description-line">L<sup>109 </sup>is preferably methylene, ethylene, propylene or the like, more preferably methylene, ethylene or the like. L<sup>110 </sup>is preferably a single bond, methylene, ethylene or the like, more preferably a single bond, methylene or the like. The sum of the numbers of carbon atoms of L<sup>109 </sup>and L<sup>110 </sup>is preferably 1 to 3, more preferably 2. In any of these cases, preferably, X<sup>103 </sup>and X<sup>104 </sup>are the same or different and are each methyl, ethyl or the like, and L<sup>111 </sup>is a hydrogen atom, methyl, amino, methylamino, hydroxy, methoxy or methyl substituted with one to three same or different substituents selected from amino and hydroxy, or the like; X<sup>103 </sup>and X<sup>104 </sup>together form pentylene, hexylene, heptylene or the like, and L<sup>111 </sup>is a hydrogen atom, methyl, amino, methylamino, hydroxy, methoxy or methyl substituted with one to three same or different substituents selected from amino and hydroxy, or the like; or X<sup>103 </sup>forms propylene, butylene, pentylene or the like together with L<sup>111</sup>, and X<sup>104 </sup>is methyl, ethyl or the like. More preferably, each of X<sup>103 </sup>and X<sup>104 </sup>is methyl, and L<sup>111 </sup>is a hydrogen atom; X<sup>103 </sup>and X<sup>104 </sup>together form pentylene or hexylene, and L<sup>111 </sup>is a hydrogen atom; or X<sup>103 </sup>forms propylene together with L<sup>111</sup>, and X<sup>104 </sup>is methyl or the like.</div>
    </li> <li> <para-num num="[0428]"> </para-num> <div id="p-0584" num="0428" class="description-line">Examples of the C1-C4 alkyl represented by X<sup>105 </sup>include methyl, ethyl, propyl, isopropyl, butyl and cyclobutyl, preferably methyl. X<sup>105 </sup>is further preferably a hydrogen atom.</div>
    </li> <li> <para-num num="[0429]"> </para-num> <div id="p-0585" num="0429" class="description-line">In the definition of each group in formula (CL-V), examples of the C1-C3 alkyl represented by X<sup>105</sup> include methyl, ethyl, propyl, isopropyl and cyclopropyl, preferably methyl, ethyl and isopropyl, more preferably methyl and ethyl. X<sup>105</sup> is further preferably a hydrogen atom, methyl or the like, most preferably a hydrogen atom.</div>
    </li> <li> <para-num num="[0430]"> </para-num> <div id="p-0586" num="0430" class="description-line">Examples of the C1-C3 alkylene represented by L<sup>112 </sup>include methylene, ethylene and propylene, preferably methylene and ethylene.</div>
    </li> <li> <para-num num="[0431]"> </para-num> <div id="p-0587" num="0431" class="description-line">In the definition of each group in formulas (CL-VI) and (CL-VII), the optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl and C8-C24 alkynyl are each as defined above in formulas (I) to (V).</div>
    </li> <li> <para-num num="[0432]"> </para-num> <div id="p-0588" num="0432" class="description-line">Examples of the C1-C4 alkyl in the optionally substituted C1-C4 alkyl represented by R<sup>115 </sup>in formula (CL-VII) include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclobutyl and cyclopropylmethyl, preferably methyl and ethyl, more preferably methyl.</div>
    </li> <li> <para-num num="[0433]"> </para-num> <div id="p-0589" num="0433" class="description-line">The alkyl moiety in the optionally substituted C1-C4 alkoxy is as defined in the C1-C4 alkyl.</div>
    </li> <li> <para-num num="[0434]"> </para-num> <div id="p-0590" num="0434" class="description-line">Examples of the substituent for the optionally substituted C1-C4 alkyl include amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo. Among these substituents, the alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl is as defined in the C1-C4 alkyl. Two alkyl moieties in dialkylamino and dialkylcarbamoyl may be the same as or different from each other.</div>
    </li> <li> <para-num num="[0435]"> </para-num> <div id="p-0591" num="0435" class="description-line">Examples of the acyl in the optionally substituted C1-C4 acyloxy include formyl, acetyl, propanoyl, 2-methylpropanoyl, cyclopropanoyl and butanoyl, preferably acetyl.</div>
    </li> <li> <para-num num="[0436]"> </para-num> <div id="p-0592" num="0436" class="description-line">Examples of the substituent for the optionally substituted C1-C4 acyloxy include amino, monoalkylamino, dialkylamino, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, hydroxy, alkoxy, alkoxycarbonyl, hydroxycarbonyl, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, nitro, cyano, fluoro, chloro and bromo. Among these substituents, the alkyl moiety in monoalkylamino, dialkylamino, alkoxy, alkoxycarbonyl, monoalkylcarbamoyl and dialkylcarbamoyl is as defined in the C1-C4 alkyl. Two alkyl moieties in dialkylamino and dialkylcarbamoyl may be the same as or different from each other.</div>
    </li> <li> <para-num num="[0437]"> </para-num> <div id="p-0593" num="0437" class="description-line">In formula (CL-VI), R<sup>111 </sup>and R<sup>112 </sup>are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C8-C24 alkyl or C8-C24 alkenyl.</div>
    </li> <li> <para-num num="[0438]"> </para-num> <div id="p-0594" num="0438" class="description-line">R<sup>111 </sup>and R<sup>112 </sup>are preferably the same or different and are each octyl, decyl, dodecyl, tetradecyl, hexadecyl, octadecyl, icosyl, docosyl, tetracosyl, (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 3,7,11,15-tetramethylhexadec-2-enyl or the like, more preferably are the same or different and are each dodecyl, tetradecyl, (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl or the like, further preferably are the same and (Z)-hexadec-9-enyl, (Z)-octadec-6-enyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl or the like.</div>
    </li> <li> <para-num num="[0439]"> </para-num> <div id="p-0595" num="0439" class="description-line">X<sup>106 </sup>and X<sup>107 </sup>are preferably the same or different and are each methyl or ethyl, more preferably are the same and methyl.</div>
    </li> <li> <para-num num="[0440]"> </para-num> <div id="p-0596" num="0440" class="description-line">Examples of the C2-C8 alkylene together formed by X<sup>106 </sup>and X<sup>107 </sup>include ethylene, propylene, butylene, pentylene, hexylene, heptylene and octylene, preferably butylene, pentylene and hexylene, more preferably butylene and pentylene.</div>
    </li> <li> <para-num num="[0441]"> </para-num> <div id="p-0597" num="0441" class="description-line">Preferably, X<sup>106 </sup>and X<sup>107 </sup>are the same and methyl, or together form butylene, pentylene or hexylene.</div>
    </li> <li> <para-num num="[0442]"> </para-num> <div id="p-0598" num="0442" class="description-line">p<sup>103 </sup>and p<sup>104 </sup>are preferably 0 at the same time, and p<sup>105 </sup>is preferably 1.</div>
    </li> <li> <para-num num="[0443]"> </para-num> <div id="p-0599" num="0443" class="description-line">L<sup>113 </sup>and L<sup>114 </sup>are preferably 0 at the same time.</div>
    </li> <li> <para-num num="[0444]"> </para-num> <div id="p-0600" num="0444" class="description-line">In formula (CL-VII), R<sup>113 </sup>and R<sup>114 </sup>are preferably the same linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, more preferably the same linear or branched C8-C24 alkyl or C8-C24 alkenyl.</div>
    </li> <li> <para-num num="[0445]"> </para-num> <div id="p-0601" num="0445" class="description-line">The C1-C3 alkyl and the C2-C8 alkylene represented by X<sup>109 </sup>and X<sup>110 </sup>are each as defined above in formula (CL-VI).</div>
    </li> <li> <para-num num="[0446]"> </para-num> <div id="p-0602" num="0446" class="description-line">R<sup>115 </sup>is preferably a hydrogen atom, hydroxy, methyl, methoxy or the like, more preferably a hydrogen atom, hydroxy or the like, further preferably a hydrogen atom.</div>
    </li> <li> <para-num num="[0447]"> </para-num> <div id="p-0603" num="0447" class="description-line">L<sup>115 </sup>is preferably OCO or NHCO. In this case, preferably, p<sup>106 </sup>is 0 or 1, and p<sup>107 </sup>is an integer from 1 to 3. More preferably, p<sup>106 </sup>is 0, and p<sup>107 </sup>is 1 or 3.</div>
    </li> <li> <para-num num="[0448]"> </para-num> <div id="p-0604" num="0448" class="description-line">When L<sup>115 </sup>is COO, preferably, p<sup>106 </sup>is 0, and p<sup>107 </sup>is an integer from 2 to 4. More preferably, p<sup>106 </sup>is 0, and p<sup>107 </sup>is 3.</div>
    </li> <li> <para-num num="[0449]"> </para-num> <div id="p-0605" num="0449" class="description-line">When L<sup>115 </sup>is CONH, preferably, p<sup>106 </sup>is 0, and p<sup>107 </sup>is an integer from 2 to 4. More preferably, p<sup>106 </sup>is 0, and p<sup>107 </sup>is 3.</div>
    </li> <li> <para-num num="[0450]"> </para-num> <div id="p-0606" num="0450" class="description-line">Each group in formulas (CL-VIII) to (CL-XIX) may be as defined in formulas (I) to (V), or may be as defined in formulas (CL-I) to (CL-VIII).</div>
    </li> <li> <para-num num="[0451]"> </para-num> <div id="p-0607" num="0451" class="description-line">In formula (CL-XVIII), R<sup>137 </sup>and R<sup>138 </sup>are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, C8-24 alkenylthioethyl or C8-C24 alkynylthioethyl.</div>
    </li> <li> <para-num num="[0452]"> </para-num> <div id="p-0608" num="0452" class="description-line">Examples of the linear or branched C8-C24 alkyl represented by R<sup>137 </sup>and R<sup>138 </sup>include heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl.</div>
    </li> <li> <para-num num="[0453]"> </para-num> <div id="p-0609" num="0453" class="description-line">The linear or branched C8-C24 alkenyl represented by R<sup>137 </sup>and R<sup>138 </sup>can be linear or branched C8-24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octadeca-9,12-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-nonadec-10-enyl, (Z)-icos-11-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 2,6,10,14-tetramethylpentadec-1-enyl and 3,7,11,15-tetramethylhexadec-2-enyl, preferably (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl, more preferably (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0454]"> </para-num> <div id="p-0610" num="0454" class="description-line">The linear or branched C8-C24 alkynyl represented by R<sup>137 </sup>and R<sup>138 </sup>can be linear or branched C8-24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-ynyl and octadec-9-ynyl.</div>
    </li> <li> <para-num num="[0455]"> </para-num> <div id="p-0611" num="0455" class="description-line">Examples of the C8-C24 alkyl, the C8-24 alkenyl and the C8-C24 alkynyl contained in the C8-C24 alkylthioethyl, the C8-24 alkenylthioethyl and the C8-C24 alkynylthioethyl represented by R<sup>137 </sup>and R<sup>138 </sup>can include the same groups as those of the aforementioned C8-C24 alkyl, C8-24 alkenyl and C8-C24 alkynyl, respectively.</div>
    </li> <li> <para-num num="[0456]"> </para-num> <div id="p-0612" num="0456" class="description-line">Examples of the C1-C3 alkyl represented by X<sup>135 </sup>include methyl, ethyl, n-propyl and isopropyl.</div>
    </li> <li> <para-num num="[0457]"> </para-num> <div id="p-0613" num="0457" class="description-line">Examples of the hydroxy C2-C4 alkyl represented by X<sup>135 </sup>include hydroxyethyl, hydroxypropyl and hydroxybutyl. The position of substitution with the hydroxy group is arbitrary.</div>
    </li> <li> <para-num num="[0458]"> </para-num> <div id="p-0614" num="0458" class="description-line">Examples of the C1 to C3 alkyl represented by X<sup>136</sup>, X<sup>137</sup>, X<sup>138</sup>, X<sup>139</sup>, X<sup>140 </sup>and X<sup>141 </sup>include methyl, ethyl, n-propyl and isopropyl.</div>
    </li> <li> <para-num num="[0459]"> </para-num> <div id="p-0615" num="0459" class="description-line">Examples of the C3-C6 nitrogen-containing hetero ring that may be formed by X<sup>136 </sup>and X<sup>137</sup>, X<sup>138 </sup>and X<sup>139</sup>, or X<sup>140 </sup>and X<sup>141 </sup>include pyrrolidine, piperidine, morpholine and azepane.</div>
    </li> <li> <para-num num="[0460]"> </para-num> <div id="p-0616" num="0460" class="description-line">R<sup>139 </sup>and R<sup>140 </sup>in formula (CL-XIX) are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl.</div>
    </li> <li> <para-num num="[0461]"> </para-num> <div id="p-0617" num="0461" class="description-line">Examples of the linear or branched C8-C24 alkyl represented by R<sup>139 </sup>and R<sup>140 </sup>include heptyl, octyl, nonyl, decyl, undecyl, dodecyl, tridecyl, tetradecyl, 2,6,10-trimethylundecyl, pentadecyl, 3,7,11-trimethyldodecyl, hexadecyl, heptadecyl, octadecyl, 6,10,14-trimethylpentadecan-2-yl, nonadecyl, 2,6,10,14-tetramethylpentadecyl, icosyl, 3,7,11,15-tetramethylhexadecyl, henicosyl, docosyl, tricosyl and tetracosyl.</div>
    </li> <li> <para-num num="[0462]"> </para-num> <div id="p-0618" num="0462" class="description-line">The linear or branched C8-C24 alkenyl represented by R<sup>139 </sup>and R<sup>140 </sup>can be linear or branched C8-24 alkenyl containing one to three double bonds. Examples thereof include (Z)-tridec-8-enyl, (Z)-tetradec-9-enyl, (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (E)-heptadec-8-enyl, (E)-octadec-9-enyl, (Z)-heptadec-10-enyl, (Z)-octadec-11-enyl, (8Z,11Z)-heptadeca-8,11-dienyl, (9Z,12Z)-octadeca-9,12-dienyl, (8Z,11Z,14Z)-octadeca-8,11,14-trienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-nonadec-10-enyl, (Z)-icos-11-enyl, (10Z,13Z)-nonadeca-10,13-dienyl, (11Z,14Z)-icosa-11,14-dienyl, 2,6,10-trimethylundeca-1,5,9-trienyl, 3,7,11-trimethyldodeca-2,6,10-trienyl, 2,6,10,14-tetramethylpentadec-1-enyl and 3,7,11,15-tetramethylhexadec-2-enyl, preferably (Z)-pentadec-8-enyl, (Z)-hexadec-9-enyl, (Z)-heptadec-5-enyl, (Z)-octadec-6-enyl, (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl, more preferably (Z)-heptadec-8-enyl, (Z)-octadec-9-enyl, (8Z,11Z)-heptadeca-8,11-dienyl and (9Z,12Z)-octadeca-9,12-dienyl.</div>
    </li> <li> <para-num num="[0463]"> </para-num> <div id="p-0619" num="0463" class="description-line">The linear or branched C8-C24 alkynyl represented by R<sup>139 </sup>and R<sup>140 </sup>can be linear or branched C8-24 alkynyl containing one to three triple bonds. Examples thereof include dodec-11-ynyl, tridec-12-ynyl, pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, preferably pentadec-6-ynyl, hexadec-7-ynyl, pentadeca-4,6-diynyl, hexadeca-5,7-diynyl, heptadec-8-ynyl and octadec-9-ynyl, more preferably heptadec-8-ynyl and octadec-9-ynyl.</div>
    </li> <li> <para-num num="[0464]"> </para-num> <div id="p-0620" num="0464" class="description-line">Examples of the C1-C3 alkyl represented by X<sup>146 </sup>include methyl, ethyl, n-propyl and isopropyl.</div>
    </li> <li> <para-num num="[0465]"> </para-num> <div id="p-0621" num="0465" class="description-line">Examples of the hydroxy C2-C4 alkyl represented by X<sup>146 </sup>include hydroxyethyl, hydroxypropyl and hydroxybutyl. The position of substitution with the hydroxy group is arbitrary.</div>
    </li> <li> <para-num num="[0466]"> </para-num> <div id="p-0622" num="0466" class="description-line">Examples of the C1 to C3 alkyl represented by X<sup>143</sup>, X<sup>144</sup>, X<sup>145 </sup>and X<sup>146 </sup>include methyl, ethyl, n-propyl and isopropyl.</div>
    </li> <li> <para-num num="[0467]"> </para-num> <div id="p-0623" num="0467" class="description-line">Examples of the C3-C6 nitrogen-containing hetero ring that may be formed by X<sup>143 </sup>and X<sup>144</sup>, or X<sup>145 </sup>and X<sup>146 </sup>include pyrrolidine, piperidine, morpholine and azepane.</div>
    </li> <li> <para-num num="[0468]"> </para-num> <div id="p-0624" num="0468" class="description-line">Each group in formula (CL-VIII) may be a preferred form of the corresponding group described in WO 2016/002753; each group in formula (CL-X) may be a preferred form of the corresponding group described in WO 2009/129385; each group in formula (CL-XI) may be a preferred form of the corresponding group described in WO 2013/149140; each group in formula (CL-XII) may be a preferred form of the corresponding group described in WO 2009/129395; each group in formula (CL-XIII) may be a preferred form of the corresponding group described in WO 2013/059496; each group in formula (CL-XIV) may be a preferred form of the corresponding group described in WO 2011/149733; each group in formula (CL-XV) may be a preferred form of the corresponding group described in WO 2011/153493; each group in formula (CL-XVI) may be a preferred form of the corresponding group described in WO 2015/074085; and each group in formula (CL-XVII) may be a preferred form of the corresponding group described in WO 2013/064911.</div>
    </li> <li> <para-num num="[0469]"> </para-num> <div id="p-0625" num="0469" class="description-line">L<sup>118 </sup>and L<sup>119 </sup>in formula (CL-IX) are the same or different and are each preferably linear or branched C8-C24 alkylene or C8-C24 alkenylene, more preferably linear or branched C8-C20 alkylene or C8-C20 alkenylene.</div>
    </li> <li> <para-num num="[0470]"> </para-num> <div id="p-0626" num="0470" class="description-line">The C1-C6 alkyl, the heterocyclyl or the polyamine of X<sup>117 </sup>and X<sup>118 </sup>in formula (CL-X) may be substituted with one to three substituents selected from a halogen atom, R, OR, SR, ON, CO<sub>2</sub>R and CONR<sub>2</sub>.</div>
    </li> <li> <para-num num="[0471]"> </para-num> <div id="p-0627" num="0471" class="description-line">When X<sup>117 </sup>and X<sup>118 </sup>in formula (CL-X) form, together with the nitrogen to which they are bonded, a 4- to 7-membered monocyclic hetero ring optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen, the monocyclic hetero ring may be substituted with one to three substituents selected from a halogen atom, R, OR, SR, ON, CO<sub>2</sub>R and CONR<sub>2</sub>.</div>
    </li> <li> <para-num num="[0472]"> </para-num> <div id="p-0628" num="0472" class="description-line">In this context, R is a hydrogen atom or C1-C6 alkyl, and the C1-C6 alkyl represented by R may be substituted with a halogen atom or OH.</div>
    </li> <li> <para-num num="[0473]"> </para-num> <div id="p-0629" num="0473" class="description-line">R<sup>120 </sup>and R<sup>121 </sup>in formula (CL-X) are the same or different and are each preferably linear or branched C4-C24 alkyl or C4-C24 alkenyl, more preferably linear or branched C4-C20 alkyl or C4-C20 alkenyl.</div>
    </li> <li> <para-num num="[0474]"> </para-num> <div id="p-0630" num="0474" class="description-line">The C4-C24 alkyl or the C4-C24 alkenyl may be substituted with one or more substituents selected from a halogen atom, R, OR, SR, CN, CO<sub>2</sub>R and CONR<sub>2</sub>.</div>
    </li> <li> <para-num num="[0475]"> </para-num> <div id="p-0631" num="0475" class="description-line">In this context, R is a hydrogen atom or C1-C6 alkyl, and the C1-C6 alkyl represented by R may be substituted with a halogen atom or OH.</div>
    </li> <li> <para-num num="[0476]"> </para-num> <div id="p-0632" num="0476" class="description-line">When each of X<sup>119 </sup>and X<sup>120 </sup>in formula (CL-XI) is optionally substituted linear or branched C6-C20 acyl, a structure other than the carbonyl group in the C6-C20 acyl can be C5-C19 alkyl, C5-C19 alkenyl or C5-C19 alkynyl.</div>
    </li> <li> <para-num num="[0477]"> </para-num> <div id="p-0633" num="0477" class="description-line">R<sup>124 </sup>and R<sup>125 </sup>in formula (CL-XII) are the same or different and are each preferably linear or branched C8-C24 alkyl or C8-C24 alkenyl, more preferably linear or branched C14-C20 alkyl or C14-C20 alkenyl.</div>
    </li> <li> <para-num num="[0478]"> </para-num> <div id="p-0634" num="0478" class="description-line">The C1-C6 alkyl, the heterocyclyl or the polyamine of X<sup>125 </sup>and X<sup>126 </sup>in formula (CL-XIV) may be substituted with one to three substituents selected from a halogen atom, R, OR, SR, CN, CO<sub>2</sub>R and CONR<sub>2</sub>.</div>
    </li> <li> <para-num num="[0479]"> </para-num> <div id="p-0635" num="0479" class="description-line">When X<sup>125 </sup>and X<sup>126 </sup>in formula (CL-XIV) form, together with the nitrogen to which they are bonded, a 4- to 7-membered monocyclic hetero ring optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen, the monocyclic hetero ring may be substituted with one to three substituents selected from a halogen atom, R, OR, SR, CN, CO<sub>2</sub>R and CONR<sub>2</sub>.</div>
    </li> <li> <para-num num="[0480]"> </para-num> <div id="p-0636" num="0480" class="description-line">In this context, R is a hydrogen atom or C1-C6 alkyl, and the C1-C6 alkyl represented by R may be substituted with a halogen atom or OH.</div>
    </li> <li> <para-num num="[0481]"> </para-num> <div id="p-0637" num="0481" class="description-line">R<sup>128 </sup>and R<sup>129 </sup>in formula (CL-XIV) are the same or different and are each preferably linear or branched C4-C24 alkyl or C4-C24 alkenyl, more preferably linear or branched C4-C20 alkyl or C4-C20 alkenyl.</div>
    </li> <li> <para-num num="[0482]"> </para-num> <div id="p-0638" num="0482" class="description-line">The C4-C24 alkyl or the C4-C24 alkenyl may be substituted with one or more substituents selected from a halogen atom, R, OR, SR, CN, CO<sub>2</sub>R and CONR<sub>2</sub>.</div>
    </li> <li> <para-num num="[0483]"> </para-num> <div id="p-0639" num="0483" class="description-line">In this context, R is a hydrogen atom or C1-C6 alkyl, and the C1-C6 alkyl represented by R may be substituted with a halogen atom or OH.</div>
    </li> <li> <para-num num="[0484]"> </para-num> <div id="p-0640" num="0484" class="description-line">R<sup>137 </sup>and R<sup>138 </sup>in formula (CL-XVIII) are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, 08-24 alkenylthioethyl or C8-C24 alkynylthioethyl, preferably are the same or different and are each linear C8-C24 alkenyl.</div>
    </li> <li> <para-num num="[0485]"> </para-num> <div id="p-0641" num="0485" class="description-line">X<sup>135 </sup>is a hydrogen atom, C1-C3 alkyl, or hydroxy C2-C4 alkyl, formula (C), formula (D) or formula (E), preferably a hydrogen atom or formula (C) or formula (D), more preferably a hydrogen atom or formula (E), further preferably a hydrogen atom.</div>
    </li> <li> <para-num num="[0486]"> </para-num> <div id="p-0642" num="0486" class="description-line">R<sup>139 </sup>and R<sup>140 </sup>in formula (CL-XIX) are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl, preferably are the same or different and are each linear C8-C24 alkenyl.</div>
    </li> <li> <para-num num="[0487]"> </para-num> <div id="p-0643" num="0487" class="description-line">L<sup>133 </sup>is S or O, preferably S.</div>
    </li> <li> <para-num num="[0488]"> </para-num> <div id="p-0644" num="0488" class="description-line">X<sup>142 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (F) or formula (G), preferably C1-C3 alkyl, further preferably methyl.</div>
    </li> <li> <para-num num="[0489]"> </para-num> <div id="p-0645" num="0489" class="description-line">Lipid B in the nucleic acid-containing lipid nanoparticle of the present invention is preferably a lipid represented by formula (CL-I) or a lipid represented by formula (CL-II), more preferably a lipid represented by formula (CL-I).</div>
    </li> <li> <para-num num="[0490]"> </para-num> <div id="p-0646" num="0490" class="description-line">Specific examples of lipid B used in the present invention will be shown below in Tables 1 to 15, though lipid B used in the present invention is not limited thereto.</div>
    </li> <li> <div id="p-0647" num="0000" class="description-line">
      <tables id="TABLE-US-00001" num="00001">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 1</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-1 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00069" num="00069">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/03/9b/68/0b78e9ca72e5ca/US20200368173A1-20201126-C00069.png"><img id="EMI-C00069" he="19.22mm" wi="103.80mm" file="US20200368173A1-20201126-C00069.TIF" alt="Figure US20200368173A1-20201126-C00069" img-content="table" img-format="tif" orientation="portrait" inline="no" width="415" height="77" alt="Figure US20200368173A1-20201126-C00069" class="patent-full-image" src="https://patentimages.storage.googleapis.com/03/9b/68/0b78e9ca72e5ca/US20200368173A1-20201126-C00069.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00069" attachment-type="cdx" file="US20200368173A1-20201126-C00069.CDX"> </attachment>
                      <attachment idref="CHEM-US-00069" attachment-type="mol" file="US20200368173A1-20201126-C00069.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-2 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00070" num="00070">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a5/83/b1/2be3aeb900220b/US20200368173A1-20201126-C00070.png"><img id="EMI-C00070" he="11.51mm" wi="97.28mm" file="US20200368173A1-20201126-C00070.TIF" alt="Figure US20200368173A1-20201126-C00070" img-content="table" img-format="tif" orientation="portrait" inline="no" width="389" height="46" alt="Figure US20200368173A1-20201126-C00070" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a5/83/b1/2be3aeb900220b/US20200368173A1-20201126-C00070.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00070" attachment-type="cdx" file="US20200368173A1-20201126-C00070.CDX"> </attachment>
                      <attachment idref="CHEM-US-00070" attachment-type="mol" file="US20200368173A1-20201126-C00070.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-3 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00071" num="00071">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/86/c2/916ca03119f82b/US20200368173A1-20201126-C00071.png"><img id="EMI-C00071" he="11.94mm" wi="112.95mm" file="US20200368173A1-20201126-C00071.TIF" alt="Figure US20200368173A1-20201126-C00071" img-content="table" img-format="tif" orientation="portrait" inline="no" width="452" height="48" alt="Figure US20200368173A1-20201126-C00071" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/86/c2/916ca03119f82b/US20200368173A1-20201126-C00071.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00071" attachment-type="cdx" file="US20200368173A1-20201126-C00071.CDX"> </attachment>
                      <attachment idref="CHEM-US-00071" attachment-type="mol" file="US20200368173A1-20201126-C00071.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-4 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00072" num="00072">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/96/51/fc/9891fa802da8ca/US20200368173A1-20201126-C00072.png"><img id="EMI-C00072" he="24.38mm" wi="113.71mm" file="US20200368173A1-20201126-C00072.TIF" alt="Figure US20200368173A1-20201126-C00072" img-content="table" img-format="tif" orientation="portrait" inline="no" width="455" height="98" alt="Figure US20200368173A1-20201126-C00072" class="patent-full-image" src="https://patentimages.storage.googleapis.com/96/51/fc/9891fa802da8ca/US20200368173A1-20201126-C00072.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00072" attachment-type="cdx" file="US20200368173A1-20201126-C00072.CDX"> </attachment>
                      <attachment idref="CHEM-US-00072" attachment-type="mol" file="US20200368173A1-20201126-C00072.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-5 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00073" num="00073">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/79/97/c7/91d8bbfe9cb49f/US20200368173A1-20201126-C00073.png"><img id="EMI-C00073" he="15.07mm" wi="123.02mm" file="US20200368173A1-20201126-C00073.TIF" alt="Figure US20200368173A1-20201126-C00073" img-content="table" img-format="tif" orientation="portrait" inline="no" width="492" height="60" alt="Figure US20200368173A1-20201126-C00073" class="patent-full-image" src="https://patentimages.storage.googleapis.com/79/97/c7/91d8bbfe9cb49f/US20200368173A1-20201126-C00073.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00073" attachment-type="cdx" file="US20200368173A1-20201126-C00073.CDX"> </attachment>
                      <attachment idref="CHEM-US-00073" attachment-type="mol" file="US20200368173A1-20201126-C00073.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-6 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00074" num="00074">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/e8/18/e5c7a1b62eb273/US20200368173A1-20201126-C00074.png"><img id="EMI-C00074" he="11.60mm" wi="110.24mm" file="US20200368173A1-20201126-C00074.TIF" alt="Figure US20200368173A1-20201126-C00074" img-content="table" img-format="tif" orientation="portrait" inline="no" width="441" height="46" alt="Figure US20200368173A1-20201126-C00074" class="patent-full-image" src="https://patentimages.storage.googleapis.com/23/e8/18/e5c7a1b62eb273/US20200368173A1-20201126-C00074.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00074" attachment-type="cdx" file="US20200368173A1-20201126-C00074.CDX"> </attachment>
                      <attachment idref="CHEM-US-00074" attachment-type="mol" file="US20200368173A1-20201126-C00074.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-7 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00075" num="00075">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/63/78/86/5965f6196da4c2/US20200368173A1-20201126-C00075.png"><img id="EMI-C00075" he="11.77mm" wi="105.75mm" file="US20200368173A1-20201126-C00075.TIF" alt="Figure US20200368173A1-20201126-C00075" img-content="table" img-format="tif" orientation="portrait" inline="no" width="423" height="47" alt="Figure US20200368173A1-20201126-C00075" class="patent-full-image" src="https://patentimages.storage.googleapis.com/63/78/86/5965f6196da4c2/US20200368173A1-20201126-C00075.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00075" attachment-type="cdx" file="US20200368173A1-20201126-C00075.CDX"> </attachment>
                      <attachment idref="CHEM-US-00075" attachment-type="mol" file="US20200368173A1-20201126-C00075.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-8 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00076" num="00076">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0a/bc/01/4c2e5e749a6b6a/US20200368173A1-20201126-C00076.png"><img id="EMI-C00076" he="8.38mm" wi="102.36mm" file="US20200368173A1-20201126-C00076.TIF" alt="Figure US20200368173A1-20201126-C00076" img-content="table" img-format="tif" orientation="portrait" inline="no" width="409" height="34" alt="Figure US20200368173A1-20201126-C00076" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0a/bc/01/4c2e5e749a6b6a/US20200368173A1-20201126-C00076.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00076" attachment-type="cdx" file="US20200368173A1-20201126-C00076.CDX"> </attachment>
                      <attachment idref="CHEM-US-00076" attachment-type="mol" file="US20200368173A1-20201126-C00076.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0648" num="0000" class="description-line">
      <tables id="TABLE-US-00002" num="00002">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 2</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-9 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00077" num="00077">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/94/27/79/11afdb39aafc8b/US20200368173A1-20201126-C00077.png"><img id="EMI-C00077" he="15.58mm" wi="103.80mm" file="US20200368173A1-20201126-C00077.TIF" alt="Figure US20200368173A1-20201126-C00077" img-content="table" img-format="tif" orientation="portrait" inline="no" width="415" height="62" alt="Figure US20200368173A1-20201126-C00077" class="patent-full-image" src="https://patentimages.storage.googleapis.com/94/27/79/11afdb39aafc8b/US20200368173A1-20201126-C00077.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00077" attachment-type="cdx" file="US20200368173A1-20201126-C00077.CDX"> </attachment>
                      <attachment idref="CHEM-US-00077" attachment-type="mol" file="US20200368173A1-20201126-C00077.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-10 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00078" num="00078">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/35/c5/ce/d46474e2a3bc44/US20200368173A1-20201126-C00078.png"><img id="EMI-C00078" he="11.60mm" wi="95.67mm" file="US20200368173A1-20201126-C00078.TIF" alt="Figure US20200368173A1-20201126-C00078" img-content="table" img-format="tif" orientation="portrait" inline="no" width="383" height="46" alt="Figure US20200368173A1-20201126-C00078" class="patent-full-image" src="https://patentimages.storage.googleapis.com/35/c5/ce/d46474e2a3bc44/US20200368173A1-20201126-C00078.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00078" attachment-type="cdx" file="US20200368173A1-20201126-C00078.CDX"> </attachment>
                      <attachment idref="CHEM-US-00078" attachment-type="mol" file="US20200368173A1-20201126-C00078.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-11 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00079" num="00079">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d1/9d/c5/769169b338ed3a/US20200368173A1-20201126-C00079.png"><img id="EMI-C00079" he="13.04mm" wi="110.32mm" file="US20200368173A1-20201126-C00079.TIF" alt="Figure US20200368173A1-20201126-C00079" img-content="table" img-format="tif" orientation="portrait" inline="no" width="441" height="52" alt="Figure US20200368173A1-20201126-C00079" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d1/9d/c5/769169b338ed3a/US20200368173A1-20201126-C00079.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00079" attachment-type="cdx" file="US20200368173A1-20201126-C00079.CDX"> </attachment>
                      <attachment idref="CHEM-US-00079" attachment-type="mol" file="US20200368173A1-20201126-C00079.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-12 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00080" num="00080">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d0/d3/f8/b0e66e246c1198/US20200368173A1-20201126-C00080.png"><img id="EMI-C00080" he="10.50mm" wi="99.06mm" file="US20200368173A1-20201126-C00080.TIF" alt="Figure US20200368173A1-20201126-C00080" img-content="table" img-format="tif" orientation="portrait" inline="no" width="396" height="42" alt="Figure US20200368173A1-20201126-C00080" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d0/d3/f8/b0e66e246c1198/US20200368173A1-20201126-C00080.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00080" attachment-type="cdx" file="US20200368173A1-20201126-C00080.CDX"> </attachment>
                      <attachment idref="CHEM-US-00080" attachment-type="mol" file="US20200368173A1-20201126-C00080.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-13 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00081" num="00081">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9f/b6/3e/ce50ece630c4dd/US20200368173A1-20201126-C00081.png"><img id="EMI-C00081" he="15.07mm" wi="113.28mm" file="US20200368173A1-20201126-C00081.TIF" alt="Figure US20200368173A1-20201126-C00081" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="60" alt="Figure US20200368173A1-20201126-C00081" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9f/b6/3e/ce50ece630c4dd/US20200368173A1-20201126-C00081.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00081" attachment-type="cdx" file="US20200368173A1-20201126-C00081.CDX"> </attachment>
                      <attachment idref="CHEM-US-00081" attachment-type="mol" file="US20200368173A1-20201126-C00081.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-14 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00082" num="00082">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ba/3b/6a/03f4eeae574809/US20200368173A1-20201126-C00082.png"><img id="EMI-C00082" he="25.65mm" wi="103.80mm" file="US20200368173A1-20201126-C00082.TIF" alt="Figure US20200368173A1-20201126-C00082" img-content="table" img-format="tif" orientation="portrait" inline="no" width="415" height="103" alt="Figure US20200368173A1-20201126-C00082" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ba/3b/6a/03f4eeae574809/US20200368173A1-20201126-C00082.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00082" attachment-type="cdx" file="US20200368173A1-20201126-C00082.CDX"> </attachment>
                      <attachment idref="CHEM-US-00082" attachment-type="mol" file="US20200368173A1-20201126-C00082.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-15 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00083" num="00083">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3f/e9/fa/a8afcfcca48078/US20200368173A1-20201126-C00083.png"><img id="EMI-C00083" he="11.60mm" wi="90.76mm" file="US20200368173A1-20201126-C00083.TIF" alt="Figure US20200368173A1-20201126-C00083" img-content="table" img-format="tif" orientation="portrait" inline="no" width="363" height="46" alt="Figure US20200368173A1-20201126-C00083" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3f/e9/fa/a8afcfcca48078/US20200368173A1-20201126-C00083.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00083" attachment-type="cdx" file="US20200368173A1-20201126-C00083.CDX"> </attachment>
                      <attachment idref="CHEM-US-00083" attachment-type="mol" file="US20200368173A1-20201126-C00083.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-16 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00084" num="00084">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a4/02/6a/61a33a9e77c960/US20200368173A1-20201126-C00084.png"><img id="EMI-C00084" he="13.04mm" wi="107.44mm" file="US20200368173A1-20201126-C00084.TIF" alt="Figure US20200368173A1-20201126-C00084" img-content="table" img-format="tif" orientation="portrait" inline="no" width="430" height="52" alt="Figure US20200368173A1-20201126-C00084" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a4/02/6a/61a33a9e77c960/US20200368173A1-20201126-C00084.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00084" attachment-type="cdx" file="US20200368173A1-20201126-C00084.CDX"> </attachment>
                      <attachment idref="CHEM-US-00084" attachment-type="mol" file="US20200368173A1-20201126-C00084.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0649" num="0000" class="description-line">
      <tables id="TABLE-US-00003" num="00003">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 3</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-17 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00085" num="00085">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/43/eb/bd/2f2c059db0fcae/US20200368173A1-20201126-C00085.png"><img id="EMI-C00085" he="11.77mm" wi="109.39mm" file="US20200368173A1-20201126-C00085.TIF" alt="Figure US20200368173A1-20201126-C00085" img-content="table" img-format="tif" orientation="portrait" inline="no" width="438" height="47" alt="Figure US20200368173A1-20201126-C00085" class="patent-full-image" src="https://patentimages.storage.googleapis.com/43/eb/bd/2f2c059db0fcae/US20200368173A1-20201126-C00085.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00085" attachment-type="cdx" file="US20200368173A1-20201126-C00085.CDX"> </attachment>
                      <attachment idref="CHEM-US-00085" attachment-type="mol" file="US20200368173A1-20201126-C00085.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-18 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00086" num="00086">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cf/4b/0c/6347f326ea3d7a/US20200368173A1-20201126-C00086.png"><img id="EMI-C00086" he="11.01mm" wi="111.42mm" file="US20200368173A1-20201126-C00086.TIF" alt="Figure US20200368173A1-20201126-C00086" img-content="table" img-format="tif" orientation="portrait" inline="no" width="446" height="44" alt="Figure US20200368173A1-20201126-C00086" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cf/4b/0c/6347f326ea3d7a/US20200368173A1-20201126-C00086.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00086" attachment-type="cdx" file="US20200368173A1-20201126-C00086.CDX"> </attachment>
                      <attachment idref="CHEM-US-00086" attachment-type="mol" file="US20200368173A1-20201126-C00086.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-19 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00087" num="00087">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e4/cd/04/3cffaf42a20920/US20200368173A1-20201126-C00087.png"><img id="EMI-C00087" he="17.95mm" wi="132.08mm" file="US20200368173A1-20201126-C00087.TIF" alt="Figure US20200368173A1-20201126-C00087" img-content="table" img-format="tif" orientation="portrait" inline="no" width="528" height="72" alt="Figure US20200368173A1-20201126-C00087" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e4/cd/04/3cffaf42a20920/US20200368173A1-20201126-C00087.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00087" attachment-type="cdx" file="US20200368173A1-20201126-C00087.CDX"> </attachment>
                      <attachment idref="CHEM-US-00087" attachment-type="mol" file="US20200368173A1-20201126-C00087.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-20 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00088" num="00088">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/ec/b5/566472d20743e0/US20200368173A1-20201126-C00088.png"><img id="EMI-C00088" he="14.22mm" wi="113.28mm" file="US20200368173A1-20201126-C00088.TIF" alt="Figure US20200368173A1-20201126-C00088" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="57" alt="Figure US20200368173A1-20201126-C00088" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/ec/b5/566472d20743e0/US20200368173A1-20201126-C00088.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00088" attachment-type="cdx" file="US20200368173A1-20201126-C00088.CDX"> </attachment>
                      <attachment idref="CHEM-US-00088" attachment-type="mol" file="US20200368173A1-20201126-C00088.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-21 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00089" num="00089">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/16/ae/28/a848baad42a86a/US20200368173A1-20201126-C00089.png"><img id="EMI-C00089" he="17.78mm" wi="122.00mm" file="US20200368173A1-20201126-C00089.TIF" alt="Figure US20200368173A1-20201126-C00089" img-content="table" img-format="tif" orientation="portrait" inline="no" width="488" height="71" alt="Figure US20200368173A1-20201126-C00089" class="patent-full-image" src="https://patentimages.storage.googleapis.com/16/ae/28/a848baad42a86a/US20200368173A1-20201126-C00089.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00089" attachment-type="cdx" file="US20200368173A1-20201126-C00089.CDX"> </attachment>
                      <attachment idref="CHEM-US-00089" attachment-type="mol" file="US20200368173A1-20201126-C00089.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-22 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00090" num="00090">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2c/44/c9/6baa5df5079841/US20200368173A1-20201126-C00090.png"><img id="EMI-C00090" he="10.50mm" wi="116.42mm" file="US20200368173A1-20201126-C00090.TIF" alt="Figure US20200368173A1-20201126-C00090" img-content="table" img-format="tif" orientation="portrait" inline="no" width="466" height="42" alt="Figure US20200368173A1-20201126-C00090" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2c/44/c9/6baa5df5079841/US20200368173A1-20201126-C00090.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00090" attachment-type="cdx" file="US20200368173A1-20201126-C00090.CDX"> </attachment>
                      <attachment idref="CHEM-US-00090" attachment-type="mol" file="US20200368173A1-20201126-C00090.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-23 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00091" num="00091">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/be/5d/c1/283bda3cd899a7/US20200368173A1-20201126-C00091.png"><img id="EMI-C00091" he="11.85mm" wi="123.44mm" file="US20200368173A1-20201126-C00091.TIF" alt="Figure US20200368173A1-20201126-C00091" img-content="table" img-format="tif" orientation="portrait" inline="no" width="494" height="47" alt="Figure US20200368173A1-20201126-C00091" class="patent-full-image" src="https://patentimages.storage.googleapis.com/be/5d/c1/283bda3cd899a7/US20200368173A1-20201126-C00091.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00091" attachment-type="cdx" file="US20200368173A1-20201126-C00091.CDX"> </attachment>
                      <attachment idref="CHEM-US-00091" attachment-type="mol" file="US20200368173A1-20201126-C00091.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-24 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00092" num="00092">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ab/5b/d7/cbb22702bc0c5e/US20200368173A1-20201126-C00092.png"><img id="EMI-C00092" he="18.97mm" wi="109.64mm" file="US20200368173A1-20201126-C00092.TIF" alt="Figure US20200368173A1-20201126-C00092" img-content="table" img-format="tif" orientation="portrait" inline="no" width="439" height="76" alt="Figure US20200368173A1-20201126-C00092" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ab/5b/d7/cbb22702bc0c5e/US20200368173A1-20201126-C00092.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00092" attachment-type="cdx" file="US20200368173A1-20201126-C00092.CDX"> </attachment>
                      <attachment idref="CHEM-US-00092" attachment-type="mol" file="US20200368173A1-20201126-C00092.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0650" num="0000" class="description-line">
      <tables id="TABLE-US-00004" num="00004">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" rowsep="1" class="description-td" colspan="3">TABLE 4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CL-25 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00093" num="00093">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/17/30/b5/80774d92ca8f11/US20200368173A1-20201126-C00093.png"><img id="EMI-C00093" he="18.71mm" wi="116.16mm" file="US20200368173A1-20201126-C00093.TIF" alt="Figure US20200368173A1-20201126-C00093" img-content="table" img-format="tif" orientation="portrait" inline="no" width="465" height="75" alt="Figure US20200368173A1-20201126-C00093" class="patent-full-image" src="https://patentimages.storage.googleapis.com/17/30/b5/80774d92ca8f11/US20200368173A1-20201126-C00093.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00093" attachment-type="cdx" file="US20200368173A1-20201126-C00093.CDX"> </attachment>
                      <attachment idref="CHEM-US-00093" attachment-type="mol" file="US20200368173A1-20201126-C00093.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CL-26 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00094" num="00094">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5c/99/40/22480235400712/US20200368173A1-20201126-C00094.png"><img id="EMI-C00094" he="15.07mm" wi="122.26mm" file="US20200368173A1-20201126-C00094.TIF" alt="Figure US20200368173A1-20201126-C00094" img-content="table" img-format="tif" orientation="portrait" inline="no" width="489" height="60" alt="Figure US20200368173A1-20201126-C00094" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5c/99/40/22480235400712/US20200368173A1-20201126-C00094.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00094" attachment-type="cdx" file="US20200368173A1-20201126-C00094.CDX"> </attachment>
                      <attachment idref="CHEM-US-00094" attachment-type="mol" file="US20200368173A1-20201126-C00094.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CL-27 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00095" num="00095">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2e/0a/2d/c59c407a8354b8/US20200368173A1-20201126-C00095.png"><img id="EMI-C00095" he="15.16mm" wi="127.68mm" file="US20200368173A1-20201126-C00095.TIF" alt="Figure US20200368173A1-20201126-C00095" img-content="table" img-format="tif" orientation="portrait" inline="no" width="511" height="61" alt="Figure US20200368173A1-20201126-C00095" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2e/0a/2d/c59c407a8354b8/US20200368173A1-20201126-C00095.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00095" attachment-type="cdx" file="US20200368173A1-20201126-C00095.CDX"> </attachment>
                      <attachment idref="CHEM-US-00095" attachment-type="mol" file="US20200368173A1-20201126-C00095.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CL-28 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00096" num="00096">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/39/24/0d/a4c1c68790a1b2/US20200368173A1-20201126-C00096.png"><img id="EMI-C00096" he="11.51mm" wi="105.83mm" file="US20200368173A1-20201126-C00096.TIF" alt="Figure US20200368173A1-20201126-C00096" img-content="table" img-format="tif" orientation="portrait" inline="no" width="423" height="46" alt="Figure US20200368173A1-20201126-C00096" class="patent-full-image" src="https://patentimages.storage.googleapis.com/39/24/0d/a4c1c68790a1b2/US20200368173A1-20201126-C00096.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00096" attachment-type="cdx" file="US20200368173A1-20201126-C00096.CDX"> </attachment>
                      <attachment idref="CHEM-US-00096" attachment-type="mol" file="US20200368173A1-20201126-C00096.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CL-29 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00097" num="00097">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/92/f8/cb/9d0b96222a849c/US20200368173A1-20201126-C00097.png"><img id="EMI-C00097" he="15.32mm" wi="110.41mm" file="US20200368173A1-20201126-C00097.TIF" alt="Figure US20200368173A1-20201126-C00097" img-content="table" img-format="tif" orientation="portrait" inline="no" width="442" height="61" alt="Figure US20200368173A1-20201126-C00097" class="patent-full-image" src="https://patentimages.storage.googleapis.com/92/f8/cb/9d0b96222a849c/US20200368173A1-20201126-C00097.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00097" attachment-type="cdx" file="US20200368173A1-20201126-C00097.CDX"> </attachment>
                      <attachment idref="CHEM-US-00097" attachment-type="mol" file="US20200368173A1-20201126-C00097.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CL-30 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00098" num="00098">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c5/2e/16/1c9e0b0b7eabf9/US20200368173A1-20201126-C00098.png"><img id="EMI-C00098" he="11.60mm" wi="96.52mm" file="US20200368173A1-20201126-C00098.TIF" alt="Figure US20200368173A1-20201126-C00098" img-content="table" img-format="tif" orientation="portrait" inline="no" width="386" height="46" alt="Figure US20200368173A1-20201126-C00098" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c5/2e/16/1c9e0b0b7eabf9/US20200368173A1-20201126-C00098.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00098" attachment-type="cdx" file="US20200368173A1-20201126-C00098.CDX"> </attachment>
                      <attachment idref="CHEM-US-00098" attachment-type="mol" file="US20200368173A1-20201126-C00098.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">CL-31 </td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00099" num="00099">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8b/a6/df/3645e48e9d3132/US20200368173A1-20201126-C00099.png"><img id="EMI-C00099" he="15.41mm" wi="107.78mm" file="US20200368173A1-20201126-C00099.TIF" alt="Figure US20200368173A1-20201126-C00099" img-content="table" img-format="tif" orientation="portrait" inline="no" width="431" height="62" alt="Figure US20200368173A1-20201126-C00099" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8b/a6/df/3645e48e9d3132/US20200368173A1-20201126-C00099.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00099" attachment-type="cdx" file="US20200368173A1-20201126-C00099.CDX"> </attachment>
                      <attachment idref="CHEM-US-00099" attachment-type="mol" file="US20200368173A1-20201126-C00099.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td namest="offset" nameend="2" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0651" num="0000" class="description-line">
      <tables id="TABLE-US-00005" num="00005">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 5</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-32</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00100" num="00100">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d4/f5/5d/a7111a06b19a1e/US20200368173A1-20201126-C00100.png"><img id="EMI-C00100" he="13.04mm" wi="108.03mm" file="US20200368173A1-20201126-C00100.TIF" alt="Figure US20200368173A1-20201126-C00100" img-content="table" img-format="tif" orientation="portrait" inline="no" width="432" height="52" alt="Figure US20200368173A1-20201126-C00100" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d4/f5/5d/a7111a06b19a1e/US20200368173A1-20201126-C00100.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00100" attachment-type="cdx" file="US20200368173A1-20201126-C00100.CDX"> </attachment>
                      <attachment idref="CHEM-US-00100" attachment-type="mol" file="US20200368173A1-20201126-C00100.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-33</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00101" num="00101">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cd/1b/6a/3270e225ed7f15/US20200368173A1-20201126-C00101.png"><img id="EMI-C00101" he="15.92mm" wi="137.41mm" file="US20200368173A1-20201126-C00101.TIF" alt="Figure US20200368173A1-20201126-C00101" img-content="table" img-format="tif" orientation="portrait" inline="no" width="550" height="64" alt="Figure US20200368173A1-20201126-C00101" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cd/1b/6a/3270e225ed7f15/US20200368173A1-20201126-C00101.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00101" attachment-type="cdx" file="US20200368173A1-20201126-C00101.CDX"> </attachment>
                      <attachment idref="CHEM-US-00101" attachment-type="mol" file="US20200368173A1-20201126-C00101.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-34</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00102" num="00102">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2a/d3/57/a68b73538ae6ec/US20200368173A1-20201126-C00102.png"><img id="EMI-C00102" he="12.36mm" wi="105.92mm" file="US20200368173A1-20201126-C00102.TIF" alt="Figure US20200368173A1-20201126-C00102" img-content="table" img-format="tif" orientation="portrait" inline="no" width="424" height="49" alt="Figure US20200368173A1-20201126-C00102" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2a/d3/57/a68b73538ae6ec/US20200368173A1-20201126-C00102.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00102" attachment-type="cdx" file="US20200368173A1-20201126-C00102.CDX"> </attachment>
                      <attachment idref="CHEM-US-00102" attachment-type="mol" file="US20200368173A1-20201126-C00102.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-35</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00103" num="00103">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0c/f9/88/31c7b4a22dc6ed/US20200368173A1-20201126-C00103.png"><img id="EMI-C00103" he="12.36mm" wi="95.42mm" file="US20200368173A1-20201126-C00103.TIF" alt="Figure US20200368173A1-20201126-C00103" img-content="table" img-format="tif" orientation="portrait" inline="no" width="382" height="49" alt="Figure US20200368173A1-20201126-C00103" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0c/f9/88/31c7b4a22dc6ed/US20200368173A1-20201126-C00103.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00103" attachment-type="cdx" file="US20200368173A1-20201126-C00103.CDX"> </attachment>
                      <attachment idref="CHEM-US-00103" attachment-type="mol" file="US20200368173A1-20201126-C00103.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-36</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00104" num="00104">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a7/65/3d/742b72d485c268/US20200368173A1-20201126-C00104.png"><img id="EMI-C00104" he="15.75mm" wi="106.60mm" file="US20200368173A1-20201126-C00104.TIF" alt="Figure US20200368173A1-20201126-C00104" img-content="table" img-format="tif" orientation="portrait" inline="no" width="426" height="63" alt="Figure US20200368173A1-20201126-C00104" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a7/65/3d/742b72d485c268/US20200368173A1-20201126-C00104.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00104" attachment-type="cdx" file="US20200368173A1-20201126-C00104.CDX"> </attachment>
                      <attachment idref="CHEM-US-00104" attachment-type="mol" file="US20200368173A1-20201126-C00104.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-37</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00105" num="00105">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fa/17/db/99a15e69ff581e/US20200368173A1-20201126-C00105.png"><img id="EMI-C00105" he="15.16mm" wi="122.00mm" file="US20200368173A1-20201126-C00105.TIF" alt="Figure US20200368173A1-20201126-C00105" img-content="table" img-format="tif" orientation="portrait" inline="no" width="488" height="61" alt="Figure US20200368173A1-20201126-C00105" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fa/17/db/99a15e69ff581e/US20200368173A1-20201126-C00105.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00105" attachment-type="cdx" file="US20200368173A1-20201126-C00105.CDX"> </attachment>
                      <attachment idref="CHEM-US-00105" attachment-type="mol" file="US20200368173A1-20201126-C00105.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-38</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00106" num="00106">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/db/fe/a4/e552b09deaf8ca/US20200368173A1-20201126-C00106.png"><img id="EMI-C00106" he="12.36mm" wi="105.16mm" file="US20200368173A1-20201126-C00106.TIF" alt="Figure US20200368173A1-20201126-C00106" img-content="table" img-format="tif" orientation="portrait" inline="no" width="421" height="49" alt="Figure US20200368173A1-20201126-C00106" class="patent-full-image" src="https://patentimages.storage.googleapis.com/db/fe/a4/e552b09deaf8ca/US20200368173A1-20201126-C00106.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00106" attachment-type="cdx" file="US20200368173A1-20201126-C00106.CDX"> </attachment>
                      <attachment idref="CHEM-US-00106" attachment-type="mol" file="US20200368173A1-20201126-C00106.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-39</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00107" num="00107">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e5/23/9f/f43e426e8da567/US20200368173A1-20201126-C00107.png"><img id="EMI-C00107" he="12.36mm" wi="114.89mm" file="US20200368173A1-20201126-C00107.TIF" alt="Figure US20200368173A1-20201126-C00107" img-content="table" img-format="tif" orientation="portrait" inline="no" width="460" height="49" alt="Figure US20200368173A1-20201126-C00107" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e5/23/9f/f43e426e8da567/US20200368173A1-20201126-C00107.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00107" attachment-type="cdx" file="US20200368173A1-20201126-C00107.CDX"> </attachment>
                      <attachment idref="CHEM-US-00107" attachment-type="mol" file="US20200368173A1-20201126-C00107.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0652" num="0000" class="description-line">
      <tables id="TABLE-US-00006" num="00006">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 6</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-40</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00108" num="00108">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4c/3e/bc/61f0a25f17ea93/US20200368173A1-20201126-C00108.png"><img id="EMI-C00108" he="12.36mm" wi="114.89mm" file="US20200368173A1-20201126-C00108.TIF" alt="Figure US20200368173A1-20201126-C00108" img-content="table" img-format="tif" orientation="portrait" inline="no" width="460" height="49" alt="Figure US20200368173A1-20201126-C00108" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4c/3e/bc/61f0a25f17ea93/US20200368173A1-20201126-C00108.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00108" attachment-type="cdx" file="US20200368173A1-20201126-C00108.CDX"> </attachment>
                      <attachment idref="CHEM-US-00108" attachment-type="mol" file="US20200368173A1-20201126-C00108.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-41</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00109" num="00109">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f7/1f/96/bdafdba6465fbe/US20200368173A1-20201126-C00109.png"><img id="EMI-C00109" he="13.04mm" wi="115.65mm" file="US20200368173A1-20201126-C00109.TIF" alt="Figure US20200368173A1-20201126-C00109" img-content="table" img-format="tif" orientation="portrait" inline="no" width="463" height="52" alt="Figure US20200368173A1-20201126-C00109" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f7/1f/96/bdafdba6465fbe/US20200368173A1-20201126-C00109.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00109" attachment-type="cdx" file="US20200368173A1-20201126-C00109.CDX"> </attachment>
                      <attachment idref="CHEM-US-00109" attachment-type="mol" file="US20200368173A1-20201126-C00109.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-42</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00110" num="00110">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c6/67/e5/26b0733b0c4270/US20200368173A1-20201126-C00110.png"><img id="EMI-C00110" he="12.36mm" wi="105.16mm" file="US20200368173A1-20201126-C00110.TIF" alt="Figure US20200368173A1-20201126-C00110" img-content="table" img-format="tif" orientation="portrait" inline="no" width="421" height="49" alt="Figure US20200368173A1-20201126-C00110" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c6/67/e5/26b0733b0c4270/US20200368173A1-20201126-C00110.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00110" attachment-type="cdx" file="US20200368173A1-20201126-C00110.CDX"> </attachment>
                      <attachment idref="CHEM-US-00110" attachment-type="mol" file="US20200368173A1-20201126-C00110.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-43</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00111" num="00111">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ad/af/da/0388c5ae003f8e/US20200368173A1-20201126-C00111.png"><img id="EMI-C00111" he="12.28mm" wi="105.16mm" file="US20200368173A1-20201126-C00111.TIF" alt="Figure US20200368173A1-20201126-C00111" img-content="table" img-format="tif" orientation="portrait" inline="no" width="421" height="49" alt="Figure US20200368173A1-20201126-C00111" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ad/af/da/0388c5ae003f8e/US20200368173A1-20201126-C00111.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00111" attachment-type="cdx" file="US20200368173A1-20201126-C00111.CDX"> </attachment>
                      <attachment idref="CHEM-US-00111" attachment-type="mol" file="US20200368173A1-20201126-C00111.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-44</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00112" num="00112">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f3/26/c5/544799a2dcb938/US20200368173A1-20201126-C00112.png"><img id="EMI-C00112" he="12.36mm" wi="105.16mm" file="US20200368173A1-20201126-C00112.TIF" alt="Figure US20200368173A1-20201126-C00112" img-content="table" img-format="tif" orientation="portrait" inline="no" width="421" height="49" alt="Figure US20200368173A1-20201126-C00112" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f3/26/c5/544799a2dcb938/US20200368173A1-20201126-C00112.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00112" attachment-type="cdx" file="US20200368173A1-20201126-C00112.CDX"> </attachment>
                      <attachment idref="CHEM-US-00112" attachment-type="mol" file="US20200368173A1-20201126-C00112.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-45</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00113" num="00113">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b1/c5/87/2e65ccd3b1f54d/US20200368173A1-20201126-C00113.png"><img id="EMI-C00113" he="12.36mm" wi="105.16mm" file="US20200368173A1-20201126-C00113.TIF" alt="Figure US20200368173A1-20201126-C00113" img-content="table" img-format="tif" orientation="portrait" inline="no" width="421" height="49" alt="Figure US20200368173A1-20201126-C00113" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b1/c5/87/2e65ccd3b1f54d/US20200368173A1-20201126-C00113.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00113" attachment-type="cdx" file="US20200368173A1-20201126-C00113.CDX"> </attachment>
                      <attachment idref="CHEM-US-00113" attachment-type="mol" file="US20200368173A1-20201126-C00113.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0653" num="0000" class="description-line">
      <tables id="TABLE-US-00007" num="00007">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 7</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-46</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00114" num="00114">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/62/a6/fe/9bc407a1e21760/US20200368173A1-20201126-C00114.png"><img id="EMI-C00114" he="16.43mm" wi="123.53mm" file="US20200368173A1-20201126-C00114.TIF" alt="Figure US20200368173A1-20201126-C00114" img-content="table" img-format="tif" orientation="portrait" inline="no" width="494" height="66" alt="Figure US20200368173A1-20201126-C00114" class="patent-full-image" src="https://patentimages.storage.googleapis.com/62/a6/fe/9bc407a1e21760/US20200368173A1-20201126-C00114.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00114" attachment-type="cdx" file="US20200368173A1-20201126-C00114.CDX"> </attachment>
                      <attachment idref="CHEM-US-00114" attachment-type="mol" file="US20200368173A1-20201126-C00114.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-47</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00115" num="00115">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/bc/6c/7e/257e6c6bb56dd4/US20200368173A1-20201126-C00115.png"><img id="EMI-C00115" he="13.12mm" wi="105.16mm" file="US20200368173A1-20201126-C00115.TIF" alt="Figure US20200368173A1-20201126-C00115" img-content="table" img-format="tif" orientation="portrait" inline="no" width="421" height="52" alt="Figure US20200368173A1-20201126-C00115" class="patent-full-image" src="https://patentimages.storage.googleapis.com/bc/6c/7e/257e6c6bb56dd4/US20200368173A1-20201126-C00115.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00115" attachment-type="cdx" file="US20200368173A1-20201126-C00115.CDX"> </attachment>
                      <attachment idref="CHEM-US-00115" attachment-type="mol" file="US20200368173A1-20201126-C00115.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-48</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00116" num="00116">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ec/5d/ab/8b46f17875ddc9/US20200368173A1-20201126-C00116.png"><img id="EMI-C00116" he="17.19mm" wi="122.00mm" file="US20200368173A1-20201126-C00116.TIF" alt="Figure US20200368173A1-20201126-C00116" img-content="table" img-format="tif" orientation="portrait" inline="no" width="488" height="69" alt="Figure US20200368173A1-20201126-C00116" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ec/5d/ab/8b46f17875ddc9/US20200368173A1-20201126-C00116.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00116" attachment-type="cdx" file="US20200368173A1-20201126-C00116.CDX"> </attachment>
                      <attachment idref="CHEM-US-00116" attachment-type="mol" file="US20200368173A1-20201126-C00116.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-49</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00117" num="00117">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f7/de/82/6294e648e7c7a9/US20200368173A1-20201126-C00117.png"><img id="EMI-C00117" he="17.78mm" wi="123.02mm" file="US20200368173A1-20201126-C00117.TIF" alt="Figure US20200368173A1-20201126-C00117" img-content="table" img-format="tif" orientation="portrait" inline="no" width="492" height="71" alt="Figure US20200368173A1-20201126-C00117" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f7/de/82/6294e648e7c7a9/US20200368173A1-20201126-C00117.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00117" attachment-type="cdx" file="US20200368173A1-20201126-C00117.CDX"> </attachment>
                      <attachment idref="CHEM-US-00117" attachment-type="mol" file="US20200368173A1-20201126-C00117.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-50</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00118" num="00118">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d1/ff/39/d09450e3a3ae13/US20200368173A1-20201126-C00118.png"><img id="EMI-C00118" he="12.36mm" wi="119.80mm" file="US20200368173A1-20201126-C00118.TIF" alt="Figure US20200368173A1-20201126-C00118" img-content="table" img-format="tif" orientation="portrait" inline="no" width="479" height="49" alt="Figure US20200368173A1-20201126-C00118" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d1/ff/39/d09450e3a3ae13/US20200368173A1-20201126-C00118.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00118" attachment-type="cdx" file="US20200368173A1-20201126-C00118.CDX"> </attachment>
                      <attachment idref="CHEM-US-00118" attachment-type="mol" file="US20200368173A1-20201126-C00118.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0654" num="0000" class="description-line">
      <tables id="TABLE-US-00008" num="00008">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 8</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-51</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00119" num="00119">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/72/ec/c5/27795159997c46/US20200368173A1-20201126-C00119.png"><img id="EMI-C00119" he="21.59mm" wi="122.77mm" file="US20200368173A1-20201126-C00119.TIF" alt="Figure US20200368173A1-20201126-C00119" img-content="table" img-format="tif" orientation="portrait" inline="no" width="491" height="86" alt="Figure US20200368173A1-20201126-C00119" class="patent-full-image" src="https://patentimages.storage.googleapis.com/72/ec/c5/27795159997c46/US20200368173A1-20201126-C00119.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00119" attachment-type="cdx" file="US20200368173A1-20201126-C00119.CDX"> </attachment>
                      <attachment idref="CHEM-US-00119" attachment-type="mol" file="US20200368173A1-20201126-C00119.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-52</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00120" num="00120">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/91/c8/af/00138b50156ae0/US20200368173A1-20201126-C00120.png"><img id="EMI-C00120" he="21.51mm" wi="117.09mm" file="US20200368173A1-20201126-C00120.TIF" alt="Figure US20200368173A1-20201126-C00120" img-content="table" img-format="tif" orientation="portrait" inline="no" width="468" height="86" alt="Figure US20200368173A1-20201126-C00120" class="patent-full-image" src="https://patentimages.storage.googleapis.com/91/c8/af/00138b50156ae0/US20200368173A1-20201126-C00120.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00120" attachment-type="cdx" file="US20200368173A1-20201126-C00120.CDX"> </attachment>
                      <attachment idref="CHEM-US-00120" attachment-type="mol" file="US20200368173A1-20201126-C00120.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-53</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00121" num="00121">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1d/2d/9b/45b538d84a11cb/US20200368173A1-20201126-C00121.png"><img id="EMI-C00121" he="17.95mm" wi="118.19mm" file="US20200368173A1-20201126-C00121.TIF" alt="Figure US20200368173A1-20201126-C00121" img-content="table" img-format="tif" orientation="portrait" inline="no" width="473" height="72" alt="Figure US20200368173A1-20201126-C00121" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1d/2d/9b/45b538d84a11cb/US20200368173A1-20201126-C00121.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00121" attachment-type="cdx" file="US20200368173A1-20201126-C00121.CDX"> </attachment>
                      <attachment idref="CHEM-US-00121" attachment-type="mol" file="US20200368173A1-20201126-C00121.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-54</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00122" num="00122">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/15/9f/f4/c79031d218edfa/US20200368173A1-20201126-C00122.png"><img id="EMI-C00122" he="11.60mm" wi="120.82mm" file="US20200368173A1-20201126-C00122.TIF" alt="Figure US20200368173A1-20201126-C00122" img-content="table" img-format="tif" orientation="portrait" inline="no" width="483" height="46" alt="Figure US20200368173A1-20201126-C00122" class="patent-full-image" src="https://patentimages.storage.googleapis.com/15/9f/f4/c79031d218edfa/US20200368173A1-20201126-C00122.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00122" attachment-type="cdx" file="US20200368173A1-20201126-C00122.CDX"> </attachment>
                      <attachment idref="CHEM-US-00122" attachment-type="mol" file="US20200368173A1-20201126-C00122.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0655" num="0000" class="description-line">
      <tables id="TABLE-US-00009" num="00009">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 9</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-55</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00123" num="00123">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3f/8a/bb/758ee554d27109/US20200368173A1-20201126-C00123.png"><img id="EMI-C00123" he="11.51mm" wi="111.93mm" file="US20200368173A1-20201126-C00123.TIF" alt="Figure US20200368173A1-20201126-C00123" img-content="table" img-format="tif" orientation="portrait" inline="no" width="448" height="46" alt="Figure US20200368173A1-20201126-C00123" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3f/8a/bb/758ee554d27109/US20200368173A1-20201126-C00123.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00123" attachment-type="cdx" file="US20200368173A1-20201126-C00123.CDX"> </attachment>
                      <attachment idref="CHEM-US-00123" attachment-type="mol" file="US20200368173A1-20201126-C00123.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-56</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00124" num="00124">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0a/22/bb/3f4c5ceba65301/US20200368173A1-20201126-C00124.png"><img id="EMI-C00124" he="9.82mm" wi="117.01mm" file="US20200368173A1-20201126-C00124.TIF" alt="Figure US20200368173A1-20201126-C00124" img-content="table" img-format="tif" orientation="portrait" inline="no" width="468" height="39" alt="Figure US20200368173A1-20201126-C00124" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0a/22/bb/3f4c5ceba65301/US20200368173A1-20201126-C00124.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00124" attachment-type="cdx" file="US20200368173A1-20201126-C00124.CDX"> </attachment>
                      <attachment idref="CHEM-US-00124" attachment-type="mol" file="US20200368173A1-20201126-C00124.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-57</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00125" num="00125">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5b/d7/0a/9e10f1b2fa6c2a/US20200368173A1-20201126-C00125.png"><img id="EMI-C00125" he="11.60mm" wi="121.67mm" file="US20200368173A1-20201126-C00125.TIF" alt="Figure US20200368173A1-20201126-C00125" img-content="table" img-format="tif" orientation="portrait" inline="no" width="487" height="46" alt="Figure US20200368173A1-20201126-C00125" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5b/d7/0a/9e10f1b2fa6c2a/US20200368173A1-20201126-C00125.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00125" attachment-type="cdx" file="US20200368173A1-20201126-C00125.CDX"> </attachment>
                      <attachment idref="CHEM-US-00125" attachment-type="mol" file="US20200368173A1-20201126-C00125.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL 58</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00126" num="00126">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b6/70/0c/8a1866fd3a2a7a/US20200368173A1-20201126-C00126.png"><img id="EMI-C00126" he="8.30mm" wi="114.05mm" file="US20200368173A1-20201126-C00126.TIF" alt="Figure US20200368173A1-20201126-C00126" img-content="table" img-format="tif" orientation="portrait" inline="no" width="456" height="33" alt="Figure US20200368173A1-20201126-C00126" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b6/70/0c/8a1866fd3a2a7a/US20200368173A1-20201126-C00126.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00126" attachment-type="cdx" file="US20200368173A1-20201126-C00126.CDX"> </attachment>
                      <attachment idref="CHEM-US-00126" attachment-type="mol" file="US20200368173A1-20201126-C00126.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-59</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00127" num="00127">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a4/d9/66/7bda895d01f612/US20200368173A1-20201126-C00127.png"><img id="EMI-C00127" he="8.30mm" wi="118.96mm" file="US20200368173A1-20201126-C00127.TIF" alt="Figure US20200368173A1-20201126-C00127" img-content="table" img-format="tif" orientation="portrait" inline="no" width="476" height="33" alt="Figure US20200368173A1-20201126-C00127" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a4/d9/66/7bda895d01f612/US20200368173A1-20201126-C00127.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00127" attachment-type="cdx" file="US20200368173A1-20201126-C00127.CDX"> </attachment>
                      <attachment idref="CHEM-US-00127" attachment-type="mol" file="US20200368173A1-20201126-C00127.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-60</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00128" num="00128">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/80/35/a2/90b39dc9e3a2b3/US20200368173A1-20201126-C00128.png"><img id="EMI-C00128" he="15.07mm" wi="130.98mm" file="US20200368173A1-20201126-C00128.TIF" alt="Figure US20200368173A1-20201126-C00128" img-content="table" img-format="tif" orientation="portrait" inline="no" width="524" height="60" alt="Figure US20200368173A1-20201126-C00128" class="patent-full-image" src="https://patentimages.storage.googleapis.com/80/35/a2/90b39dc9e3a2b3/US20200368173A1-20201126-C00128.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00128" attachment-type="cdx" file="US20200368173A1-20201126-C00128.CDX"> </attachment>
                      <attachment idref="CHEM-US-00128" attachment-type="mol" file="US20200368173A1-20201126-C00128.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0656" num="0000" class="description-line">
      <tables id="TABLE-US-00010" num="00010">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 10</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-61</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00129" num="00129">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/6e/79/d3c0d66b7573fa/US20200368173A1-20201126-C00129.png"><img id="EMI-C00129" he="11.60mm" wi="105.07mm" file="US20200368173A1-20201126-C00129.TIF" alt="Figure US20200368173A1-20201126-C00129" img-content="table" img-format="tif" orientation="portrait" inline="no" width="420" height="46" alt="Figure US20200368173A1-20201126-C00129" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/6e/79/d3c0d66b7573fa/US20200368173A1-20201126-C00129.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00129" attachment-type="cdx" file="US20200368173A1-20201126-C00129.CDX"> </attachment>
                      <attachment idref="CHEM-US-00129" attachment-type="mol" file="US20200368173A1-20201126-C00129.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-62</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00130" num="00130">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/cb/01/d3eff3abbf28b1/US20200368173A1-20201126-C00130.png"><img id="EMI-C00130" he="11.60mm" wi="109.98mm" file="US20200368173A1-20201126-C00130.TIF" alt="Figure US20200368173A1-20201126-C00130" img-content="table" img-format="tif" orientation="portrait" inline="no" width="440" height="46" alt="Figure US20200368173A1-20201126-C00130" class="patent-full-image" src="https://patentimages.storage.googleapis.com/97/cb/01/d3eff3abbf28b1/US20200368173A1-20201126-C00130.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00130" attachment-type="cdx" file="US20200368173A1-20201126-C00130.CDX"> </attachment>
                      <attachment idref="CHEM-US-00130" attachment-type="mol" file="US20200368173A1-20201126-C00130.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-63</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00131" num="00131">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/76/b5/81/318230b0762ee5/US20200368173A1-20201126-C00131.png"><img id="EMI-C00131" he="15.66mm" wi="100.08mm" file="US20200368173A1-20201126-C00131.TIF" alt="Figure US20200368173A1-20201126-C00131" img-content="table" img-format="tif" orientation="portrait" inline="no" width="400" height="63" alt="Figure US20200368173A1-20201126-C00131" class="patent-full-image" src="https://patentimages.storage.googleapis.com/76/b5/81/318230b0762ee5/US20200368173A1-20201126-C00131.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00131" attachment-type="cdx" file="US20200368173A1-20201126-C00131.CDX"> </attachment>
                      <attachment idref="CHEM-US-00131" attachment-type="mol" file="US20200368173A1-20201126-C00131.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-64</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00132" num="00132">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d3/70/d3/abe3feca81890d/US20200368173A1-20201126-C00132.png"><img id="EMI-C00132" he="15.66mm" wi="99.65mm" file="US20200368173A1-20201126-C00132.TIF" alt="Figure US20200368173A1-20201126-C00132" img-content="table" img-format="tif" orientation="portrait" inline="no" width="399" height="63" alt="Figure US20200368173A1-20201126-C00132" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d3/70/d3/abe3feca81890d/US20200368173A1-20201126-C00132.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00132" attachment-type="cdx" file="US20200368173A1-20201126-C00132.CDX"> </attachment>
                      <attachment idref="CHEM-US-00132" attachment-type="mol" file="US20200368173A1-20201126-C00132.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-65</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00133" num="00133">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/73/cd/bd/7165c37b756aeb/US20200368173A1-20201126-C00133.png"><img id="EMI-C00133" he="15.66mm" wi="109.64mm" file="US20200368173A1-20201126-C00133.TIF" alt="Figure US20200368173A1-20201126-C00133" img-content="table" img-format="tif" orientation="portrait" inline="no" width="439" height="63" alt="Figure US20200368173A1-20201126-C00133" class="patent-full-image" src="https://patentimages.storage.googleapis.com/73/cd/bd/7165c37b756aeb/US20200368173A1-20201126-C00133.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00133" attachment-type="cdx" file="US20200368173A1-20201126-C00133.CDX"> </attachment>
                      <attachment idref="CHEM-US-00133" attachment-type="mol" file="US20200368173A1-20201126-C00133.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-66</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00134" num="00134">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fd/c9/dc/83ebbf635e7b24/US20200368173A1-20201126-C00134.png"><img id="EMI-C00134" he="32.34mm" wi="115.49mm" file="US20200368173A1-20201126-C00134.TIF" alt="Figure US20200368173A1-20201126-C00134" img-content="table" img-format="tif" orientation="portrait" inline="no" width="462" height="129" alt="Figure US20200368173A1-20201126-C00134" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fd/c9/dc/83ebbf635e7b24/US20200368173A1-20201126-C00134.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00134" attachment-type="cdx" file="US20200368173A1-20201126-C00134.CDX"> </attachment>
                      <attachment idref="CHEM-US-00134" attachment-type="mol" file="US20200368173A1-20201126-C00134.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0657" num="0000" class="description-line">
      <tables id="TABLE-US-00011" num="00011">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 11</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-67</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00135" num="00135">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ad/78/2e/9ae92143f8dc66/US20200368173A1-20201126-C00135.png"><img id="EMI-C00135" he="12.36mm" wi="105.16mm" file="US20200368173A1-20201126-C00135.TIF" alt="Figure US20200368173A1-20201126-C00135" img-content="table" img-format="tif" orientation="portrait" inline="no" width="421" height="49" alt="Figure US20200368173A1-20201126-C00135" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ad/78/2e/9ae92143f8dc66/US20200368173A1-20201126-C00135.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00135" attachment-type="cdx" file="US20200368173A1-20201126-C00135.CDX"> </attachment>
                      <attachment idref="CHEM-US-00135" attachment-type="mol" file="US20200368173A1-20201126-C00135.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-68</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00136" num="00136">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1e/d1/85/03b853371b0087/US20200368173A1-20201126-C00136.png"><img id="EMI-C00136" he="13.63mm" wi="110.49mm" file="US20200368173A1-20201126-C00136.TIF" alt="Figure US20200368173A1-20201126-C00136" img-content="table" img-format="tif" orientation="portrait" inline="no" width="442" height="55" alt="Figure US20200368173A1-20201126-C00136" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1e/d1/85/03b853371b0087/US20200368173A1-20201126-C00136.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00136" attachment-type="cdx" file="US20200368173A1-20201126-C00136.CDX"> </attachment>
                      <attachment idref="CHEM-US-00136" attachment-type="mol" file="US20200368173A1-20201126-C00136.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-69</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00137" num="00137">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/68/54/57/253edfff36a8fe/US20200368173A1-20201126-C00137.png"><img id="EMI-C00137" he="19.30mm" wi="125.14mm" file="US20200368173A1-20201126-C00137.TIF" alt="Figure US20200368173A1-20201126-C00137" img-content="table" img-format="tif" orientation="portrait" inline="no" width="501" height="77" alt="Figure US20200368173A1-20201126-C00137" class="patent-full-image" src="https://patentimages.storage.googleapis.com/68/54/57/253edfff36a8fe/US20200368173A1-20201126-C00137.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00137" attachment-type="cdx" file="US20200368173A1-20201126-C00137.CDX"> </attachment>
                      <attachment idref="CHEM-US-00137" attachment-type="mol" file="US20200368173A1-20201126-C00137.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-70</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00138" num="00138">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/72/d9/e3/46ea3c355e9d9e/US20200368173A1-20201126-C00138.png"><img id="EMI-C00138" he="12.28mm" wi="106.26mm" file="US20200368173A1-20201126-C00138.TIF" alt="Figure US20200368173A1-20201126-C00138" img-content="table" img-format="tif" orientation="portrait" inline="no" width="425" height="49" alt="Figure US20200368173A1-20201126-C00138" class="patent-full-image" src="https://patentimages.storage.googleapis.com/72/d9/e3/46ea3c355e9d9e/US20200368173A1-20201126-C00138.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00138" attachment-type="cdx" file="US20200368173A1-20201126-C00138.CDX"> </attachment>
                      <attachment idref="CHEM-US-00138" attachment-type="mol" file="US20200368173A1-20201126-C00138.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-71</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00139" num="00139">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/59/22/88/ff939eefee515c/US20200368173A1-20201126-C00139.png"><img id="EMI-C00139" he="17.95mm" wi="130.81mm" file="US20200368173A1-20201126-C00139.TIF" alt="Figure US20200368173A1-20201126-C00139" img-content="table" img-format="tif" orientation="portrait" inline="no" width="523" height="72" alt="Figure US20200368173A1-20201126-C00139" class="patent-full-image" src="https://patentimages.storage.googleapis.com/59/22/88/ff939eefee515c/US20200368173A1-20201126-C00139.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00139" attachment-type="cdx" file="US20200368173A1-20201126-C00139.CDX"> </attachment>
                      <attachment idref="CHEM-US-00139" attachment-type="mol" file="US20200368173A1-20201126-C00139.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-72</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00140" num="00140">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/00/81/f4/c07105501bb346/US20200368173A1-20201126-C00140.png"><img id="EMI-C00140" he="18.54mm" wi="130.05mm" file="US20200368173A1-20201126-C00140.TIF" alt="Figure US20200368173A1-20201126-C00140" img-content="table" img-format="tif" orientation="portrait" inline="no" width="520" height="74" alt="Figure US20200368173A1-20201126-C00140" class="patent-full-image" src="https://patentimages.storage.googleapis.com/00/81/f4/c07105501bb346/US20200368173A1-20201126-C00140.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00140" attachment-type="cdx" file="US20200368173A1-20201126-C00140.CDX"> </attachment>
                      <attachment idref="CHEM-US-00140" attachment-type="mol" file="US20200368173A1-20201126-C00140.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-73</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00141" num="00141">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/04/eb/2b/fbdfca3b10c370/US20200368173A1-20201126-C00141.png"><img id="EMI-C00141" he="19.30mm" wi="134.96mm" file="US20200368173A1-20201126-C00141.TIF" alt="Figure US20200368173A1-20201126-C00141" img-content="table" img-format="tif" orientation="portrait" inline="no" width="540" height="77" alt="Figure US20200368173A1-20201126-C00141" class="patent-full-image" src="https://patentimages.storage.googleapis.com/04/eb/2b/fbdfca3b10c370/US20200368173A1-20201126-C00141.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00141" attachment-type="cdx" file="US20200368173A1-20201126-C00141.CDX"> </attachment>
                      <attachment idref="CHEM-US-00141" attachment-type="mol" file="US20200368173A1-20201126-C00141.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0658" num="0000" class="description-line">
      <tables id="TABLE-US-00012" num="00012">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 12</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-74</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00142" num="00142">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ac/60/e4/94a956322fd6ff/US20200368173A1-20201126-C00142.png"><img id="EMI-C00142" he="17.10mm" wi="128.86mm" file="US20200368173A1-20201126-C00142.TIF" alt="Figure US20200368173A1-20201126-C00142" img-content="table" img-format="tif" orientation="portrait" inline="no" width="515" height="68" alt="Figure US20200368173A1-20201126-C00142" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ac/60/e4/94a956322fd6ff/US20200368173A1-20201126-C00142.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00142" attachment-type="cdx" file="US20200368173A1-20201126-C00142.CDX"> </attachment>
                      <attachment idref="CHEM-US-00142" attachment-type="mol" file="US20200368173A1-20201126-C00142.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-75</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00143" num="00143">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/44/a5/9b/f1a06ee9b49f2f/US20200368173A1-20201126-C00143.png"><img id="EMI-C00143" he="17.27mm" wi="128.10mm" file="US20200368173A1-20201126-C00143.TIF" alt="Figure US20200368173A1-20201126-C00143" img-content="table" img-format="tif" orientation="portrait" inline="no" width="512" height="69" alt="Figure US20200368173A1-20201126-C00143" class="patent-full-image" src="https://patentimages.storage.googleapis.com/44/a5/9b/f1a06ee9b49f2f/US20200368173A1-20201126-C00143.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00143" attachment-type="cdx" file="US20200368173A1-20201126-C00143.CDX"> </attachment>
                      <attachment idref="CHEM-US-00143" attachment-type="mol" file="US20200368173A1-20201126-C00143.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-76</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00144" num="00144">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6c/a1/b4/8ca7691c9561b4/US20200368173A1-20201126-C00144.png"><img id="EMI-C00144" he="10.50mm" wi="117.52mm" file="US20200368173A1-20201126-C00144.TIF" alt="Figure US20200368173A1-20201126-C00144" img-content="table" img-format="tif" orientation="portrait" inline="no" width="470" height="42" alt="Figure US20200368173A1-20201126-C00144" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6c/a1/b4/8ca7691c9561b4/US20200368173A1-20201126-C00144.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00144" attachment-type="cdx" file="US20200368173A1-20201126-C00144.CDX"> </attachment>
                      <attachment idref="CHEM-US-00144" attachment-type="mol" file="US20200368173A1-20201126-C00144.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-77</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00145" num="00145">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/99/89/49db375e90d730/US20200368173A1-20201126-C00145.png"><img id="EMI-C00145" he="12.53mm" wi="116.84mm" file="US20200368173A1-20201126-C00145.TIF" alt="Figure US20200368173A1-20201126-C00145" img-content="table" img-format="tif" orientation="portrait" inline="no" width="467" height="50" alt="Figure US20200368173A1-20201126-C00145" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/99/89/49db375e90d730/US20200368173A1-20201126-C00145.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00145" attachment-type="cdx" file="US20200368173A1-20201126-C00145.CDX"> </attachment>
                      <attachment idref="CHEM-US-00145" attachment-type="mol" file="US20200368173A1-20201126-C00145.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-78</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00146" num="00146">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/81/21/8e/d27cb03ff2bd1d/US20200368173A1-20201126-C00146.png"><img id="EMI-C00146" he="17.02mm" wi="128.86mm" file="US20200368173A1-20201126-C00146.TIF" alt="Figure US20200368173A1-20201126-C00146" img-content="table" img-format="tif" orientation="portrait" inline="no" width="515" height="68" alt="Figure US20200368173A1-20201126-C00146" class="patent-full-image" src="https://patentimages.storage.googleapis.com/81/21/8e/d27cb03ff2bd1d/US20200368173A1-20201126-C00146.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00146" attachment-type="cdx" file="US20200368173A1-20201126-C00146.CDX"> </attachment>
                      <attachment idref="CHEM-US-00146" attachment-type="mol" file="US20200368173A1-20201126-C00146.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-79</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00147" num="00147">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0e/9d/4c/4b4af24deaea55/US20200368173A1-20201126-C00147.png"><img id="EMI-C00147" he="10.50mm" wi="117.52mm" file="US20200368173A1-20201126-C00147.TIF" alt="Figure US20200368173A1-20201126-C00147" img-content="table" img-format="tif" orientation="portrait" inline="no" width="470" height="42" alt="Figure US20200368173A1-20201126-C00147" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0e/9d/4c/4b4af24deaea55/US20200368173A1-20201126-C00147.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00147" attachment-type="cdx" file="US20200368173A1-20201126-C00147.CDX"> </attachment>
                      <attachment idref="CHEM-US-00147" attachment-type="mol" file="US20200368173A1-20201126-C00147.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-80</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00148" num="00148">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/65/07/e9/dfe5fe448ae661/US20200368173A1-20201126-C00148.png"><img id="EMI-C00148" he="17.19mm" wi="128.10mm" file="US20200368173A1-20201126-C00148.TIF" alt="Figure US20200368173A1-20201126-C00148" img-content="table" img-format="tif" orientation="portrait" inline="no" width="512" height="69" alt="Figure US20200368173A1-20201126-C00148" class="patent-full-image" src="https://patentimages.storage.googleapis.com/65/07/e9/dfe5fe448ae661/US20200368173A1-20201126-C00148.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00148" attachment-type="cdx" file="US20200368173A1-20201126-C00148.CDX"> </attachment>
                      <attachment idref="CHEM-US-00148" attachment-type="mol" file="US20200368173A1-20201126-C00148.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-81</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00149" num="00149">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7d/81/93/d3f00a32b05751/US20200368173A1-20201126-C00149.png"><img id="EMI-C00149" he="12.53mm" wi="116.84mm" file="US20200368173A1-20201126-C00149.TIF" alt="Figure US20200368173A1-20201126-C00149" img-content="table" img-format="tif" orientation="portrait" inline="no" width="467" height="50" alt="Figure US20200368173A1-20201126-C00149" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7d/81/93/d3f00a32b05751/US20200368173A1-20201126-C00149.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00149" attachment-type="cdx" file="US20200368173A1-20201126-C00149.CDX"> </attachment>
                      <attachment idref="CHEM-US-00149" attachment-type="mol" file="US20200368173A1-20201126-C00149.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0659" num="0000" class="description-line">
      <tables id="TABLE-US-00013" num="00013">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 13</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-82</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00150" num="00150">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f6/11/e1/8adfc0558284fb/US20200368173A1-20201126-C00150.png"><img id="EMI-C00150" he="12.95mm" wi="124.29mm" file="US20200368173A1-20201126-C00150.TIF" alt="Figure US20200368173A1-20201126-C00150" img-content="table" img-format="tif" orientation="portrait" inline="no" width="497" height="52" alt="Figure US20200368173A1-20201126-C00150" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f6/11/e1/8adfc0558284fb/US20200368173A1-20201126-C00150.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00150" attachment-type="cdx" file="US20200368173A1-20201126-C00150.CDX"> </attachment>
                      <attachment idref="CHEM-US-00150" attachment-type="mol" file="US20200368173A1-20201126-C00150.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-83</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00151" num="00151">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/37/45/c0/9211bf3d6ec4d6/US20200368173A1-20201126-C00151.png"><img id="EMI-C00151" he="19.30mm" wi="139.87mm" file="US20200368173A1-20201126-C00151.TIF" alt="Figure US20200368173A1-20201126-C00151" img-content="table" img-format="tif" orientation="portrait" inline="no" width="559" height="77" alt="Figure US20200368173A1-20201126-C00151" class="patent-full-image" src="https://patentimages.storage.googleapis.com/37/45/c0/9211bf3d6ec4d6/US20200368173A1-20201126-C00151.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00151" attachment-type="cdx" file="US20200368173A1-20201126-C00151.CDX"> </attachment>
                      <attachment idref="CHEM-US-00151" attachment-type="mol" file="US20200368173A1-20201126-C00151.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-84</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00152" num="00152">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/90/b0/8c/625fb44c1d793a/US20200368173A1-20201126-C00152.png"><img id="EMI-C00152" he="22.18mm" wi="130.05mm" file="US20200368173A1-20201126-C00152.TIF" alt="Figure US20200368173A1-20201126-C00152" img-content="table" img-format="tif" orientation="portrait" inline="no" width="520" height="89" alt="Figure US20200368173A1-20201126-C00152" class="patent-full-image" src="https://patentimages.storage.googleapis.com/90/b0/8c/625fb44c1d793a/US20200368173A1-20201126-C00152.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00152" attachment-type="cdx" file="US20200368173A1-20201126-C00152.CDX"> </attachment>
                      <attachment idref="CHEM-US-00152" attachment-type="mol" file="US20200368173A1-20201126-C00152.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-85</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00153" num="00153">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5f/bb/4b/ebe8b8e3dcaa35/US20200368173A1-20201126-C00153.png"><img id="EMI-C00153" he="19.30mm" wi="130.05mm" file="US20200368173A1-20201126-C00153.TIF" alt="Figure US20200368173A1-20201126-C00153" img-content="table" img-format="tif" orientation="portrait" inline="no" width="520" height="77" alt="Figure US20200368173A1-20201126-C00153" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5f/bb/4b/ebe8b8e3dcaa35/US20200368173A1-20201126-C00153.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00153" attachment-type="cdx" file="US20200368173A1-20201126-C00153.CDX"> </attachment>
                      <attachment idref="CHEM-US-00153" attachment-type="mol" file="US20200368173A1-20201126-C00153.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-86</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00154" num="00154">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a9/3d/36/78ddcb5b818a0d/US20200368173A1-20201126-C00154.png"><img id="EMI-C00154" he="19.30mm" wi="134.96mm" file="US20200368173A1-20201126-C00154.TIF" alt="Figure US20200368173A1-20201126-C00154" img-content="table" img-format="tif" orientation="portrait" inline="no" width="540" height="77" alt="Figure US20200368173A1-20201126-C00154" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a9/3d/36/78ddcb5b818a0d/US20200368173A1-20201126-C00154.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00154" attachment-type="cdx" file="US20200368173A1-20201126-C00154.CDX"> </attachment>
                      <attachment idref="CHEM-US-00154" attachment-type="mol" file="US20200368173A1-20201126-C00154.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-87</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00155" num="00155">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a1/1b/f7/f13a048bf5ea5b/US20200368173A1-20201126-C00155.png"><img id="EMI-C00155" he="13.63mm" wi="115.40mm" file="US20200368173A1-20201126-C00155.TIF" alt="Figure US20200368173A1-20201126-C00155" img-content="table" img-format="tif" orientation="portrait" inline="no" width="462" height="55" alt="Figure US20200368173A1-20201126-C00155" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a1/1b/f7/f13a048bf5ea5b/US20200368173A1-20201126-C00155.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00155" attachment-type="cdx" file="US20200368173A1-20201126-C00155.CDX"> </attachment>
                      <attachment idref="CHEM-US-00155" attachment-type="mol" file="US20200368173A1-20201126-C00155.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-88</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00156" num="00156">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/df/1c/dc/c287a5ab8137df/US20200368173A1-20201126-C00156.png"><img id="EMI-C00156" he="12.28mm" wi="107.02mm" file="US20200368173A1-20201126-C00156.TIF" alt="Figure US20200368173A1-20201126-C00156" img-content="table" img-format="tif" orientation="portrait" inline="no" width="428" height="49" alt="Figure US20200368173A1-20201126-C00156" class="patent-full-image" src="https://patentimages.storage.googleapis.com/df/1c/dc/c287a5ab8137df/US20200368173A1-20201126-C00156.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00156" attachment-type="cdx" file="US20200368173A1-20201126-C00156.CDX"> </attachment>
                      <attachment idref="CHEM-US-00156" attachment-type="mol" file="US20200368173A1-20201126-C00156.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0660" num="0000" class="description-line">
      <tables id="TABLE-US-00014" num="00014">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 14</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-89</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00157" num="00157">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/13/af/a2/eb514c65f29349/US20200368173A1-20201126-C00157.png"><img id="EMI-C00157" he="10.50mm" wi="107.70mm" file="US20200368173A1-20201126-C00157.TIF" alt="Figure US20200368173A1-20201126-C00157" img-content="table" img-format="tif" orientation="portrait" inline="no" width="431" height="42" alt="Figure US20200368173A1-20201126-C00157" class="patent-full-image" src="https://patentimages.storage.googleapis.com/13/af/a2/eb514c65f29349/US20200368173A1-20201126-C00157.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00157" attachment-type="cdx" file="US20200368173A1-20201126-C00157.CDX"> </attachment>
                      <attachment idref="CHEM-US-00157" attachment-type="mol" file="US20200368173A1-20201126-C00157.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-90</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00158" num="00158">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/25/a8/75/1b16c29033238d/US20200368173A1-20201126-C00158.png"><img id="EMI-C00158" he="10.50mm" wi="106.93mm" file="US20200368173A1-20201126-C00158.TIF" alt="Figure US20200368173A1-20201126-C00158" img-content="table" img-format="tif" orientation="portrait" inline="no" width="428" height="42" alt="Figure US20200368173A1-20201126-C00158" class="patent-full-image" src="https://patentimages.storage.googleapis.com/25/a8/75/1b16c29033238d/US20200368173A1-20201126-C00158.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00158" attachment-type="cdx" file="US20200368173A1-20201126-C00158.CDX"> </attachment>
                      <attachment idref="CHEM-US-00158" attachment-type="mol" file="US20200368173A1-20201126-C00158.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-91</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00159" num="00159">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c1/e9/e0/bd805760e5065a/US20200368173A1-20201126-C00159.png"><img id="EMI-C00159" he="12.53mm" wi="119.63mm" file="US20200368173A1-20201126-C00159.TIF" alt="Figure US20200368173A1-20201126-C00159" img-content="table" img-format="tif" orientation="portrait" inline="no" width="479" height="50" alt="Figure US20200368173A1-20201126-C00159" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c1/e9/e0/bd805760e5065a/US20200368173A1-20201126-C00159.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00159" attachment-type="cdx" file="US20200368173A1-20201126-C00159.CDX"> </attachment>
                      <attachment idref="CHEM-US-00159" attachment-type="mol" file="US20200368173A1-20201126-C00159.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-92</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00160" num="00160">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/19/4e/09/601d64426ed36b/US20200368173A1-20201126-C00160.png"><img id="EMI-C00160" he="12.53mm" wi="125.31mm" file="US20200368173A1-20201126-C00160.TIF" alt="Figure US20200368173A1-20201126-C00160" img-content="table" img-format="tif" orientation="portrait" inline="no" width="501" height="50" alt="Figure US20200368173A1-20201126-C00160" class="patent-full-image" src="https://patentimages.storage.googleapis.com/19/4e/09/601d64426ed36b/US20200368173A1-20201126-C00160.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00160" attachment-type="cdx" file="US20200368173A1-20201126-C00160.CDX"> </attachment>
                      <attachment idref="CHEM-US-00160" attachment-type="mol" file="US20200368173A1-20201126-C00160.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-93</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00161" num="00161">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/87/08/af/9ee44bdc1cbba6/US20200368173A1-20201126-C00161.png"><img id="EMI-C00161" he="11.51mm" wi="98.21mm" file="US20200368173A1-20201126-C00161.TIF" alt="Figure US20200368173A1-20201126-C00161" img-content="table" img-format="tif" orientation="portrait" inline="no" width="393" height="46" alt="Figure US20200368173A1-20201126-C00161" class="patent-full-image" src="https://patentimages.storage.googleapis.com/87/08/af/9ee44bdc1cbba6/US20200368173A1-20201126-C00161.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00161" attachment-type="cdx" file="US20200368173A1-20201126-C00161.CDX"> </attachment>
                      <attachment idref="CHEM-US-00161" attachment-type="mol" file="US20200368173A1-20201126-C00161.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-94</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00162" num="00162">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/39/bb/cc/512f21bd80c591/US20200368173A1-20201126-C00162.png"><img id="EMI-C00162" he="11.60mm" wi="108.12mm" file="US20200368173A1-20201126-C00162.TIF" alt="Figure US20200368173A1-20201126-C00162" img-content="table" img-format="tif" orientation="portrait" inline="no" width="432" height="46" alt="Figure US20200368173A1-20201126-C00162" class="patent-full-image" src="https://patentimages.storage.googleapis.com/39/bb/cc/512f21bd80c591/US20200368173A1-20201126-C00162.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00162" attachment-type="cdx" file="US20200368173A1-20201126-C00162.CDX"> </attachment>
                      <attachment idref="CHEM-US-00162" attachment-type="mol" file="US20200368173A1-20201126-C00162.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-95</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00163" num="00163">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/35/bf/83/8ee1c0aa318152/US20200368173A1-20201126-C00163.png"><img id="EMI-C00163" he="17.02mm" wi="119.46mm" file="US20200368173A1-20201126-C00163.TIF" alt="Figure US20200368173A1-20201126-C00163" img-content="table" img-format="tif" orientation="portrait" inline="no" width="478" height="68" alt="Figure US20200368173A1-20201126-C00163" class="patent-full-image" src="https://patentimages.storage.googleapis.com/35/bf/83/8ee1c0aa318152/US20200368173A1-20201126-C00163.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00163" attachment-type="cdx" file="US20200368173A1-20201126-C00163.CDX"> </attachment>
                      <attachment idref="CHEM-US-00163" attachment-type="mol" file="US20200368173A1-20201126-C00163.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-0661" num="0000" class="description-line">
      <tables id="TABLE-US-00015" num="00015">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 15</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">CL-96</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00164" num="00164">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fa/6d/d1/c76486a113caf8/US20200368173A1-20201126-C00164.png"><img id="EMI-C00164" he="11.51mm" wi="108.03mm" file="US20200368173A1-20201126-C00164.TIF" alt="Figure US20200368173A1-20201126-C00164" img-content="table" img-format="tif" orientation="portrait" inline="no" width="432" height="46" alt="Figure US20200368173A1-20201126-C00164" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fa/6d/d1/c76486a113caf8/US20200368173A1-20201126-C00164.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00164" attachment-type="cdx" file="US20200368173A1-20201126-C00164.CDX"> </attachment>
                      <attachment idref="CHEM-US-00164" attachment-type="mol" file="US20200368173A1-20201126-C00164.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-97</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00165" num="00165">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9a/f6/f7/b0771be4bc5094/US20200368173A1-20201126-C00165.png"><img id="EMI-C00165" he="11.60mm" wi="117.94mm" file="US20200368173A1-20201126-C00165.TIF" alt="Figure US20200368173A1-20201126-C00165" img-content="table" img-format="tif" orientation="portrait" inline="no" width="472" height="46" alt="Figure US20200368173A1-20201126-C00165" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9a/f6/f7/b0771be4bc5094/US20200368173A1-20201126-C00165.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00165" attachment-type="cdx" file="US20200368173A1-20201126-C00165.CDX"> </attachment>
                      <attachment idref="CHEM-US-00165" attachment-type="mol" file="US20200368173A1-20201126-C00165.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-98</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00166" num="00166">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/13/4c/76/4d5316e2152c5d/US20200368173A1-20201126-C00166.png"><img id="EMI-C00166" he="17.02mm" wi="129.20mm" file="US20200368173A1-20201126-C00166.TIF" alt="Figure US20200368173A1-20201126-C00166" img-content="table" img-format="tif" orientation="portrait" inline="no" width="517" height="68" alt="Figure US20200368173A1-20201126-C00166" class="patent-full-image" src="https://patentimages.storage.googleapis.com/13/4c/76/4d5316e2152c5d/US20200368173A1-20201126-C00166.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00166" attachment-type="cdx" file="US20200368173A1-20201126-C00166.CDX"> </attachment>
                      <attachment idref="CHEM-US-00166" attachment-type="mol" file="US20200368173A1-20201126-C00166.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-99</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00167" num="00167">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8a/6e/98/85a2873088d7a0/US20200368173A1-20201126-C00167.png"><img id="EMI-C00167" he="11.60mm" wi="88.48mm" file="US20200368173A1-20201126-C00167.TIF" alt="Figure US20200368173A1-20201126-C00167" img-content="table" img-format="tif" orientation="portrait" inline="no" width="354" height="46" alt="Figure US20200368173A1-20201126-C00167" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8a/6e/98/85a2873088d7a0/US20200368173A1-20201126-C00167.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00167" attachment-type="cdx" file="US20200368173A1-20201126-C00167.CDX"> </attachment>
                      <attachment idref="CHEM-US-00167" attachment-type="mol" file="US20200368173A1-20201126-C00167.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-100</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00168" num="00168">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/51/3c/01/1b25f31bea7a4f/US20200368173A1-20201126-C00168.png"><img id="EMI-C00168" he="11.60mm" wi="98.38mm" file="US20200368173A1-20201126-C00168.TIF" alt="Figure US20200368173A1-20201126-C00168" img-content="table" img-format="tif" orientation="portrait" inline="no" width="394" height="46" alt="Figure US20200368173A1-20201126-C00168" class="patent-full-image" src="https://patentimages.storage.googleapis.com/51/3c/01/1b25f31bea7a4f/US20200368173A1-20201126-C00168.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00168" attachment-type="cdx" file="US20200368173A1-20201126-C00168.CDX"> </attachment>
                      <attachment idref="CHEM-US-00168" attachment-type="mol" file="US20200368173A1-20201126-C00168.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-101</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00169" num="00169">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/eb/d9/9a/61aee2d76cd2b6/US20200368173A1-20201126-C00169.png"><img id="EMI-C00169" he="17.02mm" wi="109.64mm" file="US20200368173A1-20201126-C00169.TIF" alt="Figure US20200368173A1-20201126-C00169" img-content="table" img-format="tif" orientation="portrait" inline="no" width="439" height="68" alt="Figure US20200368173A1-20201126-C00169" class="patent-full-image" src="https://patentimages.storage.googleapis.com/eb/d9/9a/61aee2d76cd2b6/US20200368173A1-20201126-C00169.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00169" attachment-type="cdx" file="US20200368173A1-20201126-C00169.CDX"> </attachment>
                      <attachment idref="CHEM-US-00169" attachment-type="mol" file="US20200368173A1-20201126-C00169.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-102</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00170" num="00170">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f9/9a/ba/1c1cd404040a40/US20200368173A1-20201126-C00170.png"><img id="EMI-C00170" he="10.50mm" wi="106.93mm" file="US20200368173A1-20201126-C00170.TIF" alt="Figure US20200368173A1-20201126-C00170" img-content="table" img-format="tif" orientation="portrait" inline="no" width="428" height="42" alt="Figure US20200368173A1-20201126-C00170" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f9/9a/ba/1c1cd404040a40/US20200368173A1-20201126-C00170.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00170" attachment-type="cdx" file="US20200368173A1-20201126-C00170.CDX"> </attachment>
                      <attachment idref="CHEM-US-00170" attachment-type="mol" file="US20200368173A1-20201126-C00170.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">CL-103</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00171" num="00171">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/37/ef/a5/a73272152657fc/US20200368173A1-20201126-C00171.png"><img id="EMI-C00171" he="16.34mm" wi="119.46mm" file="US20200368173A1-20201126-C00171.TIF" alt="Figure US20200368173A1-20201126-C00171" img-content="table" img-format="tif" orientation="portrait" inline="no" width="478" height="65" alt="Figure US20200368173A1-20201126-C00171" class="patent-full-image" src="https://patentimages.storage.googleapis.com/37/ef/a5/a73272152657fc/US20200368173A1-20201126-C00171.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00171" attachment-type="cdx" file="US20200368173A1-20201126-C00171.CDX"> </attachment>
                      <attachment idref="CHEM-US-00171" attachment-type="mol" file="US20200368173A1-20201126-C00171.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0491]"> </para-num> <div id="p-0662" num="0491" class="description-line">Next, methods for producing lipid A used in the present invention will be described. In the production methods shown below, if defined groups react under conditions of the production methods or are unsuitable for carrying out the production methods, the desired compounds can be obtained by use of introduction and removal methods of protective groups commonly used in organic synthetic chemistry [e.g., methods described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999)] or the like. If necessary, the order of reaction steps including substituent introduction or the like may be changed.</div>
    </li> <li> <para-num num="[0492]"> </para-num> <div id="p-0663" num="0492" class="description-line">General unit reactions such as etherification (The Fourth Series of <figure-callout id="20" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Experimental Chemistry</figure-callout> 20, Synthesis of Organic Compound II, 4th edition, p. 187, Maruzen Co., Ltd. (1992), etc.), amination (The Fourth Series of <figure-callout id="20" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Experimental Chemistry</figure-callout> 20, Synthesis of Organic Compound II, 4th edition, p. 279, Maruzen Co., Ltd. (1992), etc.), esterification (The Fourth Series of Experimental Chemistry 22, Synthesis of Organic Compound IV, 4th edition, p. 43, Maruzen Co., Ltd. (1992), etc.), and amidation (The Fourth Series of Experimental Chemistry 22, Synthesis of Organic Compound IV, 4th edition, p. 137, Maruzen Co., Ltd. (1992), etc.) described in the production methods shown below may each be performed under general reaction conditions described in the existing literatures.</div>
    </li> <li> <para-num num="[0493]"> </para-num> <div id="p-0664" num="0493" class="description-line">Compound (I) can be obtained by any method of <figure-callout id="1" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}"> <figure-callout id="2" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> </figure-callout> 1 or 2 given below, a method equivalent to the method, or the like.</div>
    </li> <li> <para-num num="[0494]"> </para-num> <div id="p-0665" num="0494" class="description-line">Compound (I) can be obtained from ammonia according to <figure-callout id="1" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 1.</div>
    </li> <li> <div id="p-0666" num="0000" class="description-line">
      <chemistry id="CHEM-US-00172" num="00172">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2b/7b/bf/47c28ea260023d/US20200368173A1-20201126-C00172.png"><img id="EMI-C00172" he="107.19mm" wi="75.78mm" file="US20200368173A1-20201126-C00172.TIF" alt="Figure US20200368173A1-20201126-C00172" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="429" alt="Figure US20200368173A1-20201126-C00172" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2b/7b/bf/47c28ea260023d/US20200368173A1-20201126-C00172.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00172" attachment-type="cdx" file="US20200368173A1-20201126-C00172.CDX"> </attachment>
          <attachment idref="CHEM-US-00172" attachment-type="mol" file="US20200368173A1-20201126-C00172.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0667" num="0000" class="description-line">wherein Ms represents a methanesulfonyl group; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0495]"> </para-num> <div id="p-0668" num="0495" class="description-line"> <figure-callout id="2" label="Compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Compound</figure-callout> 2 can be obtained by reacting ammonia with <figure-callout id="1" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 1 in a solvent (e.g., polar solvents such as tetrahydrofuran and methanol) at a high temperature (e.g., 80 C. or higher).</div>
    </li> <li> <para-num num="[0496]"> </para-num> <div id="p-0669" num="0496" class="description-line">Compound 4 is obtained by reacting <figure-callout id="2" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 2 with <figure-callout id="3" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 3 in the presence of a base (e.g., inorganic bases such as sodium hydroxide) at a high temperature (e.g., 100 C. or higher). Although no solvent is particularly necessary, a high-boiling solvent (e.g., polar solvents such as ethylene glycol) may be used in some cases.</div>
    </li> <li> <para-num num="[0497]"> </para-num> <div id="p-0670" num="0497" class="description-line">Compound 6 is obtained by reacting compound 4 with compound 5 in the presence of a base (e.g., inorganic bases such as sodium hydroxide) at a high temperature (e.g., 100 C. or higher). Although no solvent is particularly necessary, a high-boiling solvent (e.g., polar solvents such as ethylene glycol) may be used in some cases.</div>
    </li> <li> <para-num num="[0498]"> </para-num> <div id="p-0671" num="0498" class="description-line">Each of these three heating reactions may suitably employ a microwave reaction apparatus. Alternatively, a halide such as bromide or iodide corresponding to compound 1, <figure-callout id="3" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 3 or compound 5 may be used instead of the compound.</div>
    </li> <li> <para-num num="[0499]"> </para-num> <div id="p-0672" num="0499" class="description-line">Compound 4 wherein R<sup>1</sup>-L<sup>1 </sup>and R<sup>2</sup>-L<sup>2 </sup>are the same is also obtained from ammonia using <figure-callout id="1" label="excessive compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">excessive compound</figure-callout> 1. Compound 6 wherein R<sup>2</sup>-L<sup>2 </sup>and R<sup>3</sup>-L<sup>3 </sup>are the same is also obtained from <figure-callout id="2" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 2 using <figure-callout id="3" label="excessive compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">excessive compound</figure-callout> 3. Compound 6 wherein R<sup>2</sup>-L<sup>2</sup>, R<sup>2</sup>-L<sup>2 </sup>and R<sup>3</sup>-L<sup>3 </sup>are the same is also obtained from ammonia using more <figure-callout id="1" label="excessive compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">excessive compound</figure-callout> 1.</div>
    </li> <li> <para-num num="[0500]"> </para-num> <div id="p-0673" num="0500" class="description-line">Compound (I) is obtained by reacting compound 6 with <figure-callout id="7" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 7 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher). Anion A<sup>1 </sup>of compound (I) may be converted to another anion, for example, by treating the compound (I) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0501]"> </para-num> <div id="p-0674" num="0501" class="description-line">Each compound such as <figure-callout id="1" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 1, <figure-callout id="3" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 3, compound 5 and <figure-callout id="7" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 7, etc. for use in the reactions can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fifth Series of <figure-callout id="13" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0502]"> </para-num> <div id="p-0675" num="0502" class="description-line">Alternatively, <figure-callout id="1" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 1 may be obtained by treating corresponding R<sup>1</sup>-L<sup>1</sup>-OH with mesyl anhydride or mesyl chloride.</div>
    </li> <li> <para-num num="[0503]"> </para-num> <div id="p-0676" num="0503" class="description-line">Compound R<sup>1</sup>-L<sup>1</sup>-OH wherein L<sup>1 </sup>is Z<sup>1</sup>(CY<sup>1</sup>Y<sup>2</sup>)<sub>p2</sub> (wherein each group is as defined above) can be obtained by subjecting any one of R<sup>1</sup>OMs, R<sup>1</sup>OH, R<sup>1</sup>NY<sup>7A</sup>H (wherein Y<sup>7A </sup>is as defined above) and R<sup>1</sup>CO<sub>2</sub>H and any one of HO(CY<sup>7</sup>Y<sup>2</sup>)<sub>p1</sub>OPRO<sup>1</sup>, MsO(CY<sup>7</sup>Y<sup>2</sup>)<sub>p1</sub>OPRO<sup>1</sup>, HO<sub>2</sub>C(CY<sup>2</sup>Y<sup>2</sup>)<sub>p1</sub>OPRO<sup>1 </sup>and HNY<sup>7A</sup>(CY<sup>2</sup>Y<sup>2</sup>)<sub>p1</sub>OPRO<sup>1 </sup>(wherein PRO<sup>1 </sup>is a silyl-based protective group (e.g., triethylsilyl (TES), tert-butyldimethylsilyl (TBS) and tert-butyldiphenylsilyl (TBDPS))) to any reaction of etherification (e.g., using a strong base such as sodium hydride), amination (e.g., substitution reaction), esterification (e.g., using a condensing agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), and amidation (e.g., using the same condensing agent thereas), followed by deprotection.</div>
    </li> <li> <para-num num="[0504]"> </para-num> <div id="p-0677" num="0504" class="description-line">Likewise, compound R<sup>1</sup>-L<sup>1</sup>-OH wherein L<sup>1 </sup>is Z<sup>2</sup>(CY<sup>3</sup>Y<sup>4</sup>)<sub>p2</sub>Z<sup>3</sup>(CY<sup>5</sup>Y<sup>6</sup>)<sub>p3</sub> (wherein each group is as defined above) can also be obtained by the application of reaction known in the art one to several times using a reaction substrate appropriate for the desired compound.</div>
    </li> <li> <para-num num="[0505]"> </para-num> <div id="p-0678" num="0505" class="description-line"> <figure-callout id="3" label="Compounds" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Compounds</figure-callout> 3 and 5 can be prepared by the same approach as in <figure-callout id="1" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 1.</div>
    </li> <li> <para-num num="[0506]"> </para-num> <div id="p-0679" num="0506" class="description-line">Compound (Ia) can be obtained from <figure-callout id="8" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 8 according to <figure-callout id="2" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 2.</div>
    </li> <li> <div id="p-0680" num="0000" class="description-line">
      <chemistry id="CHEM-US-00173" num="00173">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/43/3f/0b/e5312864ceb0d1/US20200368173A1-20201126-C00173.png"><img id="EMI-C00173" he="204.22mm" wi="75.78mm" file="US20200368173A1-20201126-C00173.TIF" alt="Figure US20200368173A1-20201126-C00173" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="817" alt="Figure US20200368173A1-20201126-C00173" class="patent-full-image" src="https://patentimages.storage.googleapis.com/43/3f/0b/e5312864ceb0d1/US20200368173A1-20201126-C00173.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00173" attachment-type="cdx" file="US20200368173A1-20201126-C00173.CDX"> </attachment>
          <attachment idref="CHEM-US-00173" attachment-type="mol" file="US20200368173A1-20201126-C00173.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0681" num="0000" class="description-line">wherein M<sup>1 </sup>to M<sup>3 </sup>are the same or different and are each (CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> or (CY<sup>3</sup>Y<sup>4</sup>)<sub>p2</sub>Z<sup>3</sup>(CY<sup>5</sup>Y<sup>6</sup>)<sub>p3</sub> (wherein each group is as defined above); and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0507]"> </para-num> <div id="p-0682" num="0507" class="description-line">Compound 10 is obtained by treating <figure-callout id="8" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 8 and <figure-callout id="9" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 9 with a base (e.g., organic bases such as triethylamine), a condensing agent (e.g., condensing agents such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate) and an activator (activators such as N,N-dimethylaminopyridine) in a solvent (e.g., halogen-based solvents such as chloroform).</div>
    </li> <li> <para-num num="[0508]"> </para-num> <div id="p-0683" num="0508" class="description-line">Compound 12 is obtained by esterifying compound 10 and compound 11 in the same way as above.</div>
    </li> <li> <para-num num="[0509]"> </para-num> <div id="p-0684" num="0509" class="description-line"> <figure-callout id="14" label="Compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Compound</figure-callout> 14 is obtained by esterifying compound 12 and <figure-callout id="13" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 13 in the same way as above.</div>
    </li> <li> <para-num num="[0510]"> </para-num> <div id="p-0685" num="0510" class="description-line">Compound 12 wherein R<sup>1 </sup>and R<sup>2 </sup>are the same is also obtained from <figure-callout id="8" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 8 using <figure-callout id="9" label="excessive compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">excessive compound</figure-callout> 9. <figure-callout id="14" label="Compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Compound</figure-callout> 14 wherein R<sup>2 </sup>and R<sup>3 </sup>are the same is also obtained from compound 10 using excessive compound 11. <figure-callout id="14" label="Compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Compound</figure-callout> 14 wherein R<sup>1</sup>, R<sup>2 </sup>and R<sup>3 </sup>are the same is also obtained from <figure-callout id="8" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 8 using more <figure-callout id="9" label="excessive compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">excessive compound</figure-callout> 9.</div>
    </li> <li> <para-num num="[0511]"> </para-num> <div id="p-0686" num="0511" class="description-line">Compound (Ia) is obtained by reacting <figure-callout id="14" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 14 with compound 15 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher). Anion A<sup>1 </sup>of compound (Ia) may be converted to another anion, for example, by treating the compound (Ia) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0512]"> </para-num> <div id="p-0687" num="0512" class="description-line">Each compound such as <figure-callout id="8" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 8, <figure-callout id="9" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 9, compound 11, <figure-callout id="14" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 14 and compound 15, etc. for use in the reaction can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fifth Series of <figure-callout id="14" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 14, Synthesis of Organic Compound II, 5th edition, p. 1, Maruzen Co., Ltd. (2005) or The Fourth Series of Experimental Chemistry 22, Synthesis of Organic Compound IV, 4th edition, p. 1, Maruzen Co., Ltd. (1992)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0513]"> </para-num> <div id="p-0688" num="0513" class="description-line">Compound (II) can be obtained by any method of <figure-callout id="3" label="synthesis routes" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis routes</figure-callout> 3 to 16 shown below, a method equivalent to the method, or the like.</div>
    </li> <li> <para-num num="[0514]"> </para-num> <div id="p-0689" num="0514" class="description-line">Compound (IIa) can be obtained from compound 15 according to <figure-callout id="3" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 3.</div>
    </li> <li> <div id="p-0690" num="0000" class="description-line">
      <chemistry id="CHEM-US-00174" num="00174">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a6/d5/2d/96912d4bc0eb68/US20200368173A1-20201126-C00174.png"><img id="EMI-C00174" he="218.19mm" wi="75.78mm" file="US20200368173A1-20201126-C00174.TIF" alt="Figure US20200368173A1-20201126-C00174" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="873" alt="Figure US20200368173A1-20201126-C00174" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a6/d5/2d/96912d4bc0eb68/US20200368173A1-20201126-C00174.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00174" attachment-type="cdx" file="US20200368173A1-20201126-C00174.CDX"> </attachment>
          <attachment idref="CHEM-US-00174" attachment-type="mol" file="US20200368173A1-20201126-C00174.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0691" num="0000" class="description-line">wherein M<sup>7 </sup>is absent, and M<sup>4 </sup>is (CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>; M<sup>7 </sup>is absent, and M<sup>4 </sup>is (CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>Z<sup>6</sup>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>; or M<sup>7 </sup>is Z<sup>5</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>, and M<sup>4 </sup>is (CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub> (wherein each group is as defined above); M<sup>8 </sup>is absent, and M<sup>5 </sup>is (CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>; M<sup>8 </sup>is absent, and M<sup>5 </sup>is (CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>Z<sup>6</sup>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>; or M<sup>8 </sup>is Z<sup>5</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>, and M<sup>5 </sup>is (CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>; M<sup>9 </sup>is absent, and M<sup>6 </sup>is (CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub>; M<sup>9 </sup>is absent, and M<sup>6 </sup>is (CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>Z<sup>6</sup>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>; or M<sup>9 </sup>is Z<sup>5</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>, and M<sup>6 </sup>is (CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub>; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0515]"> </para-num> <div id="p-0692" num="0515" class="description-line">Compound 22 is obtained by reacting compound 16 with compound 17, <figure-callout id="19" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 19 and <figure-callout id="21" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 21 in order by the application of the same reaction conditions as in the esterification reaction of <figure-callout id="8" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 8 with <figure-callout id="9" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 9 in <figure-callout id="2" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 2.</div>
    </li> <li> <para-num num="[0516]"> </para-num> <div id="p-0693" num="0516" class="description-line">Compound (IIa) is obtained by reacting compound 22 with compound 23 by the application of the same conditions as the reaction conditions for the synthesis of compound (Ia) through the reaction of <figure-callout id="14" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 14 with compound 15 in <figure-callout id="2" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 2. Anion A<sup>2 </sup>of compound (IIa) may be converted to another anion, for example, by treating the compound (IIa) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0517]"> </para-num> <div id="p-0694" num="0517" class="description-line">Each compound such as compound 16, compound 17, <figure-callout id="19" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 19, <figure-callout id="21" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 21 and compound 23, etc. for use in the reaction can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fifth Series of <figure-callout id="14" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 14, Synthesis of Organic Compound II, 5th edition, p. 1, Maruzen Co., Ltd. (2005) or The Fourth Series of Experimental Chemistry 22, Synthesis of Organic Compound IV, 4th edition, p. 1, Maruzen Co., Ltd. (1992)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0518]"> </para-num> <div id="p-0695" num="0518" class="description-line">Compound 16 can also be obtained by any method of synthesis routes 11 to 15 mentioned later.</div>
    </li> <li> <para-num num="[0519]"> </para-num> <div id="p-0696" num="0519" class="description-line">Compound 17 wherein M<sup>7 </sup>is Z<sup>5</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub> can be obtained by subjecting any one of R<sup>4</sup>OMs, R<sup>4</sup>OH, R<sup>4</sup>NY<sup>14A</sup>H (wherein Y<sup>14A </sup>is as defined above) and R<sup>4</sup>CO<sub>2</sub>H and any one of HO(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>COOPRO<sup>2</sup>, MsO(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>COOPRO<sup>2</sup>, HO<sub>2</sub>C(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>COOPRO<sup>2 </sup>and HNY<sup>14A</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub> <sup></sup>COOPRO<sup>2 </sup>(wherein PRO<sup>2 </sup>is a protective group for carboxylic acid (e.g., methyl, tert-butyl and benzyl)) to any reaction of etherification (e.g., using a strong base such as sodium hydride), amination (e.g., substitution reaction), esterification (e.g., using a condensing agent such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride), and amidation (e.g., using the same condensing agent thereas), followed by deprotection.</div>
    </li> <li> <para-num num="[0520]"> </para-num> <div id="p-0697" num="0520" class="description-line"> <figure-callout id="19" label="Compounds" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}"> <figure-callout id="21" label="Compounds" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Compounds</figure-callout> </figure-callout> 19 and 21 can be prepared by the same approach as in compound 17.</div>
    </li> <li> <para-num num="[0521]"> </para-num> <div id="p-0698" num="0521" class="description-line">In <figure-callout id="3" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 3, the introduction of X<sup>4 </sup>may be performed first. Specifically, first, compound 23 may be allowed to act on compound 16, followed by the esterification of <figure-callout id="19" label="compounds" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}"> <figure-callout id="21" label="compounds" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compounds</figure-callout> </figure-callout> 17, 19 and 21 in order to obtain compound (IIa).</div>
    </li> <li> <para-num num="[0522]"> </para-num> <div id="p-0699" num="0522" class="description-line">Compound (IIb) can be obtained from compound 16 according to synthesis route 4.</div>
    </li> <li> <div id="p-0700" num="0000" class="description-line">
      <chemistry id="CHEM-US-00175" num="00175">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5d/49/da/71ab5e7307da38/US20200368173A1-20201126-C00175.png"><img id="EMI-C00175" he="218.19mm" wi="75.78mm" file="US20200368173A1-20201126-C00175.TIF" alt="Figure US20200368173A1-20201126-C00175" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="873" alt="Figure US20200368173A1-20201126-C00175" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5d/49/da/71ab5e7307da38/US20200368173A1-20201126-C00175.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00175" attachment-type="cdx" file="US20200368173A1-20201126-C00175.CDX"> </attachment>
          <attachment idref="CHEM-US-00175" attachment-type="mol" file="US20200368173A1-20201126-C00175.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0701" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0523]"> </para-num> <div id="p-0702" num="0523" class="description-line">Compound 25 can be obtained by reacting compound 16 with compound 24 in the presence of a base (e.g., inorganic bases such as sodium hydride) in a solvent (e.g., aprotic solvents such as tetrahydrofuran and toluene) at a high temperature (e.g., 100 C. or higher).</div>
    </li> <li> <para-num num="[0524]"> </para-num> <div id="p-0703" num="0524" class="description-line">Compound 27 is obtained by etherifying compound 25 and compound 26 in the same way as above.</div>
    </li> <li> <para-num num="[0525]"> </para-num> <div id="p-0704" num="0525" class="description-line">Compound 29 is obtained by etherifying compound 27 and compound 28 in the same way as above.</div>
    </li> <li> <para-num num="[0526]"> </para-num> <div id="p-0705" num="0526" class="description-line">Each of these three heating reactions may suitably employ a microwave reaction apparatus. Alternatively, bromide, iodide or the like corresponding to compound 24, compound 26 and compound 28 may be used instead of the compound.</div>
    </li> <li> <para-num num="[0527]"> </para-num> <div id="p-0706" num="0527" class="description-line">Compound 27 wherein R<sup>4</sup>-M<sup>7 </sup>and R<sup>5</sup>-M<sup>8 </sup>are the same is also obtained from compound 16 using excessive compound 24. Compound 29 wherein R<sup>5</sup>-M<sup>8 </sup>and R<sup>6</sup>-M<sup>9 </sup>are the same is also obtained from compound 25 using excessive compound 26. Compound 29 wherein R<sup>4</sup>-M<sup>7</sup>, R<sup>5</sup>-M<sup>8 </sup>and R<sup>6</sup>-M<sup>9 </sup>are the same is also obtained from compound 16 using more excessive compound 24.</div>
    </li> <li> <para-num num="[0528]"> </para-num> <div id="p-0707" num="0528" class="description-line">Compound (IIb) is obtained by reacting compound 29 with compound 23 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher). Anion A<sup>2 </sup>of compound (IIb) may be converted to another anion, for example, by treating the compound (lib) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0529]"> </para-num> <div id="p-0708" num="0529" class="description-line">Each compound such as compound 16, compound 24, compound 26, compound 28 and compound 23, etc. for use in the reaction can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fifth Series of <figure-callout id="14" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 14, Synthesis of Organic Compound II, 5th edition, p. 1, Maruzen Co., Ltd. (2005) or The Fifth Series of <figure-callout id="13" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0530]"> </para-num> <div id="p-0709" num="0530" class="description-line">Alternatively, compound 24 may be obtained by treating corresponding R<sup>4</sup>-M<sup>7</sup>-OH with mesyl anhydride or mesyl chloride.</div>
    </li> <li> <para-num num="[0531]"> </para-num> <div id="p-0710" num="0531" class="description-line">Compound R<sup>4</sup>-M<sup>7</sup>-OH wherein M<sup>7 </sup>is Z<sup>5</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub> (wherein each group is as defined above) can be obtained by subjecting any one of R<sup>4</sup>OMs, R<sup>4</sup>OH, R<sup>4</sup>NY<sup>14A</sup>H (wherein Y<sup>14A </sup>is as defined above) and R<sup>4</sup>CO<sub>2</sub>H and any one of HO(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>OPRO<sup>1</sup>, MsO(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>OPRO<sup>1</sup>, HO<sub>2</sub>C(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>OPRO<sup>1 </sup>and HNY<sup>14A</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>OPRO<sup>1 </sup>(wherein each group is as defined above) to any reaction of etherification, amination, esterification and amidation, followed by deprotection.</div>
    </li> <li> <para-num num="[0532]"> </para-num> <div id="p-0711" num="0532" class="description-line">Compounds 26 and 28 can be prepared by the same approach as in compound 24.</div>
    </li> <li> <para-num num="[0533]"> </para-num> <div id="p-0712" num="0533" class="description-line">As shown in synthesis route 5, compound (IIe) can be obtained from compound 25 obtained in synthesis route 4 by appropriately combining the reactions such as esterification in <figure-callout id="3" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 3. As shown in synthesis route 5, compound (IId) can be obtained from compound 27 obtained in synthesis route 4 by appropriately combining the reactions such as esterification in <figure-callout id="3" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 3.</div>
    </li> <li> <div id="p-0713" num="0000" class="description-line">
      <chemistry id="CHEM-US-00176" num="00176">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b7/dc/5d/e060b48ccd095a/US20200368173A1-20201126-C00176.png"><img id="EMI-C00176" he="81.20mm" wi="155.45mm" file="US20200368173A1-20201126-C00176.TIF" alt="Figure US20200368173A1-20201126-C00176" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="622" height="325" alt="Figure US20200368173A1-20201126-C00176" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b7/dc/5d/e060b48ccd095a/US20200368173A1-20201126-C00176.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00176" attachment-type="cdx" file="US20200368173A1-20201126-C00176.CDX"> </attachment>
          <attachment idref="CHEM-US-00176" attachment-type="mol" file="US20200368173A1-20201126-C00176.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0714" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0534]"> </para-num> <div id="p-0715" num="0534" class="description-line">Compound (IIe) can be obtained from compound 30 according to synthesis route 6.</div>
    </li> <li> <div id="p-0716" num="0000" class="description-line">
      <chemistry id="CHEM-US-00177" num="00177">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/64/84/53/2a7f009e9be7ee/US20200368173A1-20201126-C00177.png"><img id="EMI-C00177" he="196.60mm" wi="75.78mm" file="US20200368173A1-20201126-C00177.TIF" alt="Figure US20200368173A1-20201126-C00177" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="786" alt="Figure US20200368173A1-20201126-C00177" class="patent-full-image" src="https://patentimages.storage.googleapis.com/64/84/53/2a7f009e9be7ee/US20200368173A1-20201126-C00177.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00177" attachment-type="cdx" file="US20200368173A1-20201126-C00177.CDX"> </attachment>
          <attachment idref="CHEM-US-00177" attachment-type="mol" file="US20200368173A1-20201126-C00177.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0717" num="0000" class="description-line">wherein M<sup>10</sup>, M<sup>11 </sup>and M<sup>12 </sup>are each independently 0 or NY<sup>14A</sup>; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0535]"> </para-num> <div id="p-0718" num="0535" class="description-line">Compound 33 is obtained through the esterification or amidation reaction of compound 30 with compound 17, <figure-callout id="19" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 19 and <figure-callout id="21" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 21 in order.</div>
    </li> <li> <para-num num="[0536]"> </para-num> <div id="p-0719" num="0536" class="description-line">Compound (IIe) is obtained by reacting compound 33 with compound 23 by the application of the same conditions as the reaction conditions for the synthesis of compound (Ia) through the reaction of <figure-callout id="14" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 14 with compound 15 in <figure-callout id="2" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 2. Anion A<sup>2 </sup>of compound (lie) may be converted to another anion, for example, by treating the compound (IIe) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0537]"> </para-num> <div id="p-0720" num="0537" class="description-line">Compound 30 can also be obtained by any method of synthesis routes 11 to 15 mentioned later.</div>
    </li> <li> <para-num num="[0538]"> </para-num> <div id="p-0721" num="0538" class="description-line">Compound (IIf) can be obtained from compound 34 according to <figure-callout id="7" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 7.</div>
    </li> <li> <div id="p-0722" num="0000" class="description-line">
      <chemistry id="CHEM-US-00178" num="00178">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1f/ac/d2/4df7df0986cbed/US20200368173A1-20201126-C00178.png"><img id="EMI-C00178" he="251.38mm" wi="75.95mm" file="US20200368173A1-20201126-C00178.TIF" alt="Figure US20200368173A1-20201126-C00178" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="1006" alt="Figure US20200368173A1-20201126-C00178" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1f/ac/d2/4df7df0986cbed/US20200368173A1-20201126-C00178.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00178" attachment-type="cdx" file="US20200368173A1-20201126-C00178.CDX"> </attachment>
          <attachment idref="CHEM-US-00178" attachment-type="mol" file="US20200368173A1-20201126-C00178.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0723" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0539]"> </para-num> <div id="p-0724" num="0539" class="description-line">Compound 35 is obtained by protecting compound 34 with an appropriate protective group.</div>
    </li> <li> <para-num num="[0540]"> </para-num> <div id="p-0725" num="0540" class="description-line">Compound 36 is obtained by reacting compound 35 with compound 23 by the application of the same conditions as the reaction conditions for the synthesis of compound (la) through the reaction of <figure-callout id="14" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 14 with compound 15 in <figure-callout id="2" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 2, followed by deprotection under appropriate conditions.</div>
    </li> <li> <para-num num="[0541]"> </para-num> <div id="p-0726" num="0541" class="description-line">Compound (IIf) is obtained by the esterification or amidation reaction of compound 36 with <figure-callout id="37" label="compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 37, compound 39 and compound 41 in order. Anion A<sup>2 </sup>of compound (IIf) may be converted to another anion, for example, by treating the compound (IIf) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0542]"> </para-num> <div id="p-0727" num="0542" class="description-line">Each of compounds 34, 35 and 36 can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0543]"> </para-num> <div id="p-0728" num="0543" class="description-line"> <figure-callout id="37" label="Compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Compound</figure-callout> 37 wherein M<sup>10 </sup>is NY<sup>14A </sup>can also be obtained by reacting R<sup>4</sup>-M<sup>7</sup>-OMs (compound 24) with Y<sup>14A</sup>NH<sub>2</sub>.</div>
    </li> <li> <para-num num="[0544]"> </para-num> <div id="p-0729" num="0544" class="description-line"> <figure-callout id="37" label="Compounds" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Compounds</figure-callout> 37 and 39 can be prepared by the same approach as in compound 35.</div>
    </li> <li> <para-num num="[0545]"> </para-num> <div id="p-0730" num="0545" class="description-line">As shown in <figure-callout id="8" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 8, compound (IIf) can also be obtained by performing the esterification or amidation of compound 24 with <figure-callout id="37" label="compounds" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">compounds</figure-callout> 37, 39 and 41 in order, and finally introducing X<sup>4 </sup>by the action of compound 23.</div>
    </li> <li> <div id="p-0731" num="0000" class="description-line">
      <chemistry id="CHEM-US-00179" num="00179">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3d/61/d8/4fffc179b6fef9/US20200368173A1-20201126-C00179.png"><img id="EMI-C00179" he="251.38mm" wi="127.59mm" file="US20200368173A1-20201126-C00179.TIF" alt="Figure US20200368173A1-20201126-C00179" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="510" height="1006" alt="Figure US20200368173A1-20201126-C00179" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3d/61/d8/4fffc179b6fef9/US20200368173A1-20201126-C00179.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00179" attachment-type="cdx" file="US20200368173A1-20201126-C00179.CDX"> </attachment>
          <attachment idref="CHEM-US-00179" attachment-type="mol" file="US20200368173A1-20201126-C00179.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0732" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0546]"> </para-num> <div id="p-0733" num="0546" class="description-line">Compound (IIg) can be obtained from ethyl cyanoacetate according to <figure-callout id="9" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 9.</div>
    </li> <li> <div id="p-0734" num="0000" class="description-line">
      <chemistry id="CHEM-US-00180" num="00180">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/40/78/4c/bcba4891e6b624/US20200368173A1-20201126-C00180.png"><img id="EMI-C00180" he="215.73mm" wi="75.78mm" file="US20200368173A1-20201126-C00180.TIF" alt="Figure US20200368173A1-20201126-C00180" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="863" alt="Figure US20200368173A1-20201126-C00180" class="patent-full-image" src="https://patentimages.storage.googleapis.com/40/78/4c/bcba4891e6b624/US20200368173A1-20201126-C00180.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00180" attachment-type="cdx" file="US20200368173A1-20201126-C00180.CDX"> </attachment>
          <attachment idref="CHEM-US-00180" attachment-type="mol" file="US20200368173A1-20201126-C00180.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0735" num="0000" class="description-line">wherein Et represents an ethyl group; LAH is lithium aluminum hydride; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0547]"> </para-num> <div id="p-0736" num="0547" class="description-line">Compound 42 can be obtained by reacting ethyl cyanoacetate with compound 24 in the presence of a base (e.g., inorganic bases such as sodium hydride) and, in some cases, an additive (e.g., additives such as tetrabutylammonium iodide) in a solvent (e.g., aprotic solvents such as tetrahydrofuran) at a high temperature (e.g., 60 C. or higher).</div>
    </li> <li> <para-num num="[0548]"> </para-num> <div id="p-0737" num="0548" class="description-line"> <figure-callout id="43" label="Compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Compound</figure-callout> 43 can be obtained by reacting compound 42 with compound 26 in the presence of a base (e.g., inorganic bases such as sodium hydride) and, in some cases, an additive (e.g., additives such as tetrabutylammonium iodide) in a solvent (e.g., aprotic solvents such as tetrahydrofuran) at a high temperature (e.g., 60 C. or higher).</div>
    </li> <li> <para-num num="[0549]"> </para-num> <div id="p-0738" num="0549" class="description-line"> <figure-callout id="43" label="Compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Compound</figure-callout> 43 wherein R<sup>4 </sup>and R<sup>5 </sup>are the same can also be obtained from ethyl cyanoacetate using excessive compound 24.</div>
    </li> <li> <para-num num="[0550]"> </para-num> <div id="p-0739" num="0550" class="description-line"> <figure-callout id="44" label="Compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Compound</figure-callout> 44 can be obtained by reducing <figure-callout id="43" label="compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 43 with excessive lithium aluminum hydride (LAH) in a solvent (e.g., aprotic solvents such as tetrahydrofuran).</div>
    </li> <li> <para-num num="[0551]"> </para-num> <div id="p-0740" num="0551" class="description-line">Compound 47 can be obtained by allowing compound 45, compound 46 and compound 23 in order to act on <figure-callout id="44" label="compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 44 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform). Compound 47 wherein X<sup>2</sup>, X<sup>3 </sup>and X<sup>4 </sup>are the same can also be obtained from <figure-callout id="44" label="compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 44 using excessive compound 45.</div>
    </li> <li> <para-num num="[0552]"> </para-num> <div id="p-0741" num="0552" class="description-line">Compound (IIg) is obtained by reacting compound 47 with <figure-callout id="21" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 21 by the application of the same reaction conditions as in the esterification reaction of <figure-callout id="8" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 8 with <figure-callout id="9" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 9 in <figure-callout id="2" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 2. Anion A<sup>2 </sup>of compound (IIg) may be converted to another anion, for example, by treating the compound (IIg) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0553]"> </para-num> <div id="p-0742" num="0553" class="description-line">Compounds 45 and 46 are obtained in the same way as in compound 23.</div>
    </li> <li> <para-num num="[0554]"> </para-num> <div id="p-0743" num="0554" class="description-line">Compound (IIh) can be obtained from dimethyl malonate according to synthesis route 10.</div>
    </li> <li> <div id="p-0744" num="0000" class="description-line">
      <chemistry id="CHEM-US-00181" num="00181">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/f3/b3/7295537e45f372/US20200368173A1-20201126-C00181.png"><img id="EMI-C00181" he="215.90mm" wi="75.78mm" file="US20200368173A1-20201126-C00181.TIF" alt="Figure US20200368173A1-20201126-C00181" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="864" alt="Figure US20200368173A1-20201126-C00181" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/f3/b3/7295537e45f372/US20200368173A1-20201126-C00181.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00181" attachment-type="cdx" file="US20200368173A1-20201126-C00181.CDX"> </attachment>
          <attachment idref="CHEM-US-00181" attachment-type="mol" file="US20200368173A1-20201126-C00181.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0745" num="0000" class="description-line">wherein Me represents a methyl group; LAH is lithium aluminum hydride; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0555]"> </para-num> <div id="p-0746" num="0555" class="description-line">Compound 48 can be obtained by reacting dimethyl malonate with compound 24 in the presence of a base (e.g., inorganic bases such as cesium carbonate) and, in some cases, an additive (e.g., additives such as tetrabutylammonium iodide) in a solvent (e.g., aprotic solvents such as acetonitrile) under heating (e.g., 50 C.).</div>
    </li> <li> <para-num num="[0556]"> </para-num> <div id="p-0747" num="0556" class="description-line">Compound 50 can be obtained by reacting compound 48 with compound 49 in the presence of acetic anhydride and a base (e.g., inorganic bases such as sodium hydride) in a solvent (e.g., aprotic solvents such as acetonitrile).</div>
    </li> <li> <para-num num="[0557]"> </para-num> <div id="p-0748" num="0557" class="description-line">Compound 51 can be obtained by reducing compound 50 with excessive lithium aluminum hydride (LAH) in a solvent (e.g., aprotic solvents such as tetrahydrofuran).</div>
    </li> <li> <para-num num="[0558]"> </para-num> <div id="p-0749" num="0558" class="description-line">Compound 52 is obtained by reacting compound 51 with <figure-callout id="19" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 19 and <figure-callout id="21" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 21 by the application of the same reaction conditions as in the esterification of <figure-callout id="8" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 8 and <figure-callout id="9" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 9 in <figure-callout id="2" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 2.</div>
    </li> <li> <para-num num="[0559]"> </para-num> <div id="p-0750" num="0559" class="description-line">Compound (IIh) is obtained by reacting compound 52 with compound 53 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher). Anion A<sup>2 </sup>of compound (IIh) may be converted to another anion, for example, by treating the compound (IIh) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0560]"> </para-num> <div id="p-0751" num="0560" class="description-line">Compound 49 can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in Helvetica Chimica Acta, Vol. 92, No. 8, p. 1644-1656, 2009) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0561]"> </para-num> <div id="p-0752" num="0561" class="description-line">Compounds 54 and 56 can be obtained according to synthesis route 11.</div>
    </li> <li> <div id="p-0753" num="0000" class="description-line">
      <chemistry id="CHEM-US-00182" num="00182">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2d/43/81/e40f5012969dc1/US20200368173A1-20201126-C00182.png"><img id="EMI-C00182" he="66.21mm" wi="75.86mm" file="US20200368173A1-20201126-C00182.TIF" alt="Figure US20200368173A1-20201126-C00182" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="265" alt="Figure US20200368173A1-20201126-C00182" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2d/43/81/e40f5012969dc1/US20200368173A1-20201126-C00182.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00182" attachment-type="cdx" file="US20200368173A1-20201126-C00182.CDX"> </attachment>
          <attachment idref="CHEM-US-00182" attachment-type="mol" file="US20200368173A1-20201126-C00182.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0754" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0562]"> </para-num> <div id="p-0755" num="0562" class="description-line">Compound 54 can be obtained by protecting hydroxy of compound 53.</div>
    </li> <li> <para-num num="[0563]"> </para-num> <div id="p-0756" num="0563" class="description-line">Compound 53 can be obtained as a commercially available product.</div>
    </li> <li> <para-num num="[0564]"> </para-num> <div id="p-0757" num="0564" class="description-line">Compound 55 can be obtained by allowing compound 45 and compound 46 to act on compound 54.</div>
    </li> <li> <para-num num="[0565]"> </para-num> <div id="p-0758" num="0565" class="description-line">Compound 56 can be obtained by deprotecting compound 55.</div>
    </li> <li> <para-num num="[0566]"> </para-num> <div id="p-0759" num="0566" class="description-line">Compounds 58 to 65 can be obtained according to synthesis route 12.</div>
    </li> <li> <div id="p-0760" num="0000" class="description-line">
      <chemistry id="CHEM-US-00183" num="00183">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/32/b4/3b/cf98b39cf2aa25/US20200368173A1-20201126-C00183.png"><img id="EMI-C00183" he="105.41mm" wi="147.07mm" file="US20200368173A1-20201126-C00183.TIF" alt="Figure US20200368173A1-20201126-C00183" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="588" height="422" alt="Figure US20200368173A1-20201126-C00183" class="patent-full-image" src="https://patentimages.storage.googleapis.com/32/b4/3b/cf98b39cf2aa25/US20200368173A1-20201126-C00183.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00183" attachment-type="cdx" file="US20200368173A1-20201126-C00183.CDX"> </attachment>
          <attachment idref="CHEM-US-00183" attachment-type="mol" file="US20200368173A1-20201126-C00183.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0761" num="0000" class="description-line">wherein Hal is a halogen atom such as chlorine, bromine or iodine; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0567]"> </para-num> <div id="p-0762" num="0567" class="description-line">Compound 58 can be obtained by protecting hydroxy of compound 57.</div>
    </li> <li> <para-num num="[0568]"> </para-num> <div id="p-0763" num="0568" class="description-line">Compound 57 can be obtained as a commercially available product.</div>
    </li> <li> <para-num num="[0569]"> </para-num> <div id="p-0764" num="0569" class="description-line">Compound 59 can be obtained by allowing a halogenation reagent (e.g., chlorine, bromine, iodine and iodine chloride) to act on compound 58.</div>
    </li> <li> <para-num num="[0570]"> </para-num> <div id="p-0765" num="0570" class="description-line"> <figure-callout id="60" label="Compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Compound</figure-callout> 60 is obtained by reacting compound 59 with ammonia. Compound 61 is obtained by allowing compound 45 to act on <figure-callout id="60" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 60. Compound 63 is obtained by allowing compound 46 to act on compound 61.</div>
    </li> <li> <para-num num="[0571]"> </para-num> <div id="p-0766" num="0571" class="description-line">Alternatively, compound 63 may be obtained by reacting compound 59 with compound 62.</div>
    </li> <li> <para-num num="[0572]"> </para-num> <div id="p-0767" num="0572" class="description-line">Compound 63 is obtained by deprotecting compound 62.</div>
    </li> <li> <para-num num="[0573]"> </para-num> <div id="p-0768" num="0573" class="description-line">Compound 64 is obtained by oxidizing compound 58 with an appropriate oxidizing agent (e.g., potassium permanganate and Jones reagent).</div>
    </li> <li> <para-num num="[0574]"> </para-num> <div id="p-0769" num="0574" class="description-line">Compounds 67 to 73 can be obtained according to <figure-callout id="13" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 13.</div>
    </li> <li> <div id="p-0770" num="0000" class="description-line">
      <chemistry id="CHEM-US-00184" num="00184">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/44/c2/94/35adde65e34242/US20200368173A1-20201126-C00184.png"><img id="EMI-C00184" he="113.62mm" wi="141.14mm" file="US20200368173A1-20201126-C00184.TIF" alt="Figure US20200368173A1-20201126-C00184" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="565" height="454" alt="Figure US20200368173A1-20201126-C00184" class="patent-full-image" src="https://patentimages.storage.googleapis.com/44/c2/94/35adde65e34242/US20200368173A1-20201126-C00184.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00184" attachment-type="cdx" file="US20200368173A1-20201126-C00184.CDX"> </attachment>
          <attachment idref="CHEM-US-00184" attachment-type="mol" file="US20200368173A1-20201126-C00184.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0771" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0575]"> </para-num> <div id="p-0772" num="0575" class="description-line">Compound 66 is obtained by allowing a cyanide (e.g., sodium cyanide, potassium cyanide and lithium cyanide) to act on compound 59.</div>
    </li> <li> <para-num num="[0576]"> </para-num> <div id="p-0773" num="0576" class="description-line">Compound 67 is obtained by reducing compound 66 with lithium aluminum hydride or the like.</div>
    </li> <li> <para-num num="[0577]"> </para-num> <div id="p-0774" num="0577" class="description-line">Compound 68 is obtained by allowing compound 45 to act on compound 67. Compound 69 is obtained by allowing compound 46 to act on compound 68.</div>
    </li> <li> <para-num num="[0578]"> </para-num> <div id="p-0775" num="0578" class="description-line">Compound 70 is obtained by deprotecting compound 69.</div>
    </li> <li> <para-num num="[0579]"> </para-num> <div id="p-0776" num="0579" class="description-line">Compound 71 is obtained by hydrolyzing compound 66 with a base (e.g., sodium hydroxide).</div>
    </li> <li> <para-num num="[0580]"> </para-num> <div id="p-0777" num="0580" class="description-line">Compound 72 is obtained by reducing compound 71 with a reducing agent (e.g., borane).</div>
    </li> <li> <para-num num="[0581]"> </para-num> <div id="p-0778" num="0581" class="description-line">Compound 73 can be obtained by allowing a halogenation reagent (e.g., chlorine, bromine, iodine and iodine chloride) to act on compound 72.</div>
    </li> <li> <para-num num="[0582]"> </para-num> <div id="p-0779" num="0582" class="description-line">A compound having a further extended alkylene chain between each functional group (amino group, monoalkylamino group, dialkylamino group, carboxylic acid, hydroxy and halogen) and quaternary carbon of compounds 67, 68, 69, 71, 72 and 73 can be obtained by performing a series of reactions from compound 59 in <figure-callout id="13" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 13 for compound 73. Also, the alkylene chain between each functional group and quaternary carbon can be freely extended by repeating this operation.</div>
    </li> <li> <para-num num="[0583]"> </para-num> <div id="p-0780" num="0583" class="description-line">Compound 76 can be synthesized according to <figure-callout id="14" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 14.</div>
    </li> <li> <div id="p-0781" num="0000" class="description-line">
      <chemistry id="CHEM-US-00185" num="00185">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d8/58/de/2254897d1115b9/US20200368173A1-20201126-C00185.png"><img id="EMI-C00185" he="94.49mm" wi="75.78mm" file="US20200368173A1-20201126-C00185.TIF" alt="Figure US20200368173A1-20201126-C00185" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="378" alt="Figure US20200368173A1-20201126-C00185" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d8/58/de/2254897d1115b9/US20200368173A1-20201126-C00185.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00185" attachment-type="cdx" file="US20200368173A1-20201126-C00185.CDX"> </attachment>
          <attachment idref="CHEM-US-00185" attachment-type="mol" file="US20200368173A1-20201126-C00185.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0782" num="0000" class="description-line">wherein M<sup>13 </sup>is (CH<sub>2</sub>)<sub>p201</sub>; M<sup>15 </sup>is (CH<sub>2</sub>)<sub>p202</sub> wherein each of p<sup>201 </sup>and p<sup>202 </sup>is an integer from 1 to 5; M<sup>14 </sup>is O, COO or NY<sup>27A</sup>; and PRO<sup>4 </sup>represents any of protective group PRO<sup>1 </sup>for hydroxy, protective group PRO<sup>2 </sup>for carboxylic acid and protective group PRO<sup>3 </sup>for amine (e.g., carbamate-based protective groups such as tert-butoxycarbonyl, and benzyl) according to M<sup>14</sup>.</div>
    </li> <li> <para-num num="[0584]"> </para-num> <div id="p-0783" num="0584" class="description-line">Compound 74 is obtained by any method described in synthesis routes 11 to 13, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0585]"> </para-num> <div id="p-0784" num="0585" class="description-line">Compound 75 is obtained by appropriately protecting and deprotecting compound 74.</div>
    </li> <li> <para-num num="[0586]"> </para-num> <div id="p-0785" num="0586" class="description-line">Compound 76 is obtained by any method described in synthesis routes 11 to 13, or a method equivalent thereto with compound 75 as a starting material.</div>
    </li> <li> <para-num num="[0587]"> </para-num> <div id="p-0786" num="0587" class="description-line">As shown in synthesis route 15, compounds 77 to 79 can be obtained by performing protection and deprotection, and a method equivalent to <figure-callout id="14" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 14 in order with compound 76 as a starting material.</div>
    </li> <li> <div id="p-0787" num="0000" class="description-line">
      <chemistry id="CHEM-US-00186" num="00186">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/9f/96/eb72438435e6ab/US20200368173A1-20201126-C00186.png"><img id="EMI-C00186" he="69.34mm" wi="139.87mm" file="US20200368173A1-20201126-C00186.TIF" alt="Figure US20200368173A1-20201126-C00186" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="559" height="277" alt="Figure US20200368173A1-20201126-C00186" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cc/9f/96/eb72438435e6ab/US20200368173A1-20201126-C00186.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00186" attachment-type="cdx" file="US20200368173A1-20201126-C00186.CDX"> </attachment>
          <attachment idref="CHEM-US-00186" attachment-type="mol" file="US20200368173A1-20201126-C00186.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0788" num="0000" class="description-line">wherein M<sup>16 </sup>and M<sup>17 </sup>each represent (CH<sub>2</sub>)<sub>p203</sub> and (CH<sub>2</sub>)<sub>p204</sub> wherein each of p<sup>203 </sup>and p<sup>204 </sup>is an integer from 1 to 5; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0588]"> </para-num> <div id="p-0789" num="0588" class="description-line">Compounds 82, 84, 87, 89, 92 and 95 can be synthesized according to synthesis route 16.</div>
    </li> <li> <div id="p-0790" num="0000" class="description-line">
      <chemistry id="CHEM-US-00187" num="00187">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/44/56/e582b72d53ea0d/US20200368173A1-20201126-C00187.png"><img id="EMI-C00187" he="221.83mm" wi="75.78mm" file="US20200368173A1-20201126-C00187.TIF" alt="Figure US20200368173A1-20201126-C00187" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="887" alt="Figure US20200368173A1-20201126-C00187" class="patent-full-image" src="https://patentimages.storage.googleapis.com/78/44/56/e582b72d53ea0d/US20200368173A1-20201126-C00187.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00187" attachment-type="cdx" file="US20200368173A1-20201126-C00187.CDX"> </attachment>
          <attachment idref="CHEM-US-00187" attachment-type="mol" file="US20200368173A1-20201126-C00187.MOL"> </attachment>
        </attachments>
      </chemistry>
      <chemistry id="CHEM-US-00188" num="00188">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/c7/f5/f31b38f771c80d/US20200368173A1-20201126-C00188.png"><img id="EMI-C00188" he="106.43mm" wi="75.78mm" file="US20200368173A1-20201126-C00188.TIF" alt="Figure US20200368173A1-20201126-C00188" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="426" alt="Figure US20200368173A1-20201126-C00188" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cc/c7/f5/f31b38f771c80d/US20200368173A1-20201126-C00188.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00188" attachment-type="cdx" file="US20200368173A1-20201126-C00188.CDX"> </attachment>
          <attachment idref="CHEM-US-00188" attachment-type="mol" file="US20200368173A1-20201126-C00188.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0791" num="0000" class="description-line">wherein M<sup>18 </sup>is (CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub> or (CY<sup>23</sup>Y<sup>24</sup>)<sub>p11</sub>Z<sup>9</sup>(CY<sup>25</sup>Y<sup>26</sup>)<sub>p12</sub>; b<sup>1 </sup>is</div>
    </li> <li> <div id="p-0792" num="0000" class="description-line">
      <chemistry id="CHEM-US-00189" num="00189">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/50/ff/78/b74a78623aac65/US20200368173A1-20201126-C00189.png"><img id="EMI-C00189" he="70.10mm" wi="55.29mm" file="US20200368173A1-20201126-C00189.TIF" alt="Figure US20200368173A1-20201126-C00189" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="221" height="280" alt="Figure US20200368173A1-20201126-C00189" class="patent-full-image" src="https://patentimages.storage.googleapis.com/50/ff/78/b74a78623aac65/US20200368173A1-20201126-C00189.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00189" attachment-type="cdx" file="US20200368173A1-20201126-C00189.CDX"> </attachment>
          <attachment idref="CHEM-US-00189" attachment-type="mol" file="US20200368173A1-20201126-C00189.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0793" num="0000" class="description-line">Ar is a p-nitrophenyl group; Hal is a halogen atom such as chlorine, bromine or iodine; the other groups are each as defined above; and when p13 is 0, N is directly bonded to the carbon atom adjacent to Z<sup>10</sup>.</div>
    </li> <li> <para-num num="[0589]"> </para-num> <div id="p-0794" num="0589" class="description-line">Compound 82 is obtained by condensing <figure-callout id="80" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 80 and compound 81 through esterification, followed by deprotection.</div>
    </li> <li> <para-num num="[0590]"> </para-num> <div id="p-0795" num="0590" class="description-line">Compound 84 is obtained by condensing compound 83 and compound 81 through amidation, followed by deprotection.</div>
    </li> <li> <para-num num="[0591]"> </para-num> <div id="p-0796" num="0591" class="description-line">Compound 87 is obtained by condensing compound 85 and compound 86 through esterification, followed by deprotection.</div>
    </li> <li> <para-num num="[0592]"> </para-num> <div id="p-0797" num="0592" class="description-line">Compound 89 is obtained by condensing compound 85 and compound 88 through amidation, followed by deprotection.</div>
    </li> <li> <para-num num="[0593]"> </para-num> <div id="p-0798" num="0593" class="description-line">Compound 92 is obtained by subjecting compound 90 and compound 91 to nucleophilic substitution reaction, followed by deprotection.</div>
    </li> <li> <para-num num="[0594]"> </para-num> <div id="p-0799" num="0594" class="description-line">Compound 95 is obtained by subjecting compound 93 and compound 94 to transesterification reaction, followed by deprotection.</div>
    </li> <li> <para-num num="[0595]"> </para-num> <div id="p-0800" num="0595" class="description-line"> <figure-callout id="80" label="Compounds" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Compounds</figure-callout> 80, 83, 85, 90 and 93 can be obtained by synthesis routes 12 to 15 or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0596]"> </para-num> <div id="p-0801" num="0596" class="description-line">Each of compounds 81, 86, 88, 91 and 94 wherein M<sup>18 </sup>is (CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub> can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by the conversion of a functional group of a commercially available product according to a conventional method.</div>
    </li> <li> <para-num num="[0597]"> </para-num> <div id="p-0802" num="0597" class="description-line">In this case, a compound wherein b<sup>1 </sup>is</div>
    </li> <li> <div id="p-0803" num="0000" class="description-line">
      <chemistry id="CHEM-US-00190" num="00190">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5f/31/c3/2c3373ac9b008c/US20200368173A1-20201126-C00190.png"><img id="EMI-C00190" he="25.40mm" wi="69.43mm" file="US20200368173A1-20201126-C00190.TIF" alt="Figure US20200368173A1-20201126-C00190" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="278" height="102" alt="Figure US20200368173A1-20201126-C00190" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5f/31/c3/2c3373ac9b008c/US20200368173A1-20201126-C00190.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00190" attachment-type="cdx" file="US20200368173A1-20201126-C00190.CDX"> </attachment>
          <attachment idref="CHEM-US-00190" attachment-type="mol" file="US20200368173A1-20201126-C00190.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0804" num="0000" class="description-line">can be obtained by condensing</div>
    </li> <li> <div id="p-0805" num="0000" class="description-line">
      <chemistry id="CHEM-US-00191" num="00191">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/39/7d/29/a82f56820b596f/US20200368173A1-20201126-C00191.png"><img id="EMI-C00191" he="25.40mm" wi="62.74mm" file="US20200368173A1-20201126-C00191.TIF" alt="Figure US20200368173A1-20201126-C00191" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="251" height="102" alt="Figure US20200368173A1-20201126-C00191" class="patent-full-image" src="https://patentimages.storage.googleapis.com/39/7d/29/a82f56820b596f/US20200368173A1-20201126-C00191.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00191" attachment-type="cdx" file="US20200368173A1-20201126-C00191.CDX"> </attachment>
          <attachment idref="CHEM-US-00191" attachment-type="mol" file="US20200368173A1-20201126-C00191.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0806" num="0000" class="description-line">wherein M<sup>37 </sup>is OH, CO<sub>2</sub>H or NY<sup>38 </sup>(provided that Y<sup>38 </sup>is a hydrogen atom or optionally substituted C1-C4 alkyl) with each corresponding appropriate fragment through etherification, amination, esterification, amidation or the like.</div>
    </li> <li> <para-num num="[0598]"> </para-num> <div id="p-0807" num="0598" class="description-line">Compounds 81, 86, 88, 91 and 94 wherein M<sup>18 </sup>is (CY<sup>23</sup>Y<sup>24</sup>)<sub>p11</sub>Z<sup>9</sup>(CY<sup>25</sup>Y<sup>26</sup>)<sub>p12</sub> can be obtained by condensing the same compound as compound 81, 86, 88, 91 or 94 wherein M<sup>18 </sup>is (CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub> with each corresponding appropriate fragment through etherification, amination, esterification, amidation or the like.</div>
    </li> <li> <para-num num="[0599]"> </para-num> <div id="p-0808" num="0599" class="description-line">Compound (III) can be obtained by any method of synthesis routes 17 to 21 given below, a method equivalent to the method, or the like.</div>
    </li> <li> <para-num num="[0600]"> </para-num> <div id="p-0809" num="0600" class="description-line">Compound (IIIa) can be obtained from compound 96 according to synthesis route 17.</div>
    </li> <li> <div id="p-0810" num="0000" class="description-line">
      <chemistry id="CHEM-US-00192" num="00192">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/71/bc/53/05dfa7c249ecd3/US20200368173A1-20201126-C00192.png"><img id="EMI-C00192" he="60.45mm" wi="75.78mm" file="US20200368173A1-20201126-C00192.TIF" alt="Figure US20200368173A1-20201126-C00192" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="242" alt="Figure US20200368173A1-20201126-C00192" class="patent-full-image" src="https://patentimages.storage.googleapis.com/71/bc/53/05dfa7c249ecd3/US20200368173A1-20201126-C00192.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00192" attachment-type="cdx" file="US20200368173A1-20201126-C00192.CDX"> </attachment>
          <attachment idref="CHEM-US-00192" attachment-type="mol" file="US20200368173A1-20201126-C00192.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0811" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0601]"> </para-num> <div id="p-0812" num="0601" class="description-line">Compound (IIIa) is obtained by reacting compound 96 with compound 97 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher). Anion A<sup>3 </sup>of compound (IIIa) may be converted to another anion, for example, by treating the compound (IIIa) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0602]"> </para-num> <div id="p-0813" num="0602" class="description-line">Compound 96 can be obtained by a method described in Examples or a method equivalent thereto, or by a method described in the literature (U.S. Patent Application Publication No. 2012/0172411) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0603]"> </para-num> <div id="p-0814" num="0603" class="description-line">Each compound such as compound 97, etc. for use in the reaction can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0604]"> </para-num> <div id="p-0815" num="0604" class="description-line">Compound (IIIb) can be obtained from ethyl glyoxylate according to synthesis route 18.</div>
    </li> <li> <div id="p-0816" num="0000" class="description-line">
      <chemistry id="CHEM-US-00193" num="00193">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/78/73/353c3ed5ee72e7/US20200368173A1-20201126-C00193.png"><img id="EMI-C00193" he="112.86mm" wi="75.78mm" file="US20200368173A1-20201126-C00193.TIF" alt="Figure US20200368173A1-20201126-C00193" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="451" alt="Figure US20200368173A1-20201126-C00193" class="patent-full-image" src="https://patentimages.storage.googleapis.com/88/78/73/353c3ed5ee72e7/US20200368173A1-20201126-C00193.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00193" attachment-type="cdx" file="US20200368173A1-20201126-C00193.CDX"> </attachment>
          <attachment idref="CHEM-US-00193" attachment-type="mol" file="US20200368173A1-20201126-C00193.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0817" num="0000" class="description-line">wherein M<sup>19 </sup>is (CY<sup>50</sup>Y<sup>51</sup>)<sub>p23</sub> or (CY<sup>54</sup>Y<sup>55</sup>)<sub>p25</sub>Z<sup>17</sup>(CY<sup>56</sup>Y<sup>57</sup>)<sub>p26</sub> (wherein each group is as defined above); b<sup>2 </sup>is</div>
    </li> <li> <div id="p-0818" num="0000" class="description-line">
      <chemistry id="CHEM-US-00194" num="00194">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e9/49/dc/1f97e321ea2309/US20200368173A1-20201126-C00194.png"><img id="EMI-C00194" he="67.14mm" wi="56.73mm" file="US20200368173A1-20201126-C00194.TIF" alt="Figure US20200368173A1-20201126-C00194" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="227" height="269" alt="Figure US20200368173A1-20201126-C00194" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e9/49/dc/1f97e321ea2309/US20200368173A1-20201126-C00194.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00194" attachment-type="cdx" file="US20200368173A1-20201126-C00194.CDX"> </attachment>
          <attachment idref="CHEM-US-00194" attachment-type="mol" file="US20200368173A1-20201126-C00194.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0819" num="0000" class="description-line">and the other groups are each as defined above; and when p33 is 0, N is directly bonded to the carbon atom adjacent to Z<sup>21</sup>.</div>
    </li> <li> <para-num num="[0605]"> </para-num> <div id="p-0820" num="0605" class="description-line">Compound 101 is obtained by reacting ethyl glyoxylate with <figure-callout id="100" label="Grignard reagents" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Grignard reagents</figure-callout> 98, 99 and 100 in order in a solvent (e.g., ether-based solvents such as tetrahydrofuran). Compound 101 wherein R<sup>7</sup>, R<sup>8 </sup>and R<sup>9 </sup>are the same is also obtained by allowing excessive compound 98 to act on ethyl glyoxylate.</div>
    </li> <li> <para-num num="[0606]"> </para-num> <div id="p-0821" num="0606" class="description-line">Compound 103 is obtained by treating compound 101 and compound 102 with a base (e.g., organic bases such as triethylamine), a condensing agent (e.g., condensing agents such as 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride) and an activator (activators such as N,N-dimethylaminopyridine) in a solvent (e.g., halogen-based solvents such as chloroform).</div>
    </li> <li> <para-num num="[0607]"> </para-num> <div id="p-0822" num="0607" class="description-line">Compound (IIIb) is obtained by reacting compound 103 with compound 97, 104 or 105 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher). Anion A<sup>3 </sup>of compound (IIIb) may be converted to another anion, for example, by treating the compound (IIIb) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0608]"> </para-num> <div id="p-0823" num="0608" class="description-line">Compound 98 is obtained by allowing a mesylation reagent (mesyl anhydride or mesyl chloride, etc.), a bromide (magnesium bromide or lithium bromide, etc.), and metal magnesium in order to act on R<sup>7</sup>OH (which is a commercially available product or is obtained by a method described in Examples or a method equivalent thereto). <figure-callout id="100" label="Compounds" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Compounds</figure-callout> 99 and 100 are obtained in the same way as in compound 98.</div>
    </li> <li> <para-num num="[0609]"> </para-num> <div id="p-0824" num="0609" class="description-line">Compounds 104 and 105 are obtained in the same way as in compound 23.</div>
    </li> <li> <para-num num="[0610]"> </para-num> <div id="p-0825" num="0610" class="description-line">Compound 102 is obtained in the same way as in compound 54.</div>
    </li> <li> <para-num num="[0611]"> </para-num> <div id="p-0826" num="0611" class="description-line">Compounds 108, 109 and 112 can be obtained from ammonia, ethyl formate and compound 99, respectively according to <figure-callout id="19" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 19.</div>
    </li> <li> <div id="p-0827" num="0000" class="description-line">
      <chemistry id="CHEM-US-00195" num="00195">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b4/86/28/eeed30706fbd01/US20200368173A1-20201126-C00195.png"><img id="EMI-C00195" he="127.76mm" wi="75.78mm" file="US20200368173A1-20201126-C00195.TIF" alt="Figure US20200368173A1-20201126-C00195" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="511" alt="Figure US20200368173A1-20201126-C00195" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b4/86/28/eeed30706fbd01/US20200368173A1-20201126-C00195.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00195" attachment-type="cdx" file="US20200368173A1-20201126-C00195.CDX"> </attachment>
          <attachment idref="CHEM-US-00195" attachment-type="mol" file="US20200368173A1-20201126-C00195.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0828" num="0000" class="description-line">wherein M<sup>21 </sup>is OH, M<sup>22 </sup>is HOCO, and M<sup>25 </sup>is OCO; M<sup>21 </sup>is NY<sup>45C</sup>H, M<sup>22 </sup>is HOCO, and M<sup>25 </sup>is NY<sup>45C</sup>CO; M<sup>21 </sup>is COOH, M<sup>22 </sup>is HO, and M<sup>25 </sup>is COO; or M<sup>21 </sup>is COOH, M<sup>22 </sup>is HNY<sup>14B</sup>, and M<sup>25 </sup>is CONY<sup>14B</sup>; M<sup>20 </sup>is absent, and M<sup>23 </sup>is (CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub>; M<sup>20 </sup>is absent, and M<sup>23 </sup>is (CY<sup>41</sup>Y<sup>42</sup>)<sub>p19</sub>Z<sup>14</sup>(CY<sup>43</sup>Y<sup>44</sup>)<sub>p20</sub>; or M<sup>20 </sup>is Z<sup>13</sup>(CY<sup>41</sup>Y<sup>42</sup>)<sub>p19</sub>, and M<sup>23 </sup>is (CY<sup>43</sup>Y<sup>44</sup>)<sub>p20</sub>; M<sup>24 </sup>is (CY<sup>63</sup>Y<sup>64</sup>)<sub>p29</sub> or (CY<sup>67</sup>Y<sup>68</sup>)<sub>p31</sub>Z<sup>20</sup>(CY<sup>69</sup>Y<sup>70</sup>)<sub>p32</sub>; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0612]"> </para-num> <div id="p-0829" num="0612" class="description-line">Compound 108 is obtained by reacting ammonia with compound 106 and compound 107 by the application of the same reaction conditions as those for the synthesis of compound 4 from ammonia in <figure-callout id="1" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 1.</div>
    </li> <li> <para-num num="[0613]"> </para-num> <div id="p-0830" num="0613" class="description-line">Compound 109 is obtained by reacting ethyl formate with compound 99 and <figure-callout id="100" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 100 by the application of the same reaction conditions as those for the synthesis of compound 101 from ethyl glyoxylate in synthesis route 18.</div>
    </li> <li> <para-num num="[0614]"> </para-num> <div id="p-0831" num="0614" class="description-line">Compound 112 can be obtained by condensing compound 110 and compound 111 through esterification or amidation, followed by deprotection.</div>
    </li> <li> <para-num num="[0615]"> </para-num> <div id="p-0832" num="0615" class="description-line">Compounds 106 and 107 are obtained in the same way as in <figure-callout id="1" label="compound" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">compound</figure-callout> 1.</div>
    </li> <li> <para-num num="[0616]"> </para-num> <div id="p-0833" num="0616" class="description-line">Compound 110 wherein M<sup>21 </sup>is OH is obtained in the same way as in R<sup>1</sup>-L<sup>1</sup>-OH described in <figure-callout id="1" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis route</figure-callout> 1. Compound 110 wherein M<sup>21 </sup>is NY<sup>45C</sup>H is obtained in the same way as in <figure-callout id="37" label="compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 37. Compound 110 wherein M<sup>21 </sup>is COOH is obtained in the same way as in compound 17.</div>
    </li> <li> <para-num num="[0617]"> </para-num> <div id="p-0834" num="0617" class="description-line">Compound 111 can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fourth Series of <figure-callout id="20" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Experimental Chemistry</figure-callout> 20, Synthesis of Organic Compound II, 4th edition, p. 187, Maruzen Co., Ltd. (1992)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0618]"> </para-num> <div id="p-0835" num="0618" class="description-line">Compounds (IIIc) and (IIId) can be obtained from compounds 108 and 112, and compounds 109 and 112, respectively, according to <figure-callout id="20" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">synthesis route</figure-callout> 20.</div>
    </li> <li> <div id="p-0836" num="0000" class="description-line">
      <chemistry id="CHEM-US-00196" num="00196">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1a/20/c0/771997d3a60055/US20200368173A1-20201126-C00196.png"><img id="EMI-C00196" he="157.06mm" wi="75.78mm" file="US20200368173A1-20201126-C00196.TIF" alt="Figure US20200368173A1-20201126-C00196" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="628" alt="Figure US20200368173A1-20201126-C00196" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1a/20/c0/771997d3a60055/US20200368173A1-20201126-C00196.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00196" attachment-type="cdx" file="US20200368173A1-20201126-C00196.CDX"> </attachment>
          <attachment idref="CHEM-US-00196" attachment-type="mol" file="US20200368173A1-20201126-C00196.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0837" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0619]"> </para-num> <div id="p-0838" num="0619" class="description-line">Compound (IIIc) is obtained by condensing compounds 108 and 112 through amidation, and then allowing compound 114, 115, or 116 to act on the condensate.</div>
    </li> <li> <para-num num="[0620]"> </para-num> <div id="p-0839" num="0620" class="description-line">Compound (IIId) is obtained by condensing compounds 109 and 112 through esterification, and then allowing compound 114, 115, or 116 to act on the condensate.</div>
    </li> <li> <para-num num="[0621]"> </para-num> <div id="p-0840" num="0621" class="description-line">Anion A<sup>3 </sup>of compound (IIIc) or (IIId) may be converted to another anion, for example, by treating the compound (IIIc) or (IIId) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0622]"> </para-num> <div id="p-0841" num="0622" class="description-line">Each compound for use in the reactions is as mentioned above.</div>
    </li> <li> <para-num num="[0623]"> </para-num> <div id="p-0842" num="0623" class="description-line">Compound (IV) can be obtained by any method of synthesis routes 11 and 12 given below, a method equivalent to the method, or the like.</div>
    </li> <li> <para-num num="[0624]"> </para-num> <div id="p-0843" num="0624" class="description-line">Compound 127 can be obtained according to <figure-callout id="21" label="synthesis route" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">synthesis route</figure-callout> 21.</div>
    </li> <li> <div id="p-0844" num="0000" class="description-line">
      <chemistry id="CHEM-US-00197" num="00197">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9f/7b/8a/8a8e4fcaec808a/US20200368173A1-20201126-C00197.png"><img id="EMI-C00197" he="61.98mm" wi="144.53mm" file="US20200368173A1-20201126-C00197.TIF" alt="Figure US20200368173A1-20201126-C00197" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="578" height="248" alt="Figure US20200368173A1-20201126-C00197" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9f/7b/8a/8a8e4fcaec808a/US20200368173A1-20201126-C00197.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00197" attachment-type="cdx" file="US20200368173A1-20201126-C00197.CDX"> </attachment>
          <attachment idref="CHEM-US-00197" attachment-type="mol" file="US20200368173A1-20201126-C00197.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0845" num="0000" class="description-line">wherein M<sup>26 </sup>and M<sup>27 </sup>are the same or different and are each (CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>; M<sup>28 </sup>and M<sup>29 </sup>are the same or different and are each OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>; M<sup>30 </sup>and M<sup>31 </sup>are the same or different and are each absent, or OCO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub> or COO(CY<sup>91</sup>Y<sup>92</sup>)<sub>p41</sub>; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0625]"> </para-num> <div id="p-0846" num="0625" class="description-line">Compound 121 can be obtained by condensing compound 118 with compound 119 and <figure-callout id="120" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 120 in order through esterification reaction, or condensing compound 122 with compound 123 and compound 124 in order through esterification reaction.</div>
    </li> <li> <para-num num="[0626]"> </para-num> <div id="p-0847" num="0626" class="description-line">Compound 125 can be obtained by allowing a deprotection reagent (e.g., deprotection reagents such as tetra-n-butylammonium fluoride) to act on compound 121 in a solvent (e.g., ether-based solvents such as tetrahydrofuran), or subjecting ethyl formate to addition reaction with compound 126 and compound 127 in order in a solvent (e.g., ether-based solvents such as tetrahydrofuran).</div>
    </li> <li> <para-num num="[0627]"> </para-num> <div id="p-0848" num="0627" class="description-line">Compound 128 can be obtained by allowing an oxidizing agent (e.g., organic oxidizing agents such as Dess-Martin reagent, and inorganic oxidizing agents such as pyridinium chlorochromate) to act on compound 125 in a solvent (e.g., aprotic solvents such as chloroform).</div>
    </li> <li> <para-num num="[0628]"> </para-num> <div id="p-0849" num="0628" class="description-line">Each compound such as compound 118, compound 119, <figure-callout id="120" label="compound" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 120, compound 122, compound 123, compound 124, compound 126 and compound 127, etc. for use in the reaction can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., The Fourth Series of Experimental Chemistry 22, Synthesis of Organic Compound IV, 4th edition, p. 1, Maruzen Co., Ltd. (1992), The Fourth Series of <figure-callout id="20" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Experimental Chemistry</figure-callout> 20, Synthesis of Organic Compound II, 4th edition, p. 1, Maruzen Co., Ltd. (1992), and The Fourth Series of Experimental Chemistry 25, Synthesis of Organic Compound VII, 4th edition, p. 59, Maruzen Co., Ltd. (1991)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0629]"> </para-num> <div id="p-0850" num="0629" class="description-line">Compound (IVa) can be obtained from compound 128 according to synthesis route 22.</div>
    </li> <li> <div id="p-0851" num="0000" class="description-line">
      <chemistry id="CHEM-US-00198" num="00198">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f0/10/80/54c9854a7c8fc7/US20200368173A1-20201126-C00198.png"><img id="EMI-C00198" he="89.32mm" wi="75.78mm" file="US20200368173A1-20201126-C00198.TIF" alt="Figure US20200368173A1-20201126-C00198" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="357" alt="Figure US20200368173A1-20201126-C00198" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f0/10/80/54c9854a7c8fc7/US20200368173A1-20201126-C00198.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00198" attachment-type="cdx" file="US20200368173A1-20201126-C00198.CDX"> </attachment>
          <attachment idref="CHEM-US-00198" attachment-type="mol" file="US20200368173A1-20201126-C00198.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0852" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0630]"> </para-num> <div id="p-0853" num="0630" class="description-line">Compound 130 can be obtained by reacting compound 128 with compound 129 in the presence of a reducing agent (e.g., hydride compounds such as sodium borohydride and triacetoxyborohydride) and, in some cases, an additive (e.g., acids such as acetic acid) in a solvent (e.g., halogen-based solvents such as 1,2-dichloroethane).</div>
    </li> <li> <para-num num="[0631]"> </para-num> <div id="p-0854" num="0631" class="description-line">Compound 132 is obtained by reacting compound 130 with compound 131 in the presence of a base (e.g., inorganic bases such as sodium hydroxide) at a high temperature (e.g., 100 C. or higher). Although no solvent is particularly necessary, a solvent such as ethylene glycol may be used in some cases.</div>
    </li> <li> <para-num num="[0632]"> </para-num> <div id="p-0855" num="0632" class="description-line">Compound (IVa) is obtained by reacting compound 132 with compound 133 in the presence or absence of a solvent (e.g., halogen-based solvents such as chloroform) at room temperature or a high temperature (e.g., 100 C. or higher). Anion A<sup>4 </sup>of compound (IVa) may be converted to another anion, for example, by treating the compound (IVa) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0633]"> </para-num> <div id="p-0856" num="0633" class="description-line">Each compound such as compound 129, compound 131 and compound 133, etc. for use in the reaction can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in WO 2010/042877, WO 2010/054401, or The Fifth Series of <figure-callout id="13" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0634]"> </para-num> <div id="p-0857" num="0634" class="description-line">Compound (IVb) can be obtained according to synthesis route 23.</div>
    </li> <li> <div id="p-0858" num="0000" class="description-line">
      <chemistry id="CHEM-US-00199" num="00199">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/85/00/aa/65a88610c10398/US20200368173A1-20201126-C00199.png"><img id="EMI-C00199" he="118.03mm" wi="75.78mm" file="US20200368173A1-20201126-C00199.TIF" alt="Figure US20200368173A1-20201126-C00199" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="472" alt="Figure US20200368173A1-20201126-C00199" class="patent-full-image" src="https://patentimages.storage.googleapis.com/85/00/aa/65a88610c10398/US20200368173A1-20201126-C00199.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00199" attachment-type="cdx" file="US20200368173A1-20201126-C00199.CDX"> </attachment>
          <attachment idref="CHEM-US-00199" attachment-type="mol" file="US20200368173A1-20201126-C00199.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0859" num="0000" class="description-line">wherein M<sup>32 </sup>is absent, or Z<sup>27</sup>(CY<sup>93</sup>Y<sup>94</sup>)<sub>p42</sub>; Ns represents an o-nitrobenzenesulfonyl group; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0635]"> </para-num> <div id="p-0860" num="0635" class="description-line">Compound 136 is obtained by reacting compound 134, compound 135, triphenylphosphine, and diethyl azodicarboxylate, and then removing Ns from the obtained condensate by the action of thiol (e.g., dodecane-1-thiol and thiophenol).</div>
    </li> <li> <para-num num="[0636]"> </para-num> <div id="p-0861" num="0636" class="description-line">Compound 138 is obtained by amidating compounds 136 and 137.</div>
    </li> <li> <para-num num="[0637]"> </para-num> <div id="p-0862" num="0637" class="description-line">Compound (IVb) is obtained by allowing compound 139 to act on compound 138. Anion A<sup>4 </sup>of compound (IVb) may be converted to another anion, for example, by treating the compound (IVb) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0638]"> </para-num> <div id="p-0863" num="0638" class="description-line">Compound 134 is obtained by allowing o-nitrobenzenesulfonyl chloride to act on R<sup>11</sup>-L<sup>14</sup>-NH<sub>2</sub>. R<sup>11</sup>-L<sup>14</sup>-NH<sub>2 </sub>can be obtained as a commercially available product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Fourth Series of <figure-callout id="20" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Experimental Chemistry</figure-callout> 20, Synthesis of Organic Compound II, 4th edition, p. 279, Maruzen Co., Ltd. (1992)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0639]"> </para-num> <div id="p-0864" num="0639" class="description-line">Each compound such as compounds 135, 137 and 139, etc. for use in the reaction is obtained by any of the methods mentioned above.</div>
    </li> <li> <para-num num="[0640]"> </para-num> <div id="p-0865" num="0640" class="description-line">Compound (Va) can be obtained according to synthesis route 24.</div>
    </li> <li> <div id="p-0866" num="0000" class="description-line">
      <chemistry id="CHEM-US-00200" num="00200">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f0/4d/f5/3b8a9fd7f29387/US20200368173A1-20201126-C00200.png"><img id="EMI-C00200" he="144.61mm" wi="104.90mm" file="US20200368173A1-20201126-C00200.TIF" alt="Figure US20200368173A1-20201126-C00200" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="420" height="578" alt="Figure US20200368173A1-20201126-C00200" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f0/4d/f5/3b8a9fd7f29387/US20200368173A1-20201126-C00200.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00200" attachment-type="cdx" file="US20200368173A1-20201126-C00200.CDX"> </attachment>
          <attachment idref="CHEM-US-00200" attachment-type="mol" file="US20200368173A1-20201126-C00200.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0867" num="0000" class="description-line">wherein DMTr represents a 2,2-dimethoxytrityl group; M<sup>33 </sup>represents (CY<sup>123</sup>R<sup>124</sup>)<sub>p54</sub>, (CY<sup>125</sup>Y<sup>126</sup>)<sub>p55</sub>Z<sup>35</sup>(CY<sup>127</sup>R<sup>128</sup>)<sub>p56</sub> or (CY<sup>129</sup>R<sup>130</sup>)<sub>p57</sub>Z<sup>36</sup>(CY<sup>131</sup>Y<sup>132</sup>)<sub>p58</sub>Z<sup>37</sup>(CY<sup>133</sup>Y<sup>134</sup>)<sub>p59</sub>; M<sup>34</sup>, M<sup>35 </sup>and M<sup>36 </sup>are each independently O or COO; and the other groups are each as defined above.</div>
    </li> <li> <para-num num="[0641]"> </para-num> <div id="p-0868" num="0641" class="description-line">Compound 141 is obtained by allowing 2,2-dimethoxytrityl chloride to act on <figure-callout id="140" label="compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">compound</figure-callout> 140.</div>
    </li> <li> <para-num num="[0642]"> </para-num> <div id="p-0869" num="0642" class="description-line">Compound 142 is obtained by etherifying or esterifying compound 141 at 3 stages.</div>
    </li> <li> <para-num num="[0643]"> </para-num> <div id="p-0870" num="0643" class="description-line">Compound 143 is obtained by treating compound 142 with an acid.</div>
    </li> <li> <para-num num="[0644]"> </para-num> <div id="p-0871" num="0644" class="description-line">Compound 144 is obtained by activating compound 143 with a halogenation reagent, followed by treatment with a corresponding amine compound.</div>
    </li> <li> <para-num num="[0645]"> </para-num> <div id="p-0872" num="0645" class="description-line">Compound (Va) is obtained by allowing compound 145 to act on compound 144. Anion A<sup>5 </sup>of compound (Va) may be converted to another anion, for example, by treating the compound (Va) with an appropriate anion-exchange resin.</div>
    </li> <li> <para-num num="[0646]"> </para-num> <div id="p-0873" num="0646" class="description-line"> <figure-callout id="140" label="Compound" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Compound</figure-callout> 140 can be obtained as a commercially available product, as a natural product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Organic Chemistry of Sugars, Daniel E. Levy, et al. ed., Taylor &amp; Francis Group, 2005) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0647]"> </para-num> <div id="p-0874" num="0647" class="description-line">Compound (Va) can be obtained in the same way as in synthesis route 25 with compound 146 as a starting material.</div>
    </li> <li> <div id="p-0875" num="0000" class="description-line">
      <chemistry id="CHEM-US-00201" num="00201">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fe/97/aa/b900861a5a0d0b/US20200368173A1-20201126-C00201.png"><img id="EMI-C00201" he="82.13mm" wi="75.78mm" file="US20200368173A1-20201126-C00201.TIF" alt="Figure US20200368173A1-20201126-C00201" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="329" alt="Figure US20200368173A1-20201126-C00201" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fe/97/aa/b900861a5a0d0b/US20200368173A1-20201126-C00201.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00201" attachment-type="cdx" file="US20200368173A1-20201126-C00201.CDX"> </attachment>
          <attachment idref="CHEM-US-00201" attachment-type="mol" file="US20200368173A1-20201126-C00201.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0876" num="0000" class="description-line">wherein each group is as defined above.</div>
    </li> <li> <para-num num="[0648]"> </para-num> <div id="p-0877" num="0648" class="description-line">Compound 146 can be obtained as a commercially available product, as a natural product, or by a method described in Examples or a method equivalent thereto, or by a known method described in a literature (e.g., a method described in The Organic Chemistry of Sugars, Daniel E. Levy, et al. ed., Taylor &amp; Francis Group, 2005) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0649]"> </para-num> <div id="p-0878" num="0649" class="description-line">Compounds (I) to (V) can be obtained by any method of <figure-callout id="1" label="synthesis routes" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">synthesis routes</figure-callout> 1 to 25 described above, or an appropriate combination of methods equivalent to these methods, or the like.</div>
    </li> <li> <para-num num="[0650]"> </para-num> <div id="p-0879" num="0650" class="description-line">The lipid represented by compound (CL-I) can be obtained by a method described in WO 2013/089151, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0651]"> </para-num> <div id="p-0880" num="0651" class="description-line">The lipid represented by compound (CL-II) can be obtained by a method described in WO 2011/136368, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0652]"> </para-num> <div id="p-0881" num="0652" class="description-line">The lipids represented by compound (CL-III), compound (CL-IV) and compound (CL-V) can be obtained by a method described in WO 2014/007398, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0653]"> </para-num> <div id="p-0882" num="0653" class="description-line">The lipid represented by compound (CL-VI) can be obtained by a method described in WO 2010/042877, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0654]"> </para-num> <div id="p-0883" num="0654" class="description-line">Compound (CL-VII) can be obtained by a method described in WO 2010/054401, a method described in WO 2013/059496, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0655]"> </para-num> <div id="p-0884" num="0655" class="description-line">Compound (CL-VIII) can be obtained by a method described in WO 2016/002753, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0656]"> </para-num> <div id="p-0885" num="0656" class="description-line">Compound (CL-IX) can be obtained by a method described below, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0657]"> </para-num> <div id="p-0886" num="0657" class="description-line">Methods for producing the compound of the present invention will be described. In the production methods shown below, if defined groups react under conditions of the production methods or are unsuitable for carrying out the production methods, the desired compounds can be produced by use of introduction and removal methods of protective groups commonly used in organic synthetic chemistry [e.g., methods described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999)] or the like. If necessary, the order of reaction steps including substituent introduction or the like may be changed.</div>
    </li> <li> <para-num num="[0658]"> </para-num> <div id="p-0887" num="0658" class="description-line"> <figure-callout id="1" label="Production Method" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Production Method</figure-callout> 1</div>
    </li> <li> <para-num num="[0659]"> </para-num> <div id="p-0888" num="0659" class="description-line">Compounds (CL-IX) wherein both of X<sup>115 </sup>and X<sup>116 </sup>are hydrogen atoms, that is, compound (CL-IXa), and wherein X<sup>115 </sup>and X<sup>116 </sup>are the same, that is, compound (CL-IXb), can be produced by the following method:</div>
    </li> <li> <div id="p-0889" num="0000" class="description-line">
      <chemistry id="CHEM-US-00202" num="00202">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b7/36/a8/f3e42b583ac93e/US20200368173A1-20201126-C00202.png"><img id="EMI-C00202" he="63.58mm" wi="101.60mm" file="US20200368173A1-20201126-C00202.TIF" alt="Figure US20200368173A1-20201126-C00202" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="406" height="254" alt="Figure US20200368173A1-20201126-C00202" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b7/36/a8/f3e42b583ac93e/US20200368173A1-20201126-C00202.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00202" attachment-type="cdx" file="US20200368173A1-20201126-C00202.CDX"> </attachment>
          <attachment idref="CHEM-US-00202" attachment-type="mol" file="US20200368173A1-20201126-C00202.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0660]"> </para-num> <div id="p-0890" num="0660" class="description-line">wherein R<sup>118</sup>, R<sup>119</sup>, M<sup>101</sup>, M<sup>102</sup>, L<sup>118 </sup>and L<sup>119 </sup>are each as defined above; X in IX-IIIa and X in IX-IIIb are the same or different and are each a leaving group such as a chlorine atom, a bromine atom, an iodine atom, trifluoromethanesulfonyloxy, methanesulfonyloxy, benzenesulfonyloxy or p-toluenesulfonyloxy; R<sup>141 </sup>is a hydrogen atom, methyl or ethyl; and R<sup>142 </sup>is a hydrogen atom or methyl, or R<sup>141 </sup>and R<sup>142 </sup>form a cyclopropyl ring together with the adjacent carbon (provided that when R<sup>141 </sup>is a hydrogen atom or ethyl, R<sup>142 </sup>is not methyl.</div>
    </li> <li> <para-num num="[0661]"> </para-num> <div id="p-0891" num="0661" class="description-line">Steps 26 and 27</div>
    </li> <li> <para-num num="[0662]"> </para-num> <div id="p-0892" num="0662" class="description-line">Compound (IX-IIa) can be produced by reacting compound (IX-IIIa) with 2-amino-2-methyl-1,3-propanediol at a temperature between room temperature and 200 C. for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a base without a solvent or in a solvent. Compound (CL-IXa) can be produced by reacting compound (IX-IIa) with compound (IX-IIIb) at a temperature between room temperature and 200 C. for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a base without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0663]"> </para-num> <div id="p-0893" num="0663" class="description-line">Examples of the solvent include dichloromethane, 1,2-dichloroethane, toluene, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane and pyridine. These solvents can be used alone or as a mixture.</div>
    </li> <li> <para-num num="[0664]"> </para-num> <div id="p-0894" num="0664" class="description-line">Examples of the base include sodium methoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide, lithium hexamethyldisilazane, sodium hexamethyldisilazane and n-butyllithium.</div>
    </li> <li> <para-num num="[0665]"> </para-num> <div id="p-0895" num="0665" class="description-line">Compound (IX-IIIa) and compound (IX-IIIb) can each be obtained as a commercially available product or by a method known in the art (e.g., The Fifth Series of <figure-callout id="13" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0666]"> </para-num> <div id="p-0896" num="0666" class="description-line">When R<sup>118</sup>-M<sup>101</sup>-L<sup>118 </sup>and R<sup>119</sup>-M<sup>102</sup>-L<sup>119 </sup>are the same, compound (CL-IXa) can be obtained by using 2 equivalents or more of compound (IX-IIIa) in step 26.</div>
    </li> <li> <para-num num="[0667]"> </para-num> <div id="p-0897" num="0667" class="description-line">2-Amino-2-methyl-1,3-propanediol can be obtained as a commercially available product.</div>
    </li> <li> <para-num num="[0668]"> </para-num> <div id="p-0898" num="0668" class="description-line">Step 28 Compound (CL-IXb) can be produced by reacting compound (CL-IXa) with 2 to 20 equivalents of compound (IX-IV) at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of preferably 1 equivalent to a large excess of a reducing agent and, if necessary, preferably 1 to 10 equivalents of an acid, in a solvent.</div>
    </li> <li> <para-num num="[0669]"> </para-num> <div id="p-0899" num="0669" class="description-line">Examples of the solvent include methanol, ethanol, tert-butyl alcohol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, ti-methylpyrrolidone and water. These solvents are used alone or as a mixture.</div>
    </li> <li> <para-num num="[0670]"> </para-num> <div id="p-0900" num="0670" class="description-line">Examples of the reducing agent include sodium triacetoxyborohydride and sodium cyanoborohydride.</div>
    </li> <li> <para-num num="[0671]"> </para-num> <div id="p-0901" num="0671" class="description-line">Examples of the acid include hydrochloric acid and acetic acid.</div>
    </li> <li> <para-num num="[0672]"> </para-num> <div id="p-0902" num="0672" class="description-line">Compound (IX-IV) can be obtained as a commercially available product.</div>
    </li> <li> <para-num num="[0673]"> </para-num> <div id="p-0903" num="0673" class="description-line"> <figure-callout id="2" label="Production Method" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Production Method</figure-callout> 2</div>
    </li> <li> <para-num num="[0674]"> </para-num> <div id="p-0904" num="0674" class="description-line">Compounds (CL-IX) wherein X<sup>115 </sup>and X<sup>116 </sup>are different, that is, compounds (CL-IXc) and (CL-IXd), can be produced by the following method:</div>
    </li> <li> <div id="p-0905" num="0000" class="description-line">
      <chemistry id="CHEM-US-00203" num="00203">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9a/e3/aa/274f49440a60b8/US20200368173A1-20201126-C00203.png"><img id="EMI-C00203" he="64.26mm" wi="148.59mm" file="US20200368173A1-20201126-C00203.TIF" alt="Figure US20200368173A1-20201126-C00203" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="594" height="257" alt="Figure US20200368173A1-20201126-C00203" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9a/e3/aa/274f49440a60b8/US20200368173A1-20201126-C00203.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00203" attachment-type="cdx" file="US20200368173A1-20201126-C00203.CDX"> </attachment>
          <attachment idref="CHEM-US-00203" attachment-type="mol" file="US20200368173A1-20201126-C00203.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0675]"> </para-num> <div id="p-0906" num="0675" class="description-line">wherein R<sup>118</sup>, R<sup>119</sup>, M<sup>101</sup>, M<sup>102</sup>, L<sup>118</sup>, L<sup>119</sup>, R<sup>141</sup>, R<sup>142 </sup>and X are each as defined above; R<sup>143 </sup>is as defined in X<sup>115</sup>; and PC represents a protective group.</div>
    </li> <li> <para-num num="[0676]"> </para-num> <div id="p-0907" num="0676" class="description-line">Step 29</div>
    </li> <li> <para-num num="[0677]"> </para-num> <div id="p-0908" num="0677" class="description-line">Compound (IX-IIb) can be produced by protecting compound (CL-IXa) by a protective group commonly used in organic synthetic chemistry [e.g., protective groups described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc.].</div>
    </li> <li> <para-num num="[0678]"> </para-num> <div id="p-0909" num="0678" class="description-line">Step 30</div>
    </li> <li> <para-num num="[0679]"> </para-num> <div id="p-0910" num="0679" class="description-line">Compound (IX-IIc) can be produced by reacting compound (IX-IIb) with compound (IX-IIIc) at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of 1 to 10 equivalents of a base without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0680]"> </para-num> <div id="p-0911" num="0680" class="description-line">Examples of the solvent include dichloromethane, 1,2-dichloroethane, toluene, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, pyridine, N,N-dimethylformamide and N,N-dimethylacetamide. These solvents can be used alone or as a mixture.</div>
    </li> <li> <para-num num="[0681]"> </para-num> <div id="p-0912" num="0681" class="description-line">Examples of the base include sodium methoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide, lithium hexamethyldisilazane, sodium hexamethyldisilazane, n-butyllithium, potassium carbonate, cesium carbonate and triethylamine.</div>
    </li> <li> <para-num num="[0682]"> </para-num> <div id="p-0913" num="0682" class="description-line">Compound (IX-IIIc) can be obtained as a commercially available product.</div>
    </li> <li> <para-num num="[0683]"> </para-num> <div id="p-0914" num="0683" class="description-line">Step 31</div>
    </li> <li> <para-num num="[0684]"> </para-num> <div id="p-0915" num="0684" class="description-line">Compound (CL-IXc) is obtained by removing the protective group PG on compound (IX-IIc) by an appropriate method. Methods for removing protective groups commonly used in organic synthetic chemistry [e.g., removal methods described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999)] can be used as the protective group removal method. The compound of interest can thereby be produced.</div>
    </li> <li> <para-num num="[0685]"> </para-num> <div id="p-0916" num="0685" class="description-line">Step 32</div>
    </li> <li> <para-num num="[0686]"> </para-num> <div id="p-0917" num="0686" class="description-line">Compound (CL-IXd) can be produced by reacting compound (CL-IXc) with 1 to 10 equivalents of compound (IX-IV) at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of preferably 1 equivalent to a large excess of a reducing agent and, if necessary, preferably 1 to 10 equivalents of an acid in a solvent.</div>
    </li> <li> <para-num num="[0687]"> </para-num> <div id="p-0918" num="0687" class="description-line">Examples of the solvent, the reducing agent and the acid include those listed in step 28.</div>
    </li> <li> <para-num num="[0688]"> </para-num> <div id="p-0919" num="0688" class="description-line"> <figure-callout id="3" label="Production Method" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Production Method</figure-callout> 3</div>
    </li> <li> <para-num num="[0689]"> </para-num> <div id="p-0920" num="0689" class="description-line">Compounds (CL-IX) wherein each of M<sup>101 </sup>and M<sup>102 </sup>is OC(O), that is, compounds (CL-IXc) and (CL-IXd), can also be produced by the following method:</div>
    </li> <li> <div id="p-0921" num="0000" class="description-line">
      <chemistry id="CHEM-US-00204" num="00204">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/81/6d/e5/f0f138ea0d1396/US20200368173A1-20201126-C00204.png"><img id="EMI-C00204" he="134.03mm" wi="153.25mm" file="US20200368173A1-20201126-C00204.TIF" alt="Figure US20200368173A1-20201126-C00204" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="613" height="536" alt="Figure US20200368173A1-20201126-C00204" class="patent-full-image" src="https://patentimages.storage.googleapis.com/81/6d/e5/f0f138ea0d1396/US20200368173A1-20201126-C00204.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00204" attachment-type="cdx" file="US20200368173A1-20201126-C00204.CDX"> </attachment>
          <attachment idref="CHEM-US-00204" attachment-type="mol" file="US20200368173A1-20201126-C00204.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0690]"> </para-num> <div id="p-0922" num="0690" class="description-line">wherein R<sup>118</sup>, R<sup>119</sup>, M<sup>101</sup>, M<sup>102</sup>, L<sup>118</sup>, L<sup>119</sup>, R<sup>141</sup>, R<sup>142</sup>, R<sup>143 </sup>and PG are each as defined above; and each of B and B is linear or branched C1-C16 alkyl or C2-C16 alkenyl.</div>
    </li> <li> <para-num num="[0691]"> </para-num> <div id="p-0923" num="0691" class="description-line">Step 33</div>
    </li> <li> <para-num num="[0692]"> </para-num> <div id="p-0924" num="0692" class="description-line">Compound (IX-IId) can be produced by reacting compound (IX-IIc) with an oxidizing agent at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in a solvent.</div>
    </li> <li> <para-num num="[0693]"> </para-num> <div id="p-0925" num="0693" class="description-line">Examples of the oxidizing agent include ozone, osmium tetroxide/sodium periodate and osmium tetroxide/lead tetraacetate.</div>
    </li> <li> <para-num num="[0694]"> </para-num> <div id="p-0926" num="0694" class="description-line">Examples of the solvent include those listed in step 28.</div>
    </li> <li> <para-num num="[0695]"> </para-num> <div id="p-0927" num="0695" class="description-line">Compound (IX-IIc) can be produced by the method described in <figure-callout id="2" label="Production Method" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Production Method</figure-callout> 2.</div>
    </li> <li> <para-num num="[0696]"> </para-num> <div id="p-0928" num="0696" class="description-line">Step 34</div>
    </li> <li> <para-num num="[0697]"> </para-num> <div id="p-0929" num="0697" class="description-line">Compound (IX-IIe) can be produced by reacting compound (IX-IId) with an oxidizing agent at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in a solvent.</div>
    </li> <li> <para-num num="[0698]"> </para-num> <div id="p-0930" num="0698" class="description-line">Examples of the oxidizing agent include Jones reagent, pyridinium dichromate, ruthenium tetroxide and sodium chlorite.</div>
    </li> <li> <para-num num="[0699]"> </para-num> <div id="p-0931" num="0699" class="description-line">Examples of the solvent include tert-butyl alcohol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetone, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl pyrrolidone and water. These solvents can be used alone or as a mixture.</div>
    </li> <li> <para-num num="[0700]"> </para-num> <div id="p-0932" num="0700" class="description-line">Steps 35 and 36</div>
    </li> <li> <para-num num="[0701]"> </para-num> <div id="p-0933" num="0701" class="description-line">Compound (IX-IIf) can be produced by reacting compound (IX-IIe) with compound (IX-Va) at a temperature between room temperature and 200 C. for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a condensing agent and 1 to 10 equivalents of a base without a solvent or in a solvent. Compound (IX-IIc) can be produced by reacting compound (IX-IIf) with compound (IX-Vb) at a temperature between room temperature and 200 C. for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a condensing agent and 1 to 10 equivalents of a base without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0702]"> </para-num> <div id="p-0934" num="0702" class="description-line">Examples of the solvent include dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methyl pyrrolidone and pyridine. These solvents can be used alone or as a mixture.</div>
    </li> <li> <para-num num="[0703]"> </para-num> <div id="p-0935" num="0703" class="description-line">Examples of the condensing agent include 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, N,N-dicyclohexylcarbodiimide, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride n hydrate, 1H-benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate and O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate.</div>
    </li> <li> <para-num num="[0704]"> </para-num> <div id="p-0936" num="0704" class="description-line">Examples of the base include potassium carbonate, cesium carbonate, triethylamine, N,N-diisopropylethylamine, N-methylmorpholine and pyridine.</div>
    </li> <li> <para-num num="[0705]"> </para-num> <div id="p-0937" num="0705" class="description-line">Each of compound (IX-Va) and compound (IX-Vb) can be obtained as a commercially available product.</div>
    </li> <li> <para-num num="[0706]"> </para-num> <div id="p-0938" num="0706" class="description-line">Compound (IX-IIc) wherein R<sup>118 </sup>and R<sup>119 </sup>are the same can be obtained by using 2 or more equivalents of compound (IX-Va) in step 35.</div>
    </li> <li> <para-num num="[0707]"> </para-num> <div id="p-0939" num="0707" class="description-line"> <figure-callout id="37" label="Step" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Step</figure-callout> 37</div>
    </li> <li> <para-num num="[0708]"> </para-num> <div id="p-0940" num="0708" class="description-line">Compound (CL-IXc) is obtained by removing the protective group PC on compound (IX-IIc) by appropriate methods. Methods for removing protective groups commonly used in organic synthetic chemistry [e.g., removal methods described in Protective Groups in Organic Synthesis, third edition, T. W. Greene, John Wiley &amp; Sons Inc. (1999) or the like] can be used as the protective group removal methods, and thus, the compound of interest can be produced.</div>
    </li> <li> <para-num num="[0709]"> </para-num> <div id="p-0941" num="0709" class="description-line"> <figure-callout id="38" label="Step" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Step</figure-callout> 38</div>
    </li> <li> <para-num num="[0710]"> </para-num> <div id="p-0942" num="0710" class="description-line">Compound (CL-IXd) can be produced by reacting compound (CL-IXc) with 1 to 10 equivalents of compound (IX-IV) at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of preferably 1 equivalent to a large excess of a reducing agent and, if necessary, preferably 1 to 10 equivalents of an acid in a solvent.</div>
    </li> <li> <para-num num="[0711]"> </para-num> <div id="p-0943" num="0711" class="description-line">Examples of the solvent and the acid include those listed in step 28.</div>
    </li> <li> <para-num num="[0712]"> </para-num> <div id="p-0944" num="0712" class="description-line">Among compounds (CL-IX), compounds other than compounds (CL-IXa) to (CL-IXd) described above can be produced according to the production methods described above or by the application of general production methods commonly used in organic synthetic chemistry, by adopting starting materials, reagents, or the like suitable for the structures of the compounds of interest.</div>
    </li> <li> <para-num num="[0713]"> </para-num> <div id="p-0945" num="0713" class="description-line">The intermediates and the desired compounds in the production methods described above can each be isolated and purified by separation and purification methods commonly used in organic synthetic chemistry, for example, filtration, extraction, washing, drying, concentration, recrystallization, various chromatography techniques, or the like. Alternatively, each intermediate may be subjected to the next reaction without being particularly purified.</div>
    </li> <li> <para-num num="[0714]"> </para-num> <div id="p-0946" num="0714" class="description-line">R<sup>115 </sup>and R<sup>116 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl.</div>
    </li> <li> <para-num num="[0715]"> </para-num> <div id="p-0947" num="0715" class="description-line">R<sup>115 </sup>and R<sup>116 </sup>are the same or different and are each preferably a hydrogen atom, methyl, ethyl or propyl, more preferably a hydrogen atom or methyl.</div>
    </li> <li> <para-num num="[0716]"> </para-num> <div id="p-0948" num="0716" class="description-line">The combination (R<sup>115</sup>,R<sup>116</sup>) is preferably (a hydrogen atom,a hydrogen atom), (a hydrogen atom,methyl) or (methyl,methyl), more preferably (a hydrogen atom,methyl) or (methyl,methyl).</div>
    </li> <li> <para-num num="[0717]"> </para-num> <div id="p-0949" num="0717" class="description-line">L<sup>118 </sup>and L<sup>119 </sup>are the same or different and are each linear or branched C8-C24 alkylene or C8-C24 alkenylene.</div>
    </li> <li> <para-num num="[0718]"> </para-num> <div id="p-0950" num="0718" class="description-line">When L<sup>118 </sup>and L<sup>119 </sup>are the same or different and are each alkylene, the alkylene is preferably linear C8-C24 alkylene, more preferably linear C8-C20 alkylene, further preferably linear C8-C12 alkylene.</div>
    </li> <li> <para-num num="[0719]"> </para-num> <div id="p-0951" num="0719" class="description-line">L<sup>118 </sup>and L<sup>119 </sup>are the same or different and are each preferably octylene, nonylene, undecylene, tridecylene or pentadecylene, more preferably octylene, nonylene or undecylene.</div>
    </li> <li> <para-num num="[0720]"> </para-num> <div id="p-0952" num="0720" class="description-line">When L<sup>118 </sup>and L<sup>119 </sup>are the same or different and are each alkenylene, the alkenylene is preferably linear C8-C24 alkenylene, more preferably linear C10-C20 alkenylene, further preferably linear C10-C12 alkenylene.</div>
    </li> <li> <para-num num="[0721]"> </para-num> <div id="p-0953" num="0721" class="description-line">L<sup>118 </sup>and L<sup>119 </sup>are the same or different and are each preferably (Z)-undec-9-enylene, (Z)-tridec-11-enylene, (Z)-tetradec-9-enylene, (Z)-hexadec-9-enylene, (Z)-octadec-9-enylene, (Z)-octadec-11-enylene or (9Z,12Z)-octadeca-9,12-dienylene.</div>
    </li> <li> <para-num num="[0722]"> </para-num> <div id="p-0954" num="0722" class="description-line">L<sup>118 </sup>and L<sup>119 </sup>are preferably the same.</div>
    </li> <li> <para-num num="[0723]"> </para-num> <div id="p-0955" num="0723" class="description-line">M<sup>101 </sup>and M<sup>102 </sup>are the same or different and are each CC, OC(O)C(O)O, SC(O)C(O)S, OC(S), C(S)O, SS, C(R)N, NC(R), C(R)NO, ONC(R), N(R)C(O)C(O)N(R)N(R)C(S)C(S)N(R), N(R)C(O)N(R), N(R<sup>3</sup>)C(O)O, OC(O)N(R) or OC(O)O.</div>
    </li> <li> <para-num num="[0724]"> </para-num> <div id="p-0956" num="0724" class="description-line">M<sup>101 </sup>and M<sup>102 </sup>are the same or different and are each preferably CC, OC(O), C(O)O, C(O)(NR), N(R)C(O), N(R)C(O), N(R)C(O)N(R), N(R)C(O)O, OC(O)N(R) or OC(O)O, more preferably CC, OC(O) or C(O)O.</div>
    </li> <li> <para-num num="[0725]"> </para-num> <div id="p-0957" num="0725" class="description-line">Bonds in the structures of M<sup>101 </sup>and M<sup>102 </sup>mean a structure of R<sup>118</sup>OC(O)-L<sup>118 </sup>when OC(O) is taken as an example.</div>
    </li> <li> <para-num num="[0726]"> </para-num> <div id="p-0958" num="0726" class="description-line">M<sup>101 </sup>and M<sup>102 </sup>are preferably the same.</div>
    </li> <li> <para-num num="[0727]"> </para-num> <div id="p-0959" num="0727" class="description-line">R and R in M<sup>101 </sup>and M<sup>102 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl.</div>
    </li> <li> <para-num num="[0728]"> </para-num> <div id="p-0960" num="0728" class="description-line">Each of R and R is preferably a hydrogen atom, methyl, ethyl or propyl, more preferably a hydrogen atom or methyl, further preferably a hydrogen atom.</div>
    </li> <li> <para-num num="[0729]"> </para-num> <div id="p-0961" num="0729" class="description-line">R<sup>118 </sup>and R<sup>119 </sup>are the same or different and are each linear or branched C1-C16 alkyl or C2-C16 alkenyl.</div>
    </li> <li> <para-num num="[0730]"> </para-num> <div id="p-0962" num="0730" class="description-line">When R<sup>118 </sup>and R<sup>119 </sup>are the same or different and are each alkyl, the alkyl is preferably linear C1-C16 alkyl, more preferably linear C2-C9 alkyl.</div>
    </li> <li> <para-num num="[0731]"> </para-num> <div id="p-0963" num="0731" class="description-line">R<sup>118 </sup>and R<sup>119 </sup>are the same or different and are each preferably pentyl, octyl, nonyl, decyl or dodecyl.</div>
    </li> <li> <para-num num="[0732]"> </para-num> <div id="p-0964" num="0732" class="description-line">When R<sup>118 </sup>and R<sup>119 </sup>are the same or different and are each alkenyl, the alkenyl is preferably linear C2-C16 alkenyl, more preferably linear C3-C9 alkenyl.</div>
    </li> <li> <para-num num="[0733]"> </para-num> <div id="p-0965" num="0733" class="description-line">R<sup>118 </sup>and R<sup>119 </sup>are the same or different and are each preferably (Z)-hept-2-ene, (Z)-oct-2-ene, (Z)-non-2-ene, (Z)-non-3-ene, non-8-ene, (Z)-dodec-2-ene or (Z)-tridec-2-ene.</div>
    </li> <li> <para-num num="[0734]"> </para-num> <div id="p-0966" num="0734" class="description-line">R<sup>118 </sup>and R<sup>119 </sup>are preferably the same.</div>
    </li> <li> <para-num num="[0735]"> </para-num> <div id="p-0967" num="0735" class="description-line">R<sup>118</sup>-M<sup>101</sup>-L<sup>118 </sup>and R<sup>119</sup>-M<sup>102</sup>-L<sup>119 </sup>are the same or different, R<sup>118 </sup>and R<sup>119</sup>, M<sup>101 </sup>and M<sup>102</sup>, or L<sup>118 </sup>and L<sup>119 </sup>may be a combination selected from the structures described about each group.</div>
    </li> <li> <para-num num="[0736]"> </para-num> <div id="p-0968" num="0736" class="description-line">R<sup>118</sup>-M<sup>101</sup>-L<sup>118 </sup>and R<sup>119</sup>-M<sup>102</sup>-L<sup>119 </sup>are preferably the same.</div>
    </li> <li> <para-num num="[0737]"> </para-num> <div id="p-0969" num="0737" class="description-line">R<sup>118</sup>-M<sup>101</sup>-L<sup>118 </sup>and R<sup>119</sup>-M<sup>102</sup>-L<sup>119 </sup>are the same or different and are each preferably selected from the group consisting of (Z)-tetradec-9-enyl, (Z)-hexadec-9-enyl, (Z)-octadec-9-enyl, (E)-octadec-9-enyl, (Z)-octadec-11-enyl, (9Z,12Z)-octadeca-9,12-dienyl, (9Z,12Z,15Z)-octadeca-9,12,15-trienyl, (Z)-icos-11-enyl, (11Z,14Z)-icosa-11,14-dienyl and (Z)-docos-13-enyl, more preferably selected from the group consisting of (Z)-hexadec-9-enyl, (Z)-octadec-9-enyl, (9Z,12Z)-octadeca-9,12-dienyl and (11Z,14Z)-icosa-11,14-dienyl.</div>
    </li> <li> <para-num num="[0738]"> </para-num> <div id="p-0970" num="0738" class="description-line">R<sup>118</sup>-M<sup>101</sup>-L<sup>118 </sup>and R<sup>119</sup>-M<sup>102</sup>-L<sup>119 </sup>are the same or different and are each preferably any of the following structures (1) to (5), more preferably are the same and any of the following structures (1) to (5):</div>
    </li> <li> <div id="p-0971" num="0000" class="description-line">
      <chemistry id="CHEM-US-00205" num="00205">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/18/30/07/c76fce3a163bbc/US20200368173A1-20201126-C00205.png"><img id="EMI-C00205" he="116.42mm" wi="76.12mm" file="US20200368173A1-20201126-C00205.TIF" alt="Figure US20200368173A1-20201126-C00205" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="304" height="466" alt="Figure US20200368173A1-20201126-C00205" class="patent-full-image" src="https://patentimages.storage.googleapis.com/18/30/07/c76fce3a163bbc/US20200368173A1-20201126-C00205.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00205" attachment-type="cdx" file="US20200368173A1-20201126-C00205.CDX"> </attachment>
          <attachment idref="CHEM-US-00205" attachment-type="mol" file="US20200368173A1-20201126-C00205.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <div id="p-0972" num="0000" class="description-line">wherein n is an integer from 1 to 4.</div>
    </li> <li> <para-num num="[0739]"> </para-num> <div id="p-0973" num="0739" class="description-line">The lipid represented by compound (CL-X) can be obtained by a method described in WO 2009/129385, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0740]"> </para-num> <div id="p-0974" num="0740" class="description-line">The lipid represented by compound (CL-XI) can be obtained by a method described in WO 2013/1491401, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0741]"> </para-num> <div id="p-0975" num="0741" class="description-line">The lipid represented by compound (CL-XII) can be obtained by a method described in WO 2009/129395, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0742]"> </para-num> <div id="p-0976" num="0742" class="description-line">The lipid represented by compound (CL-XIII) can be obtained by a method described in WO 2013/059496, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0743]"> </para-num> <div id="p-0977" num="0743" class="description-line">The lipid represented by compound (CL-XIV) can be obtained by a method described in WO 2011/149733, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0744]"> </para-num> <div id="p-0978" num="0744" class="description-line">The lipid represented by formula (CL-XV) can be obtained by a method described in WO 2011/153493, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0745]"> </para-num> <div id="p-0979" num="0745" class="description-line">The lipid represented by formula (CL-XVI) can be obtained by a method described in WO 2015/074085, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0746]"> </para-num> <div id="p-0980" num="0746" class="description-line">The lipid represented by formula (CL-XVII) can be obtained by a method described in WO 2012/170952, or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0747]"> </para-num> <div id="p-0981" num="0747" class="description-line">The lipid represented by formula (CL-XVIII) can be synthesized according to methods given below.</div>
    </li> <li> <para-num num="[0748]"> </para-num> <div id="p-0982" num="0748" class="description-line">Examples of the method for synthesizing the lipid represented by formula (CL-XVIII) include Synthesis Method I for formula (CL-XVIII) and Synthesis Method II for formula (CL-XVIII) given below.</div>
    </li> <li> <para-num num="[0749]"> </para-num> <div id="p-0983" num="0749" class="description-line">(Synthesis Method I for Formula (CL-XVIII))</div>
    </li> <li> <div id="p-0984" num="0000" class="description-line">
      <chemistry id="CHEM-US-00206" num="00206">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d2/f5/5c/8a63515f35d6b8/US20200368173A1-20201126-C00206.png"><img id="EMI-C00206" he="71.20mm" wi="75.78mm" file="US20200368173A1-20201126-C00206.TIF" alt="Figure US20200368173A1-20201126-C00206" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="285" alt="Figure US20200368173A1-20201126-C00206" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d2/f5/5c/8a63515f35d6b8/US20200368173A1-20201126-C00206.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00206" attachment-type="cdx" file="US20200368173A1-20201126-C00206.CDX"> </attachment>
          <attachment idref="CHEM-US-00206" attachment-type="mol" file="US20200368173A1-20201126-C00206.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0750]"> </para-num> <div id="p-0985" num="0750" class="description-line">wherein R<sup>137</sup>, R<sup>138 </sup>and X<sup>135 </sup>are each as defined above; Ms in compound (XVIII-a) and compound (XVIII-c) represents a methanesulfonyl group; and X represents a halogen atom.</div>
    </li> <li> <para-num num="[0751]"> </para-num> <div id="p-0986" num="0751" class="description-line">Step 39</div>
    </li> <li> <para-num num="[0752]"> </para-num> <div id="p-0987" num="0752" class="description-line">Compound (XVIII-b) can be obtained by subjecting compound (XVIII-a) and 2-mercaptoethanol to thioetherification reaction for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a base without a solvent or in a solvent to obtain an alcohol compound, followed by the halogenation reaction of the alcohol. The halogenation reaction is preferably chlorination. Examples thereof can include a method of reaction with methanesulfonyl chloride for 5 minutes to 100 hours in the presence of 1 to 10 equivalents of a base without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0753]"> </para-num> <div id="p-0988" num="0753" class="description-line">Examples of the solvent include methanol, ethanol, tert-butyl alcohol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, ti-methylpyrrolidone and water. These solvents are used alone or as a mixture.</div>
    </li> <li> <para-num num="[0754]"> </para-num> <div id="p-0989" num="0754" class="description-line">Examples of the base include cesium carbonate, triethylamine, sodium methoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide, lithium hexamethyldisilazane, sodium hexamethyldisilazane and n-butyllithium.</div>
    </li> <li> <para-num num="[0755]"> </para-num> <div id="p-0990" num="0755" class="description-line">Compound (XVIII-a) may be obtained as a commercially available product or by a method known in the art (e.g., The Fifth Series of <figure-callout id="13" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0756]"> </para-num> <div id="p-0991" num="0756" class="description-line"> <figure-callout id="40" label="Step" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Step</figure-callout> 40</div>
    </li> <li> <para-num num="[0757]"> </para-num> <div id="p-0992" num="0757" class="description-line">Compound (XVIII-d) can be produced by reacting compound (XVIII-c) with N-(tert-butoxycarbonyl)-2-nitrobenzenesulfonamide at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of a base without a solvent or in a solvent to obtain a carbamate intermediate, and then reacting the intermediate with an acid at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0758]"> </para-num> <div id="p-0993" num="0758" class="description-line">A phase transfer catalyst such as tetrabutylammonium iodide may be used at the stage of reacting compound (XVIII-c) with N-(tert-butoxycarbonyl)-2-nitrobenzenesulfonamide.</div>
    </li> <li> <para-num num="[0759]"> </para-num> <div id="p-0994" num="0759" class="description-line">Examples of the solvent include the same solvents as in step 39.</div>
    </li> <li> <para-num num="[0760]"> </para-num> <div id="p-0995" num="0760" class="description-line">Examples of the base include the same bases as in step 39.</div>
    </li> <li> <para-num num="[0761]"> </para-num> <div id="p-0996" num="0761" class="description-line">Examples of the acid include hydrochloric acid, acetic acid and trifluoroacetic acid.</div>
    </li> <li> <para-num num="[0762]"> </para-num> <div id="p-0997" num="0762" class="description-line">Compound (XVIII-c) may be obtained as a commercially available product or by a method known in the art (e.g., The Fifth Series of <figure-callout id="13" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0763]"> </para-num> <div id="p-0998" num="0763" class="description-line">Step 41</div>
    </li> <li> <para-num num="[0764]"> </para-num> <div id="p-0999" num="0764" class="description-line">A lipid represented by formula (CL-XVIII) wherein X<sup>135 </sup>is a hydrogen atom can be obtained by reacting compound (XVIII-b) with compound (XVIII-d) at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of a base without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0765]"> </para-num> <div id="p-1000" num="0765" class="description-line">A phase transfer catalyst such as tetrabutylammonium iodide may be used in the reaction of compound (XVIII-b) with compound (XVIII-d).</div>
    </li> <li> <para-num num="[0766]"> </para-num> <div id="p-1001" num="0766" class="description-line">Step 42</div>
    </li> <li> <para-num num="[0767]"> </para-num> <div id="p-1002" num="0767" class="description-line">A lipid represented by formula (CL-XVIII) wherein X<sup>135 </sup>is any of C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (C), formula (D) and formula (E) can be obtained by performing N-alkylation, N-carbonylation, N-acylation or N-sulfonylation reaction by use of a method known in the art (e.g., The Fifth Series of <figure-callout id="13" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0768]"> </para-num> <div id="p-1003" num="0768" class="description-line">(Synthesis Method II for Formula (CL-XVIII))</div>
    </li> <li> <para-num num="[0769]"> </para-num> <div id="p-1004" num="0769" class="description-line">A lipid represented by formula (CL-XVIII) wherein R<sup>138 </sup>is C8-C24 alkynyl C8-C24 alkylthioethyl, C8-24 alkenylthioethyl or C8-C24 alkynylthioethyl can be suitably produced by Synthesis Method II for formula (CL-XVIII).</div>
    </li> <li> <div id="p-1005" num="0000" class="description-line">
      <chemistry id="CHEM-US-00207" num="00207">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fd/32/8b/e1c9d0acd3fada/US20200368173A1-20201126-C00207.png"><img id="EMI-C00207" he="66.89mm" wi="75.78mm" file="US20200368173A1-20201126-C00207.TIF" alt="Figure US20200368173A1-20201126-C00207" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="268" alt="Figure US20200368173A1-20201126-C00207" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fd/32/8b/e1c9d0acd3fada/US20200368173A1-20201126-C00207.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00207" attachment-type="cdx" file="US20200368173A1-20201126-C00207.CDX"> </attachment>
          <attachment idref="CHEM-US-00207" attachment-type="mol" file="US20200368173A1-20201126-C00207.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0770]"> </para-num> <div id="p-1006" num="0770" class="description-line">wherein R<sup>137 </sup>and X<sup>135 </sup>are each as defined above; R<sup>138 </sup>is C8-C24 alkynyl C8-C24 alkylthioethyl, C8-24 alkenylthioethyl or C8-C24 alkynylthioethyl; Ms in compound (XVIII-a) and compound (XVIII-g) represents a methanesulfonyl group; and Boc represents a benzyloxycarbonyl group.</div>
    </li> <li> <para-num num="[0771]"> </para-num> <div id="p-1007" num="0771" class="description-line"> <figure-callout id="43" label="Step" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Step</figure-callout> 43</div>
    </li> <li> <para-num num="[0772]"> </para-num> <div id="p-1008" num="0772" class="description-line">Compound (XVIII-e) can be obtained by reacting compound (XVIII-a) with S-potassium thioacetate at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0773]"> </para-num> <div id="p-1009" num="0773" class="description-line">Examples of the solvent include methanol, ethanol, tert-butyl alcohol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, ti-methylpyrrolidone and water. These solvents are used alone or as a mixture.</div>
    </li> <li> <para-num num="[0774]"> </para-num> <div id="p-1010" num="0774" class="description-line"> <figure-callout id="44" label="Step" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Step</figure-callout> 44</div>
    </li> <li> <para-num num="[0775]"> </para-num> <div id="p-1011" num="0775" class="description-line">Compound (XVIII-g) can be obtained by reacting compound (XVIII-f) with methanesulfonyl chloride at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of a base without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0776]"> </para-num> <div id="p-1012" num="0776" class="description-line">Examples of the solvent include the same solvents as in <figure-callout id="43" label="step" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">step</figure-callout> 43.</div>
    </li> <li> <para-num num="[0777]"> </para-num> <div id="p-1013" num="0777" class="description-line">Examples of the base include cesium carbonate, triethylamine, sodium methoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide, lithium hexamethyldisilazane, sodium hexamethyldisilazane and n-butyllithium.</div>
    </li> <li> <para-num num="[0778]"> </para-num> <div id="p-1014" num="0778" class="description-line">Step 45</div>
    </li> <li> <para-num num="[0779]"> </para-num> <div id="p-1015" num="0779" class="description-line">A lipid represented by formula (CL-XVIII) wherein X<sup>135 </sup>is a hydrogen atom can be obtained by reacting compound (XVIII-e) with compound (XVIII-g) at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of a base without a solvent or in a solvent to obtain thioether, and then eliminating the Boc group through reaction at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of an acid without a solvent or in a solvent</div>
    </li> <li> <para-num num="[0780]"> </para-num> <div id="p-1016" num="0780" class="description-line">Examples of the solvent include the same solvents as in <figure-callout id="43" label="step" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">step</figure-callout> 43.</div>
    </li> <li> <para-num num="[0781]"> </para-num> <div id="p-1017" num="0781" class="description-line">Examples of the base include the same bases as in <figure-callout id="43" label="step" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">step</figure-callout> 43.</div>
    </li> <li> <para-num num="[0782]"> </para-num> <div id="p-1018" num="0782" class="description-line">Examples of the acid include hydrochloric acid, acetic acid and trifluoroacetic acid.</div>
    </li> <li> <para-num num="[0783]"> </para-num> <div id="p-1019" num="0783" class="description-line">Step 46</div>
    </li> <li> <para-num num="[0784]"> </para-num> <div id="p-1020" num="0784" class="description-line">Step 46 can be performed in the same way as in step 42 described above.</div>
    </li> <li> <para-num num="[0785]"> </para-num> <div id="p-1021" num="0785" class="description-line">A lipid represented by formula (CL-XIX) can be synthesized according to methods given below.</div>
    </li> <li> <para-num num="[0786]"> </para-num> <div id="p-1022" num="0786" class="description-line">Examples of the method for synthesizing the lipid represented by formula (CL-XIX) include Synthesis Method I for formula (CL-XIX) and Synthesis Method II for formula (CL-XIX) given below.</div>
    </li> <li> <para-num num="[0787]"> </para-num> <div id="p-1023" num="0787" class="description-line">(Synthesis Method I for Formula (CL-XIX))</div>
    </li> <li> <para-num num="[0788]"> </para-num> <div id="p-1024" num="0788" class="description-line">Synthesis Method I for formula (CL-XIX) is suitable for formula (CL-XIX) wherein L<sup>133 </sup>is S.</div>
    </li> <li> <div id="p-1025" num="0000" class="description-line">
      <chemistry id="CHEM-US-00208" num="00208">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/20/b1/31/096a93d26391e8/US20200368173A1-20201126-C00208.png"><img id="EMI-C00208" he="57.40mm" wi="75.78mm" file="US20200368173A1-20201126-C00208.TIF" alt="Figure US20200368173A1-20201126-C00208" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="230" alt="Figure US20200368173A1-20201126-C00208" class="patent-full-image" src="https://patentimages.storage.googleapis.com/20/b1/31/096a93d26391e8/US20200368173A1-20201126-C00208.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00208" attachment-type="cdx" file="US20200368173A1-20201126-C00208.CDX"> </attachment>
          <attachment idref="CHEM-US-00208" attachment-type="mol" file="US20200368173A1-20201126-C00208.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0789]"> </para-num> <div id="p-1026" num="0789" class="description-line">wherein R<sup>139</sup>, R<sup>140 </sup>and X<sup>142 </sup>are each as defined above; and Boc in compound (XIX-b) represents a benzyloxycarbonyl group.</div>
    </li> <li> <para-num num="[0790]"> </para-num> <div id="p-1027" num="0790" class="description-line">Step 47</div>
    </li> <li> <para-num num="[0791]"> </para-num> <div id="p-1028" num="0791" class="description-line">A dimesyl form is obtained by protecting N in azetidine-3,3-diyl dimethanol (XIX-a) with a Boc group according to a routine method, and then allowing methanesulfonyl chloride to act thereon at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of a base without a solvent or in a solvent. Compound (XIX-b) can be obtained by reacting the dimesyl form with S-potassium thioacetate for 5 minutes to 72 hours without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0792]"> </para-num> <div id="p-1029" num="0792" class="description-line">Examples of the solvent include methanol, ethanol, tert-butyl alcohol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, N-methylpyrrolidone and water. These solvents are used alone or as a mixture.</div>
    </li> <li> <para-num num="[0793]"> </para-num> <div id="p-1030" num="0793" class="description-line">Examples of the base include cesium carbonate, triethylamine, sodium methoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide, lithium hexamethyldisilazane, sodium hexamethyldisilazane and n-butyllithium.</div>
    </li> <li> <para-num num="[0794]"> </para-num> <div id="p-1031" num="0794" class="description-line">Step 48</div>
    </li> <li> <para-num num="[0795]"> </para-num> <div id="p-1032" num="0795" class="description-line">A thioether form can be obtained by allowing R<sup>139</sup>OMs and R<sup>140</sup>OMs (wherein Ms is a me thane sulfonyl group) to act on compound (XIX-b) at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of a base without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0796]"> </para-num> <div id="p-1033" num="0796" class="description-line">A lipid represented by formula (CL-XIX) wherein X<sup>142 </sup>is a hydrogen atom can be obtained by eliminating the Boc group from the obtained thioether form through reaction at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of an acid without a solvent or in a solvent</div>
    </li> <li> <para-num num="[0797]"> </para-num> <div id="p-1034" num="0797" class="description-line">Examples of the base include the same bases as in step 47.</div>
    </li> <li> <para-num num="[0798]"> </para-num> <div id="p-1035" num="0798" class="description-line">Examples of the solvent include the same solvents as in step 47.</div>
    </li> <li> <para-num num="[0799]"> </para-num> <div id="p-1036" num="0799" class="description-line">Examples of the acid include hydrochloric acid, acetic acid and trifluoroacetic acid.</div>
    </li> <li> <para-num num="[0800]"> </para-num> <div id="p-1037" num="0800" class="description-line">Step 49</div>
    </li> <li> <para-num num="[0801]"> </para-num> <div id="p-1038" num="0801" class="description-line">A lipid represented by formula (CL-XIX) wherein X<sup>142 </sup>is any of C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (F) and formula (G) can be obtained by performing N-alkylation, N-carbonylation or N-acylation reaction by use of a method known in the art (e.g., The Fifth Series of <figure-callout id="13" label="Experimental Chemistry" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Experimental Chemistry</figure-callout> 13, Synthesis of Organic Compound I, 5th edition, p. 374, Maruzen Co., Ltd. (2005)) or a method equivalent thereto.</div>
    </li> <li> <para-num num="[0802]"> </para-num> <div id="p-1039" num="0802" class="description-line">(Synthesis Method II for Formula (CL-XIX))</div>
    </li> <li> <para-num num="[0803]"> </para-num> <div id="p-1040" num="0803" class="description-line">Synthesis Method II for formula (CL-XIX) is suitable for formula (CL-XIX) wherein L<sup>133 </sup>is 0.</div>
    </li> <li> <div id="p-1041" num="0000" class="description-line">
      <chemistry id="CHEM-US-00209" num="00209">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/6d/2d/576f4b2d3bec5e/US20200368173A1-20201126-C00209.png"><img id="EMI-C00209" he="80.09mm" wi="75.78mm" file="US20200368173A1-20201126-C00209.TIF" alt="Figure US20200368173A1-20201126-C00209" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="303" height="320" alt="Figure US20200368173A1-20201126-C00209" class="patent-full-image" src="https://patentimages.storage.googleapis.com/23/6d/2d/576f4b2d3bec5e/US20200368173A1-20201126-C00209.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00209" attachment-type="cdx" file="US20200368173A1-20201126-C00209.CDX"> </attachment>
          <attachment idref="CHEM-US-00209" attachment-type="mol" file="US20200368173A1-20201126-C00209.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[0804]"> </para-num> <div id="p-1042" num="0804" class="description-line">Step 50</div>
    </li> <li> <para-num num="[0805]"> </para-num> <div id="p-1043" num="0805" class="description-line">Compound (XIX-c) is obtained by protecting N in azetidine-3,3-diyl dimethanol (XIX-a) with a Boc group according to a routine method, and then allowing R<sup>140</sup>OMs to act thereon at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of a base without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0806]"> </para-num> <div id="p-1044" num="0806" class="description-line">Examples of the base include cesium carbonate, triethylamine, sodium methoxide, potassium tert-butoxide, sodium hydride, lithium diisopropylamide, lithium hexamethyldisilazane, sodium hexamethyldisilazane and n-butyllithium.</div>
    </li> <li> <para-num num="[0807]"> </para-num> <div id="p-1045" num="0807" class="description-line">Examples of the solvent include methanol, ethanol, tert-butyl alcohol, dichloromethane, chloroform, 1,2-dichloroethane, toluene, ethyl acetate, acetonitrile, diethyl ether, tetrahydrofuran, 1,2-dimethoxyethane, 1,4-dioxane, N,N-dimethylformamide, N,N-dimethylacetamide, ti-methylpyrrolidone and water. These solvents are used alone or as a mixture.</div>
    </li> <li> <para-num num="[0808]"> </para-num> <div id="p-1046" num="0808" class="description-line">Step 51</div>
    </li> <li> <para-num num="[0809]"> </para-num> <div id="p-1047" num="0809" class="description-line">A mesyl form is obtained by allowing methanesulfonyl chloride to act on compound (XIX-c) at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of a base without a solvent or in a solvent. Compound (XIX-d) can be obtained by reacting the mesyl form with S-potassium thioacetate for 5 minutes to 72 hours without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0810]"> </para-num> <div id="p-1048" num="0810" class="description-line">Examples of the base include the same bases as in step 50.</div>
    </li> <li> <para-num num="[0811]"> </para-num> <div id="p-1049" num="0811" class="description-line">Examples of the solvent include the same solvents as in step 50.</div>
    </li> <li> <para-num num="[0812]"> </para-num> <div id="p-1050" num="0812" class="description-line">Step 52</div>
    </li> <li> <para-num num="[0813]"> </para-num> <div id="p-1051" num="0813" class="description-line">A thioether form can be obtained by allowing R<sup>139</sup>OMs (wherein Ms is a methanesulfonyl group) to act on compound (XIX-d) at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of a base without a solvent or in a solvent.</div>
    </li> <li> <para-num num="[0814]"> </para-num> <div id="p-1052" num="0814" class="description-line">A lipid represented by formula (CL-XIX) wherein X<sup>142 </sup>is a hydrogen atom can be obtained by eliminating the Boc group from the obtained thioether form through reaction at a temperature between 20 C. and 150 C. for 5 minutes to 72 hours in the presence of an acid without a solvent or in a solvent</div>
    </li> <li> <para-num num="[0815]"> </para-num> <div id="p-1053" num="0815" class="description-line">Examples of the base include the same bases as in step 50.</div>
    </li> <li> <para-num num="[0816]"> </para-num> <div id="p-1054" num="0816" class="description-line">Examples of the solvent include the same solvents as in step 50.</div>
    </li> <li> <para-num num="[0817]"> </para-num> <div id="p-1055" num="0817" class="description-line">Examples of the acid include hydrochloric acid, acetic acid and trifluoroacetic acid.</div>
    </li> <li> <para-num num="[0818]"> </para-num> <div id="p-1056" num="0818" class="description-line">Step 53</div>
    </li> <li> <para-num num="[0819]"> </para-num> <div id="p-1057" num="0819" class="description-line">Step 53 can be performed in the same way as in step 49 described above.</div>
    </li> <li> <para-num num="[0820]"> </para-num> <div id="p-1058" num="0820" class="description-line">Specific examples of lipid A according to the present invention will be shown in Tables 16 to 31, though lipid A is not limited thereto.</div>
    </li> <li> <div id="p-1059" num="0000" class="description-line">
      <tables id="TABLE-US-00016" num="00016">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 16</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">I-1</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00210" num="00210">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/af/ea/2c/f4e93a754689ca/US20200368173A1-20201126-C00210.png"><img id="EMI-C00210" he="30.06mm" wi="108.46mm" file="US20200368173A1-20201126-C00210.TIF" alt="Figure US20200368173A1-20201126-C00210" img-content="table" img-format="tif" orientation="portrait" inline="no" width="434" height="120" alt="Figure US20200368173A1-20201126-C00210" class="patent-full-image" src="https://patentimages.storage.googleapis.com/af/ea/2c/f4e93a754689ca/US20200368173A1-20201126-C00210.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00210" attachment-type="cdx" file="US20200368173A1-20201126-C00210.CDX"> </attachment>
                      <attachment idref="CHEM-US-00210" attachment-type="mol" file="US20200368173A1-20201126-C00210.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">I-2</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00211" num="00211">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ba/a6/b9/d999b1ffd0863a/US20200368173A1-20201126-C00211.png"><img id="EMI-C00211" he="29.97mm" wi="109.22mm" file="US20200368173A1-20201126-C00211.TIF" alt="Figure US20200368173A1-20201126-C00211" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="120" alt="Figure US20200368173A1-20201126-C00211" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ba/a6/b9/d999b1ffd0863a/US20200368173A1-20201126-C00211.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00211" attachment-type="cdx" file="US20200368173A1-20201126-C00211.CDX"> </attachment>
                      <attachment idref="CHEM-US-00211" attachment-type="mol" file="US20200368173A1-20201126-C00211.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">I-3</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00212" num="00212">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/51/5d/ce/908f4f3f4d0cac/US20200368173A1-20201126-C00212.png"><img id="EMI-C00212" he="17.27mm" wi="95.25mm" file="US20200368173A1-20201126-C00212.TIF" alt="Figure US20200368173A1-20201126-C00212" img-content="table" img-format="tif" orientation="portrait" inline="no" width="381" height="69" alt="Figure US20200368173A1-20201126-C00212" class="patent-full-image" src="https://patentimages.storage.googleapis.com/51/5d/ce/908f4f3f4d0cac/US20200368173A1-20201126-C00212.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00212" attachment-type="cdx" file="US20200368173A1-20201126-C00212.CDX"> </attachment>
                      <attachment idref="CHEM-US-00212" attachment-type="mol" file="US20200368173A1-20201126-C00212.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">I-4</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00213" num="00213">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6f/34/c2/de62e1831d9a8a/US20200368173A1-20201126-C00213.png"><img id="EMI-C00213" he="17.19mm" wi="94.49mm" file="US20200368173A1-20201126-C00213.TIF" alt="Figure US20200368173A1-20201126-C00213" img-content="table" img-format="tif" orientation="portrait" inline="no" width="378" height="69" alt="Figure US20200368173A1-20201126-C00213" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6f/34/c2/de62e1831d9a8a/US20200368173A1-20201126-C00213.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00213" attachment-type="cdx" file="US20200368173A1-20201126-C00213.CDX"> </attachment>
                      <attachment idref="CHEM-US-00213" attachment-type="mol" file="US20200368173A1-20201126-C00213.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">I-5</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00214" num="00214">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ed/57/74/f48eee1c1c731e/US20200368173A1-20201126-C00214.png"><img id="EMI-C00214" he="17.19mm" wi="105.16mm" file="US20200368173A1-20201126-C00214.TIF" alt="Figure US20200368173A1-20201126-C00214" img-content="table" img-format="tif" orientation="portrait" inline="no" width="421" height="69" alt="Figure US20200368173A1-20201126-C00214" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ed/57/74/f48eee1c1c731e/US20200368173A1-20201126-C00214.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00214" attachment-type="cdx" file="US20200368173A1-20201126-C00214.CDX"> </attachment>
                      <attachment idref="CHEM-US-00214" attachment-type="mol" file="US20200368173A1-20201126-C00214.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">I-6</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00215" num="00215">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/88/ed/df/736105e74612c3/US20200368173A1-20201126-C00215.png"><img id="EMI-C00215" he="17.19mm" wi="111.84mm" file="US20200368173A1-20201126-C00215.TIF" alt="Figure US20200368173A1-20201126-C00215" img-content="table" img-format="tif" orientation="portrait" inline="no" width="447" height="69" alt="Figure US20200368173A1-20201126-C00215" class="patent-full-image" src="https://patentimages.storage.googleapis.com/88/ed/df/736105e74612c3/US20200368173A1-20201126-C00215.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00215" attachment-type="cdx" file="US20200368173A1-20201126-C00215.CDX"> </attachment>
                      <attachment idref="CHEM-US-00215" attachment-type="mol" file="US20200368173A1-20201126-C00215.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">I-7</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00216" num="00216">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b0/d4/da/32e0b83e35b07e/US20200368173A1-20201126-C00216.png"><img id="EMI-C00216" he="17.27mm" wi="106.93mm" file="US20200368173A1-20201126-C00216.TIF" alt="Figure US20200368173A1-20201126-C00216" img-content="table" img-format="tif" orientation="portrait" inline="no" width="428" height="69" alt="Figure US20200368173A1-20201126-C00216" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b0/d4/da/32e0b83e35b07e/US20200368173A1-20201126-C00216.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00216" attachment-type="cdx" file="US20200368173A1-20201126-C00216.CDX"> </attachment>
                      <attachment idref="CHEM-US-00216" attachment-type="mol" file="US20200368173A1-20201126-C00216.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1060" num="0000" class="description-line">
      <tables id="TABLE-US-00017" num="00017">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 17</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">II-1</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00217" num="00217">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0d/68/30/4af2934229cda8/US20200368173A1-20201126-C00217.png"><img id="EMI-C00217" he="35.73mm" wi="109.22mm" file="US20200368173A1-20201126-C00217.TIF" alt="Figure US20200368173A1-20201126-C00217" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="143" alt="Figure US20200368173A1-20201126-C00217" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0d/68/30/4af2934229cda8/US20200368173A1-20201126-C00217.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00217" attachment-type="cdx" file="US20200368173A1-20201126-C00217.CDX"> </attachment>
                      <attachment idref="CHEM-US-00217" attachment-type="mol" file="US20200368173A1-20201126-C00217.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-2</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00218" num="00218">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/ef/e5/044259714c273d/US20200368173A1-20201126-C00218.png"><img id="EMI-C00218" he="35.64mm" wi="88.90mm" file="US20200368173A1-20201126-C00218.TIF" alt="Figure US20200368173A1-20201126-C00218" img-content="table" img-format="tif" orientation="portrait" inline="no" width="356" height="143" alt="Figure US20200368173A1-20201126-C00218" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/ef/e5/044259714c273d/US20200368173A1-20201126-C00218.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00218" attachment-type="cdx" file="US20200368173A1-20201126-C00218.CDX"> </attachment>
                      <attachment idref="CHEM-US-00218" attachment-type="mol" file="US20200368173A1-20201126-C00218.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-3</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00219" num="00219">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c7/ca/5a/5354c595591631/US20200368173A1-20201126-C00219.png"><img id="EMI-C00219" he="35.64mm" wi="108.46mm" file="US20200368173A1-20201126-C00219.TIF" alt="Figure US20200368173A1-20201126-C00219" img-content="table" img-format="tif" orientation="portrait" inline="no" width="434" height="143" alt="Figure US20200368173A1-20201126-C00219" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c7/ca/5a/5354c595591631/US20200368173A1-20201126-C00219.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00219" attachment-type="cdx" file="US20200368173A1-20201126-C00219.CDX"> </attachment>
                      <attachment idref="CHEM-US-00219" attachment-type="mol" file="US20200368173A1-20201126-C00219.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-4</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00220" num="00220">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/dc/a8/d0/9314d7dd7071b5/US20200368173A1-20201126-C00220.png"><img id="EMI-C00220" he="35.73mm" wi="107.70mm" file="US20200368173A1-20201126-C00220.TIF" alt="Figure US20200368173A1-20201126-C00220" img-content="table" img-format="tif" orientation="portrait" inline="no" width="431" height="143" alt="Figure US20200368173A1-20201126-C00220" class="patent-full-image" src="https://patentimages.storage.googleapis.com/dc/a8/d0/9314d7dd7071b5/US20200368173A1-20201126-C00220.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00220" attachment-type="cdx" file="US20200368173A1-20201126-C00220.CDX"> </attachment>
                      <attachment idref="CHEM-US-00220" attachment-type="mol" file="US20200368173A1-20201126-C00220.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-5</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00221" num="00221">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f5/2e/d0/820ba4c071def7/US20200368173A1-20201126-C00221.png"><img id="EMI-C00221" he="35.64mm" wi="98.64mm" file="US20200368173A1-20201126-C00221.TIF" alt="Figure US20200368173A1-20201126-C00221" img-content="table" img-format="tif" orientation="portrait" inline="no" width="395" height="143" alt="Figure US20200368173A1-20201126-C00221" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f5/2e/d0/820ba4c071def7/US20200368173A1-20201126-C00221.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00221" attachment-type="cdx" file="US20200368173A1-20201126-C00221.CDX"> </attachment>
                      <attachment idref="CHEM-US-00221" attachment-type="mol" file="US20200368173A1-20201126-C00221.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-6</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00222" num="00222">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7a/99/1e/efc4b1896cf36a/US20200368173A1-20201126-C00222.png"><img id="EMI-C00222" he="18.71mm" wi="109.22mm" file="US20200368173A1-20201126-C00222.TIF" alt="Figure US20200368173A1-20201126-C00222" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="75" alt="Figure US20200368173A1-20201126-C00222" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7a/99/1e/efc4b1896cf36a/US20200368173A1-20201126-C00222.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00222" attachment-type="cdx" file="US20200368173A1-20201126-C00222.CDX"> </attachment>
                      <attachment idref="CHEM-US-00222" attachment-type="mol" file="US20200368173A1-20201126-C00222.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1061" num="0000" class="description-line">
      <tables id="TABLE-US-00018" num="00018">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 18</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">II-7</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00223" num="00223">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/da/ba/e8/c5184958b5d13c/US20200368173A1-20201126-C00223.png"><img id="EMI-C00223" he="18.71mm" wi="95.42mm" file="US20200368173A1-20201126-C00223.TIF" alt="Figure US20200368173A1-20201126-C00223" img-content="table" img-format="tif" orientation="portrait" inline="no" width="382" height="75" alt="Figure US20200368173A1-20201126-C00223" class="patent-full-image" src="https://patentimages.storage.googleapis.com/da/ba/e8/c5184958b5d13c/US20200368173A1-20201126-C00223.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00223" attachment-type="cdx" file="US20200368173A1-20201126-C00223.CDX"> </attachment>
                      <attachment idref="CHEM-US-00223" attachment-type="mol" file="US20200368173A1-20201126-C00223.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">II-8</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00224" num="00224">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a8/8d/16/3b5a8e86e5fe87/US20200368173A1-20201126-C00224.png"><img id="EMI-C00224" he="18.80mm" wi="100.25mm" file="US20200368173A1-20201126-C00224.TIF" alt="Figure US20200368173A1-20201126-C00224" img-content="table" img-format="tif" orientation="portrait" inline="no" width="401" height="75" alt="Figure US20200368173A1-20201126-C00224" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a8/8d/16/3b5a8e86e5fe87/US20200368173A1-20201126-C00224.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00224" attachment-type="cdx" file="US20200368173A1-20201126-C00224.CDX"> </attachment>
                      <attachment idref="CHEM-US-00224" attachment-type="mol" file="US20200368173A1-20201126-C00224.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">II-9</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00225" num="00225">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8d/72/2a/1759b75a07cab5/US20200368173A1-20201126-C00225.png"><img id="EMI-C00225" he="35.73mm" wi="133.94mm" file="US20200368173A1-20201126-C00225.TIF" alt="Figure US20200368173A1-20201126-C00225" img-content="table" img-format="tif" orientation="portrait" inline="no" width="536" height="143" alt="Figure US20200368173A1-20201126-C00225" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8d/72/2a/1759b75a07cab5/US20200368173A1-20201126-C00225.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00225" attachment-type="cdx" file="US20200368173A1-20201126-C00225.CDX"> </attachment>
                      <attachment idref="CHEM-US-00225" attachment-type="mol" file="US20200368173A1-20201126-C00225.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">II-10</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00226" num="00226">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/04/70/12/a6716050d0592b/US20200368173A1-20201126-C00226.png"><img id="EMI-C00226" he="35.64mm" wi="124.04mm" file="US20200368173A1-20201126-C00226.TIF" alt="Figure US20200368173A1-20201126-C00226" img-content="table" img-format="tif" orientation="portrait" inline="no" width="496" height="143" alt="Figure US20200368173A1-20201126-C00226" class="patent-full-image" src="https://patentimages.storage.googleapis.com/04/70/12/a6716050d0592b/US20200368173A1-20201126-C00226.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00226" attachment-type="cdx" file="US20200368173A1-20201126-C00226.CDX"> </attachment>
                      <attachment idref="CHEM-US-00226" attachment-type="mol" file="US20200368173A1-20201126-C00226.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">II-11</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00227" num="00227">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c3/b0/9c/d59ff70cde9212/US20200368173A1-20201126-C00227.png"><img id="EMI-C00227" he="35.64mm" wi="113.45mm" file="US20200368173A1-20201126-C00227.TIF" alt="Figure US20200368173A1-20201126-C00227" img-content="table" img-format="tif" orientation="portrait" inline="no" width="454" height="143" alt="Figure US20200368173A1-20201126-C00227" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c3/b0/9c/d59ff70cde9212/US20200368173A1-20201126-C00227.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00227" attachment-type="cdx" file="US20200368173A1-20201126-C00227.CDX"> </attachment>
                      <attachment idref="CHEM-US-00227" attachment-type="mol" file="US20200368173A1-20201126-C00227.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">II-12</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00228" num="00228">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2a/1c/02/d1a28e195f41a6/US20200368173A1-20201126-C00228.png"><img id="EMI-C00228" he="27.26mm" wi="101.35mm" file="US20200368173A1-20201126-C00228.TIF" alt="Figure US20200368173A1-20201126-C00228" img-content="table" img-format="tif" orientation="portrait" inline="no" width="405" height="109" alt="Figure US20200368173A1-20201126-C00228" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2a/1c/02/d1a28e195f41a6/US20200368173A1-20201126-C00228.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00228" attachment-type="cdx" file="US20200368173A1-20201126-C00228.CDX"> </attachment>
                      <attachment idref="CHEM-US-00228" attachment-type="mol" file="US20200368173A1-20201126-C00228.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
                <td class="description-td">II-13</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00229" num="00229">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/90/bf/72747277474506/US20200368173A1-20201126-C00229.png"><img id="EMI-C00229" he="28.53mm" wi="139.28mm" file="US20200368173A1-20201126-C00229.TIF" alt="Figure US20200368173A1-20201126-C00229" img-content="table" img-format="tif" orientation="portrait" inline="no" width="557" height="114" alt="Figure US20200368173A1-20201126-C00229" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/90/bf/72747277474506/US20200368173A1-20201126-C00229.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00229" attachment-type="cdx" file="US20200368173A1-20201126-C00229.CDX"> </attachment>
                      <attachment idref="CHEM-US-00229" attachment-type="mol" file="US20200368173A1-20201126-C00229.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1062" num="0000" class="description-line">
      <tables id="TABLE-US-00019" num="00019">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 19</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">II-14</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00230" num="00230">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7f/62/ec/f68df1a6741291/US20200368173A1-20201126-C00230.png"><img id="EMI-C00230" he="22.61mm" wi="106.93mm" file="US20200368173A1-20201126-C00230.TIF" alt="Figure US20200368173A1-20201126-C00230" img-content="table" img-format="tif" orientation="portrait" inline="no" width="428" height="90" alt="Figure US20200368173A1-20201126-C00230" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7f/62/ec/f68df1a6741291/US20200368173A1-20201126-C00230.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00230" attachment-type="cdx" file="US20200368173A1-20201126-C00230.CDX"> </attachment>
                      <attachment idref="CHEM-US-00230" attachment-type="mol" file="US20200368173A1-20201126-C00230.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-15</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00231" num="00231">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f8/fb/8d/4b102195186a8a/US20200368173A1-20201126-C00231.png"><img id="EMI-C00231" he="22.61mm" wi="106.34mm" file="US20200368173A1-20201126-C00231.TIF" alt="Figure US20200368173A1-20201126-C00231" img-content="table" img-format="tif" orientation="portrait" inline="no" width="425" height="90" alt="Figure US20200368173A1-20201126-C00231" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f8/fb/8d/4b102195186a8a/US20200368173A1-20201126-C00231.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00231" attachment-type="cdx" file="US20200368173A1-20201126-C00231.CDX"> </attachment>
                      <attachment idref="CHEM-US-00231" attachment-type="mol" file="US20200368173A1-20201126-C00231.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-16</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00232" num="00232">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8b/68/55/3954a346742043/US20200368173A1-20201126-C00232.png"><img id="EMI-C00232" he="38.27mm" wi="104.31mm" file="US20200368173A1-20201126-C00232.TIF" alt="Figure US20200368173A1-20201126-C00232" img-content="table" img-format="tif" orientation="portrait" inline="no" width="417" height="153" alt="Figure US20200368173A1-20201126-C00232" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8b/68/55/3954a346742043/US20200368173A1-20201126-C00232.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00232" attachment-type="cdx" file="US20200368173A1-20201126-C00232.CDX"> </attachment>
                      <attachment idref="CHEM-US-00232" attachment-type="mol" file="US20200368173A1-20201126-C00232.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-17</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00233" num="00233">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/70/f7/7c/02f051b7c29d2e/US20200368173A1-20201126-C00233.png"><img id="EMI-C00233" he="35.73mm" wi="114.05mm" file="US20200368173A1-20201126-C00233.TIF" alt="Figure US20200368173A1-20201126-C00233" img-content="table" img-format="tif" orientation="portrait" inline="no" width="456" height="143" alt="Figure US20200368173A1-20201126-C00233" class="patent-full-image" src="https://patentimages.storage.googleapis.com/70/f7/7c/02f051b7c29d2e/US20200368173A1-20201126-C00233.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00233" attachment-type="cdx" file="US20200368173A1-20201126-C00233.CDX"> </attachment>
                      <attachment idref="CHEM-US-00233" attachment-type="mol" file="US20200368173A1-20201126-C00233.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-18</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00234" num="00234">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/5c/30/e56c1663eb21df/US20200368173A1-20201126-C00234.png"><img id="EMI-C00234" he="35.73mm" wi="113.28mm" file="US20200368173A1-20201126-C00234.TIF" alt="Figure US20200368173A1-20201126-C00234" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="143" alt="Figure US20200368173A1-20201126-C00234" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/5c/30/e56c1663eb21df/US20200368173A1-20201126-C00234.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00234" attachment-type="cdx" file="US20200368173A1-20201126-C00234.CDX"> </attachment>
                      <attachment idref="CHEM-US-00234" attachment-type="mol" file="US20200368173A1-20201126-C00234.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-19</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00235" num="00235">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8b/ae/29/ea1bd8eebdd3b8/US20200368173A1-20201126-C00235.png"><img id="EMI-C00235" he="18.71mm" wi="114.05mm" file="US20200368173A1-20201126-C00235.TIF" alt="Figure US20200368173A1-20201126-C00235" img-content="table" img-format="tif" orientation="portrait" inline="no" width="456" height="75" alt="Figure US20200368173A1-20201126-C00235" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8b/ae/29/ea1bd8eebdd3b8/US20200368173A1-20201126-C00235.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00235" attachment-type="cdx" file="US20200368173A1-20201126-C00235.CDX"> </attachment>
                      <attachment idref="CHEM-US-00235" attachment-type="mol" file="US20200368173A1-20201126-C00235.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-20</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00236" num="00236">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6b/40/6c/8c67481ff10fd6/US20200368173A1-20201126-C00236.png"><img id="EMI-C00236" he="27.18mm" wi="114.30mm" file="US20200368173A1-20201126-C00236.TIF" alt="Figure US20200368173A1-20201126-C00236" img-content="table" img-format="tif" orientation="portrait" inline="no" width="457" height="109" alt="Figure US20200368173A1-20201126-C00236" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6b/40/6c/8c67481ff10fd6/US20200368173A1-20201126-C00236.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00236" attachment-type="cdx" file="US20200368173A1-20201126-C00236.CDX"> </attachment>
                      <attachment idref="CHEM-US-00236" attachment-type="mol" file="US20200368173A1-20201126-C00236.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1063" num="0000" class="description-line">
      <tables id="TABLE-US-00020" num="00020">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 20</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">II-21</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00237" num="00237">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2f/02/ba/c99799c22d183b/US20200368173A1-20201126-C00237.png"><img id="EMI-C00237" he="35.73mm" wi="133.60mm" file="US20200368173A1-20201126-C00237.TIF" alt="Figure US20200368173A1-20201126-C00237" img-content="table" img-format="tif" orientation="portrait" inline="no" width="534" height="143" alt="Figure US20200368173A1-20201126-C00237" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2f/02/ba/c99799c22d183b/US20200368173A1-20201126-C00237.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00237" attachment-type="cdx" file="US20200368173A1-20201126-C00237.CDX"> </attachment>
                      <attachment idref="CHEM-US-00237" attachment-type="mol" file="US20200368173A1-20201126-C00237.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-22</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00238" num="00238">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/65/e1/0a/11b1d2576b2710/US20200368173A1-20201126-C00238.png"><img id="EMI-C00238" he="35.64mm" wi="133.60mm" file="US20200368173A1-20201126-C00238.TIF" alt="Figure US20200368173A1-20201126-C00238" img-content="table" img-format="tif" orientation="portrait" inline="no" width="534" height="143" alt="Figure US20200368173A1-20201126-C00238" class="patent-full-image" src="https://patentimages.storage.googleapis.com/65/e1/0a/11b1d2576b2710/US20200368173A1-20201126-C00238.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00238" attachment-type="cdx" file="US20200368173A1-20201126-C00238.CDX"> </attachment>
                      <attachment idref="CHEM-US-00238" attachment-type="mol" file="US20200368173A1-20201126-C00238.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-23</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00239" num="00239">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1a/e6/d0/4f9ff698775667/US20200368173A1-20201126-C00239.png"><img id="EMI-C00239" he="35.64mm" wi="123.87mm" file="US20200368173A1-20201126-C00239.TIF" alt="Figure US20200368173A1-20201126-C00239" img-content="table" img-format="tif" orientation="portrait" inline="no" width="495" height="143" alt="Figure US20200368173A1-20201126-C00239" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1a/e6/d0/4f9ff698775667/US20200368173A1-20201126-C00239.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00239" attachment-type="cdx" file="US20200368173A1-20201126-C00239.CDX"> </attachment>
                      <attachment idref="CHEM-US-00239" attachment-type="mol" file="US20200368173A1-20201126-C00239.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1064" num="0000" class="description-line">
      <tables id="TABLE-US-00021" num="00021">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 21</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">III-1</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00240" num="00240">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fc/c9/ca/1d71f1cc088e7c/US20200368173A1-20201126-C00240.png"><img id="EMI-C00240" he="17.95mm" wi="123.87mm" file="US20200368173A1-20201126-C00240.TIF" alt="Figure US20200368173A1-20201126-C00240" img-content="table" img-format="tif" orientation="portrait" inline="no" width="495" height="72" alt="Figure US20200368173A1-20201126-C00240" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fc/c9/ca/1d71f1cc088e7c/US20200368173A1-20201126-C00240.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00240" attachment-type="cdx" file="US20200368173A1-20201126-C00240.CDX"> </attachment>
                      <attachment idref="CHEM-US-00240" attachment-type="mol" file="US20200368173A1-20201126-C00240.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1065" num="0000" class="description-line">
      <tables id="TABLE-US-00022" num="00022">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 22</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">IV-1</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00241" num="00241">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/28/d4/b911e75e36767d/US20200368173A1-20201126-C00241.png"><img id="EMI-C00241" he="17.53mm" wi="100.50mm" file="US20200368173A1-20201126-C00241.TIF" alt="Figure US20200368173A1-20201126-C00241" img-content="table" img-format="tif" orientation="portrait" inline="no" width="402" height="70" alt="Figure US20200368173A1-20201126-C00241" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/28/d4/b911e75e36767d/US20200368173A1-20201126-C00241.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00241" attachment-type="cdx" file="US20200368173A1-20201126-C00241.CDX"> </attachment>
                      <attachment idref="CHEM-US-00241" attachment-type="mol" file="US20200368173A1-20201126-C00241.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1066" num="0000" class="description-line">
      <tables id="TABLE-US-00023" num="00023">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 23</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">II-24</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00242" num="00242">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/06/52/88/b1ed77661f9460/US20200368173A1-20201126-C00242.png"><img id="EMI-C00242" he="35.73mm" wi="102.79mm" file="US20200368173A1-20201126-C00242.TIF" alt="Figure US20200368173A1-20201126-C00242" img-content="table" img-format="tif" orientation="portrait" inline="no" width="411" height="143" alt="Figure US20200368173A1-20201126-C00242" class="patent-full-image" src="https://patentimages.storage.googleapis.com/06/52/88/b1ed77661f9460/US20200368173A1-20201126-C00242.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00242" attachment-type="cdx" file="US20200368173A1-20201126-C00242.CDX"> </attachment>
                      <attachment idref="CHEM-US-00242" attachment-type="mol" file="US20200368173A1-20201126-C00242.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-25</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00243" num="00243">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/e7/6e/9165348cb749a1/US20200368173A1-20201126-C00243.png"><img id="EMI-C00243" he="35.64mm" wi="93.05mm" file="US20200368173A1-20201126-C00243.TIF" alt="Figure US20200368173A1-20201126-C00243" img-content="table" img-format="tif" orientation="portrait" inline="no" width="372" height="143" alt="Figure US20200368173A1-20201126-C00243" class="patent-full-image" src="https://patentimages.storage.googleapis.com/97/e7/6e/9165348cb749a1/US20200368173A1-20201126-C00243.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00243" attachment-type="cdx" file="US20200368173A1-20201126-C00243.CDX"> </attachment>
                      <attachment idref="CHEM-US-00243" attachment-type="mol" file="US20200368173A1-20201126-C00243.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-26</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00244" num="00244">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/52/08/55/bbeb95b6c340f3/US20200368173A1-20201126-C00244.png"><img id="EMI-C00244" he="35.64mm" wi="83.23mm" file="US20200368173A1-20201126-C00244.TIF" alt="Figure US20200368173A1-20201126-C00244" img-content="table" img-format="tif" orientation="portrait" inline="no" width="333" height="143" alt="Figure US20200368173A1-20201126-C00244" class="patent-full-image" src="https://patentimages.storage.googleapis.com/52/08/55/bbeb95b6c340f3/US20200368173A1-20201126-C00244.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00244" attachment-type="cdx" file="US20200368173A1-20201126-C00244.CDX"> </attachment>
                      <attachment idref="CHEM-US-00244" attachment-type="mol" file="US20200368173A1-20201126-C00244.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-27</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00245" num="00245">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/da/8c/eb/5786c92cfaa856/US20200368173A1-20201126-C00245.png"><img id="EMI-C00245" he="35.64mm" wi="113.28mm" file="US20200368173A1-20201126-C00245.TIF" alt="Figure US20200368173A1-20201126-C00245" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="143" alt="Figure US20200368173A1-20201126-C00245" class="patent-full-image" src="https://patentimages.storage.googleapis.com/da/8c/eb/5786c92cfaa856/US20200368173A1-20201126-C00245.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00245" attachment-type="cdx" file="US20200368173A1-20201126-C00245.CDX"> </attachment>
                      <attachment idref="CHEM-US-00245" attachment-type="mol" file="US20200368173A1-20201126-C00245.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-28</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00246" num="00246">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/75/1d/6247657c118081/US20200368173A1-20201126-C00246.png"><img id="EMI-C00246" he="38.27mm" wi="113.28mm" file="US20200368173A1-20201126-C00246.TIF" alt="Figure US20200368173A1-20201126-C00246" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="153" alt="Figure US20200368173A1-20201126-C00246" class="patent-full-image" src="https://patentimages.storage.googleapis.com/23/75/1d/6247657c118081/US20200368173A1-20201126-C00246.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00246" attachment-type="cdx" file="US20200368173A1-20201126-C00246.CDX"> </attachment>
                      <attachment idref="CHEM-US-00246" attachment-type="mol" file="US20200368173A1-20201126-C00246.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-29</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00247" num="00247">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/af/a8/f4/bbef7005dbb984/US20200368173A1-20201126-C00247.png"><img id="EMI-C00247" he="35.64mm" wi="112.61mm" file="US20200368173A1-20201126-C00247.TIF" alt="Figure US20200368173A1-20201126-C00247" img-content="table" img-format="tif" orientation="portrait" inline="no" width="450" height="143" alt="Figure US20200368173A1-20201126-C00247" class="patent-full-image" src="https://patentimages.storage.googleapis.com/af/a8/f4/bbef7005dbb984/US20200368173A1-20201126-C00247.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00247" attachment-type="cdx" file="US20200368173A1-20201126-C00247.CDX"> </attachment>
                      <attachment idref="CHEM-US-00247" attachment-type="mol" file="US20200368173A1-20201126-C00247.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-30</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00248" num="00248">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/73/25/54/d8c71789448123/US20200368173A1-20201126-C00248.png"><img id="EMI-C00248" he="35.64mm" wi="113.28mm" file="US20200368173A1-20201126-C00248.TIF" alt="Figure US20200368173A1-20201126-C00248" img-content="table" img-format="tif" orientation="portrait" inline="no" width="453" height="143" alt="Figure US20200368173A1-20201126-C00248" class="patent-full-image" src="https://patentimages.storage.googleapis.com/73/25/54/d8c71789448123/US20200368173A1-20201126-C00248.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00248" attachment-type="cdx" file="US20200368173A1-20201126-C00248.CDX"> </attachment>
                      <attachment idref="CHEM-US-00248" attachment-type="mol" file="US20200368173A1-20201126-C00248.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1067" num="0000" class="description-line">
      <tables id="TABLE-US-00024" num="00024">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 24</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">II-31</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00249" num="00249">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d4/88/dd/1ae51e6c486b7e/US20200368173A1-20201126-C00249.png"><img id="EMI-C00249" he="35.64mm" wi="118.19mm" file="US20200368173A1-20201126-C00249.TIF" alt="Figure US20200368173A1-20201126-C00249" img-content="table" img-format="tif" orientation="portrait" inline="no" width="473" height="143" alt="Figure US20200368173A1-20201126-C00249" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d4/88/dd/1ae51e6c486b7e/US20200368173A1-20201126-C00249.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00249" attachment-type="cdx" file="US20200368173A1-20201126-C00249.CDX"> </attachment>
                      <attachment idref="CHEM-US-00249" attachment-type="mol" file="US20200368173A1-20201126-C00249.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-32</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00250" num="00250">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/19/7b/45/16f89a30774c70/US20200368173A1-20201126-C00250.png"><img id="EMI-C00250" he="35.64mm" wi="123.11mm" file="US20200368173A1-20201126-C00250.TIF" alt="Figure US20200368173A1-20201126-C00250" img-content="table" img-format="tif" orientation="portrait" inline="no" width="492" height="143" alt="Figure US20200368173A1-20201126-C00250" class="patent-full-image" src="https://patentimages.storage.googleapis.com/19/7b/45/16f89a30774c70/US20200368173A1-20201126-C00250.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00250" attachment-type="cdx" file="US20200368173A1-20201126-C00250.CDX"> </attachment>
                      <attachment idref="CHEM-US-00250" attachment-type="mol" file="US20200368173A1-20201126-C00250.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-33</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00251" num="00251">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7f/db/16/f5a750ca66d9ce/US20200368173A1-20201126-C00251.png"><img id="EMI-C00251" he="35.64mm" wi="89.75mm" file="US20200368173A1-20201126-C00251.TIF" alt="Figure US20200368173A1-20201126-C00251" img-content="table" img-format="tif" orientation="portrait" inline="no" width="359" height="143" alt="Figure US20200368173A1-20201126-C00251" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7f/db/16/f5a750ca66d9ce/US20200368173A1-20201126-C00251.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00251" attachment-type="cdx" file="US20200368173A1-20201126-C00251.CDX"> </attachment>
                      <attachment idref="CHEM-US-00251" attachment-type="mol" file="US20200368173A1-20201126-C00251.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-34</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00252" num="00252">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/61/56/6b/6a2857080fe32f/US20200368173A1-20201126-C00252.png"><img id="EMI-C00252" he="35.64mm" wi="109.14mm" file="US20200368173A1-20201126-C00252.TIF" alt="Figure US20200368173A1-20201126-C00252" img-content="table" img-format="tif" orientation="portrait" inline="no" width="437" height="143" alt="Figure US20200368173A1-20201126-C00252" class="patent-full-image" src="https://patentimages.storage.googleapis.com/61/56/6b/6a2857080fe32f/US20200368173A1-20201126-C00252.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00252" attachment-type="cdx" file="US20200368173A1-20201126-C00252.CDX"> </attachment>
                      <attachment idref="CHEM-US-00252" attachment-type="mol" file="US20200368173A1-20201126-C00252.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-35</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00253" num="00253">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/01/eb/63/9328528edda150/US20200368173A1-20201126-C00253.png"><img id="EMI-C00253" he="35.64mm" wi="99.40mm" file="US20200368173A1-20201126-C00253.TIF" alt="Figure US20200368173A1-20201126-C00253" img-content="table" img-format="tif" orientation="portrait" inline="no" width="398" height="143" alt="Figure US20200368173A1-20201126-C00253" class="patent-full-image" src="https://patentimages.storage.googleapis.com/01/eb/63/9328528edda150/US20200368173A1-20201126-C00253.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00253" attachment-type="cdx" file="US20200368173A1-20201126-C00253.CDX"> </attachment>
                      <attachment idref="CHEM-US-00253" attachment-type="mol" file="US20200368173A1-20201126-C00253.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-36</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00254" num="00254">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/2e/ef/36/2060427630be63/US20200368173A1-20201126-C00254.png"><img id="EMI-C00254" he="37.59mm" wi="93.05mm" file="US20200368173A1-20201126-C00254.TIF" alt="Figure US20200368173A1-20201126-C00254" img-content="table" img-format="tif" orientation="portrait" inline="no" width="372" height="150" alt="Figure US20200368173A1-20201126-C00254" class="patent-full-image" src="https://patentimages.storage.googleapis.com/2e/ef/36/2060427630be63/US20200368173A1-20201126-C00254.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00254" attachment-type="cdx" file="US20200368173A1-20201126-C00254.CDX"> </attachment>
                      <attachment idref="CHEM-US-00254" attachment-type="mol" file="US20200368173A1-20201126-C00254.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-37</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00255" num="00255">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b7/a2/9d/00251288d12a85/US20200368173A1-20201126-C00255.png"><img id="EMI-C00255" he="37.59mm" wi="112.61mm" file="US20200368173A1-20201126-C00255.TIF" alt="Figure US20200368173A1-20201126-C00255" img-content="table" img-format="tif" orientation="portrait" inline="no" width="450" height="150" alt="Figure US20200368173A1-20201126-C00255" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b7/a2/9d/00251288d12a85/US20200368173A1-20201126-C00255.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00255" attachment-type="cdx" file="US20200368173A1-20201126-C00255.CDX"> </attachment>
                      <attachment idref="CHEM-US-00255" attachment-type="mol" file="US20200368173A1-20201126-C00255.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1068" num="0000" class="description-line">
      <tables id="TABLE-US-00025" num="00025">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 25</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">II-38</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00256" num="00256">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cc/36/c5/87c9eb868825d4/US20200368173A1-20201126-C00256.png"><img id="EMI-C00256" he="35.73mm" wi="102.79mm" file="US20200368173A1-20201126-C00256.TIF" alt="Figure US20200368173A1-20201126-C00256" img-content="table" img-format="tif" orientation="portrait" inline="no" width="411" height="143" alt="Figure US20200368173A1-20201126-C00256" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cc/36/c5/87c9eb868825d4/US20200368173A1-20201126-C00256.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00256" attachment-type="cdx" file="US20200368173A1-20201126-C00256.CDX"> </attachment>
                      <attachment idref="CHEM-US-00256" attachment-type="mol" file="US20200368173A1-20201126-C00256.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-39</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00257" num="00257">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d0/d9/ad/88deee7081a064/US20200368173A1-20201126-C00257.png"><img id="EMI-C00257" he="35.64mm" wi="93.81mm" file="US20200368173A1-20201126-C00257.TIF" alt="Figure US20200368173A1-20201126-C00257" img-content="table" img-format="tif" orientation="portrait" inline="no" width="375" height="143" alt="Figure US20200368173A1-20201126-C00257" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d0/d9/ad/88deee7081a064/US20200368173A1-20201126-C00257.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00257" attachment-type="cdx" file="US20200368173A1-20201126-C00257.CDX"> </attachment>
                      <attachment idref="CHEM-US-00257" attachment-type="mol" file="US20200368173A1-20201126-C00257.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-40</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00258" num="00258">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b8/17/32/57a8f63c263852/US20200368173A1-20201126-C00258.png"><img id="EMI-C00258" he="35.64mm" wi="127.25mm" file="US20200368173A1-20201126-C00258.TIF" alt="Figure US20200368173A1-20201126-C00258" img-content="table" img-format="tif" orientation="portrait" inline="no" width="509" height="143" alt="Figure US20200368173A1-20201126-C00258" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b8/17/32/57a8f63c263852/US20200368173A1-20201126-C00258.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00258" attachment-type="cdx" file="US20200368173A1-20201126-C00258.CDX"> </attachment>
                      <attachment idref="CHEM-US-00258" attachment-type="mol" file="US20200368173A1-20201126-C00258.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-41</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00259" num="00259">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a2/0d/29/55443275300535/US20200368173A1-20201126-C00259.png"><img id="EMI-C00259" he="35.64mm" wi="127.25mm" file="US20200368173A1-20201126-C00259.TIF" alt="Figure US20200368173A1-20201126-C00259" img-content="table" img-format="tif" orientation="portrait" inline="no" width="509" height="143" alt="Figure US20200368173A1-20201126-C00259" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a2/0d/29/55443275300535/US20200368173A1-20201126-C00259.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00259" attachment-type="cdx" file="US20200368173A1-20201126-C00259.CDX"> </attachment>
                      <attachment idref="CHEM-US-00259" attachment-type="mol" file="US20200368173A1-20201126-C00259.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-42</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00260" num="00260">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/81/05/4b/244a49a07694bc/US20200368173A1-20201126-C00260.png"><img id="EMI-C00260" he="39.37mm" wi="97.87mm" file="US20200368173A1-20201126-C00260.TIF" alt="Figure US20200368173A1-20201126-C00260" img-content="table" img-format="tif" orientation="portrait" inline="no" width="391" height="157" alt="Figure US20200368173A1-20201126-C00260" class="patent-full-image" src="https://patentimages.storage.googleapis.com/81/05/4b/244a49a07694bc/US20200368173A1-20201126-C00260.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00260" attachment-type="cdx" file="US20200368173A1-20201126-C00260.CDX"> </attachment>
                      <attachment idref="CHEM-US-00260" attachment-type="mol" file="US20200368173A1-20201126-C00260.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-43</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00261" num="00261">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4a/bb/63/f758e5b43f6f6b/US20200368173A1-20201126-C00261.png"><img id="EMI-C00261" he="43.35mm" wi="97.87mm" file="US20200368173A1-20201126-C00261.TIF" alt="Figure US20200368173A1-20201126-C00261" img-content="table" img-format="tif" orientation="portrait" inline="no" width="391" height="173" alt="Figure US20200368173A1-20201126-C00261" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4a/bb/63/f758e5b43f6f6b/US20200368173A1-20201126-C00261.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00261" attachment-type="cdx" file="US20200368173A1-20201126-C00261.CDX"> </attachment>
                      <attachment idref="CHEM-US-00261" attachment-type="mol" file="US20200368173A1-20201126-C00261.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-44</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00262" num="00262">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cf/c1/75/e6c6e32b062261/US20200368173A1-20201126-C00262.png"><img id="EMI-C00262" he="28.96mm" wi="88.90mm" file="US20200368173A1-20201126-C00262.TIF" alt="Figure US20200368173A1-20201126-C00262" img-content="table" img-format="tif" orientation="portrait" inline="no" width="356" height="116" alt="Figure US20200368173A1-20201126-C00262" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cf/c1/75/e6c6e32b062261/US20200368173A1-20201126-C00262.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00262" attachment-type="cdx" file="US20200368173A1-20201126-C00262.CDX"> </attachment>
                      <attachment idref="CHEM-US-00262" attachment-type="mol" file="US20200368173A1-20201126-C00262.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1069" num="0000" class="description-line">
      <tables id="TABLE-US-00026" num="00026">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 26</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">II-45</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00263" num="00263">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/87/7d/01/60a33c5559a88f/US20200368173A1-20201126-C00263.png"><img id="EMI-C00263" he="29.04mm" wi="96.60mm" file="US20200368173A1-20201126-C00263.TIF" alt="Figure US20200368173A1-20201126-C00263" img-content="table" img-format="tif" orientation="portrait" inline="no" width="386" height="116" alt="Figure US20200368173A1-20201126-C00263" class="patent-full-image" src="https://patentimages.storage.googleapis.com/87/7d/01/60a33c5559a88f/US20200368173A1-20201126-C00263.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00263" attachment-type="cdx" file="US20200368173A1-20201126-C00263.CDX"> </attachment>
                      <attachment idref="CHEM-US-00263" attachment-type="mol" file="US20200368173A1-20201126-C00263.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-46</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00264" num="00264">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ab/66/7e/f1fddc7f48e5ca/US20200368173A1-20201126-C00264.png"><img id="EMI-C00264" he="28.96mm" wi="106.34mm" file="US20200368173A1-20201126-C00264.TIF" alt="Figure US20200368173A1-20201126-C00264" img-content="table" img-format="tif" orientation="portrait" inline="no" width="425" height="116" alt="Figure US20200368173A1-20201126-C00264" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ab/66/7e/f1fddc7f48e5ca/US20200368173A1-20201126-C00264.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00264" attachment-type="cdx" file="US20200368173A1-20201126-C00264.CDX"> </attachment>
                      <attachment idref="CHEM-US-00264" attachment-type="mol" file="US20200368173A1-20201126-C00264.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-47</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00265" num="00265">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b7/e9/2a/df0c2dd4f4e0e2/US20200368173A1-20201126-C00265.png"><img id="EMI-C00265" he="35.64mm" wi="112.61mm" file="US20200368173A1-20201126-C00265.TIF" alt="Figure US20200368173A1-20201126-C00265" img-content="table" img-format="tif" orientation="portrait" inline="no" width="450" height="143" alt="Figure US20200368173A1-20201126-C00265" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b7/e9/2a/df0c2dd4f4e0e2/US20200368173A1-20201126-C00265.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00265" attachment-type="cdx" file="US20200368173A1-20201126-C00265.CDX"> </attachment>
                      <attachment idref="CHEM-US-00265" attachment-type="mol" file="US20200368173A1-20201126-C00265.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-48</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00266" num="00266">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f0/22/3e/956ccf436c50eb/US20200368173A1-20201126-C00266.png"><img id="EMI-C00266" he="35.73mm" wi="102.79mm" file="US20200368173A1-20201126-C00266.TIF" alt="Figure US20200368173A1-20201126-C00266" img-content="table" img-format="tif" orientation="portrait" inline="no" width="411" height="143" alt="Figure US20200368173A1-20201126-C00266" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f0/22/3e/956ccf436c50eb/US20200368173A1-20201126-C00266.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00266" attachment-type="cdx" file="US20200368173A1-20201126-C00266.CDX"> </attachment>
                      <attachment idref="CHEM-US-00266" attachment-type="mol" file="US20200368173A1-20201126-C00266.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-49</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00267" num="00267">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3e/c7/7e/d455d15de71871/US20200368173A1-20201126-C00267.png"><img id="EMI-C00267" he="35.64mm" wi="102.79mm" file="US20200368173A1-20201126-C00267.TIF" alt="Figure US20200368173A1-20201126-C00267" img-content="table" img-format="tif" orientation="portrait" inline="no" width="411" height="143" alt="Figure US20200368173A1-20201126-C00267" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3e/c7/7e/d455d15de71871/US20200368173A1-20201126-C00267.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00267" attachment-type="cdx" file="US20200368173A1-20201126-C00267.CDX"> </attachment>
                      <attachment idref="CHEM-US-00267" attachment-type="mol" file="US20200368173A1-20201126-C00267.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-50</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00268" num="00268">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/6a/45/5f/5cdcb261ac326d/US20200368173A1-20201126-C00268.png"><img id="EMI-C00268" he="35.64mm" wi="102.79mm" file="US20200368173A1-20201126-C00268.TIF" alt="Figure US20200368173A1-20201126-C00268" img-content="table" img-format="tif" orientation="portrait" inline="no" width="411" height="143" alt="Figure US20200368173A1-20201126-C00268" class="patent-full-image" src="https://patentimages.storage.googleapis.com/6a/45/5f/5cdcb261ac326d/US20200368173A1-20201126-C00268.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00268" attachment-type="cdx" file="US20200368173A1-20201126-C00268.CDX"> </attachment>
                      <attachment idref="CHEM-US-00268" attachment-type="mol" file="US20200368173A1-20201126-C00268.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-51</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00269" num="00269">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4d/da/8e/65eb70681c0e92/US20200368173A1-20201126-C00269.png"><img id="EMI-C00269" he="35.64mm" wi="112.61mm" file="US20200368173A1-20201126-C00269.TIF" alt="Figure US20200368173A1-20201126-C00269" img-content="table" img-format="tif" orientation="portrait" inline="no" width="450" height="143" alt="Figure US20200368173A1-20201126-C00269" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4d/da/8e/65eb70681c0e92/US20200368173A1-20201126-C00269.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00269" attachment-type="cdx" file="US20200368173A1-20201126-C00269.CDX"> </attachment>
                      <attachment idref="CHEM-US-00269" attachment-type="mol" file="US20200368173A1-20201126-C00269.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1070" num="0000" class="description-line">
      <tables id="TABLE-US-00027" num="00027">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 27</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">II-52</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00270" num="00270">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5f/ca/7a/6395deb7600076/US20200368173A1-20201126-C00270.png"><img id="EMI-C00270" he="35.64mm" wi="112.61mm" file="US20200368173A1-20201126-C00270.TIF" alt="Figure US20200368173A1-20201126-C00270" img-content="table" img-format="tif" orientation="portrait" inline="no" width="450" height="143" alt="Figure US20200368173A1-20201126-C00270" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5f/ca/7a/6395deb7600076/US20200368173A1-20201126-C00270.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00270" attachment-type="cdx" file="US20200368173A1-20201126-C00270.CDX"> </attachment>
                      <attachment idref="CHEM-US-00270" attachment-type="mol" file="US20200368173A1-20201126-C00270.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">II-53</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00271" num="00271">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ad/48/0b/1a790d2a9f5a7c/US20200368173A1-20201126-C00271.png"><img id="EMI-C00271" he="35.64mm" wi="112.61mm" file="US20200368173A1-20201126-C00271.TIF" alt="Figure US20200368173A1-20201126-C00271" img-content="table" img-format="tif" orientation="portrait" inline="no" width="450" height="143" alt="Figure US20200368173A1-20201126-C00271" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ad/48/0b/1a790d2a9f5a7c/US20200368173A1-20201126-C00271.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00271" attachment-type="cdx" file="US20200368173A1-20201126-C00271.CDX"> </attachment>
                      <attachment idref="CHEM-US-00271" attachment-type="mol" file="US20200368173A1-20201126-C00271.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1071" num="0000" class="description-line">
      <tables id="TABLE-US-00028" num="00028">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 28</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">III-2</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00272" num="00272">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1e/94/07/043a086698405c/US20200368173A1-20201126-C00272.png"><img id="EMI-C00272" he="29.29mm" wi="123.87mm" file="US20200368173A1-20201126-C00272.TIF" alt="Figure US20200368173A1-20201126-C00272" img-content="table" img-format="tif" orientation="portrait" inline="no" width="495" height="117" alt="Figure US20200368173A1-20201126-C00272" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1e/94/07/043a086698405c/US20200368173A1-20201126-C00272.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00272" attachment-type="cdx" file="US20200368173A1-20201126-C00272.CDX"> </attachment>
                      <attachment idref="CHEM-US-00272" attachment-type="mol" file="US20200368173A1-20201126-C00272.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">III-3</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00273" num="00273">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/09/a0/8b/aac55ff9f25a2e/US20200368173A1-20201126-C00273.png"><img id="EMI-C00273" he="27.18mm" wi="93.56mm" file="US20200368173A1-20201126-C00273.TIF" alt="Figure US20200368173A1-20201126-C00273" img-content="table" img-format="tif" orientation="portrait" inline="no" width="374" height="109" alt="Figure US20200368173A1-20201126-C00273" class="patent-full-image" src="https://patentimages.storage.googleapis.com/09/a0/8b/aac55ff9f25a2e/US20200368173A1-20201126-C00273.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00273" attachment-type="cdx" file="US20200368173A1-20201126-C00273.CDX"> </attachment>
                      <attachment idref="CHEM-US-00273" attachment-type="mol" file="US20200368173A1-20201126-C00273.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">III-4</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00274" num="00274">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/83/71/48/26858158f0bee3/US20200368173A1-20201126-C00274.png"><img id="EMI-C00274" he="27.18mm" wi="93.56mm" file="US20200368173A1-20201126-C00274.TIF" alt="Figure US20200368173A1-20201126-C00274" img-content="table" img-format="tif" orientation="portrait" inline="no" width="374" height="109" alt="Figure US20200368173A1-20201126-C00274" class="patent-full-image" src="https://patentimages.storage.googleapis.com/83/71/48/26858158f0bee3/US20200368173A1-20201126-C00274.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00274" attachment-type="cdx" file="US20200368173A1-20201126-C00274.CDX"> </attachment>
                      <attachment idref="CHEM-US-00274" attachment-type="mol" file="US20200368173A1-20201126-C00274.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">III-5</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00275" num="00275">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/37/86/82/911b5805a20874/US20200368173A1-20201126-C00275.png"><img id="EMI-C00275" he="27.26mm" wi="98.38mm" file="US20200368173A1-20201126-C00275.TIF" alt="Figure US20200368173A1-20201126-C00275" img-content="table" img-format="tif" orientation="portrait" inline="no" width="394" height="109" alt="Figure US20200368173A1-20201126-C00275" class="patent-full-image" src="https://patentimages.storage.googleapis.com/37/86/82/911b5805a20874/US20200368173A1-20201126-C00275.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00275" attachment-type="cdx" file="US20200368173A1-20201126-C00275.CDX"> </attachment>
                      <attachment idref="CHEM-US-00275" attachment-type="mol" file="US20200368173A1-20201126-C00275.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">III-6</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00276" num="00276">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/61/64/6cb0a9b2a9b8da/US20200368173A1-20201126-C00276.png"><img id="EMI-C00276" he="27.18mm" wi="108.20mm" file="US20200368173A1-20201126-C00276.TIF" alt="Figure US20200368173A1-20201126-C00276" img-content="table" img-format="tif" orientation="portrait" inline="no" width="433" height="109" alt="Figure US20200368173A1-20201126-C00276" class="patent-full-image" src="https://patentimages.storage.googleapis.com/97/61/64/6cb0a9b2a9b8da/US20200368173A1-20201126-C00276.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00276" attachment-type="cdx" file="US20200368173A1-20201126-C00276.CDX"> </attachment>
                      <attachment idref="CHEM-US-00276" attachment-type="mol" file="US20200368173A1-20201126-C00276.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">III-7</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00277" num="00277">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ff/74/d3/be3c5b3cb6a0b3/US20200368173A1-20201126-C00277.png"><img id="EMI-C00277" he="27.26mm" wi="108.97mm" file="US20200368173A1-20201126-C00277.TIF" alt="Figure US20200368173A1-20201126-C00277" img-content="table" img-format="tif" orientation="portrait" inline="no" width="436" height="109" alt="Figure US20200368173A1-20201126-C00277" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ff/74/d3/be3c5b3cb6a0b3/US20200368173A1-20201126-C00277.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00277" attachment-type="cdx" file="US20200368173A1-20201126-C00277.CDX"> </attachment>
                      <attachment idref="CHEM-US-00277" attachment-type="mol" file="US20200368173A1-20201126-C00277.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1072" num="0000" class="description-line">
      <tables id="TABLE-US-00029" num="00029">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 29</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">IV-2</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00278" num="00278">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1c/c5/cc/8b83815e495bfd/US20200368173A1-20201126-C00278.png"><img id="EMI-C00278" he="34.88mm" wi="105.75mm" file="US20200368173A1-20201126-C00278.TIF" alt="Figure US20200368173A1-20201126-C00278" img-content="table" img-format="tif" orientation="portrait" inline="no" width="423" height="140" alt="Figure US20200368173A1-20201126-C00278" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1c/c5/cc/8b83815e495bfd/US20200368173A1-20201126-C00278.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00278" attachment-type="cdx" file="US20200368173A1-20201126-C00278.CDX"> </attachment>
                      <attachment idref="CHEM-US-00278" attachment-type="mol" file="US20200368173A1-20201126-C00278.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">IV-3</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00279" num="00279">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f9/4d/75/695f2ad90b90c2/US20200368173A1-20201126-C00279.png"><img id="EMI-C00279" he="21.93mm" wi="110.83mm" file="US20200368173A1-20201126-C00279.TIF" alt="Figure US20200368173A1-20201126-C00279" img-content="table" img-format="tif" orientation="portrait" inline="no" width="443" height="88" alt="Figure US20200368173A1-20201126-C00279" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f9/4d/75/695f2ad90b90c2/US20200368173A1-20201126-C00279.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00279" attachment-type="cdx" file="US20200368173A1-20201126-C00279.CDX"> </attachment>
                      <attachment idref="CHEM-US-00279" attachment-type="mol" file="US20200368173A1-20201126-C00279.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1073" num="0000" class="description-line">
      <tables id="TABLE-US-00030" num="00030">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 30</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound</td>
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">V-1</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00280" num="00280">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/65/6a/0f/71fc89de01d074/US20200368173A1-20201126-C00280.png"><img id="EMI-C00280" he="29.04mm" wi="114.64mm" file="US20200368173A1-20201126-C00280.TIF" alt="Figure US20200368173A1-20201126-C00280" img-content="table" img-format="tif" orientation="portrait" inline="no" width="459" height="116" alt="Figure US20200368173A1-20201126-C00280" class="patent-full-image" src="https://patentimages.storage.googleapis.com/65/6a/0f/71fc89de01d074/US20200368173A1-20201126-C00280.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00280" attachment-type="cdx" file="US20200368173A1-20201126-C00280.CDX"> </attachment>
                      <attachment idref="CHEM-US-00280" attachment-type="mol" file="US20200368173A1-20201126-C00280.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">V-2</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00281" num="00281">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/8e/62/e6/0eea0c7ac28a2d/US20200368173A1-20201126-C00281.png"><img id="EMI-C00281" he="38.35mm" wi="83.82mm" file="US20200368173A1-20201126-C00281.TIF" alt="Figure US20200368173A1-20201126-C00281" img-content="table" img-format="tif" orientation="portrait" inline="no" width="335" height="153" alt="Figure US20200368173A1-20201126-C00281" class="patent-full-image" src="https://patentimages.storage.googleapis.com/8e/62/e6/0eea0c7ac28a2d/US20200368173A1-20201126-C00281.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00281" attachment-type="cdx" file="US20200368173A1-20201126-C00281.CDX"> </attachment>
                      <attachment idref="CHEM-US-00281" attachment-type="mol" file="US20200368173A1-20201126-C00281.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">V-3</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00282" num="00282">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c3/67/ff/2c77d627d63771/US20200368173A1-20201126-C00282.png"><img id="EMI-C00282" he="38.35mm" wi="93.56mm" file="US20200368173A1-20201126-C00282.TIF" alt="Figure US20200368173A1-20201126-C00282" img-content="table" img-format="tif" orientation="portrait" inline="no" width="374" height="153" alt="Figure US20200368173A1-20201126-C00282" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c3/67/ff/2c77d627d63771/US20200368173A1-20201126-C00282.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00282" attachment-type="cdx" file="US20200368173A1-20201126-C00282.CDX"> </attachment>
                      <attachment idref="CHEM-US-00282" attachment-type="mol" file="US20200368173A1-20201126-C00282.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">V-4</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00283" num="00283">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7a/6f/98/cfb66ec7e6532d/US20200368173A1-20201126-C00283.png"><img id="EMI-C00283" he="38.44mm" wi="103.38mm" file="US20200368173A1-20201126-C00283.TIF" alt="Figure US20200368173A1-20201126-C00283" img-content="table" img-format="tif" orientation="portrait" inline="no" width="414" height="154" alt="Figure US20200368173A1-20201126-C00283" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7a/6f/98/cfb66ec7e6532d/US20200368173A1-20201126-C00283.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00283" attachment-type="cdx" file="US20200368173A1-20201126-C00283.CDX"> </attachment>
                      <attachment idref="CHEM-US-00283" attachment-type="mol" file="US20200368173A1-20201126-C00283.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">V-5</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00284" num="00284">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/07/0a/70/43982093c2576a/US20200368173A1-20201126-C00284.png"><img id="EMI-C00284" he="38.35mm" wi="113.11mm" file="US20200368173A1-20201126-C00284.TIF" alt="Figure US20200368173A1-20201126-C00284" img-content="table" img-format="tif" orientation="portrait" inline="no" width="452" height="153" alt="Figure US20200368173A1-20201126-C00284" class="patent-full-image" src="https://patentimages.storage.googleapis.com/07/0a/70/43982093c2576a/US20200368173A1-20201126-C00284.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00284" attachment-type="cdx" file="US20200368173A1-20201126-C00284.CDX"> </attachment>
                      <attachment idref="CHEM-US-00284" attachment-type="mol" file="US20200368173A1-20201126-C00284.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <div id="p-1074" num="0000" class="description-line">
      <tables id="TABLE-US-00031" num="00031">
        <patent-tables frame="none" colsep="0" rowsep="0" pgwide="1">
          <table align="left" colsep="0" rowsep="0" cols="2" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="2" rowsep="1" class="description-td" colspan="2">TABLE 31</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Compound No.</td>
                <td class="description-td">Structural formula</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td">V-1</td>
                <td class="description-td">
                  <chemistry id="CHEM-US-00285" num="00285">
                    <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/63/14/d2/afa7d5dfea9ac6/US20200368173A1-20201126-C00285.png"><img id="EMI-C00285" he="24.21mm" wi="134.54mm" file="US20200368173A1-20201126-C00285.TIF" alt="Figure US20200368173A1-20201126-C00285" img-content="table" img-format="tif" orientation="portrait" inline="no" width="538" height="97" alt="Figure US20200368173A1-20201126-C00285" class="patent-full-image" src="https://patentimages.storage.googleapis.com/63/14/d2/afa7d5dfea9ac6/US20200368173A1-20201126-C00285.png"/></a></div>
                    <attachments>
                      <attachment idref="CHEM-US-00285" attachment-type="cdx" file="US20200368173A1-20201126-C00285.CDX"> </attachment>
                      <attachment idref="CHEM-US-00285" attachment-type="mol" file="US20200368173A1-20201126-C00285.MOL"> </attachment>
                    </attachments>
                  </chemistry>
                </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="2" align="center" rowsep="1" class="description-td" colspan="2"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[0821]"> </para-num> <div id="p-1075" num="0821" class="description-line">Lipid A in the nucleic acid-containing lipid nanoparticle of the present invention is preferably a lipid represented by formula (II), (V) or (V), more preferably a lipid represented by formula (II) or (V), among the lipids represented by formulas (I), (II), (III), (IV), (V), and (V).</div>
    </li> <li> <para-num num="[0822]"> </para-num> <div id="p-1076" num="0822" class="description-line">The lipid represented by formula (II) is preferably a lipid of formula (II) wherein at least one of R<sup>4 </sup>to R<sup>6 </sup>is linear C8-C24 alkyl, more preferably a lipid of formula (II) wherein two of R<sup>4 </sup>to R<sup>6 </sup>are each linear C8-C24 alkyl, further preferably a lipid of formula (II) wherein all of R<sup>4 </sup>to R<sup>6 </sup>are each linear C8-C24 alkyl.</div>
    </li> <li> <para-num num="[0823]"> </para-num> <div id="p-1077" num="0823" class="description-line">Lipid B to be combined with a lipid selected from the group consisting of formulas (II), (V) and (V) is preferably a lipid represented by formula (CL-I), (CL-II), (CL-III), (CL-IV), (CL-V), (CL-VI), (CL-VII), (CL-VIII), (CL-IX), (CL-XII), (CL-XIV), (CL-XVIII) or (CL-XIX), more preferably a lipid represented by formula (CL-XVIII) or formula (CL-XIX).</div>
    </li> <li> <para-num num="[0824]"> </para-num> <div id="p-1078" num="0824" class="description-line">The lipid represented by formula (CL-II) is preferably a lipid of formula (CL-II) wherein L<sup>106 </sup>and L<sup>107 </sup>together form a single bond or C2-C8 alkylene, and each of p<sup>101 </sup>and p<sup>102 </sup>is an integer from 1 to 3, more preferably a lipid of formula (CL-II) wherein L<sup>106 </sup>and L<sup>107 </sup>together form a single bond, and each of p<sup>101 </sup>and p<sup>102 </sup>is 1.</div>
    </li> <li> <para-num num="[0825]"> </para-num> <div id="p-1079" num="0825" class="description-line">The combination of lipid A and lipid B is more preferably a combination of a lipid represented by formula (II) as the lipid A and a lipid represented by formula (CL-XVIII) and/or formula (CL-XIX) as the lipid B.</div>
    </li> <li> <para-num num="[0826]"> </para-num> <div id="p-1080" num="0826" class="description-line">The nucleic acid used in the present invention can be any molecule as long as the molecule is obtained by the polymerization of, for example, nucleotides and/or molecules having functions equivalent to nucleotides. Examples thereof include ribonucleic acid (RNA) which is a polymer of ribonucleotides, deoxyribonucleic acid (DNA) which is a polymer of deoxyribonucleotides, chimeric nucleic acids consisting of RNA and DNA, and nucleotide polymers derived from these nucleic acids by the replacement of at least one nucleotide with a molecule having a function equivalent to the nucleotide. A derivative at least partially containing the structure of the molecule obtained by the polymerization of nucleotides and/or molecules having functions equivalent to nucleotides is also included in the nucleic acid of the present invention. In the present invention, uracil U and thymine T can be used interchangeably with each other.</div>
    </li> <li> <para-num num="[0827]"> </para-num> <div id="p-1081" num="0827" class="description-line">Examples of the molecules having functions equivalent to nucleotides include nucleotide derivatives.</div>
    </li> <li> <para-num num="[0828]"> </para-num> <div id="p-1082" num="0828" class="description-line">The nucleotide derivative can be any molecule as long as the molecule is, for example, a modified nucleotide. For example, a modified ribonucleotide or deoxyribonucleotide molecule is suitably used for improving nuclease resistance or stabilizing the molecule against the other decomposition factors, for enhancing affinity for a complementary strand nucleic acid, for enhancing cell permeability, or for visualizing the molecule, as compared with RNA or DNA.</div>
    </li> <li> <para-num num="[0829]"> </para-num> <div id="p-1083" num="0829" class="description-line">Examples of the nucleotide derivative include nucleotides modified at the sugar moiety, nucleotides modified at the phosphodiester bond, and nucleotides modified at the base.</div>
    </li> <li> <para-num num="[0830]"> </para-num> <div id="p-1084" num="0830" class="description-line">The nucleotide modified at the sugar moiety can be, for example, any nucleotide in which a part or the whole of the chemical structure of its sugar is modified or substituted with an arbitrary substituent or substituted with an arbitrary atom. A 2-modified nucleotide is preferably used.</div>
    </li> <li> <para-num num="[0831]"> </para-num> <div id="p-1085" num="0831" class="description-line">Examples of the modifying group in the nucleotide modified at the sugar moiety include 2-cyano, 2-alkyl, 2-substituted alkyl, 2-alkenyl, 2-substituted alkenyl, 2-halogen, 2-O-cyano, 2-O-alkyl, 2-O-substituted alkyl, 2-O-alkenyl, 2-O-substituted alkenyl, 2-S-alkyl, 2-S-substituted alkyl, 2-S-alkenyl, 2-S-substituted alkenyl, 2-amino, 2-NH-alkyl, 2-NH-substituted alkyl, 2-NH-alkenyl, 2-NH-substituted alkenyl, 2-SO-alkyl, 2-SO-substituted alkyl, 2-carboxy, 2-CO-alkyl, 2-CO-substituted alkyl, 2-Se-alkyl, 2-Se-substituted alkyl, 2-SiH<sub>2</sub>-alkyl, 2-SiH<sub>2</sub>-substituted alkyl, 2-ONO<sub>2</sub>, 2-NO<sub>2</sub>, 2-N<sub>3</sub>, 2-amino acid residues (which results from the removal of a hydroxy group from the carboxylic acids of amino acids), and 2-O-amino acid residues (as defined in the amino acid residues).</div>
    </li> <li> <para-num num="[0832]"> </para-num> <div id="p-1086" num="0832" class="description-line">Examples of the nucleotide modified at the sugar moiety include bridged nucleic acid (BNA) having a structure with the modifying group at <figure-callout id="2" label="position" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">position</figure-callout> 2 bridged to the carbon atom at position 4, and more specifically include locked nucleic acid (LNA) having the oxygen atom at <figure-callout id="2" label="position" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">position</figure-callout> 2 and the carbon atom at position 4 bridged via methylene, and ethylene bridged nucleic acid (ENA) [Nucleic Acid Research, 32, e175 (2004)], all of which are included in the 2-modified nucleotide.</div>
    </li> <li> <para-num num="[0833]"> </para-num> <div id="p-1087" num="0833" class="description-line">Examples of the nucleotide modified at the sugar moiety also include peptide nucleic acid (PNA) [Acc. Chem. Res., 32, 624 (1999)], oxypeptide nucleic acid (OPNA) [J. Am. Chem. Soc., 123, 4653 (2001)], and peptide ribonucleic acid (PRNA) [J. Am. Chem. Soc., 122, 6900 (2000)].</div>
    </li> <li> <para-num num="[0834]"> </para-num> <div id="p-1088" num="0834" class="description-line">The modifying group in the nucleotide modified at the sugar moiety is preferably 2-cyano, 2-halogen, 2-O-cyano, 2-alkyl, 2-substituted alkyl, 2-O-alkyl, 2-O-substituted alkyl, 2-O-alkenyl, 2-O-substituted alkenyl, 2-Se-alkyl, 2-Se-substituted alkyl or the like, more preferably 2-cyano, 2-fluoro, 2-chloro, 2-bromo, 2-trifluoromethyl, 2-O-methyl, 2-O-ethyl, 2-O-isopropyl, 2-O-trifluoromethyl, 2-O-[2-(methoxy)ethyl], 2-O-(3-aminopropyl), 2-O-[2-(N,N-dimethylaminooxy)ethyl], 2-O-[3-(N,N-dimethylamino)propyl], 2-O-{2-[2-(N,N-dimethylamino)ethoxy]ethyl}, 2-O-[2-(methylamino)-2-oxoethyl], 2-Se-methyl or the like, further preferably 2-O-methyl, 2-O-ethyl, 2-fluoro or the like, most preferably 2-O-methyl or 2-O-ethyl.</div>
    </li> <li> <para-num num="[0835]"> </para-num> <div id="p-1089" num="0835" class="description-line">The modifying group in the nucleotide modified at the sugar moiety can also be defined from its size, preferably the modifying group corresponds to a size from fluoro to O-butyl, and more preferably the modifying group corresponds to a size from O-methyl to O-ethyl.</div>
    </li> <li> <para-num num="[0836]"> </para-num> <div id="p-1090" num="0836" class="description-line">Examples of the alkyl in the modifying group in the nucleotide modified at the sugar moiety include C1-C6 alkyl and more specifically include C1-C6 alkyl such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl and hexyl.</div>
    </li> <li> <para-num num="[0837]"> </para-num> <div id="p-1091" num="0837" class="description-line">Examples of the alkenyl in the modifying group in the nucleotide modified at the sugar moiety include C3-C6 alkenyl and more specifically include C3-C6 alkenyl such as allyl, 1-propenyl, butenyl, pentenyl and hexenyl.</div>
    </li> <li> <para-num num="[0838]"> </para-num> <div id="p-1092" num="0838" class="description-line">Examples of the halogen in the modifying group in the nucleotide modified at the sugar moiety include a fluorine atom, a chlorine atom, a bromine atom and an iodine atom.</div>
    </li> <li> <para-num num="[0839]"> </para-num> <div id="p-1093" num="0839" class="description-line">Examples of the amino acid in the amino acid residue include aliphatic amino acids (specifically, glycine, alanine, valine, leucine, isoleucine, etc.), hydroxyamino acids (specifically, serine, threonine, etc.), acidic amino acids (specifically, aspartic acid, glutamic acid, etc.), acidic amino acid amides (specifically, asparagine, glutamine, etc.), basic amino acids (specifically, lysine, hydroxylysine, arginine, ornithine, etc.), sulfur-containing amino acids (specifically, cysteine, cystine, methionine, etc.), and imino acids (specifically, proline, 4-hydroxyproline etc.).</div>
    </li> <li> <para-num num="[0840]"> </para-num> <div id="p-1094" num="0840" class="description-line">Examples of the substituent for the substituted alkyl or the substituted alkenyl in the modifying group in the nucleotide modified at the sugar moiety include halogen (as defined above), hydroxy, sulfanyl, amino, oxo, O-alkyl (the alkyl moiety of the O-alkyl is as defined in the C1-C6 alkyl in the above-described modifying group), S-alkyl (the alkyl moiety of the S-alkyl is as defined in the C1-C6 alkyl in the above-described modifying group), NH-alkyl (the alkyl moiety of the NH-alkyl is as defined in the C1-C6 alkyl in the above-described modifying group), dialkylaminooxy (the two alkyl moieties of the dialkylaminooxy are the same or different and are each as defined in the C1-C6 alkyl in the above-described modifying group), dialkylamino (the two alkyl moieties of the dialkylamino are the same or different and are each as defined in the C1-C6 alkyl in the above-described modifying group) and dialkylaminoalkyloxy (the two alkyl moieties of the dialkylaminoalkyloxy are the same or different and are each as defined in the C1-C6 alkyl in the above-described modifying group, and the alkylene moiety means a moiety obtained by removal of one hydrogen atom from the C1-C6 alkyl in the above-described modifying group). The number of substituents is preferably 1 to 3.</div>
    </li> <li> <para-num num="[0841]"> </para-num> <div id="p-1095" num="0841" class="description-line">The nucleotide modified at the phosphodiester bond can be any nucleotide in which a part or the whole of the chemical structure of its phosphodiester bond is modified or substituted with an arbitrary substituent or substituted with an arbitrary atom. Examples thereof include a nucleotide resulting from the substitution of the phosphodiester bond with a phosphorothioate bond, a nucleotide resulting from the substitution of the phosphodiester bond with a phosphorodithioate bond, a nucleotide resulting from the substitution of the phosphodiester bond with an alkyl phosphonate bond, and a nucleotide resulting from the substitution of the phosphodiester bond with a phosphoramidate bond.</div>
    </li> <li> <para-num num="[0842]"> </para-num> <div id="p-1096" num="0842" class="description-line">The nucleotide modified at the base can be any nucleotide in which a part or the whole of the chemical structure of its base is modified or substituted with an arbitrary substituent or substituted with an arbitrary atom. Examples thereof include a nucleotide resulting from the substitution of an oxygen atom in the base with a sulfur atom, a nucleotide resulting from the substitution of a hydrogen atom with a C1-C6 alkyl group, a nucleotide resulting from the substitution of a methyl group with a hydrogen atom or a C2-C6 alkyl group, and a nucleotide resulting from the protection of an amino group with a protective group such as a C1-C6 alkyl group or a C1-C6 alkanoyl group.</div>
    </li> <li> <para-num num="[0843]"> </para-num> <div id="p-1097" num="0843" class="description-line">Further examples of the nucleotide derivative include nucleotide derivatives that are modified nucleotides or each have at least one modified sugar moiety, phosphodiester bond or base, and contain an additional chemical substance, such as lipid, phospholipid, phenazine, folate, phenanthridine, anthraquinone, acridine, fluorescein, rhodamine, coumarin, or dye, added thereto, and specifically include 5-polyamine-added nucleotide derivatives, cholesterol-added nucleotide derivatives, steroid-added nucleotide derivatives, bile acid-added nucleotide derivatives, vitamin-added nucleotide derivatives, green fluorescent dye (Cy3)-added nucleotide derivatives, red fluorescent dye (Cy5)-added nucleotide derivatives, fluorescein (6-FAM)-added nucleotide derivatives and biotin-added nucleotide derivatives.</div>
    </li> <li> <para-num num="[0844]"> </para-num> <div id="p-1098" num="0844" class="description-line">In the nucleic acid used in the present invention, the nucleotide or the nucleotide derivative may form a bridged structure, such as an alkylene structure, a peptide structure, a nucleotide structure, an ether structure, an ester structure, and a structure combined with at least one of these structures, with another nucleotide or nucleotide derivative within the nucleic acid.</div>
    </li> <li> <para-num num="[0845]"> </para-num> <div id="p-1099" num="0845" class="description-line">The molecular weight of the nucleic acid used in the present invention is preferably 1,000 kDa or smaller, more preferably 100 kDa or smaller, further preferably 30 kDa or smaller. Examples of the nucleic acid used in the present invention preferably include nucleic acids silencing a target gene and more preferably include nucleic acids having a silencing effect on a target gene through the use of RNA interference (RNAi).</div>
    </li> <li> <para-num num="[0846]"> </para-num> <div id="p-1100" num="0846" class="description-line">The target gene in the present invention is not particularly limited as long as the gene is expressed by producing mRNA. For example, a gene related to tumor or inflammation is preferred. Examples thereof include genes encoding proteins such as vascular endothelial growth factor (hereinafter, abbreviated to VEGF), vascular endothelial growth factor receptor (hereinafter, abbreviated to VEGFR), fibroblast growth factor, fibroblast growth factor receptor, platelet-derived growth factor, platelet-derived growth factor receptor, hepatocyte growth factor, hepatocyte growth factor receptor, Kruppel-like factor (hereinafter, abbreviated to KLF), expressed sequence tag (Ets) transcription factor, nuclear factor, hypoxia-inducible factor, cell cycle-related factor, chromosomal replication-related factor, chromosomal repair-related factor, microtubule-related factor, growth signal pathway-related factor, growth-related transcription factor, and apoptosis-related factor, and specifically include VEGF gene, VEGFR gene, fibroblast growth factor gene, fibroblast growth factor receptor gene, platelet-derived growth factor gene, platelet-derived growth factor receptor gene, hepatocyte growth factor gene, hepatocyte growth factor receptor gene, KLF gene, Ets transcription factor gene, nuclear factor gene, hypoxia-inducible factor gene, cell cycle-related factor gene, chromosomal replication-related factor gene, chromosomal repair-related factor gene, microtubule-related factor gene (e.g., CKAP5 gene), growth signal pathway-related factor gene (e.g., KRAS gene), growth-related transcription factor gene and apoptosis-related factor (e.g., BCL-2 gene).</div>
    </li> <li> <para-num num="[0847]"> </para-num> <div id="p-1101" num="0847" class="description-line">The target gene according to the present invention is preferably, for example, a gene expressed in the liver, the lung, the kidney, or the spleen, more preferably a gene expressed in the liver. Examples thereof include the aforementioned genes related to tumor or inflammation, and genes encoding proteins such as hepatitis B virus genome, hepatitis C virus genome, apolipoprotein (APO), hydroxymethylglutaryl (HMG) CoA reductase, <figure-callout id="9" label="kexin type" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">kexin type</figure-callout> 9 serine protease (PCSK9), factor 12, glucagon receptor, glucocorticoid receptor, leukotriene receptor, thromboxane A2 receptor, histamine HI receptor, carbonic anhydrase, angiotensin-converting enzyme, renin, p53, tyrosine phosphatase (PTP), sodium-dependent glucose transport carrier, tumor necrosis factor, interleukin, hepcidin, trans siren, antithrombin, protein C and matriptase enzyme (e.g., TMPRSS6 gene).</div>
    </li> <li> <para-num num="[0848]"> </para-num> <div id="p-1102" num="0848" class="description-line">Any nucleic acid such as a double-stranded nucleic acid (e.g., siRNA (short interference RNA) and miRNA (micro RNA)) or a single-stranded nucleic acid (e.g., shRNA (short hairpin RNA) antisense nucleic acid and ribozyme) may be used as the nucleic acid silencing a target gene as long as the nucleic acid comprises a nucleotide sequence complementary to, for example, a partial nucleotide sequence of the mRNA of a gene (target gene) encoding a protein or the like and silences the target gene. A double-stranded nucleic acid is preferred.</div>
    </li> <li> <para-num num="[0849]"> </para-num> <div id="p-1103" num="0849" class="description-line">The nucleic acid comprising a nucleotide sequence complementary to a partial nucleotide sequence of the mRNA of the target gene is referred to as an antisense strand nucleic acid. A nucleic acid comprising a nucleotide sequence complementary to the nucleotide sequence of the antisense strand nucleic acid is also referred to as a sense strand nucleic acid. The sense strand nucleic acid refers to a nucleic acid capable of forming a duplex formation moiety by pairing with the antisense strand nucleic acid, such as a nucleic acid itself consisting of the partial nucleotide sequence of the target gene.</div>
    </li> <li> <para-num num="[0850]"> </para-num> <div id="p-1104" num="0850" class="description-line">The double-stranded nucleic acid refers to a nucleic acid having a duplex formation moiety composed of paired two strands. The duplex formation moiety refers to a part in which nucleotides constituting the double-stranded nucleic acid, or derivatives thereof have formed a duplex by constituting base pairs. The base pairs constituting the duplex formation moiety are usually 15 to 27 base pairs, preferably 15 to 25 base pairs, more preferably 15 to 23 base pairs, further preferably 15 to 21 base pairs, particularly preferably 15 to 19 base pairs.</div>
    </li> <li> <para-num num="[0851]"> </para-num> <div id="p-1105" num="0851" class="description-line">For example, a nucleic acid consisting of a partial sequence of the mRNA of the target gene, or a nucleic acid derived from the nucleic acid by the substitution, deletion or addition of 1 to 3 bases, preferably 1 or 2 bases, more preferably 1 base, and having silencing activity against the target protein is suitably used as the antisense strand nucleic acid of the duplex formation moiety. Each single-stranded nucleic acid constituting the double-stranded nucleic acid usually consists of a sequence of 15 to 30 bases (nucleosides), preferably 15 to 29 bases, more preferably 15 to 27 bases, further preferably 15 to 25 bases, particularly preferably 17 to 23 bases, most preferably 19 to 21 bases.</div>
    </li> <li> <para-num num="[0852]"> </para-num> <div id="p-1106" num="0852" class="description-line">Either of the antisense strand or the sense strand constituting the double-stranded nucleic acid, or both of these nucleic acids may have a non-duplex-forming additional nucleic acid on the 3 or 5 side subsequent to the duplex formation moiety. This non-duplex-forming moiety is also referred to as an overhang.</div>
    </li> <li> <para-num num="[0853]"> </para-num> <div id="p-1107" num="0853" class="description-line">For example, a double-stranded nucleic acid having an overhang consisting of 1 to 4 bases, usually 1 to 3 bases, at the 3 end or the 5 end of at least one of the strands is used as the double-stranded nucleic acid having the overhang. A double-stranded nucleic acid having an overhang consisting of 2 bases is preferably used, and a double-stranded nucleic acid having an overhang consisting of dTdT or UU is more preferably used. The overhang can be located in only the antisense strand, only the sense strand, and both of the antisense strand and the sense strand. A double-stranded nucleic acid having overhangs in both of the antisense strand and the sense strand is preferably used.</div>
    </li> <li> <para-num num="[0854]"> </para-num> <div id="p-1108" num="0854" class="description-line">A sequence partially or completely matching the nucleotide sequence of the mRNA of the target gene, or a sequence partially or completely matching the nucleotide sequence of a complementary strand of the mRNA of the target gene may be used subsequently to the duplex formation moiety. Alternatively, for example, a nucleic acid molecule that forms the double-stranded nucleic acid by the action of ribonuclease such as Dicer (WO 2005/089287), or a double-stranded nucleic acid having no 3-terminal or 5-terminal overhang can also be used as the nucleic acid silencing the target gene.</div>
    </li> <li> <para-num num="[0855]"> </para-num> <div id="p-1109" num="0855" class="description-line">When the double-stranded nucleic acid is siRNA, preferably, the antisense strand is an antisense strand in which a sequence of at least the 1st to 17th bases (nucleosides) counted from the 5 end toward the 3 end is a sequence of bases complementary to a sequence of 17 consecutive bases of the mRNA of the target gene. More preferably, the antisense strand is an antisense strand in which a sequence of the 1st to 19th bases counted from the 5 end toward the 3 end is a sequence of bases complementary to a sequence of 19 consecutive bases of the mRNA of the target gene, a sequence of the 1st to 21st bases counted from the 5 end toward the 3 end is a sequence of bases complementary to a sequence of 21 consecutive bases of the mRNA of the target gene, or a sequence of the 1st to 25th bases counted from the 5 end toward the 3 end is a sequence of bases complementary to a sequence of 25 consecutive bases of the mRNA of the target gene.</div>
    </li> <li> <para-num num="[0856]"> </para-num> <div id="p-1110" num="0856" class="description-line">When the nucleic acid used in the present invention is siRNA, preferably 10 to 70%, more preferably 15 to 60%, further preferably 20 to 50%, of sugars in the nucleic acid is ribose substituted at <figure-callout id="2" label="position" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">position</figure-callout> 2 with a modifying group. The ribose substituted at <figure-callout id="2" label="position" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">position</figure-callout> 2 with a modifying group according to the present invention means that the hydroxy group at <figure-callout id="2" label="position" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">position</figure-callout> 2 of the ribose is substituted with a modifying group. The resulting configuration may be the same as or different from that of the hydroxy group at <figure-callout id="2" label="position" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">position</figure-callout> 2 of the ribose and is preferably the same as that of the hydroxy group at <figure-callout id="2" label="position" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">position</figure-callout> 2 of the ribose. Examples of the modifying group in the ribose substituted at <figure-callout id="2" label="position" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">position</figure-callout> 2 therewith include those listed in the definition of the modifying group in the 2-modified nucleotide in the nucleotide modified at the sugar moiety, and a hydrogen atom. The modifying group is preferably 2-cyano, 2-halogen, 2-O-cyano, 2-alkyl, 2-substituted alkyl, 2-O-alkyl, 2-O-substituted alkyl, 2-O-alkenyl, 2-O-substituted alkenyl, 2-Se-alkyl, 2-Se-substituted alkyl or the like, more preferably 2-cyano, 2-fluoro, 2-chloro, 2-bromo, 2-trifluoromethyl, 2-O-methyl, 2-O-ethyl, 2-O-isopropyl, 2-O-trifluoromethyl, 2-O-[2-(methoxy)ethyl], 2-O-(3-aminopropyl), 2-O-[2-(N,N-dimethyl)aminooxy]ethyl, 2-O-[3-(N,N-dimethylamino)propyl], 2-O-{2-[2-(N,N-dimethylamino)ethoxy]ethyl}, 2-O-[2-(methylamino)-2-oxoethyl], 2-Se-methyl, a hydrogen atom or the like, further preferably 2-O-methyl, 2-O-ethyl, 2-fluoro, a hydrogen atom or the like, most preferably 2-O-methyl or 2-O-fluoro.</div>
    </li> <li> <para-num num="[0857]"> </para-num> <div id="p-1111" num="0857" class="description-line">The nucleic acid used in the present invention encompasses derivatives in which, for example, an oxygen atom contained in a phosphoric acid moiety, an ester moiety or the like in the structure of the nucleic acid is substituted with a different atom such as a sulfur atom.</div>
    </li> <li> <para-num num="[0858]"> </para-num> <div id="p-1112" num="0858" class="description-line">The hydroxy group at position 5 of a sugar attached to the 5 terminal base of the antisense strand or the sense strand may be modified with a phosphoric acid group or any of the aforementioned modifying groups, or with a group that is converted to a phosphoric acid group or any of the aforementioned modifying groups by an in vivo nucleolytic enzyme or the like.</div>
    </li> <li> <para-num num="[0859]"> </para-num> <div id="p-1113" num="0859" class="description-line">The hydroxy group at <figure-callout id="3" label="position" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">position</figure-callout> 3 of a sugar attached to the 3 terminal base of the antisense strand or the sense strand may be modified with a phosphoric acid group or any of the aforementioned modifying groups, or with a group that is converted to a phosphoric acid group or any of the aforementioned modifying groups by an in vivo nucleolytic enzyme or the like.</div>
    </li> <li> <para-num num="[0860]"> </para-num> <div id="p-1114" num="0860" class="description-line">The single-stranded nucleic acid can be, for example, any nucleic acid consisting of a sequence complementary to a sequence consisting of 15 to 27 consecutive bases (nucleosides), preferably 15 to 25 consecutive bases, more preferably 15 to 23 consecutive bases, further preferably 15 to 21 consecutive bases, particularly preferably 15 to 19 consecutive bases, of the target gene, or any nucleic acid derived from the nucleic acid by the substitution, deletion or addition of 1 to 3 bases, preferably 1 or 2 bases, more preferably 1 base, and having silencing activity against the target protein. The single-stranded nucleic acid preferably consists of a sequence of 10 to 30 bases (nucleosides). More preferably, a single-stranded nucleic acid of 10 to 27 bases, further preferably 10 to 25 bases, particularly preferably 10 to 23 bases, is suitably used.</div>
    </li> <li> <para-num num="[0861]"> </para-num> <div id="p-1115" num="0861" class="description-line">A linkage via a spacer sequence (spacer oligonucleotide) of the antisense strand and the sense strand constituting the double-stranded nucleic acid described above may be used as the single-stranded nucleic acid. The spacer oligonucleotide is preferably a single-stranded nucleic acid molecule of 6 to 12 bases. Its 5-terminal sequence is preferably UU. Examples of the spacer oligonucleotide include a nucleic acid consisting of a sequence UUCAAGAGA. The order in which the antisense strand and the sense strand are linked via the spacer oligonucleotide can be any order in which either of the strands may be positioned on the 5 side. The single-stranded nucleic acid is preferably a single-stranded nucleic acid such as shRNA having a duplex formation moiety by, for example, a stem-loop structure. The single-stranded nucleic acid such as shRNA is usually 50 to 70 bases long.</div>
    </li> <li> <para-num num="[0862]"> </para-num> <div id="p-1116" num="0862" class="description-line">A nucleic acid of 70 bases or smaller in length, preferably 50 bases or smaller in length, more preferably 30 bases or smaller in length, designed to form the single-stranded nucleic acid or the double-stranded nucleic acid by the action of ribonuclease or the like may be used.</div>
    </li> <li> <para-num num="[0863]"> </para-num> <div id="p-1117" num="0863" class="description-line">The nucleic acid used in the present invention can be obtained by use of a known RNA or DNA synthesis method and RNA or DNA modification method.</div>
    </li> <li> <para-num num="[0864]"> </para-num> <div id="p-1118" num="0864" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention may contain one or two or more lipids A.</div>
    </li> <li> <para-num num="[0865]"> </para-num> <div id="p-1119" num="0865" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention may contain one or two or more lipids B.</div>
    </li> <li> <para-num num="[0866]"> </para-num> <div id="p-1120" num="0866" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention may also contain a neutral lipid and/or a lipid derivative or a fatty acid derivative of water-soluble polymer.</div>
    </li> <li> <para-num num="[0867]"> </para-num> <div id="p-1121" num="0867" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention may contain one or two or more lipids A, and one or two or more lipids B.</div>
    </li> <li> <para-num num="[0868]"> </para-num> <div id="p-1122" num="0868" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention may contain not only the nucleic acid but a compound chemically analogous to the nucleic acid (e.g., an anionic polymer such as an anionic peptide).</div>
    </li> <li> <para-num num="[0869]"> </para-num> <div id="p-1123" num="0869" class="description-line">In the present invention, the nucleic acid is dissolved, with the cationic lipid and other optional lipids (a lipid derivative or a fatty acid derivative of a water-soluble polymer and a neutral lipid), in a water-miscible organic solvent (first lipid solution). In the preparation of the first lipid solution, the nucleic acid is dissolved in water or an aqueous solution of a buffer, and the solution may be added to solutions of lipids in an organic solvent, or solutions of lipids in an organic solvent may be added to water or an aqueous solution of a buffer containing the nucleic acid. Alternatively, solutions of lipids in an organic solvent may be added to the nucleic acid in a freeze-dried state.</div>
    </li> <li> <para-num num="[0870]"> </para-num> <div id="p-1124" num="0870" class="description-line">An organic solvent solution (first lipid solution) is once prepared using the nucleic acid, the cationic lipid and other optional lipids (a lipid derivative or a fatty acid derivative of a water-soluble polymer and a neutral lipid), and an organic solvent solution supplemented with the analog of the fatty acid ester of glycerol that is not hydrolyzable by a lipase, and optionally the lipid derivative or the fatty acid derivative of the water-soluble polymer (second lipid solution) may then be added to the first lipid solution to prepare a third lipid solution.</div>
    </li> <li> <para-num num="[0871]"> </para-num> <div id="p-1125" num="0871" class="description-line">In the present invention, the first or third lipid solution is mixed with water or an aqueous solution of a buffer. In this respect, a lipid nanoparticle having a small size is obtained without aggregation by immediately decreasing the organic solvent concentration.</div>
    </li> <li> <para-num num="[0872]"> </para-num> <div id="p-1126" num="0872" class="description-line">In the mixing of the first or third lipid solution with water or an aqueous solution of a buffer, the former one may be added to the latter one, or the latter one may be added to the former one. The former one and the latter one may be added at the same time to a container with stirring. Alternatively, the former one and the latter one may be mixed in line. In this case, for example, a T-connector can be used as an in-line mixing device.</div>
    </li> <li> <para-num num="[0873]"> </para-num> <div id="p-1127" num="0873" class="description-line">The average particle size of the nucleic acid-containing lipid nanoparticle of the present invention is freely controllable with various parameters in a production process, though also influenced by the nucleic acid used, and the cationic lipid and other lipids. Those skilled in the art can prepare a particle sample by appropriately changing various parameters in a production process necessary for controlling the average particle size of the nucleic acid-containing lipid nanoparticle of the present invention, and measure and determine the average particle size of the obtained sample. Examples of the parameters necessary for controlling the average particle size include the nucleic acid concentration of an organic solvent solution, the concentration of each lipid, temperature, and the composition of an organic solvent. Examples of the parameters necessary for controlling the average particle size also include temperature, the amount of water or an aqueous solution of a buffer, and the addition rate of each solution at the time of operation of dilution of the organic solvent solution of the nucleic acid and lipids with water or the aqueous solution of a buffer.</div>
    </li> <li> <para-num num="[0874]"> </para-num> <div id="p-1128" num="0874" class="description-line">The concentration of the cationic lipid in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing neither phosphatidylcholine (PC) nor cholesterol (Choi) is not particularly limited and is preferably 1 to 2000 M, more preferably 5 to 400 M, further preferably 10 to 200 M, most preferably 20 to 100 M.</div>
    </li> <li> <para-num num="[0875]"> </para-num> <div id="p-1129" num="0875" class="description-line">The concentration of the nucleic acid in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing neither PC nor Choi is not particularly limited and is preferably 0.03 to 15 M, more preferably 0.15 to 3.0 M, further preferably 0.3 to 1.5 M.</div>
    </li> <li> <para-num num="[0876]"> </para-num> <div id="p-1130" num="0876" class="description-line">The concentration of the lipid derivative or the fatty acid derivative of the water-soluble polymer in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing neither PC nor Choi is not particularly limited and is preferably 0.5 to 200 M, more preferably 2.5 to 40 M, further preferably 5 to 20 M.</div>
    </li> <li> <para-num num="[0877]"> </para-num> <div id="p-1131" num="0877" class="description-line">The total concentration of all lipids in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing neither PC nor Choi is not particularly limited and is preferably 5 to 2000 M, more preferably 25 to 400 M, further preferably 50 to 200 M.</div>
    </li> <li> <para-num num="[0878]"> </para-num> <div id="p-1132" num="0878" class="description-line">The concentration of the lipid having one quaternary ammonium group as a hydrophilic unit and having optionally substituted three independent hydrocarbon groups (lipid A) in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing PC and Choi is preferably 0.2 to 1800 M, more preferably 1 to 360 M, further preferably 2 to 180 M, most preferably 5 to 100 M.</div>
    </li> <li> <para-num num="[0879]"> </para-num> <div id="p-1133" num="0879" class="description-line">The concentration of the nucleic acid in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing PC and Choi is preferably 0.02 to 45 M, more preferably 0.1 to 10 M, further preferably 0.2 to 5 M, most preferably 0.3 to 3 M.</div>
    </li> <li> <para-num num="[0880]"> </para-num> <div id="p-1134" num="0880" class="description-line">The concentration of the lipid derivative or the fatty acid derivative of the water-soluble polymer in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing PC and Choi is preferably 0.3 to 1000 M, more preferably 1.5 to 200 M, further preferably 3 to 100 M, most preferably 5 to 50 M.</div>
    </li> <li> <para-num num="[0881]"> </para-num> <div id="p-1135" num="0881" class="description-line">The concentration of the cationic lipid in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing PC and Choi is preferably 2.5 to 4200 M, more preferably 12.5 to 840 M, further preferably 25 to 420 M, most preferably 50 to 210 M.</div>
    </li> <li> <para-num num="[0882]"> </para-num> <div id="p-1136" num="0882" class="description-line">The concentration of the neutral lipid in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing PC and Choi is preferably 2.5 to 5000 M, more preferably 12.5 to 1000 M, further preferably 25 to 500 M, most preferably 50 to 250 M.</div>
    </li> <li> <para-num num="[0883]"> </para-num> <div id="p-1137" num="0883" class="description-line">The total concentration of all lipids in the organic solvent solution before mixing with water or an aqueous solution of a buffer in the case of containing PC and Choi is preferably 10 to 8000 M, more preferably 50 to 1600 M, further preferably 100 to 800 M, most preferably 150 to 400 M.</div>
    </li> <li> <para-num num="[0884]"> </para-num> <div id="p-1138" num="0884" class="description-line">The temperature for preparing the organic solvent solution containing the nucleic acid and the lipids is not particularly limited as long as the nucleic acid and the lipids are dissolved. The temperature is preferably 10 to 60 C., more preferably 20 to 50 C., further preferably 20 to 30 C. Heating to 30 C. or higher increases the degrees of dissolution of the nucleic acid and the lipids and permits lipid nanoparticle production using a smaller amount of a solvent.</div>
    </li> <li> <para-num num="[0885]"> </para-num> <div id="p-1139" num="0885" class="description-line">The organic solvent in the organic solvent solution containing the nucleic acid and the lipids is not particularly limited and is preferably a C1-C6 alcohol, such as methanol, ethanol, propanol or butanol, containing 0 to 50% (v/v) of water, or a mixture thereof, more preferably ethanol or propanol containing 0 to 50% (v/v) of water, further preferably ethanol containing 0 to 50% (v/v) of water. In this context, the term % (v/v) denotes the volume percentage of a solute occupying the volume of the whole solution. The same holds true for the description below.</div>
    </li> <li> <para-num num="[0886]"> </para-num> <div id="p-1140" num="0886" class="description-line">The solvent in the organic solvent solution containing the nucleic acid and the lipids may be supplemented with an inorganic acid such as hydrochloric acid, acetic acid or phosphoric acid, or a salt of the acid, etc. In this case, the pH of the solvent is preferably 1 to 7, more preferably 1 to 5, further preferably 2 to 4.</div>
    </li> <li> <para-num num="[0887]"> </para-num> <div id="p-1141" num="0887" class="description-line">In the operation of adding water or an aqueous solution of a buffer to the organic solvent solution containing the nucleic acid and the lipids, the amount of water or the aqueous solution of a buffer used is not particularly limited and is preferably 0.5 to 100 times, more preferably 1.5 to 20 times, further preferably 2.0 to 10 times, with respect to the amount of the organic solvent solution containing the nucleic acid and the lipids.</div>
    </li> <li> <para-num num="[0888]"> </para-num> <div id="p-1142" num="0888" class="description-line">In this case, the organic solvent concentration after the addition of water or the aqueous solution of a buffer is not particularly limited and is preferably 50% (v/v) or lower, more preferably 40% (v/v) or lower, further preferably 30% (v/v) or lower, most preferably 20% (v/v) or lower, with respect to the obtained solution. The aqueous solution of a buffer is not particularly limited as long as the aqueous solution of a buffer has a buffering effect. Examples thereof include aqueous phosphate buffer solutions, aqueous citrate buffer solutions and aqueous acetate buffer solutions.</div>
    </li> <li> <para-num num="[0889]"> </para-num> <div id="p-1143" num="0889" class="description-line">The temperature for performing the addition operation is not particularly limited and is preferably 10 to 60 C., more preferably 20 to 50 C., further preferably 20 to 30 C.</div>
    </li> <li> <para-num num="[0890]"> </para-num> <div id="p-1144" num="0890" class="description-line">For the addition operation, it is important to immediately decrease the organic solvent solution. Specifically, the organic solvent concentration is preferably changed from 70% (v/v) or higher to 50% (v/v) or lower within 1 minute, more preferably within 0.5 minutes, further preferably within 0.1 minutes, most preferably within 0.05 minutes.</div>
    </li> <li> <para-num num="[0891]"> </para-num> <div id="p-1145" num="0891" class="description-line">When the nucleic acid-containing lipid nanoparticle of the present invention contains lipid A, the total number of molecules of lipid A is not particularly limited. The molar number of the quaternary ammonium group in lipid A is preferably 0.01-fold molar amount or more, more preferably 0.1- to 10-fold molar amount, further preferably 0.1- to 4-fold molar amount, still further preferably 0.1- to 2-fold molar amount, most preferably 0.1- to 1-fold molar amount, with respect to the molar number of a phosphorus atom in the nucleic acid constituting the nucleic acid-containing lipid nanoparticle of the present invention.</div>
    </li> <li> <para-num num="[0892]"> </para-num> <div id="p-1146" num="0892" class="description-line">When the nucleic acid-containing lipid nanoparticle of the present invention contains lipid B, the total number of molecules of lipid B is not particularly limited. The molar number of lipid B is preferably 0.1- to 10-fold molar amount, more preferably 0.5- to 9-fold molar amount, further preferably 1- to 8-fold molar amount, most preferably 1.5- to 6-fold molar amount, with respect to the molar number of a phosphorus atom in the nucleic acid constituting the nucleic acid-containing lipid nanoparticle of the present invention.</div>
    </li> <li> <para-num num="[0893]"> </para-num> <div id="p-1147" num="0893" class="description-line">When the nucleic acid-containing lipid nanoparticle of the present invention contains lipid A and lipid B, the ratio of the molar number of lipid A to the molar number of lipid B (lipid A molar number/lipid B molar number) is preferably 0.001 or more, more preferably 0.003 to 10, further preferably 0.005 to 5, still further preferably 0.01 to 3, most preferably 0.01 to 2.</div>
    </li> <li> <para-num num="[0894]"> </para-num> <div id="p-1148" num="0894" class="description-line">In the nucleic acid-containing lipid nanoparticle of the present invention, the ratio of the molar number of total lipid to the molar number of the nucleic acid (total lipid molar number/nucleic acid molar number) is preferably 50 or more, more preferably 100 to 1000, further preferably 120 to 800, still further preferably 140 to 600, most preferably 200 to 500.</div>
    </li> <li> <para-num num="[0895]"> </para-num> <div id="p-1149" num="0895" class="description-line">When the nucleic acid-containing lipid nanoparticle of the present invention contains lipid B, the total number of molecules of lipid B in the nucleic acid-containing lipid nanoparticle is not particularly limited and is preferably 0.1-fold molar amount or more, more preferably 0.15-fold molar amount or more, further preferably 0.2-fold molar amount or more, still further preferably 0.25-fold molar amount or more, with respect to the molar number of total lipid. Also, the total number of molecules of lipid B in the nucleic acid-containing lipid nanoparticle is not particularly limited and is preferably 0.7-fold molar amount or less, more preferably 0.65-fold molar amount or less, further preferably 0.6-fold molar amount or less, with respect to the molar number of total lipid.</div>
    </li> <li> <para-num num="[0896]"> </para-num> <div id="p-1150" num="0896" class="description-line">The total number of molecules of lipid B in the nucleic acid-containing lipid nanoparticle is preferably 0.10- to 0.70-fold molar amount, more preferably 0.15- to 0.65-fold molar amount, further preferably 0.20- to 0.65-fold molar amount, most preferably 0.25- to 0.60-fold molar amount, among combinations of the preferred ranges of the upper and lower limits described above with respect to the molar number of total lipid.</div>
    </li> <li> <para-num num="[0897]"> </para-num> <div id="p-1151" num="0897" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention preferably further comprises a neutral lipid.</div>
    </li> <li> <para-num num="[0898]"> </para-num> <div id="p-1152" num="0898" class="description-line">The neutral lipid can be any of simple lipids, complex lipids and derived lipids. Examples thereof include, but are not limited to, phospholipid, glyceroglycolipid, sphingoglycolipid, sphingoid and sterol. These neutral lipids may be used alone or in combination of two or more thereof.</div>
    </li> <li> <para-num num="[0899]"> </para-num> <div id="p-1153" num="0899" class="description-line">In this context, the neutral lipid refers to a neutral lipid other than the analog of the fatty acid ester of glycerol that is not hydrolyzable by a lipase.</div>
    </li> <li> <para-num num="[0900]"> </para-num> <div id="p-1154" num="0900" class="description-line">When the nucleic acid-containing lipid nanoparticle of the present invention contains a neutral lipid, the total number of molecules of the neutral lipid is not particularly limited and is preferably 0.10- to 0.75-fold molar amount, more preferably 0.20- to 0.70-fold molar amount, further preferably 0.20- to 0.65-fold molar amount, most preferably 0.30- to 0.60-fold molar amount, with respect to the molar number of total lipid (the total lipid includes the analog of the fatty acid ester of glycerol that is not hydrolyzable by a lipase).</div>
    </li> <li> <para-num num="[0901]"> </para-num> <div id="p-1155" num="0901" class="description-line">In the nucleic acid-containing lipid nanoparticle of the present invention, the analog of the fatty acid ester of glycerol that is not hydrolyzable by a lipase is contained in preferably 0.001-fold molar amount or more, more preferably 0.001- to 0.75-fold molar amount, further preferably 0.05- to 0.70-fold molar amount, still further preferably 0.10- to 0.65-fold molar amount, most preferably 0.12- to 0.60-fold molar amount, with respect to the molar number of total lipid (the total lipid includes the analog of the fatty acid ester of glycerol that is not hydrolyzable by a lipase).</div>
    </li> <li> <para-num num="[0902]"> </para-num> <div id="p-1156" num="0902" class="description-line">Examples of the phospholipid as the neutral lipid include, but are not limited to, natural or synthetic phospholipids such as phosphatidylcholines (PCs) (specifically, soybean phosphatidylcholine, egg phosphatidylcholine (EPC), distearoyl phosphatidylcholine, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), dipalmitoyl phosphatidylcholine, 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), palmitoyl oleoyl phosphatidylcholine (POPC), dimyristoyl phosphatidylcholine (DMPC), dioleoyl phosphatidylcholine (DOPC), etc.), phosphatidylethanolamines (specifically distearoyl phosphatidylethanolamine (DSPE), dipalmitoyl phosphatidylethanolamine (DPPE), dioleoyl phosphatidylethanolamine (DOPE), dimyristoyl phosphatidylethanolamine (DMPE), 16-O-monomethyl PE, 16-0-dimethyl PE, 18-1-trans PE, palmitoyl oleoyl-phosphatidylethanolamine (POPE), 1-stearoyl-2-oleoyl-phosphatidylethanolamine (SOPE), etc.), glycerophospholipids (specifically, phosphatidylserine, phosphatidic acid, phosphatidylglycerol, phosphatidylinositol, palmitoyl oleoyl phosphatidylglycerol (POPG), lysophosphatidylcholine, etc.), sphingophospholipids (specifically, sphingomyelin, ceramide phosphoethanolamine, ceramide phosphoglycerol, ceramide phosphoglycerophosphoric acid, etc.), glycerophosphonolipids, sphingophosphonolipids, natural lecithins (specifically, egg lecithin, soybean lecithin, etc.), and hydrogenated phospholipids (specifically, hydrogenated soybean phosphatidylcholine, etc.).</div>
    </li> <li> <para-num num="[0903]"> </para-num> <div id="p-1157" num="0903" class="description-line">Examples of the glyceroglycolipid as the neutral lipid include, but are not limited to, sulfoxyribosyl glyceride, diglycosyl diglyceride, digalactosyl diglyceride, galactosyl diglyceride and glycosyl diglyceride.</div>
    </li> <li> <para-num num="[0904]"> </para-num> <div id="p-1158" num="0904" class="description-line">Examples of the sphingoglycolipid as the neutral lipid include, but are not limited to, galactosyl cerebroside, lactosyl cerebroside and ganglioside.</div>
    </li> <li> <para-num num="[0905]"> </para-num> <div id="p-1159" num="0905" class="description-line">Examples of the sphingoid as the neutral lipid include, but are not limited to, sphingan, icosasphingan, sphingosine, and derivatives of the foregoing. Examples of the derivatives include, but are not limited to, substances derived from sphingan, icosasphingan, sphingosine, or the like by the conversion of NH<sub>2 </sub>to NHCO(CH<sub>2</sub>)<sub>x</sub>CH<sub>3 </sub>wherein x is an integer from 0 to 18 and is particularly preferably 6, 12, or 18.</div>
    </li> <li> <para-num num="[0906]"> </para-num> <div id="p-1160" num="0906" class="description-line">Examples of the sterol as the neutral lipid include, but are not limited to, cholesterol (Choi), dihydrocholesterol, lanosterol, -sitosterol, campesterol, stigmasterol, brassicasterol, erugosterol, fucosterol and 3-[N(N,N-dimethylaminoethyl)carbamoyl]cholesterol (DC-Chol).</div>
    </li> <li> <para-num num="[0907]"> </para-num> <div id="p-1161" num="0907" class="description-line">Examples of the polymer include, but are not limited to, polymers such as proteins, albumin, dextran, polyfect, chitosan, dextran sulfate, poly-L-lysine, polyethylenimine, polyaspartic acid, styrene-maleic acid copolymers, isopropylacrylamide-acrylpyrrolidone copolymers, polyethylene glycol-modified dendrimers, polylactic acid, polylactic acid-polyglycolic acid, and polyethylene glycolated polylactic acid, and micelles consisting of one or more of salts of the foregoing.</div>
    </li> <li> <para-num num="[0908]"> </para-num> <div id="p-1162" num="0908" class="description-line">In this context, the salt of the polymer encompasses, for example, metal salts, ammonium group salts, acid-addition salts, organic amine-addition salts and amino acid-addition salts. Examples of the metal salts include, but are not limited to: alkali metal salts such as lithium salt, sodium salt, and potassium salt; alkaline earth metal salts such as magnesium salt and calcium salt; aluminum salts; and zinc salts. Examples of the ammonium group salts include, but are not limited to, salts of an ammonium group, a tetramethylammonium group or the like. Examples of the acid-addition salts include, but are not limited to: inorganic acid salts such as hydrochloride, sulfate, nitrate, and phosphate; and organic acid salts such as acetate, maleate, fumarate, and citrate. Examples of the organic amine-addition salts include, but are not limited to, addition salts of morpholine, piperidine or the like. Examples of the amino acid-addition salts include, but are not limited to, addition salts of glycine, phenylalanine, aspartic acid, glutamic acid, lysine or the like.</div>
    </li> <li> <para-num num="[0909]"> </para-num> <div id="p-1163" num="0909" class="description-line">Any nucleic acid-containing lipid nanoparticle of the present invention may contain, for example, a lipid derivative or a fatty acid derivative of one or more substances selected from a sugar, a peptide, a nucleic acid and a water-soluble polymer, or a surfactant.</div>
    </li> <li> <para-num num="[0910]"> </para-num> <div id="p-1164" num="0910" class="description-line">Examples of the lipid derivative or the fatty acid derivative of one or more substances selected from a sugar, a peptide, a nucleic acid and a water-soluble polymer, or the surfactant preferably include glycolipids, and lipid derivatives or fatty acid derivatives of water-soluble polymers and more preferably include lipid derivatives or fatty acid derivatives of water-soluble polymers. The lipid derivative or the fatty acid derivative of one or more substances selected from a sugar, a peptide, a nucleic acid and a water-soluble polymer, or the surfactant is preferably a two-faced substance in which a part of the molecule has the properties of binding to other constituents of the composition via, for example, hydrophobic affinity or electrostatic interaction and the other moiety has the properties of binding to a solvent for use in the production of the composition via, for example, hydrophilic affinity or electrostatic interaction.</div>
    </li> <li> <para-num num="[0911]"> </para-num> <div id="p-1165" num="0911" class="description-line">Examples of the lipid derivatives or the fatty acid derivatives of sugars, peptides or nucleic acids include substances obtained by the binding of sugars such as sucrose, sorbitol, and lactose, peptides such as casein-derived peptides, ovalbumin-derived peptides, soybean-derived peptides, and glutathione, or nucleic acids such as DNA, RNA, plasmids, siRNA, and ODN to the neutral lipids listed in the definition of the composition or to fatty acids such as stearic acid, palmitic acid, myristic acid, and lauric acid.</div>
    </li> <li> <para-num num="[0912]"> </para-num> <div id="p-1166" num="0912" class="description-line">Examples of the lipid derivatives or the fatty acid derivatives of sugars also include the glyceroglycolipids or the sphingoglycolipids listed in the definition of the composition.</div>
    </li> <li> <para-num num="[0913]"> </para-num> <div id="p-1167" num="0913" class="description-line">Examples of the lipid derivatives or the fatty acid derivatives of water-soluble polymers include substances obtained by the binding of polyethylene glycol, polyglycerin, polyethylenimine, polyvinyl alcohol, polyacrylic acid, polyacrylamide, oligosaccharide, dextrin, water-soluble cellulose, dextran, chondroitin sulfate, polyglycerin, chitosan, polyvinylpyrrolidone, polyaspartic acid amide, poly-L-lysine, mannan, pullulan, oligoglycerol, or the like or derivatives of the foregoing to the neutral lipids listed in the definition of the composition or to fatty acids such as stearic acid, palmitic acid, myristic acid, and lauric acid, salts of the foregoing. Examples thereof more preferably include lipid derivatives or fatty acid derivatives of polyethylene glycol or polyglycerin, and salts of the foregoing and further preferably include lipid derivatives or fatty acid derivatives of polyethylene glycol and salts of the foregoing.</div>
    </li> <li> <para-num num="[0914]"> </para-num> <div id="p-1168" num="0914" class="description-line">Examples of the lipid derivatives or the fatty acid derivatives of polyethylene glycol include polyethylene glycolated lipids [specifically, polyethylene glycol-phosphatidylethanolamine (more specifically, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DPPE), 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DMPE), etc.), polyoxyethylene hydrogenated <figure-callout id="60" label="castor oil" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">castor oil</figure-callout> 60, CREMOPHOR EL, etc.], and polyethylene glycol sorbitan fatty acid esters (specifically, polyoxyethylene sorbitan monooleate, etc.), and polyethylene glycol fatty acid esters and more preferably include polyethylene glycolated lipids.</div>
    </li> <li> <para-num num="[0915]"> </para-num> <div id="p-1169" num="0915" class="description-line">Examples of the lipid derivatives or the fatty acid derivatives of polyglycerin include polyglycerinated lipids (specifically, polyglycerin-phosphatidyl ethanol amine, etc.), and polyglycerin fatty acid esters and more preferably include polyglycerinated lipids.</div>
    </li> <li> <para-num num="[0916]"> </para-num> <div id="p-1170" num="0916" class="description-line">Examples of the surfactant include polyoxyethylene sorbitan monooleate (specifically, <figure-callout id="80" label="polysorbate" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">polysorbate</figure-callout> 80, etc.), polyoxyethylene polyoxypropylene glycol (specifically, Pluronic F68, etc.), sorbitan fatty acid esters (specifically, sorbitan monolaurate, sorbitan monooleate, etc.), polyoxyethylene derivatives (specifically, polyoxyethylene hydrogenated <figure-callout id="60" label="castor oil" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">castor oil</figure-callout> 60, polyoxyethylene lauryl alcohol, etc.), glycerin fatty acid esters and polyethylene glycol alkyl ethers and preferably include polyoxyethylene polyoxypropylene glycol, glycerin fatty acid esters and polyethylene glycol alkyl ethers.</div>
    </li> <li> <para-num num="[0917]"> </para-num> <div id="p-1171" num="0917" class="description-line">In the nucleic acid-containing lipid nanoparticle of the present invention, the total number of molecules of the lipid derivatives and the fatty acid derivatives of water-soluble polymers in the nucleic acid-containing lipid nanoparticle is not particularly limited and is preferably 0.005-fold molar amount or more, more preferably 0.01 to 0.30-fold molar amount, further preferably 0.02 to 0.25-fold molar amount, still further preferably 0.03 to 0.20-fold molar amount, even further preferably 0.04 to 0.15-fold molar amount, most preferably 0.04 to 0.12-fold molar amount, with respect to the molar number of total lipid.</div>
    </li> <li> <para-num num="[0918]"> </para-num> <div id="p-1172" num="0918" class="description-line">In the present invention, the total lipid includes lipid A and lipid derivatives and fatty acid derivatives of water-soluble polymers and optionally includes lipid B and a neutral lipid. Specifically, the molar number of lipid A is fold molar amount obtained by subtracting 1 from the sum of the fold molar amounts of the lipid derivatives and the fatty acid derivatives of water-soluble polymers and, in some cases, the fold molar amount of lipid B and the fold molar amount of the neutral lipid, in terms of fold molar amount with the molar number of the total lipid defined as 1.</div>
    </li> <li> <para-num num="[0919]"> </para-num> <div id="p-1173" num="0919" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention may be arbitrarily surface-modified with, for example, a water-soluble polymer [see D. D. Basic and F. Martin ed., Stealth Liposomes (USA), CRC Press Inc., 1995, p. 93-102]. Examples of the water-soluble polymer that may be used in the surface modification include, but are not limited to, polyethylene glycol, polyglycerin, polyethylenimine, polyvinyl alcohol, polyacrylic acid, polyacrylamide, oligosaccharides, dextrin, water-soluble cellulose, dextran, chondroitin sulfate, polyglycerin, chitosan, polyvinylpyrrolidone, polyaspartic acid amide, poly-L-lysine, mannan, pullulan and oligoglycerol, preferably polyethylene glycol, polyglycerin, polyethyleneimine, polyvinyl alcohol, polyacrylic acid and polyacrylamide, more preferably polyethylene glycol and polyglycerin. The lipid derivative or the fatty acid derivative of one or more substances selected from a sugar, a peptide, a nucleic acid and a water-soluble polymer (as defined above), or the surfactant, etc. can also be used in the surface modification. The surface modification is a method for allowing the nucleic acid-containing lipid nanoparticle of the present invention to contain the lipid derivative or the fatty acid derivative of one or more substances selected from a sugar, a peptide, a nucleic acid and a water-soluble polymer, or the surfactant.</div>
    </li> <li> <para-num num="[0920]"> </para-num> <div id="p-1174" num="0920" class="description-line">A targeting ligand can be arbitrarily bonded directly to the surface of the nucleic acid-containing lipid nanoparticle of the present invention through a covalent bond to a polar head residue of a lipid component in the nucleic acid-containing lipid nanoparticle of the present invention (see WO 2006/116107).</div>
    </li> <li> <para-num num="[0921]"> </para-num> <div id="p-1175" num="0921" class="description-line">The average particle size of the nucleic acid-containing lipid nanoparticle of the present invention may be further adjusted after preparation of the lipid nanoparticle. Examples of a method for adjusting the average particle size include an extrusion method and a method of mechanically pulverizing a large multilamellar vesicle (MLV) or the like (specifically, using Manton Gaulin, Microfluidizer, etc.) [see R. H. Muller, S. Benita and B. Bohm ed., Emulsion and Nanosuspensions for the Formulation of Poorly Soluble Drugs, Germany, Scientific Publishers Stuttgart, 1998, p. 267-294].</div>
    </li> <li> <para-num num="[0922]"> </para-num> <div id="p-1176" num="0922" class="description-line">The size of the nucleic acid-containing lipid nanoparticle of the present invention is preferably 1.00 to 2000 nm, more preferably 10.0 to 500 nm, further preferably 20.0 to 300 nm, most preferably 20.0 to 150 nm.</div>
    </li> <li> <para-num num="[0923]"> </para-num> <div id="p-1177" num="0923" class="description-line">The size of the nucleic acid-containing lipid nanoparticle of the present invention can be measured by, for example, a dynamic light scattering method.</div>
    </li> <li> <para-num num="[0924]"> </para-num> <div id="p-1178" num="0924" class="description-line">The nucleic acid in the nucleic acid-containing lipid nanoparticle of the present invention can be introduced into a mammalian cell by introducing the nucleic acid-containing lipid nanoparticle of the present invention into the cell.</div>
    </li> <li> <para-num num="[0925]"> </para-num> <div id="p-1179" num="0925" class="description-line">The in vivo introduction of the nucleic acid-containing lipid nanoparticle of the present invention into a mammalian cell can be performed according to procedures of transfection known in the art that can be performed in vivo. For example, the nucleic acid-containing lipid nanoparticle of the present invention can be intravenously administered to a mammal including a human and thereby delivered to, for example, an organ or a site having tumor or inflammation so that the nucleic acid in the nucleic acid-containing lipid nanoparticle of the present invention is introduced into a cell of the organ or the site that has received the nucleic acid-containing lipid nanoparticle. Examples of the organ or the site having tumor or inflammation include, but are not particularly limited to, the stomach, the large intestine, the liver, the lung, the spleen, the pancreas, the kidney, the bladder, the skin, vascular vessels and eye balls. Also, the nucleic acid-containing lipid nanoparticle of the present invention can be intravenously administered to a mammal including a human and thereby delivered to, for example, the liver, the stomach, the lung, the spleen, the pancreas and/or the kidney so that the nucleic acid in the nucleic acid-containing lipid nanoparticle of the present invention is introduced into a cell of the organ or the site that has received the nucleic acid-containing lipid nanoparticle. The cell of the liver, the lung, the spleen, and/or the kidney can be any of normal cells, cells related to tumor or inflammation, and cells related to the other diseases.</div>
    </li> <li> <para-num num="[0926]"> </para-num> <div id="p-1180" num="0926" class="description-line">Provided that the nucleic acid in the nucleic acid-containing lipid nanoparticle of the present invention is a nucleic acid having a silencing effect on a target gene through the use of RNA interference (RNAi), for example, the nucleic acid silencing a target gene or the like can be introduced into a mammalian cell in vivo. As a result, the expression of the target gene can be suppressed. The recipient is preferably a human.</div>
    </li> <li> <para-num num="[0927]"> </para-num> <div id="p-1181" num="0927" class="description-line">Provided that the target gene in the nucleic acid-containing lipid nanoparticle of the present invention is, for example, a gene expressed in the liver, the stomach, the lung, the kidney, the pancreas and/or the spleen, preferably a gene expressed in the liver, the nucleic acid-containing lipid nanoparticle of the present invention can be used as a therapeutic agent or a prophylactic agent for a disease related to the liver, the stomach, the lung, the kidney, the pancreas or the spleen, preferably a therapeutic agent or a prophylactic agent for a disease related to the liver. Specifically, the present invention also provides a method for treating a disease or the like related to the liver, the stomach, the lung, the kidney, the pancreas or the spleen, comprising administering the nucleic acid-containing lipid nanoparticle of the present invention described above to a mammal. The recipient is preferably a human, more preferably a human having the disease or the like related to the liver, the stomach, the lung, the kidney, the pancreas or the spleen.</div>
    </li> <li> <para-num num="[0928]"> </para-num> <div id="p-1182" num="0928" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention can also be used as a tool for verifying the effectiveness of suppression of a target gene in an in vivo drug efficacy evaluation model as to a therapeutic agent or a prophylactic agent for a disease or the like related to the liver, the stomach, the lung, the kidney, the pancreas or the spleen.</div>
    </li> <li> <para-num num="[0929]"> </para-num> <div id="p-1183" num="0929" class="description-line">The nucleic acid-containing lipid nanoparticle of the present invention can also be used as a preparation aimed at, for example, stabilizing the nucleic acid in a biogenic substance such as a blood component (e.g., in blood or the digestive tract), reducing adverse reactions, and enhancing drug accumulation to a tissue or an organ containing an expression site of the target gene.</div>
    </li> <li> <para-num num="[0930]"> </para-num> <div id="p-1184" num="0930" class="description-line">When the nucleic acid-containing lipid nanoparticle of the present invention is pharmaceutically used as a therapeutic agent or a prophylactic agent for, for example, a disease or the like related to the liver, the lung, the kidney or the spleen, an administration route most effective for treatment is desirably used. Examples of such an administration route can include parenteral or oral administration such as administration into the oral cavity, intratracheal administration, intrarectal administration, subcutaneous administration, intramuscular administration, intravenous administration, or the like. Examples thereof can preferably include intravenous administration, subcutaneous administration, and intramuscular administration and more preferably include intravenous administration.</div>
    </li> <li> <para-num num="[0931]"> </para-num> <div id="p-1185" num="0931" class="description-line">The dose differs depending on the pathological condition or age of the recipient, the administration route, or the like. For example, the nucleic acid-containing lipid nanoparticle of the present invention can be administered, for example, at a daily dose of approximately 0.1 g to 1000 mg in terms of the amount of the nucleic acid.</div>
    </li> <li> <para-num num="[0932]"> </para-num> <div id="p-1186" num="0932" class="description-line">Examples of the preparation suitable for intravenous administration or intramuscular administration include injections. A dispersion of the composition prepared by the aforementioned method may be used directly in the form of, for example, an injection. Alternatively, the dispersion may be used after removal of the solvent by, for example, filtration or centrifugation, or the dispersion may be used after being freeze-dried and/or may be used after being supplemented with, for example, an excipient such as mannitol, lactose, trehalose, maltose or glycine and then freeze-dried.</div>
    </li> <li> <para-num num="[0933]"> </para-num> <div id="p-1187" num="0933" class="description-line">In the case of an injection, the dispersion of the composition or the solvent-free or freeze-dried composition described above is preferably mixed with, for example, water, an acid, an alkali, various buffer solutions, physiological saline or an amino acid transfusion to prepare the injection. Alternatively, the injection may be prepared by the addition of, for example, an antioxidant such as citric acid, ascorbic acid, cysteine, or EDTA or a tonicity agent such as glycerin, glucose or sodium chloride. Also, the injection can also be cryopreserved by the addition of a cryopreserving agent such as glycerin.</div>
    </li> <heading id="h-0012">EXAMPLES</heading>
    <li> <para-num num="[0934]"> </para-num> <div id="p-1188" num="0934" class="description-line">Next, the present invention will be specifically described with reference to Examples, Reference Examples, Comparative Examples and Test Examples. However, the present invention is not intended to be limited by these Examples, Reference Examples, Comparative Examples and Test Examples.</div>
    </li> <li> <para-num num="[0935]"> </para-num> <div id="p-1189" num="0935" class="description-line">Proton nuclear magnetic resonance spectra (<sup>1</sup>H NMR) shown in Examples and Reference Examples were measured at 270 MHz, 300 MHz or 400 MHz, and no exchangeable proton may be clearly observed depending on compounds and measurement conditions. The multiplicity of signals is indicated as usually used, and br denotes an apparently broad signal.</div>
    </li> <li> <para-num num="[0936]"> </para-num> <div id="p-1190" num="0936" class="description-line">(Synthesis of Cationic Lipid)</div>
    </li> <li> <para-num num="[0937]"> </para-num> <div id="p-1191" num="0937" class="description-line">Hereinafter, methods for synthesizing lipid A will be shown in Reference Examples A1 to A71.</div>
    </li> <heading id="h-0013">Reference Example A1</heading>
    <heading id="h-0014">N-Methyl-2-(oleoyloxy)-N,N-bis(2-(oleoyloxy)ethyl)ethanaminium chloride (Compound I-1)</heading>
    <li> <para-num num="[0938]"> </para-num> <div id="p-1192" num="0938" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[0939]"> </para-num> <div id="p-1193" num="0939" class="description-line">To a solution of triethanolamine (manufactured by Sigma-Aldrich Corp., 0.115 g, 0.771 mmol) in chloroform (5 mL), oleic acid (manufactured by Tokyo Chemical Industry Co., Ltd., 0.784 g, 2.78 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (manufactured by Tokyo Chemical Industry Co., Ltd., 0.591 g, 3.08 mmol), triethylamine (0.430 mL, 3.08 mmol) and N,N-dimethylaminopyridine (manufactured by Nacalai Tesque, Inc., 0.024 g, 0.19 mmol) were added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, followed by extraction with chloroform. The organic layer was washed with a saturated aqueous solution of sodium bicarbonate and then saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/hexane=50/50 to 100/0) to obtain 2,2,2-nitrilotris(ethane-2,1-diyl) trioleate (0.439 g, 0.466 mmol, yield: 60%).</div>
    </li> <li> <para-num num="[0940]"> </para-num> <div id="p-1194" num="0940" class="description-line">ESI-MS m/z: 943 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.9 Hz, 9H), 1.23-1.36 (m, 60H), 1.58-1.63 (m, 6H), 1.98-2.04 (m, 12H), 2.29 (t, J=7.6 Hz, 6H), 2.83 (t, J=6.1 Hz, 6H), 4.11 (t, J=6.1 Hz, 6H), 5.31-5.38 (m, 6H).</div>
    </li> <li> <para-num num="[0941]"> </para-num> <div id="p-1195" num="0941" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[0942]"> </para-num> <div id="p-1196" num="0942" class="description-line">To 2,2,2-nitrilotris(ethane-2,1-diyl) trioleate (0.439 g, 0.466 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1, methyl iodide (manufactured by Tokyo Chemical Industry Co., Ltd., 3 mL) was added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (manufactured by The Dow Chemical Company, <figure-callout id="1" label="DowexTM" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Dowex</figure-callout> 1-2 100 mesh, Cl type, approximately 20-fold amount, prewashed with water and methanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 88/12) to obtain the title compound (0.342 g, 0.344 mmol, yield: 74%).</div>
    </li> <li> <para-num num="[0943]"> </para-num> <div id="p-1197" num="0943" class="description-line">ESI-MS m/z: 957 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.9 Hz, 9H), 1.25-1.35 (m, 60H), 1.59-1.63 (m, 6H), 1.99-2.03 (m, 12H), 2.35 (t, J=7.6 Hz, 6H), 3.56 (s, 3H), 4.21 (t, J=4.9 Hz, 6H), 4.61 (t, J=4.9 Hz, 6H), 5.30-5.38 (m, 6H).</div>
    </li> <heading id="h-0015">Reference Example A2</heading>
    <heading id="h-0016">N-Methyl-2-((9Z,12Z)-octadeca-9,12-dienoyloxy)-N,N-bis(2-((9Z,12Z)-octadeca-9,12-dienoyloxy)ethyl)ethanaminium chloride (Compound I-2)</heading>
    <li> <para-num num="[0944]"> </para-num> <div id="p-1198" num="0944" class="description-line">The title compound (0.100 g, overall yield: 22%) was obtained in the same way as in Reference Example A1 using (9Z,12Z)-octadeca-9,12-dienoic acid (manufactured by Sigma-Aldrich Corp., 0.704 g, 2.51 mmol) instead of oleic acid.</div>
    </li> <li> <para-num num="[0945]"> </para-num> <div id="p-1199" num="0945" class="description-line">ESI-MS m/z: 950 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) 0.89 (t, J=7.0 Hz, 9H), 1.25-1.40 (m, 42H), 1.55-1.66 (m, 6H), 2.05 (q, J=6.9 Hz, 12H), 2.35 (t, J=7.6 Hz, 6H), 2.77 (t, J=6.3 Hz, 6H), 3.54 (s, 3H), 4.21 (t, J=5.1 Hz, 6H), 4.59 (br s, 6H), 5.28-5.43 (m, 12H).</div>
    </li> <heading id="h-0017">Reference Example A3</heading>
    <heading id="h-0018">(9Z,12Z)N-Methyl-N,N-di((9Z,12Z)-octadeca-9,12-dienyl)octadeca-9,12-dien-1-aminium chloride (Compound I-3)</heading>
    <li> <para-num num="[0946]"> </para-num> <div id="p-1200" num="0946" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[0947]"> </para-num> <div id="p-1201" num="0947" class="description-line">To ammonia (manufactured by Tokyo Chemical Industry Co., Ltd., approximately 7 mol/L solution in methanol, 8.00 mL, 56.0 mmol), (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (manufactured by Nu-Chek Prep, Inc., 3.55 g, 10.1 mmol) was added, and the mixture was stirred at 130 C. for 3 hours using a microwave reaction apparatus. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform five times. The organic layers were combined, washed with saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain a crude product of (9Z,12Z)-octadeca-9,12-dien-1-amine.</div>
    </li> <li> <para-num num="[0948]"> </para-num> <div id="p-1202" num="0948" class="description-line">To the obtained crude product, (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (2.78 g, 8.07 mmol) and a 50% aqueous sodium hydroxide solution (2.00 mL, 50.0 mmol) were added, and the mixture was stirred at 110 C. for 60 minutes in an oil bath. After cooling to room temperature, the reaction solution was diluted with ethyl acetate, washed with water and then saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=100/0 to 90/10) to obtain (9Z,12Z)-tri(9Z,12Z)-octadeca-9,12-dienylamine (1.09 g, 1.43 mmol, yield: 18%).</div>
    </li> <li> <para-num num="[0949]"> </para-num> <div id="p-1203" num="0949" class="description-line">ESI-MS m/z: 763 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[0950]"> </para-num> <div id="p-1204" num="0950" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[0951]"> </para-num> <div id="p-1205" num="0951" class="description-line">The title compound (1.06 g, 1.30 mol, yield: 94%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (9Z,12Z)-tri(9Z,12Z)-octadeca-9,12-dienylamine (1.05 g, 1.38 mol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 instead of 2,2,2-nitrilotris(ethane-2,1-diyl)trioleate.</div>
    </li> <li> <para-num num="[0952]"> </para-num> <div id="p-1206" num="0952" class="description-line">ESI-MS m/z: 111 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.1 Hz, 9H), 1.22-1.45 (m, 48H), 1.61-1.69 (m, 6H), 2.05 (q, J=6.8 Hz, 12H), 2.77 (t, J=6.5 Hz, 6H), 3.35 (s, 3H), 3.44-3.50 (m, 6H), 5.29-5.42 (m, 12H).</div>
    </li> <heading id="h-0019">Reference Example A4</heading>
    <heading id="h-0020">(Z)N-Methyl-N,N-di((Z)-octadec-9-enyl)octadec-9-en-1-aminium chloride (Compound I-4)</heading>
    <li> <para-num num="[0953]"> </para-num> <div id="p-1207" num="0953" class="description-line">The title compound (0.410 g, 0.501 mmol, overall yield: 24%) was obtained in the same way as in Reference Example A3 using (Z)-octadec-9-enyl methanesulfonate (manufactured by Nu-Chek Prep, Inc.) instead of (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate.</div>
    </li> <li> <para-num num="[0954]"> </para-num> <div id="p-1208" num="0954" class="description-line">ESI-MS m/z: 783 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.9 Hz, 9H), 1.22-1.44 (m, 66H), 1.62-1.69 (m, 6H), 1.98-2.04 (m, 12H), 3.35 (s, 3H), 3.45-3.51 (m, 6H), 5.30-5.39 (m, 6H).</div>
    </li> <heading id="h-0021">Reference Example A5</heading>
    <heading id="h-0022">(11Z,14Z)N,N-Di((11Z,14Z)-icosa-11,14-dienyl)-N-methylicosa-11,14-dien-1-aminium chloride (Compound I-5)</heading>
    <li> <para-num num="[0955]"> </para-num> <div id="p-1209" num="0955" class="description-line">The title compound (0.323 g, 0.360 mmol, overall yield: 25%) was obtained in the same way as in Reference Example A3 using (11Z,14Z)-icosa-11,14-dienyl methanesulfonate (manufactured by Nu-Chek Prep, Inc.) instead of (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate.</div>
    </li> <li> <para-num num="[0956]"> </para-num> <div id="p-1210" num="0956" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.9 Hz, 9H), 1.24-1.43 (m, 63H), 1.61-1.69 (m, 6H), 2.05 (q, J=6.8 Hz, 12H), 2.77 (t, J=6.6 Hz, 6H), 3.35 (s, 3H), 3.45-3.50 (m, 6H), 5.30-5.42 (m, 12H).</div>
    </li> <heading id="h-0023">Reference Example A6</heading>
    <heading id="h-0024">(9Z,12Z)N-(3-Hydroxypropyl)-N,N-di((9Z,12Z)-octadeca-9,12-dienyl)octadeca-9,12-dien-1-aminium chloride (Compound I-6)</heading>
    <li> <para-num num="[0957]"> </para-num> <div id="p-1211" num="0957" class="description-line">To a solution of tri((9Z,12Z)-octadeca-9,12-dienyl)amine (0.199 g, 0.261 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A3 in chloroform (0.3 mL), 3-iodopropan-1-ol (manufactured by Wako Pure Chemical Industries Ltd., 0.194 g, 1.04 mmol) was added, and the mixture was reacted at 130 C. for 40 minutes in a microwave reaction apparatus. The reaction solution was dissolved in a small amount of ethanol, and the solution was loaded to an ion-exchange resin (manufactured by Sigma-Aldrich Corp., Amberlite IRA-400, Cl type, approximately 20-fold amount, prewashed with water and ethanol), followed by elution with ethanol. The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 88/12) to obtain the title compound (0.146 g, 0.170 mmol, yield: 65%).</div>
    </li> <li> <para-num num="[0958]"> </para-num> <div id="p-1212" num="0958" class="description-line">ESI-MS m/z: 821 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.27-1.39 (m, 49H), 1.67-1.74 (m, 6H), 1.93-1.99 (m, 2H), 2.05 (q, J=6.9 Hz, 12H), 2.77 (t, J=6.2 Hz, 6H), 3.14-3.19 (m, 6H), 3.70-3.74 (m, 2H), 3.79 (t, J=5.1 Hz, 2H), 5.29-5.42 (m, 12H).</div>
    </li> <heading id="h-0025">Reference Example A7</heading>
    <heading id="h-0026">(9Z,12Z)N-(2-Hydroxyethyl)-N,N-di((9Z,12Z)-octadeca-9,12-dienyl)octadeca-9,12-dien-1-aminium chloride (Compound I-7)</heading>
    <li> <para-num num="[0959]"> </para-num> <div id="p-1213" num="0959" class="description-line">The title compound (0.211 g, 0.250 mmol, yield: 85%) was obtained in the same way as in Reference Example A6 using 2-iodoethan-1-ol (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of 3-iodopropan-1-ol.</div>
    </li> <li> <para-num num="[0960]"> </para-num> <div id="p-1214" num="0960" class="description-line">ESI-MS m/z: 807 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.27-1.40 (m, 49H), 1.64-1.71 (m, 6H), 2.05 (q, J=6.8 Hz, 12H), 2.77 (t, J=6.3 Hz, 6H), 3.36-3.41 (m, 6H), 3.53-3.56 (m, 2H), 4.08-4.12 (m, 2H), 5.29-5.42 (m, 12H).</div>
    </li> <heading id="h-0027">Reference Example A8</heading>
    <heading id="h-0028">N,N,N-Trimethyl-1,3-bis((9Z,12Z)-octadeca-9,12-dienoyloxy)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propan-2-aminium chloride (Compound II-1)</heading>
    <li> <para-num num="[0961]"> </para-num> <div id="p-1215" num="0961" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[0962]"> </para-num> <div id="p-1216" num="0962" class="description-line">To a solution of 2-(dimethylamino)-2-(hydroxymethyl)propane-1,3-diol (manufactured by Zylexa Pharma Ltd., 0.252 g, 1.69 mmol) in chloroform (10 mL), (9Z,12Z)-octadeca-9,12-dienoic acid (2.37 g, 8.45 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.62 g, 8.45 mmol) and N,N-dimethylaminopyridine (0.206 g, 1.69 mmol) were added, and the mixture was stirred overnight at 60 C. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0) to obtain (9Z,9Z,12Z,12Z)-2-(dimethylamino)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propane-1,3-diyl dioctadeca-9,12-dienoate (0.334 g, 0.356 mmol, yield: 21%).</div>
    </li> <li> <para-num num="[0963]"> </para-num> <div id="p-1217" num="0963" class="description-line">ESI-MS m/z: 937 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[0964]"> </para-num> <div id="p-1218" num="0964" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[0965]"> </para-num> <div id="p-1219" num="0965" class="description-line">To a solution of (9Z,9Z,12Z,12Z)-2-(dimethylamino)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propane-1,3-diyl dioctadeca-9,12-dienoate (0.324 g, 0.346 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in chloroform (3 mL), methyl iodide (0.216 mL) was added, and the mixture was stirred at room temperature for 5 hours. Methyl iodide (0.216 mL) was added to the reaction solution, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (manufactured by The Dow Chemical Company, <figure-callout id="1" label="DowexTM" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Dowex</figure-callout> 1-2 100 mesh, Cl type, approximately 20-fold amount, prewashed with water and methanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 90/10) to obtain the title compound (0.161 g, 0.164 mmol, yield: 47%).</div>
    </li> <li> <para-num num="[0966]"> </para-num> <div id="p-1220" num="0966" class="description-line">ESI-MS m/z: 951 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.86 (t, J=6.9 Hz, 9H), 1.22-1.36 (m, 42H), 1.54-1.61 (m, 6H), 2.02 (q, J=6.8 Hz, 12H), 2.34 (t, J=7.7 Hz, 6H), 2.74 (t, J=6.8 Hz, 6H), 3.69 (s, 9H), 4.57 (s, 6H), 5.26-5.39 (m, 12H).</div>
    </li> <heading id="h-0029">Reference Example A9</heading>
    <heading id="h-0030">N,N,N-Trimethyl-1,3-bis((Z)-tetradec-9-enoyloxy)-2-(((Z)-tetradec-9-enoyloxy)methyl)propan-2-aminium chloride (Compound II-2)</heading>
    <li> <para-num num="[0967]"> </para-num> <div id="p-1221" num="0967" class="description-line">The title compound (0.0854 g, 0.104 mmol, overall yield: 16%) was obtained in the same way as in Reference Example A8 using cis-9-tetradecenoic acid (manufactured by Nu-Chek Prep, Inc.) instead of (9Z,12Z)-octadeca-9,12-dienoic acid.</div>
    </li> <li> <para-num num="[0968]"> </para-num> <div id="p-1222" num="0968" class="description-line">ESI-MS m/z: 789 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.1 Hz, 9H), 1.27-1.36 (m, 36H), 1.58-1.64 (m, 6H), 2.02 (q, J=6.5 Hz, 12H), 2.37 (t, J=7.6 Hz, 6H), 3.72 (s, 9H), 4.55 (s, 6H), 5.30-5.38 (m, 6H).</div>
    </li> <heading id="h-0031">Reference Example A10</heading>
    <heading id="h-0032">N,N,N-Trimethyl-1,3-bis(oleoyloxy)-2-(oleoyloxymethyl)propan-2-aminium chloride (Compound II-3)</heading>
    <li> <para-num num="[0969]"> </para-num> <div id="p-1223" num="0969" class="description-line">The title compound (1.14 g, 1.15 mmol, overall yield: 34%) was obtained in the same way as in Reference Example A8 using oleic acid instead of (9Z,12Z)-octadeca-9,12-dienoic acid.</div>
    </li> <li> <para-num num="[0970]"> </para-num> <div id="p-1224" num="0970" class="description-line">ESI-MS m/z: 957 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.83 (t, J=6.9 Hz, 9H), 1.17-1.32 (m, 60H), 1.51-1.59 (m, 6H), 1.96 (t, J=5.5 Hz, 12H), 2.32 (t, J=7.6 Hz, 6H), 3.70 (s, 9H), 4.56 (s, 6H), 5.25-5.34 (m, 6H).</div>
    </li> <heading id="h-0033">Reference Example A11</heading>
    <heading id="h-0034">N,N,N-Trimethyl-1,3-bis(stearoyloxy)-2-(stearoyloxymethyl)propan-2-aminium chloride (Compound II-4)</heading>
    <li> <para-num num="[0971]"> </para-num> <div id="p-1225" num="0971" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[0972]"> </para-num> <div id="p-1226" num="0972" class="description-line">To 2-(dimethylamino)-2-(hydroxymethyl)propane-1,3-diol (0.100 g, 0.670 mmol), toluene (10 mL), stearic acid (manufactured by Tokyo Chemical Industry Co., Ltd., 0.763 g, 2.68 mmol), and p-toluenesulfonic acid monohydrate (0.191 g, 1.01 mmol) were added in order, and the mixture was stirred overnight under conditions of heating to reflux. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by amino silica gel column chromatography (chloroform) to obtain 2-(dimethylamino)-2-((stearoyloxy)methyl)propane-1,3-diyl distearate (0.120 g, 0.127 mmol, yield: 19%).</div>
    </li> <li> <para-num num="[0973]"> </para-num> <div id="p-1227" num="0973" class="description-line">ESI-MS m/z: 948 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[0974]"> </para-num> <div id="p-1228" num="0974" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[0975]"> </para-num> <div id="p-1229" num="0975" class="description-line">The title compound (0.0260 g, 0.0260 mmol, yield: 21%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-(dimethylamino)-2-((stearoyloxy)methyl)propane-1,3-diyl distearate (0.120 g, 0.127 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[0976]"> </para-num> <div id="p-1230" num="0976" class="description-line">ESI-MS m/z: 963 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.22-1.36 (m, 84H), 1.56-1.65 (m, 6H), 2.37 (t, J=7.6 Hz, 6H), 3.72 (s, 9H), 4.56 (s, 6H).</div>
    </li> <heading id="h-0035"> <figure-callout id="1" label="Reference Example A12" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Reference Example A12</figure-callout> </heading>
    <heading id="h-0036">1,3-Bis((Z)-hexadec-9-enoyloxy)-2-(((Z)-hexadec-9-enoyloxy)methyl)-N,N,N-trimethylpropan-2-aminium chloride (Compound II-5)</heading>
    <li> <para-num num="[0977]"> </para-num> <div id="p-1231" num="0977" class="description-line">The title compound (0.680 g, 0.748 mmol, overall yield: 63%) was obtained in the same way as in Reference Example A8 using cis-9-hexadecenoic acid instead of (9Z,12Z)-octadeca-9,12-dienoic acid.</div>
    </li> <li> <para-num num="[0978]"> </para-num> <div id="p-1232" num="0978" class="description-line">ESI-MS m/z: 873 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.24-1.36 (m, 48H), 1.56-1.67 (m, 13H), 1.98-2.05 (m, 12H), 2.37 (t, J=7.6 Hz, 6H), 3.75 (s, 9H), 4.53 (s, 6H), 5.29-5.40 (m, 6H).</div>
    </li> <heading id="h-0037">Reference Example A13</heading>
    <heading id="h-0038">N,N,N-Trimethyl-1,3-bis((9Z,12Z)-octadeca-9,12-dienyloxy)-2-(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-2-aminium chloride (Compound II-6)</heading>
    <li> <para-num num="[0979]"> </para-num> <div id="p-1233" num="0979" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[0980]"> </para-num> <div id="p-1234" num="0980" class="description-line">To a solution of 2-dimethylamino-2-hydroxymethylpropane-1,3-diol (manufactured by Zylexa Pharma Ltd., 0.115 g, 0.768 mmol) in toluene (5 mL), sodium hydride (manufactured by Nacalai Tesque, Inc., 60% oil, 0.154 g, 3.84 mmol) and (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (1.32 g, 3.84 mmol) were added, and the mixture was stirred overnight under heating to reflux. After cooling to room temperature, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with hexane. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=100/0 to 95/5) to obtain N,N-dimethyl-1,3-bis((9Z,12Z)-octadeca-9,12-dienyloxy)-2-(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-2-amine (0.195 g, 0.217 mmol, yield: 28%).</div>
    </li> <li> <para-num num="[0981]"> </para-num> <div id="p-1235" num="0981" class="description-line">ESI-MS m/z: 895 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[0982]"> </para-num> <div id="p-1236" num="0982" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[0983]"> </para-num> <div id="p-1237" num="0983" class="description-line">To a solution of N,N-dimethyl-1,3-bis((9Z,12Z)-octadeca-9,12-dienyloxy)-2-(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-2-amine (0.0849 g, 0.0949 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in chloroform (1 mL), methyl iodide (0.119 mL) was added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (manufactured by The Dow Chemical Company, <figure-callout id="1" label="DowexTM" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Dowex</figure-callout> 1-2 100 mesh, Cl type, approximately 20-fold amount, prewashed with water and methanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 90/10) to obtain the title compound (0.0646 g, 0.0684 mmol, yield: 72%).</div>
    </li> <li> <para-num num="[0984]"> </para-num> <div id="p-1238" num="0984" class="description-line">ESI-MS m/z: 909 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.9 Hz, 9H), 1.25-1.40 (m, 48H), 1.55-1.63 (m, 6H), 2.02-2.09 (m, 12H), 2.77 (t, J=6.8 Hz, 6H), 3.44 (t, J=6.6 Hz, 6H), 3.62 (s, 9H), 3.82 (s, 6H), 5.29-5.42 (m, 12H).</div>
    </li> <heading id="h-0039">Reference Example A14</heading>
    <heading id="h-0040">N,N,N-Trimethyl-1,3-bis((Z)-tetradec-9-enyloxy)-2-(((Z)-tetradec-9-enyloxy)methyl)propan-2-aminium chloride (Compound II-7)</heading>
    <li> <para-num num="[0985]"> </para-num> <div id="p-1239" num="0985" class="description-line">The title compound (0.0729 g, 0.0931 mmol, overall yield: 12%) was obtained in the same way as in Reference Example A13 using myristoleyl methanesulfonate (manufactured by Nu-Chek Prep, Inc.) instead of (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate.</div>
    </li> <li> <para-num num="[0986]"> </para-num> <div id="p-1240" num="0986" class="description-line">ESI-MS m/z: 747 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.90 (t, J=7.1 Hz, 9H), 1.27-1.37 (m, 42H), 1.54-1.61 (m, 6H), 2.02 (q, J=6.5 Hz, 12H), 3.43 (t, J=6.6 Hz, 6H), 3.64 (s, 8H), 3.81 (s, 6H), 5.31-5.39 (m, 6H).</div>
    </li> <heading id="h-0041"> <figure-callout id="1" label="Reference Example A15" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Reference Example A15</figure-callout> </heading>
    <heading id="h-0042">1,3-Bis((Z)-hexadec-9-enyloxy)-2-(((Z)-hexadec-9-enyloxy)methyl)-N,N,N-trimethylpropan-2-aminium chloride (Compound II-8)</heading>
    <li> <para-num num="[0987]"> </para-num> <div id="p-1241" num="0987" class="description-line">The title compound (0.466 g, 0.538 mmol, overall yield: 71%) was obtained in the same way as in Reference Example A13 using palmitoleyl methanesulfonate (manufactured by Nu-Chek Prep, Inc.) instead of (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate.</div>
    </li> <li> <para-num num="[0988]"> </para-num> <div id="p-1242" num="0988" class="description-line">ESI-MS m/z: 831 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.23-1.37 (m, 54H), 1.53-1.61 (m, 14H), 2.02 (q, J=5.8 Hz, 12H), 3.43 (t, J=6.5 Hz, 6H), 3.65 (s, 9H), 3.81 (s, 6H), 5.30-5.40 (m, 6H).</div>
    </li> <heading id="h-0043">Reference Example A16</heading>
    <heading id="h-0044">(6Z,9Z,40Z,43Z)N,N,N-Trimethyl-25-((3-((9Z,12Z)-octadeca-9,12-dienyloxy)-3-oxopropoxy)methyl)-20,30-dioxo-19,23,27,31-tetraoxanonatetraconta-6,9,40,43-tetraen-25-aminium chloride (Compound II-9)</heading>
    <li> <para-num num="[0989]"> </para-num> <div id="p-1243" num="0989" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[0990]"> </para-num> <div id="p-1244" num="0990" class="description-line">Di-tert-<figure-callout id="3" label="butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}"> <figure-callout id="3" label="butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">butyl</figure-callout> </figure-callout> 3,3-((2-amino-2-((3-(tert-butoxy)-3-oxopropoxy)methyl)propane-1,3-diyl)bis(oxy))dipropanoate (0.500 g, 0.989 mmol) synthesized by a method equivalent to the method described in J. Org. Chem., 2002, Vol. 67, p. 1411-1413 was dissolved in dichloromethane (5 mL). To the solution, methyl iodide (1.40 g, 9.89 mmol) was added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (<figure-callout id="1" label="DowexTM" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Dowex</figure-callout> 1-2 100 mesh, Cl type, approximately 20-fold amount, prewashed with water and methanol), followed by elution with methanol. The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=97/3 to 80/20) to obtain 9-((3-(tert-butoxy)-3-oxopropoxy)methyl)-N,N,N,2,2,16,16-heptamethyl-4,14-dioxo-3,7,11,15-tetraoxaheptadecan-9-aminium chloride (0.144 g, 0.246 mmol, yield: 25%).</div>
    </li> <li> <para-num num="[0991]"> </para-num> <div id="p-1245" num="0991" class="description-line">ESI-MS m/z: 548 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[0992]"> </para-num> <div id="p-1246" num="0992" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[0993]"> </para-num> <div id="p-1247" num="0993" class="description-line">9-((3-(tert-Butoxy)-3-oxopropoxy)methyl)-N,N,N,2,2,16,16-heptamethyl-4,14-dioxo-3,7,11,15-tetraoxaheptadecan-9-aminium chloride (0.350 g, 0.246 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in dichloromethane (2 mL). To the solution, trifluoroacetic acid (0.380 mL, 4.92 mmol) was added, and the mixture was stirred at room temperature for 3 hours. Toluene was added to the reaction solution, and the mixture was concentrated under reduced pressure to obtain a crude product of 1,3-bis(2-carboxyethoxy)-2-((2-carboxyethoxy)methyl)-N,N,N-trimethylpropan-2-aminium chloride trifluoroacetate (0.102 g, 0.246 mmol, crude yield: 100%).</div>
    </li> <li> <para-num num="[0994]"> </para-num> <div id="p-1248" num="0994" class="description-line">ESI-MS m/z: 422 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[0995]"> </para-num> <div id="p-1249" num="0995" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[0996]"> </para-num> <div id="p-1250" num="0996" class="description-line">The crude product of 1,3-bis(2-carboxyethoxy)-2-((2-carboxyethoxy)methyl)-N,N,N-trimethylpropan-2-aminium chloride trifluoroacetate (0.055 g, 0.13 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 was dissolved in dichloromethane (2 mL). To the solution, O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (manufactured by Wako Pure Chemical Industries Ltd., 0.20 g, 0.53 mmol), N,N-diisopropylethylamine (0.23 mL, 1.3 mmol), and (9Z,12Z)-octadeca-9,12-dien-1-ol (manufactured by Tokyo Chemical Industry Co., Ltd., 0.141 g, 0.53 mmol) were added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, followed by extraction with chloroform. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=90/10 to 80/20) to obtain the title compound (8.0 mg, 6.9 mmol, yield: 5%).</div>
    </li> <li> <para-num num="[0997]"> </para-num> <div id="p-1251" num="0997" class="description-line">ESI-MS m/z: 1125 (MH)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.25-1.39 (m, 48H), 1.58-1.66 (m, 6H), 2.05 (q, J=6.9 Hz, 12H), 2.59 (t, J=5.7 Hz, 6H), 2.77 (t, J=6.7 Hz, 6H), 3.42 (s, 9H), 3.74 (t, J=5.7 Hz, 6H), 4.00 (s, 6H), 4.07 (t, J=6.8 Hz, 6H), 5.29-5.40 (m, 12H).</div>
    </li> <heading id="h-0045">Reference Example A17</heading>
    <heading id="h-0046">(7Z,38Z)-23-((3-((Z)-Hexadec-9-enyloxy)-3-oxopropoxy)methyl)-N,N,N-trimethyl-18,28-dioxo-17,21,25,29-tetraoxapentatetraconta-7,38-dien-23-aminium chloride (Compound II-10)</heading>
    <li> <para-num num="[0998]"> </para-num> <div id="p-1252" num="0998" class="description-line">The title compound (0.145 g, 0.134 mmol, overall yield: 17%) was obtained in the same way as in Reference Example A16 using (Z)-hexadec-9-en-1-ol (manufactured by Nu-Chek Prep, Inc.) instead of (9Z,12Z)-octadeca-9,12-dien-1-ol.</div>
    </li> <li> <para-num num="[0999]"> </para-num> <div id="p-1253" num="0999" class="description-line">ESI-MS m/z: 1047 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.24-1.38 (m, 54H), 1.58-1.66 (m, 6H), 1.98-2.05 (m, 12H), 2.58 (t, J=5.7 Hz, 6H), 3.47 (s, 9H), 3.74 (t, J=5.7 Hz, 6H), 4.02 (s, 6H), 4.07 (t, J=6.8 Hz, 6H), 5.30-5.40 (m, 6H).</div>
    </li> <heading id="h-0047">Reference Example A18</heading>
    <heading id="h-0048">(5Z,36Z)N,N,N-Trimethyl-16,26-dioxo-21-((3-oxo-3-((Z)-tetradec-9-enyloxy)propoxy)methyl)-15,19,23,27-tetraoxahentetraconta-5,36-dien-21-aminium chloride (Compound II-11)</heading>
    <li> <para-num num="[1000]"> </para-num> <div id="p-1254" num="1000" class="description-line">The title compound (0.189 g, 0.189 mmol, overall yield: 24%) was obtained in the same way as in Reference Example A16 using (Z)-tetradec-9-en-1-ol (manufactured by Nu-Chek Prep, Inc.) instead of (9Z,12Z)-octadeca-9,12-dien-1-ol.</div>
    </li> <li> <para-num num="[1001]"> </para-num> <div id="p-1255" num="1001" class="description-line">ESI-MS m/z: 963 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.87-0.92 (m, 9H), 1.25-1.38 (m, 42H), 1.55-1.66 (m, 6H), 1.98-2.05 (m, 12H), 2.58 (t, J=5.7 Hz, 6H), 3.47 (s, 9H), 3.75 (t, J=5.7 Hz, 6H), 4.01 (s, 6H), 4.07 (t, J=6.8 Hz, 6H), 5.30-5.41 (m, 6H).</div>
    </li> <heading id="h-0049">Reference Example A19</heading>
    <heading id="h-0050">(11Z,14Z)N,N,N-Trimethyl-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)-2-((9Z,12Z)-octadeca-9,12-dienyl)icosa-11,14-dien-1-aminium chloride (Compound II-12)</heading>
    <li> <para-num num="[1002]"> </para-num> <div id="p-1256" num="1002" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1003]"> </para-num> <div id="p-1257" num="1003" class="description-line">Ethyl cyanoacetate (manufactured by Tokyo Chemical Industry Co., Ltd., 1.00 g, 8.84 mmol) and (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (7.62 g, 22.1 mmol) were dissolved in tetrahydrofuran (30 mL). To the solution, sodium hydride (60% oil, 1.06 g, 26.5 mmol) and tetra-n-butylammonium iodide (manufactured by Nacalai Tesque, Inc., 3.27 g, 8.84 mmol) were added under ice cooling. After foaming was completed, the mixture was stirred at 60 C. for 3 hours. Water was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product of (11Z,14Z)-ethyl 2-cyano-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoate (3.50 g, 5.74 mmol, crude yield: 65%).</div>
    </li> <li> <para-num num="[1004]"> </para-num> <div id="p-1258" num="1004" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1005]"> </para-num> <div id="p-1259" num="1005" class="description-line">The crude product of (11Z,14Z)-ethyl 2-cyano-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoate 1.50 g, 2.46 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in tetrahydrofuran (10 mL). To the solution, lithium aluminum hydride (manufactured by Junsei Chemical Co., Ltd., 0.467 g, 12.3 mmol) was added under ice cooling, and the mixture was stirred for 30 minutes. Water (0.5 mL), a 15% aqueous sodium hydroxide solution (0.5 mL), water (1.5 mL), and magnesium sulfate were added in order to the reaction solution, and the mixture was stirred for a while and then filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 85/15) to obtain (11Z,14Z)-2-(aminoethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (1.00 g, 2.46 mmol, yield: 71%).</div>
    </li> <li> <para-num num="[1006]"> </para-num> <div id="p-1260" num="1006" class="description-line">ESI-MS m/z: 573 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1007]"> </para-num> <div id="p-1261" num="1007" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1008]"> </para-num> <div id="p-1262" num="1008" class="description-line">(11Z,14Z)-2-(Aminoethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (0.350 g, 0.612 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 was dissolved in acetonitrile (2 mL) and tetrahydrofuran (2 mL). To the solution, a 38% aqueous formaldehyde solution (manufactured by Wako Pure Chemical Industries Ltd., 0.145 mL, 1.84 mmol), acetic acid (0.035 mL, 0.612 mmol), and sodium triacetoxyborohydride (manufactured by Acros Organics B.V.B.A., 0.389 g, 1.84 mmol) were added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, followed by extraction with chloroform. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 85/15) to obtain (11Z,14Z)-2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl) icosa-11,14-dien-1-ol (0.252 g, 0.420 mmol, yield: 69%).</div>
    </li> <li> <para-num num="[1009]"> </para-num> <div id="p-1263" num="1009" class="description-line">ESI-MS m/z: 600 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1010]"> </para-num> <div id="p-1264" num="1010" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1011]"> </para-num> <div id="p-1265" num="1011" class="description-line">To a solution of (11Z,14Z)-2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (0.252 g, 0.420 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 in dichloromethane (4 mL), (9Z,12Z)-octadeca-9,12-dienoic acid (0.141 g, 0.504 mmol), O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (0.192 mmol, 0.504 mmol), and N,N-diisopropylethylamine (0.147 mL, 0.840 mmol) were added in order, and the mixture was stirred at room temperature for 4 hours. Water was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5 to 85/15) to obtain (9Z,12Z)-(11Z,14Z)-2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl octadeca-9,12-dienoate (0.307 g, 0.356 mmol, yield: 85%).</div>
    </li> <li> <para-num num="[1012]"> </para-num> <div id="p-1266" num="1012" class="description-line">ESI-MS m/z: 863 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1013]"> </para-num> <div id="p-1267" num="1013" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1014]"> </para-num> <div id="p-1268" num="1014" class="description-line">The title compound (0.260 g, 0.285 mmol, yield: 80%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (9Z,12Z)-(11Z,14Z)-2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl octadeca-9,12-dienoate (0.307 g, 0.356 mmol) obtained in step 4.</div>
    </li> <li> <para-num num="[1015]"> </para-num> <div id="p-1269" num="1015" class="description-line">ESI-MS m/z: 877 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.22-1.48 (m, 54H), 1.60-1.66 (m, 2H), 2.05 (q, J=6.8 Hz, 12H), 2.38 (t, J=7.6 Hz, 2H), 2.77 (t, J=6.3 Hz, 6H), 3.50 (s, 2H), 3.60 (s, 9H), 4.13 (s, 2H), 5.27-5.44 (m, 12H).</div>
    </li> <heading id="h-0051">Reference Example A20</heading>
    <heading id="h-0052">N,N,N-Trimethyl-3-((11Z,14Z)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)-2-((9Z,12Z)-octadeca-9,12-dienyl)icosa-11,14-dienylcarbamoyloxy)propan-1-aminium chloride (Compound II-13)</heading>
    <li> <para-num num="[1016]"> </para-num> <div id="p-1270" num="1016" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1017]"> </para-num> <div id="p-1271" num="1017" class="description-line">(11Z,14Z)-2-(Aminoethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (0.918 g, 1.61 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A19 was dissolved in tetrahydrofuran (20 mL). To the solution, triethylamine (0.671 mL, 4.81 mmol) and di-tert-butyl dicarbonate (manufactured by Kokusan Chemical Co., Ltd., 0.373 mL, 1.61 mmol) were added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5 to 50/50) to obtain tert-butyl ((11Z,14Z)-2-(hydroxymethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl)carbamate (0.918 g, 1.37 mmol, yield: 85%).</div>
    </li> <li> <para-num num="[1018]"> </para-num> <div id="p-1272" num="1018" class="description-line">ESI-MS m/z: 672 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1019]"> </para-num> <div id="p-1273" num="1019" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1020]"> </para-num> <div id="p-1274" num="1020" class="description-line">tert-Butyl ((11Z,14Z)-2-(hydroxymethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl)carbamate (0.357 g, 0.531 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in dichloromethane (5 mL). To the solution, (9Z,12Z)-octadeca-9,12-dienoic acid (0.223 g, 0.797 mmol), O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (0.303 mmol, 0.797 mmol), N,N-diisopropylethylamine (0.186 mL, 1.06 mmol), and N,N-dimethylaminopyridine (0.0650 g, 0.531 mmol) were added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, followed by extraction with chloroform. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=99/1 to 90/10) to obtain (9Z,12Z)-(11Z,14Z)-2-(((tert-butoxycarbonylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl octadeca-9,12-dienoate (0.395 g, 0.423 mmol, yield: 80%).</div>
    </li> <li> <para-num num="[1021]"> </para-num> <div id="p-1275" num="1021" class="description-line">ESI-MS m/z: 935 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1022]"> </para-num> <div id="p-1276" num="1022" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1023]"> </para-num> <div id="p-1277" num="1023" class="description-line">(9Z,12Z)-(11Z,14Z)-2-(((tert-Butoxycarbonylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl) icosa-11,14-dien-1-yl octadeca-9,12-dienoate (0.395 g, 0.423 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 was dissolved in dichloromethane (3 mL). To the solution, trifluoroacetic acid (1.00 mL, 4.92 mmol) was added under ice cooling, and the mixture was stirred at 0 C. for 2 hours. 1,2-Dichloroethane was added to the reaction solution, and the mixture was concentrated under reduced pressure to obtain a crude product of (9Z,12Z)-(11Z,14Z)-2-(aminoethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl octadeca-9,12-dienoate trifluoroacetate (0.394 g, 0.423 mmol, crude yield: 100%).</div>
    </li> <li> <para-num num="[1024]"> </para-num> <div id="p-1278" num="1024" class="description-line">ESI-MS m/z: 834 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1025]"> </para-num> <div id="p-1279" num="1025" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1026]"> </para-num> <div id="p-1280" num="1026" class="description-line">The crude product of (9Z,12Z)-(11Z,14Z)-2-(aminoethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl octadeca-9,12-dienoate trifluoroacetate (0.200 g, 0.215 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 was dissolved in acetonitrile (2 mL). To the solution, 3-(dimethylamino)propyl 4-nitrophenyl carbonate hydrochloride (0.279 g, 1.07 mmol) synthesized by a method equivalent to the method described in J. Am. Chem. Soc., 1981, Vol. 103, p. 4194-4199, triethylamine (0.299 mL, 2.15 mmol), and N,N-dimethylaminopyridine (0.0520 g, 0.429 mmol) were added, and the mixture was stirred at 60 C. for 2 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=99/1 to 60/40) to obtain (9Z,12Z)-(11Z,14Z)-2-((((3-(dimethylamino)propoxy)carbonyl)amino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl octadeca-9,12-dienoate (0.0800 g, 0.0830 mmol, yield: 39%).</div>
    </li> <li> <para-num num="[1027]"> </para-num> <div id="p-1281" num="1027" class="description-line">ESI-MS m/z: 964 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1028]"> </para-num> <div id="p-1282" num="1028" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1029]"> </para-num> <div id="p-1283" num="1029" class="description-line">The title compound (0.025 g, 0.025 mmol, yield: 45%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (9Z,12Z)-(11Z,14Z)-2-((((3-(dimethylamino)propoxy)carbonyl)amino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl octadeca-9,12-dienoate (0.053 g, 0.055 mmol) obtained in step 4.</div>
    </li> <li> <para-num num="[1030]"> </para-num> <div id="p-1284" num="1030" class="description-line">ESI-MS m/z: 978 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.17-1.40 (m, 54H), 1.56-1.66 (m, 2H), 2.05 (q, J=6.8 Hz, 12H), 2.09-2.17 (m, 2H), 2.33 (t, J=7.6 Hz, 2H), 2.77 (t, J=6.2 Hz, 6H), 3.05 (d, J=6.6 Hz, 2H), 3.44 (s, 9H), 3.73-3.79 (m, 2H), 3.85 (s, 2H), 4.16 (t, J=5.7 Hz, 2H), 5.27-5.44 (m, 12H), 5.72 (t, J=6.5 Hz, 1H).</div>
    </li> <heading id="h-0053">Reference Example A21</heading>
    <heading id="h-0054">(12Z,15Z)-3-Hydroxy-N,N,N-trimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)henicosa-12,15-dien-1-aminium chloride (Compound II-14)</heading>
    <li> <para-num num="[1031]"> </para-num> <div id="p-1285" num="1031" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1032]"> </para-num> <div id="p-1286" num="1032" class="description-line">(11Z,14Z)-2-(Aminoethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl) icosa-11,14-dien-1-ol (1.35 g, 2.36 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A19 was dissolved in tetrahydrofuran (10 mL). To the solution, a 38% aqueous formaldehyde solution (manufactured by Wako Pure Chemical Industries Ltd., 0.559 mL, 7.08 mmol), acetic acid (0.135 mL, 2.36 mmol), and sodium triacetoxyborohydride (1.50 g, 7.08 mmol) were added, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with chloroform. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 85/15) to obtain (11Z,14Z)-2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (0.610 g, 1.02 mmol, yield: 43%).</div>
    </li> <li> <para-num num="[1033]"> </para-num> <div id="p-1287" num="1033" class="description-line">ESI-MS m/z: 600 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1034]"> </para-num> <div id="p-1288" num="1034" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1035]"> </para-num> <div id="p-1289" num="1035" class="description-line">(11Z,14Z)-2-((Dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (0.300 g, 0.500 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in dichloromethane (3 mL). To the solution, Dess-Martin reagent (manufactured by Tokyo Chemical Industry Co., Ltd., 0.233 g, 0.550 mmol) was added, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with chloroform. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5 to 70/30) to obtain (11Z,14Z)-2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienal (0.160 g, 0.268 mmol, yield: 54%).</div>
    </li> <li> <para-num num="[1036]"> </para-num> <div id="p-1290" num="1036" class="description-line">ESI-MS m/z: 598 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1037]"> </para-num> <div id="p-1291" num="1037" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1038]"> </para-num> <div id="p-1292" num="1038" class="description-line">To magnesium (manufactured by Sigma-Aldrich Corp., 0.0140 g, 0.562 mmol), diethyl ether (1 mL) and iodine (a little piece) were added, and the mixture was stirred at room temperature for 5 minutes. A solution of (6Z,9Z)-18-bromooctadeca-6,9-diene (0.176 g, 0.535 mmol) synthesized by a method equivalent to the method described in WO 2010/42877 in diethyl ether (1 mL) was added thereto, and the mixture was stirred under heating to reflux. After confirmation that the color of iodine disappeared, a solution of (11Z,14Z)-2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienal (0.160 g, 0.268 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 in diethyl ether (1 mL) was added thereto, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=99/1 to 85/15) to obtain (6Z,9Z,29Z,32Z)-20-((dimethylamino)methyl)-20-((9Z,12Z)-octadeca-9,12-dien-1-yl)octatriaconta-6,9,29,32-tetraen-19-ol (0.0470 g, 0.0550 mmol, yield: 21%).</div>
    </li> <li> <para-num num="[1039]"> </para-num> <div id="p-1293" num="1039" class="description-line">ESI-MS m/z: 848 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1040]"> </para-num> <div id="p-1294" num="1040" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1041]"> </para-num> <div id="p-1295" num="1041" class="description-line">The title compound (0.0012 g, 0.0013 mmol, yield: 2%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (6Z,9Z,29Z,32Z)-20-((dimethylamino)methyl)-20-((9Z,12Z)-octadeca-9,12-dien-1-yl)octatriaconta-6,9,29,32-tetraen-19-ol (0.047 g, 0.055 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3.</div>
    </li> <li> <para-num num="[1042]"> </para-num> <div id="p-1296" num="1042" class="description-line">ESI-MS m/z: 863 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.17-1.40 (m, 58H), 1.54-1.65 (m, 2H), 2.05 (q, J=6.8 Hz, 12H), 2.77 (t, J=6.5 Hz, 6H), 3.29 (d, J=14.4 Hz, 1H), 3.51 (s, 9H), 3.56 (d, J=14.2 Hz, 1H), 3.62-3.70 (m, 1H), 5.29-5.42 (m, 12H).</div>
    </li> <heading id="h-0055">Reference Example A22</heading>
    <heading id="h-0056">(11Z,14Z)N,N,N-Trimethyl-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)-2-(((9Z,12Z)-octadeca-9,12-dienyloxy)carbonyl)icosa-11,14-dien-1-aminium chloride (Compound II-15)</heading>
    <li> <para-num num="[1043]"> </para-num> <div id="p-1297" num="1043" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1044]"> </para-num> <div id="p-1298" num="1044" class="description-line">tert-Butyl ((11Z,14Z)-2-(hydroxymethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-yl)carbamate (0.300 g, 0.448 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A20 was dissolved in acetone (2 mL). To the solution, Jones reagent (manufactured by Sigma-Aldrich Corp., 2 mol/L, 0.224 mL, 0.448 mmol) was added under ice cooling, and the mixture was then stirred at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5 to 50/50) to obtain (11Z,14Z)-2-(((tert-butoxycarbonyl)amino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoic acid (0.136 g, 0.198 mmol, yield: 44%).</div>
    </li> <li> <para-num num="[1045]"> </para-num> <div id="p-1299" num="1045" class="description-line">ESI-MS m/z: 684 (MH)<sup></sup>.</div>
    </li> <li> <para-num num="[1046]"> </para-num> <div id="p-1300" num="1046" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1047]"> </para-num> <div id="p-1301" num="1047" class="description-line">(11Z,14Z)-(9Z,12Z)-Octadeca-9,12-dien-1-yl 2-(((tert-butoxycarbonyl)amino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoate (0.123 g, 0.132 mmol, yield: 75%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A20 using (11Z,14Z)-2-(((tert-butoxycarbonyl)amino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoic acid (0.120 g, 0.175 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 and (9Z,12Z)-octadeca-9,12-dien-1-ol (manufactured by Nu-Chek Prep, Inc., 0.0930 g, 0.350 mmol).</div>
    </li> <li> <para-num num="[1048]"> </para-num> <div id="p-1302" num="1048" class="description-line">ESI-MS m/z: 935 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1049]"> </para-num> <div id="p-1303" num="1049" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1050]"> </para-num> <div id="p-1304" num="1050" class="description-line">(11Z,14Z)-(9Z,12Z)-Octadeca-9,12-dien-1-yl 2-(((tert-butoxycarbonyl)amino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoate (0.123 g, 0.132 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 was dissolved in dichloromethane (1 mL). To the solution, trifluoroacetic acid (0.300 mL, 3.89 mmol) was added under ice cooling, and the mixture was stirred for 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=99/1 to 80/20) to obtain (11Z,14Z)-(9Z,12Z)-octadeca-9,12-dien-1-yl 2-(aminomethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoate (0.110 g, 0.132 mmol, yield: 100%).</div>
    </li> <li> <para-num num="[1051]"> </para-num> <div id="p-1305" num="1051" class="description-line">ESI-MS m/z: 835 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1052]"> </para-num> <div id="p-1306" num="1052" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1053]"> </para-num> <div id="p-1307" num="1053" class="description-line">(11Z,14Z)-(9Z,12Z)-Octadeca-9,12-dien-1-yl 2-((dimethylaminomethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl) icosa-11,14-dienoate (0.0720 g, 0.0830 mmol, yield: 63%) was obtained in the same way as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A21 using (11Z,14Z)-(9Z,12Z)-octadeca-9,12-dien-1-yl 2-(aminomethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl) icosa-11,14-dienoate (0.110 g, 0.132 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3.</div>
    </li> <li> <para-num num="[1054]"> </para-num> <div id="p-1308" num="1054" class="description-line">ESI-MS m/z: 862 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1055]"> </para-num> <div id="p-1309" num="1055" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1056]"> </para-num> <div id="p-1310" num="1056" class="description-line">The title compound (0.052 g, 0.057 mmol, yield: 68%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (11Z,14Z)-(9Z,12Z)-octadeca-9,12-dien-1-yl 2-((dimethylaminomethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl) icosa-11,14-dienoate (0.072 g, 0.083 mmol) obtained in step 4.</div>
    </li> <li> <para-num num="[1057]"> </para-num> <div id="p-1311" num="1057" class="description-line">ESI-MS m/z: 877 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.09-1.42 (m, 52H), 1.52-1.81 (m, 6H), 2.05 (q, J=6.8 Hz, 12H), 2.77 (t, J=6.6 Hz, 6H), 3.46 (s, 9H), 3.79 (s, 2H), 4.14 (t, J=6.8 Hz, 2H), 5.28-5.43 (m, 12H).</div>
    </li> <heading id="h-0057">Reference Example A23</heading>
    <heading id="h-0058">(11Z,14Z)N,N,N-Trimethyl-2,2-bis(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)icosa-11,14-dien-1-aminium chloride (Compound II-16)</heading>
    <li> <para-num num="[1058]"> </para-num> <div id="p-1312" num="1058" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1059]"> </para-num> <div id="p-1313" num="1059" class="description-line">Dimethyl malonate (manufactured by Tokyo Chemical Industry Co., Ltd., 1.00 g, 7.57 mmol) was dissolved in acetonitrile (20 mL). To the solution, (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (2.61 g, 7.57 mmol), cesium carbonate (manufactured by Wako Pure Chemical Industries Ltd., 4.93 g, 15.1 mmol) and tetra-n-butylammonium iodide (2.80 g, 7.57 mmol) were added, and the mixture was stirred overnight at 50 C. Water was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=90/10 to 70/30) to obtain dimethyl 2-((9Z,12Z)-octadeca-9,12-dien-1-yl)malonate (1.22 g, 3.21 mmol, yield: 42%).</div>
    </li> <li> <para-num num="[1060]"> </para-num> <div id="p-1314" num="1060" class="description-line">ESI-MS m/z: 381 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1061]"> </para-num> <div id="p-1315" num="1061" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1062]"> </para-num> <div id="p-1316" num="1062" class="description-line">Dimethyl 2-((9Z,12Z)-octadeca-9,12-dien-1-yl)malonate (0.200 g, 0.526 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in acetonitrile (3 mL). To the solution, N,N,N,N-tetramethyldiaminomethane (manufactured by Tokyo Chemical Industry Co., Ltd., 0.0860 mL, 0.631 mmol) and acetic anhydride (0.0600 mL, 0.631 mmol) were added. Then, sodium hydride (60% oil, 0.0320 g, 0.788 mmol) was added thereto under ice cooling, and the mixture was stirred at room temperature for 3 hours. A saturated aqueous solution of ammonium chloride was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=100/0 to 60/40) to obtain dimethyl 2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)malonate (0.0660 g, 0.151 mmol, yield: 29%).</div>
    </li> <li> <para-num num="[1063]"> </para-num> <div id="p-1317" num="1063" class="description-line">ESI-MS m/z: 438 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1064]"> </para-num> <div id="p-1318" num="1064" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1065]"> </para-num> <div id="p-1319" num="1065" class="description-line">2-((Dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)propane-1,3-diol (0.013 g, 0.034 mmol, yield: 23%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A19 using dimethyl 2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)malonate (0.066 g, 0.15 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2.</div>
    </li> <li> <para-num num="[1066]"> </para-num> <div id="p-1320" num="1066" class="description-line">ESI-MS m/z: 382 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1067]"> </para-num> <div id="p-1321" num="1067" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1068]"> </para-num> <div id="p-1322" num="1068" class="description-line">(9Z,9Z,12Z,12)-2-((Dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)propane-1,3-diyl bis(octadeca-9,12-dienoate (0.017 g, 0.019 mmol, yield: 56%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A20 using 2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)propane-1,3-diol (0.013 g, 0.034 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3.</div>
    </li> <li> <para-num num="[1069]"> </para-num> <div id="p-1323" num="1069" class="description-line">ESI-MS m/z: 906 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1070]"> </para-num> <div id="p-1324" num="1070" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1071]"> </para-num> <div id="p-1325" num="1071" class="description-line">The title compound (5.5 mg, 0.0058 mmol, yield: 31%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (9Z,9Z,12Z,12Z)-2-((dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl) propane-1,3-diyl bis(octadeca-9,12-dienoate (0.017 g, 0.019 mmol) obtained in step 4.</div>
    </li> <li> <para-num num="[1072]"> </para-num> <div id="p-1326" num="1072" class="description-line">ESI-MS m/z: 921 (M)<sup>+</sup>. <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.23-1.40 (m, 48H), 1.53-1.65 (m, 4H), 2.05 (q, J=6.9 Hz, 12H), 2.38 (t, J=7.6 Hz, 4H), 2.77 (t, J=6.6 Hz, 6H), 3.59 (s, 9H), 3.72 (s, 2H), 4.20 (dd, J=22.1, 12.2 Hz, 4H), 5.28-5.44 (m, 12H).</div>
    </li> <heading id="h-0059">Reference Example A24</heading>
    <heading id="h-0060">N,N,N-Trimethyl-3-((9Z,12Z)-octadeca-9,12-dienoyloxy)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propan-1-aminium chloride (Compound II-17)</heading>
    <li> <para-num num="[1073]"> </para-num> <div id="p-1327" num="1073" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1074]"> </para-num> <div id="p-1328" num="1074" class="description-line">To 2-(bromomethyl)-2-(hydroxymethyl)propane-1,3-diol (0.200 g, 1.01 mmol), dimethylamine (manufactured by Sigma-Aldrich Corp., 2.0 mol/L solution in tetrahydrofuran, 5.02 mL, 10.1 mmol) was added, and the mixture was stirred at 120 C. for 15 hours under microwave irradiation. Lithium hydroxide monohydrate (0.0290 g, 1.21 mmol) was added to the reaction solution, and the resulting precipitate was filtered off. The filtrate was concentrated under reduced pressure to obtain a crude product of 2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diol (0.200 g, 1.23 mmol, quantitative).</div>
    </li> <li> <para-num num="[1075]"> </para-num> <div id="p-1329" num="1075" class="description-line">ESI-MS m/z: 164 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1076]"> </para-num> <div id="p-1330" num="1076" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1077]"> </para-num> <div id="p-1331" num="1077" class="description-line">The title compound (0.0470 g, 0.047 mmol overall yield: 4.4%) was obtained in the same way as in Reference Example A8 using the crude product of 2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diol (0.200 g, 1.23 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[1078]"> </para-num> <div id="p-1332" num="1078" class="description-line">ESI-MS m/z: 965 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.85-0.94 (m, 9H), 1.24-1.40 (m, 42H), 1.53-1.63 (m, 6H), 2.00-2.10 (m, 12H), 2.38 (t, J=6.9 Hz, 6H), 2.77 (t, J=6.5 Hz, 6H), 3.64 (s, 9H), 3.95 (s, 2H), 4.30 (s, 6H), 5.27-5.43 (m, 12H).</div>
    </li> <heading id="h-0061">Reference Example A25</heading>
    <heading id="h-0062">N,N,N-Trimethyl-3-(oleoyloxy)-2,2-bis(oleoyloxymethyl)propan-1-aminium chloride (Compound II-18)</heading>
    <li> <para-num num="[1079]"> </para-num> <div id="p-1333" num="1079" class="description-line">The title compound (0.663 g, 0.658 mmol, overall yield: 28%) was obtained in the same way as in Reference Example A8 using oleic acid instead of (9Z,12Z)-octadeca-9,12-dienoic acid used in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A8.</div>
    </li> <li> <para-num num="[1080]"> </para-num> <div id="p-1334" num="1080" class="description-line">ESI-MS m/z: 971 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.22-1.38 (m, 60H), 1.55-1.65 (m, 6H), 2.01 (q, J=5.9 Hz, 12H), 2.38 (t, J=7.6 Hz, 6H), 3.64 (s, 9H), 3.98 (s, 2H), 4.29 (s, 6H), 5.29-5.39 (m, 6H).</div>
    </li> <heading id="h-0063">Reference Example A26</heading>
    <heading id="h-0064">N,N,N-Trimethyl-3-((9Z,12Z)-octadeca-9,12-dienyloxy)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-1-aminium chloride (Compound IT-19)</heading>
    <li> <para-num num="[1081]"> </para-num> <div id="p-1335" num="1081" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1082]"> </para-num> <div id="p-1336" num="1082" class="description-line">To dimethylamine (approximately 2 mol/L solution in tetrahydrofuran, 15.0 mL, 30.0 mmol), 2-(bromomethyl)-2-(hydroxymethyl)propane-1,3-diol (1.52 g, 7.56 mmol) was added, and the mixture was stirred under heating at 120 C. for 15 hours using a microwave reaction apparatus. After cooling to room temperature, lithium hydroxide (0.217 g, 9.07 mmol) was added to the reaction solution, and the mixture was filtered and concentrated under reduced pressure to obtain a crude product of 2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diol.</div>
    </li> <li> <para-num num="[1083]"> </para-num> <div id="p-1337" num="1083" class="description-line">To the obtained crude product, toluene (30 mL), (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (6.51 g, 18.9 mmol) and sodium hydride (60% oil, 0.756 g, 18.9 mmol) were added, and the mixture was stirred overnight under heating to reflux. After cooling to room temperature, a saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with hexane. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=100/0 to 90/10) to obtain N,N-dimethyl-3-((9Z,12Z)-octadeca-9,12-dienyloxy)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-1-amine (0.196 g, 0.216 mmol, 3%) and 3-(dimethylamino)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-1-ol (1.80 g, 2.73 mmol, yield: 36%). N,N-Dimethyl-3-((9Z,12Z)-octadeca-9,12-dienyloxy)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-1-amine</div>
    </li> <li> <para-num num="[1084]"> </para-num> <div id="p-1338" num="1084" class="description-line">ESI-MS m/z: 909 (M+H)<sup>+</sup>. 3-(Dimethylamino)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-1-ol</div>
    </li> <li> <para-num num="[1085]"> </para-num> <div id="p-1339" num="1085" class="description-line">ESI-MS m/z: 661 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1086]"> </para-num> <div id="p-1340" num="1086" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1087]"> </para-num> <div id="p-1341" num="1087" class="description-line">To a solution of N,N-dimethyl-3-((9Z,12Z)-octadeca-9,12-dienyloxy)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-1-amine (0.120 g, 0.132 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in chloroform (1 mL), methyl iodide (0.500 mL) was added, and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (Amberlite IRA-400, Cl type, approximately 20-fold amount, prewashed with water and ethanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 90/10) to obtain the title compound (0.0654 g, 0.0682 mmol, yield: 57%).</div>
    </li> <li> <para-num num="[1088]"> </para-num> <div id="p-1342" num="1088" class="description-line">ESI-MS m/z: 923 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.8 Hz, 9H), 1.22-1.40 (m, 1H), 1.49-1.59 (m, 6H), 2.05 (q, J=6.9 Hz, 12H), 2.77 (t, J=6.7 Hz, 6H), 3.37 (t, J=6.6 Hz, 6H), 3.45 (s, 6H), 3.55 (s, 9H), 3.58 (s, 2H), 5.28-5.42 (m, 12H).</div>
    </li> <heading id="h-0065">Reference Example A27</heading>
    <heading id="h-0066">N,N,N-Trimethyl-3-((9Z,12Z)-octadeca-9,12-dienoyloxy)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-1-aminium chloride (Compound II-20)</heading>
    <li> <para-num num="[1089]"> </para-num> <div id="p-1343" num="1089" class="description-line">To a solution of 3-(dimethylamino)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propan-1-ol (0.265 g, 0.401 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A26 in 1,2-dichloroethane (4 mL), (9Z,12Z)-octadeca-9,12-dienoic acid (0.169 g, 0.602 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.154 g, 0.802 mmol) and N,N-dimethylaminopyridine (0.0250 g, 0.201 mmol) were added, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5 to 90/10) to obtain a crude product of (9Z,12Z)-3-(dimethylamino)-2,2-bis(((9Z,12Z)-octadeca-9,12-dienyloxy)methyl)propyl octadeca-9,12-dienoate.</div>
    </li> <li> <para-num num="[1090]"> </para-num> <div id="p-1344" num="1090" class="description-line">To the obtained crude product, chloroform (2 mL) and methyl iodide (manufactured by Tokyo Chemical Industry Co., Ltd., 1.00 mL) were added, and the mixture was stirred at room temperature for 5 hours. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (manufactured by Sigma-Aldrich Corp., Amberlite IRA-400, Cl type, approximately 20-fold amount, prewashed with water and ethanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 90/10) to obtain the title compound (0.220 g, 0.226 mmol, yield: 56%).</div>
    </li> <li> <para-num num="[1091]"> </para-num> <div id="p-1345" num="1091" class="description-line">ESI-MS m/z: 937 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.22-1.41 (m, 51H), 1.50-1.66 (m, 6H), 2.05 (q, J=6.9 Hz, 12H), 2.38 (t, J=7.5 Hz, 2H), 2.77 (t, J=6.1 Hz, 6H), 3.39 (t, J=6.6 Hz, 4H), 3.44-3.48 (m, 2H), 3.54-3.58 (m, 11H), 3.73 (s, 2H), 4.18 (s, 2H), 5.28-5.43 (m, 11H).</div>
    </li> <heading id="h-0067">Reference Example A28</heading>
    <heading id="h-0068">N,N, N-Trimethyl-4-(2-(9Z,12Z)-octadeca-9,12-dienamido-3-((9Z,12Z)-octadeca-9,12-dienoyloxy)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propoxy)-4-oxybutan-1-aminium chloride (Compound II-21)</heading>
    <li> <para-num num="[1092]"> </para-num> <div id="p-1346" num="1092" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1093]"> </para-num> <div id="p-1347" num="1093" class="description-line">To a solution of tert-butyl (1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)carbamate (manufactured by Key Organics Ltd., 0.505 g, 2.28 mmol) in dichloromethane (15 mL), (9Z,12Z)-octadeca-9,12-dienoic acid (3.23 g, 11.4 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (2.19 g, 11.4 mmol) and N,N-dimethylaminopyridine (0.279 g, 2.28 mmol) were added, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/chloroform=100/0 to 95/5) to obtain (9Z,9Z,12Z,12Z)-2-(tert-butoxycarbonylamino-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propane-1,3-diyl dioctadeca-9,12-dienoate (2.08 g, 2.06 mmol, yield: 90%).</div>
    </li> <li> <para-num num="[1094]"> </para-num> <div id="p-1348" num="1094" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.7 Hz, 9H), 1.23-1.40 (m, 9H), 1.43 (s, 9H), 1.57-1.66 (m, 14H), 2.05 (q, J=6.8 Hz, 12H), 2.32 (t, J=7.6 Hz, 6H), 2.77 (t, J=6.5 Hz, 6H), 4.34 (s, 6H), 4.81 (br s, 1H), 5.28-5.43 (m, 12H).</div>
    </li> <li> <para-num num="[1095]"> </para-num> <div id="p-1349" num="1095" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1096]"> </para-num> <div id="p-1350" num="1096" class="description-line">To a solution of (9Z,9Z,12Z,12Z)-2-(tert-butoxycarbonylamino-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propane-1,3-diyl dioctadeca-9,12-dienoate (2.05 g, 2.03 mmol, 90%) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in dichloromethane (10 mL), trifluoroacetic acid (2 mL, 26.0 mmol) was added, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=100/0 to 95/5) to obtain (9Z,9Z,12Z,12Z)-2-(hydroxymethyl)-2-(9Z,12Z)-octadeca-9,12-dienamidopropane-1,3-diyl dioctadeca-9,12-dienoate (1.70 g, 1.84 mmol, yield: 91%).</div>
    </li> <li> <para-num num="[1097]"> </para-num> <div id="p-1351" num="1097" class="description-line">ESI-MS m/z: 909 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1098]"> </para-num> <div id="p-1352" num="1098" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1099]"> </para-num> <div id="p-1353" num="1099" class="description-line">To a solution of (9Z,9Z,12Z,12Z)-2-(hydroxymethyl)-2-(9Z,12Z)-octadeca-9,12-dienamidopropane-1,3-diyl dioctadeca-9,12-dienoate (0.8933 g, 0.983 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 in dichloromethane (9 mL), (9Z,12Z)-octadeca-9,12-dienoic acid (manufactured by Sigma-Aldrich Corp., 2.37 g, 8.45 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.62 g, 8.45 mmol) and N,N-dimethylaminopyridine (0.206 g, 1.69 mmol) were added, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=90/10 to 75/25) to obtain (9Z,9Z,12Z,12Z)-2-((4-(dimethylamino)butanoyloxy)methyl)-2-(9Z,12Z)-octadeca-9,12-dienamidopropane-1,3-diyl dioctadeca-9,12-dienoate (0.900 g, 0.881 mmol, yield: 90%).</div>
    </li> <li> <para-num num="[1100]"> </para-num> <div id="p-1354" num="1100" class="description-line">ESI-MS m/z: 1022 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1101]"> </para-num> <div id="p-1355" num="1101" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1102]"> </para-num> <div id="p-1356" num="1102" class="description-line">To a solution of (9Z,9Z,12Z,12Z)-2-((4-(dimethylamino)butanoyloxy)methyl)-2-(9Z,12Z)-octadeca-9,12-dienamidopropane-1,3-diyl dioctadeca-9,12-dienoate (0.805 g, 0.788 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 in chloroform (4 mL), methyl iodide (0.493 mL) was added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (<figure-callout id="1" label="DowexTM" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Dowex</figure-callout> 1-2 100 mesh, Cl type, approximately 20-fold amount, prewashed with water and methanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=90/10 to 80/20) to obtain the title compound (0.740 g, 0.690 mmol, yield: 88%).</div>
    </li> <li> <para-num num="[1103]"> </para-num> <div id="p-1357" num="1103" class="description-line">ESI-MS m/z: 1036 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.4 Hz, 9H), 1.21-1.40 (m, 45H), 1.54-1.65 (m, 6H), 2.01-2.08 (m, 12H), 2.09-2.19 (m, 2H), 2.24 (t, J=7.4 Hz, 2H), 2.32 (t, J=7.5 Hz, 4H), 2.57 (t, J=6.2 Hz, 2H), 2.77 (t, J=6.3 Hz, 6H), 3.41 (s, 9H), 3.84 (t, J=8.3 Hz, 2H), 4.37-4.50 (m, 6H), 5.28-5.43 (m, 12H), 6.72 (br s, 1H).</div>
    </li> <heading id="h-0069">Reference Example A29</heading>
    <heading id="h-0070">4-(1,3-Bis((9Z,12Z)-octadeca-9,12-dienoyloxy)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propan-2-ylamino)-N,N,N-trimethyl-4-oxobutan-1-aminium chloride (Compound II-22)</heading>
    <li> <para-num num="[1104]"> </para-num> <div id="p-1358" num="1104" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1105]"> </para-num> <div id="p-1359" num="1105" class="description-line">To a solution of 2-amino-2-(hydroxymethyl)-1,3-propanediol (manufactured by Wako Pure Chemical Industries Ltd., 7.41 g, 61.2 mmol) in dichloromethane (60 mL), tert-butyldimethylsilyl chloride (manufactured by Sigma-Aldrich Corp., 9.43 g, 60.7 mmol) and imidazole (manufactured by Nacalai Tesque, Inc., 5.51 g, 80.9 mmol) were added, and the mixture was stirred overnight at room temperature. Saturated saline was added to the reaction solution, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=100/0 to 95/5) to obtain 6-((tert-butyldimethylsilyloxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-amine (3.80 g, 8.19 mmol, yield: 40%).</div>
    </li> <li> <para-num num="[1106]"> </para-num> <div id="p-1360" num="1106" class="description-line">ESI-MS m/z: 464 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1107]"> </para-num> <div id="p-1361" num="1107" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1108]"> </para-num> <div id="p-1362" num="1108" class="description-line">To a solution of 6-((tert-butyldimethylsilyloxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-amine (1.28 g, 2.76 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in dichloromethane (10 mL), 4-(dimethylamino)butyric acid hydrochloride (manufactured by Sigma-Aldrich Corp., 0.708 g, 4.14 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.810 g, 4.14 mmol), N,N-dimethylaminopyridine (0.0170 g, 0.138 mmol) and N,N-diisopropylethylamine (1.45 mL, 8.31 mmol) were added, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=95/5 to 90/10) to obtain N-(6-((tert-butyldimethylsilyloxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-yl)-4-(dimethylamino)butanamide (1.22 g, 2.11 mmol, yield: 76%).</div>
    </li> <li> <para-num num="[1109]"> </para-num> <div id="p-1363" num="1109" class="description-line">ESI-MS m/z: 578 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1110]"> </para-num> <div id="p-1364" num="1110" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1111]"> </para-num> <div id="p-1365" num="1111" class="description-line">To a solution of N-(6-((tert-butyldimethylsilyloxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecan-6-yl)-4-(dimethylamino)butanamide (1.08 g, 1.87 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 in tetrahydrofuran (10 mL), tetrabutylammonium fluoride (manufactured by Tokyo Chemical Industry Co., Ltd., approximately 1 mol/L solution in tetrahydrofuran, 7.49 mL, 7.49 mmol) was added, and the mixture was stirred at room temperature for 2 hours. (9Z,12Z)Octadeca-9,12-dienoic acid (2.05 g, 7.31 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.44 g, 7.51 mmol) and N,N-dimethylaminopyridine (0.0340 g, 0.278 mmol) were added to the reaction solution, and the mixture was stirred overnight at room temperature. The reaction mixture was concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=60/40 to 50/50) to obtain (9Z,9Z,12Z,12Z)-2-(4-(dimethylamino)butanamido)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propane-1,3-diyl dioctadeca-9,12-dienoate (0.405 g, 0.396 mmol, yield: 21%).</div>
    </li> <li> <para-num num="[1112]"> </para-num> <div id="p-1366" num="1112" class="description-line">ESI-MS m/z: 1022 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1113]"> </para-num> <div id="p-1367" num="1113" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1114]"> </para-num> <div id="p-1368" num="1114" class="description-line">To a solution of (9Z,9Z,12Z,12Z)-2-(4-(dimethylamino)butanamido)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propane-1,3-diyl dioctadeca-9,12-dienoate (0.335 g, 0.328 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 in chloroform (3 mL), methyl iodide (manufactured by Tokyo Chemical Industry Co., Ltd., 0.200 mL) was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (<figure-callout id="1" label="DowexTM" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Dowex</figure-callout> 1-2 100 mesh, Cl type, approximately 20-fold amount, prewashed with water and methanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=90/10 to 80/20) to obtain the title compound (0.324 g, 0.302 mmol, yield: 92%).</div>
    </li> <li> <para-num num="[1115]"> </para-num> <div id="p-1369" num="1115" class="description-line">ESI-MS m/z: 1036 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.23-1.40 (m, 45H), 1.55-1.64 (m, 6H), 2.01-2.12 (m, 14H), 2.34 (t, J=7.6 Hz, 6H), 2.43 (t, J=6.3 Hz, 2H), 2.77 (t, J=6.6 Hz, 6H), 3.37 (s, 9H), 3.77-3.83 (m, 2H), 4.43 (s, 6H), 5.28-5.42 (m, 12H), 6.62 (br s, 1H).</div>
    </li> <heading id="h-0071">Reference Example A30</heading>
    <heading id="h-0072">2-(1,3-Bis((9Z,12Z)-octadeca-9,12-dienoyloxy)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propan-2-ylamino)-N,N,N-trimethyl-2-oxoethanaminium chloride (Compound II-23)</heading>
    <li> <para-num num="[1116]"> </para-num> <div id="p-1370" num="1116" class="description-line">The title compound (0.356 g, 0.341 mmol, overall yield: 17%) was obtained in the same way as in Reference Example A29 using N,N-dimethylglycine (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of 4-(dimethylamino)butyric acid hydrochloride.</div>
    </li> <li> <para-num num="[1117]"> </para-num> <div id="p-1371" num="1117" class="description-line">ESI-MS m/z: 1008 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.23-1.40 (m, 44H), 1.54-1.64 (m, 26H), 2.01-2.08 (m, 12H), 2.35 (t, J=7.6 Hz, 6H), 2.77 (t, J=6.8 Hz, 6H), 3.40 (s, 9H), 4.46 (s, 6H), 4.70 (s, 2H), 5.28-5.42 (m, 12H), 9.54 (br s, 1H).</div>
    </li> <heading id="h-0073">Reference Example A31</heading>
    <heading id="h-0074">4-((6Z,9Z,29Z,32Z)-20-Hydroxy-20-((9Z,12Z)-octadeca-9,12-dienyl)octatriaconta-6,9,29,32-tetraen-19-yloxy)-N,N,N-trimethyl-4-oxobutan-1-aminium chloride (Compound III-1)</heading>
    <li> <para-num num="[1118]"> </para-num> <div id="p-1372" num="1118" class="description-line">The title compound (0.146 g, 0.150 mmol, yield: 96%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (6Z,9Z,29Z,32Z)-20-hydroxy-20-((9Z,12Z)-octadeca-9,12-dienyl)octatriaconta-6,9,29,32-tetraen-19-yl 4-(dimethylamino)butanoate (0.144 g, 0.156 mmol) obtained by a method equivalent to the method described in U.S. Patent Application Publication No. 2012/0172411.</div>
    </li> <li> <para-num num="[1119]"> </para-num> <div id="p-1373" num="1119" class="description-line">ESI-MS m/z: 935 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.9 Hz, 9H), 1.16-1.79 (m, 60H), 1.98-2.17 (m, 15H), 2.52-2.59 (m, 2H), 2.77 (t, J=6.6 Hz, 6H), 3.44 (s, 9H), 3.69-3.81 (m, 2H), 4.94-4.98 (m, 1H), 5.29-5.42 (m, 12H).</div>
    </li> <heading id="h-0075">Reference Example A32</heading>
    <heading id="h-0076">(6Z,9Z,28Z,31Z)N,N-Dimethyl-N-((9Z,12Z)-octadeca-9,12-dienyl)heptatriaconta-6,9,28,31-tetraen-19-aminium chloride (Compound IV-1)</heading>
    <li> <para-num num="[1120]"> </para-num> <div id="p-1374" num="1120" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1121]"> </para-num> <div id="p-1375" num="1121" class="description-line">To a solution of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-one (0.194 g, 0.368 mmol) obtained by a method equivalent to the method described in WO 2010/042877 in 1,2-dichloroethane (2 mL), methylamine (manufactured by Tokyo Chemical Industry Co., Ltd., approximately 40% solution in methanol, 0.110 mL, 1.1 mmol) and acetic acid (0.063 mL, 1.1 mmol) were added. Sodium triacetoxyborohydride (0.117 g, 0.552 mmol) was further added thereto, and the mixture was then stirred at room temperature for 2 hours. Methylamine (approximately 40% solution in methanol, 0.110 mL, 1.1 mmol), acetic acid (0.063 mL, 1.1 mmol), and sodium triacetoxyborohydride (0.117 g, 0.552 mmol) were added to the reaction solution, and the mixture was stirred for 2 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with hexane twice. The organic layers were combined, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by column chromatography (chloroform/methanol=100/0 to 90/10) to obtain (6Z,9Z,28Z,31Z)N-methylheptatriaconta-6,9,28,31-tetraen-19-amine (0.121 g, 0.223 mmol, yield: 61%).</div>
    </li> <li> <para-num num="[1122]"> </para-num> <div id="p-1376" num="1122" class="description-line">ESI-MS m/z: 543 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1123]"> </para-num> <div id="p-1377" num="1123" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1124]"> </para-num> <div id="p-1378" num="1124" class="description-line">To (6Z,9Z,28Z,31Z)N-methylheptatriaconta-6,9,28,31-tetraen-19-amine (0.121 g, 0.223 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1, (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (0.154 g, 0.446 mmol) and a 50% aqueous sodium hydroxide solution (0.107 g, 1.34 mmol) were added, and the mixture was stirred at 135 C. for 2 hours in an oil bath. The reaction solution was cooled to room temperature. Saturated saline was added thereto, and the mixture was washed with hexane. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=100/0 to 85/15) to obtain (6Z,9Z,28Z,31Z)N-methyl-N-((9Z,12Z)-octadeca-9,12-dienyl)heptatriaconta-6,9,28,31-tetraen-19-amine (0.139 g, 0.175 mmol, yield: 79%).</div>
    </li> <li> <para-num num="[1125]"> </para-num> <div id="p-1379" num="1125" class="description-line">ESI-MS m/z: 792 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1126]"> </para-num> <div id="p-1380" num="1126" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1127]"> </para-num> <div id="p-1381" num="1127" class="description-line">The title compound (0.114 g, 0.135 mmol, yield: 77%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (6Z,9Z,28Z,31Z)N-methyl-N-((9Z,12Z)-octadeca-9,12-dienyl)heptatriaconta-6,9,28,31-tetraen-19-amine (0.139 g, 0.175 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2.</div>
    </li> <li> <para-num num="[1128]"> </para-num> <div id="p-1382" num="1128" class="description-line">ESI-MS m/z: 806 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.26-1.56 (m, 54H), 1.65-1.73 (m, 2H), 1.80-1.88 (m, 2H), 2.05 (q, J=7.0 Hz, 12H), 2.77 (t, J=6.3 Hz, 6H), 3.22-3.27 (m, 1H), 3.31 (s, 6H), 3.58-3.62 (m, 2H), 5.29-5.42 (m, 12H).</div>
    </li> <heading id="h-0077">Reference Example A33</heading>
    <heading id="h-0078">N,N,N-Trimethyl-3-(palmitoyloxy)-2,2-bis((palmitoyloxy)methyl)propan-1-aminium chloride (Compound II-24)</heading>
    <li> <para-num num="[1129]"> </para-num> <div id="p-1383" num="1129" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1130]"> </para-num> <div id="p-1384" num="1130" class="description-line">To a solution of 2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diol (0.420 g, 2.57 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A24 in 1,2-dichloroethane (5 mL), pyridine (3.12 mL, 38.6 mmol) was added, then palmitoyl chloride (manufactured by Tokyo Chemical Industry Co., Ltd., 6.22 mL, 20.6 mmol) was added at room temperature, and the mixture was stirred at 70 C. for 2 hours. The reaction solution was cooled to room temperature, and water was added thereto, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform) to obtain 2-((dimethylamino)methyl)-2-((palmitoyloxy)methyl)propane-1,3-diyl dipalmitate (0.650 g, 0.740 mmol, yield: 29%).</div>
    </li> <li> <para-num num="[1131]"> </para-num> <div id="p-1385" num="1131" class="description-line">ESI-MS m/z: 879 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1132]"> </para-num> <div id="p-1386" num="1132" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1133]"> </para-num> <div id="p-1387" num="1133" class="description-line">The title compound (0.056 g, 0.060 mmol, yield: 8%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-((dimethylamino)methyl)-2-((palmitoyloxy)methyl)propane-1,3-diyl dipalmitate (0.65 g, 0.74 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[1134]"> </para-num> <div id="p-1388" num="1134" class="description-line">ESI-MS m/z: 893 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.21-1.34 (m, 72H), 1.54-1.64 (m, 6H), 2.38 (t, J=7.6 Hz, 6H), 3.62 (s, 9H), 3.95 (s, 2H), 4.29 (s, 6H).</div>
    </li> <heading id="h-0079">Reference Example A34</heading>
    <heading id="h-0080">N,N,N-Trimethyl-3-(tetradecanoyloxy)-2,2-bis((tetradecanoyloxy)methyl)propan-1-aminium chloride (Compound II-25)</heading>
    <li> <para-num num="[1135]"> </para-num> <div id="p-1389" num="1135" class="description-line">The title compound (0.045 g, 0.053 mmol, overall yield: 4%) was obtained in the same way as in Reference Example A33 using myristoyl chloride (Wako Pure Chemical Industries Ltd.) instead of palmitoyl chloride.</div>
    </li> <li> <para-num num="[1136]"> </para-num> <div id="p-1390" num="1136" class="description-line">ESI-MS m/z: 809 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.21-1.34 (m, 60H), 1.54-1.64 (m, 6H), 2.38 (t, J=7.6 Hz, 6H), 3.64 (s, 9H), 3.96 (s, 2H), 4.29 (s, 6H).</div>
    </li> <heading id="h-0081">Reference Example A35</heading>
    <heading id="h-0082">3-(Dodecanoyloxy)-2,2-bis((dodecanoyloxy)methyl)-N,N,N-trimethylpropan-1-aminium chloride (Compound II-26)</heading>
    <li> <para-num num="[1137]"> </para-num> <div id="p-1391" num="1137" class="description-line">The title compound (0.085 g, 0.112 mmol, overall yield: 9%) was obtained in the same way as in Reference Example A33 using lauroyl chloride (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of palmitoyl chloride.</div>
    </li> <li> <para-num num="[1138]"> </para-num> <div id="p-1392" num="1138" class="description-line">ESI-MS m/z: 725 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.19-1.34 (m, 48H), 1.54-1.64 (m, 6H), 2.38 (t, J=7.6 Hz, 6H), 3.66 (s, 9H), 3.97 (s, 2H), 4.30 (s, 6H).</div>
    </li> <heading id="h-0083">Reference Example A36</heading>
    <heading id="h-0084">(Z)N,N,N-Trimethyl-3,3-bis((oleoyloxy)methyl)henicos-12-en-1-aminium chloride (Compound II-27)</heading>
    <li> <para-num num="[1139]"> </para-num> <div id="p-1393" num="1139" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1140]"> </para-num> <div id="p-1394" num="1140" class="description-line">Dimethyl malonate (1.00 g, 7.57 mmol) was dissolved in acetonitrile (25 mL). To the solution, (Z)-oct-9-en-1-yl methanesulfonate (3.15 g, 9.08 mmol), cesium carbonate (4.93 g, 15.1 mmol) and tetrabutylammonium iodide (3.35 g, 9.08 mmol) were added, and the mixture was stirred at 60 C. for 1 hour. Water was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=90/10 to 70/30) to obtain (Z)-dimethyl 2-(octadec-9-en-1-yl)malonate (2.54 g, 6.64 mmol, yield: 88%).</div>
    </li> <li> <para-num num="[1141]"> </para-num> <div id="p-1395" num="1141" class="description-line">ESI-MS m/z: 383 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1142]"> </para-num> <div id="p-1396" num="1142" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1143]"> </para-num> <div id="p-1397" num="1143" class="description-line">(Z)-Dimethyl 2-(octadec-9-en-1-yl)malonate (0.500 g, 1.31 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in toluene (6 mL). To the solution, sodium hydride (60% oil, 0.209 g, 5.23 mmol) was added under ice cooling, and the mixture was stirred until foaming disappeared. Subsequently, 2-chloro-N,N-dimethylethanamine hydrochloride (manufactured by Tokyo Chemical Industry Co., Ltd., 0.377 g, 2.61 mmol) was added thereto, and the mixture was stirred at 100 C. for 2 hours. Water was added to the reaction solution under ice cooling, followed by extraction with chloroform. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 90/10) to obtain (Z)-dimethyl 2-(2-(dimethylamino)ethyl)-2-(octadec-9-en-1-yl)malonate (0.258 g, 0.569 mmol, yield: 44%).</div>
    </li> <li> <para-num num="[1144]"> </para-num> <div id="p-1398" num="1144" class="description-line">ESI-MS m/z: 454 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1145]"> </para-num> <div id="p-1399" num="1145" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1146]"> </para-num> <div id="p-1400" num="1146" class="description-line">(Z)-2-(2-(Dimethylamino)ethyl)-2-(octadec-9-en-1-yl)propane-1,3-diol (0.220 g, 0.553 mmol, quantitative) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A19 using (Z)-dimethyl 2-(2-(dimethylamino)ethyl)-2-(octadec-9-en-1-yl)malonate (0.250 g, 0.551 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2.</div>
    </li> <li> <para-num num="[1147]"> </para-num> <div id="p-1401" num="1147" class="description-line">ESI-MS m/z: 398 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1148]"> </para-num> <div id="p-1402" num="1148" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1149]"> </para-num> <div id="p-1403" num="1149" class="description-line">(Z)-2-(2-(Dimethylamino)ethyl)-2-(octadec-9-en-1-yl)propane-1,3-diol (0.220 g, 0.553 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 was dissolved in dichloromethane (2 mL). To the solution, N,N-diisopropylethylamine (0.386 mL, 2.21 mmol) was added, then oleoyl chloride (manufactured by Sigma-Aldrich Corp., 0.457 mL, 1.38 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 10 minutes. Water was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=90/10 to 50/50) to obtain (Z)-2-(2-(dimethylamino)ethyl)-2-((Z)-octadec-9-en-1-yl)propane-1,3-diyl dioleate (0.280 g, 0.302 mmol, yield: 55%).</div>
    </li> <li> <para-num num="[1150]"> </para-num> <div id="p-1404" num="1150" class="description-line">ESI-MS m/z: 927 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1151]"> </para-num> <div id="p-1405" num="1151" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1152]"> </para-num> <div id="p-1406" num="1152" class="description-line">The title compound (0.199 g, 0.204 mmol, yield: 67%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (Z)-2-(2-(dimethylamino)ethyl)-2-((Z)-octadec-9-en-1-yl)propane-1,3-diyl dioleate (0.280 g, 0.302 mmol) obtained in step 4.</div>
    </li> <li> <para-num num="[1153]"> </para-num> <div id="p-1407" num="1153" class="description-line">ESI-MS m/z: 941 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.22-1.39 (m, 66H), 1.55-1.65 (m, 4H), 1.70-1.78 (m, 2H), 1.98-2.06 (m, 12H), 2.33 (t, J=7.6 Hz, 4H), 3.46 (s, 9H), 3.58-3.65 (m, 2H), 3.93-4.03 (m, 4H), 5.29-5.39 (m, 6H).</div>
    </li> <heading id="h-0085">Reference Example A37</heading>
    <heading id="h-0086">(Z)N,N,N-Trimethyl-4,4-bis((oleoyloxy)methyl)docos-13-en-1-aminium chloride (Compound II-28)</heading>
    <li> <para-num num="[1154]"> </para-num> <div id="p-1408" num="1154" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1155]"> </para-num> <div id="p-1409" num="1155" class="description-line">(Z)-Dimethyl 2-(3-(dimethylamino)propyl)-2-(octadec-9-en-1-yl)malonate (0.210 g, 0.449 mmol, yield: 34%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A36 using 3-chloro-N,N-dimethylpropan-1-amine hydrochloride (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of 2-chloro-N,N-dimethylethanamine hydrochloride.</div>
    </li> <li> <para-num num="[1156]"> </para-num> <div id="p-1410" num="1156" class="description-line">ESI-MS m/z: 468 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1157]"> </para-num> <div id="p-1411" num="1157" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1158]"> </para-num> <div id="p-1412" num="1158" class="description-line">The title compound (0.042 g, 0.042 mmol, overall yield: 9%) was obtained in the same way as in <figure-callout id="3" label="steps" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">steps</figure-callout> 3, 4 and 5 of Reference Example A36 using (Z)-dimethyl2-(3-(dimethylamino)propyl)-2-(octadec-9-en-1-yl)malonate (0.210 g, 0.449 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 instead of (Z)-dimethyl 2-(2-(dimethylamino)ethyl)-2-(octadec-9-en-1-yl)malonate.</div>
    </li> <li> <para-num num="[1159]"> </para-num> <div id="p-1413" num="1159" class="description-line">ESI-MS m/z: 955 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.22-1.36 (m, 68H), 1.56-1.64 (m, 4H), 1.72-1.82 (m, 2H), 1.96-2.07 (m, 12H), 2.32 (t, J=7.5 Hz, 4H), 3.38 (s, 9H), 3.39-3.46 (m, 2H), 3.93 (d, J=11.2 Hz, 2H), 3.99 (d, J=11.2 Hz, 2H), 5.28-5.40 (m, 6H).</div>
    </li> <heading id="h-0087">Reference Example A38</heading>
    <heading id="h-0088">N,N,N-Trimethyl-3-(stearoyloxy)-2,2-bis((stearoyloxy)methyl)propan-1-aminium chloride (Compound II-29)</heading>
    <li> <para-num num="[1160]"> </para-num> <div id="p-1414" num="1160" class="description-line">The title compound (0.085 g, 0.112 mmol, overall yield: 6%) was obtained in the same way as in Reference Example A33 using stearoyl chloride (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of palmitoyl chloride.</div>
    </li> <li> <para-num num="[1161]"> </para-num> <div id="p-1415" num="1161" class="description-line">ESI-MS m/z: 977 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.21-1.37 (m, 84H), 1.54-1.64 (m, 6H), 2.38 (t, J=7.6 Hz, 6H), 3.65 (s, 9H), 3.96 (s, 2H), 4.30 (s, 6H).</div>
    </li> <heading id="h-0089">Reference Example A39</heading>
    <heading id="h-0090">N,N,N-Trimethyl-3-oleamido-2,2-bis((oleoyloxy)methyl)propan-1-aminium chloride (Compound II-30)</heading>
    <li> <para-num num="[1162]"> </para-num> <div id="p-1416" num="1162" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1163]"> </para-num> <div id="p-1417" num="1163" class="description-line">2-((Dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diol (0.410 g, 2.51 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A24 was dissolved in a mixed solvent of dichloromethane (5 mL) and pyridine (5.08 mL, 62.8 mmol). To the solution, oleoyl chloride (1.25 mL, 3.77 mmol) was added under ice cooling. Water was added to the reaction solution, followed by extraction with chloroform. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 90/10) to obtain (Z)-2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diyl dioleate (0.190 g, 0.275 mmol, yield: 11%).</div>
    </li> <li> <para-num num="[1164]"> </para-num> <div id="p-1418" num="1164" class="description-line">ESI-MS m/z: 693 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1165]"> </para-num> <div id="p-1419" num="1165" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1166]"> </para-num> <div id="p-1420" num="1166" class="description-line">(Z)-2-((Dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diyl dioleate (0.190 g, 2.51 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in toluene (2 mL). To the solution, diphenylphosphoryl azide (manufactured by Tokyo Chemical Industry Co., Ltd., 0.118 mL, 0.549 mmol) and 1,8-diazabicyclo[5.4.0]-7-undecene (0.0830 mL, 0.549 mmol) were added at room temperature, and the mixture was stirred for 1 hour. Since the progression of the reaction was insufficient, diphenylphosphoryl azide (0.118 mL, 0.549 mmol) was further added thereto, and the mixture was stirred under heating at 80 C. for 3 hours. The reaction solution was cooled to room temperature, and water was added thereto, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5 to 60/40) to obtain (Z)-2-(azidomethyl)-2-((dimethylamino)methyl)propane-1,3-diyl dioleate (0.135 g, 0.188 mmol, yield: 69%).</div>
    </li> <li> <para-num num="[1167]"> </para-num> <div id="p-1421" num="1167" class="description-line">ESI-MS m/z: 718 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1168]"> </para-num> <div id="p-1422" num="1168" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1169]"> </para-num> <div id="p-1423" num="1169" class="description-line">(Z)-2-(Azidomethyl)-2-((dimethylamino)methyl)propane-1,3-diyl dioleate (0.135 g, 2.51 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 was dissolved in a mixed solution of tetrahydrofuran (1 mL) and water (0.1 mL). To the solution, triphenylphosphine (manufactured by Junsei Chemical Co., Ltd., 0.0740 g, 0.282 mmol) was added, and the mixture was stirred for 3 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain a crude product of (Z)-2-(aminoethyl)-2-((dimethylamino)methyl)propane-1,3-diyl dioleate (0.130 g, 0.188 mmol, yield: 100%).</div>
    </li> <li> <para-num num="[1170]"> </para-num> <div id="p-1424" num="1170" class="description-line">ESI-MS m/z: 691 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1171]"> </para-num> <div id="p-1425" num="1171" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1172]"> </para-num> <div id="p-1426" num="1172" class="description-line">To a solution of (Z)-2-(aminoethyl)-2-((dimethylamino)methyl)propane-1,3-diyl dioleate (0.130 g, 0.188 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 in dichloromethane (2 mL), N,N-diisopropylethylamine (0.0990 mL, 0.564 mmol) was added, then oleoyl chloride (0.0850 g, 0.282 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=97/3 to 60/40) to obtain (Z)-2-((dimethylamino)methyl)-2-(oleamidomethyl)propane-1,3-diyl dioleate (0.105 g, 0.110 mmol, yield: 58%).</div>
    </li> <li> <para-num num="[1173]"> </para-num> <div id="p-1427" num="1173" class="description-line">ESI-MS m/z: 956 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1174]"> </para-num> <div id="p-1428" num="1174" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1175]"> </para-num> <div id="p-1429" num="1175" class="description-line">The title compound (0.0480 g, 0.0480 mmol, yield: 43%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (Z)-2-((dimethylamino)methyl)-2-(oleamidomethyl)propane-1,3-diyl dioleate (0.105 g, 0.110 mmol) obtained in step 4.</div>
    </li> <li> <para-num num="[1176]"> </para-num> <div id="p-1430" num="1176" class="description-line">ESI-MS m/z: 970 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.21-1.37 (m, 60H), 1.56-1.65 (m, 6H), 1.96-2.05 (m, 12H), 2.36 (t, J=7.6 Hz, 6H), 3.51 (s, 9H), 3.51-3.56 (m, 2H), 4.02 (s, 2H), 4.20 (d, J=12.2 Hz, 2H), 4.30 (d, J=12.2 Hz, 2H), 5.27-5.40 (m, 6H), 8.11-8.20 (m, 1H).</div>
    </li> <heading id="h-0091">Reference Example A40</heading>
    <heading id="h-0092">N,N,N-Trimethyl-4-(oleoyloxy)-3,3-bis(oleoyloxymethyl)butan-1-aminium chloride (Compound II-31)</heading>
    <li> <para-num num="[1177]"> </para-num> <div id="p-1431" num="1177" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1178]"> </para-num> <div id="p-1432" num="1178" class="description-line">To a solution of 2-(bromomethyl)-2-(hydroxymethyl)propane-1,3-diol (manufactured by Tokyo Chemical Industry Co., Ltd., 1.00 g, 5.02 mmol) in tetrahydrofuran (10 mL), tert-butyldimethylchlorosilane (manufactured by Tokyo Chemical Industry Co., Ltd., 3.79 g, 25.1 mmol), imidazole (manufactured by Nacalai Tesque, Inc., 3.42 g, 50.2 mmol), and N,N-dimethylaminopyridine (0.061 g, 0.502 mmol) were added, and the mixture was stirred overnight at room temperature. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with hexane twice. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane) to obtain 6-(bromomethyl)-6-((tert-butyldimethylsilyloxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecane (2.50 g, 4.61 mmol, 92%).</div>
    </li> <li> <para-num num="[1179]"> </para-num> <div id="p-1433" num="1179" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.04 (s, 18H), 0.89 (s, 27H), 3.41 (s, 2H), 3.49 (s, 6H).</div>
    </li> <li> <para-num num="[1180]"> </para-num> <div id="p-1434" num="1180" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1181]"> </para-num> <div id="p-1435" num="1181" class="description-line">To a solution of 6-(bromomethyl)-6-((tert-butyldimethylsilyloxy)methyl)-2,2,3,3,9,9,10,10-octamethyl-4,8-dioxa-3,9-disilaundecane (1.849 g, 3.41 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in dimethyl sulfoxide (10 mL), sodium cyanide (manufactured by Nacalai Tesque, Inc., 0.529 g, 10.8 mmol) was added, and the mixture was stirred at 85 C. for 3 days. After cooling to room temperature, the reaction solution was diluted with hexane, washed with water and then saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=90/10) to obtain 4-(tert-butyldimethylsilyloxy)-3,3-bis((tert-butyldimethylsilyloxy)methyl)butanenitrile (1.35 g, 2.77 mmol, yield: 81%).</div>
    </li> <li> <para-num num="[1182]"> </para-num> <div id="p-1436" num="1182" class="description-line">ESI-MS m/z: 489 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.05 (s, 18H), 0.89 (s, 27H), 2.34 (s, 2H), 3.51 (s, 6H).</div>
    </li> <li> <para-num num="[1183]"> </para-num> <div id="p-1437" num="1183" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1184]"> </para-num> <div id="p-1438" num="1184" class="description-line">To a solution of 4-(tert-butyldimethylsilyloxy)-3,3-bis((tert-butyldimethylsilyloxy)methyl)butanenitrile (1.34 g, 2.75 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 in tetrahydrofuran (10 mL), lithium aluminum hydride (0.104 g, 2.75 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 2 hours. Water (0.495 mL, 27.5 mmol) and sodium fluoride (3.46 g, 82.0 mmol) were added to the reaction solution, and the mixture was stirred overnight at room temperature. Insoluble matter was removed by filtration through celite, and the filtrate was concentrated. The obtained residue was purified by amino silica gel column chromatography (ethyl acetate) to obtain 4-(tert-butyldimethylsilyloxy)-3,3-bis((tert-butyldimethylsilyloxy)methyl)butan-1-amine (0.435 g, 0.884 mmol, yield: 32%).</div>
    </li> <li> <para-num num="[1185]"> </para-num> <div id="p-1439" num="1185" class="description-line">ESI-MS m/z: 493 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.02 (s, 18H), 0.88 (s, 27H), 1.38-1.43 (m, 2H), 2.71-2.75 (m, 2H), 3.40 (s, 6H).</div>
    </li> <li> <para-num num="[1186]"> </para-num> <div id="p-1440" num="1186" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1187]"> </para-num> <div id="p-1441" num="1187" class="description-line">To a solution of 4-(tert-butyldimethylsilyloxy)-3,3-bis((tert-butyldimethylsilyloxy)methyl)butan-1-amine (0.200 g, 0.407 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 in 1,2-dichloroethane (3 mL), a 38% aqueous formaldehyde solution (0.295 mL) and sodium triacetoxyborohydride (0.431 g, 2.03 mmol) were added, and the mixture was stirred overnight at room temperature. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform twice. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=90/10) to obtain a crude product of 4-(tert-butyldimethylsilyloxy)-3,3-bis((tert-butyldimethylsilyloxy)methyl)-N,N-dimethylbutan-1-amine.</div>
    </li> <li> <para-num num="[1188]"> </para-num> <div id="p-1442" num="1188" class="description-line">To the obtained crude product, tetrahydrofuran (2 mL) and tetrabutylammonium fluoride (manufactured by Tokyo Chemical Industry Co., Ltd., approximately 1 mol/L solution in tetrahydrofuran, 2.06 mL, 2.06 mmol) were added, and the mixture was stirred at room temperature for 5 hours and then stirred overnight at 60 C. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, and the mixture was washed twice with chloroform. The aqueous layer was concentrated under reduced pressure. To the obtained residue, acetone (2 mL), sodium hydroxide (manufactured by Wako Pure Chemical Industries Ltd., 2 mol/L aqueous solution, 3 mL, 6 mmol), and oleoyl chloride (0.681 mL, 2.06 mmol) were added, and the mixture was stirred at room temperature for 3 hours. Oleoyl chloride (0.681 mL, 2.06 mmol) was added to the reaction solution, and the mixture was stirred overnight at 60 C. After cooling to room temperature, water was added to the reaction solution, followed by extraction with chloroform twice. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=90/10) to obtain a crude product of (Z)-2-(2-(dimethylamino)ethyl)-2-(oleyloxymethyl)propane-1,3-diyl dioleate. The obtained crude product was dissolved in a small amount of methanol-chloroform (9:1), and the solution was loaded to an ion-exchange resin (manufactured by Waters Corp., PoraPack Rxn CX, prewashed with methanol), followed by elution with ammonia (manufactured by Sigma-Aldrich Corp., 2 mol/L solution in methanol). The eluate was concentrated under reduced pressure to obtain (Z)-2-(2-(dimethylamino)ethyl)-2-(oleyloxymethyl)propane-1,3-diyl dioleate (0.387 g, 0.399 mmol, yield: 98%).</div>
    </li> <li> <para-num num="[1189]"> </para-num> <div id="p-1443" num="1189" class="description-line">ESI-MS m/z: 971 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.21-1.38 (m, 62H), 1.54-1.65 (m, 6H), 1.97-2.04 (m, 12H), 2.20 (s, 6H), 2.25-2.32 (m, 8H), 4.04 (s, 6H), 5.29-5.39 (m, 6H).</div>
    </li> <li> <para-num num="[1190]"> </para-num> <div id="p-1444" num="1190" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1191]"> </para-num> <div id="p-1445" num="1191" class="description-line">The title compound (0.0642 g, 0.0630 mol, yield: 56%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using (Z)-2-(2-(dimethylamino)ethyl)-2-(oleyloxymethyl)propane-1,3-diyl dioleate (0.109 g, 0.112 mol) obtained in step 4 instead of 2,2,2-nitrilotris(ethane-2,1-diyl) trioleate.</div>
    </li> <li> <para-num num="[1192]"> </para-num> <div id="p-1446" num="1192" class="description-line">ESI-MS m/z: 986 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.23-1.37 (m, 74H), 1.55-1.64 (m, 65H), 1.78-1.84 (m, 2H), 1.95-2.06 (m, 13H), 2.35 (t, J=7.6 Hz, 6H), 3.42 (s, 8H), 3.70-3.77 (m, 2H), 4.08 (s, 6H), 5.29-5.39 (m, 6H).</div>
    </li> <heading id="h-0093">Reference Example A41</heading>
    <heading id="h-0094">N,N,N-Trimethyl-2-(3-(oleoyloxy)-2,2-bis((oleoyloxy)methyl)propoxy)-2-oxyethan-1-aminium chloride (Compound II-32)</heading>
    <li> <para-num num="[1193]"> </para-num> <div id="p-1447" num="1193" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1194]"> </para-num> <div id="p-1448" num="1194" class="description-line">To a solution of 2,2-(dimethyl-1,3-dioxane-5,5-diyl)dimethanol (0.200 g, 1.14 mmol) synthesized by the method described in U.S. Pat. No. 8,816,099 in tetrahydrofuran (5 mL), triethylamine (0.475 mL, 3.40 mmol) was added, then oleoyl chloride (0.854 g, 2.84 mmol) was added under ice cooling, and the mixture was stirred for 1 hour under this ice cooling. Water was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5) to obtain (2,2-dimethyl-1,3-dioxane-5,5-diyl)bis(methylene) dioleate (0.500 g, 0.709 mmol, yield: 63%).</div>
    </li> <li> <para-num num="[1195]"> </para-num> <div id="p-1449" num="1195" class="description-line">ESI-MS m/z: 705 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1196]"> </para-num> <div id="p-1450" num="1196" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1197]"> </para-num> <div id="p-1451" num="1197" class="description-line">To a solution of (2,2-dimethyl-1,3-dioxane-5,5-diyl)bis(methylene) dioleate (0.500 g, 0.709 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in dichloromethane (5 mL), trifluoroacetic acid (2.00 mL, 26.0 mmol) was added in two divided portions under ice cooling, and the mixture was stirred for 1 hour under this ice cooling. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=90/10 to 50/50) to obtain 2,2-bis(hydroxymethyl)propane-1,3-diyl dioleate (0.207 g, 0.311 mmol, yield: 44%).</div>
    </li> <li> <para-num num="[1198]"> </para-num> <div id="p-1452" num="1198" class="description-line">ESI-MS m/z: 665 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1199]"> </para-num> <div id="p-1453" num="1199" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1200]"> </para-num> <div id="p-1454" num="1200" class="description-line">To N,N-dimethylglycine (manufactured by Tokyo Chemical Industry Co., Ltd., 0.049 g, 0.474 mmol), thionyl chloride (1 mL, 13.7 mmol) was added, and the mixture was stirred under heating at 70 C. for 30 minutes. The reaction solution was cooled to room temperature and then concentrated under reduced pressure to obtain a crude product of N,N-dimethylglycinoyl chloride. To a solution of 2,2-bis(hydroxymethyl)propane-1,3-diyl dioleate (0.207 g, 0.311 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 in dichloromethane (5 mL), N,N-diisopropylethylamine (0.110 mL, 0.632 mmol) and the crude product of N,N-dimethylglycinoyl chloride were added under ice cooling, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=90/10 to 40/60) to obtain 2-(((dimethylglycyl)oxy)methyl)-2-(hydroxymethyl)propane-1,3-diyl dioleate (0.077 g, 0.103 mmol, yield: 33%).</div>
    </li> <li> <para-num num="[1201]"> </para-num> <div id="p-1455" num="1201" class="description-line">ESI-MS m/z: 751 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1202]"> </para-num> <div id="p-1456" num="1202" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1203]"> </para-num> <div id="p-1457" num="1203" class="description-line">To a solution of 2-(((dimethylglycyl)oxy)methyl)-2-(hydroxymethyl)propane-1,3-diyl dioleate (0.0770 g, 0.103 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 in dichloromethane (3 mL), pyridine (0.0330 mL, 0.411 mmol) was added, then oleoyl chloride (0.0620 g, 0.205 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 30 minutes. Water was added to the reaction solution, followed by extraction with a mixed solvent of hexane/ethyl acetate=1/1. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5) to obtain 2-(((dimethylglycyl)oxy)methyl)-2-((oleoyl)methyl)propane-1,3-diyl dioleate (0.122 g, 0.0600 mmol, yield: 59%).</div>
    </li> <li> <para-num num="[1204]"> </para-num> <div id="p-1458" num="1204" class="description-line">ESI-MS m/z: 1015 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1205]"> </para-num> <div id="p-1459" num="1205" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1206]"> </para-num> <div id="p-1460" num="1206" class="description-line">The title compound (0.017 g, 0.016 mmol, yield: 27%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-(((dimethylglycyl)oxy)methyl)-2-((oleoyl)methyl)propane-1,3-diyl dioleate (0.122 g, 0.060 mmol) obtained in step 4.</div>
    </li> <li> <para-num num="[1207]"> </para-num> <div id="p-1461" num="1207" class="description-line">ESI-MS m/z: 1029 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.19-1.38 (m, 58H), 1.54-1.66 (m, 6H), 1.98-2.04 (m, 12H), 2.28-2.35 (m, 6H), 3.60 (s, 9H), 4.11 (d, J=1.8 Hz, 6H), 4.20 (s, 2H), 5.08 (s, 2H), 5.29-5.41 (m, 6H).</div>
    </li> <heading id="h-0095">Reference Example A42</heading>
    <heading id="h-0096">N,N, N-Trimethyl-1,3-bis(tetradecanoyloxy)-2-((tetradecanoyloxy)methyl)propan-2-aminium chloride (Compound II-33)</heading>
    <li> <para-num num="[1208]"> </para-num> <div id="p-1462" num="1208" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1209]"> </para-num> <div id="p-1463" num="1209" class="description-line">To 2-(dimethylamino)-2-(hydroxymethyl)propane-1,3-diol (1.50 g, 10.1 mmol) in tetrahydrofuran (10 mL), pyridine (4.07 mL, 50.3 mmol) and then tetradecanoyl chloride (4.09 mL, 15.1 mmol) were added, and the mixture was stirred under heating at 60 C. for 2 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 90/10) to obtain 2-(dimethylamino)-2-((tetradecanoyloxy)methyl)propane-1,3-diyl ditetradecanoate (1.50 g, 1.92 mmol, yield: 19%), 2-(dimethylamino)-2-(hydroxymethyl)propane-1,3-diyl ditetradecanoate (0.750 g, 1.32 mmol, yield: 13%), and 2-(dimethylamino)-3-hydroxy-2-(hydroxymethyl)propyl tetradecanoate (0.220 g, 0.612 mmol, yield: 6%).</div>
    </li> <li> <para-num num="[1210]"> </para-num> <div id="p-1464" num="1210" class="description-line">ESI-MS m/z: 781 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1211]"> </para-num> <div id="p-1465" num="1211" class="description-line">ESI-MS m/z: 570 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1212]"> </para-num> <div id="p-1466" num="1212" class="description-line">ESI-MS m/z: 360 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1213]"> </para-num> <div id="p-1467" num="1213" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1214]"> </para-num> <div id="p-1468" num="1214" class="description-line">The title compound (0.530 g, 0.638 mmol, yield: 33%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-(dimethylamino)-2-((tetradecanoyloxy)methyl)propane-1,3-diyl ditetradecanoate (1.50 g, 1.92 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[1215]"> </para-num> <div id="p-1469" num="1215" class="description-line">ESI-MS m/z: 795 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.21-1.33 (m, 60H), 1.55-1.65 (m, 6H), 2.37 (t, J=7.6 Hz, 6H), 3.71 (s, 9H), 4.59 (s, 6H).</div>
    </li> <heading id="h-0097">Reference Example A43</heading>
    <heading id="h-0098">N,N,N-Trimethyl-1,3-bis(oleoyloxy)-2-((tetradecanoyloxy)methyl)propan-2-aminium chloride (Compound II-34)</heading>
    <li> <para-num num="[1216]"> </para-num> <div id="p-1470" num="1216" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1217]"> </para-num> <div id="p-1471" num="1217" class="description-line">To a solution of 2-(dimethylamino)-3-hydroxy-2-(hydroxymethyl)propyl tetradecanoate (0.220 g, 0.612 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A42 in 1,2-dichloroethane (3 mL), pyridine (0.297 mL, 3.67 mmol) and then oleoyl chloride (0.552 g, 1.84 mmol) were added, and the mixture was stirred under heating at 60 C. for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=98/2 to 85/15) to obtain 2-(dimethylamino)-2-((tetradecanoyloxy)methyl)propane-1,3-diyl dioleate (0.250 g, 0.281 mmol, yield: 46%).</div>
    </li> <li> <para-num num="[1218]"> </para-num> <div id="p-1472" num="1218" class="description-line">ESI-MS m/z: 889 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1219]"> </para-num> <div id="p-1473" num="1219" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1220]"> </para-num> <div id="p-1474" num="1220" class="description-line">The title compound (0.065 g, 0.069 mmol, yield: 25%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-(dimethylamino)-2-((tetradecanoyloxy)methyl)propane-1,3-diyl dioleate (0.250 g, 0.281 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[1221]"> </para-num> <div id="p-1475" num="1221" class="description-line">ESI-MS m/z: 903 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.22-1.38 (m, 60H), 1.56-1.66 (m, 6H), 1.97-2.05 (m, 8H), 2.39 (t, J=7.6 Hz, 6H), 3.72 (s, 9H), 4.58 (s, 6H), 5.28-5.40 (m, 4H).</div>
    </li> <heading id="h-0099">Reference Example A44</heading>
    <heading id="h-0100">N,N,N-Trimethyl-1-(oleyloxy)-3-(tetradecanoyloxy)-2-((tetradecanoyloxy)methyl)propan-2-aminium chloride (Compound II-35)</heading>
    <li> <para-num num="[1222]"> </para-num> <div id="p-1476" num="1222" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1223]"> </para-num> <div id="p-1477" num="1223" class="description-line">To a solution of 2-(dimethylamino)-2-(hydroxymethyl)propane-1,3-diyl ditetradecanoate (0.750 g, 1.32 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A42 in 1,2-dichloroethane (3 mL), pyridine (0.532 mL, 6.58 mmol) and then oleoyl chloride (0.792 g, 1.84 mmol) were added, and the mixture was stirred under heating at 60 C. for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5) to obtain 2-(dimethylamino)-2-((oleyloxy)methyl)propane-1,3-diyl ditetradecanoate (0.750 g, 0.899 mmol, yield: 68%).</div>
    </li> <li> <para-num num="[1224]"> </para-num> <div id="p-1478" num="1224" class="description-line">ESI-MS m/z: 835 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1225]"> </para-num> <div id="p-1479" num="1225" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1226]"> </para-num> <div id="p-1480" num="1226" class="description-line">The title compound (0.092 g, 0.104 mmol, yield: 12%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-(dimethylamino)-2-((oleyloxy)methyl)propane-1,3-diyl ditetradecanoate (0.750 g, 0.899 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[1227]"> </para-num> <div id="p-1481" num="1227" class="description-line">ESI-MS m/z: 849 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.19-1.38 (m, 60H), 1.56-1.65 (m, 6H), 1.98-2.06 (m, 4H), 2.39 (t, J=7.6 Hz, 6H), 3.72 (s, 9H), 4.59 (s, 6H), 5.30-5.39 (m, 2H).</div>
    </li> <heading id="h-0101">Reference Example A45</heading>
    <heading id="h-0102">N,N, N-Trimethyl-3-(tetradecanoyloxy)-2-((tetradecanoyloxy)methyl)-2-(((tetradecylcarbamoyl)oxy)methyl)propan-1-aminium chloride (Compound II-36)</heading>
    <li> <para-num num="[1228]"> </para-num> <div id="p-1482" num="1228" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1229]"> </para-num> <div id="p-1483" num="1229" class="description-line">To a solution of 2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diol (0.820 g, 5.02 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A24 in tetrahydrofuran (7 mL), pyridine (2.03 mL, 38.6 mmol) was added, then tetradecanoyl chloride (0.930 mL, 3.77 mmol) was added under ice cooling, and the mixture was stirred at 60 C. for 2 hours. The reaction solution was cooled to room temperature, and water was added thereto, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5 to 70/30) to obtain 2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diyl ditetradecanoate (0.150 g, 0.257 mmol, yield: 5%).</div>
    </li> <li> <para-num num="[1230]"> </para-num> <div id="p-1484" num="1230" class="description-line">ESI-MS m/z: 584 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1231]"> </para-num> <div id="p-1485" num="1231" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1232]"> </para-num> <div id="p-1486" num="1232" class="description-line">To a solution of 2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diyl ditetradecanoate (0.060 g, 0.103 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in dichloromethane (3 mL), triethylamine (0.017 mL, 0.123 mmol) was added, then 4-nitrophenyl chloroformate (manufactured by Tokyo Chemical Industry Co., Ltd., 0.025 g, 0.123 mmol) and then tetradecylamine (manufactured by Tokyo Chemical Industry Co., Ltd., 0.022 g, 0.103 mmol) were added under ice cooling, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5 to 70/30) to obtain 2-((dimethylamino)methyl)-2-(((tetradecylcarbamoyl)oxy)methyl)propane-1,3-diyl ditetradecanoate (0.052 g, 0.063 mmol, yield: 62%).</div>
    </li> <li> <para-num num="[1233]"> </para-num> <div id="p-1487" num="1233" class="description-line">ESI-MS m/z: 824 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1234]"> </para-num> <div id="p-1488" num="1234" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1235]"> </para-num> <div id="p-1489" num="1235" class="description-line">The title compound (0.012 g, 0.014 mmol, yield: 21%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-((dimethylamino)methyl)-2-(((tetradecylcarbamoyl)oxy)methyl)propane-1,3-diyl ditetradecanoate (0.052 g, 0.063 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2.</div>
    </li> <li> <para-num num="[1236]"> </para-num> <div id="p-1490" num="1236" class="description-line">ESI-MS m/z: 838 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.22-1.33 (m, 62H), 1.51-1.61 (m, 6H), 2.38 (t, J=7.6 Hz, 4H), 3.13 (dd, J=14.2, 5.8 Hz, 2H), 3.59 (s, 9H), 4.12 (s, 2H), 4.19 (s, 2H), 4.21 (d, J=12.0 Hz, 2H), 4.25 (d, J=12.0 Hz, 2H), 6.72 (t, J=5.8 Hz, 1H).</div>
    </li> <heading id="h-0103">Reference Example A46</heading>
    <heading id="h-0104">N,N,N-Trimethyl-3-((octadecylcarbamoyl)oxy)-2,2-bis((tetradecanoyloxy)methyl)propan-1-aminium chloride (Compound II-37)</heading>
    <li> <para-num num="[1237]"> </para-num> <div id="p-1491" num="1237" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1238]"> </para-num> <div id="p-1492" num="1238" class="description-line">The title compound (0.015 g, 0.016 mmol, overall yield: 0.5%) was obtained in the same way as in Reference Example A45 using stearylamine (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of tetradecylamine.</div>
    </li> <li> <para-num num="[1239]"> </para-num> <div id="p-1493" num="1239" class="description-line">ESI-MS m/z: 894 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.21-1.34 (m, 70H), 1.51-1.62 (m, 6H), 2.38 (t, J=7.6 Hz, 4H), 3.13 (dd, J=14.3, 5.8 Hz, 2H), 3.60 (s, 9H), 4.12 (s, 2H), 4.19 (s, 2H), 4.21 (d, J=12.2 Hz, 2H), 4.25 (d, J=12.2 Hz, 2H), 6.69 (t, J=5.8 Hz, 1H).</div>
    </li> <heading id="h-0105">Reference Example A47</heading>
    <heading id="h-0106">N,N,N-Trimethyl-3-(stearoyloxy)-2,2-bis((tetradecanoyloxy)methyl)propan-1-aminium chloride (Compound II-37)</heading>
    <li> <para-num num="[1240]"> </para-num> <div id="p-1494" num="1240" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1241]"> </para-num> <div id="p-1495" num="1241" class="description-line">To a solution of (5-(bromomethyl)-2,2-dimethyl-1,3-dioxan-5-yl)methanol (1.00 g, 4.18 mmol) synthesized by the method described in Angewandte Chemie International Edition, 2009, Vol. 48, p. 2126-2130 in pyridine (10 mL), stearoyl chloride (2.53 g, 8.36 mmol) was added, and the mixture was stirred at room temperature for 30 minutes. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=90/10) to obtain (5-(bromomethyl)-2,2-dimethyl-1,3-dioxan-5-yl)methyl stearate (0.95 g, 1.879 mmol, yield: 45%).</div>
    </li> <li> <para-num num="[1242]"> </para-num> <div id="p-1496" num="1242" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.23-1.40 (m, 44H), 1.54-1.64 (m, 26H), 2.01-2.08 (m, 12H), 2.35 (t, J=7.6 Hz, 6H), 2.77 (t, J=6.8 Hz, 6H), 3.40 (s, 9H), 4.46 (s, 6H), 4.70 (s, 2H), 28-5.42 (m, 12H), 9.54 (br s, 1H).</div>
    </li> <li> <para-num num="[1243]"> </para-num> <div id="p-1497" num="1243" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1244]"> </para-num> <div id="p-1498" num="1244" class="description-line">To a solution of (5-(bromomethyl)-2,2-dimethyl-1,3-dioxan-5-yl)methyl stearate (0.95 g, 1.879 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in N,N-dimethylformamide (10 mL), dimethylamine (2.0 mol/L solution in tetrahydrofuran, 5.64 mL, 11.3 mmol) was added, and the mixture was stirred at 120 C. for 13 hours under microwave irradiation. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 90/10) to obtain (5-((dimethylamino)methyl)-2,2-dimethyl-1,3-dioxan-5-yl)methyl stearate (0.14 g, 0.298 mmol, yield: 16%).</div>
    </li> <li> <para-num num="[1245]"> </para-num> <div id="p-1499" num="1245" class="description-line">ESI-MS m/z: 470 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1246]"> </para-num> <div id="p-1500" num="1246" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1247]"> </para-num> <div id="p-1501" num="1247" class="description-line">3-(Dimethylamino)-2,2-bis(hydroxymethyl)propyl stearate (0.12 g, 0.279 mmol, yield: 94%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A41 using (5-((dimethylamino)methyl)-2,2-dimethyl-1,3-dioxan-5-yl)methyl stearate (0.140 g, 0.298 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[1248]"> </para-num> <div id="p-1502" num="1248" class="description-line">ESI-MS m/z: 430 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1249]"> </para-num> <div id="p-1503" num="1249" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1250]"> </para-num> <div id="p-1504" num="1250" class="description-line">To a solution of 3-(dimethylamino)-2,2-bis(hydroxymethyl)propyl stearate (0.12 g, 0.279 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 in dichloromethane (2 mL), pyridine (0.122 mL, 1.51 mmol) was added, then tetradecanoyl chloride (0.224 g, 0.98 mmol) was added under ice cooling, and the mixture was stirred at room temperature for 1 hour. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5) to obtain 2-((dimethylamino)methyl)-2-((stearoyloxy)methyl)propane-1,3-diyl ditetradecanoate (0.150 g, 0.176 mmol, yield: 63%).</div>
    </li> <li> <para-num num="[1251]"> </para-num> <div id="p-1505" num="1251" class="description-line">ESI-MS m/z: 851 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1252]"> </para-num> <div id="p-1506" num="1252" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1253]"> </para-num> <div id="p-1507" num="1253" class="description-line">The title compound (0.032 g, 0.056 mmol, yield: 32%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using -((dimethylamino)methyl)-2-((stearoyloxy)methyl)propane-1,3-diyl ditetradecanoate (0.150 g, 0.176 mmol) obtained in step 4.</div>
    </li> <li> <para-num num="[1254]"> </para-num> <div id="p-1508" num="1254" class="description-line">ESI-MS m/z: 865 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.19-1.33 (m, 68H), 1.54-1.65 (m, 6H), 2.38 (t, J=7.6 Hz, 6H), 3.63 (s, 9H), 3.95 (s, 2H), 4.29 (s, 6H).</div>
    </li> <heading id="h-0107">Reference Example A48</heading>
    <heading id="h-0108">N,N,N-Trimethyl-3-(((Z)-tetradec-9-enoyl)oxy)-2,2-bis((((Z)-tetradec-9-enoyl)oxy)methyl)propan-1-aminium chloride (Compound II-39)</heading>
    <li> <para-num num="[1255]"> </para-num> <div id="p-1509" num="1255" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1256]"> </para-num> <div id="p-1510" num="1256" class="description-line">To a solution of myristoleic acid (manufactured by Nu-Chek Prep, Inc., 2.50 g, 11.0 mmol) in dichloromethane (20 mL), thionyl chloride (1.61 mL, 22.1 mmol) and N,N-dimethylformamide (8.55 mL, 0.110 mmol) were added, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure to obtain a crude product of myristoleyl chloride (2.70 g, 11.04 mmol, yield: 100%).</div>
    </li> <li> <para-num num="[1257]"> </para-num> <div id="p-1511" num="1257" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1258]"> </para-num> <div id="p-1512" num="1258" class="description-line">The title compound (0.350 g, 0.417 mmol, overall yield: 27%) was obtained in the same way as in Reference Example A33 using myristoleyl chloride (1.88 g, 7.66 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 instead of palmitoyl chloride.</div>
    </li> <li> <para-num num="[1259]"> </para-num> <div id="p-1513" num="1259" class="description-line">ESI-MS m/z: 803 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.86-0.94 (m, 9H), 1.26-1.39 (m, 36H), 1.53-1.64 (m, 6H), 1.97-2.07 (m, 12H), 2.38 (t, J=7.6 Hz, 6H), 3.67 (s, 9H), 3.99 (s, 2H), 4.30 (s, 6H), 5.29-5.39 (m, 6H).</div>
    </li> <heading id="h-0109">Reference Example A49</heading>
    <heading id="h-0110">2-((4-((1,3-Bis(tetradecanoyloxy)-2-((tetradecanoyloxy)methyl)propan-2-yl)amino)-4-oxobutanoyl)oxy)-N,N,N-trimethylethan-1-aminium chloride (Compound II-40)</heading>
    <li> <para-num num="[1260]"> </para-num> <div id="p-1514" num="1260" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1261]"> </para-num> <div id="p-1515" num="1261" class="description-line">To a solution of 4-((1,3-bis(tetradecanoyloxy)-2-((tetradecanoyloxy)methyl)propan-2-yl)amino)-4-oxobutanoic acid (0.250 g, 0.293 mmol) synthesized by a method equivalent to the method described in Australian Journal of Chemistry, 2013, Vol. 66, p. 23-29 in dichloromethane (3 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.084 g, 0.440 mmol), 2-(dimethylamino)ethan-1-ol (manufactured by Tokyo Chemical Industry Co., Ltd., 0.039 g, 0.440 mmol), and 4-dimethylaminopyridine (0.036 g, 0.293 mmol) were added in order, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 90/10) to obtain 2-(4-(2-(dimethylamino)ethoxy)-4-oxobutanamido)-2-((tetradecanoyloxy)methyl)propane-1,3-diyl ditetradecanoate (0.200 g, 0.217 mmol, yield: 74%).</div>
    </li> <li> <para-num num="[1262]"> </para-num> <div id="p-1516" num="1262" class="description-line">ESI-MS m/z: 924 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1263]"> </para-num> <div id="p-1517" num="1263" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1264]"> </para-num> <div id="p-1518" num="1264" class="description-line">The title compound (0.150 g, 0.154 mmol, yield: 71%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-(4-(2-(dimethylamino)ethoxy)-4-oxobutanamido)-2-((tetradecanoyloxy)methyl)propane-1,3-diyl ditetradecanoate (0.200 g, 0.217 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[1265]"> </para-num> <div id="p-1519" num="1265" class="description-line">ESI-MS m/z: 938 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.20-1.34 (m, 60H), 1.56-1.65 (m, 6H), 2.34 (t, J=7.6 Hz, 6H), 2.54 (br s, 4H), 3.48 (s, 9H), 4.13-4.21 (m, 2H), 4.40 (s, 6H), 4.57-4.65 (m, 2H), 6.22 (s, 1H).</div>
    </li> <heading id="h-0111">Reference Example A50</heading>
    <heading id="h-0112">3-((4-((1,3-Bis(tetradecanoyloxy)-2-((tetradecanoyloxy)methyl)propan-2-yl)amino)-4-oxobutanoyl)oxy)-1-methylquinuclidin-1-nium chloride (Compound II-41)</heading>
    <li> <para-num num="[1266]"> </para-num> <div id="p-1520" num="1266" class="description-line">The title compound (0.350 g, 0.417 mmol, overall yield: 46%) was obtained in the same way as in Reference Example A49 using quinuclidin-3-ol (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of 2-(dimethylamino)ethan-1-ol.</div>
    </li> <li> <para-num num="[1267]"> </para-num> <div id="p-1521" num="1267" class="description-line">ESI-MS m/z: 976 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.18-1.35 (m, 66H), 1.55-1.66 (m, 6H), 1.97-2.10 (m, 1H), 2.14-2.26 (m, 2H), 2.45-2.70 (m, 6H), 3.34 (s, 3H), 3.61-4.07 (m, 6H), 4.41 (s, 6H), 5.03-5.10 (m, 1H), 6.50 (s, 1H).</div>
    </li> <heading id="h-0113">Reference Example A51</heading>
    <heading id="h-0114">N,N,N-Trimethyl-16,22-dioxo-19-(((tetradecylcarbamoyl)oxy)methyl)-17,21-dioxa-15,23-diazaheptatriacontan-19-aminium chloride (Compound II-42)</heading>
    <li> <para-num num="[1268]"> </para-num> <div id="p-1522" num="1268" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1269]"> </para-num> <div id="p-1523" num="1269" class="description-line">To 2-(dimethylamino)-2-(hydroxymethyl)propane-1,3-diol (0.15 g, 1.01 mmol), toluene (4 mL), triethylamine (0.280 mL, 2.01 mmol), and 1-tetradecane isocyanate (1.66 mL, 6.03 mmol) were added in order, and the mixture was reacted at 100 C. for 4 hours in a microwave reaction apparatus. Water was added to the reaction solution, followed by extraction with chloroform. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 90/10) to obtain 2-(dimethylamino)-2-(((tetradecylcarbamoyl)oxy)methyl)propane-1,3-diyl bis(tetradecylcarbamate) (0.872 g, 1.01 mmol, yield: 100%).</div>
    </li> <li> <para-num num="[1270]"> </para-num> <div id="p-1524" num="1270" class="description-line">ESI-MS m/z: 868 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1271]"> </para-num> <div id="p-1525" num="1271" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1272]"> </para-num> <div id="p-1526" num="1272" class="description-line">The title compound (0.761 g, 0.829 mmol, yield: 82%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-(dimethylamino)-2-(((tetradecylcarbamoyl)oxy)methyl)propane-1,3-diyl bis(tetradecylcarbamate) (0.872 g, 1.01 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[1273]"> </para-num> <div id="p-1527" num="1273" class="description-line">ESI-MS m/z: 882 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.22-1.32 (m, 66H), 1.47-1.56 (m, 6H), 3.13 (td, J=14.3, 6.0 Hz, 6H), 3.58 (s, 9H), 4.52 (s, 6H), 6.69 (t, J=6.0 Hz, 3H).</div>
    </li> <heading id="h-0115">Reference Example A52</heading>
    <heading id="h-0116">N,N,N-Trimethyl-1,3-bis(3,7,11,15-tetramethylhexadecanoyloxy)-2-((3,7,11,15-tetramethylhexadecanoyl)methyl)propan-2-aminium chloride (Compound II-43)</heading>
    <li> <para-num num="[1274]"> </para-num> <div id="p-1528" num="1274" class="description-line">To a solution of 2-dimethylamino-2-hydroxymethylpropane-1,3-diol (0.0170 g, 0.112 mmol) in 1,2-dichloroethane (1 mL), 3,7,11,15-tetramethylhexadecanoic acid (0.1826 g, 0.561 mmol), ((((1-cyano-2-ethoxy-2-oxoethylidene)amino)oxy)-4-morpholinomethylene)dimethylammonium hexafluorophosphate (manufactured by Sigma-Aldrich Corp., 0.240 g, 0.561 mmol), and N,N-diisopropylethylamine (0.098 mL, 0.561 mmol) were added, and the mixture was stirred overnight at 60 C. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=95/5) to obtain a crude product of 2-(dimethylamino)-2-((3,7,11,15-tetramethylhexadecanoyloxy)methyl)propane-1,3-diyl bis(3,7,11,15-tetramethylhexadecanoate). To the obtained crude product, methyl iodide (1.00 mL, 16.0 mmol) was added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (manufactured by The Dow Chemical Company, <figure-callout id="1" label="DowexTM" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Dowex</figure-callout> 1-2 100 mesh, Cl type, approximately 20-fold amount, prewashed with water and methanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=90/10) to obtain the title compound (0.0766 g, 0.071 mmol, yield: 63%).</div>
    </li> <li> <para-num num="[1275]"> </para-num> <div id="p-1529" num="1275" class="description-line">ESI-MS m/z: 1043 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.81-0.87 (m, 36H), 0.92 (d, J=6.7 Hz, 9H), 0.97-1.42 (m, 60H), 1.51 (tt, J=19.8, 6.7 Hz, 3H), 1.84-1.97 (m, 3H), 2.16 (ddd, J=15.5, 8.4, 2.3 Hz, 3H), 2.38 (ddd, J=15.5, 5.6, 1.6 Hz, 3H), 3.72 (s, 9H), 4.55 (s, 6H).</div>
    </li> <heading id="h-0117">Reference Example A53</heading>
    <heading id="h-0118">N,N,N-Trimethyl-2-((tetradecanoyloxy)methyl)-2-tetradecylhexadecan-1-aminium chloride (Compound II-44)</heading>
    <li> <para-num num="[1276]"> </para-num> <div id="p-1530" num="1276" class="description-line">The title compound (0.292 g, 0.39 mmol, overall yield: 22%) was obtained in the same way as in Reference Example A19 using 1-bromotetradecane (manufactured by Tokyo Chemical Industry Co., Ltd.) and myristic acid (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate used in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A19 and (9Z,12Z)-octadeca-9,12-dienoic acid used in step 4, respectively.</div>
    </li> <li> <para-num num="[1277]"> </para-num> <div id="p-1531" num="1277" class="description-line">ESI-MS m/z: 721 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CD<sub>3</sub>OD) : 0.90 (t, J=6.8 Hz, 9H), 1.28-1.32 (m, 70H), 1.49 (br s, 2H), 1.63-1.66 (m, 2H), 2.42 (t, J=7.2 Hz, 2H), 3.26 (s, 9H), 3.43 (s, 2H), 4.18 (s, 2H).</div>
    </li> <heading id="h-0119">Reference Example A54</heading>
    <heading id="h-0120">2-Hexadecyl-N,N,N-trimethyl-2-((palmitoyloxy)methyl)octadecan-1-aminium chloride (Compound II-45)</heading>
    <li> <para-num num="[1278]"> </para-num> <div id="p-1532" num="1278" class="description-line">The title compound (0.195 g, 0.23 mmol, overall yield: 5%) was obtained in the same way as in Reference Example A19 using 1-bromohexadecane (manufactured by Tokyo Chemical Industry Co., Ltd.) and palmitic acid (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate used in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A19 and (9Z,12Z)-octadeca-9,12-dienoic acid used in step 4, respectively.</div>
    </li> <li> <para-num num="[1279]"> </para-num> <div id="p-1533" num="1279" class="description-line">ESI-MS m/z: 805 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CD<sub>3</sub>OD) : 0.90 (t, J=6.8 Hz, 9H), 1.28-1.33 (m, 82H), 1.49 (br s, 2H), 1.63-1.67 (m, 2H), 2.43 (t, J=7.2 Hz, 2H), 3.26 (s, 9H), 3.43 (s, 2H), 4.18 (s, 2H).</div>
    </li> <heading id="h-0121">Reference Example A55</heading>
    <heading id="h-0122">N,N,N-Trimethyl-2-((stearoyloxy)methyl)-2-tetradecylhexadec-1-aminium chloride (Compound II-46)</heading>
    <li> <para-num num="[1280]"> </para-num> <div id="p-1534" num="1280" class="description-line">The title compound (0.421 g, 0.52 mmol, overall yield: 20%) was obtained in the same way as in Reference Example A19 using 1-bromotetradecane (manufactured by Tokyo Chemical Industry Co., Ltd.) and stearic acid (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate used in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A19 and (9Z,12Z)-octadeca-9,12-dienoic acid used in step 4, respectively.</div>
    </li> <li> <para-num num="[1281]"> </para-num> <div id="p-1535" num="1281" class="description-line">ESI-MS m/z: 111 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CD<sub>3</sub>OD) : 0.90 (t, J=6.8 Hz, 9H), 1.29-1.33 (m, 78H), 1.49 (br s, 2H),1.63-1.67 (m, 2H), 2.43 (t, J=7.2 Hz, 2H), 3.27 (s, 9H), 3.44 (s, 2H), 4.18 (s, 2H).</div>
    </li> <heading id="h-0123">Reference Example A56</heading>
    <heading id="h-0124">3-(Dodecanoyloxy)-N,N,N-trimethyl-2,2-bis((stearoyloxy)methyl)propan-1-aminium chloride (Compound II-47)</heading>
    <li> <para-num num="[1282]"> </para-num> <div id="p-1536" num="1282" class="description-line">The title compound (0.200 g, 0.417 mmol, overall yield: 0.3%) was obtained in the same way as in Reference Example A46 using lauroyl chloride (manufactured by Tokyo Chemical Industry Co., Ltd.) and stearoyl chloride (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of stearoyl chloride used in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A46 and tetradecanoyl chloride used in step 4, respectively.</div>
    </li> <li> <para-num num="[1283]"> </para-num> <div id="p-1537" num="1283" class="description-line">ESI-MS m/z: 893 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.9 Hz, 9H), 1.21-1.32 (m, 72H), 1.57-1.64 (m, 6H), 2.38 (t, J=7.6 Hz, 6H), 3.63 (s, 9H), 3.99 (s, 2H), 4.29 (s, 6H).</div>
    </li> <heading id="h-0125">Reference Example A57</heading>
    <heading id="h-0126">3-(Dodecanoyloxy)-N,N,N-trimethyl-2,2-bis((palmitoyloxy)methyl)propan-1-aminium chloride (Compound II-48)</heading>
    <li> <para-num num="[1284]"> </para-num> <div id="p-1538" num="1284" class="description-line">The title compound (0.350 g, 0.40 mmol, overall yield: 0.6%) was obtained in the same way as in Reference Example A47 using lauroyl chloride (manufactured by Tokyo Chemical Industry Co., Ltd.) and palmitoyl chloride (manufactured by Wako Pure Chemical Industries Ltd.) instead of stearoyl chloride used in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A47 and tetradecanoyl chloride used in step 4, respectively.</div>
    </li> <li> <para-num num="[1285]"> </para-num> <div id="p-1539" num="1285" class="description-line">ESI-MS m/z: 837 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.9 Hz, 9H), 1.21-1.33 (m, 64H), 1.56-1.64 (m, 6H), 2.38 (t, J=7.6 Hz, 6H), 3.66 (s, 9H), 3.98 (s, 2H), 4.29 (s, 6H).</div>
    </li> <heading id="h-0127">Reference Example A58</heading>
    <heading id="h-0128">3-(Dodecanoyloxy)-2-((dodecanoyloxy)methyl)-N,N,N-trimethyl-2-((stearoyloxy)methyl)propan-1-aminium chloride (Compound II-49)</heading>
    <li> <para-num num="[1286]"> </para-num> <div id="p-1540" num="1286" class="description-line">The title compound (0.210 g, 0.249 mmol, overall yield: 0.3%) was obtained in the same way as in Reference Example A47 using lauroyl chloride (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of tetradecanoyl chloride used in step 4 of Reference Example A47.</div>
    </li> <li> <para-num num="[1287]"> </para-num> <div id="p-1541" num="1287" class="description-line">ESI-MS m/z: 809 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.9 Hz, 9H), 1.23-1.34 (m, 60H), 1.53-1.65 (m, 6H), 2.38 (t, J=7.6 Hz, 6H), 3.63 (s, 9H), 3.97 (s, 2H), 4.29 (s, 6H).</div>
    </li> <heading id="h-0129">Reference Example A59</heading>
    <heading id="h-0130">N,N,N-Trimethyl-3-(palmitoyloxy)-2-((palmitoyloxy)methyl)-2-((stearoyloxy)methyl)propan-1-aminium chloride (Compound II-50)</heading>
    <li> <para-num num="[1288]"> </para-num> <div id="p-1542" num="1288" class="description-line">The title compound (0.420 g, 0.44 mmol, overall yield: 0.5%) was obtained in the same way as in Reference Example A47 using palmitoyl chloride (manufactured by Tokyo Chemical Industry Co., Ltd.) instead of tetradecanoyl chloride used in step 4 of Reference Example A47.</div>
    </li> <li> <para-num num="[1289]"> </para-num> <div id="p-1543" num="1289" class="description-line">ESI-MS m/z: 921 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.9 Hz, 9H), 1.21-1.32 (m, 76H), 1.55-1.65 (m, 6H), 2.38 (t, J=7.6 Hz, 6H), 3.67 (s, 9H), 399 (s, 2H), 4.29 (s, 6H).</div>
    </li> <heading id="h-0131">Reference Example A60</heading>
    <heading id="h-0132">3-(Icosanoyloxy)-N,N,N-trimethyl-2,2-bis((tetradecanoyloxy)methyl)propan-1-aminium chloride (Compound II-51)</heading>
    <li> <para-num num="[1290]"> </para-num> <div id="p-1544" num="1290" class="description-line">The title compound is obtained in the same way as in Reference Example A47 using eicosanoyl chloride (manufactured by Nu-Chek Prep, Inc.) instead of stearoyl chloride used in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A47.</div>
    </li> <heading id="h-0133">Reference Example A61</heading>
    <heading id="h-0134">3-(Dodecanoyloxy)-2-((dodecanoyloxy)methyl)-2-((icosanoyloxy)methyl)-N,N,N-trimethylpropan-1-aminium chloride (Compound II-52)</heading>
    <li> <para-num num="[1291]"> </para-num> <div id="p-1545" num="1291" class="description-line">The title compound is obtained in the same way as in Reference Example A47 using eicosanoyl chloride (manufactured by Nu-Chek Prep, Inc.) and lauroyl chloride (manufactured by Wako Pure Chemical Industries Ltd.) instead of stearoyl chloride used in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example A47 and tetradecanoyl chloride used in step 4, respectively.</div>
    </li> <heading id="h-0135">Reference Example A62</heading>
    <heading id="h-0136">N,N, N-Trimethyl-3-(methyl(3-(tetradecanoyloxy)-2,2-bis((tetradecanoyloxy)methyl)propyl)amino)propan-1-aminium chloride (Compound II-53)</heading>
    <li> <para-num num="[1292]"> </para-num> <div id="p-1546" num="1292" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1293]"> </para-num> <div id="p-1547" num="1293" class="description-line">To a solution of 2-(bromomethyl)-2-(hydroxymethyl)propane-1,3-diol (0.15 g, 0.754 mmol) in N,N-dimethylacetamide (1 mL), N,N,N-trimethylpropane-1,3-diamine (0.263 g, 2.26 mmol) was added, and the mixture was reacted at 100 C. for 2 hours in a microwave reaction apparatus. Then, N,N-diisopropylethylamine (0.395 mL, 2.26 mmol) and then tetradecanoyl chloride (1.12 g, 4.52 mmol) were added thereto under ice cooling, and the mixture was stirred at room temperature for 2 hours. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium bicarbonate and saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 90/10) to obtain 2-(((3-(dimethylamino)propyl)(methyl)amino)methyl)-2-((tetradecanoyloxy)methyl)propane-1,3-diyl ditetradecanoate (0.040 g, 0.046 mmol, yield: 6%).</div>
    </li> <li> <para-num num="[1294]"> </para-num> <div id="p-1548" num="1294" class="description-line">ESI-MS m/z: 866 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1295]"> </para-num> <div id="p-1549" num="1295" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1296]"> </para-num> <div id="p-1550" num="1296" class="description-line">The title compound (0.015 g, 0.016 mmol, yield: 35%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A1 using 2-(((3-(dimethylamino)propyl)(methyl)amino)methyl)-2-((tetradecanoyloxy)methyl)propane-1,3-diyl ditetradecanoate (0.040 g, 0.046 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1.</div>
    </li> <li> <para-num num="[1297]"> </para-num> <div id="p-1551" num="1297" class="description-line">ESI-MS m/z: 880 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.20-1.35 (m, 62H), 1.54-1.65 (m, 6H), 1.87-2.03 (m, 2H), 2.21-2.31 (m, 2H), 2.31 (t, J=7.6 Hz, 6H), 2.49 (br s, 3H), 3.40 (s, 9H), 3.52-3.63 (m, 2H), 4.05 (s, 6H).</div>
    </li> <heading id="h-0137">Reference Example A63</heading>
    <heading id="h-0138">(S)-6-(Di(9Z,12Z)-octadeca-9,12-dienylamino)-N,N,N-trimethyl-5-oleamido-6-oxohexan-1-aminium chloride (Compound III-2)</heading>
    <li> <para-num num="[1298]"> </para-num> <div id="p-1552" num="1298" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1299]"> </para-num> <div id="p-1553" num="1299" class="description-line">To ammonia (approximately 2 mol/L solution in methanol, 18.0 mL, 36.0 mmol), (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (1.55 g, 4.50 mmol) was added, and the mixture was stirred at 130 C. for 3 hours using a microwave reaction apparatus. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform five times. The organic layers were combined, washed with saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain a crude product of (Z)-octadec-9-enylamine.</div>
    </li> <li> <para-num num="[1300]"> </para-num> <div id="p-1554" num="1300" class="description-line">To the obtained crude product, (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (1.24 g, 3.60 mmol) and a 50% aqueous sodium hydroxide solution (1.44 g, 18.0 mmol) were added, and the mixture was stirred at 110 C. for 60 minutes in an oil bath. After cooling to room temperature, the reaction solution was diluted with ethyl acetate, washed with water and then saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 95/5) to obtain (9Z,12Z)-di(9Z,12Z)-octadeca-9,12-dienylamine (0.838 g, 1.631 mmol, yield: 36%).</div>
    </li> <li> <para-num num="[1301]"> </para-num> <div id="p-1555" num="1301" class="description-line">ESI-MS m/z: 515 (M+H)<sup>+</sup>; 1H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.8 Hz, 6H), 1.26-1.38 (m, 32H), 1.45-1.54 (m, 4H), 2.05 (q, J=6.6 Hz, 8H), 2.60 (t, J=7.1 Hz, 4H), 2.77 (t, J=5.9 Hz, 4H), 5.29-5.43 (m, 8H).</div>
    </li> <li> <para-num num="[1302]"> </para-num> <div id="p-1556" num="1302" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1303]"> </para-num> <div id="p-1557" num="1303" class="description-line">To a solution of (S)-2-amino-6-(tert-butoxycarbonylamino)hexanoic acid (1.94 g, 7.88 mmol) in acetone (5 mL), sodium hydroxide (2 mol/L aqueous solution, 5 mL) and oleoyl chloride (2.09 g, 6.89 mmol) were added, and the mixture was stirred overnight at room temperature. An aqueous hydrochloric acid solution (6 mol/L) was added to the reaction solution, followed by extraction with chloroform twice. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=90/10 to 80/20) to obtain (S)-6-(tert-butoxycarbonylamino)-2-oleamidohexanoic acid (2.50 g, 4.89 mmol, yield: 71%).</div>
    </li> <li> <para-num num="[1304]"> </para-num> <div id="p-1558" num="1304" class="description-line">ESI-MS m/z: 510 (MH)<sup></sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.87 (t, J=7.0 Hz, 3H), 1.20-1.54 (m, 33H), 1.57-1.68 (m, 2H), 1.71-1.93 (m, 2H), 1.96-2.05 (m, 4H), 2.18-2.29 (m, 2H), 3.07-3.16 (m, 2H), 4.50-4.60 (m, 1H), 4.63-4.76 (m, 1H), 5.28-5.39 (m, 2H), 6.49-6.57 (m, 1H).</div>
    </li> <li> <para-num num="[1305]"> </para-num> <div id="p-1559" num="1305" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1306]"> </para-num> <div id="p-1560" num="1306" class="description-line">To a solution of (S)-6-(tert-butoxycarbonylamino)-2-oleamidohexanoic acid (0.291 g, 0.570 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 in 1,2-dichloroethane (4 mL), O-(7-aza-1H-benzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (0.433 g, 1.14 mmol), N,N-diisopropylethylamine (0.498 mL, 2.85 mmol), and (9Z,12Z)-di(9Z,12Z)-octadeca-9,12-dienylamine (0.293 g, 0.570 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 were added, and the mixture was stirred at room temperature for 4 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform twice. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate=80/20) to obtain tert-butyl (S)-6-(di(9Z,12Z)-octadeca-9,12-dienylamino)-5-oleamido-6-oxohexylcarbamate (0.489 g, 0.486 mmol, yield: 85%).</div>
    </li> <li> <para-num num="[1307]"> </para-num> <div id="p-1561" num="1307" class="description-line">ESI-MS m/z: 1008 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.85-0.92 (m, 9H), 1.20-1.72 (m, 73H), 1.97-2.08 (m, 12H), 2.18 (t, J=7.6 Hz, 2H), 2.74-2.80 (m, 4H), 3.02-3.34 (m, 5H), 3.44-3.53 (m, 1H), 4.55-4.63 (m, 1H), 4.88 (td, J=8.2, 4.6 Hz, 1H), 5.28-5.43 (m, 10H), 6.30 (d, J=8.4 Hz, 1H).</div>
    </li> <li> <para-num num="[1308]"> </para-num> <div id="p-1562" num="1308" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1309]"> </para-num> <div id="p-1563" num="1309" class="description-line">To a solution of tert-butyl (S)-6-(di(9Z,12Z)-octadeca-9,12-dienylamino)-5-oleamido-6-oxohexylcarbamate (0.459 g, 0.456 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 in 1,2-dichloroethane (2 mL), trifluoroacetic acid (0.500 mL, 6.49 mmol) was added, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and chloroform and a saturated aqueous solution of sodium bicarbonate were then added to the residue, followed by extraction with chloroform twice. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate=90/10 to 80/20) to obtain N((S)-6-amino-1-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)-1-oxohexan-2-yl)oleamide (0.259 g, 0.286 mmol, yield: 63%).</div>
    </li> <li> <para-num num="[1310]"> </para-num> <div id="p-1564" num="1310" class="description-line">ESI-MS m/z: 907 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.86-0.91 (m, 9H), 1.20-1.71 (m, 64H), 1.96-2.09 (m, 12H), 2.21 (t, J=7.5 Hz, 2H), 2.73-2.88 (m, 6H), 3.08-3.47 (m, 4H), 4.81-4.88 (m, 1H), 5.28-5.43 (m, 10H), 6.67 (br s, 1H).</div>
    </li> <li> <para-num num="[1311]"> </para-num> <div id="p-1565" num="1311" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1312]"> </para-num> <div id="p-1566" num="1312" class="description-line">To a solution of N((S)-6-amino-1-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)-1-oxohexan-2-yl)oleamide (0.137 g, 0.151 mmol) obtained in step 4 in 1,2-dichloroethane (1 mL), a 38% aqueous formaldehyde solution (0.300 mL) and sodium triacetoxyborohydride (0.096 g, 0.453 mmol) were added, and the mixture was stirred overnight at room temperature. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform twice. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=50/50) to obtain N((S)-1-(di(9Z,12Z)-octadeca-9,12-dienylamino)-6-(dimethylamino)-1-oxohexan-2-yl)oleamide (0.122 g, 0.130 mmol, yield: 86%).</div>
    </li> <li> <para-num num="[1313]"> </para-num> <div id="p-1567" num="1313" class="description-line">ESI-MS m/z: 936 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.83-0.93 (m, 9H), 1.12-1.77 (m, 64H), 1.95-2.25 (m, 22H), 2.73-2.80 (m, 4H), 3.04-3.15 (m, 1H), 3.20-3.34 (m, 2H), 3.44-3.54 (m, 1H), 4.85-4.91 (m, 1H), 5.28-5.43 (m, 10H), 6.28 (d, J=8.6 Hz, 1H).</div>
    </li> <li> <para-num num="[1314]"> </para-num> <div id="p-1568" num="1314" class="description-line">Step 6</div>
    </li> <li> <para-num num="[1315]"> </para-num> <div id="p-1569" num="1315" class="description-line">The title compound (0.0707 g, 0.0718 mol, 65%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A8 using N((S)-1-(di(9Z,12Z)-octadeca-9,12-dienylamino)-6-(dimethylamino)-1-oxohexan-2-yl)oleamide (0.104 g, 0.111 mol) obtained in step 5 instead of (9Z,9Z,12Z,12Z)-2-(dimethylamino)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propane-1,3-diyl dioctadeca-9,12-dienoate.</div>
    </li> <li> <para-num num="[1316]"> </para-num> <div id="p-1570" num="1316" class="description-line">ESI-MS m/z: 950 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.85-0.91 (m, 9H), 1.21-1.83 (m, 64H), 1.97-2.08 (m, 12H), 2.19 (t, J=7.7 Hz, 2H), 2.74-2.80 (m, 4H), 3.05-3.84 (m, 15H), 4.82-4.90 (m, 1H), 5.28-5.43 (m, 10H), 6.41-6.46 (m, 1H).</div>
    </li> <heading id="h-0139">Reference Example A64</heading>
    <heading id="h-0140">(S)N,N,N-Trimethyl-5-(nonacosan-15-yloxy)-1,5-dioxo-1-(tetradexyloxy)pentan-2-aminium chloride (Compound III-3)</heading>
    <li> <para-num num="[1317]"> </para-num> <div id="p-1571" num="1317" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1318]"> </para-num> <div id="p-1572" num="1318" class="description-line">To a solution of ethyl formate (manufactured by Nacalai Tesque, Inc., 2.4 mL, 29.7 mmol) in tetrahydrofuran (9 mL), tetradecyl magnesium chloride (manufactured by Sigma-Aldrich Corp., 1.0 mol/L solution in tetrahydrofuran, 59.4 mL, 59.4 mmol) was added, and the mixture was stirred at 60 C. for 2 hours. The reaction solution was cooled in ice, and water and sulfuric acid (manufactured by Nacalai Tesque, Inc., 2.0 mol/L aqueous solution) were added thereto. The precipitate was collected by filtration to obtain nonacosan-15-ol (6.90 g, 16.2 mmol, yield: 55%).</div>
    </li> <li> <para-num num="[1319]"> </para-num> <div id="p-1573" num="1319" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 6H), 1.22-1.34 (m, 48H), 1.37-1.49 (m, 2H), 3.54-3.64 (m, 1H).</div>
    </li> <li> <para-num num="[1320]"> </para-num> <div id="p-1574" num="1320" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1321]"> </para-num> <div id="p-1575" num="1321" class="description-line">To a solution of 1-tert-butyl 2-aminopentanedioate hydrochloride (manufactured by Watanabe Chemical Industries, Ltd., 10.0 g, 30.3 mmol) in ethanol (150 mL), paraformaldehyde (manufactured by Sigma-Aldrich Corp., 5.50 g, 183 mmol) and sodium cyanoborohydride (5.70 g, 90.7 mmol) were added, and the mixture was stirred overnight at room temperature. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform twice. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate=35/65) to obtain (S)-5-benzyl 1-tert-butyl 2-(dimethylamino)pentanedioate (8.20 g, 25.5 mmol, yield: 84%).</div>
    </li> <li> <para-num num="[1322]"> </para-num> <div id="p-1576" num="1322" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 1.48 (s, 9H), 1.95-2.00 (m, 2H), 2.32 (s, 6H), 2.43 (t, J=7.8 Hz, 2H), 3.04 (t, J=7.5 Hz, 1H), 5.12 (s, 6H), 7.29-7.40 (m, 5H).</div>
    </li> <li> <para-num num="[1323]"> </para-num> <div id="p-1577" num="1323" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1324]"> </para-num> <div id="p-1578" num="1324" class="description-line">To a solution of (S)-5-benzyl 1-tert-butyl 2-(dimethylamino)pentanedioate (8.20 g, 25.5 mmol) in ethanol (200 mL), palladium-carbon (manufactured by Tokyo Chemical Industry Co., Ltd., 10% palladium, product wetted with approximately 55% water, 820 mg) was added, and the mixture was stirred at room temperature for 7 hours in a hydrogen atmosphere. Insoluble matter was removed by filtration through celite, and the filtrate was concentrated. The obtained residue was purified by silica gel column chromatography (dichloromethane/methanol=85/15) to obtain a crude product of (S)-5-tert-butoxy-4-(dimethylamino)-5-oxopentanoic acid (4.83 g, 20.9 mmol, crude yield: 82%).</div>
    </li> <li> <para-num num="[1325]"> </para-num> <div id="p-1579" num="1325" class="description-line">To the obtained crude product of (S)-5-tert-butoxy-4-(dimethylamino)-5-oxopentanoic acid (4.83 g, 20.9 mmol), 1.2-dichloroethane (200 mL), nonacosan-15-ol (9.75 g, 23.0 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (8.01 g, 41.8 mmol), and N,N-dimethylaminopyridine (255 mg, 2.09 mmol) were added, and the mixture was stirred at 50 C. for 3 hours. Water was added to the reaction solution, followed by extraction with dichloromethane twice. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=85/15) to obtain (S)-1-tert-butyl 5-nonacosan-15-yl 2-(dimethylamino)pentanedioate (8.13 g, 12.7 mmol, yield: 61%).</div>
    </li> <li> <para-num num="[1326]"> </para-num> <div id="p-1580" num="1326" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 6H), 1.20-1.38 (m, 48H), 1.46-1.57 (m, 4H), 1.91-2.00 (m, 2H), 2.33-2.41 (m, 8H), 3.05 (t, J=7.6 Hz, 1H), 4.82-4.93 (m, 1H).</div>
    </li> <li> <para-num num="[1327]"> </para-num> <div id="p-1581" num="1327" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1328]"> </para-num> <div id="p-1582" num="1328" class="description-line">To a solution of (S)-1-tert-butyl 5-nonacosan-15-yl 2-(dimethylamino)pentanedioate (8.13 g, 12.7 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 in dichloromethane (40 mL), trifluoroacetic acid (20 mL) was added, and the mixture was stirred overnight at 40 C. The reaction solution was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (dichloromethane/methanol=85/15) to obtain (S)-2-(dimethylamino)-5-(nonacosan-15-yloxy)-5-oxopentanoic acid (6.70 g, 11.5 mmol, yield: 90%).</div>
    </li> <li> <para-num num="[1329]"> </para-num> <div id="p-1583" num="1329" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 6H), 1.18-1.37 (m, 48H), 1.44-1.60 (m, 4H), 2.00-2.13 (m, 2H), 2.52-2.74 (m, 2H), 2.87 (s, 6H), 3.62-3.73 (m, 1H), 4.80-4.89 (m, 1H).</div>
    </li> <li> <para-num num="[1330]"> </para-num> <div id="p-1584" num="1330" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1331]"> </para-num> <div id="p-1585" num="1331" class="description-line">To a solution of (S)-2-(dimethylamino)-5-(nonacosan-15-yloxy)-5-oxopentanoic acid (100 mg, 0.172 mmol) obtained in step 4 in 1,2-dichloroethane (2.0 mL), (1-cyano-2-ethoxy-2-oxoethylideneaminooxy)dimethylamino-morpholino-carbenium hexafluorophosphate (96.0 mg, 0.224 mmol), N,N-diisopropylethylamine (0.060 mL, 0.344 mmol), and tetradecan-1-ol ( ) were added, and the mixture was stirred overnight at room temperature. Water was added to the reaction solution, followed by extraction with dichloromethane. The organic layer was washed with water, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5 to 85/15) to obtain (S)-5-nonacosan-15-yl 1-tetradecyl 2-(dimethylamino)pentanedioate (64.0 mg, 0.0822 mmol, yield: 48%).</div>
    </li> <li> <para-num num="[1332]"> </para-num> <div id="p-1586" num="1332" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 9H), 1.12-1.39 (m, 70H), 1.45-1.69 (m, 6H), 1.93-2.03 (m, 2H), 2.29-2.38 (m, 8H), 3.16 (t, J=7.4 Hz, 1H), 4.03-4.17 (m, 2H), 4.80-4.91 (m, 1H).</div>
    </li> <li> <para-num num="[1333]"> </para-num> <div id="p-1587" num="1333" class="description-line">Step 6</div>
    </li> <li> <para-num num="[1334]"> </para-num> <div id="p-1588" num="1334" class="description-line">The title compound is obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A8 using (S)-5-nonacosan-15-yl 1-tetradecyl 2-(dimethylamino)pentanedioate obtained in step 5 instead of (9Z,9Z,12Z,12Z)-2-(dimethylamino)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propane-1,3-diyl dioctadeca-9,12-dienoate.</div>
    </li> <heading id="h-0141">Reference Example A65</heading>
    <heading id="h-0142">(S)-1-(Dodecyloxy)-N,N,N-trimethyl-5-(nonacosan-15-yloxy)-1,5-dioxopentan-2-aminium chloride (Compound III-4)</heading>
    <li> <para-num num="[1335]"> </para-num> <div id="p-1589" num="1335" class="description-line">The title compound is obtained in the same way as in Reference Example A64 using dodecan-1-ol instead of tetradecan-1-ol used in step 5 of Reference Example A64.</div>
    </li> <heading id="h-0143">Reference Example A66</heading>
    <heading id="h-0144">(S)-1-(Hexadecyloxy)-N,N,N-trimethyl-5-(nonacosan-15-yloxy)-1,5-dioxopentan-2-aminium chloride (Compound III-5)</heading>
    <li> <para-num num="[1336]"> </para-num> <div id="p-1590" num="1336" class="description-line">The title compound is obtained in the same way as in Reference Example A64 using hexadecan-1-ol instead of tetradecan-1-ol used in step 5 of Reference Example A64.</div>
    </li> <heading id="h-0145">Reference Example A67</heading>
    <heading id="h-0146">(S)N,N,N-Trimethyl-5-(nonacosan-15-yloxy)-1-(octadecyloxy)-1,5-dioxopentan-2-aminium chloride (Compound III-6)</heading>
    <li> <para-num num="[1337]"> </para-num> <div id="p-1591" num="1337" class="description-line">The title compound is obtained in the same way as in Reference Example A64 using octadecan-1-ol instead of tetradecan-1-ol used in step 5 of Reference Example A64.</div>
    </li> <heading id="h-0147">Reference Example A68</heading>
    <heading id="h-0148">(S,Z)N,N,N-Triethyl-5-(nonacosan-15-yloxy)-1-(octadec-9-enyloxy)-1,5-dioxopentan-2-aminium chloride (Compound III-7)</heading>
    <li> <para-num num="[1338]"> </para-num> <div id="p-1592" num="1338" class="description-line">The title compound is obtained in the same way as in Reference Example A64 using (Z)-octadec-9-en-1-ol instead of tetradecan-1-ol used in step 5 of Reference Example A64.</div>
    </li> <heading id="h-0149">Reference Example A69</heading>
    <heading id="h-0150">(6Z,9Z,28Z,31Z)N,N-Dimethyl-N-(2-(N-methylstearamido)ethyl)heptatriaconta-6,9,28,31-tetraen-19-aminium chloride (Compound IV-2)</heading>
    <li> <para-num num="[1339]"> </para-num> <div id="p-1593" num="1339" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1340]"> </para-num> <div id="p-1594" num="1340" class="description-line">To a solution of (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-one (0.50 g, 0.256 mmol) obtained by a method equivalent to the method described in WO 2010/042877 in 1,2-dichloroethane (2 mL), methanol (2 mL), N1,N2-dimethylethane-1,2-diamine (manufactured by Tokyo Chemical Industry Co., Ltd., 0.085 mL, 0.767 mmol), and sodium triacetoxyborohydride (0.325 g, 1.53 mmol) were added, and the mixture was stirred at 50 C. for 5 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform twice. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica column chromatography (hexane/ethyl acetate=90/10 to 80/20) to obtain N1-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl)-N1,N2-dimethylethane-1,2-diamine (0.0303 g, 0.0506 mmol, yield: 20%).</div>
    </li> <li> <para-num num="[1341]"> </para-num> <div id="p-1595" num="1341" class="description-line">ESI-MS m/z: 600 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.8 Hz, 6H), 1.13-1.45 (m, 40H), 2.01-2.09 (m, 8H), 2.14 (s, 3H), 2.28-2.40 (m, 1H), 2.43 (s, 3H), 2.52-2.60 (m, 4H), 2.75-2.80 (m, 4H), 5.29-5.42 (m, 8H).</div>
    </li> <li> <para-num num="[1342]"> </para-num> <div id="p-1596" num="1342" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1343]"> </para-num> <div id="p-1597" num="1343" class="description-line">To a solution of N1-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl)-N1,N2-dimethylethane-1,2-diamine (0.0258 g, 0.0431 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in 1,2-dichloroethane (1 mL), stearoyl chloride (0.0390 g, 0.129 mmol) and N,N-diisopropylethylamine (0.038 mL, 0.215 mmol) were added, and the mixture was stirred at room temperature for 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform twice. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica column chromatography (hexane/ethyl acetate=90/10) to obtain a crude product of N-(2-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl(methyl)amino)ethyl)-N-methylstearamide.</div>
    </li> <li> <para-num num="[1344]"> </para-num> <div id="p-1598" num="1344" class="description-line">To the obtained crude product, methyl iodide (1.00 mL, 16.0 mmol) was added, and the mixture was stirred at 50 C. for 1 hour. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (manufactured by The Dow Chemical Company, <figure-callout id="1" label="DowexTM" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Dowex</figure-callout> 1-2 100 mesh, Cl type, approximately 20-fold amount, prewashed with water and methanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=80/20) to obtain the title compound (0.0149 g, 0.0163 mmol, yield: 38%).</div>
    </li> <li> <para-num num="[1345]"> </para-num> <div id="p-1599" num="1345" class="description-line">ESI-MS m/z: 881 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.84-0.92 (m, 9H), 1.20-2.09 (m, 78H), 2.27-2.38 (m, 2H), 2.74-2.80 (m, 4H), 3.14-3.45 (m, 9H), 3.77-4.09 (m, 5H), 5.28-5.43 (m, 8H).</div>
    </li> <heading id="h-0151">Reference Example A70</heading>
    <heading id="h-0152">(9Z,12Z)N,N-Dimethyl-N-(3-((9Z,12Z)N-((9Z,12Z)-octadeca-9,12-dienyl)octadeca-9,12-dienamido)propyl)octadeca-9,12-dien-1-aminium chloride (Compound IV-3)</heading>
    <li> <para-num num="[1346]"> </para-num> <div id="p-1600" num="1346" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1347]"> </para-num> <div id="p-1601" num="1347" class="description-line">To (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (0.838 g, 2.43 mmol), 3-aminopropan-1-ol (1.66 g, 21.9 mmol) was added, and the mixture was stirred at 90 C. for 3 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by amino silica gel chromatography (hexane/ethyl acetate) to obtain 3-((9Z,12Z)-octadeca-9,12-dienylamino)propan-1-ol (0.722 g, 2.23 mmol, yield: 92%).</div>
    </li> <li> <para-num num="[1348]"> </para-num> <div id="p-1602" num="1348" class="description-line">ESI-MS m/z: 325 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.9 Hz, 3H), 1.26-1.39 (m, 17H), 1.46 (tt, J=7.1, 6.9 Hz, 3H), 1.69 (tt, J=5.7, 5.4 Hz, 2H), 2.02-2.08 (m, 4H), 2.60 (t, J=7.1 Hz, 2H), 2.75-2.80 (m, 2H), 2.88 (t, J=5.7 Hz, 2H), 3.81 (t, J=5.4 Hz, 2H), 5.30-5.42 (m, 4H).</div>
    </li> <li> <para-num num="[1349]"> </para-num> <div id="p-1603" num="1349" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1350]"> </para-num> <div id="p-1604" num="1350" class="description-line">3-(Methyl((9Z,12Z)-octadeca-9,12-dienyl)amino)propan-1-ol (0.220 g, 0.652 mol, yield: 90%) was obtained in the same way as in step 5 of Reference Example A63 using 3-((9Z,12Z)-octadeca-9,12-dienylamino) propan-1-ol (0.233 g, 0.722 mol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 instead of N((S)-6-amino-1-(di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)-1-oxohexan-2-yl)oleamide.</div>
    </li> <li> <para-num num="[1351]"> </para-num> <div id="p-1605" num="1351" class="description-line">ESI-MS m/z: 338 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 3H), 1.24-1.40 (m, 16H), 1.47 (tt, J=7.6, 7.0 Hz, 2H), 1.69 (tt, J=5.7, 5.2 Hz, 2H), 2.01-2.08 (m, 4H), 2.23 (s, 3H), 2.34 (t, J=7.6 Hz, 2H), 2.59 (t, J=5.7 Hz, 2H), 2.75-2.80 (m, 2H), 3.80 (t, J=5.2 Hz, 2H), 5.29-5.42 (m, 4H).</div>
    </li> <li> <para-num num="[1352]"> </para-num> <div id="p-1606" num="1352" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1353]"> </para-num> <div id="p-1607" num="1353" class="description-line">To a solution of (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (2.85 g, 8.27 mmol) in acetonitrile (30 mL), cesium carbonate (6.74 g, 20.7 mmol), tetra-n-butylammonium iodide (3.05 g, 8.27 mmol) and N-(tert-butoxycarbonyl)-2-nitrobenzenesulfonamide (2.50 g, 8.27 mmol) were added, and the mixture was stirred for 3 hours under heating to reflux. The reaction solution was cooled to room temperature, and water was added thereto, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=70/30) to obtain tert-butyl 2-nitrophenylsulfonyl((9Z,12Z)-octadeca-9,12-dienyl)carbamate (3.21 g, 5.83 mmol).</div>
    </li> <li> <para-num num="[1354]"> </para-num> <div id="p-1608" num="1354" class="description-line">To a solution of the obtained tert-butyl 2-nitrophenylsulfonyl((9Z,12Z)-octadeca-9,12-dienyl)carbamate (3.21 g, 5.83 mmol) in dichloromethane (23 mL), trifluoroacetic acid (9.63 mL, 126 mmol) was added, and the mixture was stirred at room temperature for 0.5 hours. The reaction solution was diluted with dichloromethane, and an aqueous sodium hydroxide solution (1 mol/L) and a saturated aqueous solution of sodium bicarbonate were added thereto. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5) to obtain 2-nitro-N-((9Z,12Z)-octadeca-9,12-dienyl)benzenesulfonamide (2.48 g, 5.50 mmol, yield: 67%).</div>
    </li> <li> <para-num num="[1355]"> </para-num> <div id="p-1609" num="1355" class="description-line">ESI-MS m/z: 338 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 3H), 1.22-1.39 (m, 16H), 1.52 (m, 2H), 2.01-2.05 (m, 4H), 2.77 (t, J=6.6 Hz, 2H), 3.09 (q, J=6.7 Hz, 2H), 5.23 (m, 1H), 5.31-5.42 (m, 4H), 7.71-7.76 (m, 2H), 7.78-7.87 (1H), 813-8.15 (m, 1H).</div>
    </li> <li> <para-num num="[1356]"> </para-num> <div id="p-1610" num="1356" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1357]"> </para-num> <div id="p-1611" num="1357" class="description-line">To a solution of 3-(methyl((9Z,12Z)-octadeca-9,12-dienyl)amino)propan-1-ol (0.220 g, 0.652 mol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 in tetrahydrofuran (4 mL), 2-nitro-N-((9Z,12Z)-octadeca-9,12-dienyl)benzenesulfonamide (0.441 g, 0.978 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3, triphenylphosphine (0.257 g, 0.978 mmol), and diethyl azodicarboxylate (manufactured by Nacalai Tesque, Inc., 40% solution in toluene, 0.387 mL, 0.851 mmol) were added, and the mixture was stirred at 50 C. for 2 hours. The reaction solution was cooled to room temperature, and saturated saline was added thereto, followed by extraction with hexane twice. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=80/20) to obtain a crude product of N-(3-(methyl((9Z,12Z)-octadeca-9,12-dienyl)amino)propyl)-2-nitro-N-((9Z,12Z)-octadeca-9,12-dienyl)benzenesulfonamide.</div>
    </li> <li> <para-num num="[1358]"> </para-num> <div id="p-1612" num="1358" class="description-line">To a solution of the obtained crude product of N-(3-(methyl((9Z,12Z)-octadeca-9,12-dienyl)amino)propyl)-2-nitro-N-((9Z,12Z)-octadeca-9,12-dienyl)benzenesulfonamide in acetonitrile (5 mL), dodecane-1-thiol (0.409 mL, 1.63 mmol) and 1,8-diazabicyclo[5.4.0]-7-undecene (0.246 mL, 1.630 mmol) were added, and the mixture was stirred at 60 C. for 2 hours. Water was added to the reaction solution, followed by extraction with hexane twice. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=75/25) to obtain N1-methyl-N1,N3-di ((9Z,12Z)-octadeca-9,12-dienyl)propane-1,3-diamine (0.212 g, 0.363 mmol, yield: 56%).</div>
    </li> <li> <para-num num="[1359]"> </para-num> <div id="p-1613" num="1359" class="description-line">ESI-MS m/z: 586 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 6H), 1.22-1.51 (m, 36H), 1.66 (tt, J=7.2, 7.1 Hz, 2H), 2.01-2.08 (m, 8H), 2.20 (s, 3H), 2.29 (t, J=7.6 Hz, 2H), 2.36 (t, J=7.2 Hz, 2H), 2.58 (t, J=7.4 Hz, 2H), 2.62 (t, J=7.1 Hz, 2H), 2.75-2.80 (m, 4H), 5.29-5.43 (m, 8H).</div>
    </li> <li> <para-num num="[1360]"> </para-num> <div id="p-1614" num="1360" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1361]"> </para-num> <div id="p-1615" num="1361" class="description-line">To a solution of N1-methyl-N1,N3-di((9Z,12Z)-octadeca-9,12-dienyl)propane-1,3-diamine (0.108 g, 0.185 mmol) obtained in step 4 in 1,2-dichloroethane (1 mL), (9Z,12Z)-octadeca-9,12-dienoic acid (0.104 g, 0.370 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.106 g, 0.555 mmol), and N,N-dimethylaminopyridine (0.0023 g, 0.0188 mmol) were added, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=85/15) to obtain (9Z,12Z)N-(3-(methyl((9Z,12Z)-octadeca-9,12-dienyl)amino)propyl)-N-((9Z,12Z)-octadeca-9,12-dienyl)octadeca-9,12-dienamide (0.146 g, 0.172 mmol, yield: 93%).</div>
    </li> <li> <para-num num="[1362]"> </para-num> <div id="p-1616" num="1362" class="description-line">ESI-MS m/z: 848 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.21-1.74 (m, 54H), 2.01-2.08 (m, 12H), 2.18 (s, 3H), 2.24-2.33 (m, 6H), 2.74-2.80 (m, 6H), 3.18-3.35 (m, 4H), 5.29-5.42 (m, 12H).</div>
    </li> <li> <para-num num="[1363]"> </para-num> <div id="p-1617" num="1363" class="description-line">Step 6</div>
    </li> <li> <para-num num="[1364]"> </para-num> <div id="p-1618" num="1364" class="description-line">The title compound (0.0804 g, 0.0895 mol, yield: 76%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example A8 using (9Z,12Z)N-(3-(methyl((9Z,12Z)-octadeca-9,12-dienyl)amino)propyl)-N-((9Z,12Z)-octadeca-9,12-dienyl)octadeca-9,12-dienamide (0.100 g, 0.118 mmol) obtained in step 5 instead of (9Z,9Z,12Z,12Z)-2-(dimethylamino)-2-(((9Z,12Z)-octadeca-9,12-dienoyloxy)methyl)propane-1,3-diyl dioctadeca-9,12-dienoate.</div>
    </li> <li> <para-num num="[1365]"> </para-num> <div id="p-1619" num="1365" class="description-line">ESI-MS m/z: 862 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=7.0 Hz, 9H), 1.22-1.41 (m, 46H), 1.49-1.78 (m, 6H), 1.93-2.10 (m, 14H), 2.30 (t, J=7.6 Hz, 2H), 2.74-2.79 (m, 6H), 3.24-3.35 (m, 8H), 3.36-3.47 (m, 4H), 3.59-3.67 (m, 2H), 5.28-5.42 (m, 12H).</div>
    </li> <heading id="h-0153">Reference Example A71</heading>
    <heading id="h-0154">(R)-2-((2R,3R,4S)-3,4-Bis((9Z,12Z)-octadeca-9,12-dienyloxy)tetrahydrofuran-2-yl)-N,N,N-trimethyl-2-((9Z,12Z)-octadeca-9,12-dienyloxy)ethanaminium chloride (Compound V-1)</heading>
    <li> <para-num num="[1366]"> </para-num> <div id="p-1620" num="1366" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1367]"> </para-num> <div id="p-1621" num="1367" class="description-line">To a solution of (2R,3R,4S)-2-((R)-1,2-dihydroxyethyl)tetrahydrofuran-3,4-diol (manufactured by Sigma-Aldrich Corp., 0.315 g, 1.92 mmol) in pyridine (manufactured by Wako Pure Chemical Industries Ltd., 10 mL), 4,4-dimethoxytrityl chloride (0.704 g, 2.02 mmol) and N,N-dimethylaminopyridine (0.047 g, 0.384 mmol) were added, and the mixture was stirred overnight at 50 C. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (chloroform/methanol=90/10) to obtain (2R,3R,4S)-2-((R)-2-(bis(4-methoxyphenyl)phenyl)methoxy)-1-hydroxyethyl)tetrahydrofuran-3,4-diol (0.465 g, 0.997 mmol, yield: 52%).</div>
    </li> <li> <para-num num="[1368]"> </para-num> <div id="p-1622" num="1368" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 1.67-1.74 (m, 1H), 2.73-2.77 (m, 1H), 3.31 (dd, J=9.8, 6.2 Hz, 1H), 3.41-3.50 (m, 2H), 3.70 (dd, J=9.6, 1.3 Hz, 1H), 3.79 (s, 6H), 3.94 (dd, J=6.2, 3.5 Hz, 1H), 4.10-4.24 (m, 3H), 4.26-4.30 (m, 1H), 6.81-6.86 (m, 4H), 7.20-7.36 (m, 7H), 7.41-7.45 (m, 2H).</div>
    </li> <li> <para-num num="[1369]"> </para-num> <div id="p-1623" num="1369" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1370]"> </para-num> <div id="p-1624" num="1370" class="description-line">To a solution of (2R,3R,4S)-2-((R)-2-(bis(4-methoxyphenyl)phenyl)methoxy)-1-hydroxyethyl)tetrahydrofuran-3,4-diol (0.0669 g, 0.143 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in tetrahydrofuran (1 mL), (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (0.247 g, 0.717 mmol) and sodium hydride (60% oil, 0.0459 g, 1.15 mmol) were added, and the mixture was stirred overnight under heating to reflux. After cooling to room temperature, saturated saline was added to the reaction solution, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=90/10) to obtain a crude product of (2R,3R,4S)-2-((R)-2-(bis(4-methoxyphenyl)(phenyl)methoxy)-1-((9Z,12Z)-octadeca-9,12-dienyloxy)ethyl)-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)tetrahydrofuran.</div>
    </li> <li> <para-num num="[1371]"> </para-num> <div id="p-1625" num="1371" class="description-line">To the obtained crude product of (2R,3R,4S)-2-((R)-2-(bis(4-methoxyphenyl)(phenyl)methoxy)-1-((9Z,12Z)-octadeca-9,12-dienyloxy)ethyl)-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)tetrahydrofuran, dichloromethane (1 mL) and trifluoroacetic acid (0.0500 mL, 0.649 mmol) were added, and the mixture was stirred at room temperature for 5 minutes. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by silica gel chromatography (hexane/ethyl acetate=70/30) to obtain (R)-2-((2R,3R,4S)-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)tetrahydrofuran-2-yl)-2-((9Z,12Z)-octadeca-9,12-dienyloxy)ethanol (0.0531 g, 0.0584 mmol, yield: 41%).</div>
    </li> <li> <para-num num="[1372]"> </para-num> <div id="p-1626" num="1372" class="description-line"> <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.23-1.43 (m, 48H), 1.50-1.62 (m, 6H), 2.01-2.09 (m, 12H), 2.32 (dd, J=8.2, 4.2 Hz, 1H), 2.74-2.80 (m, 6H), 3.37-3.50 (m, 4H), 3.54-3.69 (m, 3H), 3.69-3.77 (m, 2H), 3.80-3.87 (m, 2H), 3.88-3.95 (m, 2H), 4.06 (dd, J=9.8, 4.7 Hz, 1H), 5.28-5.42 (m, 12H).</div>
    </li> <li> <para-num num="[1373]"> </para-num> <div id="p-1627" num="1373" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1374]"> </para-num> <div id="p-1628" num="1374" class="description-line">To a solution of (R)-2-((2R,3R,4S)-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)tetrahydrofuran-2-yl)-2-((9Z,12Z)-octadeca-9,12-dienyloxy)ethanol (0.0491 g, 0.0540 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 in dichloromethane (1 mL), methanesulfonyl chloride (manufactured by Junsei Chemical Co., Ltd., 0.0500 mL, 0.642 mmol) and triethylamine (0.150 mL, 1.08 mmol) were added, and the mixture was stirred at room temperature for 1 hour. Methanesulfonyl chloride (0.0500 mL, 0.642 mmol) and triethylamine (0.150 mL, 1.08 mmol) were added to the reaction solution, and the mixture was stirred at room temperature for 1 hour. Chloroform (1 mL) was added to the reaction solution, and the mixture was stirred at room temperature for 1 hour. Methanesulfonyl chloride (0.0500 mL, 0.642 mmol) and triethylamine (0.150 mL, 1.08 mmol) were added to the reaction solution, and the mixture was stirred at 40 C. for 2 hours and then stirred for 2 hours under heating to reflux. Saturated saline was added to the reaction solution, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. To the obtained residue, tetrahydrofuran (1 mL) and dimethylamine (2.0 mol/L solution in tetrahydrofuran, 2 mL, 2.00 mmol) were added, and the mixture was stirred at 130 C. for 5 hours using a microwave reaction apparatus. The reaction solution was concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=95/5) to obtain a crude product of (R)-2-((2R,3R,4S)-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)tetrahydrofuran-2-yl)-N,N-dimethyl-2-((9Z,12Z)-octadeca-9,12-dienyloxy)ethanamine. To the obtained crude product of (R)-2-((2R,3R,4S)-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)tetrahydrofuran-2-yl)-N,N-dimethyl-2-((9Z,12Z)-octadeca-9,12-dienyloxy) ethanamine, chloroform (0.5 mL) and methyl iodide (1.00 mL, 16.0 mmol) were added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure. The residue was dissolved in a small amount of methanol-chloroform (1:1), and the solution was loaded to an ion-exchange resin (manufactured by The Dow Chemical Company, <figure-callout id="1" label="DowexTM" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Dowex</figure-callout> 1-2 100 mesh, Cl type, approximately 20-fold amount, prewashed with water and methanol), followed by elution with methanol-chloroform (1:1). The eluate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=90/10) to obtain the title compound (0.0130 g, 0.0132 mmol, yield: 24%).</div>
    </li> <li> <para-num num="[1375]"> </para-num> <div id="p-1629" num="1375" class="description-line">ESI-MS m/z: 951 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 9H), 1.23-1.40 (m, 48H), 1.51-1.61 (m, 6H), 2.01-2.09 (m, 12H), 2.74-2.80 (m, 6H), 3.34-3.68 (m, 17H), 3.70-3.74 (m, 1H), 3.81-3.84 (m, 1H), 3.93-4.02 (m, 3H), 4.07-4.12 (m, 1H), 5.28-5.43 (m, 12H).</div>
    </li> <li> <para-num num="[1376]"> </para-num> <div id="p-1630" num="1376" class="description-line">Hereinafter, methods for producing lipid B will be shown.</div>
    </li> <heading id="h-0155">Reference Example B1</heading>
    <heading id="h-0156">N,N-Dimethyl-2,3-bis(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)propan-1-amine (Compound CL-1)</heading>
    <li> <para-num num="[1377]"> </para-num> <div id="p-1631" num="1377" class="description-line">Compound CL-1 was synthesized by the method described in J. Control. Release., 2005, Vol. 107, p. 276-287.</div>
    </li> <heading id="h-0157">Reference Example B2</heading>
    <heading id="h-0158">N-Methyl-N,N-bis(2-((Z)-hexadec-9-enyloxy)ethyl)amine (Compound CL-2)</heading>
    <li> <para-num num="[1378]"> </para-num> <div id="p-1632" num="1378" class="description-line">To a suspension of sodium hydride (60% oil, 222 mg, 5.55 mmol) in toluene (2 mL), a solution of N-methyldiethanolamine (manufactured by Tokyo Chemical Industry Co., Ltd., 82.6 mg, 0.693 mmol) in toluene (2 mL) was added with stirring, and a solution of (Z)-hexadec-9-enyl methanesulfonate (530 mg, 1.66 mmol) in toluene (2 mL) was then added dropwise. The obtained mixture was stirred for 2 hours under heating to reflux. After cooling to room temperature, the reaction was terminated with water. To the obtained mixture, saturated saline was added, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 98/2) to obtain the title compound (199 mg, 0.353 mmol, yield: 51%).</div>
    </li> <li> <para-num num="[1379]"> </para-num> <div id="p-1633" num="1379" class="description-line">ESI-MS m/z: 565 (M+H)<sup>+</sup>;</div>
    </li> <heading id="h-0159">Reference Example B3</heading>
    <heading id="h-0160">trans-1-Methyl-3,4-bis((((Z)-octadec-9-en-1-yl)oxy)methyl)pyrrolidine (Compound CL-3)</heading>
    <li> <para-num num="[1380]"> </para-num> <div id="p-1634" num="1380" class="description-line">Compound CL-3 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0161">Reference Example B4</heading>
    <heading id="h-0162">trans-1-Methylpyrrolidine-3,4-diyl)bis(methylene)(9Z,9Z,12Z,12Z)-bis(octadeca-9,12-dienoate) (Compound CL-4)</heading>
    <li> <para-num num="[1381]"> </para-num> <div id="p-1635" num="1381" class="description-line">Compound CL-4 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0163">Reference Example B5</heading>
    <heading id="h-0164">(6Z,9Z,28Z,31Z)-Heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate (Compound CL-5)</heading>
    <li> <para-num num="[1382]"> </para-num> <div id="p-1636" num="1382" class="description-line">Compound CL-5 was synthesized by a method equivalent to the method described in WO 2010/054401.</div>
    </li> <li> <para-num num="[1383]"> </para-num> <div id="p-1637" num="1383" class="description-line">ESI-MS m/z: 642</div>
    </li> <heading id="h-0165">Reference Example B6</heading>
    <heading id="h-0166">3-(Di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)propan-1-ol (Compound CL-6)</heading>
    <li> <para-num num="[1384]"> </para-num> <div id="p-1638" num="1384" class="description-line">Compound CL-6 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0167">Reference Example B7</heading>
    <heading id="h-0168">(9Z,12Z)N-(2-(((Z)-Octadec-9-en-1-yl)oxy)ethyl)octadeca-9,12-dien-1-amine (Compound CL-7)</heading>
    <li> <para-num num="[1385]"> </para-num> <div id="p-1639" num="1385" class="description-line">Compound CL-7 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0169">Reference Example B8</heading>
    <heading id="h-0170">1-Methyl-3,3-di((9Z,12Z)-octadeca-9,12-dien-1-yl)azetidine (Compound CL-8)</heading>
    <li> <para-num num="[1386]"> </para-num> <div id="p-1640" num="1386" class="description-line">Compound CL-8 was synthesized by the method described in WO 2016/002753.</div>
    </li> <heading id="h-0171">Reference Example B9</heading>
    <heading id="h-0172">N,2-Dimethyl-1,3-bis(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)propan-2-amine (Compound CL-9)</heading>
    <li> <para-num num="[1387]"> </para-num> <div id="p-1641" num="1387" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1388]"> </para-num> <div id="p-1642" num="1388" class="description-line">2-Amino-2-methylpropane-1,3-diol (manufactured by Tokyo Chemical Industry Co., Ltd., 0.300 g, 4.76 mmol) was dissolved in tetrahydrofuran (3 mL). To the solution, sodium hydride (60% oil, 0.171 g, 7.13 mmol) was added at room temperature. After foaming was completed, (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (manufactured by Nu-Chek Prep, Inc, 2.458 g, 7.13 mmol) was added thereto, and the mixture was stirred for 2 hours under heating to reflux. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, followed by extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 90/10) to obtain 2-methyl-1,3-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)propan-2-amine (0.280 g, yield: 16%).</div>
    </li> <li> <para-num num="[1389]"> </para-num> <div id="p-1643" num="1389" class="description-line">ESI-MS m/z: 602 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1390]"> </para-num> <div id="p-1644" num="1390" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1391]"> </para-num> <div id="p-1645" num="1391" class="description-line">2-Methyl-1,3-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)propan-2-amine (0.500 g, 0.831 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in dichloromethane (3 mL). To the solution, triethylamine (manufactured by Wako Pure Chemical Industries Ltd., 2.55 mL, 18.3 mmol) and 2-nitrobenzene-1-sulfonyl chloride (manufactured by Sigma-Aldrich Corp., 0.368 g, 1.66 mmol) were added under ice cooling, and the mixture was brought back to room temperature and then stirred for 1 hour. Water was added to the reaction mixture, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=99/1 to 85/15) to obtain N-(2-methyl-1,3-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)propan-2-yl)-2-nitrobenzenesulfonamide (0.400 g, yield: 61%).</div>
    </li> <li> <para-num num="[1392]"> </para-num> <div id="p-1646" num="1392" class="description-line">ESI-MS m/z: 787 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1393]"> </para-num> <div id="p-1647" num="1393" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1394]"> </para-num> <div id="p-1648" num="1394" class="description-line">N-(2-Methyl-1,3-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy) propan-2-yl)-2-nitrobenzenesulfonamide (0.200 g, 0.274 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 was dissolved in tetrahydrofuran (3 mL). To the solution, cesium carbonate (manufactured by Wako Pure Chemical Industries Ltd., 0.248 g, 0.726 mmol) and methyl iodide (manufactured by Tokyo Chemical Industry Co., Ltd., 0.048 mL, 0.762 mmol) were added, and the mixture was stirred at 70 C. for 1 hour using a microwave reaction apparatus. Water was added to the reaction mixture, followed by extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain N-methyl-N-(2-methyl-1,3-bis(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)propan-2-yl)-2-nitrobenzenesulfonamide (0.200 g, yield: 91%) as a crude product.</div>
    </li> <li> <para-num num="[1395]"> </para-num> <div id="p-1649" num="1395" class="description-line">ESI-MS m/z: 801 (M+H)<sup>+</sup> </div>
    </li> <li> <para-num num="[1396]"> </para-num> <div id="p-1650" num="1396" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1397]"> </para-num> <div id="p-1651" num="1397" class="description-line">N-Methyl-N-(2-methyl-1,3-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)propan-2-yl)-2-nitrobenzenesulfonamide (0.200 g, 0.250 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 was dissolved in acetonitrile (2 mL). To the solution, 1-dodecanethiol (manufactured by Tokyo Chemical Industry Co., Ltd., 0.149 mL, 0.624 mmol) and 1,8-diazabicyclo[5.4.0]-7-undecene (manufactured by Nacalai Tesque, Inc., 0.0940 mL, 0.624 mmol) were added, and the mixture was stirred at 80 C. for 1 hour. Water was added to the reaction mixture, and the aqueous layer was subjected to extraction with ethyl acetate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by NH silica gel column chromatography (hexane/ethyl acetate=90/10 to 75/25) to obtain compound CL-9 (0.070 g, yield: 46%).</div>
    </li> <li> <para-num num="[1398]"> </para-num> <div id="p-1652" num="1398" class="description-line">ESI-MS m/z: 616 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.8 Hz, 6H), 1.02 (s, 3H), 1.25-1.40 (m, 32H), 1.50-1.59 (m, 4H), 2.05 (q, J=6.8 Hz, 8H), 2.32 (s, 3H), 2.77 (t, J=6.3 Hz, 4H), 3.26 (s, 4H), 3.40 (t, J=6.6 Hz, 4H), 5.28-5.43 (m, 8H).</div>
    </li> <heading id="h-0173">Reference Example B10</heading>
    <heading id="h-0174">Methyl di((9Z,12Z)-octadeca-9,12-dienyl)amine (Compound CL-10)</heading>
    <li> <para-num num="[1399]"> </para-num> <div id="p-1653" num="1399" class="description-line">To methylamine (manufactured by Sigma-Aldrich Corp., approximately 2 mol/L solution in tetrahydrofuran, 10.5 mL, 21.0 mmol), (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (1.03 g, 3.00 mmol) was added, and the mixture was stirred under heating at 150 C. for 90 minutes using a microwave reaction apparatus. The reaction solution was diluted with ethyl acetate, washed with a 2 mol/L aqueous sodium hydroxide solution and then saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain a crude product of methyl((9Z,12Z)-octadeca-9,12-dienyl)amine.</div>
    </li> <li> <para-num num="[1400]"> </para-num> <div id="p-1654" num="1400" class="description-line">To the obtained crude product, (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (0.93 g, 2.70 mmol) and a 50% aqueous sodium hydroxide solution (0.960 g, 12.0 mmol) were added, and the mixture was stirred under heating at 135 C. for 60 minutes in an oil bath. After cooling to room temperature, the reaction solution was diluted with ethyl acetate, washed with water and then saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 97/3) to obtain compound CL-10 (1.07 g, 2.03 mmol, overall yield: 67%).</div>
    </li> <li> <para-num num="[1401]"> </para-num> <div id="p-1655" num="1401" class="description-line">ESI-MS m/z: 529 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.7 Hz, 6H), 1.29 (br s, 32H), 1.40-1.51 (m, 4H), 1.97-2.06 (m, 8H), 2.20 (s, 3H), 2.30 (t, J=7.6 Hz, 4H), 2.77 (t, J=5.8 Hz, 4H), 5.28-5.43 (m, 8H).</div>
    </li> <heading id="h-0175">Reference Example B11</heading>
    <heading id="h-0176">N-Methyl-2-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-N-(2-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)ethyl)ethan-1-amine (Compound CL-11)</heading>
    <li> <para-num num="[1402]"> </para-num> <div id="p-1656" num="1402" class="description-line">Compound CL-11 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0177">Reference Example B12</heading>
    <heading id="h-0178">(3R,4R)-3,4-Bis(((Z)-hexadec-9-en-1-yl)oxy)-1-methylpyrrolidine (Compound CL-12)</heading>
    <li> <para-num num="[1403]"> </para-num> <div id="p-1657" num="1403" class="description-line">Compound CL-12 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0179">Reference Example B13</heading>
    <heading id="h-0180">2-(Dimethylamino)-N-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl)acetamide (Compound CL-13)</heading>
    <li> <para-num num="[1404]"> </para-num> <div id="p-1658" num="1404" class="description-line">Compound CL-13 was synthesized by the method described in WO 2013/059496.</div>
    </li> <heading id="h-0181">Reference Example B14</heading>
    <heading id="h-0182">3-(Dimethylamino)propane-1,2-diyl (9Z,9Z,12Z,12Z)-bis(octadeca-9,12-dienoate) (Compound CL-14)</heading>
    <li> <para-num num="[1405]"> </para-num> <div id="p-1659" num="1405" class="description-line">Compound CL-14 was synthesized by the method described in Biochemistry, 1994, Vol. 33, p. 12573-12580.</div>
    </li> <heading id="h-0183">Reference Example B15</heading>
    <heading id="h-0184">(9Z,12Z)-Di((9Z,12Z)-octadeca-9,12-dien-1-yl)amine (Compound CL-15)</heading>
    <li> <para-num num="[1406]"> </para-num> <div id="p-1660" num="1406" class="description-line">Compound CL-15 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0185">Reference Example B16</heading>
    <heading id="h-0186">Bis(2-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)ethyl)amine (Compound CL-16)</heading>
    <li> <para-num num="[1407]"> </para-num> <div id="p-1661" num="1407" class="description-line">Compound CL-16 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0187">Reference Example B17</heading>
    <heading id="h-0188">(9Z,12Z)N-Methyl-N-(2-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)ethyl)octadeca-9,12-dien-1-amine (Compound CL-17)</heading>
    <li> <para-num num="[1408]"> </para-num> <div id="p-1662" num="1408" class="description-line">2-(Methylamino)ethanol (manufactured by Tokyo Chemical Industry Co., Ltd., 0.125 g, 1.66 mmol) was dissolved in toluene (2.5 mL). To the solution, sodium hydride (60% oil, 0.333 g, 8.32 mmol) and a solution of (9Z,12Z)-octadeca-9,12-dien-1-yl methanesulfonate (manufactured by Nu-Chek Prep, Inc., 1.32 g, 3.83 mmol) in toluene (2.5 mL) were added in order, and the mixture was stirred for 2 hours under heating to reflux. The reaction mixture was cooled to room temperature. Then, ethanol and water were added thereto, and the aqueous layer was subjected to extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 97/3) to obtain compound CL-17 (0.211 g, yield: 22%).</div>
    </li> <li> <para-num num="[1409]"> </para-num> <div id="p-1663" num="1409" class="description-line">ESI-MS m/z: 572 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.9 Hz, 6H), 1.24-1.38 (m, 32H), 1.43-1.49 (m, 2H), 1.53-1.59 (m, 2H), 2.05 (q, J=7.2 Hz, 8H), 2.27 (s, 3H), 2.37 (t, J=7.7 Hz, 2H), 2.57 (t, J=6.2 Hz, 2H), 2.78 (t, J=6.8 Hz, 4H), 3.42 (t, J=6.8 Hz, 2H), 3.52 (t, J=6.2 Hz, 2H), 5.30-5.41 (m, 8H).</div>
    </li> <heading id="h-0189">Reference Example B18</heading>
    <heading id="h-0190">(9Z,12Z)N-(3-(((9Z,12Z)-Octadeca-9,12-dien-1-yl)oxy)propyl)octadeca-9,12-dien-1-amine (Compound CL-18)</heading>
    <li> <para-num num="[1410]"> </para-num> <div id="p-1664" num="1410" class="description-line">Compound CL-18 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <li> <para-num num="[1411]"> </para-num> <div id="p-1665" num="1411" class="description-line">ESI-MS m/z: 572</div>
    </li> <heading id="h-0191">Reference Example B19</heading>
    <heading id="h-0192">(1-Methylpiperidin-3-yl)methyl di((11Z,14Z)-icosa-11,14-dien-1-yl)carbamate (Compound CL-19)</heading>
    <li> <para-num num="[1412]"> </para-num> <div id="p-1666" num="1412" class="description-line">Compound CL-19 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0193">Reference Example B20</heading>
    <heading id="h-0194">(13Z,16Z)N,N-Dimethyl-4-((9Z,12Z)-octadeca-9,12-dien-1-yl)docosa-3,13,16-trien-1-amine (Compound CL-20)</heading>
    <li> <para-num num="[1413]"> </para-num> <div id="p-1667" num="1413" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1414]"> </para-num> <div id="p-1668" num="1414" class="description-line">To a solution of heptatriaconta-6,9,28,31-tetraen-19-one (0.353 g, 0.186 mmol) synthesized by the method described in WO 2009/132131 in tetrahydrofuran (0.882 mL), anhydrous cerium(III) chloride (manufactured by Tokyo Chemical Industry Co., Ltd., 0.174 g, 0.706 mmol) was added in an argon atmosphere. Then, cyclopropyl magnesium bromide (manufactured by Sigma-Aldrich Corp., 0.5 mmol/L. 1.06 mL, 0.529 mmol) was added under ice cooling, and the mixture was stirred for 5 minutes and then stirred at room temperature for 1 hour. A saturated aqueous solution of ammonium chloride was added to the reaction mixture, and the aqueous layer was subjected to extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=97/3 to 94/6) to obtain (6Z,9Z,28Z,31Z)-19-cyclopropylheptatriaconta-6,9,28,31-tetraen-19-ol (0.141 g, yield: 70%).</div>
    </li> <li> <para-num num="[1415]"> </para-num> <div id="p-1669" num="1415" class="description-line">ESI-MS m/z: 569</div>
    </li> <li> <para-num num="[1416]"> </para-num> <div id="p-1670" num="1416" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1417]"> </para-num> <div id="p-1671" num="1417" class="description-line">To a solution of (6Z,9Z,28Z,31Z)-19-cyclopropylheptatriaconta-6,9,28,31-tetraen-19-ol (0.141 g, 0.248 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 in dichloromethane (2 mL), lithium bromide (manufactured by Sigma-Aldrich Corp., 0.108 g, 1.24 mmol) and chlorotrimethylsilane (manufactured by Tokyo Chemical Industry Co., Ltd., 0.135 g, 1.24 mmol) were added at room temperature, and the mixture was stirred for 1 hour. Then, lithium bromide (manufactured by Sigma-Aldrich Corp., 0.108 g, 1.24 mmol) and chlorotrimethylsilane (manufactured by Tokyo Chemical Industry Co., Ltd., 0.135 g, 1.24 mmol) were further added thereto, and the mixture was stirred for 1 hour. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and the aqueous layer was subjected to extraction with hexane. The organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=100/0 to 90/10 to obtain (6Z,9Z,28Z,31Z)-19-(3-bromopropylidene)heptatriaconta-6,9,28,31-tetraene (0.074 g, yield: 47%).</div>
    </li> <li> <para-num num="[1418]"> </para-num> <div id="p-1672" num="1418" class="description-line">ESI-MS m/z: 632</div>
    </li> <li> <para-num num="[1419]"> </para-num> <div id="p-1673" num="1419" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1420]"> </para-num> <div id="p-1674" num="1420" class="description-line">To (6Z,9Z,28Z,31Z)-19-(3-bromopropylidene)heptatriaconta-6,9,28,31-tetraene (0.074 g, 0.117 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2, dimethylamine (manufactured by Sigma-Aldrich Corp., 2.0 mmol/L solution in tetrahydrofuran, 1.5 mL, 3.0 mmol) was added, and the mixture was stirred under heating at 130 C. for 90 minutes under microwave irradiation. A saturated aqueous solution of sodium bicarbonate was added to the reaction mixture, and the aqueous layer was subjected to extraction with hexane. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by NH silica gel column chromatography (hexane/ethyl acetate=97/3 to 88/12 to obtain CL-20 (0.062 g, yield: 69%).</div>
    </li> <li> <para-num num="[1421]"> </para-num> <div id="p-1675" num="1421" class="description-line">ESI-MS m/z: 596</div>
    </li> <heading id="h-0195">Reference Example B21</heading>
    <heading id="h-0196">(S)-2-Amino-3-hydroxy-N,N-bis(2-(((Z)-octadec-9-en-1-yl)oxy)ethyl)propanamide (Compound CL-21)</heading>
    <li> <para-num num="[1422]"> </para-num> <div id="p-1676" num="1422" class="description-line">Compound CL-21 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0197">Reference Example B22</heading>
    <heading id="h-0198">(3R,4R)-3,4-Bis(((11Z,14Z)-icosa-11,14-dien-1-yl)oxy)pyrrolidine (Compound CL-22)</heading>
    <li> <para-num num="[1423]"> </para-num> <div id="p-1677" num="1423" class="description-line">Compound CL-22 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0199">Reference Example B23</heading>
    <heading id="h-0200">trans-3,4-Bis((((11Z,14Z)-icosa-11,14-dien-1-yl)oxy)methyl)-1-methylpyrrolidine (Compound CL-23)</heading>
    <li> <para-num num="[1424]"> </para-num> <div id="p-1678" num="1424" class="description-line">Compound CL-23 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0201">Reference Example B24</heading>
    <heading id="h-0202">1-((S)-2,3-Bis(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)propyl)pyrrolidine (Compound CL-24)</heading>
    <li> <para-num num="[1425]"> </para-num> <div id="p-1679" num="1425" class="description-line">Compound CL-24 was synthesized by the method described in WO 2009/129395.</div>
    </li> <heading id="h-0203">Reference Example B25</heading>
    <heading id="h-0204">2-(2,2-Di((9Z,12Z)-octadeca-9,12-dien-1-yl)-1,3-dioxolan-4-yl)-N,N-dimethylethan-1-amine (Compound CL-25)</heading>
    <li> <para-num num="[1426]"> </para-num> <div id="p-1680" num="1426" class="description-line">Compound CL-25 was synthesized by the method described in WO 2010/042877.</div>
    </li> <heading id="h-0205">Reference Example B26</heading>
    <heading id="h-0206">3-(Dimethylamino)propyl di((9Z,12Z)-oxadeca-9,12-dien-1-yl)carbamate (Compound CL-26)</heading>
    <li> <para-num num="[1427]"> </para-num> <div id="p-1681" num="1427" class="description-line">Compound CL-26 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0207">Reference Example B27</heading>
    <heading id="h-0208">4-(Dimethylamino)butyl di((9Z,12Z)-oxadeca-9,12-dien-1-yl)carbamate (Compound CL-27)</heading>
    <li> <para-num num="[1428]"> </para-num> <div id="p-1682" num="1428" class="description-line">Compound CL-27 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0209">Reference Example B28</heading>
    <heading id="h-0210">2-(Di((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)ethan-1-ol (Compound CL-28)</heading>
    <li> <para-num num="[1429]"> </para-num> <div id="p-1683" num="1429" class="description-line">Compound CL-28 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0211">Reference Example B29</heading>
    <heading id="h-0212">2-(Dimethylamino)-3-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)-2-((((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)methyl)propan-1-ol (Compound CL-29)</heading>
    <li> <para-num num="[1430]"> </para-num> <div id="p-1684" num="1430" class="description-line">Compound CL-29 was synthesized by the method described in WO 2011/149733.</div>
    </li> <heading id="h-0213">Reference Example B30</heading>
    <heading id="h-0214">(6Z,9Z,28Z,31Z)N,N-Dimethylheptatriaconta-6,9,28,31-tetraen-19-amine (Compound CL-30)</heading>
    <li> <para-num num="[1431]"> </para-num> <div id="p-1685" num="1431" class="description-line">Compound CL-30 was synthesized by the method described in WO 2010/054405.</div>
    </li> <heading id="h-0215">Reference Example B31</heading>
    <heading id="h-0216">N,N,2-Trimethyl-1,3-bis(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)propan-2-amine (Compound CL-31)</heading>
    <li> <para-num num="[1432]"> </para-num> <div id="p-1686" num="1432" class="description-line">2-Methyl-1,3-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)propan-2-amine (0.240 g, 0.399 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example B9 was dissolved in a mixed solvent of 1,2-dichloroethane (1 mL) and methanol (1 mL). To the solution, formaldehyde (manufactured by Wako Pure Chemical Industries Ltd., 37% aqueous solution, 0.144 mL, 1.99 mmol) and sodium triacetoxyborohydride (manufactured by Tokyo Chemical Industry Co., Ltd., 0.211 g, 0.997 mmol) were added, and the mixture was stirred overnight at room temperature. Water was added to the reaction mixture, and the aqueous layer was subjected to extraction with ethyl acetate. The organic layer was washed with saturated sodium bicarbonate, then dried over anhydrous magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure, and the obtained residue was purified by NH silica gel column chromatography (hexane/ethyl acetate=99/1 to 80/20) to obtain compound 2 (0.191 g, yield: 76%).</div>
    </li> <li> <para-num num="[1433]"> </para-num> <div id="p-1687" num="1433" class="description-line">ESI-MS m/z: 630 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 6H), 0.95 (s, 3H), 1.26-1.39 (m, 32H), 1.53-1.58 (m, 4H), 2.05 (q, J=6.9 Hz, 8H), 2.31 (s, 6H), 2.77 (t, J=6.3 Hz, 4H), 3.33-3.42 (m, 8H), 5.27-5.43 (m, 8H).</div>
    </li> <heading id="h-0217">Reference Example B32</heading>
    <heading id="h-0218">N-Methyl-2-(((Z)-octadec-6-en-1-yl)oxy)-N-(2-(((Z)-octadec-6-en-1-yl)oxy)ethyl)ethan-1-amine (Compound CL-32)</heading>
    <li> <para-num num="[1434]"> </para-num> <div id="p-1688" num="1434" class="description-line">Compound CL-32 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0219">Reference Example B33</heading>
    <heading id="h-0220">(3R,4R)-3-(Dimethylamino)propyl 3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)pyrrolidine-1-carboxylate (Compound CL-33)</heading>
    <li> <para-num num="[1435]"> </para-num> <div id="p-1689" num="1435" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1436]"> </para-num> <div id="p-1690" num="1436" class="description-line">To a suspension of sodium hydride (60% oil, 5.80 g, 145 mmol) in toluene (100 mL), a solution of (3R,4R)-1-benzylpyrrolidine-3,4-diol (manufactured by Diverchim S.A., 3.50 g, 18.1 mmol) in toluene (70 mL) was added with stirring, and a solution of (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (15.6 g, 45.3 mmol) in toluene (30 mL) was then added dropwise. The obtained mixture was stirred overnight under heating to reflux. After cooling to room temperature, the reaction was terminated with a saturated aqueous solution of ammonium chloride. To the obtained mixture, saturated saline was added, followed by extraction with ethyl acetate twice. The organic layers were combined, dried over anhydrous magnesium sulfate, and then concentrated under reduced pressure. The residue was purified by silica gel column chromatography (methanol/chloroform=0/100 to 2/98) to obtain (3R,4R)-1-benzyl-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)pyrrolidine (6.96 g, 10.1 mmol, yield: 56%).</div>
    </li> <li> <para-num num="[1437]"> </para-num> <div id="p-1691" num="1437" class="description-line">ESI-MS m/z: 691 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.9 Hz, 6H), 1.26-1.38 (m, 30H), 1.52-1.62 (m, 6H), 2.05 (q, J=6.3 Hz, 8H), 2.50 (dd, J=9.9, 4.3 Hz, 2H), 2.77 (t, J=5.8 Hz, 4H), 2.85 (dd, J=9.6, 5.9 Hz, 2H), 3.37-3.45 (m, 4H), 3.52-3.66 (m, 2H), 3.83 (t, J=4.6 Hz, 2H), 5.28-5.43 (m, 8H), 7.23-7.33 (m, 5H).</div>
    </li> <li> <para-num num="[1438]"> </para-num> <div id="p-1692" num="1438" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1439]"> </para-num> <div id="p-1693" num="1439" class="description-line">(3R,4R)-1-Benzyl-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)pyrrolidine (6.96 g, 10.1 mmol)) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in 1,2-dichloroethane (100 mL). To the solution, 1-chloroethyl chloroformate (3.30 mL, 30.3 mmol) was added, and the mixture was stirred at 130 C. for 1 hour. Methanol (100 mL) was added to the reaction solution, and the mixture was further stirred at 130 C. for 1 hour. The reaction mixture was cooled to room temperature and then concentrated under reduced pressure, and the obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 92/8). The obtained organic layer was washed with a saturated aqueous solution of sodium bicarbonate and then a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain (3R,4R)-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy)pyrrolidine (5.56 g, 9.27 mmol, yield: 92%).</div>
    </li> <li> <para-num num="[1440]"> </para-num> <div id="p-1694" num="1440" class="description-line">ESI-MS m/z: 601 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.9 Hz, 6H), 1.29-1.41 (m, 30H), 1.49-1.60 (m, 4H), 1.67 (br s, 3H), 2.05 (q, J=6.5 Hz, 8H), 2.75-2.85 (m, 6H), 3.09 (dd, J=12.4, 5.1 Hz, 2H), 3.37-3.49 (m, 4H), 3.76 (dd, J=5.0, 3.3 Hz, 2H), 5.28-5.43 (m, 8H).</div>
    </li> <li> <para-num num="[1441]"> </para-num> <div id="p-1695" num="1441" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1442]"> </para-num> <div id="p-1696" num="1442" class="description-line">The title compound (0.101 g, 0.139 mmol, 75%) was obtained in the same way as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Reference Example B4 using (3R,4R)-3,4-bis((9Z,12Z)-octadeca-9,12-dienyloxy) pyrrolidine (0.111 g, 0.185 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 instead of di((Z)-octadec-9-enyl)amine.</div>
    </li> <li> <para-num num="[1443]"> </para-num> <div id="p-1697" num="1443" class="description-line">ESI-MS m/z: 730 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.9 Hz, 6H), 1.24-1.40 (m, 32H), 1.50-1.57 (m, 4H), 1.77-1.83 (m, 2H), 2.02-2.08 (m, 8H), 2.23 (s, 6H), 2.34 (t, J=7.4 Hz, 2H), 2.77 (t, J=6.8 Hz, 4H), 3.38-3.56 (m, 8H), 3.83-3.86 (m, 2H), 4.11 (t, J=6.5 Hz, 2H), 5.30-5.42 (m, 8H).</div>
    </li> <heading id="h-0221">Reference Example B34</heading>
    <heading id="h-0222">(9Z,12Z)N-(2-(((9Z,12Z)-Octadeca-9,12-dien-1-yl)oxy)ethyl)octadeca-9,12-dien-1-amine (Compound CL-34)</heading>
    <li> <para-num num="[1444]"> </para-num> <div id="p-1698" num="1444" class="description-line">Compound CL-34 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0223">Reference Example B35</heading>
    <heading id="h-0224">(9Z,12Z)N-(2-(((Z)-Hexadec-9-en-1-yl)oxy)ethyl)octadeca-9,12-dien-1-amine (Compound CL-35)</heading>
    <li> <para-num num="[1445]"> </para-num> <div id="p-1699" num="1445" class="description-line">Compound CL-35 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0225">Reference Example B36</heading>
    <heading id="h-0226">N,N-Dimethyl-1,3-bis(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)propan-2-amine (Compound CL-36)</heading>
    <li> <para-num num="[1446]"> </para-num> <div id="p-1700" num="1446" class="description-line">Compound CL-36 was synthesized by the method described in WO 2009/129385.</div>
    </li> <heading id="h-0227">Reference Example B37</heading>
    <heading id="h-0228">3-(Dimethylamino)propyl di((Z)-octadec-9-enyl)carbamate (Compound CL-37)</heading>
    <li> <para-num num="[1447]"> </para-num> <div id="p-1701" num="1447" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1448]"> </para-num> <div id="p-1702" num="1448" class="description-line">To ammonia (manufactured by Tokyo Chemical Industry Co., Ltd., approximately 2 mol/L solution in methanol, 12.0 mL, 24.0 mmol), (Z)-octadec-9-enyl methanesulfonate (1.04 g, 3.00 mmol) was added, and the mixture was stirred at 130 C. for 3 hours using a microwave reaction apparatus. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with chloroform five times. The organic layers were combined, washed with saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain a crude product of (Z)-octadec-9-enylamine.</div>
    </li> <li> <para-num num="[1449]"> </para-num> <div id="p-1703" num="1449" class="description-line">To the obtained crude product, (Z)-octadec-9-enyl methanesulfonate (0.832 g, 2.40 mmol) and a 50% aqueous sodium hydroxide solution (0.960 g, 12.0 mmol) were added, and the mixture was stirred at 110 C. for 60 minutes in an oil bath. After cooling to room temperature, the reaction solution was diluted with ethyl acetate, washed with water and then saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 95/5) to obtain di((Z)-octadec-9-enyl)amine (0.562 g, 1.085 mmol, yield: 36%).</div>
    </li> <li> <para-num num="[1450]"> </para-num> <div id="p-1704" num="1450" class="description-line">ESI-MS m/z: 519 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.7 Hz, 6H), 1.29 (br s, 45H), 1.41-1.52 (m, 4H), 1.97-2.05 (m, 8H), 2.58 (t, J=7.2 Hz, 4H), 5.28-5.40 (m, 4H).</div>
    </li> <li> <para-num num="[1451]"> </para-num> <div id="p-1705" num="1451" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1452]"> </para-num> <div id="p-1706" num="1452" class="description-line">Di((Z)-octadec-9-enyl)amine (0.156 g, 0.301 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 was dissolved in chloroform (3 mL). To the solution, 3-(dimethylamino)propyl 4-nitrophenyl carbonate hydrochloride (0.138 g, 0.452 mmol) synthesized by a method equivalent to the method described in J. Am. Chem. Soc., 1981, Vol. 103, p. 4194-4199 and triethylamine (0.168 mL, 1.21 mmol) were added, and the mixture was stirred at 110 C. for 60 minutes using a microwave reaction apparatus. 3-(Dimethylamino)propyl 4-nitrophenyl carbonate hydrochloride (22.9 mg, 0.0753 mmol) was added to the reaction solution, and the mixture was stirred at 110 C. for 20 minutes using a microwave reaction apparatus. 3-(Dimethylamino)propyl 4-nitrophenyl carbonate hydrochloride (22.9 mg, 0.0753 mmol) was added to the reaction solution, and the mixture was stirred at 110 C. for 20 minutes using a microwave reaction apparatus. 3-(Dimethylamino)propyl 4-nitrophenyl carbonate hydrochloride (22.9 mg, 0.0753 mmol) was added to the reaction solution, and the mixture was stirred at 110 C. for 20 minutes using a microwave reaction apparatus. The reaction solution was diluted with chloroform, washed with a saturated aqueous solution of sodium bicarbonate, then washed with saturated saline, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was dissolved in a small amount of n-hexane/ethyl acetate (1/4) and adsorbed to a pad of amino-modified silica gel, followed by elution with n-hexane/ethyl acetate (1/4). The eluate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 95/5) to obtain the title compound (0.173 g, 0.267 mmol, yield: 89%).</div>
    </li> <li> <para-num num="[1453]"> </para-num> <div id="p-1707" num="1453" class="description-line">ESI-MS m/z: 648 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.6 Hz, 6H), 1.28 (br s, 44H), 1.45-1.55 (m, 4H), 1.75-1.85 (m, 2H), 1.97-2.04 (m, 8H), 2.23 (s, 6H), 2.34 (t, J=7.6 Hz, 2H), 3.13-3.24 (m, 4H), 4.10 (t, J=6.4 Hz, 2H), 5.28-5.40 (m, 4H).</div>
    </li> <heading id="h-0229">Reference Example B38</heading>
    <heading id="h-0230">(11Z,14Z)N-(2-(((Z)-Octadec-9-en-1-yl)oxy)ethyl)icosa-11,14-dien-1-amine (Compound CL-38)</heading>
    <li> <para-num num="[1454]"> </para-num> <div id="p-1708" num="1454" class="description-line">Compound CL-38 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <li> <para-num num="[1455]"> </para-num> <div id="p-1709" num="1455" class="description-line">ESI-MS m/z: 588</div>
    </li> <heading id="h-0231">Reference Example B39</heading>
    <heading id="h-0232">(9Z,12Z)N-(2-(((Z)-Icos-11-en-1-yl)oxy)ethyl)octadeca-9,12-dien-1-amine (Compound CL-39)</heading>
    <li> <para-num num="[1456]"> </para-num> <div id="p-1710" num="1456" class="description-line">Compound CL-39 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <li> <para-num num="[1457]"> </para-num> <div id="p-1711" num="1457" class="description-line">ESI-MS m/z: 588</div>
    </li> <heading id="h-0233">Reference Example B40</heading>
    <heading id="h-0234">(11Z,14Z)N-(2-(((Z)-Icos-11-en-1-yl)oxy)ethylicosa-11,14-dien-1-amine (Compound CL-40)</heading>
    <li> <para-num num="[1458]"> </para-num> <div id="p-1712" num="1458" class="description-line">Compound CL-40 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <li> <para-num num="[1459]"> </para-num> <div id="p-1713" num="1459" class="description-line">ESI-MS m/z: 616</div>
    </li> <heading id="h-0235">Reference Example B41</heading>
    <heading id="h-0236">(Z)N-(2-(((Z)-Octadec-9-en-1-yl)oxy)ethyl)octadec-9-en-1-amine (Compound CL-41)</heading>
    <li> <para-num num="[1460]"> </para-num> <div id="p-1714" num="1460" class="description-line">Compound CL-41 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <li> <para-num num="[1461]"> </para-num> <div id="p-1715" num="1461" class="description-line">ESI-MS m/z: 562</div>
    </li> <heading id="h-0237">Reference Example B42</heading>
    <heading id="h-0238">Bis(2-(((11Z,14Z)-icosa-11,14-dien-1-yl)oxy)ethyl)amine (Compound CL-42)</heading>
    <li> <para-num num="[1462]"> </para-num> <div id="p-1716" num="1462" class="description-line">Compound CL-42 was synthesized by a method equivalent to the method described in WO 2011/136368.</div>
    </li> <li> <para-num num="[1463]"> </para-num> <div id="p-1717" num="1463" class="description-line">ESI-MS m/z: 658</div>
    </li> <heading id="h-0239">Reference Example B43</heading>
    <heading id="h-0240">(Z)N-(2-(((Z)-Octadec-9-en-1-yl)oxy)ethyl)hexadec-9-en-1-amine (Compound CL-43)</heading>
    <li> <para-num num="[1464]"> </para-num> <div id="p-1718" num="1464" class="description-line">Compound CL-43 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <li> <para-num num="[1465]"> </para-num> <div id="p-1719" num="1465" class="description-line">ESI-MS m/z: 534</div>
    </li> <heading id="h-0241">Reference Example B44</heading>
    <heading id="h-0242">(Z)N-(2-(Octadec-9-en-1-yloxy)ethyl)octadecan-1-amine (Compound CL-44)</heading>
    <li> <para-num num="[1466]"> </para-num> <div id="p-1720" num="1466" class="description-line">Compound CL-44 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <li> <para-num num="[1467]"> </para-num> <div id="p-1721" num="1467" class="description-line">ESI-MS m/z: 564</div>
    </li> <heading id="h-0243">Reference Example B45</heading>
    <heading id="h-0244">(Z)N-(2-(Octadec-9-en-1-yloxy)ethyl)tetradecan-1-amine (Compound CL-45)</heading>
    <li> <para-num num="[1468]"> </para-num> <div id="p-1722" num="1468" class="description-line">Compound CL-45 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <li> <para-num num="[1469]"> </para-num> <div id="p-1723" num="1469" class="description-line">ESI-MS m/z: 508</div>
    </li> <heading id="h-0245">Reference Example B46</heading>
    <heading id="h-0246">3-((3R,4R)-3,4-Bis(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)pyrrolidin-1-yl)propane-1,2-diol (Compound CL-46)</heading>
    <li> <para-num num="[1470]"> </para-num> <div id="p-1724" num="1470" class="description-line">Compound CL-46 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0247">Reference Example B47</heading>
    <heading id="h-0248">Bis(2-(((Z)-octadec-9-en-1-yl)oxy)ethyl)amine (Compound CL-47)</heading>
    <li> <para-num num="[1471]"> </para-num> <div id="p-1725" num="1471" class="description-line">Compound CL-47 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0249">Reference Example B48</heading>
    <heading id="h-0250">3-(Bis(2-(((Z)-octadec-9-en-1-yl)oxy)ethyl)amino)propane-1,2-diol (Compound CL-48)</heading>
    <li> <para-num num="[1472]"> </para-num> <div id="p-1726" num="1472" class="description-line">Compound CL-48 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0251">Reference Example B49</heading>
    <heading id="h-0252">3-(Bis(2-(((Z)-octadec-9-en-1-yl)oxy)ethyl)amino)propanamide (Compound CL-49)</heading>
    <li> <para-num num="[1473]"> </para-num> <div id="p-1727" num="1473" class="description-line">Compound CL-49 was synthesized by the method described in WO 2011/136368.</div>
    </li> <heading id="h-0253">Reference Example B50</heading>
    <heading id="h-0254">(9Z,12Z)N-(2-(2-(((Z)-Octadec-9-en-1-yl)oxy)ethoxy)ethyl)octadeca-9,12-dien-1-amine (Compound CL-50)</heading>
    <li> <para-num num="[1474]"> </para-num> <div id="p-1728" num="1474" class="description-line">Compound CL-50 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <li> <para-num num="[1475]"> </para-num> <div id="p-1729" num="1475" class="description-line">ESI-MS m/z: 604</div>
    </li> <heading id="h-0255">Reference Example B51</heading>
    <heading id="h-0256">Di((Z)-non-2-en-1-yl) 9-((4-(dimethylamino)butanoyl)oxy)heptadecanedioate (Compound CL-51)</heading>
    <li> <para-num num="[1476]"> </para-num> <div id="p-1730" num="1476" class="description-line">Compound CL-51 was synthesized by the method described in WO 2011/153493.</div>
    </li> <heading id="h-0257">Reference Example B52</heading>
    <heading id="h-0258">Di((Z)-non-2-en-1-yl) 8,8-((((2-(dimethylamino)ethyl)thio)carbonyl)azanediyl)dioctanoate (Compound CL-52)</heading>
    <li> <para-num num="[1477]"> </para-num> <div id="p-1731" num="1477" class="description-line">Compound CL-52 was synthesized by the method described in WO 2017/023817.</div>
    </li> <heading id="h-0259">Reference Example B53</heading>
    <heading id="h-0260">2-(Dimethylamino)-N-(2-(((Z)-octadec-9-en-1-yl)oxy)ethyl)-N-((9Z,12Z)-octadeca-9,12-dien-1-yl)acetamide (Compound CL-53)</heading>
    <li> <para-num num="[1478]"> </para-num> <div id="p-1732" num="1478" class="description-line">Compound CL-53 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <heading id="h-0261">Reference Example B54</heading>
    <heading id="h-0262">3-((2-(((Z)-Octadec-9-en-1-yl)oxy)ethyl) ((9Z,12Z)-octadeca-9,12-dien-1-yl)amino)propan-1-ol (Compound CL-54)</heading>
    <li> <para-num num="[1479]"> </para-num> <div id="p-1733" num="1479" class="description-line">Compound CL-54 was synthesized by a method equivalent to the method described in WO 2014/007398.</div>
    </li> <heading id="h-0263">Reference Example B55</heading>
    <heading id="h-0264">1-Methyl-3,3-bis((((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)methyl)azetidine (Compound CL-55)</heading>
    <li> <para-num num="[1480]"> </para-num> <div id="p-1734" num="1480" class="description-line">Compound CL-55 was synthesized by the method described in WO 2012/108397.</div>
    </li> <heading id="h-0265">Reference Example B56</heading>
    <heading id="h-0266">1-Methyl-3,3-bis(2-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)ethyl)azetidine (Compound CL-56)</heading>
    <li> <para-num num="[1481]"> </para-num> <div id="p-1735" num="1481" class="description-line">Compound CL-56 was synthesized by the method described in WO 2016/002753.</div>
    </li> <heading id="h-0267">Reference Example B57</heading>
    <heading id="h-0268">1-Methyl-3,3-bis(2-(((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)propyl)azetidine (Compound CL-57)</heading>
    <li> <para-num num="[1482]"> </para-num> <div id="p-1736" num="1482" class="description-line">Compound CL-57 was synthesized by the method described in WO 2016/002753.</div>
    </li> <heading id="h-0269">Reference Example B58</heading>
    <heading id="h-0270">2-(3,3-Di((9Z,12Z)-octadeca-9,12-dien-1-yl)azetidin-1-yl)ethan-1-ol (Compound CL-58)</heading>
    <li> <para-num num="[1483]"> </para-num> <div id="p-1737" num="1483" class="description-line">Compound CL-58 was synthesized by the method described in WO 2016/002753.</div>
    </li> <heading id="h-0271">Reference Example B59</heading>
    <heading id="h-0272">2-(3,3-Di((9Z,12Z)-octadeca-9,12-dien-1-yl)azetidin-1-yl)propan-1-ol (Compound CL-59)</heading>
    <li> <para-num num="[1484]"> </para-num> <div id="p-1738" num="1484" class="description-line">Compound CL-59 was synthesized by the method described in WO 2016/002753.</div>
    </li> <heading id="h-0273">Reference Example B60</heading>
    <heading id="h-0274">3-(Dimethylamino)propyl 3,3-di((9Z,12Z)-octadeca-9,12-dien-1-yl)azetidine-1-carboxylate (Compound CL-60)</heading>
    <li> <para-num num="[1485]"> </para-num> <div id="p-1739" num="1485" class="description-line">Compound CL-60 was synthesized by the method described in WO 2016/002753.</div>
    </li> <heading id="h-0275">Reference Example B61</heading>
    <heading id="h-0276">2-(Di((Z)-octadec-9-en-1-yl)amino)ethan-1-ol (Compound CL-61)</heading>
    <li> <para-num num="[1486]"> </para-num> <div id="p-1740" num="1486" class="description-line">Compound CL-61 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0277">Reference Example B62</heading>
    <heading id="h-0278">3-(Di((Z)-octadec-9-en-1-yl)amino)propan-1-ol (Compound CL-62)</heading>
    <li> <para-num num="[1487]"> </para-num> <div id="p-1741" num="1487" class="description-line">Compound CL-62 was synthesized by the method described in WO 2014/007398.</div>
    </li> <heading id="h-0279">Reference Example B63</heading>
    <heading id="h-0280">(11Z,14Z)-2-((Dimethylamino)methyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (Compound CL-63)</heading>
    <li> <para-num num="[1488]"> </para-num> <div id="p-1742" num="1488" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1489]"> </para-num> <div id="p-1743" num="1489" class="description-line">To a solution of (9Z,12Z)-octadeca-9,12-dien-1-yl methanesulfonate (7.62 g, 22.1 mmol) in tetrahydrofuran (30.0 mL), ethyl 2-cyanoacetate (0.943 mL, 8.84 mmol), sodium hydride (1.06 g, 26.5 mmol), and tetrabutylammonium iodide (3.27 g, 8.84 mmol) were added, and the mixture was stirred at 60 C. for 2 hours. Water was added to the reaction solution, followed by extraction with heptane. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=99/1 to 85/15) to obtain ethyl (11Z,14Z)-2-cyano-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoate (3.50 g, 5.74 mmol, yield: 64.9%).</div>
    </li> <li> <para-num num="[1490]"> </para-num> <div id="p-1744" num="1490" class="description-line">To a solution of ethyl (11Z,14Z)-2-cyano-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoate (1.50 g, 2.46 mmol) in tetrahydrofuran (10.0 mL), lithium aluminum hydride (0.467 g, 12.3 mmol) was added, and the mixture was stirred for 30 minutes under ice cooling. Water, sodium hydroxide, and water were added at a ratio of 1:1:3 to the reaction solution, and the mixture was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=90/10) to obtain (11Z,14Z)-2-(aminomethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (1.00 g, 1.75 mmol, yield: 71.1%).</div>
    </li> <li> <para-num num="[1491]"> </para-num> <div id="p-1745" num="1491" class="description-line">ESI-MS m/z: 573 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1492]"> </para-num> <div id="p-1746" num="1492" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1493]"> </para-num> <div id="p-1747" num="1493" class="description-line">To a solution of (11Z,14Z)-2-(aminomethyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (0.200 g, 0.350 mmol) in dichloroethane (2.00 mL), a paraformaldehyde solution (0.276 g, 3.50 mmol, 37% solution in methanol) and sodium triacetoxyborohydride (1.48 g, 6.99 mmol) were added, and the mixture was stirred at room temperature for 3 hours. Water was added to the reaction solution, followed by extraction using chloroform. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=99/1 to 85/15) to obtain the title compound (0.0280 g, 0.0470 mmol, yield: 13.3%).</div>
    </li> <li> <para-num num="[1494]"> </para-num> <div id="p-1748" num="1494" class="description-line">ESI-MS m/z: 601 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=6.8 Hz, 6H), 1.23-1.29 (m, 40H), 2.05 (q, J=6.8 Hz, 8H), 2.32 (s, 6H), 2.40 (s, 2H), 2.77 (dd, J=9.8, 3.4 Hz, 4H), 3.53 (s, 2H), 5.29-5.42 (m, 8H).</div>
    </li> <heading id="h-0281">Reference Example B64</heading>
    <heading id="h-0282">(11Z,14Z)-2-(Dimethylamino)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (Compound CL-64)</heading>
    <li> <para-num num="[1495]"> </para-num> <div id="p-1749" num="1495" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1496]"> </para-num> <div id="p-1750" num="1496" class="description-line">To a solution of sodium hydride (1.21 g, 30.3 mmol) in THE (30.0 mL), tert-butyl ethyl malonate (manufactured by Tokyo Chemical Industry Co., Ltd., 2.00 mL, 10.1 mmol), tetra-n-butylammonium iodide (manufactured by Nacalai Tesque, Inc., 0.746 g, 2.02 mmol), and (9Z,12Z)-octadeca-9,12-dienyl methanesulfonate (manufactured by Nu-Chek Prep, Inc., 8.70 g, 25.2 mmol) were added, and the mixture was stirred for 2 hours under heating to reflux. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=95/5) to obtain 1-tert-butyl 3-<figure-callout id="2" label="ethyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">ethyl</figure-callout> 2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)malonic acid (5.52 g, 80.0%).</div>
    </li> <li> <para-num num="[1497]"> </para-num> <div id="p-1751" num="1497" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1498]"> </para-num> <div id="p-1752" num="1498" class="description-line">To a solution of 1-tert-butyl 3-<figure-callout id="2" label="ethyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">ethyl</figure-callout> 2,2-di((9Z,12Z)-octadeca-9,12-dien-1-yl)malonic acid (5.52 g, 8.06 mmol) in dichloromethane (30.0 mL), trifluoroacetic acid (5.00 mL, 64.9 mmol) was added, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure. The residue was separated into aqueous and organic layers with chloroform and a saturated aqueous solution of sodium bicarbonate. The organic layer was washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=95/5) to obtain (11Z,14Z)-2-(ethoxycarbonyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoic acid (4.04 g, 6.42 mmol, 80.0%).</div>
    </li> <li> <para-num num="[1499]"> </para-num> <div id="p-1753" num="1499" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1500]"> </para-num> <div id="p-1754" num="1500" class="description-line">To a solution of (11Z,14Z)-2-(ethoxycarbonyl)-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoic acid (0.284 g, 0.452 mmol) in toluene (3.00 mL), triethylamine (0.315 mL, 2.26 mmol) and diphenylphosphoryl azide (manufactured by Tokyo Chemical Industry Co., Ltd., 0.121 mL, 0.542 mmol) were added, and the mixture was stirred at room temperature for 1 hour. Water (0.0200 mL, 1.11 mmol) was added to the reaction solution, and the mixture was stirred for 5 hours under heating to reflux. Water was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate and filtered, and the solvent was distilled off under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane/ethyl acetate=80/20) to obtain ethyl (11Z,14Z)-2-amino-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoate (0.0457 g, 0.0762 mmol, 17.0%).</div>
    </li> <li> <para-num num="[1501]"> </para-num> <div id="p-1755" num="1501" class="description-line">ESI-MS m/z: 601 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1502]"> </para-num> <div id="p-1756" num="1502" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1503]"> </para-num> <div id="p-1757" num="1503" class="description-line">To a solution of ethyl (11Z,14Z)-2-amino-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dienoate (0.299 g, 0.498 mmol) in THE (3.00 mL), lithium aluminum hydride (manufactured by Junsei Chemical Co., Ltd., 0.0190 g, 0.498 mmol) was added, and the mixture was stirred at room temperature for 30 minutes. Water and an aqueous sodium hydroxide solution were added to the reaction solution, and insoluble matter was removed by filtration through celite. The filtrate was concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (hexane/ethyl acetate=50/50) to obtain (11Z,14Z)-2-amino-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (0.0667 g, 0.120 mmol, 24.0%).</div>
    </li> <li> <para-num num="[1504]"> </para-num> <div id="p-1758" num="1504" class="description-line">ESI-MS m/z: 559 (M+H)<sup>+</sup>.</div>
    </li> <li> <para-num num="[1505]"> </para-num> <div id="p-1759" num="1505" class="description-line">Step 5</div>
    </li> <li> <para-num num="[1506]"> </para-num> <div id="p-1760" num="1506" class="description-line">To a solution of (11Z,14Z)-2-amino-2-((9Z,12Z)-octadeca-9,12-dien-1-yl)icosa-11,14-dien-1-ol (0.0664 g, 0.119 mmol) in dichloroethane (1.00 mL), formaldehyde (0.500 mL, 6.72 mmol) and sodium triacetoxyborohydride (manufactured by Tokyo Chemical Industry Co., Ltd., 0.101 g, 0.476 mmol) were added, and the mixture was stirred overnight at room temperature. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was washed with a saturated aqueous solution of sodium chloride, dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=80/20) to obtain the title compound (0.0474 g, 0.0809 mmol, 68.0%).</div>
    </li> <li> <para-num num="[1507]"> </para-num> <div id="p-1761" num="1507" class="description-line">ESI-MS m/z: 587 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 6H), 1.24-1.39 (m, 40H), 2.05 (q, J=6.8 Hz, 8H), 2.38 (s, 6H), 2.77 (t, J=6.7 Hz, 4H), 5.29-5.42 (m, 8H).</div>
    </li> <heading id="h-0283">Reference Example B65</heading>
    <heading id="h-0284">3-(Dimethylamino)-2,2-bis((((9Z,12Z)-octadeca-9,12-dien-1-yl)oxy)methyl)propan-1-ol (Compound CL-65)</heading>
    <li> <para-num num="[1508]"> </para-num> <div id="p-1762" num="1508" class="description-line">To 2-(bromomethyl)-2-(hydroxymethyl)propane-1,3-diol (1.52 g, 7.56 mmol), a dimethylamine solution (15.0 mL, 30.0 mmol, 2 M in THE) was added, and the mixture was stirred at 120 C. for 15 hours under microwave irradiation. Lithium hydroxide was added to the reaction solution, and the mixture was filtered. The filtrate was concentrated under reduced pressure to obtain 2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diol (1.23 g, quantitative).</div>
    </li> <li> <para-num num="[1509]"> </para-num> <div id="p-1763" num="1509" class="description-line">To a solution of 2-((dimethylamino)methyl)-2-(hydroxymethyl)propane-1,3-diol (1.23 g, 7.56 mmol) in toluene (30.0 mL), sodium hydride (0.756 g, 18.9 mmol) and (9Z,12Z)-octadeca-9,12-dien-1-yl methanesulfonate (6.51 g, 18.9 mmol) were added, and the mixture was stirred overnight under heating to reflux. Saturated saline was added to the reaction solution, followed by extraction using hexane. The organic layer was dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=90/10) and amino silica gel column chromatography (hexane/ethyl acetate=90/10) to obtain the title compound (1.80 g, 2.73 mmol, yield: 36.1%).</div>
    </li> <li> <para-num num="[1510]"> </para-num> <div id="p-1764" num="1510" class="description-line">ESI-MS m/z: 661 (M)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.89 (t, J=7.0 Hz, 6H), 1.24-1.39 (m, 32H), 1.50-1.56 (m, 4H), 2.05 (q, J=6.8 Hz, 8H), 2.30 (s, 6H), 2.53 (s, 2H), 2.77 (t, J=6.3 Hz, 4H), 3.30-3.41 (m, 8H), 3.71 (s, 2H), 5.29-5.42 (m, 8H).</div>
    </li> <heading id="h-0285">Reference Example B66</heading>
    <heading id="h-0286">((2-((2-(Dimethylamino)ethyl)thio)acetyl)azanediyl)bis(ethane-2,1-diyl) ditetradecanoate (Compound CL-66)</heading>
    <li> <para-num num="[1511]"> </para-num> <div id="p-1765" num="1511" class="description-line">Compound CL-66 was synthesized by the method described in WO 2012/170952.</div>
    </li> <heading id="h-0287">Example C1</heading>
    <heading id="h-0288">(9Z,12Z)N-(2-{[(Z)-Octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (Compound CL-67)</heading>
    <li> <para-num num="[1512]"> </para-num> <div id="p-1766" num="1512" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1513]"> </para-num> <div id="p-1767" num="1513" class="description-line">(Z)-Octadec-9-en-1-yl methanesulfonate (2.00 g, 5.77 mmol) was dissolved in acetonitrile (10.0 mL). To the solution, cesium carbonate (3.76 g, 11.5 mmol) and 2-mercaptoethanol (0.615 mL, 8.66 mmol) were added, and the mixture was stirred overnight at room temperature. Saturated saline was added to the reaction solution, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain (Z)-2-(octadec-9-en-1-ylthio)ethan-1-ol (2.35 g, quantitative).</div>
    </li> <li> <para-num num="[1514]"> </para-num> <div id="p-1768" num="1514" class="description-line">(Z)-2-(Octadec-9-en-1-ylthio)ethan-1-ol (1.50 g, 4.56 mmol) was dissolved in dichloromethane (10.0 mL). To the solution, triethylamine (1.91 mL, 13.7 mmol) and methanesulfonyl chloride (0.889 mL, 11.4 mmol) were added at 0 C., and the mixture was stirred at room temperature for 2.5 hours. Saturated saline was added to the reaction solution, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=100/0 to 90/10) to obtain (Z)-(2-chloroethyl)(octadec-9-en-1-yl)sulfane (0.630 g, yield: 39.8%).</div>
    </li> <li> <para-num num="[1515]"> </para-num> <div id="p-1769" num="1515" class="description-line"> <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.36-5.33 (m, 2H), 3.64-3.60 (m, 2H), 2.87-2.83 (m, 2H), 2.56 (t, J=7.4 Hz, 2H), 2.03-2.00 (m, 4H), 1.61-1.56 (m, 2H), 1.37-1.29 (m, 22H), 0.88 (t, J=6.8 Hz, 3H).</div>
    </li> <li> <para-num num="[1516]"> </para-num> <div id="p-1770" num="1516" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1517]"> </para-num> <div id="p-1771" num="1517" class="description-line">(9Z,12Z)-Octadeca-9,12-dien-1-yl methanesulfonate (6.00 g, 17.4 mmol) was dissolved in acetonitrile (40.0 mL). To the solution, cesium carbonate (14.2 g, 43.5 mmol), tetrabutylammonium iodide (8.36 g, 22.6 mmol), and N-(tert-butoxycarbonyl)-2-nitrobenzenesulfonamide (6.84 g, 22.6 mmol) were added, and the mixture was stirred overnight at 60 C. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=100/0 to 70/30) to obtain tert-butyl [(2-nitrophenyl)sulfonyl][(9Z,12Z)-octadeca-9,12-dien-1-yl]carbamate (7.80 g, yield: 81.0%).</div>
    </li> <li> <para-num num="[1518]"> </para-num> <div id="p-1772" num="1518" class="description-line">tert-Butyl [(2-nitrophenyl)sulfonyl][(9Z,12Z)-octadeca-9,12-dien-1-yl]carbamate (7.80 g, 14.2 mmol) was dissolved in dichloromethane (25.0 mL). To the solution, trifluoroacetic acid (21.8 mL, 283 mmol) was added, and the mixture was stirred at room temperature for 3 hours. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by amino silica gel column chromatography (heptane/ethyl acetate=100/0 to 70/30) to obtain 2-nitro-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]benzenesulfonamide (5.10 g, yield: 80.0%).</div>
    </li> <li> <para-num num="[1519]"> </para-num> <div id="p-1773" num="1519" class="description-line"> <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 8.15-8.13 (m, 1H), 7.88-7.85 (m, 1H), 7.77-7.71 (m, 2H), 5.37-5.33 (m, 4H), 5.23 (t, J=5.8 Hz, 1H), 3.09 (td, J=7.1, 5.8 Hz, 2H), 2.77 (t, J=6.2 Hz, 2H), 2.07-2.01 (m, 4H), 1.55-1.50 (m, 2H), 1.39-1.23 (m, 16H), 0.89 (t, J=6.8 Hz, 3H).</div>
    </li> <li> <para-num num="[1520]"> </para-num> <div id="p-1774" num="1520" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1521]"> </para-num> <div id="p-1775" num="1521" class="description-line">2-Nitro-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]benzenesulfonamide (0.200 g, 0.444 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 was dissolved in acetonitrile (4.00 mL). To the solution, cesium carbonate (0.289 g, 0.888 mmol), tetrabutylammonium iodide (0.164 g, 0.444 mmol), and (Z)-(2-chloroethyl)(octadec-9-en-1-yl)sulfane (0.162 g, 0.466 mmol) obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 were added, and the mixture was stirred at 80 C. for 4 hours. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=100/0 to 85/15) to obtain 2-nitro-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]benzenesulfonamide (0.277 g, yield: 82.0%).</div>
    </li> <li> <para-num num="[1522]"> </para-num> <div id="p-1776" num="1522" class="description-line">2-Nitro-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]benzenesulfonamide (0.277 g, 0.364 mmol) was dissolved in acetonitrile (4.00 mL). To the solution, diazabicycloundecene (0.137 mL, 0.909 mmol) and 1-dodecanethiol (0.217 mL, 0.909 mmol) were added, and the mixture was stirred at 70 C. for 3 hours. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (heptane/ethyl acetate=100/0 to 70/30) and silica gel column chromatography (heptane/ethyl acetate=100/0 to 50/50) to obtain (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (0.0525 g, yield: 25.1%).</div>
    </li> <li> <para-num num="[1523]"> </para-num> <div id="p-1777" num="1523" class="description-line">ESI-MS m/z: 576 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 6H), 2.82-2.76 (m, 4H), 2.67 (t, J=6.2 Hz, 2H), 2.60 (t, J=7.4 Hz, 2H), 2.51 (t, J=7.5 Hz, 2H), 2.05-2.01 (m, 8H), 1.59-1.48 (m, 4H), 1.39-1.27 (m, 38H), 0.89-0.88 (m, 6H).</div>
    </li> <heading id="h-0289">Example C2</heading>
    <heading id="h-0290">(9Z,12Z)N-Methyl-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (Compound CL-68)</heading>
    <li> <para-num num="[1524]"> </para-num> <div id="p-1778" num="1524" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1525]"> </para-num> <div id="p-1779" num="1525" class="description-line">(9Z,12Z)N-Methyl-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (0.0200 g, 37.2%) was obtained by the same approach as in Reference Example B31 using (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine instead of 2-methyl-1,3-bis((9Z,12Z)-octadeca-9,12-dien-1-yloxy)propan-2-amine.</div>
    </li> <li> <para-num num="[1526]"> </para-num> <div id="p-1780" num="1526" class="description-line">ESI-MS m/z: 590 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.29 (m, 6H), 2.77 (t, J=6.3 Hz, 2H), 2.64-2.55 (m, 4H), 2.52 (t, J=7.5 Hz, 2H), 2.35 (t, J=7.6 Hz, 2H), 2.25 (s, 3H), 2.06-2.00 (m, 8H), 1.62-1.56 (m, 2H), 1.47-1.45 (m, 2H), 1.36-1.30 (m, 38H), 0.91-0.86 (m, 6H).</div>
    </li> <heading id="h-0291">Example C3</heading>
    <heading id="h-0292">2-(Dimethylamino)-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]acetamide (Compound CL-69)</heading>
    <li> <para-num num="[1527]"> </para-num> <div id="p-1781" num="1527" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1528]"> </para-num> <div id="p-1782" num="1528" class="description-line">(9Z,12Z)N-(2-{[(Z)-Octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (1.54 g, 2.66 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 of Example C1 was dissolved in dichloromethane (10.0 mL). To the solution, N,N-diisopropylethylamine (1.16 mL, 6.66 mmol), 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate (2.53 g, 6.66 mmol), and dimethylglycine (0.550 g, 5.33 mmol) were added, and the mixture was stirred at room temperature for 2 hours. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (heptane/ethyl acetate=100/0 to 80/20) and silica gel column chromatography (chloroform/methanol=100/0 to 90/10) to obtain 2-(dimethylamino)-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]acetamide (1.41 g, yield: 80.0%).</div>
    </li> <li> <para-num num="[1529]"> </para-num> <div id="p-1783" num="1529" class="description-line">ESI-MS m/z: 661 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.29 (m, 6H), 3.57 (dt, J=15.7, 7.9 Hz, 1H), 3.47 (dt, J=15.7, 7.9 Hz, 1H), 3.36 (dt, J=15.7, 7.9 Hz, 1H), 3.29 (dt, J=15.7, 7.9 Hz, 1H), 3.10 (d, J=16.7 Hz, 2H), 2.77 (t, J=6.1 Hz, 2H), 2.69-2.65 (m, 2H), 2.57-2.54 (m, 2H), 2.29 (s, 3H), 2.27 (s, 3H), 2.05-1.99 (m, 8H), 1.60-1.56 (m, 4H), 1.39-1.27 (m, 38H), 0.89-0.88 (m, 6H).</div>
    </li> <heading id="h-0293">Example C4</heading>
    <heading id="h-0294">Bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine (Compound CL-70)</heading>
    <li> <para-num num="[1530]"> </para-num> <div id="p-1784" num="1530" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1531]"> </para-num> <div id="p-1785" num="1531" class="description-line">(Z)-2-Nitro-N-[2-(octadec-9-en-1-ylthio)ethyl]benzenesulfonamide (0.270 g, quantitative) was obtained by the same approach as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C1 using (Z)-(2-chloroethyl)(octadec-9-en-1-yl)sulfane obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C1 instead of (9Z,12Z)-octadeca-9,12-dien-1-yl methanesulfonate.</div>
    </li> <li> <para-num num="[1532]"> </para-num> <div id="p-1786" num="1532" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1533]"> </para-num> <div id="p-1787" num="1533" class="description-line">Bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine (0.0470 g, 57.2%) was obtained by the same approach as in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 of Example C1 using (Z)-2-nitro-N-[2-(octadec-9-en-1-ylthio)ethyl]benzenesulfonamide instead of 2-nitro-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]benzenesulfonamide.</div>
    </li> <li> <para-num num="[1534]"> </para-num> <div id="p-1788" num="1534" class="description-line">ESI-MS m/z: 638 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 2.82 (t, J=6.7 Hz, 4H), 2.68 (t, J=6.5 Hz, 4H), 2.51 (t, J=7.5 Hz, 4H), 2.01 (q, J=6.4 Hz, 8H), 1.59-1.55 (m, 4H), 1.39-1.27 (m, 44H), 0.89 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0295">Example C5</heading>
    <heading id="h-0296">2-(Dimethylamino)-N,N-bis(2-{[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}ethyl)acetamide (Compound CL-71)</heading>
    <li> <para-num num="[1535]"> </para-num> <div id="p-1789" num="1535" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1536]"> </para-num> <div id="p-1790" num="1536" class="description-line">2-(Dimethylamino)-N,N-bis(2-{[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}ethyl)acetamide (0.0493 g, yield: 87.0%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using bis(2-{[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}ethyl)amine obtained by the same approach as in Example C4 instead of (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine.</div>
    </li> <li> <para-num num="[1537]"> </para-num> <div id="p-1791" num="1537" class="description-line">ESI-MS m/z: 719 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 8H), 3.62 (dt, J=15.0, 7.5 Hz, 2H), 3.48 (dt, J=15.0, 7.5 Hz, 2H), 3.14 (s, 2H), 2.77 (t, J=6.7 Hz, 4H), 2.69 (t, J=7.5 Hz, 4H), 2.55 (dt, J=12.8, 7.6 Hz, 4H), 2.28 (s, 6H), 2.05 (q, J=6.8 Hz, 8H), 1.60-1.58 (m, 4H), 1.39-1.26 (m, 32H), 0.89 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0297">Example C6</heading>
    <heading id="h-0298">2-(Dimethylamino)-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]ethane-1-sulfonamide (Compound CL-72)</heading>
    <li> <para-num num="[1538]"> </para-num> <div id="p-1792" num="1538" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1539]"> </para-num> <div id="p-1793" num="1539" class="description-line">(9Z,12Z)N-(2-{[(Z)-Octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (0.183 g, 0.318 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 of Example C1 was dissolved in dichloromethane (3.00 mL). To the solution, triethylamine (0.260 mL, 1.87 mmol) and 2-chloromethanesulfonyl chloride (0.140 mL, 1.33 mmol) were added at 0 C., and the mixture was stirred overnight at room temperature. 0.01 N hydrochloric acid was added to the reaction solution, and the mixture was diluted with distilled water, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=100/0 to 86/14) to obtain N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]ethanesulfonamide (0.160 g, yield: 61.0%).</div>
    </li> <li> <para-num num="[1540]"> </para-num> <div id="p-1794" num="1540" class="description-line">N-(2-{[(Z)-Octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]ethanesulfonamide (0.113 g, 0.169 mmol) was dissolved in tetrahydrofuran (0.500 mL). To the solution, a dimethylamine solution (1.08 mL, 2.16 mmol, 2 M in THE) was added, and the mixture was stirred for 3 hours under heating to reflux. The reaction solution was concentrated under reduced pressure, and the obtained residue was purified by amino silica gel column chromatography (chloroform/methanol=100/0 to 96/4) to obtain 2-(dimethylamino)-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]ethane-1-sulfonamide (0.113 g, yield: 94.0%).</div>
    </li> <li> <para-num num="[1541]"> </para-num> <div id="p-1795" num="1541" class="description-line">ESI-MS m/z: 712 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 6H), 3.36 (t, J=7.8 Hz, 2H), 3.20 (t, J=7.8 Hz, 2H), 3.17-3.11 (m, 2H), 2.80-2.68 (m, 6H), 2.54 (t, J=7.3 Hz, 2H), 2.27 (s, 6H), 2.09-1.93 (m, 8H), 1.63-1.53 (m, 4H), 1.41-1.22 (m, 38H), 0.92-0.85 (m, 6H).</div>
    </li> <heading id="h-0299">Example C7</heading>
    <heading id="h-0300">2-(Dimethylamino)ethyl(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)[(9Z,12Z)-octadeca-9,12-dien-1-yl]carbamate (Compound CL-73)</heading>
    <li> <para-num num="[1542]"> </para-num> <div id="p-1796" num="1542" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1543]"> </para-num> <div id="p-1797" num="1543" class="description-line">(9Z,12Z)N-(2-{[(Z)-Octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (0.127 g, 0.220 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 of Example C1 was dissolved in dichloromethane (1.10 mL). To the solution, triphosgene (0.0406 g, 0.410 mmol) was added, and the mixture was stirred at room temperature for 30 minutes. Triethylamine (0.150 mL, 1.08 mmol) and 2-dimethylaminoethanol (0.100 mL, 0.998 mmol) were added to the reaction solution, and the mixture was stirred overnight at room temperature. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 90/10) to obtain 2-(dimethylamino)ethyl(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl) [(9Z,12Z)-octadeca-9,12-dien-1-yl]carbamate (0.140 g, yield: 92.0%).</div>
    </li> <li> <para-num num="[1544]"> </para-num> <div id="p-1798" num="1544" class="description-line">ESI-MS m/z: 692 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 6H), 4.18 (t, J=6.0 Hz, 2H), 3.43-3.32 (m, 2H), 3.28-3.18 (m, 2H), 2.77 (t, J=6.4 Hz, 2H), 2.70-2.60 (m, 2H), 2.60-2.49 (m, 4H), 2.28 (s, 6H), 2.09-1.93 (m, 8H), 1.61-1.47 (m, 4H), 1.42-1.19 (m, 38H), 0.91-0.86 (m, 6H).</div>
    </li> <heading id="h-0301">Example C8</heading>
    <heading id="h-0302">1-Methyl-3,3-bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (Compound CL-77)</heading>
    <li> <para-num num="[1545]"> </para-num> <div id="p-1799" num="1545" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1546]"> </para-num> <div id="p-1800" num="1546" class="description-line">Azetidine-3,3-diyl dimethanol (0.315 g, 2.96 mmol) was dissolved in methanol (5.00 mL). To the solution, di-tert-butyl dicarbonate (0.936 mL, 4.03 mmol) and triethylamine (0.750 mL, 5.38 mmol) were added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure to obtain tert-<figure-callout id="3" label="butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">butyl</figure-callout> 3,3-bis(hydroxymethyl)azetidine-1-carboxylate (0.584 g, quantitative).</div>
    </li> <li> <para-num num="[1547]"> </para-num> <div id="p-1801" num="1547" class="description-line">tert-<figure-callout id="3" label="Butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Butyl</figure-callout> 3,3-bis(hydroxymethyl)azetidine-1-carboxylate (0.584 g, 2.69 mmol) was dissolved in dichloromethane (10.0 mL). To the solution, methanesulfonyl chloride (0.524 mL, 6.73 mmol) and triethylamine (1.13 mL, 8.07 mmol) were added at 0 C., and the mixture was stirred at room temperature for 2 hours. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain tert-<figure-callout id="3" label="butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">butyl</figure-callout> 3,3-bis{[(methylsulfonyl)oxy]methyl}azetidine-1-carboxylate (1.01 g, quantitative).</div>
    </li> <li> <para-num num="[1548]"> </para-num> <div id="p-1802" num="1548" class="description-line">tert-<figure-callout id="3" label="Butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Butyl</figure-callout> 3,3-bis{[(methylsulfonyl)oxy]methyl}azetidine-1-carboxylate (0.900 g, 2.41 mmol) was dissolved in dimethylformamide (15.0 mL). To the solution, S-potassium thioacetate (0.963 g, 8.44 mmol) was added, and the mixture was stirred overnight at 55 C. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=100/0 to 34/66) to obtain tert-<figure-callout id="3" label="butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">butyl</figure-callout> 3,3-bis[(acetylthio)methyl]azetidine-1-carboxylate (0.742 g, yield: 92.0%).</div>
    </li> <li> <para-num num="[1549]"> </para-num> <div id="p-1803" num="1549" class="description-line"> <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 3.61 (s, 4H), 3.20 (s, 4H), 2.38 (s, 6H), 1.44 (s, 9H).</div>
    </li> <li> <para-num num="[1550]"> </para-num> <div id="p-1804" num="1550" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1551]"> </para-num> <div id="p-1805" num="1551" class="description-line">tert-<figure-callout id="3" label="Butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Butyl</figure-callout> 3,3-bis[(acetylthio)methyl]azetidine-1-carboxylate (0.342 g, 1.03 mmol) was dissolved in tetrahydrofuran (6.00 mL). To the solution, (Z)-octadec-9-en-1-yl methanesulfonate (1.07 g, 3.08 mmol) and a solution of 28% sodium methoxide in methanol (0.615 mL, 3.08 mmol) were added, and the mixture was stirred at room temperature for 4 hours. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=100/0 to 90/10) to obtain tert-<figure-callout id="3" label="butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">butyl</figure-callout> 3,3-bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine-1-carboxylate (0.487 g, yield: 63.3%).</div>
    </li> <li> <para-num num="[1552]"> </para-num> <div id="p-1806" num="1552" class="description-line">tert-<figure-callout id="3" label="Butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Butyl</figure-callout> 3,3-bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine-1-carboxylate (0.487 g, 0.649 mmol) was dissolved in dichloromethane (3.00 mL). To the solution, trifluoroacetic acid (1.00 mL, 13.0 mmol) was added, and the mixture was stirred at room temperature for 2 hours. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=100/0 to 25/75, chloroform/methanol=100/0 to 95/5) to obtain 3,3-bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (0.310 g, yield: 73.5%).</div>
    </li> <li> <para-num num="[1553]"> </para-num> <div id="p-1807" num="1553" class="description-line">ESI-MS m/z: 650 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 3.47 (s, 4H), 2.95 (s, 4H), 2.56 (t, J=7.5 Hz, 4H), 2.01 (q, J=6.4 Hz, 8H), 1.63-1.56 (m, 4H), 1.37-1.29 (m, 44H), 0.88 (t, J=6.8 Hz, 6H).</div>
    </li> <li> <para-num num="[1554]"> </para-num> <div id="p-1808" num="1554" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1555]"> </para-num> <div id="p-1809" num="1555" class="description-line">1-Methyl-3,3-bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (0.0925 g, yield: 88.0%) was obtained by the same approach as in Reference Example B31 using 3,3-bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine instead of bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine.</div>
    </li> <li> <para-num num="[1556]"> </para-num> <div id="p-1810" num="1556" class="description-line">ESI-MS m/z: 664 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.36-5.33 (m, 4H), 3.07 (s, 4H), 2.92 (s, 4H), 2.54 (t, J=7.5 Hz, 4H), 2.33 (s, 3H), 2.01 (q, J=6.4 Hz, 8H), 1.62-1.55 (m, 4H), 1.36-1.29 (m, 44H), 0.88 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0303">Example C9</heading>
    <heading id="h-0304">1-[3,3-Bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (Compound CL-75)</heading>
    <li> <para-num num="[1557]"> </para-num> <div id="p-1811" num="1557" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1558]"> </para-num> <div id="p-1812" num="1558" class="description-line">1-[3,3-Bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (0.0815 g, 72.1%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using 3,3-bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C8 instead of (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine.</div>
    </li> <li> <para-num num="[1559]"> </para-num> <div id="p-1813" num="1559" class="description-line">ESI-MS m/z: 735 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 3.97 (s, 2H), 3.80 (s, 2H), 2.96 (s, 2H), 2.89 (s, 4H), 2.56 (t, J=7.5 Hz, 4H), 2.28 (s, 6H), 2.01 (q, J=6.4 Hz, 8H), 1.63-1.55 (m, 4H), 1.36-1.29 (m, 44H), 0.88 (t, J=6.8 Hz, 6H).</div>
    </li> <heading id="h-0305">Example C10</heading>
    <heading id="h-0306">1-Methyl-3,3-bis({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine (Compound CL-76)</heading>
    <li> <para-num num="[1560]"> </para-num> <div id="p-1814" num="1560" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1561]"> </para-num> <div id="p-1815" num="1561" class="description-line">3,3-Bis({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine (0.338 g, 56.6%) was obtained by the same approach as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C8 using (9Z,12Z)-octadeca-9,12-dien-1-yl methanesulfonate instead of (Z)-octadec-9-en-1-yl methanesulfonate.</div>
    </li> <li> <para-num num="[1562]"> </para-num> <div id="p-1816" num="1562" class="description-line">ESI-MS m/z: 646 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.29 (m, 8H), 3.47 (s, 4H), 2.95 (s, 4H), 2.77 (t, J=6.7 Hz, 4H), 2.56 (t, J=7.4 Hz, 4H), 2.05 (q, J=6.8 Hz, 8H), 1.63-1.56 (m, 4H), 1.39-1.24 (m, 32H), 0.88 (t, J=6.8 Hz, 6H).</div>
    </li> <li> <para-num num="[1563]"> </para-num> <div id="p-1817" num="1563" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1564]"> </para-num> <div id="p-1818" num="1564" class="description-line">1-Methyl-3,3-bis({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine (0.0680 g, yield: 63.4%) was obtained by the same approach as in Reference Example B31 using 3,3-bis({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine instead of bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine.</div>
    </li> <li> <para-num num="[1565]"> </para-num> <div id="p-1819" num="1565" class="description-line">ESI-MS m/z: 660 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.29 (m, 8H), 3.07 (s, 4H), 2.92 (s, 4H), 2.77 (t, J=6.6 Hz, 4H), 2.54 (t, J=7.5 Hz, 4H), 2.33 (s, 3H), 2.05 (q, J=6.9 Hz, 8H), 1.62-1.55 (m, 4H), 1.39-1.25 (m, 32H), 0.89 (t, J=6.8 Hz, 6H).</div>
    </li> <heading id="h-0307">Example C11</heading>
    <heading id="h-0308">1-[3,3-Bis({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (Compound CL-74)</heading>
    <li> <para-num num="[1566]"> </para-num> <div id="p-1820" num="1566" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1567]"> </para-num> <div id="p-1821" num="1567" class="description-line">1-[3,3-Bis({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (0.0692 g, 61.1%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using 3,3-bis({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine obtained in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C10 instead of (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine.</div>
    </li> <li> <para-num num="[1568]"> </para-num> <div id="p-1822" num="1568" class="description-line">ESI-MS m/z: 731 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.29 (m, 8H), 3.97 (s, 2H), 3.80 (s, 2H), 2.98 (s, 2H), 2.89 (s, 4H), 2.77 (t, J=6.7 Hz, 4H), 2.56 (t, J=7.5 Hz, 4H), 2.29 (s, 6H), 2.05 (q, J=6.8 Hz, 8H), 1.63-1.55 (m, 4H), 1.39-1.24 (m, 32H), 0.89 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0309">Example C12</heading>
    <heading id="h-0310">1-Methyl-3-({[(Z)-octadec-9-en-1-yl]oxy}methyl)-3-({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (Compound CL-81)</heading>
    <li> <para-num num="[1569]"> </para-num> <div id="p-1823" num="1569" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1570]"> </para-num> <div id="p-1824" num="1570" class="description-line">Azetidine-3,3-diyl dimethanol (0.315 g, 2.96 mmol) was dissolved in methanol (5.00 mL). To the solution, di-tert-butyl dicarbonate (0.936 mL, 4.03 mmol) and triethylamine (0.750 mL, 5.38 mmol) were added, and the mixture was stirred overnight at room temperature. The reaction solution was concentrated under reduced pressure to obtain tert-<figure-callout id="3" label="butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">butyl</figure-callout> 3,3-bis(hydroxymethyl)azetidine-1-carboxylate (0.584 g, quantitative).</div>
    </li> <li> <para-num num="[1571]"> </para-num> <div id="p-1825" num="1571" class="description-line">tert-<figure-callout id="3" label="Butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Butyl</figure-callout> 3,3-bis(hydroxymethyl)azetidine-1-carboxylate (0.292 g, 1.35 mmol) was dissolved in toluene (6.00 mL). To the solution, sodium hydride (0.0810 g, 2.02 mmol) and (Z)-octadec-9-en-1-yl methanesulfonate (0.559 g, 1.61 mmol) were added, and the mixture was stirred at 100 C. for 5 hours. Distilled water and saturated saline were added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 95/5) to obtain tert-butyl (Z)-3-(hydroxymethyl)-3-[(octadec-9-en-1-yloxy)methyl]azetidine-1-carboxylate (0.296 g, yield: 47.1%).</div>
    </li> <li> <para-num num="[1572]"> </para-num> <div id="p-1826" num="1572" class="description-line"> <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.35-5.34 (m, 2H), 3.81 (d, J=5.6 Hz, 2H), 3.72 (d, J=8.4 Hz, 2H), 3.66 (s, 2H), 3.63 (d, J=8.4 Hz, 2H), 3.45 (t, J=6.6 Hz, 2H), 2.53 (t, J=5.6 Hz, 1H), 2.01 (q, J=6.4 Hz, 4H), 1.60-1.52 (m, 2H), 1.44 (s, 9H), 1.34-1.28 (m, 22H), 0.88 (t, J=6.8 Hz, 3H).</div>
    </li> <li> <para-num num="[1573]"> </para-num> <div id="p-1827" num="1573" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1574]"> </para-num> <div id="p-1828" num="1574" class="description-line">tert-Butyl (Z)-3-(hydroxymethyl)-3-[(octadec-9-en-1-yloxy)methyl]azetidine-1-carboxylate (0.296 g, 0.633 mmol) was dissolved in dichloromethane (5.00 mL). To the solution, methanesulfonyl chloride (0.0640 mL, 0.823 mmol) and triethylamine (0.132 mL, 0.949 mmol) were added, and the mixture was stirred at room temperature for 2.5 hours. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain tert-butyl (Z)-3-{[(methylsulfonyl)oxy]methyl}-3-[(octadec-9-en-1-yloxy)methyl]azetidine-1-carboxylate (0.345 g, quantitative).</div>
    </li> <li> <para-num num="[1575]"> </para-num> <div id="p-1829" num="1575" class="description-line">tert-Butyl (Z)-3-{[(methylsulfonyl)oxy]methyl}-3-[(octadec-9-en-1-yloxy)methyl]azetidine-1-carboxylate was dissolved in dimethylformamide (8.00 mL). To the solution, S-potassium thioacetate (0.130 g, 1.14 mmol) was added, and the mixture was stirred overnight at 55 C. Distilled water and saturated saline were added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=100/0 to 80/20) to obtain tert-butyl (Z)-3-[(acetylthio)methyl]-3-[(octadec-9-en-1-yloxy)methyl]azetidine-1-carboxylate (0.250 g, yield: 75.0%).</div>
    </li> <li> <para-num num="[1576]"> </para-num> <div id="p-1830" num="1576" class="description-line"> <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.36-5.33 (m, 2H), 3.67 (d, J=8.6 Hz, 2H), 3.60 (d, J=8.6 Hz, 2H), 3.43-3.41 (m, 4H), 3.24 (s, 2H), 2.36 (s, 3H), 2.01 (q, J=6.3 Hz, 4H), 1.58-1.53 (m, 2H), 1.44 (s, 9H), 1.29-1.27 (m, 22H), 0.88 (t, J=7.0 Hz, 3H).</div>
    </li> <li> <para-num num="[1577]"> </para-num> <div id="p-1831" num="1577" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1578]"> </para-num> <div id="p-1832" num="1578" class="description-line">3-({[(Z)-Octadec-9-en-1-yl]oxy}methyl)-3-({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (0.187 g, yield: 62.6%) was obtained by the same approach as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C8 using tert-butyl (Z)-3-[(acetylthio)methyl]-3-[(octadec-9-en-1-yloxy)methyl]azetidine-1-carboxylate instead of tert-<figure-callout id="3" label="butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">butyl</figure-callout> 3,3-bis[(acetylthio)methyl]azetidine-1-carboxylate.</div>
    </li> <li> <para-num num="[1579]"> </para-num> <div id="p-1833" num="1579" class="description-line">ESI-MS m/z: 634 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.35-5.34 (m, 4H), 3.57 (s, 2H), 3.46-3.40 (m, 6H), 2.88 (s, 2H), 2.52 (t, J=7.4 Hz, 2H), 2.01 (q, J=6.4 Hz, 8H), 1.59-1.56 (m, 4H), 1.34-1.27 (m, 44H), 0.88 (t, J=6.8 Hz, 6H).</div>
    </li> <li> <para-num num="[1580]"> </para-num> <div id="p-1834" num="1580" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1581]"> </para-num> <div id="p-1835" num="1581" class="description-line">1-Methyl-3-({[(Z)-octadec-9-en-1-yl]oxy}methyl)-3-({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (0.0760 g, yield: 91.0%) was obtained by the same approach as in Reference Example B31 using 3-({[(Z)-octadec-9-en-1-yl]oxy}methyl)-3-({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine instead of bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine.</div>
    </li> <li> <para-num num="[1582]"> </para-num> <div id="p-1836" num="1582" class="description-line">ESI-MS m/z: 648 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 3.53 (s, 2H), 3.44 (t, J=6.7 Hz, 2H), 3.21-3.14 (m, 4H), 2.88 (s, 2H), 2.52 (t, J=7.5 Hz, 2H), 2.39 (s, 3H), 2.01 (q, J=6.8 Hz, 8H), 1.62-1.53 (m, 4H), 1.34-1.27 (m, 44H), 0.88 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0311">Example C13</heading>
    <heading id="h-0312">2-(Dimethylamino)-1-(3-({[(Z)-octadec-9-en-1-yl]oxy}methyl)-3-({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidin-1-yl)ethan-1-one (Compound CL-80)</heading>
    <li> <para-num num="[1583]"> </para-num> <div id="p-1837" num="1583" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1584]"> </para-num> <div id="p-1838" num="1584" class="description-line">2-(Dimethylamino)-1-(3-({[(Z)-octadec-9-en-1-yl]oxy}methyl)-3-({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidin-1-yl)ethan-1-one (0.0360 g, 34.1%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using 3-({[(Z)-octadec-9-en-1-yl]oxy}methyl)-3-({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 of Example C12 instead of (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine.</div>
    </li> <li> <para-num num="[1585]"> </para-num> <div id="p-1839" num="1585" class="description-line">ESI-MS m/z: 719 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.36-5.33 (m, 4H), 3.98 (d, J=9.1 Hz, 1H), 3.92 (d, J=9.1 Hz, 1H), 3.82 (d, J=9.9 Hz, 1H), 3.74 (d, J=9.9 Hz, 1H), 3.51 (s, 2H), 3.44 (t, J=6.5 Hz, 2H), 2.95 (s, 2H), 2.84 (s, 2H), 2.53 (t, J=7.5 Hz, 2H), 2.28 (s, 6H), 2.01 (q, J=6.3 Hz, 8H), 1.59-1.54 (m, 4H), 1.31-1.28 (m, 44H), 0.88 (t, J=6.8 Hz, 6H).</div>
    </li> <heading id="h-0313">Example C14</heading>
    <heading id="h-0314">1-Methyl-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine (Compound CL-79)</heading>
    <li> <para-num num="[1586]"> </para-num> <div id="p-1840" num="1586" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1587]"> </para-num> <div id="p-1841" num="1587" class="description-line">tert-Butyl 3-(hydroxymethyl)-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)azetidine-1-carboxylate (0.166 g, yield: 26.6%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C12 using (9Z,12Z)-octadeca-9,12-dien-1-yl methanesulfonate instead of (Z)-octadec-9-en-1-yl methanesulfonate.</div>
    </li> <li> <para-num num="[1588]"> </para-num> <div id="p-1842" num="1588" class="description-line"> <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.29 (m, 4H), 3.81 (d, J=5.3 Hz, 2H), 3.72 (d, J=8.4 Hz, 2H), 3.66 (s, 2H), 3.63 (d, J=8.4 Hz, 2H), 3.45 (t, J=6.6 Hz, 2H), 2.77 (t, J=6.7 Hz, 2H), 2.53 (t, J=5.3 Hz, 1H), 2.05 (q, J=6.8 Hz, 4H), 1.57-1.43 (m, 2H), 1.44 (s, 9H), 1.39-1.25 (m, 16H), 0.89 (t, J=7.0 Hz, 3H).</div>
    </li> <li> <para-num num="[1589]"> </para-num> <div id="p-1843" num="1589" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1590]"> </para-num> <div id="p-1844" num="1590" class="description-line">tert-Butyl 3-[(acetylthio)methyl]-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)azetidine-1-carboxylate (0.0560 g, 29.9%) was obtained by the same approach as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C12 using tert-butyl 3-(hydroxymethyl)-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)azetidine-1-carboxylate instead of tert-butyl (Z)-3-(hydroxymethyl)-3-[(octadec-9-en-1-yloxy)methyl]azetidine-1-carboxylate.</div>
    </li> <li> <para-num num="[1591]"> </para-num> <div id="p-1845" num="1591" class="description-line"> <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 4H), 3.67 (d, J=8.6 Hz, 2H), 3.60 (d, J=8.6 Hz, 2H), 3.43-3.41 (m, 4H), 3.24 (s, 2H), 2.77 (t, J=6.3 Hz, 2H), 2.36 (s, 3H), 2.05 (q, J=6.8 Hz, 4H), 1.56-1.52 (m, 2H), 1.44 (s, 9H), 1.33-1.29 (m, 16H), 0.89 (t, J=6.8 Hz, 3H).</div>
    </li> <li> <para-num num="[1592]"> </para-num> <div id="p-1846" num="1592" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1593]"> </para-num> <div id="p-1847" num="1593" class="description-line">3-({[(9Z,12Z)-Octadeca-9,12-dien-1-yl]oxy}methyl)-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine (0.0335 g, yield: 68.1%) was obtained by the same approach as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C8 using tert-butyl 3-[(acetylthio)methyl]-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)azetidine-1-carboxylate instead of tert-<figure-callout id="3" label="butyl" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">butyl</figure-callout> 3,3-bis[(acetylthio)methyl]azetidine-1-carboxylate.</div>
    </li> <li> <para-num num="[1594]"> </para-num> <div id="p-1848" num="1594" class="description-line">ESI-MS m/z: 630 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 8H), 3.77 (d, J=9.9 Hz, 2H), 3.72 (d, J=9.9 Hz, 2H), 3.54 (s, 2H), 3.48 (t, J=6.8 Hz, 2H), 2.90 (s, 2H), 2.77 (d, J=6.6 Hz, 4H), 2.54 (t, J=7.5 Hz, 2H), 2.05 (q, J=6.8 Hz, 8H), 1.62-1.54 (m, 4H), 1.39-1.24 (m, 32H), 0.89 (t, J=7.0 Hz, 6H).</div>
    </li> <li> <para-num num="[1595]"> </para-num> <div id="p-1849" num="1595" class="description-line">Step 4</div>
    </li> <li> <para-num num="[1596]"> </para-num> <div id="p-1850" num="1596" class="description-line">1-Methyl-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine (0.0125 g, yield: 76.0%) was obtained by the same approach as in Reference Example B31 using 3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine instead of bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine.</div>
    </li> <li> <para-num num="[1597]"> </para-num> <div id="p-1851" num="1597" class="description-line">ESI-MS m/z: 644 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 8H), 3.52 (s, 2H), 3.44 (t, J=6.7 Hz, 2H), 3.23 (s, 4H), 2.88 (s, 2H), 2.77 (t, J=6.6 Hz, 4H), 2.53 (t, J=7.4 Hz, 2H), 2.40 (s, 3H), 2.05 (q, J=6.8 Hz, 8H), 1.59-1.57 (m, 4H), 1.39-1.25 (m, 32H), 0.89 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0315">Example C15</heading>
    <heading id="h-0316">2-(Dimethylamino)-1-[3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidin-1-yl]ethan-1-one (Compound CL-78)</heading>
    <li> <para-num num="[1598]"> </para-num> <div id="p-1852" num="1598" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1599]"> </para-num> <div id="p-1853" num="1599" class="description-line">2-(Dimethylamino)-1-[3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidin-1-yl]ethan-1-one (0.00830 g, 43.0%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using 3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]oxy}methyl)-3-({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 of Example C14 instead of (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine.</div>
    </li> <li> <para-num num="[1600]"> </para-num> <div id="p-1854" num="1600" class="description-line">ESI-MS m/z: 715 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 8H), 3.98 (d, J=9.1 Hz, 1H), 3.92 (d, J=9.1 Hz, 1H), 3.82 (d, J=9.6 Hz, 1H), 3.74 (d, J=9.6 Hz, 1H), 3.51 (s, 2H), 3.44 (t, J=6.6 Hz, 2H), 2.96 (s, 2H), 2.84 (s, 2H), 2.77 (t, J=6.7 Hz, 4H), 2.53 (t, J=7.5 Hz, 2H), 2.28 (s, 6H), 2.05 (q, J=6.8 Hz, 8H), 1.60-1.58 (m, 4H), 1.39-1.26 (m, 32H), 0.89 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0317">Example C16</heading>
    <heading id="h-0318">3-[(2-{[(Z)-Octadec-9-en-1-yl]thio}ethyl) [(9Z,12Z)-octadeca-9,12-dien-1-yl]amino]propan-1-ol (Compound CL-82)</heading>
    <li> <para-num num="[1601]"> </para-num> <div id="p-1855" num="1601" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1602]"> </para-num> <div id="p-1856" num="1602" class="description-line">(9Z,12Z)N-(2-{[(Z)-Octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (0.150 g, 0.260 mmol) was dissolved in dimethylformamide (1.00 mL). To the solution, cesium carbonate (0.255 g, 0.781 mmol) and (3-bromopropoxy)(tert-butyl)dimethylsilane (0.121 mL, 0.521 mmol) were added, and the mixture was stirred at 80 C. for 3 hours under microwave irradiation. Saturated saline was added to the reaction solution, followed by extraction with hexane. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=80/20) to obtain (9Z,12Z)N-{3-[(tert-butyldimethylsilyl)oxy]propyl}-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (0.114 g, yield: 58.5%).</div>
    </li> <li> <para-num num="[1603]"> </para-num> <div id="p-1857" num="1603" class="description-line">(9Z,12Z)N-{3-[(tert-Butyldimethylsilyl)oxy]propyl}-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (0.114 g, 0.152 mmol) was dissolved in tetrahydrofuran (1.00 mL). To the solution, tetrabutylammonium fluoride (0.228 mL, 0.228 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (heptane/ethyl acetate=100/0 to 80/20) and (chloroform/methanol=100/0 to 80/20) to obtain 3-[(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)[(9Z,12Z)-octadeca-9,12-dien-1-yl]amino]propan-1-ol (0.0640 g, yield: 66.3%).</div>
    </li> <li> <para-num num="[1604]"> </para-num> <div id="p-1858" num="1604" class="description-line">ESI-MS m/z: 635 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 6H), 3.79 (t, J=5.2 Hz, 2H), 2.78 (t, J=6.7 Hz, 2H), 2.68-2.60 (m, 6H), 2.52 (t, J=7.4 Hz, 2H), 2.44 (t, J=7.6 Hz, 2H), 2.08-1.96 (m, 8H), 1.71-1.66 (m, 2H), 1.62-1.54 (m, 2H), 1.50-1.46 (m, 2H), 1.39-1.27 (m, 38H), 0.90-0.88 (m, 6H).</div>
    </li> <heading id="h-0319">Example C17</heading>
    <heading id="h-0320">3-(Dimethylamino)propyl(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)[(9Z,12Z)-octadeca-9,12-dien-1-yl]carbamate (Compound CL-83)</heading>
    <li> <para-num num="[1605]"> </para-num> <div id="p-1859" num="1605" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1606]"> </para-num> <div id="p-1860" num="1606" class="description-line">4-Nitrophenyl carbonochloridate (5.16 g, 25.1 mmol) was dissolved in diethyl ether (150 mL). To the solution, 3-(dimethylamino)propan-1-ol (3.00 mL, 25.1 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Ethanol was added to the reaction solution, and the mixture was filtered to obtain 3-(dimethylamino)propyl(4-nitrophenyl)carbonate hydrochloride (5.49 g, 71.8%). (9Z,12Z)N-(2-{[(Z)-Octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine (0.104 g, 0.181 mmol) obtained in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 of Example C1 was dissolved in chloroform (2.00 mL). To the solution, triethylamine (0.101 mL, 0.722 mmol) and 3-(dimethylamino)propyl(4-nitrophenyl)carbonate hydrochloride (0.110 g, 0.361 mmol) were added, and the mixture was stirred at 110 C. for 2 hours. Saturated saline was added to the reaction solution, followed by extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (heptane/ethyl acetate=100/0 to 80/20) and silica gel column chromatography (chloroform/methanol=100/0 to 80/20) to obtain 3-(dimethylamino)propyl(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)[(9Z,12Z)-octadeca-9,12-dien-1-yl]carbamate (0.0510 g, yield: 40.1%).</div>
    </li> <li> <para-num num="[1607]"> </para-num> <div id="p-1861" num="1607" class="description-line">ESI-MS m/z: 706 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.29 (m, 6H), 4.12 (t, J=6.5 Hz, 2H), 3.38 (t, J=6.7 Hz, 2H), 3.22 (t, J=6.3 Hz, 2H), 2.77 (t, J=6.7 Hz, 2H), 2.65 (t, J=6.6 Hz, 2H), 2.54 (t, J=6.8 Hz, 2H), 2.35 (t, J=7.5 Hz, 2H), 2.23 (s, 6H), 2.06-2.00 (m, 8H), 1.84-1.77 (m, 2H), 1.60-1.51 (m, 4H), 1.36-1.30 (m, 38H), 0.91-0.86 (m, 6H).</div>
    </li> <heading id="h-0321">Example C18</heading>
    <heading id="h-0322">2-(Diethylamino)-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]acetamide (Compound CL-84)</heading>
    <li> <para-num num="[1608]"> </para-num> <div id="p-1862" num="1608" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1609]"> </para-num> <div id="p-1863" num="1609" class="description-line">2-(Diethylamino)-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]acetamide (0.108 g, yield: 86.0%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using N,N-diethylglycine instead of dimethylglycine.</div>
    </li> <li> <para-num num="[1610]"> </para-num> <div id="p-1864" num="1610" class="description-line">ESI-MS m/z: 690 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 6H), 3.60 (t, J=7.8 Hz, 1H), 3.48-3.47 (m, 2H), 3.28 (t, J=7.5 Hz, 1H), 3.25 (d, J=15.5 Hz, 2H), 2.77 (t, J=6.2 Hz, 2H), 2.72-2.64 (m, 2H), 2.61-2.51 (m, 6H), 2.09-1.93 (m, 8H), 1.63-1.48 (m, 4H), 1.42-1.20 (m, 38H), 1.03 (t, J=7.1 Hz, 6H), 0.92-0.84 (m, 6H).</div>
    </li> <heading id="h-0323">Example C19</heading>
    <heading id="h-0324">3-(Dimethylamino)-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]propanamide (Compound CL-85)</heading>
    <li> <para-num num="[1611]"> </para-num> <div id="p-1865" num="1611" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1612]"> </para-num> <div id="p-1866" num="1612" class="description-line">3-(Dimethylamino)-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)-N-[(9Z,12Z)-octadeca-9,12-dien-1-yl]propanamide (0.0537 g, yield: 83.0%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using 3-(dimethylamino)propanoic acid instead of dimethylglycine.</div>
    </li> <li> <para-num num="[1613]"> </para-num> <div id="p-1867" num="1613" class="description-line">ESI-MS m/z: 676 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.30 (m, 6H), 3.50-3.41 (m, 2H), 3.34-3.23 (m, 2H), 2.77 (t, J=6.2 Hz, 2H), 2.70-2.62 (m, 4H), 2.59-2.46 (m, 4H), 2.27 (s, 6H), 2.11-1.93 (m, 8H), 1.67-1.46 (m, 4H), 1.41-1.22 (m, 38H), 0.91-0.86 (m, 6H).</div>
    </li> <heading id="h-0325">Example C20</heading>
    <heading id="h-0326">S-[2-(Dimethylamino)ethyl] (2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)[(9Z,12Z)-octadeca-9,12-dien-1-yl]carbamothioate (Compound CL-86)</heading>
    <li> <para-num num="[1614]"> </para-num> <div id="p-1868" num="1614" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1615]"> </para-num> <div id="p-1869" num="1615" class="description-line">S-[2-(Dimethylamino)ethyl] (2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)[(9Z,12Z)-octadeca-9,12-dien-1-yl]carbamothioate (0.143 g, yield: 94.0%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C7 using 2-(dimethylamino)ethane-1-thiol instead of 2-dimethylaminoethanol.</div>
    </li> <li> <para-num num="[1616]"> </para-num> <div id="p-1870" num="1616" class="description-line">ESI-MS m/z: 708 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.43-5.29 (m, 6H), 3.54-3.43 (m, 2H), 3.41-3.26 (m, 2H), 3.03 (t, J=7.1 Hz, 2H), 2.77 (t, J=6.4 Hz, 2H), 2.73-2.64 (m, 2H), 2.59-2.50 (m, 4H), 2.28 (s, 6H), 2.09-1.93 (m, 8H), 1.65-1.49 (m, 4H), 1.41-1.21 (m, 38H), 0.92-0.85 (m, 6H).</div>
    </li> <heading id="h-0327">Example C21</heading>
    <heading id="h-0328">N-Methyl-2-{[(Z)-octadec-9-en-1-yl]thio}-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)ethan-1-amine (Compound CL-87)</heading>
    <li> <para-num num="[1617]"> </para-num> <div id="p-1871" num="1617" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1618]"> </para-num> <div id="p-1872" num="1618" class="description-line">Bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine (0.0300 g, 0.0470 mmol) was dissolved in a mixed solvent of 1,2-dichloroethane (1.00 mL) and methanol (1.00 mL). To the solution, a 37% formaldehyde solution (0.0170 mL, 0.235 mmol) and sodium triacetoxyborohydride (0.0250 g, 0.118 mmol) were added, and the mixture was stirred at room temperature for 3 hours. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (heptane/ethyl acetate=100/0 to 90/10) to obtain N-methyl-2-{[(Z)-octadec-9-en-1-yl]thio}-N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)ethan-1-amine (0.0146 g, yield: 47.6%).</div>
    </li> <li> <para-num num="[1619]"> </para-num> <div id="p-1873" num="1619" class="description-line">ESI-MS m/z: 652 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 2.62 (s, 8H), 2.52 (t, J=7.5 Hz, 4H), 2.29 (s, 3H), 2.01 (q, J=6.4 Hz, 8H), 1.62-1.54 (m, 4H), 1.36-1.29 (m, 44H), 0.89 (t, J=6.8 Hz, 6H).</div>
    </li> <heading id="h-0329">Example C22</heading>
    <heading id="h-0330">Bis(2-{[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}ethyl)amine (Compound CL-88)</heading>
    <li> <para-num num="[1620]"> </para-num> <div id="p-1874" num="1620" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1621]"> </para-num> <div id="p-1875" num="1621" class="description-line">(9Z,12Z)-Octadeca-9,12-dien-1-yl methanesulfonate (1.02 g, 2.96 mmol) was dissolved in dimethylformamide (20.0 mL). To the solution, S-potassium thioacetate (0.440 g, 3.85 mmol) was added, and the mixture was stirred at room temperature for 4 hours. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain S-[(9Z,12Z)-octadeca-9,12-dien-1-yl] ethanethioate (0.0146 g, yield: 47.6%).</div>
    </li> <li> <para-num num="[1622]"> </para-num> <div id="p-1876" num="1622" class="description-line"> <figure-callout id="2" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 2</div>
    </li> <li> <para-num num="[1623]"> </para-num> <div id="p-1877" num="1623" class="description-line">tert-Butyl bis(2-hydroxyethyl)carbamate (0.300 g, 1.46 mmol) was dissolved in dichloromethane (5.00 mL). To the solution, methanesulfonyl chloride (0.419 mL, 3.65 mmol) and triethylamine (0.611 mL, 4.38 mmol) were added at 0 C., and the mixture was stirred at room temperature for 1 hour. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure to obtain [(tert-butoxycarbonyl)azanediyl]bis(ethane-2,1-diyl) dimethanesulfonate (0.560 g, quantitative).</div>
    </li> <li> <para-num num="[1624]"> </para-num> <div id="p-1878" num="1624" class="description-line"> <figure-callout id="3" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 3</div>
    </li> <li> <para-num num="[1625]"> </para-num> <div id="p-1879" num="1625" class="description-line">S-[(9Z,12Z)-Octadeca-9,12-dien-1-yl] ethanethioate (0.269 g, 0.830 mmol) was dissolved in a mixed solvent of methanol (2.00 mL) and tetrahydrofuran (0.500 mL). To the solution, a solution of 28% sodium methoxide in methanol (0.133 mL, 0.664 mmol) and [(tert-butoxycarbonyl)azanediyl]bis(ethane-2,1-diyl) dimethanesulfonate (0.100 g, 0.277 mmol) were added at 0 C., and the mixture was stirred overnight at 50 C. Distilled water and saturated saline were added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by amino silica gel column chromatography (heptane/ethyl acetate=100/0 to 85/15) to obtain tert-butyl bis(2-{[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}ethyl)carbamate (0.0654 g, yield: 32.2%).</div>
    </li> <li> <para-num num="[1626]"> </para-num> <div id="p-1880" num="1626" class="description-line">tert-Butyl bis(2-{[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}ethyl) carbamate (0.0654 g, 0.0890 mmol) was dissolved in dichloromethane (1.00 mL). To the solution, trifluoroacetic acid (0.137 mL, 1.78 mmol) was added, and the mixture was stirred overnight at room temperature. A saturated aqueous solution of sodium bicarbonate was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 95/5) to obtain bis(2-{[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}ethyl)amine (0.0493 g, yield: 87.0%).</div>
    </li> <li> <para-num num="[1627]"> </para-num> <div id="p-1881" num="1627" class="description-line">ESI-MS m/z: 634 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.42-5.29 (m, 8H), 2.82 (t, J=6.6 Hz, 4H), 2.77 (t, J=6.7 Hz, 4H), 2.68 (t, J=6.5 Hz, 4H), 2.51 (t, J=7.5 Hz, 4H), 2.05 (q, J=6.8 Hz, 8H), 1.61-1.57 (m, 4H), 1.39-1.24 (m, 32H), 0.89 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0331"> <figure-callout id="3" label="Example C23" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Example C23</figure-callout> </heading>
    <heading id="h-0332">3,3-Bis({[(9Z,12Z)-octadeca-9,12-dien-1-yl]thio}methyl)azetidine (Compound CL-89)</heading>
    <li> <para-num num="[1628]"> </para-num> <div id="p-1882" num="1628" class="description-line">Compound CL-89 was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C10.</div>
    </li> <heading id="h-0333"> <figure-callout id="3" label="Example C24" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Example C24</figure-callout> </heading>
    <heading id="h-0334">3,3-Bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (Compound CL-90)</heading>
    <li> <para-num num="[1629]"> </para-num> <div id="p-1883" num="1629" class="description-line">Compound CL-90 was obtained by the same approach as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C8.</div>
    </li> <heading id="h-0335">Example C25</heading>
    <heading id="h-0336">1-Ethyl-3,3-bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (Compound CL-91)</heading>
    <li> <para-num num="[1630]"> </para-num> <div id="p-1884" num="1630" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1631]"> </para-num> <div id="p-1885" num="1631" class="description-line">3,3-Bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (0.0450 g, 0.0690 mmol) obtained in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C8 was dissolved in a mixed solvent of 1,2-dichloroethane (0.500 mL) and methanol (0.500 mL). To the solution, acetaldehyde (0.0200 mL, 0.346 mmol) and sodium triacetoxyborohydride (0.0730 g, 0.346 mmol) were added, and the mixture was stirred overnight at room temperature. Saturated saline was added to the reaction solution, followed by extraction with ethyl acetate. The organic layer was dried over anhydrous magnesium sulfate, then filtered, and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol=100/0 to 90/10) to obtain 1-ethyl-3,3-bis({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (0.0375 g, yield: 80.0%).</div>
    </li> <li> <para-num num="[1632]"> </para-num> <div id="p-1886" num="1632" class="description-line">ESI-MS m/z: 678 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 3.07 (s, 4H), 2.93 (s, 4H), 2.55 (t, J=7.5 Hz, 4H), 2.50-2.49 (m, 2H), 2.01 (q, J=6.4 Hz, 8H), 1.67-1.55 (m, 4H), 1.37-1.29 (m, 44H), 0.95 (t, J=7.2 Hz, 3H), 0.88 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0337"> <figure-callout id="3" label="Example C26" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Example C26</figure-callout> </heading>
    <heading id="h-0338">3,3-Bis({[(Z)-octadec-9-en-1-yl]thio}methyl)-1-propylazetidine (Compound CL-92)</heading>
    <li> <para-num num="[1633]"> </para-num> <div id="p-1887" num="1633" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1634]"> </para-num> <div id="p-1888" num="1634" class="description-line">3,3-Bis({[(Z)-octadec-9-en-1-yl]thio}methyl)-1-propylazetidine (0.0374 g, yield: 58.5%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Reference Example 25 using propionaldehyde instead of acetaldehyde.</div>
    </li> <li> <para-num num="[1635]"> </para-num> <div id="p-1889" num="1635" class="description-line">ESI-MS m/z: 692 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 3.04 (s, 4H), 2.93 (s, 4H), 2.54 (t, J=7.5 Hz, 4H), 2.39 (t, J=7.6 Hz, 2H), 2.01 (q, J=6.4 Hz, 8H), 1.60-1.57 (m, 4H), 1.39-1.30 (m, 46H), 0.89-0.87 (m, 9H).</div>
    </li> <heading id="h-0339"> <figure-callout id="3" label="Example C27" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Example C27</figure-callout> </heading>
    <heading id="h-0340">3,3-Bis(({(Z)-hexadec-9-en-1-yl]thio}methyl)azetidine (Compound CL-93)</heading>
    <li> <para-num num="[1636]"> </para-num> <div id="p-1890" num="1636" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1637]"> </para-num> <div id="p-1891" num="1637" class="description-line">3,3-Bis(({(Z)-hexadec-9-en-1-yl]thio}methyl)azetidine (0.208 g, yield: 62.3%) was obtained by the same approach as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C8 using (Z)-hexadec-9-en-1-yl methanesulfonate instead of (Z)-octadec-9-en-1-yl methanesulfonate.</div>
    </li> <li> <para-num num="[1638]"> </para-num> <div id="p-1892" num="1638" class="description-line">ESI-MS m/z: 595 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 3.44 (s, 4H), 2.95 (s, 4H), 2.56 (t, J=7.5 Hz, 4H), 2.01 (q, J=6.4 Hz, 8H), 1.64-1.56 (m, 4H), 1.38-1.32 (m, 36H), 0.88 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0341"> <figure-callout id="3" label="Example C28" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Example C28</figure-callout> </heading>
    <heading id="h-0342">3,3-Bis({[(Z)-hexadec-9-en-1-yl]thio}methyl)-1-methylazetidine (Compound CL-94)</heading>
    <li> <para-num num="[1639]"> </para-num> <div id="p-1893" num="1639" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1640]"> </para-num> <div id="p-1894" num="1640" class="description-line">3,3-Bis({[(Z)-hexadec-9-en-1-yl]thio}methyl)-1-methylazetidine (0.0910 g, yield: 89.0%) was obtained by the same approach as in Reference Example B31 using 3,3-bis(({(Z)-hexadec-9-en-1-yl]thio}methyl)azetidine instead of bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine.</div>
    </li> <li> <para-num num="[1641]"> </para-num> <div id="p-1895" num="1641" class="description-line">ESI-MS m/z: 609 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.36-5.34 (m, 4H), 3.07 (s, 4H), 2.92 (s, 4H), 2.54 (t, J=7.5 Hz, 4H), 2.33 (s, 3H), 2.01 (q, J=6.8 Hz, 8H), 1.62-1.55 (m, 4H), 1.39-1.32 (m, 36H), 0.88 (t, J=6.8 Hz, 6H).</div>
    </li> <heading id="h-0343">Example C29</heading>
    <heading id="h-0344">1-[3,3-Bis({[(Z)-hexadec-9-en-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (Compound CL-95)</heading>
    <li> <para-num num="[1642]"> </para-num> <div id="p-1896" num="1642" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1643]"> </para-num> <div id="p-1897" num="1643" class="description-line">1-[3,3-Bis({[(Z)-hexadec-9-en-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (0.0660 g, yield: 64.1%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using 3,3-bis(({(Z)-hexadec-9-en-1-yl]thio}methyl)azetidine instead of (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine.</div>
    </li> <li> <para-num num="[1644]"> </para-num> <div id="p-1898" num="1644" class="description-line">ESI-MS m/z: 679 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.36-5.34 (m, 4H), 3.97 (s, 2H), 3.80 (s, 2H), 2.98 (s, 2H), 2.89 (s, 4H), 2.56 (t, J=7.5 Hz, 4H), 2.28 (s, 6H), 2.01 (q, J=6.5 Hz, 8H), 1.62-1.55 (m, 4H), 1.42-1.29 (m, 36H), 0.88 (t, J=6.8 Hz, 6H).</div>
    </li> <heading id="h-0345"> <figure-callout id="3" label="Example C30" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Example C30</figure-callout> </heading>
    <heading id="h-0346">3,3-Bis({[(Z)-octadec-11-en-1-yl]thio}methyl)azetidine (Compound CL-96)</heading>
    <li> <para-num num="[1645]"> </para-num> <div id="p-1899" num="1645" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1646]"> </para-num> <div id="p-1900" num="1646" class="description-line">3,3-Bis({[(Z)-octadec-11-en-1-yl]thio}methyl)azetidine (0.365 g, yield: 85.0%) was obtained by the same approach as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C8 using (Z)-octadec-11-en-1-yl methanesulfonate instead of (Z)-octadec-9-en-1-yl methanesulfonate.</div>
    </li> <li> <para-num num="[1647]"> </para-num> <div id="p-1901" num="1647" class="description-line">ESI-MS m/z: 651 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.36-5.34 (m, 4H), 3.44 (s, 4H), 2.95 (s, 4H), 2.56 (t, J=7.5 Hz, 4H), 2.01 (q, J=6.4 Hz, 8H), 1.62-1.57 (m, 4H), 1.42-1.27 (m, 44H), 0.88 (t, J=6.8 Hz, 6H).</div>
    </li> <heading id="h-0347">Example C31</heading>
    <heading id="h-0348">1-Methyl-3,3-bis({[(Z)-octadec-11-en-1-yl]thio}methyl)azetidine (Compound CL-97)</heading>
    <li> <para-num num="[1648]"> </para-num> <div id="p-1902" num="1648" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1649]"> </para-num> <div id="p-1903" num="1649" class="description-line">1-Methyl-3,3-bis({[(Z)-octadec-11-en-1-yl]thio}methyl)azetidine (0.0780 g, yield: 77.0%) was obtained by the same approach as in Reference Example B31 using 3,3-bis({[(Z)-octadec-11-en-1-yl]thio}methyl)azetidine instead of bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine.</div>
    </li> <li> <para-num num="[1650]"> </para-num> <div id="p-1904" num="1650" class="description-line">ESI-MS m/z: 665 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 3.07 (s, 4H), 2.92 (s, 4H), 2.54 (t, J=7.5 Hz, 4H), 2.33 (s, 3H), 2.01 (q, J=6.4 Hz, 8H), 1.62-1.55 (m, 4H), 1.42-1.27 (m, 44H), 0.88 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0349">Example C32</heading>
    <heading id="h-0350">1-[3,3-Bis({[(Z)-octadec-11-en-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (Compound CL-98)</heading>
    <li> <para-num num="[1651]"> </para-num> <div id="p-1905" num="1651" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1652]"> </para-num> <div id="p-1906" num="1652" class="description-line">1-[3,3-Bis({[(Z)-octadec-11-en-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (0.0440 g, yield: 67.1%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using 3,3-bis({[(Z)-octadec-11-en-1-yl]thio}methyl)azetidine instead of (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine.</div>
    </li> <li> <para-num num="[1653]"> </para-num> <div id="p-1907" num="1653" class="description-line">ESI-MS m/z: 735 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.36-5.33 (m, 4H), 3.96 (s, 2H), 3.80 (s, 2H), 2.96 (s, 2H), 2.89 (s, 4H), 2.56 (t, J=7.4 Hz, 4H), 2.27 (s, 6H), 2.01 (q, J=6.8 Hz, 8H), 1.62-1.55 (m, 4H), 1.34-1.28 (m, 44H), 0.88 (t, J=7.0 Hz, 6H).</div>
    </li> <heading id="h-0351"> <figure-callout id="3" label="Example C33" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Example C33</figure-callout> </heading>
    <heading id="h-0352">3,3-Bis({[(Z)-tetradec-9-en-1-yl]thio}methyl)azetidine (Compound CL-99)</heading>
    <li> <para-num num="[1654]"> </para-num> <div id="p-1908" num="1654" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1655]"> </para-num> <div id="p-1909" num="1655" class="description-line">3,3-Bis({[(Z)-tetradec-9-en-1-yl]thio}methyl)azetidine (0.137 g, yield: 73.5%) was obtained by the same approach as in <figure-callout id="2" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 2 of Example C8 using (Z)-tetradec-9-en-1-yl methanesulfonate instead of (Z)-octadec-9-en-1-yl methanesulfonate.</div>
    </li> <li> <para-num num="[1656]"> </para-num> <div id="p-1910" num="1656" class="description-line">ESI-MS m/z: 539 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 3.47 (s, 4H), 2.95 (s, 4H), 2.56 (t, J=7.5 Hz, 4H), 2.01-2.00 (m, 8H), 1.63-1.56 (m, 4H), 1.36-1.31 (m, 28H), 0.90 (t, J=7.1 Hz, 6H).</div>
    </li> <heading id="h-0353">Example C34</heading>
    <heading id="h-0354">1-Methyl-3,3-bis({[(Z)-tetradec-9-en-1-yl]thio}methyl)azetidine (Compound CL-100)</heading>
    <li> <para-num num="[1657]"> </para-num> <div id="p-1911" num="1657" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1658]"> </para-num> <div id="p-1912" num="1658" class="description-line">1-Methyl-3,3-bis({[(Z)-tetradec-9-en-1-yl]thio}methyl)azetidine (0.0684 g, yield: 71.7%) was obtained by the same approach as in Reference Example B31 using 3,3-bis({[(Z)-tetradec-9-en-1-yl]thio}methyl)azetidine instead of bis(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)amine.</div>
    </li> <li> <para-num num="[1659]"> </para-num> <div id="p-1913" num="1659" class="description-line">ESI-MS m/z: 553 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.39-5.31 (m, 4H), 3.07 (s, 4H), 2.92 (s, 4H), 2.54 (t, J=7.5 Hz, 4H), 2.33 (s, 3H), 2.03-2.01 (m, 8H), 1.62-1.55 (m, 4H), 1.35-1.32 (m, 28H), 0.90 (t, J=7.1 Hz, 6H).</div>
    </li> <heading id="h-0355">Example C35</heading>
    <heading id="h-0356">1-[3,3-Bis({[(Z)-tetradec-9-en-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (Compound CL-101)</heading>
    <li> <para-num num="[1660]"> </para-num> <div id="p-1914" num="1660" class="description-line"> <figure-callout id="1" label="Step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Step</figure-callout> 1</div>
    </li> <li> <para-num num="[1661]"> </para-num> <div id="p-1915" num="1661" class="description-line">1-[3,3-Bis({[(Z)-tetradec-9-en-1-yl]thio}methyl)azetidin-1-yl]-2-(dimethylamino)ethan-1-one (0.0145 g, yield: 50.1%) was obtained by the same approach as in <figure-callout id="1" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 1 of Example C3 using 3,3-bis({[(Z)-tetradec-9-en-1-yl]thio}methyl)azetidine instead of (9Z,12Z)N-(2-{[(Z)-octadec-9-en-1-yl]thio}ethyl)octadeca-9,12-dien-1-amine.</div>
    </li> <li> <para-num num="[1662]"> </para-num> <div id="p-1916" num="1662" class="description-line">ESI-MS m/z: 623 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (400 MHz, CDCl<sub>3</sub>) : 5.37-5.33 (m, 4H), 3.97 (s, 2H), 3.80 (s, 2H), 2.96 (s, 2H), 2.89 (s, 4H), 2.56 (t, J=7.4 Hz, 4H), 2.28 (s, 6H), 2.02-2.00 (m, 8H), 1.63-1.55 (m, 4H), 1.39-1.29 (m, 28H), 0.90 (t, J=7.1 Hz, 6H).</div>
    </li> <heading id="h-0357">Example C36</heading>
    <heading id="h-0358">3-({[(Z)-Octadec-9-en-1-yl]oxy}methyl)-3-({[(Z)-octadec-9-en-1-yl]thio}methyl)azetidine (Compound CL-102)</heading>
    <li> <para-num num="[1663]"> </para-num> <div id="p-1917" num="1663" class="description-line">Compound CL-102 was obtained by the same approach as in <figure-callout id="3" label="step" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">step</figure-callout> 3 of Example C12.</div>
    </li> <heading id="h-0359">Reference Example C37</heading>
    <heading id="h-0360">2-(Dimethylamino)-N,N-bis(2-(((Z)-octadec-9-en-1-yl)oxy)ethyl)acetamide (Compound CL-103)</heading>
    <li> <para-num num="[1664]"> </para-num> <div id="p-1918" num="1664" class="description-line">Compound CL-103 was synthesized by the method described in WO 2011/136368.</div>
    </li> <li> <para-num num="[1665]"> </para-num> <div id="p-1919" num="1665" class="description-line">(Synthesis of Analog of Fatty Acid Ester of Glycerol Wherein the Analog is not Hydrolyzable by Lipase)</div>
    </li> <heading id="h-0361">[Production Example 1] Method for Producing D--Phosphatidylcholine, Distearoyl (D-DSPC) ((S)-2,3-bis(stearoyloxy)propyl(2-(trimethylammonio)ethyl)phosphoric acid)</heading>
    <li> <para-num num="[1666]"> </para-num> <div id="p-1920" num="1666" class="description-line">The synthesis scheme of D-DSPC will be shown below. Specific synthesis procedures will be shown in [Step 1] and [Step 2].</div>
    </li> <li> <div id="p-1921" num="0000" class="description-line">
      <chemistry id="CHEM-US-00286" num="00286">
        <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/91/e5/79/fdee6393971ff1/US20200368173A1-20201126-C00286.png"><img id="EMI-C00286" he="144.02mm" wi="144.36mm" file="US20200368173A1-20201126-C00286.TIF" alt="Figure US20200368173A1-20201126-C00286" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="577" height="576" alt="Figure US20200368173A1-20201126-C00286" class="patent-full-image" src="https://patentimages.storage.googleapis.com/91/e5/79/fdee6393971ff1/US20200368173A1-20201126-C00286.png"/></a></div>
        <attachments>
          <attachment idref="CHEM-US-00286" attachment-type="cdx" file="US20200368173A1-20201126-C00286.CDX"> </attachment>
          <attachment idref="CHEM-US-00286" attachment-type="mol" file="US20200368173A1-20201126-C00286.MOL"> </attachment>
        </attachments>
      </chemistry>
    </div>
    </li> <li> <para-num num="[1667]"> </para-num> <div id="p-1922" num="1667" class="description-line">[Step 1]</div>
    </li> <li> <para-num num="[1668]"> </para-num> <div id="p-1923" num="1668" class="description-line">To a solution of (S)-3-(benzyloxy)propane-1,2-diol (2.36 g, 13.0 mmol) in chloroform (14 mL), a solution of pyridine (2.09 mL, 25.9 mmol) and stearoyl chloride (7.85 g, 25.9 mmol) in chloroform (4 mL) was added, and the mixture was stirred at 55 C. for 7 hours. Hexane was added to the reaction solution, and the organic layer was washed twice with 0.5 mol/L hydrochloric acid, washed with saturated saline, dried over anhydrous magnesium sulfate, and filtered, and the solvent was distilled off under reduced pressure. The obtained residue was crystallized from ethanol, and the crystals were collected by filtration to obtain a crude product of (R)-3-(benzyloxy)propane-1,2-diyl stearate.</div>
    </li> <li> <para-num num="[1669]"> </para-num> <div id="p-1924" num="1669" class="description-line">To a solution of the obtained crude product in hexane (86 mL), palladium-carbon (10% palladium, product wetted with 50% water, 0.546 g, 0.257 nmol) was added, and the mixture was stirred at 40 C. for 6 hours under hydrogen. The reaction solution was cooled in air to room temperature. Then, insoluble matter was removed by filtration through celite, and the filtrate was concentrated under reduced pressure. The obtained residue was crystallized from hexane, and the crystals were collected by filtration to obtain (R)-3-hydroxypropane-1,2-diyl distearate (5.13 g, 8.21 mmol, 63%).</div>
    </li> <li> <para-num num="[1670]"> </para-num> <div id="p-1925" num="1670" class="description-line">ESI-MS m/z: 642 (M+NH<sub>4</sub>)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 6H), 1.21-1.36 (m, 56H), 1.57-1.67 (m, 4H), 2.01 (t, J=6.5 Hz, 1H), 2.30-2.37 (m, 4H), 3.71-3.75 (m, 2H), 4.24 (dd, J=11.9, 5.6 Hz, 1H), 4.32 (dd, J=11.9, 4.6 Hz, 1H), 5.05-5.11 (m, 1H).</div>
    </li> <li> <para-num num="[1671]"> </para-num> <div id="p-1926" num="1671" class="description-line">[Step 2]</div>
    </li> <li> <para-num num="[1672]"> </para-num> <div id="p-1927" num="1672" class="description-line">To a solution of phosphorus(V) oxychloride (0.767 g, 5.00 mmol) and triethylamine (3.48 mL, 25.0 mmol) in chloroform (15 mL), a solution of (R)-3-hydroxypropane-1,2-diyl distearate (0.313 g, 0.500 mmol) obtained in [Step 1] in chloroform (4 mL) was added under ice cooling, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure. To the obtained residue, ethyl ether was added, and insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure. The obtained residue was dissolved in chloroform (5 mL). To the solution, a solution of choline p-toluenesulfonate (0.200 g, 0.725 mmol) in pyridine (7 mL) was added under ice cooling, and the mixture was stirred overnight at room temperature. A 10% aqueous sodium bicarbonate solution was added to the reaction solution, and the mixture was stirred at room temperature for 20 minutes. Ethanol was added to the reaction solution, and the solvent was distilled off under reduced pressure. To the obtained residue, chloroform was added, and insoluble matter was removed by filtration. The filtrate was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform/methanol/water=60/30/1 to 0/100/0) and crystallized from chloroform/acetone=1/1, and the crystals were collected by filtration to obtain D-DSPC (0.0718 g, 0.0909 mmol, 18%).</div>
    </li> <li> <para-num num="[1673]"> </para-num> <div id="p-1928" num="1673" class="description-line">ESI-MS m/z: 791 (M+H)<sup>+</sup>; <sup>1</sup>H-NMR (CDCl<sub>3</sub>) : 0.88 (t, J=6.8 Hz, 6H), 1.17-1.36 (m, 56H), 1.52-1.63 (m, 4H), 2.24-2.32 (m, 4H), 3.36 (s, 9H), 3.76-3.83 (m, 2H), 3.87-4.00 (m, 2H), 4.12 (dd, J=12.0, 7.5 Hz, 1H), 4.28-4.35 (m, 2H), 4.39 (dd, J=11.9, 2.8 Hz, 1H), 5.16-5.24 (m, 1H).</div>
    </li> <heading id="h-0362">Example 1</heading>
    <li> <para-num num="[1674]"> </para-num> <div id="p-1929" num="1674" class="description-line"> <figure-callout id="1" label="Preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparation</figure-callout> 1 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-3 obtained in Reference Example A10, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, dipalmitoyl (D-DPPC) and cholesterol (Choi).</div>
    </li> <li> <para-num num="[1675]"> </para-num> <div id="p-1930" num="1675" class="description-line">The nucleic acid used was siRNA silencing luciferase (hereinafter, referred to as Luc) gene and consisting of the nucleotide sequences of a sense strand (5-CCGUCGUAUUCGUGAGCAAGA-3) and an antisense strand (5-UUGCUCACGAAUACGACGGUG-3), and was obtained from Gene Design, Inc. (hereinafter, referred to as Luc siRNA). PEG-DSPE and cholesterol were obtained from NOF Corp. D-DPPC was obtained from Sigma-Aldrich Corp.</div>
    </li> <li> <para-num num="[1676]"> </para-num> <div id="p-1931" num="1676" class="description-line">Compound II-3 was dissolved at 10 mg/mL in 100% ethanol to prepare a lipid stock solution. Compound CL-10, PEG-DSPE, D-DPPC and cholesterol were each dissolved at 20 mg/mL in 100% ethanol to prepare lipid stock solutions. Each lipid stock solution was stored at 20 C. Immediately before formulation, the lipid was dissolved by heating to 60 C., and the resulting solution was brought back to room temperature and then used.</div>
    </li> <li> <para-num num="[1677]"> </para-num> <div id="p-1932" num="1677" class="description-line">Luc siRNA was dissolved at 1 mg/mL in injectable water to prepare a Luc siRNA solution.</div>
    </li> <li> <para-num num="[1678]"> </para-num> <div id="p-1933" num="1678" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DPPC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was concentrated using Amicon Ultra (manufactured by Merck Millipore), further solvent-replaced with physiological saline, and filtered using a 0.2-m filter (manufactured by Toyo Roshi Kaisha, Ltd.) in a clean bench. The siRNA concentration of the obtained preparation was further measured, and the preparation was diluted with physiological saline such that the siRNA concentration was 0.1 mg/mL to obtain <figure-callout id="1" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 1.</div>
    </li> <heading id="h-0363">Example 2</heading>
    <li> <para-num num="[1679]"> </para-num> <div id="p-1934" num="1679" class="description-line"> <figure-callout id="2" label="Preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparation</figure-callout> 2 having a distinct content of D-DPPC was produced as described below.</div>
    </li> <li> <para-num num="[1680]"> </para-num> <div id="p-1935" num="1680" class="description-line">L--Phosphatidylcholine, dipalmitoyl (L-DPPC) was obtained from NOF Corp.</div>
    </li> <li> <para-num num="[1681]"> </para-num> <div id="p-1936" num="1681" class="description-line">L-DPPC was dissolved at 20 mg/mL in 100% ethanol to prepare a lipid stock solution.</div>
    </li> <li> <para-num num="[1682]"> </para-num> <div id="p-1937" num="1682" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DPPC, L-DPPC and Choi (1.88 mol, 0.235 mol, 0.364 mol, 0.121 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="2" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 2.</div>
    </li> <heading id="h-0364">Example 3</heading>
    <li> <para-num num="[1683]"> </para-num> <div id="p-1938" num="1683" class="description-line"> <figure-callout id="3" label="Preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparation</figure-callout> 3 having a distinct content of D-DPPC was produced as described below.</div>
    </li> <li> <para-num num="[1684]"> </para-num> <div id="p-1939" num="1684" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DPPC, L-DPPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="3" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 3.</div>
    </li> <heading id="h-0365">Example 4</heading>
    <li> <para-num num="[1685]"> </para-num> <div id="p-1940" num="1685" class="description-line">Preparation 4 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-12 obtained in Reference Example A19, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, dipalmitoyl (D-DPPC) and cholesterol.</div>
    </li> <li> <para-num num="[1686]"> </para-num> <div id="p-1941" num="1686" class="description-line">Compound II-12 was dissolved at 20 mg/mL in 100% ethanol to prepare a lipid stock solution.</div>
    </li> <li> <para-num num="[1687]"> </para-num> <div id="p-1942" num="1687" class="description-line">The lipid stock solution of compound II-12 (0.626 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution described above was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DPPC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 4.</div>
    </li> <heading id="h-0366">Example 5</heading>
    <li> <para-num num="[1688]"> </para-num> <div id="p-1943" num="1688" class="description-line">Preparation 5 having a distinct content of D-DPPC was produced as described below.</div>
    </li> <li> <para-num num="[1689]"> </para-num> <div id="p-1944" num="1689" class="description-line">The lipid stock solution of compound II-12 (0.626 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DPPC, L-DPPC and Choi (1.88 mol, 0.235 mol, 0.364 mol, 0.121 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 5.</div>
    </li> <heading id="h-0367">Example 6</heading>
    <li> <para-num num="[1690]"> </para-num> <div id="p-1945" num="1690" class="description-line">Preparation 6 having a distinct content of D-DPPC was produced as described below.</div>
    </li> <li> <para-num num="[1691]"> </para-num> <div id="p-1946" num="1691" class="description-line">The lipid stock solution of compound II-12 (0.626 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DPPC, L-DPPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 6.</div>
    </li> <heading id="h-0368">Example 7</heading>
    <li> <para-num num="[1692]"> </para-num> <div id="p-1947" num="1692" class="description-line"> <figure-callout id="7" label="Preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparation</figure-callout> 7 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-4 obtained in Reference Example A11, compound CL-2 obtained in Reference Example B2, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, dipalmitoyl (D-DPPC) and cholesterol.</div>
    </li> <li> <para-num num="[1693]"> </para-num> <div id="p-1948" num="1693" class="description-line">Compound II-4 was dissolved at 5 mg/mL in 100% ethanol to prepare a lipid stock solution. Compound CL-2 was dissolved at 20 mg/mL in 100% ethanol to prepare a lipid stock solution.</div>
    </li> <li> <para-num num="[1694]"> </para-num> <div id="p-1949" num="1694" class="description-line">The lipid stock solution of compound II-4 (0.156 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-2, PEG-DSPE, D-DPPC and Choi (1.88 mol, 0.235 mol, 0.536 mol and 1.11 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="7" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 7.</div>
    </li> <heading id="h-0369">Example 8</heading>
    <li> <para-num num="[1695]"> </para-num> <div id="p-1950" num="1695" class="description-line"> <figure-callout id="8" label="Preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparation</figure-callout> 8 having a distinct content of D-DPPC was produced as described below.</div>
    </li> <li> <para-num num="[1696]"> </para-num> <div id="p-1951" num="1696" class="description-line">The lipid stock solution of compound II-4 (0.156 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-2, PEG-DSPE, D-DPPC, L-DPPC and Choi (1.88 mol, 0.235 mol, 0.402 mol, 0.134 mol and 1.11 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="8" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 8.</div>
    </li> <heading id="h-0370">Example 9</heading>
    <li> <para-num num="[1697]"> </para-num> <div id="p-1952" num="1697" class="description-line"> <figure-callout id="9" label="Preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparation</figure-callout> 9 having a distinct content of D-DPPC was produced as described below.</div>
    </li> <li> <para-num num="[1698]"> </para-num> <div id="p-1953" num="1698" class="description-line">The lipid stock solution of compound II-4 (0.156 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-2, PEG-DSPE, D-DPPC, L-DPPC and Choi (1.88 mol, 0.235 mol, 0.268 mol, 0.268 mol and 1.11 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="9" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 9.</div>
    </li> <heading id="h-0371">Comparative Example 1</heading>
    <li> <para-num num="[1699]"> </para-num> <div id="p-1954" num="1699" class="description-line">Preparation 10 was obtained in the same way as in Example 1 except that D-DPPC of <figure-callout id="1" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 1 was changed to L-DPPC.</div>
    </li> <heading id="h-0372">Comparative Example 2</heading>
    <li> <para-num num="[1700]"> </para-num> <div id="p-1955" num="1700" class="description-line">Preparation 11 was obtained in the same way as in Example 4 except that D-DPPC of preparation 4 was changed to L-DPPC.</div>
    </li> <heading id="h-0373">Comparative Example 3</heading>
    <li> <para-num num="[1701]"> </para-num> <div id="p-1956" num="1701" class="description-line">Preparation 12 was obtained in the same way as in Example 7 except that D-DPPC of <figure-callout id="7" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 7 was changed to L-DPPC.</div>
    </li> <heading id="h-0374">Test Example 1</heading>
    <li> <para-num num="[1702]"> </para-num> <div id="p-1957" num="1702" class="description-line">Average Particle Size Measurement of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1703]"> </para-num> <div id="p-1958" num="1703" class="description-line">The average particle size of the nucleic acid-containing lipid nanoparticles in each preparation was measured with a particle size measurement apparatus (Zetasizer Nano ZS, manufactured by Malvern Panalytical Ltd.) (Table 32). PDI in the table represents polydispersity index.</div>
    </li> <li> <div id="p-1959" num="0000" class="description-line">
      <tables id="TABLE-US-00032" num="00032">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 32</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">Size (nm)</td>
                <td class="description-td"> <figure-callout id="1" label="PDI" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">PDI</figure-callout> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">39.18</td>
                <td class="description-td">0.135</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">39.36</td>
                <td class="description-td">0.108</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">38.13</td>
                <td class="description-td">0.126</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">46.00</td>
                <td class="description-td">0.068</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">5</td>
                <td class="description-td">44.82</td>
                <td class="description-td">0.087</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">45.88</td>
                <td class="description-td">0.077</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">7</td>
                <td class="description-td">44.34</td>
                <td class="description-td">0.125</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">53.57</td>
                <td class="description-td">0.127</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">9</td>
                <td class="description-td">51.04</td>
                <td class="description-td">0.104</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">10</td>
                <td class="description-td">39.10</td>
                <td class="description-td">0.116</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">11</td>
                <td class="description-td">43.35</td>
                <td class="description-td">0.101</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">12</td>
                <td class="description-td">49.44</td>
                <td class="description-td">0.132</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1704]"> </para-num> <div id="p-1960" num="1704" class="description-line">As a result, <figure-callout id="1" label="preparations" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparations</figure-callout> 1 to 12 exhibited an average particle size from 30 to 60 ran and had PDI from 0.06 to 0.14.</div>
    </li> <heading id="h-0375">Test Example 2</heading>
    <li> <para-num num="[1705]"> </para-num> <div id="p-1961" num="1705" class="description-line">In Vitro Activity Evaluation Test of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1706]"> </para-num> <div id="p-1962" num="1706" class="description-line"> <figure-callout id="1" label="Preparations" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparations</figure-callout> 1 to 9 described in Examples 1 to 9 and preparations 10 to 12 described in Comparative Examples 1 to 3 were each introduced to human pancreatic cancer-derived cell line Mia PaCa-2/Luc cells by the following method.</div>
    </li> <li> <para-num num="[1707]"> </para-num> <div id="p-1963" num="1707" class="description-line">Each preparation was treated with PLA2 and evaluated for its gene suppression ratio according to the method described in [Non Patent Literature 3]. Mia PaCa-2/Luc cells suspended in Dulbecco&#39;s modified Eagle&#39;s minimal essential medium (DMEM) containing 10% fetal bovine serum (FBS, Gibco/Thermo Fisher Scientific Inc.) were seeded in a 96-well culture plate at 7500 cells/80 L/well, and cultured at 37 C. for 24 hours under 5% CO<sub>2 </sub>conditions. Each preparation diluted with Opti-MEM (Gibco/Thermo Fisher Scientific Inc.) so as to have a final nucleic acid concentration from 3 to 100 nM was dispensed to the 96-well culture plate at 20 L/well, and the cells were cultured at 37 C. under 5% CO<sub>2 </sub>conditions to introduce each preparation into the Mia PaCa-2/Luc cells. Untreated cells were seeded as a negative control group.</div>
    </li> <li> <para-num num="[1708]"> </para-num> <div id="p-1964" num="1708" class="description-line">The cells containing each preparation thus introduced were cultured in a 5% CO<sub>2 </sub>incubator of 37 C. for 24 hours and treated using a luciferase quantification system (Steady-Glo Luciferase Assay System, Promega Corp., E2520) in accordance with the method described in the instructions attached to the product, followed by the measurement of luminescence intensity with a plate reader. The amount of luminescence of the group treated with each preparation was calculated as a relative ratio to the corrected amount of luminescence of the negative control group defined as 1 to obtain an IC50 value.</div>
    </li> <li> <para-num num="[1709]"> </para-num> <div id="p-1965" num="1709" class="description-line">As is evident from Table 33, the Luc suppression ratios of <figure-callout id="1" label="preparations" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparations</figure-callout> 1 to 9 containing D-DPPC, introduced in the human pancreatic cancer-derived cell line MIA PaCa-2/Luc cells, were consequently higher than those of preparations 10 to 12 containing L-DPPC instead of D-DPPC. When <figure-callout id="1" label="preparations" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparations</figure-callout> 1 to 3 were compared, a higher content of D-DPPC resulted in a higher suppression ratio. Similar results were also obtained about preparations 4 to 6 and 7 to 9.</div>
    </li> <li> <para-num num="[1710]"> </para-num> <div id="p-1966" num="1710" class="description-line">These results demonstrated that the lipid nanoparticle of the present invention containing an analog of a fatty acid ester of glycerol that is not hydrolyzable by a lipase can introduce a nucleic acid into cells, etc. even in the presence of PLA2.</div>
    </li> <li> <div id="p-1967" num="0000" class="description-line">
      <tables id="TABLE-US-00033" num="00033">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 33</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">KD % (3 nM)</td>
                <td class="description-td">IC50 (nM)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">1</td>
                <td class="description-td">59.5</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">2</td>
                <td class="description-td">51.1</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">3</td>
                <td class="description-td">46.0</td>
                <td class="description-td">3.69</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">4</td>
                <td class="description-td">65.2</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">5</td>
                <td class="description-td">62.9</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">6</td>
                <td class="description-td">53.0</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">7</td>
                <td class="description-td">41.5</td>
                <td class="description-td">6.06</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">8</td>
                <td class="description-td">37.8</td>
                <td class="description-td">7.58</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">9</td>
                <td class="description-td">35.2</td>
                <td class="description-td">14.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">10</td>
                <td class="description-td">34.5</td>
                <td class="description-td">6.52</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">11</td>
                <td class="description-td">28.1</td>
                <td class="description-td">8.66</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">12</td>
                <td class="description-td">18.5</td>
                <td class="description-td">&gt;100</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0376">Example 10</heading>
    <li> <para-num num="[1711]"> </para-num> <div id="p-1968" num="1711" class="description-line"> <figure-callout id="13" label="Preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparation</figure-callout> 13 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-3 obtained in Reference Example A10, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), DL--phosphatidylcholine, distearoyl (DL-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1712]"> </para-num> <div id="p-1969" num="1712" class="description-line">DL-DSPC was obtained from Sigma-Aldrich Corp.</div>
    </li> <li> <para-num num="[1713]"> </para-num> <div id="p-1970" num="1713" class="description-line">DL-DSPC was dissolved at 20 mg/mL in 100% ethanol to prepare a lipid stock solution. Each lipid stock solution was stored at 20 C. Immediately before formulation, the lipid was dissolved by heating to 60 C., and the resulting solution was brought back to room temperature and then used.</div>
    </li> <li> <para-num num="[1714]"> </para-num> <div id="p-1971" num="1714" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, DL-DSPC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="13" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 13.</div>
    </li> <heading id="h-0377">Example 11</heading>
    <li> <para-num num="[1715]"> </para-num> <div id="p-1972" num="1715" class="description-line"> <figure-callout id="14" label="Preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparation</figure-callout> 14 having a distinct content of DL-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1716]"> </para-num> <div id="p-1973" num="1716" class="description-line">L--Phosphatidylcholine, distearoyl (L-DSPC) was obtained from NOF Corp.</div>
    </li> <li> <para-num num="[1717]"> </para-num> <div id="p-1974" num="1717" class="description-line">L-DSPC was dissolved at 20 mg/mL in 100% ethanol to prepare a lipid stock solution.</div>
    </li> <li> <para-num num="[1718]"> </para-num> <div id="p-1975" num="1718" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, DL-DSPC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="14" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 14.</div>
    </li> <heading id="h-0378">Example 12</heading>
    <li> <para-num num="[1719]"> </para-num> <div id="p-1976" num="1719" class="description-line">Preparation 15 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-3 obtained in Reference Example A10, compound CL-8 obtained in Reference Example B8, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), DL--phosphatidylcholine, distearoyl (DL-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1720]"> </para-num> <div id="p-1977" num="1720" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-8, PEG-DSPE, DL-DSPC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 15.</div>
    </li> <heading id="h-0379">Example 13</heading>
    <li> <para-num num="[1721]"> </para-num> <div id="p-1978" num="1721" class="description-line">Preparation 16 having a distinct content of DL-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1722]"> </para-num> <div id="p-1979" num="1722" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-8, PEG-DSPE, DL-DSPC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 16.</div>
    </li> <heading id="h-0380">Example 14</heading>
    <li> <para-num num="[1723]"> </para-num> <div id="p-1980" num="1723" class="description-line">Preparation 17 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-12 obtained in Reference Example A19, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), DL--phosphatidylcholine, distearoyl (DL-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1724]"> </para-num> <div id="p-1981" num="1724" class="description-line">The lipid stock solution of compound II-12 (0.626 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, DL-DSPC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 17.</div>
    </li> <heading id="h-0381">Example 15</heading>
    <li> <para-num num="[1725]"> </para-num> <div id="p-1982" num="1725" class="description-line">Preparation 18 having a distinct content of DL-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1726]"> </para-num> <div id="p-1983" num="1726" class="description-line">The lipid stock solution of compound II-12 (0.626 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, DL-DSPC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 18.</div>
    </li> <heading id="h-0382">Example 16</heading>
    <li> <para-num num="[1727]"> </para-num> <div id="p-1984" num="1727" class="description-line"> <figure-callout id="19" label="Preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparation</figure-callout> 19 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-4 obtained in Reference Example A11, compound CL-2 obtained in Reference Example B2, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), DL--phosphatidylcholine, distearoyl (DL-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1728]"> </para-num> <div id="p-1985" num="1728" class="description-line">The lipid stock solution of compound II-4 (0.156 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-2, PEG-DSPE, DL-DSPC and Choi (1.88 mol, 0.235 mol, 0.536 mol and 1.11 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="19" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 19.</div>
    </li> <heading id="h-0383">Example 17</heading>
    <li> <para-num num="[1729]"> </para-num> <div id="p-1986" num="1729" class="description-line"> <figure-callout id="20" label="Preparation" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Preparation</figure-callout> 20 having a distinct content of DL-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1730]"> </para-num> <div id="p-1987" num="1730" class="description-line">The lipid stock solution of compound II-4 (0.156 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-2, PEG-DSPE, DL-DSPC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.268 mol, 0.268 mol and 1.11 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="20" label="preparation" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">preparation</figure-callout> 20.</div>
    </li> <heading id="h-0384">Comparative Example 4</heading>
    <li> <para-num num="[1731]"> </para-num> <div id="p-1988" num="1731" class="description-line"> <figure-callout id="21" label="Preparation" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Preparation</figure-callout> 21 was obtained in the same way as in Example 10 except that DL-DSPC of <figure-callout id="13" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 13 was changed to L-DSPC.</div>
    </li> <heading id="h-0385">Comparative Example 5</heading>
    <li> <para-num num="[1732]"> </para-num> <div id="p-1989" num="1732" class="description-line">Preparation 22 was obtained in the same way as in Example 12 except that DL-DSPC of preparation 15 was changed to L-DSPC.</div>
    </li> <heading id="h-0386">Comparative Example 6</heading>
    <li> <para-num num="[1733]"> </para-num> <div id="p-1990" num="1733" class="description-line">Preparation 23 was obtained in the same way as in Example 14 except that DL-DSPC of preparation 17 was changed to L-DSPC.</div>
    </li> <heading id="h-0387">Comparative Example 7</heading>
    <li> <para-num num="[1734]"> </para-num> <div id="p-1991" num="1734" class="description-line">Preparation 24 was obtained in the same way as in Example 16 except that DL-DSPC of <figure-callout id="19" label="preparation" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparation</figure-callout> 19 was changed to L-DSPC.</div>
    </li> <heading id="h-0388">Test Example 3</heading>
    <li> <para-num num="[1735]"> </para-num> <div id="p-1992" num="1735" class="description-line">Average Particle Size Measurement of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1736]"> </para-num> <div id="p-1993" num="1736" class="description-line">The average particle size of the nucleic acid-containing lipid nanoparticles in each preparation was measured with a particle size measurement apparatus (Zetasizer Nano ZS, manufactured by Malvern Panalytical Ltd.) (Table 34). PDI in the table represents polydispersity index.</div>
    </li> <li> <div id="p-1994" num="0000" class="description-line">
      <tables id="TABLE-US-00034" num="00034">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 34</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">Size (nm)</td>
                <td class="description-td"> <figure-callout id="13" label="PDI" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">PDI</figure-callout> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">13</td>
                <td class="description-td">38.87</td>
                <td class="description-td">0.128</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">14</td>
                <td class="description-td">38.37</td>
                <td class="description-td">0.094</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">15</td>
                <td class="description-td">35.65</td>
                <td class="description-td">0.133</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">16</td>
                <td class="description-td">37.10</td>
                <td class="description-td">0.132</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">17</td>
                <td class="description-td">39.00</td>
                <td class="description-td">0.095</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">37.85</td>
                <td class="description-td">0.088</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">19</td>
                <td class="description-td">50.92</td>
                <td class="description-td">0.151</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">20</td>
                <td class="description-td">56.10</td>
                <td class="description-td">0.161</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">21</td>
                <td class="description-td">39.87</td>
                <td class="description-td">0.090</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">22</td>
                <td class="description-td">32.06</td>
                <td class="description-td">0.127</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">23</td>
                <td class="description-td">37.44</td>
                <td class="description-td">0.153</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">50.06</td>
                <td class="description-td">0.175</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1737]"> </para-num> <div id="p-1995" num="1737" class="description-line">As a result, <figure-callout id="13" label="preparations" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparations</figure-callout> 13 to 24 exhibited an average particle size from 30 to 60 nm and had PDI from 0.08 to 0.18.</div>
    </li> <heading id="h-0389">Test Example 4</heading>
    <li> <para-num num="[1738]"> </para-num> <div id="p-1996" num="1738" class="description-line">In Vitro Activity Evaluation Test of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1739]"> </para-num> <div id="p-1997" num="1739" class="description-line"> <figure-callout id="13" label="Preparations" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">Preparations</figure-callout> 13 to 20 described in Examples 10 to 17 and <figure-callout id="21" label="preparations" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">preparations</figure-callout> 21 to 24 described in Comparative Examples 4 to 7 were each introduced to human pancreatic cancer-derived cell line Mia PaCa-2/Luc cells by the following method.</div>
    </li> <li> <para-num num="[1740]"> </para-num> <div id="p-1998" num="1740" class="description-line">Each preparation was treated with PLA2 and evaluated for its gene suppression ratio according to the method described in [Non Patent Literature 3]. Mia PaCa-2/Luc cells suspended in Dulbecco&#39;s modified Eagle&#39;s minimal essential medium (DMEM) containing 10% fetal bovine serum (FBS, Gibco/Thermo Fisher Scientific Inc.) were seeded in a 96-well culture plate at 7500 cells/80 L/well, and cultured at 37 C. for 24 hours under 5% CO<sub>2 </sub>conditions. Each preparation diluted with Opti-MEM (Gibco/Thermo Fisher Scientific Inc.) so as to have a final nucleic acid concentration from 3 to 100 nM was dispensed to the 96-well culture plate at 20 L/well, and the cells were cultured at 37 C. under 5% CO<sub>2 </sub>conditions to introduce each preparation into the Mia PaCa-2/Luc cells. Untreated cells were seeded as a negative control group.</div>
    </li> <li> <para-num num="[1741]"> </para-num> <div id="p-1999" num="1741" class="description-line">The cells containing each preparation thus introduced were cultured in a 5% CO<sub>2 </sub>incubator of 37 C. for 24 hours and treated using a luciferase quantification system (Steady-Glo Luciferase Assay System, Promega Corp., E2520) in accordance with the method described in the instructions attached to the product, followed by the measurement of luminescence intensity with a plate reader. The amount of luminescence of the group treated with each preparation was calculated as a relative ratio to the corrected amount of luminescence of the negative control group defined as 1 to obtain an IC50 value.</div>
    </li> <li> <para-num num="[1742]"> </para-num> <div id="p-2000" num="1742" class="description-line">As is evident from Table 35, the Luc suppression ratios of <figure-callout id="13" label="preparations" filenames="US20200368173A1-20201126-D00001.png" state="{{state}}">preparations</figure-callout> 13 to 20 containing DL-DSPC, introduced in the human pancreatic cancer-derived cell line MIA PaCa-2/Luc cells, were consequently higher than those of <figure-callout id="21" label="preparations" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">preparations</figure-callout> 21 to 24 containing L-DSPC instead of DL-DSPC.</div>
    </li> <li> <para-num num="[1743]"> </para-num> <div id="p-2001" num="1743" class="description-line">These results demonstrated that the lipid nanoparticle of the present invention containing an analog of a fatty acid ester of glycerol that is not hydrolyzable by a lipase can introduce a nucleic acid into cells, etc. even in the presence of PLA2.</div>
    </li> <li> <div id="p-2002" num="0000" class="description-line">
      <tables id="TABLE-US-00035" num="00035">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 35</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">KD % (3 nM)</td>
                <td class="description-td">IC50 (nM)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">13</td>
                <td class="description-td">43.0</td>
                <td class="description-td">4.26</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">14</td>
                <td class="description-td">38.7</td>
                <td class="description-td">5.22</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">15</td>
                <td class="description-td">70.0</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">16</td>
                <td class="description-td">56.3</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">17</td>
                <td class="description-td">40.5</td>
                <td class="description-td">4.91</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">18</td>
                <td class="description-td">26.3</td>
                <td class="description-td">10.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">19</td>
                <td class="description-td">19.3</td>
                <td class="description-td">10.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">20</td>
                <td class="description-td">15.3</td>
                <td class="description-td">16.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">21</td>
                <td class="description-td">21.6</td>
                <td class="description-td">11.4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">22</td>
                <td class="description-td">49.3</td>
                <td class="description-td">3.15</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">23</td>
                <td class="description-td">20.0</td>
                <td class="description-td">12.0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">11.1</td>
                <td class="description-td">29.2</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0390">Example 18</heading>
    <li> <para-num num="[1744]"> </para-num> <div id="p-2003" num="1744" class="description-line">A preparation having a distinct content of D-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1745]"> </para-num> <div id="p-2004" num="1745" class="description-line">Preparation 25 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-3 obtained in Reference Example A10, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, distearoyl (D-DSPC) and cholesterol (Choi).</div>
    </li> <li> <para-num num="[1746]"> </para-num> <div id="p-2005" num="1746" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DSPC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 25.</div>
    </li> <heading id="h-0391">Example 19</heading>
    <li> <para-num num="[1747]"> </para-num> <div id="p-2006" num="1747" class="description-line">A preparation having a distinct content of D-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1748]"> </para-num> <div id="p-2007" num="1748" class="description-line">Preparation 26 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-3 obtained in Reference Example A10, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, distearoyl (D-DSPC), L--phosphatidylcholine, distearoyl (L-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1749]"> </para-num> <div id="p-2008" num="1749" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DSPC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 26.</div>
    </li> <heading id="h-0392">Example 20</heading>
    <li> <para-num num="[1750]"> </para-num> <div id="p-2009" num="1750" class="description-line">A preparation having a distinct content of D-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1751]"> </para-num> <div id="p-2010" num="1751" class="description-line">Preparation 27 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-25 obtained in Reference Example A34, compound CL-2 obtained in Reference Example B2, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, distearoyl (D-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1752]"> </para-num> <div id="p-2011" num="1752" class="description-line">The lipid stock solution of compound II-25 (0.626 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-2, PEG-DSPE, D-DSPC and Choi (1.88 mol, 0.235 mol, 0.384 mol and 0.797 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 27.</div>
    </li> <heading id="h-0393">Example 21</heading>
    <li> <para-num num="[1753]"> </para-num> <div id="p-2012" num="1753" class="description-line">A preparation having a distinct content of D-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1754]"> </para-num> <div id="p-2013" num="1754" class="description-line">Preparation 28 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-25 obtained in Reference Example A34, compound CL-2 obtained in Reference Example B2, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, distearoyl (D-DSPC), L--phosphatidylcholine, distearoyl (L-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1755]"> </para-num> <div id="p-2014" num="1755" class="description-line">The lipid stock solution of compound II-25 (0.626 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-2, PEG-DSPE, D-DSPC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.192 mol, 0.192 mol and 0.797 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 28.</div>
    </li> <heading id="h-0394">Example 22</heading>
    <li> <para-num num="[1756]"> </para-num> <div id="p-2015" num="1756" class="description-line">A preparation having a distinct content of D-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1757]"> </para-num> <div id="p-2016" num="1757" class="description-line">Preparation 29 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-12 obtained in Reference Example A19, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, distearoyl (D-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1758]"> </para-num> <div id="p-2017" num="1758" class="description-line">The lipid stock solution of compound II-12 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DSPC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 29.</div>
    </li> <heading id="h-0395">Example 23</heading>
    <li> <para-num num="[1759]"> </para-num> <div id="p-2018" num="1759" class="description-line">A preparation having a distinct content of D-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1760]"> </para-num> <div id="p-2019" num="1760" class="description-line">Preparation 30 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-12 obtained in Reference Example A19, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, distearoyl (D-DSPC), L--phosphatidylcholine, distearoyl (L-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1761]"> </para-num> <div id="p-2020" num="1761" class="description-line">The lipid stock solution of compound II-12 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DSPC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 30.</div>
    </li> <heading id="h-0396">Example 24</heading>
    <li> <para-num num="[1762]"> </para-num> <div id="p-2021" num="1762" class="description-line">A preparation having a distinct content of D-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1763]"> </para-num> <div id="p-2022" num="1763" class="description-line">Preparation 31 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-18 obtained in Reference Example A25, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, distearoyl (D-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1764]"> </para-num> <div id="p-2023" num="1764" class="description-line">The lipid stock solution of compound II-18 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DSPC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 31.</div>
    </li> <heading id="h-0397">Example 25</heading>
    <li> <para-num num="[1765]"> </para-num> <div id="p-2024" num="1765" class="description-line">A preparation having a distinct content of D-DSPC was produced as described below.</div>
    </li> <li> <para-num num="[1766]"> </para-num> <div id="p-2025" num="1766" class="description-line">Preparation 32 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-18 obtained in Reference Example A25, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), D--phosphatidylcholine, distearoyl (D-DSPC), L--phosphatidylcholine, distearoyl (L-DSPC) and cholesterol.</div>
    </li> <li> <para-num num="[1767]"> </para-num> <div id="p-2026" num="1767" class="description-line">The lipid stock solution of compound II-18 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, D-DSPC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 32.</div>
    </li> <heading id="h-0398">Comparative Example 8</heading>
    <li> <para-num num="[1768]"> </para-num> <div id="p-2027" num="1768" class="description-line">Preparation 33 was obtained in the same way as in Example 18 except that D-DSPC of preparation 25 was changed to L-DSPC.</div>
    </li> <heading id="h-0399">Comparative Example 9</heading>
    <li> <para-num num="[1769]"> </para-num> <div id="p-2028" num="1769" class="description-line">Preparation 34 was obtained in the same way as in Example 20 except that D-DSPC of preparation 27 was changed to L-DSPC.</div>
    </li> <heading id="h-0400">Comparative Example 10</heading>
    <li> <para-num num="[1770]"> </para-num> <div id="p-2029" num="1770" class="description-line">Preparation 35 was obtained in the same way as in Example 22 except that D-DSPC of preparation 29 was changed to L-DSPC.</div>
    </li> <heading id="h-0401">Comparative Example 11</heading>
    <li> <para-num num="[1771]"> </para-num> <div id="p-2030" num="1771" class="description-line">Preparation 36 was obtained in the same way as in Example 24 except that D-DSPC of preparation 31 was changed to L-DSPC.</div>
    </li> <heading id="h-0402">Test Example 5</heading>
    <li> <para-num num="[1772]"> </para-num> <div id="p-2031" num="1772" class="description-line">Average Particle Size Measurement of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1773]"> </para-num> <div id="p-2032" num="1773" class="description-line">The average particle size of the nucleic acid-containing lipid nanoparticles in each preparation was measured with a particle size measurement apparatus (Zetasizer Nano ZS, manufactured by Malvern Panalytical Ltd.) (Table 36). PDI in the table represents polydispersity index.</div>
    </li> <li> <div id="p-2033" num="0000" class="description-line">
      <tables id="TABLE-US-00036" num="00036">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 36</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">Size (nm)</td>
                <td class="description-td">PDI</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">25</td>
                <td class="description-td">36.02</td>
                <td class="description-td">0.130</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">26</td>
                <td class="description-td">36.30</td>
                <td class="description-td">0.181</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">27</td>
                <td class="description-td">48.73</td>
                <td class="description-td">0.172</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">28</td>
                <td class="description-td">46.49</td>
                <td class="description-td">0.221</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">29</td>
                <td class="description-td">36.42</td>
                <td class="description-td">0.172</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">30</td>
                <td class="description-td">40.44</td>
                <td class="description-td">0.181</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">31</td>
                <td class="description-td">37.57</td>
                <td class="description-td">0.120</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">32</td>
                <td class="description-td">34.73</td>
                <td class="description-td">0.164</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">33</td>
                <td class="description-td">32.88</td>
                <td class="description-td">0.139</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">34</td>
                <td class="description-td">47.35</td>
                <td class="description-td">0.187</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">35</td>
                <td class="description-td">37.92</td>
                <td class="description-td">0.177</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">36</td>
                <td class="description-td">37.28</td>
                <td class="description-td">0.137</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0403">Test Example 6</heading>
    <li> <para-num num="[1774]"> </para-num> <div id="p-2034" num="1774" class="description-line">In Vitro Activity Evaluation Test of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1775]"> </para-num> <div id="p-2035" num="1775" class="description-line">Preparations 25 to 32 described in Examples 18 to 25 and preparations 33 to 36 described in Comparative Examples 8 to 11 were each introduced to human pancreatic cancer-derived cell line Mia PaCa-2/Luc cells by the following method.</div>
    </li> <li> <para-num num="[1776]"> </para-num> <div id="p-2036" num="1776" class="description-line">Each preparation was treated with PLA2 and evaluated for its gene suppression ratio according to the method described in [Non Patent Literature 3]. Mia PaCa-2/Luc cells suspended in Dulbecco&#39;s modified Eagle&#39;s minimal essential medium (DMEM) containing 10% fetal bovine serum (FBS, Gibco/Thermo Fisher Scientific Inc.) were seeded in a 96-well culture plate at 7500 cells/80 L/well, and cultured at 37 C. for 24 hours under 5% CO<sub>2 </sub>conditions. Each preparation diluted with Opti-MEM (Gibco/Thermo Fisher Scientific Inc.) so as to have a final nucleic acid concentration from 3 to 100 nM was dispensed to the 96-well culture plate at 20 L/well, and the cells were cultured at 37 C. under 5% CO<sub>2 </sub>conditions to introduce each preparation into the Mia PaCa-2/Luc cells. Untreated cells were seeded as a negative control group.</div>
    </li> <li> <para-num num="[1777]"> </para-num> <div id="p-2037" num="1777" class="description-line">The cells containing each preparation thus introduced were cultured in a 5% CO<sub>2 </sub>incubator of 37 C. for 24 hours and treated using a luciferase quantification system (Steady-Glo Luciferase Assay System, Promega Corp., E2520) in accordance with the method described in the instructions attached to the product, followed by the measurement of luminescence intensity with a plate reader. The amount of luminescence of the group treated with each preparation was calculated as a relative ratio to the corrected amount of luminescence of the negative control group defined as 1 to obtain an IC50 value.</div>
    </li> <li> <para-num num="[1778]"> </para-num> <div id="p-2038" num="1778" class="description-line">As is evident from Table 37, the Luc suppression ratios of preparations 25 to 32 containing D-DSPC, introduced in the human pancreatic cancer-derived cell line MIA PaCa-2/Luc cells, were consequently higher than those of preparations 33 to 36 containing L-DSPC instead of D-DSPC.</div>
    </li> <li> <para-num num="[1779]"> </para-num> <div id="p-2039" num="1779" class="description-line">These results demonstrated that the lipid nanoparticle of the present invention containing an analog of a fatty acid ester of glycerol that is not hydrolyzable by a lipase can introduce a nucleic acid into cells, etc. even in the presence of PLA2.</div>
    </li> <li> <div id="p-2040" num="0000" class="description-line">
      <tables id="TABLE-US-00037" num="00037">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 37</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">KD % (3 nM)</td>
                <td class="description-td">IC50 (nM)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">25</td>
                <td class="description-td">55.9</td>
                <td class="description-td">2.36</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">26</td>
                <td class="description-td">43.4</td>
                <td class="description-td">4.01</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">27</td>
                <td class="description-td">23.8</td>
                <td class="description-td">7.25</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">28</td>
                <td class="description-td">25.0</td>
                <td class="description-td">7.69</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">29</td>
                <td class="description-td">60.4</td>
                <td class="description-td">2.05</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">30</td>
                <td class="description-td">42.9</td>
                <td class="description-td">4.24</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">31</td>
                <td class="description-td">55.0</td>
                <td class="description-td">2.29</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">32</td>
                <td class="description-td">41.6</td>
                <td class="description-td">4.98</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">33</td>
                <td class="description-td">25.4</td>
                <td class="description-td">8.26</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">34</td>
                <td class="description-td">19.6</td>
                <td class="description-td">9.83</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">35</td>
                <td class="description-td">28.5</td>
                <td class="description-td">7.19</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">36</td>
                <td class="description-td">34.0</td>
                <td class="description-td">6.35</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0404">Example 26</heading>
    <li> <para-num num="[1780]"> </para-num> <div id="p-2041" num="1780" class="description-line"> <figure-callout id="37" label="Preparation" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Preparation</figure-callout> 37 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-3 obtained in Reference Example A10, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), 1,2-dioctadecyl-sn-glycero-3-phosphocholine (Diether-PC) and cholesterol.</div>
    </li> <li> <para-num num="[1781]"> </para-num> <div id="p-2042" num="1781" class="description-line">Diether-PC was obtained from Avanti Polar Lipids, Inc.</div>
    </li> <li> <para-num num="[1782]"> </para-num> <div id="p-2043" num="1782" class="description-line">Diether-PC was dissolved at 20 mg/mL in 100% ethanol to prepare a lipid stock solution. Each lipid stock solution was stored at 20 C. Immediately before formulation, the lipid was dissolved by heating to 60 C., and the resulting solution was brought back to room temperature and then used.</div>
    </li> <li> <para-num num="[1783]"> </para-num> <div id="p-2044" num="1783" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, Diether-PC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="37" label="preparation" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">preparation</figure-callout> 37.</div>
    </li> <heading id="h-0405">Example 27</heading>
    <li> <para-num num="[1784]"> </para-num> <div id="p-2045" num="1784" class="description-line"> <figure-callout id="38" label="Preparation" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Preparation</figure-callout> 38 having a distinct content of Diether-PC was produced as described below.</div>
    </li> <li> <para-num num="[1785]"> </para-num> <div id="p-2046" num="1785" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, Diether-PC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="38" label="preparation" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">preparation</figure-callout> 38.</div>
    </li> <heading id="h-0406">Example 28</heading>
    <li> <para-num num="[1786]"> </para-num> <div id="p-2047" num="1786" class="description-line">Preparation 39 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-3 obtained in Reference Example A10, compound CL-8 obtained in Reference Example B8, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), 1,2-dioctadecyl-sn-glycero-3-phosphocholine (Diether-PC) and cholesterol.</div>
    </li> <li> <para-num num="[1787]"> </para-num> <div id="p-2048" num="1787" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-8, PEG-DSPE, Diether-PC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 39.</div>
    </li> <heading id="h-0407">Example 29</heading>
    <li> <para-num num="[1788]"> </para-num> <div id="p-2049" num="1788" class="description-line"> <figure-callout id="40" label="Preparation" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Preparation</figure-callout> 40 having a distinct content of Diether-PC was produced as described below.</div>
    </li> <li> <para-num num="[1789]"> </para-num> <div id="p-2050" num="1789" class="description-line">The lipid stock solution of compound II-3 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-8, PEG-DSPE, Diether-PC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="40" label="preparation" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">preparation</figure-callout> 40.</div>
    </li> <heading id="h-0408">Example 30</heading>
    <li> <para-num num="[1790]"> </para-num> <div id="p-2051" num="1790" class="description-line">Preparation 41 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-12 obtained in Reference Example A19, compound CL-10 obtained in Reference Example B10, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), 1,2-dioctadecyl-sn-glycero-3-phosphocholine (Diether-PC) and cholesterol.</div>
    </li> <li> <para-num num="[1791]"> </para-num> <div id="p-2052" num="1791" class="description-line">The lipid stock solution of compound II-12 (0.626 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, Diether-PC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 41.</div>
    </li> <heading id="h-0409">Example 31</heading>
    <li> <para-num num="[1792]"> </para-num> <div id="p-2053" num="1792" class="description-line">Preparation 42 having a distinct content of Diether-PC was produced as described below.</div>
    </li> <li> <para-num num="[1793]"> </para-num> <div id="p-2054" num="1793" class="description-line">The lipid stock solution of compound II-12 (0.626 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-10, PEG-DSPE, Diether-PC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.243 mol, 0.243 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain preparation 42.</div>
    </li> <heading id="h-0410">Example 32</heading>
    <li> <para-num num="[1794]"> </para-num> <div id="p-2055" num="1794" class="description-line"> <figure-callout id="43" label="Preparation" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Preparation</figure-callout> 43 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-4 obtained in Reference Example A11, compound CL-2 obtained in Reference Example B2, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), 1,2-dioctadecyl-sn-glycero-3-phosphocholine (Diether-PC) and cholesterol.</div>
    </li> <li> <para-num num="[1795]"> </para-num> <div id="p-2056" num="1795" class="description-line">The lipid stock solution of compound II-4 (0.156 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-2, PEG-DSPE, Diether-PC and Choi (1.88 mol, 0.235 mol, 0.536 mol and 1.11 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="43" label="preparation" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">preparation</figure-callout> 43.</div>
    </li> <heading id="h-0411">Example 33</heading>
    <li> <para-num num="[1796]"> </para-num> <div id="p-2057" num="1796" class="description-line"> <figure-callout id="44" label="Preparation" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Preparation</figure-callout> 44 having a distinct content of Diether-PC was produced as described below.</div>
    </li> <li> <para-num num="[1797]"> </para-num> <div id="p-2058" num="1797" class="description-line">The lipid stock solution of compound II-4 (0.156 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-2, PEG-DSPE, Diether-PC, L-DSPC and Choi (1.88 mol, 0.235 mol, 0.268 mol, 0.268 mol and 1.11 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was treated in the same way as in Example 1 to obtain <figure-callout id="44" label="preparation" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">preparation</figure-callout> 44.</div>
    </li> <heading id="h-0412">Test Example 7</heading>
    <li> <para-num num="[1798]"> </para-num> <div id="p-2059" num="1798" class="description-line">Average Particle Size Measurement of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1799]"> </para-num> <div id="p-2060" num="1799" class="description-line">The average particle size of the nucleic acid-containing lipid nanoparticles in each preparation was measured with a particle size measurement apparatus (Zetasizer Nano ZS, manufactured by Malvern Panalytical Ltd.) (Table 38). PDI in the table represents polydispersity index.</div>
    </li> <li> <div id="p-2061" num="0000" class="description-line">
      <tables id="TABLE-US-00038" num="00038">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 38</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">Size (nm)</td>
                <td class="description-td"> <figure-callout id="37" label="PDI" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">PDI</figure-callout> </td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">37</td>
                <td class="description-td">39.06</td>
                <td class="description-td">0.118</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">38</td>
                <td class="description-td">39.51</td>
                <td class="description-td">0.142</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">39</td>
                <td class="description-td">37.67</td>
                <td class="description-td">0.189</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">40</td>
                <td class="description-td">33.24</td>
                <td class="description-td">0.210</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">41</td>
                <td class="description-td">40.31</td>
                <td class="description-td">0.123</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">42</td>
                <td class="description-td">38.49</td>
                <td class="description-td">0.120</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">43</td>
                <td class="description-td">52.34</td>
                <td class="description-td">0.131</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">44</td>
                <td class="description-td">43.94</td>
                <td class="description-td">0.150</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1800]"> </para-num> <div id="p-2062" num="1800" class="description-line">As a result, <figure-callout id="37" label="preparations" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">preparations</figure-callout> 37 to 44 exhibited an average particle size from 30 to 60 nm and had PDI from 0.11 to 0.21.</div>
    </li> <heading id="h-0413">Test Example 8</heading>
    <li> <para-num num="[1801]"> </para-num> <div id="p-2063" num="1801" class="description-line">In Vitro Activity Evaluation Test of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1802]"> </para-num> <div id="p-2064" num="1802" class="description-line"> <figure-callout id="37" label="Preparations" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">Preparations</figure-callout> 37 to 44 described in Examples 26 to 33 and <figure-callout id="21" label="preparations" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">preparations</figure-callout> 21 to 24 described in Comparative Examples 4 to 7 were each introduced to human pancreatic cancer-derived cell line Mia PaCa-2/Luc cells by the following method.</div>
    </li> <li> <para-num num="[1803]"> </para-num> <div id="p-2065" num="1803" class="description-line">Each preparation was treated with PLA2 and evaluated for its gene suppression ratio according to the method described in [Non Patent Literature 3]. Mia PaCa-2/Luc cells suspended in Dulbecco&#39;s modified Eagle&#39;s minimal essential medium (DMEM) containing 10% fetal bovine serum (FBS, Gibco/Thermo Fisher Scientific Inc.) were seeded in a 96-well culture plate at 7500 cells/80 L/well, and cultured at 37 C. for 24 hours under 5% CO<sub>2 </sub>conditions. Each preparation diluted with Opti-MEM (Gibco/Thermo Fisher Scientific Inc.) so as to have a final nucleic acid concentration from 3 to 100 nM was dispensed to the 96-well culture plate at 20 L/well, and the cells were cultured at 37 C. under 5% CO<sub>2 </sub>conditions to introduce each preparation into the Mia PaCa-2/Luc cells. Untreated cells were seeded as a negative control group.</div>
    </li> <li> <para-num num="[1804]"> </para-num> <div id="p-2066" num="1804" class="description-line">The cells containing each preparation thus introduced were cultured in a 5% CO<sub>2 </sub>incubator of 37 C. for 24 hours and treated using a luciferase quantification system (Steady-Glo Luciferase Assay System, Promega Corp., E2520) in accordance with the method described in the instructions attached to the product, followed by the measurement of luminescence intensity with a plate reader. The amount of luminescence of the group treated with each preparation was calculated as a relative ratio to the corrected amount of luminescence of the negative control group defined as 1 to obtain an IC50 value.</div>
    </li> <li> <para-num num="[1805]"> </para-num> <div id="p-2067" num="1805" class="description-line">As is evident from Table 39, the Luc suppression ratios of <figure-callout id="37" label="preparations" filenames="US20200368173A1-20201126-D00002.png" state="{{state}}">preparations</figure-callout> 37 to 44 containing Diether-PC, introduced in the human pancreatic cancer-derived cell line MIA PaCa-2/Luc cells, were consequently higher than those of <figure-callout id="21" label="preparations" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">preparations</figure-callout> 21 to 24 containing L-DSPC instead of Diether-PC.</div>
    </li> <li> <para-num num="[1806]"> </para-num> <div id="p-2068" num="1806" class="description-line">These results demonstrated that the lipid nanoparticle of the present invention containing an analog of a fatty acid ester of glycerol that is not hydrolyzable by a lipase can introduce a nucleic acid into cells, etc. even in the presence of PLA2.</div>
    </li> <li> <div id="p-2069" num="0000" class="description-line">
      <tables id="TABLE-US-00039" num="00039">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 39</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">KD % (3 nM)</td>
                <td class="description-td">IC50 (nM)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">37</td>
                <td class="description-td">51.6</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">38</td>
                <td class="description-td">45.2</td>
                <td class="description-td">3.94</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">39</td>
                <td class="description-td">57.7</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">40</td>
                <td class="description-td">60.5</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">41</td>
                <td class="description-td">63.1</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">42</td>
                <td class="description-td">54.0</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">43</td>
                <td class="description-td">32.1</td>
                <td class="description-td">9.13</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">44</td>
                <td class="description-td">34.3</td>
                <td class="description-td">6.95</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">21</td>
                <td class="description-td">21.6</td>
                <td class="description-td">11.3</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">22</td>
                <td class="description-td">49.3</td>
                <td class="description-td">3.15</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">23</td>
                <td class="description-td">20.0</td>
                <td class="description-td">12.0</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">24</td>
                <td class="description-td">11.1</td>
                <td class="description-td">29.2</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0414">Test Example 9</heading>
    <li> <para-num num="[1807]"> </para-num> <div id="p-2070" num="1807" class="description-line">Quantification of Neutral Lipid and Analog of Fatty Acid Ester of Glycerol that is not Hydrolyzable by Lipase in Nucleic Acid-Containing Lipid Nanoparticle Treated with PLA2</div>
    </li> <li> <para-num num="[1808]"> </para-num> <div id="p-2071" num="1808" class="description-line">The total amount of L-DPPC and D-DPPC in the nucleic acid-containing lipid nanoparticles used in Test Example 2 was quantified with a LC/MS/MS apparatus (ACQUITY UPLC SYSTEM (Waters Corp.) and API4000 Q TRAP (AB Sciex Pte. Ltd.)). The quantification results are shown in <figref idrefs="DRAWINGS">FIG. 1</figref>. In the LC/MS/MS analysis, 10 mM ammonium acetate/isopropanol/acetonitrile (80:10:10) and isopropanol/acetonitrile (50:50) were used as mobile phases, and ACQUITY UPLC BEH C8 (1.7 m, 2.1 mm I.D.50 mm, Waters Corp.) was used as a column.</div>
    </li> <li> <para-num num="[1809]"> </para-num> <div id="p-2072" num="1809" class="description-line">The amount of the lipids remaining in each preparation was calculated as a relative ratio to the amount of the lipids remaining in a PLA2-untreated group defined as 1.</div>
    </li> <heading id="h-0415">Test Example 10</heading>
    <li> <para-num num="[1810]"> </para-num> <div id="p-2073" num="1810" class="description-line">Quantification of Neutral Lipid and Analog of Fatty Acid Ester of Glycerol that is not Hydrolyzable by Lipase in Nucleic Acid-Containing Lipid Nanoparticle Treated with PLA2</div>
    </li> <li> <para-num num="[1811]"> </para-num> <div id="p-2074" num="1811" class="description-line">The total amount of DL-DSPC and L-DSPC in the nucleic acid-containing lipid nanoparticles used in Test Example 4 was quantified with a LC/MS/MS apparatus (ACQUITY UPLC SYSTEM (Waters Corp.) and API4000 (AB Sciex Pte. Ltd.)). The quantification results are shown in <figref idrefs="DRAWINGS">FIG. 2</figref>. In the LC/MS/MS analysis, 10 mM ammonium acetate/isopropanol/acetonitrile (80:10:10) and isopropanol/acetonitrile (50:50) were used as mobile phases, and ACQUITY UPLC BEH C8 (1.7 m, 2.1 mm I.D.50 mm, Waters Corp.) was used as a column.</div>
    </li> <li> <para-num num="[1812]"> </para-num> <div id="p-2075" num="1812" class="description-line">The amount of the lipids remaining in each preparation was calculated as a relative ratio to the amount of the lipids remaining in a PLA2-untreated group defined as 1.</div>
    </li> <heading id="h-0416">Test Example 11</heading>
    <li> <para-num num="[1813]"> </para-num> <div id="p-2076" num="1813" class="description-line">Quantification of Neutral Lipid and Analog of Fatty Acid Ester of Glycerol that is not Hydrolyzable by Lipase in Nucleic Acid-Containing Lipid Nanoparticle Treated with PLA2</div>
    </li> <li> <para-num num="[1814]"> </para-num> <div id="p-2077" num="1814" class="description-line">The total amount of Ether-PC and L-DSPC in the nucleic acid-containing lipid nanoparticles used in Test Example 8 was quantified with a LC/MS/MS apparatus (ACQUITY UPLC SYSTEM (Waters Corp.) and API4000 (AB Sciex Pte. Ltd.)). The quantification results are shown in <figref idrefs="DRAWINGS">FIG. 3</figref>. In the LC/MS/MS analysis, 10 mM ammonium acetate/isopropanol/acetonitrile (80:10:10) and isopropanol/acetonitrile (50:50) were used as mobile phases, and ACQUITY UPLC BEH C8 (1.7 m, 2.1 mm I.D.50 mm, Waters Corp.) was used as a column.</div>
    </li> <li> <para-num num="[1815]"> </para-num> <div id="p-2078" num="1815" class="description-line">The amount of the lipids remaining in each preparation was calculated as a relative ratio to the amount of the lipids remaining in a PLA2-untreated group defined as 1.</div>
    </li> <heading id="h-0417">Example 34</heading>
    <li> <para-num num="[1816]"> </para-num> <div id="p-2079" num="1816" class="description-line">Preparation 45 containing nucleic acid-containing lipid nanoparticles was produced as described below using compound II-25 obtained in Reference Example A34, compound CL-67 obtained in Reference Example C1, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (PEG-DSPE), DL--phosphatidylcholine, distearoyl (DL-DSPC) and cholesterol (Choi).</div>
    </li> <li> <para-num num="[1817]"> </para-num> <div id="p-2080" num="1817" class="description-line">The nucleic acid used was siRNA silencing luciferase (hereinafter, referred to as Luc) gene and consisting of the nucleotide sequences of a sense strand (5-CCGUCGUAUUCGUGAGCAAGA-3) and an antisense strand (5-UUGCUCACGAAUACGACGGUG-3), and was obtained from Gene Design, Inc. (hereinafter, referred to as Luc siRNA). PEG-DSPE and cholesterol were obtained from NOF Corp. DL-DSPC was obtained from Sigma-Aldrich Corp.</div>
    </li> <li> <para-num num="[1818]"> </para-num> <div id="p-2081" num="1818" class="description-line">Compound II-25 was dissolved at 5 mg/mL in 100% ethanol to prepare a lipid stock solution. Compound CL-67, PEG-DSPE, DL-DSPC and cholesterol were each dissolved at 20 mg/mL in 100% ethanol to prepare lipid stock solutions. Each lipid stock solution was stored at 20 C. Immediately before formulation, the lipid was dissolved by heating to 60 C., and the resulting solution was brought back to room temperature and then used. Luc siRNA was dissolved at 1 mg/mL in injectable water to prepare a Luc siRNA solution.</div>
    </li> <li> <para-num num="[1819]"> </para-num> <div id="p-2082" num="1819" class="description-line">The lipid stock solution of compound II-25 (0.313 mol) was added to 80% ethanol and a 0.1% aqueous HCl solution. Subsequently, 200 L of the Luc siRNA solution was added thereto, and the mixture was stirred for 1 minute. Then, the lipid stock solutions of compound CL-67, PEG-DSPE, DL-DSPC and Choi (1.88 mol, 0.235 mol, 0.486 mol and 1.01 mol, respectively) were added to the solution. Then, injectable water was added at a flow rate of 62 mL/sec or more such that an aqueous solution of 20% or less ethanol was prepared to form a crude preparation. The obtained crude preparation was concentrated using Amicon Ultra (manufactured by Merck Millipore), further solvent-replaced with physiological saline, and filtered using a 0.2-m filter (manufactured by Toyo Roshi Kaisha, Ltd.) in a clean bench. The siRNA concentration of the obtained preparation was further measured, and the preparation was diluted with physiological saline such that the siRNA concentration was 0.1 mg/mL to obtain preparation 45.</div>
    </li> <heading id="h-0418">Example 35</heading>
    <li> <para-num num="[1820]"> </para-num> <div id="p-2083" num="1820" class="description-line">Preparation 46 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-69 obtained in Example C3.</div>
    </li> <heading id="h-0419">Example 36</heading>
    <li> <para-num num="[1821]"> </para-num> <div id="p-2084" num="1821" class="description-line">Preparation 47 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-72 obtained in Example C6.</div>
    </li> <heading id="h-0420">Example 37</heading>
    <li> <para-num num="[1822]"> </para-num> <div id="p-2085" num="1822" class="description-line">Preparation 48 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-73 obtained in Example C1.</div>
    </li> <heading id="h-0421">Example 38</heading>
    <li> <para-num num="[1823]"> </para-num> <div id="p-2086" num="1823" class="description-line">Preparation 49 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-86 obtained in Example C20.</div>
    </li> <heading id="h-0422">Example 39</heading>
    <li> <para-num num="[1824]"> </para-num> <div id="p-2087" num="1824" class="description-line">Preparation 50 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-70 obtained in Example C4.</div>
    </li> <heading id="h-0423">Example 40</heading>
    <li> <para-num num="[1825]"> </para-num> <div id="p-2088" num="1825" class="description-line">Preparation 51 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-71 obtained in Example C5.</div>
    </li> <heading id="h-0424">Example 41</heading>
    <li> <para-num num="[1826]"> </para-num> <div id="p-2089" num="1826" class="description-line">Preparation 52 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-74 obtained in Example C11.</div>
    </li> <heading id="h-0425">Example 42</heading>
    <li> <para-num num="[1827]"> </para-num> <div id="p-2090" num="1827" class="description-line">Preparation 53 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-76 obtained in Example C10.</div>
    </li> <heading id="h-0426">Example 43</heading>
    <li> <para-num num="[1828]"> </para-num> <div id="p-2091" num="1828" class="description-line">Preparation 54 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-77 obtained in Example C8.</div>
    </li> <heading id="h-0427">Example 44</heading>
    <li> <para-num num="[1829]"> </para-num> <div id="p-2092" num="1829" class="description-line">Preparation 55 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-80 obtained in Example C13.</div>
    </li> <heading id="h-0428">Example 45</heading>
    <li> <para-num num="[1830]"> </para-num> <div id="p-2093" num="1830" class="description-line">Preparation 56 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-81 obtained in Example C12.</div>
    </li> <heading id="h-0429">Example 46</heading>
    <li> <para-num num="[1831]"> </para-num> <div id="p-2094" num="1831" class="description-line">Preparation 57 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-7 obtained in Reference Example B7.</div>
    </li> <heading id="h-0430">Example 47</heading>
    <li> <para-num num="[1832]"> </para-num> <div id="p-2095" num="1832" class="description-line">Preparation 58 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-47 obtained in Reference Example B47.</div>
    </li> <heading id="h-0431">Example 48</heading>
    <li> <para-num num="[1833]"> </para-num> <div id="p-2096" num="1833" class="description-line">Preparation 59 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-103 obtained in Reference Example C37.</div>
    </li> <heading id="h-0432">Example 49</heading>
    <li> <para-num num="[1834]"> </para-num> <div id="p-2097" num="1834" class="description-line"> <figure-callout id="60" label="Preparation" filenames="US20200368173A1-20201126-D00001.png,US20200368173A1-20201126-D00002.png" state="{{state}}">Preparation</figure-callout> 60 was obtained in the same way as in Example 34 except that compound CL-67 of preparation 45 was changed to compound CL-55 obtained in Reference Example B55.</div>
    </li> <heading id="h-0433">Test Example 12</heading>
    <li> <para-num num="[1835]"> </para-num> <div id="p-2098" num="1835" class="description-line">Average Particle Size Measurement of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1836]"> </para-num> <div id="p-2099" num="1836" class="description-line">The average particle size of the nucleic acid-containing lipid nanoparticles in each preparation was measured with a particle size measurement apparatus (Zetasizer Nano ZS, manufactured by Malvern Panalytical Ltd.) (Table 40). PDI in the table represents polydispersity index.</div>
    </li> <li> <div id="p-2100" num="0000" class="description-line">
      <tables id="TABLE-US-00040" num="00040">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 40</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">Size (nm)</td>
                <td class="description-td">PDI</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">45</td>
                <td class="description-td">41.98</td>
                <td class="description-td">0.106</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">46</td>
                <td class="description-td">38.83</td>
                <td class="description-td">0.170</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">47</td>
                <td class="description-td">43.41</td>
                <td class="description-td">0.136</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">43.62</td>
                <td class="description-td">0.164</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">49</td>
                <td class="description-td">38.97</td>
                <td class="description-td">0.173</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">50</td>
                <td class="description-td">41.79</td>
                <td class="description-td">0.095</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">51</td>
                <td class="description-td">43.89</td>
                <td class="description-td">0.112</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">52</td>
                <td class="description-td">43.84</td>
                <td class="description-td">0.121</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">53</td>
                <td class="description-td">47.83</td>
                <td class="description-td">0.130</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">54</td>
                <td class="description-td">43.98</td>
                <td class="description-td">0.131</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">55</td>
                <td class="description-td">42.78</td>
                <td class="description-td">0.208</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">56</td>
                <td class="description-td">38.77</td>
                <td class="description-td">0.214</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">57</td>
                <td class="description-td">41.41</td>
                <td class="description-td">0.172</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">58</td>
                <td class="description-td">40.92</td>
                <td class="description-td">0.201</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">59</td>
                <td class="description-td">36.30</td>
                <td class="description-td">0.246</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">60</td>
                <td class="description-td">38.12</td>
                <td class="description-td">0.196</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <li> <para-num num="[1837]"> </para-num> <div id="p-2101" num="1837" class="description-line">As a result, preparations 45 to 60 exhibited an average particle size from 30 to 50 ran and had PDI from 0.095 to 0.246.</div>
    </li> <heading id="h-0434">Test Example 13</heading>
    <li> <para-num num="[1838]"> </para-num> <div id="p-2102" num="1838" class="description-line">In Vitro Activity Evaluation Test of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1839]"> </para-num> <div id="p-2103" num="1839" class="description-line">Preparations 45 to 49 and 51 to 60 described in Examples 34 to 38 and 40 to 49 were each introduced to human pancreatic cancer-derived cell line Mia PaCa-2/Luc cells forced to express luciferase by the following method.</div>
    </li> <li> <para-num num="[1840]"> </para-num> <div id="p-2104" num="1840" class="description-line">Each preparation was treated with PLA2 and evaluated for its gene suppression ratio according to the method described in [Non Patent Literature 3]. Mia PaCa-2/Luc cells suspended in Dulbecco&#39;s modified Eagle&#39;s minimal essential medium (DMEM) containing 10% fetal bovine serum (FBS, Access Biologicals LLC) were seeded in a 96-well culture plate at 7500 cells/80 L/well, and cultured at 37 C. for 24 hours under 5% CO<sub>2 </sub>conditions. Each preparation diluted with Opti-MEM (Gibco/Thermo Fisher Scientific Inc.) so as to have a final nucleic acid concentration from 3 to 100 nM was dispensed to the 96-well culture plate at 20 L/well, and the cells were cultured at 37 C. under 5% CO<sub>2 </sub>conditions to introduce each preparation into the Mia PaCa-2/Luc cells. Untreated cells were seeded as a negative control group.</div>
    </li> <li> <para-num num="[1841]"> </para-num> <div id="p-2105" num="1841" class="description-line">The cells containing each preparation thus introduced were cultured in a 5% CO<sub>2 </sub>incubator of 37 C. for 24 hours and treated using a luciferase quantification system (Steady-Glo Luciferase Assay System, Promega Corp., E2520) in accordance with the method described in the instructions attached to the product, followed by the measurement of luminescence intensity with a plate reader. The amount of luminescence of the group treated with each preparation was calculated as a relative ratio to the corrected amount of luminescence of the negative control group defined as 1 to obtain an IC50 value.</div>
    </li> <li> <para-num num="[1842]"> </para-num> <div id="p-2106" num="1842" class="description-line">As is evident from Table 41, these results demonstrated that the lipid nanoparticle of the present invention containing an analog of a fatty acid ester of glycerol that is not hydrolyzable by a lipase can introduce a nucleic acid into cells, etc. even in the presence of PLA2.</div>
    </li> <li> <div id="p-2107" num="0000" class="description-line">
      <tables id="TABLE-US-00041" num="00041">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 41</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">KD % (3 nM)</td>
                <td class="description-td">IC50 (nM)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">45</td>
                <td class="description-td">51.6</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">46</td>
                <td class="description-td">68.9</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">47</td>
                <td class="description-td">9.94</td>
                <td class="description-td">11.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">58.8</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">49</td>
                <td class="description-td">19.9</td>
                <td class="description-td">12.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">51</td>
                <td class="description-td">53.1</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">52</td>
                <td class="description-td">10.2</td>
                <td class="description-td">13.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">53</td>
                <td class="description-td">38.9</td>
                <td class="description-td">5.46</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">54</td>
                <td class="description-td">42.1</td>
                <td class="description-td">4.27</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">55</td>
                <td class="description-td">1.43</td>
                <td class="description-td">22.6</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">56</td>
                <td class="description-td">67.4</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">57</td>
                <td class="description-td">24.2</td>
                <td class="description-td">8.83</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">59</td>
                <td class="description-td">2.43</td>
                <td class="description-td">27.2</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">60</td>
                <td class="description-td">26.0</td>
                <td class="description-td">7.06</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0435">Test Example 14</heading>
    <li> <para-num num="[1843]"> </para-num> <div id="p-2108" num="1843" class="description-line">In Vitro Activity Evaluation Test of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1844]"> </para-num> <div id="p-2109" num="1844" class="description-line">Preparations 45 to 60 described in Examples 34 to 49 were each introduced to human uterine cervical cancer-derived cell line HeLa cells forced to express luciferase (hereinafter, referred to as Luc2CP-HeLa) by the following method.</div>
    </li> <li> <para-num num="[1845]"> </para-num> <div id="p-2110" num="1845" class="description-line">Each preparation was treated with PLA2 and evaluated for its gene suppression ratio according to the method described in [Non Patent Literature 3]. Luc2CP-HeLa/Luc cells suspended in Dulbecco&#39;s modified Eagle&#39;s minimal essential medium (DMEM) containing 10% fetal bovine serum (FBS, Access Biologicals LLC) were seeded in a 96-well culture plate at 7500 cells/80 L/well, and cultured at 37 C. for 24 hours under 5% CO<sub>2 </sub>conditions. Each preparation diluted with Opti-MEM (Gibco/Thermo Fisher Scientific Inc.) so as to have a final nucleic acid concentration from 3 to 100 nM was dispensed to the 96-well culture plate at 20 L/well, and the cells were cultured at 37 C. under 5% CO<sub>2 </sub>conditions to introduce each preparation into the Luc2CP-HeLa/Luc cells. Untreated cells were seeded as a negative control group.</div>
    </li> <li> <para-num num="[1846]"> </para-num> <div id="p-2111" num="1846" class="description-line">The cells containing each preparation thus introduced were cultured in a 5% CO<sub>2 </sub>incubator of 37 C. for 24 hours and treated using a luciferase quantification system (Steady-Glo Luciferase Assay System, Promega Corp., E2520) in accordance with the method described in the instructions attached to the product, followed by the measurement of luminescence intensity with a plate reader. The amount of luminescence of the group treated with each preparation was calculated as a relative ratio to the corrected amount of luminescence of the negative control group defined as 1 to obtain an IC50 value.</div>
    </li> <li> <para-num num="[1847]"> </para-num> <div id="p-2112" num="1847" class="description-line">As is evident from Table 42, these results demonstrated that the lipid nanoparticle of the present invention containing a fatty acid ester analog of glycerol that is not hydrolyzable by a lipase can introduce a nucleic acid into cells, etc. even in the presence of PLA2.</div>
    </li> <li> <div id="p-2113" num="0000" class="description-line">
      <tables id="TABLE-US-00042" num="00042">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 42</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">KD % (3 nM)</td>
                <td class="description-td">IC50 (nM)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">45</td>
                <td class="description-td">57.8</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">46</td>
                <td class="description-td">86.2</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">47</td>
                <td class="description-td">4.39</td>
                <td class="description-td">22.4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">63.4</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">49</td>
                <td class="description-td">9.02</td>
                <td class="description-td">16.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">50</td>
                <td class="description-td">55.2</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">51</td>
                <td class="description-td">67.7</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">52</td>
                <td class="description-td">3.12</td>
                <td class="description-td">14.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">53</td>
                <td class="description-td">32.1</td>
                <td class="description-td">4.80</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">54</td>
                <td class="description-td">39.8</td>
                <td class="description-td">3.93</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">55</td>
                <td class="description-td">7.31</td>
                <td class="description-td">14.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">56</td>
                <td class="description-td">81.4</td>
                <td class="description-td">&lt;3.00</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">57</td>
                <td class="description-td">10.3</td>
                <td class="description-td">18.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">58</td>
                <td class="description-td">47.8</td>
                <td class="description-td">3.17</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">59</td>
                <td class="description-td">1.61</td>
                <td class="description-td">17.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">60</td>
                <td class="description-td">14.1</td>
                <td class="description-td">7.92</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0436">Test Example 15</heading>
    <li> <para-num num="[1848]"> </para-num> <div id="p-2114" num="1848" class="description-line">In Vitro Activity Evaluation Test of Nucleic Acid-Containing Lipid Nanoparticle</div>
    </li> <li> <para-num num="[1849]"> </para-num> <div id="p-2115" num="1849" class="description-line">Preparations 45 to 60 described in Examples 34 to 49 were each introduced to human lung cancer-derived cell line NCI-H358/Luc cells forced to express luciferase by the following method.</div>
    </li> <li> <para-num num="[1850]"> </para-num> <div id="p-2116" num="1850" class="description-line">Each preparation was treated with PLA2 and evaluated for its gene suppression ratio according to the method described in [Non Patent Literature 3]. NCI-H358/Luc cells suspended in Dulbecco&#39;s modified Eagle&#39;s minimal essential medium (RPMI1640) containing 10% fetal bovine serum (FBS, Access Biologicals LLC) were seeded in a 96-well culture plate at 7500 cells/80 L/well, and cultured at 37 C. for 24 hours under 5% CO<sub>2 </sub>conditions. Each preparation diluted with Opti-MEM (Gibco/Thermo Fisher Scientific Inc.) so as to have a final nucleic acid concentration from 3 to 100 nM was dispensed to the 96-well culture plate at 20 L/well, and the cells were cultured at 37 C. under 5% CO<sub>2 </sub>conditions to introduce each preparation into the NCI-H358/Luc cells. Untreated cells were seeded as a negative control group.</div>
    </li> <li> <para-num num="[1851]"> </para-num> <div id="p-2117" num="1851" class="description-line">The cells containing each preparation thus introduced were cultured in a 5% CO<sub>2 </sub>incubator of 37 C. for 24 hours and treated using a luciferase quantification system (Steady-Glo Luciferase Assay System, Promega Corp., E2520) in accordance with the method described in the instructions attached to the product, followed by the measurement of luminescence intensity with a plate reader. The amount of luminescence of the group treated with each preparation was calculated as a relative ratio to the corrected amount of luminescence of the negative control group defined as 1 to obtain an IC50 value.</div>
    </li> <li> <para-num num="[1852]"> </para-num> <div id="p-2118" num="1852" class="description-line">As is evident from Table 43, these results demonstrated that the lipid nanoparticle of the present invention containing a fatty acid ester analog of glycerol that is not hydrolyzable by a lipase can introduce a nucleic acid into cells, etc. even in the presence of PLA2.</div>
    </li> <li> <div id="p-2119" num="0000" class="description-line">
      <tables id="TABLE-US-00043" num="00043">
        <patent-tables frame="none" colsep="0" rowsep="0">
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <thead>
              <tr class="description-tr">
                <td namest="1" nameend="3" rowsep="1" class="description-td" colspan="3">TABLE 43</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">Preparation No.</td>
                <td class="description-td">KD % (3 nM)</td>
                <td class="description-td">IC50 (nM)</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            </thead>
            
              <tbody><tr class="description-tr">
                <td class="description-td"> </td>
              </tr>
            
          </tbody></table>
          <table align="left" colsep="0" rowsep="0" cols="3" class="description-table" width="100%">
            <tbody><tr class="description-tr">
                <td class="description-td">45</td>
                <td class="description-td">62.3</td>
                <td class="description-td">5.81</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">46</td>
                <td class="description-td">70.4</td>
                <td class="description-td">4.11</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">47</td>
                <td class="description-td">2.36</td>
                <td class="description-td">93.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">48</td>
                <td class="description-td">56.9</td>
                <td class="description-td">7.58</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">49</td>
                <td class="description-td">12.4</td>
                <td class="description-td">56.1</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">51</td>
                <td class="description-td">59.8</td>
                <td class="description-td">7.09</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">52</td>
                <td class="description-td">26.1</td>
                <td class="description-td">20.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">53</td>
                <td class="description-td">45.7</td>
                <td class="description-td">12.7</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">54</td>
                <td class="description-td">56.6</td>
                <td class="description-td">7.95</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">55</td>
                <td class="description-td">23.0</td>
                <td class="description-td">22.8</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">56</td>
                <td class="description-td">72.7</td>
                <td class="description-td">3.22</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">57</td>
                <td class="description-td">31.8</td>
                <td class="description-td">19.5</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">59</td>
                <td class="description-td">15.3</td>
                <td class="description-td">36.4</td>
              </tr>
              <tr class="description-tr">
                <td class="description-td">60</td>
                <td class="description-td">40.5</td>
                <td class="description-td">14.6</td>
              </tr>
              <tr class="description-tr">
                <td namest="1" nameend="3" align="center" rowsep="1" class="description-td" colspan="3"> </td>
              </tr>
            
          </tbody></table>
        </patent-tables>
      </tables>
    </div>
    </li> <heading id="h-0437">Free Text of Sequence Listing</heading>
    <li> <para-num num="[1853]"> </para-num> <div id="p-2120" num="1853" class="description-line">SEQ ID NO: 1 represents the nucleotide sequence of a Luc siRNA sense strand.</div>
    </li> <li> <para-num num="[1854]"> </para-num> <div id="p-2121" num="1854" class="description-line">SEQ ID NO: 2 represents the nucleotide sequence of a Luc siRNA antisense strand.</div>
    
  </li> </ul>
  </div>
  </section>

  <section itemprop="claims" itemscope>
    <h2>Claims (<span itemprop="count">23</span>)</h2>
    
    <div itemprop="content" html><div mxw-id="PCLM276158994" lang="EN" load-source="patent-office" class="claims">
    <div class="claim"> <div id="CLM-01-27" num="01-27" class="claim">
      <div class="claim-text"> <b>1</b>-<b>27</b>. (canceled)</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00028" num="00028" class="claim">
      <div class="claim-text"> <b>28</b>. A nucleic acid-containing lipid nanoparticle comprising
<div class="claim-text">an analog of a fatty acid ester of glycerol, and</div> <div class="claim-text">a nucleic acid,</div> </div>
      <div class="claim-text">wherein the analog is not hydrolyzable by a lipase.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00029" num="00029" class="claim">
      <div class="claim-text"> <b>29</b>. The nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>, wherein the analog of the fatty acid ester of glycerol is an analog of a glycerophospholipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00030" num="00030" class="claim">
      <div class="claim-text"> <b>30</b>. The nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>, wherein the lipase is phospholipase A2.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00031" num="00031" class="claim">
      <div class="claim-text"> <b>31</b>. The nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>, wherein the analog of the fatty acid ester of glycerol is a lipid represented by the following formula (1) or (2):</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00287" num="00287">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/de/bb/51/a43a40f847206a/US20200368173A1-20201126-C00287.png"><img id="EMI-C00287" he="26.59mm" wi="64.77mm" file="US20200368173A1-20201126-C00287.TIF" alt="Figure US20200368173A1-20201126-C00287" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="259" height="106" alt="Figure US20200368173A1-20201126-C00287" class="patent-full-image" src="https://patentimages.storage.googleapis.com/de/bb/51/a43a40f847206a/US20200368173A1-20201126-C00287.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00287" attachment-type="cdx" file="US20200368173A1-20201126-C00287.CDX"> </attachment>
            <attachment idref="CHEM-US-00287" attachment-type="mol" file="US20200368173A1-20201126-C00287.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">Rx<sup>1 </sup>and Rx<sup>2 </sup>are the same or different and are each optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl; and</div>
<div class="claim-text">Rx<sup>3 </sup>is a negative charge, a hydrogen atom, or any of the following groups:</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00288" num="00288">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/09/33/c3/3109189708d560/US20200368173A1-20201126-C00288.png"><img id="EMI-C00288" he="83.74mm" wi="75.52mm" file="US20200368173A1-20201126-C00288.TIF" alt="Figure US20200368173A1-20201126-C00288" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="302" height="335" alt="Figure US20200368173A1-20201126-C00288" class="patent-full-image" src="https://patentimages.storage.googleapis.com/09/33/c3/3109189708d560/US20200368173A1-20201126-C00288.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00288" attachment-type="cdx" file="US20200368173A1-20201126-C00288.CDX"> </attachment>
            <attachment idref="CHEM-US-00288" attachment-type="mol" file="US20200368173A1-20201126-C00288.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">Rx<sup>4 </sup>is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl or Rx<sup>41</sup>-CO;</div>
<div class="claim-text">Rx<sup>41 </sup>is optionally substituted linear or branched C7-C23 alkyl, C7-C23 alkenyl or C7-C23 alkynyl;</div>
<div class="claim-text">Rx<sup>5 </sup>is optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl; and</div>
<div class="claim-text">Rx<sup>6 </sup>is a negative charge, a hydrogen atom, or any of the following groups:</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00289" num="00289">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e5/99/21/45e5fbc07f9b34/US20200368173A1-20201126-C00289.png"><img id="EMI-C00289" he="50.46mm" wi="74.59mm" file="US20200368173A1-20201126-C00289.TIF" alt="Figure US20200368173A1-20201126-C00289" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="298" height="202" alt="Figure US20200368173A1-20201126-C00289" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e5/99/21/45e5fbc07f9b34/US20200368173A1-20201126-C00289.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00289" attachment-type="cdx" file="US20200368173A1-20201126-C00289.CDX"> </attachment>
            <attachment idref="CHEM-US-00289" attachment-type="mol" file="US20200368173A1-20201126-C00289.MOL"> </attachment>
          </attachments>
        </chemistry>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00032" num="00032" class="claim">
      <div class="claim-text"> <b>32</b>. The nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>, further comprising a cationic lipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00033" num="00033" class="claim">
      <div class="claim-text"> <b>33</b>. The nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00032">claim 32</claim-ref>, wherein the cationic lipid is lipid A represented by at least one of the following formulas (I) to (IV), (V) and (V), and/or lipid B represented by at least one of the following formulas (CL-I) to (CL-XIX):
<div class="claim-text">formula (I)</div>
</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00290" num="00290">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/05/b0/fb/169c26968c4fcb/US20200368173A1-20201126-C00290.png"><img id="EMI-C00290" he="16.43mm" wi="52.24mm" file="US20200368173A1-20201126-C00290.TIF" alt="Figure US20200368173A1-20201126-C00290" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="209" height="66" alt="Figure US20200368173A1-20201126-C00290" class="patent-full-image" src="https://patentimages.storage.googleapis.com/05/b0/fb/169c26968c4fcb/US20200368173A1-20201126-C00290.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00290" attachment-type="cdx" file="US20200368173A1-20201126-C00290.CDX"> </attachment>
            <attachment idref="CHEM-US-00290" attachment-type="mol" file="US20200368173A1-20201126-C00290.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>1 </sup>to R<sup>3 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">L<sup>1 </sup>to L<sup>3 </sup>are the same or different and are each absent, or Z<sup>1</sup>(CY<sup>1</sup>Y<sup>2</sup>)<sub>p1</sub> or Z<sup>2</sup>(CY<sup>3</sup>Y<sup>4</sup>)<sub>p2</sub>Z<sup>3</sup>(CY<sup>5</sup>Y<sup>6</sup>)<sub>p3</sub> wherein Y<sup>1 </sup>to Y<sup>6 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>1 </sup>to Z<sup>3 </sup>are the same or different and are each O, NY<sup>7A</sup>, COO, OCO, CONY<sup>7B</sup>, NY<sup>7C</sup>CO or NY<sup>7D</sup>COO wherein Y<sup>7A </sup>to Y<sup>7D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; and p<sup>1 </sup>to p<sup>3 </sup>are the same or different and are each an integer from 1 to 5;</div>
<div class="claim-text">X<sup>1 </sup>is optionally substituted C1-C4 alkyl; and</div>
<div class="claim-text">A<sup>1 </sup>is a pharmaceutically acceptable anion,</div>
</div>
        <div class="claim-text">formula (II)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00291" num="00291">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c6/69/cc/82b9d1a5fdef33/US20200368173A1-20201126-C00291.png"><img id="EMI-C00291" he="17.95mm" wi="54.44mm" file="US20200368173A1-20201126-C00291.TIF" alt="Figure US20200368173A1-20201126-C00291" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="218" height="72" alt="Figure US20200368173A1-20201126-C00291" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c6/69/cc/82b9d1a5fdef33/US20200368173A1-20201126-C00291.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00291" attachment-type="cdx" file="US20200368173A1-20201126-C00291.CDX"> </attachment>
            <attachment idref="CHEM-US-00291" attachment-type="mol" file="US20200368173A1-20201126-C00291.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>4 </sup>to R<sup>6 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">L<sup>4 </sup>to L<sup>6 </sup>are the same or different and are each absent, or Z<sup>4</sup>(CY<sup>8</sup>Y<sup>9</sup>)<sub>p4</sub> or Z<sup>5</sup>(CY<sup>10</sup>Y<sup>11</sup>)<sub>p5</sub>Z<sup>6</sup>(CY<sup>12</sup>Y<sup>13</sup>)<sub>p6</sub> wherein Y<sup>8 </sup>to Y<sup>13 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>4 </sup>to Z<sup>6 </sup>are the same or different and are each O, NY<sup>14A</sup>, COO, OCO, CONY<sup>14B</sup>, NY<sup>14C</sup>CO or NY<sup>14D</sup>COO wherein Y<sup>14A </sup>to Y<sup>14D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>4 </sup>is an integer from 0 to 5; p<sup>5 </sup>is an integer from 1 to 5; and p<sup>6 </sup>is an integer from 0 to 5;</div>
<div class="claim-text">L<sup>7 </sup>is absent, or (CY<sup>15</sup>Y<sup>16</sup>)<sub>p7</sub>, (CY<sup>17</sup>Y<sup>18</sup>)<sub>p8</sub>Z<sup>7</sup>(CY<sup>19</sup>Y<sup>20</sup>)<sub>p9</sub> or (CY<sup>21</sup>Y<sup>22</sup>)<sub>p10</sub>Z<sup>8</sup>(CY<sup>23</sup>Y<sup>24</sup>)<sub>p11</sub>Z<sup>9</sup>(CY<sup>25</sup>Y<sup>26</sup>)<sub>p12</sub> wherein Y<sup>15 </sup>to Y<sup>26 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>7 </sup>to Z<sup>9 </sup>are the same or different and are each O, NY<sup>27A</sup>, COO, OCO, CONY<sup>27B</sup>, NY<sup>27C</sup>CO or NY<sup>27D</sup>COO wherein Y<sup>27A </sup>to Y<sup>27D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>7 </sup>is an integer from 1 to 5; p<sup>8 </sup>is an integer from 0 to 5; p<sup>9 </sup>is an integer from 1 to 5; p<sup>10 </sup>is an integer from 0 to 5; p<sup>11 </sup>is an integer from 1 to 5; and p<sup>12 </sup>is an integer from 1 to 5;</div>
<div class="claim-text">B<sup>1 </sup>is</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00292" num="00292">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5d/78/ef/3eaa1201d4eba3/US20200368173A1-20201126-C00292.png"><img id="EMI-C00292" he="97.20mm" wi="64.52mm" file="US20200368173A1-20201126-C00292.TIF" alt="Figure US20200368173A1-20201126-C00292" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="258" height="389" alt="Figure US20200368173A1-20201126-C00292" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5d/78/ef/3eaa1201d4eba3/US20200368173A1-20201126-C00292.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00292" attachment-type="cdx" file="US20200368173A1-20201126-C00292.CDX"> </attachment>
            <attachment idref="CHEM-US-00292" attachment-type="mol" file="US20200368173A1-20201126-C00292.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>2 </sup>and X<sup>3 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>4 </sup>is optionally substituted C1-C4 alkyl; X<sup>5 </sup>and X<sup>6 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>7 </sup>is optionally substituted C1-C4 alkyl; Y<sup>28 </sup>to Y<sup>37 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>10 </sup>and Z<sup>11 </sup>are the same or different and are each O, NY<sup>38A</sup>, COO, OCO, CONY<sup>38B</sup>, NY<sup>38C</sup>CO or NY<sup>38D</sup>COO wherein Y<sup>38A </sup>to Y<sup>38D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>13 </sup>is an integer from 0 to 5; and p<sup>14 </sup>to p<sup>17 </sup>are the same or different and are each an integer from 1 to 5; and
<div class="claim-text">A<sup>2 </sup>is a pharmaceutically acceptable anion,</div>
</div>
        <div class="claim-text">formula (III)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00293" num="00293">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/1b/2b/67/5ca8ad21e3c08d/US20200368173A1-20201126-C00293.png"><img id="EMI-C00293" he="17.10mm" wi="60.03mm" file="US20200368173A1-20201126-C00293.TIF" alt="Figure US20200368173A1-20201126-C00293" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="240" height="68" alt="Figure US20200368173A1-20201126-C00293" class="patent-full-image" src="https://patentimages.storage.googleapis.com/1b/2b/67/5ca8ad21e3c08d/US20200368173A1-20201126-C00293.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00293" attachment-type="cdx" file="US20200368173A1-20201126-C00293.CDX"> </attachment>
            <attachment idref="CHEM-US-00293" attachment-type="mol" file="US20200368173A1-20201126-C00293.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>7 </sup>to R<sup>9 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">L<sup>8 </sup>to L<sup>10 </sup>are the same or different and are each absent, or Z<sup>12</sup>(CY<sup>39</sup>Y<sup>40</sup>)<sub>p18</sub> or Z<sup>13</sup>(CY<sup>41</sup>Y<sup>42</sup>)<sub>p19</sub>Z<sup>14</sup>(CY<sup>43</sup>Y<sup>44</sup>)<sub>p20</sub> wherein Y<sup>39 </sup>to Y<sup>44 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>12 </sup>to Z<sup>14 </sup>are the same or different and are each O, NY<sup>45A</sup>, COO, OCO, CONY<sup>45B</sup>, NY<sup>45C</sup>CO, NY<sup>45D</sup>COO or CO wherein Y<sup>45A </sup>to Y<sup>45D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl;</div>
<div class="claim-text">p<sup>18 </sup>is an integer from 0 to 5; p<sup>19 </sup>is an integer from 1 to 5; and p<sup>20 </sup>is an integer from 0 to 5;</div>
<div class="claim-text">L<sup>11 </sup>is absent, or (CY<sup>46</sup>Y<sup>47</sup>)<sub>p21</sub>, (CY<sup>48</sup>Y<sup>49</sup>)<sub>p22</sub>Z<sup>15</sup>(CY<sup>50</sup>Y<sup>51</sup>)<sub>p23</sub> or (CY<sup>52</sup>Y<sup>53</sup>)<sub>p24</sub>Z<sup>16</sup>(CY<sup>54</sup>Y<sup>55</sup>)<sub>p25</sub>Z<sup>17</sup>(CY<sup>56</sup>Y<sup>57</sup>)<sub>p26</sub> wherein Y<sup>46 </sup>to Y<sup>57 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>15 </sup>to Z<sup>17 </sup>are the same or different and are each O, NY<sup>58A</sup>, COO, OCO, CONY<sup>58B</sup>, NY<sup>58C</sup>CO, NY<sup>58D</sup>COO or CO wherein Y<sup>58A </sup>to Y<sup>58D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>21 </sup>is an integer from 1 to 5; p<sup>22 </sup>is an integer from 0 to 5; p<sup>23 </sup>is an integer from 1 to 5; p<sup>24 </sup>is an integer from 0 to 5; p<sup>25 </sup>is an integer from 1 to 5; and p<sup>26 </sup>is an integer from 1 to 5;</div>
<div class="claim-text">L<sup>12 </sup>is absent, or (CY<sup>59</sup>Y<sup>60</sup>)<sub>p27</sub>, (CY<sup>61</sup>Y<sup>62</sup>)<sub>p28</sub>Z<sup>18</sup>(CY<sup>63</sup>Y<sup>64</sup>)<sub>p29</sub> or (CY<sup>65</sup>Y<sup>66</sup>)<sub>p30</sub>Z<sup>19</sup>(CY<sup>67</sup>Y<sup>68</sup>)<sub>p31</sub>Z<sup>20</sup>(CY<sup>69</sup>Y<sup>70</sup>)<sub>p32</sub> wherein Y<sup>59 </sup>to Y<sup>70 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>18 </sup>to Z<sup>20 </sup>are the same or different and are each O, NY<sup>71A</sup>, COO, OCO, CONY<sup>71B</sup>, NY<sup>71C</sup>CO, NY<sup>71D</sup>COO or CO wherein Y<sup>71A </sup>to Y<sup>71D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>27 </sup>is an integer from 1 to 5; p<sup>28 </sup>is an integer from 0 to 5; p<sup>29 </sup>is an integer from 0 to 5; p<sup>30 </sup>is an integer from 0 to 5; p<sup>31 </sup>is an integer from 1 to 5; and p<sup>32 </sup>is an integer from 0 to 5;</div>
<div class="claim-text">J<sup>1 </sup>and J<sup>2 </sup>are the same or different and are each CY<sup>72 </sup>or N wherein Y<sup>72 </sup>is a hydrogen atom, hydroxy, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, or optionally substituted C1-C4 acyloxy;</div>
<div class="claim-text">B<sup>2 </sup>is</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00294" num="00294">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ac/8e/2d/ffcb67949855ea/US20200368173A1-20201126-C00294.png"><img id="EMI-C00294" he="67.14mm" wi="57.91mm" file="US20200368173A1-20201126-C00294.TIF" alt="Figure US20200368173A1-20201126-C00294" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="232" height="269" alt="Figure US20200368173A1-20201126-C00294" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ac/8e/2d/ffcb67949855ea/US20200368173A1-20201126-C00294.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00294" attachment-type="cdx" file="US20200368173A1-20201126-C00294.CDX"> </attachment>
            <attachment idref="CHEM-US-00294" attachment-type="mol" file="US20200368173A1-20201126-C00294.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>8 </sup>and X<sup>9 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>10 </sup>is optionally substituted C1-C4 alkyl; X<sup>11 </sup>and X<sup>12 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>13 </sup>is optionally substituted C1-C4 alkyl; Y<sup>73 </sup>to Y<sup>82 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>21 </sup>and Z<sup>22 </sup>are the same or different and are each O, NY<sup>83A</sup>, COO, OCO, CONY<sup>83B</sup>, NY<sup>83C</sup>CO or NY<sup>83D</sup>COO wherein Y<sup>83A </sup>to Y<sup>83D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>33 </sup>is an integer from 0 to 5; and p<sup>34 </sup>to p<sup>37 </sup>are the same or different and are each an integer from 1 to 5; and
<div class="claim-text">A<sup>3 </sup>is a pharmaceutically acceptable anion,</div>
</div>
        <div class="claim-text">formula (IV)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00295" num="00295">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/31/d8/ec/13069ce3c14fdb/US20200368173A1-20201126-C00295.png"><img id="EMI-C00295" he="18.03mm" wi="58.93mm" file="US20200368173A1-20201126-C00295.TIF" alt="Figure US20200368173A1-20201126-C00295" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="236" height="72" alt="Figure US20200368173A1-20201126-C00295" class="patent-full-image" src="https://patentimages.storage.googleapis.com/31/d8/ec/13069ce3c14fdb/US20200368173A1-20201126-C00295.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00295" attachment-type="cdx" file="US20200368173A1-20201126-C00295.CDX"> </attachment>
            <attachment idref="CHEM-US-00295" attachment-type="mol" file="US20200368173A1-20201126-C00295.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>10 </sup>to R<sup>12 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">L<sup>13 </sup>is absent, or Z<sup>23</sup>(CY<sup>83</sup>Y<sup>84</sup>)<sub>p38</sub> or Z<sup>24</sup>(CY<sup>85</sup>Y<sup>86</sup>)<sub>p39</sub>Z<sup>25</sup>(CY<sup>87</sup>Y<sup>88</sup>)<sub>p40</sub> wherein Y<sup>83 </sup>to Y<sup>88 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>23 </sup>to Z<sup>25 </sup>are the same or different and are each O, NY<sup>89A</sup>, COO, OCO, CONY<sup>89B</sup>, NY<sup>89C</sup>CO or NY<sup>89D</sup>COO wherein Y<sup>89A </sup>to Y<sup>89D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; and p<sup>38 </sup>to p<sup>40 </sup>are the same or different and are each an integer from 1 to 5;</div>
<div class="claim-text">L<sup>14 </sup>and L<sup>15 </sup>are the same or different and are each absent, or Z<sup>26</sup>(CY<sup>90</sup>Y<sup>91</sup>)<sub>p41</sub> or Z<sup>27</sup>(CY<sup>92</sup>Y<sup>93</sup>)<sub>p42</sub>Z<sup>28</sup>(CY<sup>94</sup>Y<sup>95</sup>)<sub>p43</sub> wherein Y<sup>90 </sup>to Y<sup>95 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>26 </sup>to Z<sup>28 </sup>are the same or different and are each O, NY<sup>96A</sup>, COO, OCO, CONY<sup>96B</sup>, NY<sup>96C</sup>CO, NY<sup>96D</sup>COO or CO wherein Y<sup>96A </sup>to Y<sup>96D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>41 </sup>is an integer from 0 to 5; p<sup>42 </sup>is an integer from 1 to 5; and p<sup>43 </sup>is an integer from 0 to 5;</div>
<div class="claim-text">L<sup>16 </sup>is absent, or (CY<sup>97</sup>Y<sup>98</sup>)<sub>p44</sub>, (CY<sup>99</sup>Y<sup>100</sup>)<sub>p45</sub>Z<sup>29</sup>(CY<sup>101</sup>Y<sup>102</sup>)<sub>p46</sub> or (CY<sup>103</sup>Y<sup>104</sup>)<sub>p47</sub>Z<sup>30</sup>(CY<sup>105</sup>Y<sup>106</sup>)<sub>p48</sub>Z<sup>31</sup>(CY<sup>107</sup>Y<sup>108</sup>)<sub>p49</sub> wherein Y<sup>97 </sup>to Y<sup>108 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>29 </sup>to Z<sup>31 </sup>are the same or different and are each O, NY<sup>109A</sup>, COO, OCO, CONY<sup>109B</sup>, NY<sup>109C</sup>CO, NY<sup>109D</sup>COO or CO wherein Y<sup>109A </sup>to Y<sup>109D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>44 </sup>is an integer from 1 to 5; p<sup>45 </sup>is an integer from 0 to 5; p<sup>46 </sup>is an integer from 1 to 5; p<sup>47 </sup>is an integer from 0 to 5; p<sup>48 </sup>is an integer from 1 to 5; and p<sup>49 </sup>is an integer from 1 to 5;</div>
<div class="claim-text">J<sup>3 </sup>is CY<sup>110 </sup>or N wherein Y<sup>110 </sup>is a hydrogen atom, hydroxy, optionally substituted C1-C4 alkyl, optionally substituted C1-C4 alkoxy, or optionally substituted C1-C4 acyloxy;</div>
<div class="claim-text">X<sup>14 </sup>and X<sup>15 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; and</div>
<div class="claim-text">A<sup>4 </sup>is a pharmaceutically acceptable anion,</div>
</div>
        <div class="claim-text">formula (V) or formula (V)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00296" num="00296">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/90/e5/07/71a256811894ac/US20200368173A1-20201126-C00296.png"><img id="EMI-C00296" he="86.02mm" wi="61.13mm" file="US20200368173A1-20201126-C00296.TIF" alt="Figure US20200368173A1-20201126-C00296" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="245" height="344" alt="Figure US20200368173A1-20201126-C00296" class="patent-full-image" src="https://patentimages.storage.googleapis.com/90/e5/07/71a256811894ac/US20200368173A1-20201126-C00296.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00296" attachment-type="cdx" file="US20200368173A1-20201126-C00296.CDX"> </attachment>
            <attachment idref="CHEM-US-00296" attachment-type="mol" file="US20200368173A1-20201126-C00296.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>13 </sup>to R<sup>18 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">Y<sup>111 </sup>to Y<sup>114 </sup>are the same or different and are each a hydrogen atom, hydroxy or optionally substituted C1-C4 alkyl;</div>
<div class="claim-text">L<sup>17 </sup>to L<sup>19 </sup>and L<sup>22 </sup>to L<sup>24 </sup>are the same or different and are each absent, or Z<sup>32</sup>(CY<sup>115</sup>Y<sup>116</sup>)<sub>p51</sub> or Z<sup>33</sup>(CY<sup>117</sup>Y<sup>118</sup>)<sub>p52</sub>Z<sup>34</sup>(CY<sup>119</sup>Y<sup>120</sup>)<sub>p53</sub> wherein Y<sup>115 </sup>to Y<sup>120 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>32 </sup>to Z<sup>34 </sup>are the same or different and are each O, NY<sup>121A</sup>, COO, OCO, CONY<sup>121B</sup>, NY<sup>121C</sup>CO, NY<sup>121D</sup>COO or CO wherein Y<sup>121A </sup>to Y<sup>121D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>51 </sup>is an integer from 0 to 5; p<sup>52 </sup>is an integer from 1 to 5; and p<sup>53 </sup>is an integer from 0 to 5;</div>
<div class="claim-text">L<sup>20 </sup>and L<sup>25 </sup>are the same or different and are each absent, or (CY<sup>122</sup>Y<sup>123</sup>)<sub>p54</sub>, (CY<sup>124</sup>Y<sup>125</sup>)<sub>p55</sub>Z<sup>35</sup>(CY<sup>126</sup>Y<sup>127</sup>)<sub>p56</sub> or (CY<sup>128</sup>Y<sup>129</sup>)<sub>p57</sub>Z<sup>36</sup>(CY<sup>130</sup>Y<sup>131</sup>)<sub>p58</sub>Z<sup>37</sup>(CY<sup>132</sup>Y<sup>133</sup>)<sub>p59</sub> wherein Y<sup>122 </sup>to Y<sup>133 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>35 </sup>to Z<sup>37 </sup>are the same or different and are each O, NY<sup>134A</sup>, COO, OCO, CONY<sup>134B</sup>, NY<sup>134C</sup>CO, NY<sup>134D</sup>COO or CO wherein Y<sup>134A </sup>to Y<sup>134D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>54 </sup>is an integer from 1 to 5; p<sup>55 </sup>is an integer from 0 to 5; p<sup>56 </sup>is an integer from 1 to 5; p<sup>57 </sup>is an integer from 0 to 5; p<sup>58 </sup>is an integer from 1 to 5; and p<sup>59 </sup>is an integer from 1 to 5;</div>
<div class="claim-text">L<sup>21 </sup>and L<sup>26 </sup>are the same or different and are each absent, or (CY<sup>135</sup>Y<sup>136</sup>)<sub>p60</sub>, (CY<sup>137</sup>Y<sup>138</sup>)<sub>p61</sub>Z<sup>38</sup>(CY<sup>139</sup>Y<sup>140</sup>)<sub>p62</sub> or (CY<sup>141</sup>Y<sup>142</sup>)<sub>p63</sub>Z<sup>39</sup>(CY<sup>143</sup>Y<sup>144</sup>)<sub>p64</sub>Z<sup>40</sup>(CY<sup>145</sup>Y<sup>146</sup>)<sub>p65</sub> wherein Y<sup>135 </sup>to Y<sup>146 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>38 </sup>to Z<sup>40 </sup>are the same or different and are each O, NY<sup>147A</sup>, COO, OCO, CONY<sup>147B</sup>, NR<sup>147C</sup>CO, NY<sup>147D</sup>COO or CO wherein Y<sup>147A </sup>to Y<sup>147D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>60 </sup>is an integer from 1 to 5; p<sup>61 </sup>is an integer from 0 to 5; p<sup>62 </sup>is an integer from 0 to 5; p<sup>63 </sup>is an integer from 0 to 5; p<sup>64 </sup>is an integer from 1 to 5; and p<sup>65 </sup>is an integer from 0 to 5;</div>
<div class="claim-text">B<sup>3 </sup>and B<sup>4 </sup>are the same or different and are each</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00297" num="00297">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/40/05/29/946dc44ed1a11f/US20200368173A1-20201126-C00297.png"><img id="EMI-C00297" he="67.14mm" wi="59.27mm" file="US20200368173A1-20201126-C00297.TIF" alt="Figure US20200368173A1-20201126-C00297" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="237" height="269" alt="Figure US20200368173A1-20201126-C00297" class="patent-full-image" src="https://patentimages.storage.googleapis.com/40/05/29/946dc44ed1a11f/US20200368173A1-20201126-C00297.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00297" attachment-type="cdx" file="US20200368173A1-20201126-C00297.CDX"> </attachment>
            <attachment idref="CHEM-US-00297" attachment-type="mol" file="US20200368173A1-20201126-C00297.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>16 </sup>and X<sup>17 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>18 </sup>is optionally substituted C1-C4 alkyl; X<sup>19 </sup>and X<sup>20 </sup>are the same or different and are each optionally substituted C1-C4 alkyl, or together form an optionally substituted C4-C6 hetero ring with the adjacent nitrogen atom; X<sup>21 </sup>is optionally substituted C1-C4 alkyl; Y<sup>148 </sup>to Y<sup>157 </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; Z<sup>41 </sup>and Z<sup>42 </sup>are the same or different and are each O, NY<sup>158A</sup>, COO, OCO, CONY<sup>158B</sup>, NY<sup>158C</sup>CO or NY<sup>158D</sup>COO wherein Y<sup>158A </sup>to Y<sup>158D </sup>are the same or different and are each a hydrogen atom or optionally substituted C1-C4 alkyl; p<sup>66 </sup>is an integer from 0 to 5; and p<sup>67 </sup>to p<sup>70 </sup>are the same or different and are each an integer from 1 to 5; and
<div class="claim-text">A<sup>5 </sup>and A<sup>6 </sup>are the same or different and are each a pharmaceutically acceptable anion,</div>
</div>
        <div class="claim-text">formula (CL-I)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00298" num="00298">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/3f/d7/4a/987e72467001dc/US20200368173A1-20201126-C00298.png"><img id="EMI-C00298" he="20.57mm" wi="57.15mm" file="US20200368173A1-20201126-C00298.TIF" alt="Figure US20200368173A1-20201126-C00298" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="229" height="82" alt="Figure US20200368173A1-20201126-C00298" class="patent-full-image" src="https://patentimages.storage.googleapis.com/3f/d7/4a/987e72467001dc/US20200368173A1-20201126-C00298.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00298" attachment-type="cdx" file="US20200368173A1-20201126-C00298.CDX"> </attachment>
            <attachment idref="CHEM-US-00298" attachment-type="mol" file="US20200368173A1-20201126-C00298.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>101 </sup>and R<sup>102 </sup>are the same or different and are each linear or branched C10-C24 alkyl, C10-C24 alkenyl or C10-C24 alkynyl;</div>
<div class="claim-text">L<sup>101 </sup>and L<sup>102 </sup>are each a hydrogen atom, or together form a single bond or C2-C8 alkylene;</div>
<div class="claim-text">L<sup>103 </sup>is a single bond, CO or COO;</div>
<div class="claim-text">when L<sup>103 </sup>is a single bond,</div>
<div class="claim-text">X<sup>101 </sup>is a hydrogen atom, C1-C6 alkyl, C3-C6 alkenyl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl; and</div>
<div class="claim-text">when L<sup>103 </sup>is CO or COO,</div>
<div class="claim-text">X<sup>101 </sup>is pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, and at least one of the substituents is amino, monoalkylamino, dialkylamino, trialkylammonio, pyrrolidinyl, piperidyl or morpholinyl,</div>
</div>
        <div class="claim-text">formula (CL-II)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00299" num="00299">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e0/c6/f3/43e2b029070fa2/US20200368173A1-20201126-C00299.png"><img id="EMI-C00299" he="24.64mm" wi="64.94mm" file="US20200368173A1-20201126-C00299.TIF" alt="Figure US20200368173A1-20201126-C00299" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="260" height="99" alt="Figure US20200368173A1-20201126-C00299" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e0/c6/f3/43e2b029070fa2/US20200368173A1-20201126-C00299.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00299" attachment-type="cdx" file="US20200368173A1-20201126-C00299.CDX"> </attachment>
            <attachment idref="CHEM-US-00299" attachment-type="mol" file="US20200368173A1-20201126-C00299.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>103 </sup>and R<sup>104 </sup>are the same or different and are each linear or branched C12-C24 alkyl, C12-C24 alkenyl or C12-C24 alkynyl;</div>
<div class="claim-text">p<sup>101 </sup>and p<sup>102 </sup>are the same or different and are each an integer from 0 to 3;</div>
<div class="claim-text">L<sup>106 </sup>and L<sup>107 </sup>are each a hydrogen atom, or together form a single bond or C2-C8 alkylene;</div>
<div class="claim-text">L<sup>104 </sup>and L<sup>105 </sup>are the same or different and are each O, COO or OCO;</div>
<div class="claim-text">L<sup>108 </sup>is a single bond, CO or COO;</div>
<div class="claim-text">when L<sup>108 </sup>is a single bond,</div>
<div class="claim-text">X<sup>102 </sup>is a hydrogen atom, C1-C6 alkyl, C3-C6 alkenyl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl; and</div>
<div class="claim-text">when L<sup>108 </sup>is CO or COO,</div>
<div class="claim-text">X<sup>102 </sup>is pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, morpholin-2-yl, morpholin-3-yl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, dialkylamino, trialkylammonio, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, pyrrolidinyl, piperidyl and morpholinyl, and at least one of the substituents is amino, monoalkylamino, dialkylamino, trialkylammonio, pyrrolidinyl, piperidyl or morpholinyl,</div>
</div>
        <div class="claim-text">formula (CL-III)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00300" num="00300">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7b/a7/12/ce348c022d7791/US20200368173A1-20201126-C00300.png"><img id="EMI-C00300" he="18.80mm" wi="65.70mm" file="US20200368173A1-20201126-C00300.TIF" alt="Figure US20200368173A1-20201126-C00300" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="263" height="75" alt="Figure US20200368173A1-20201126-C00300" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7b/a7/12/ce348c022d7791/US20200368173A1-20201126-C00300.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00300" attachment-type="cdx" file="US20200368173A1-20201126-C00300.CDX"> </attachment>
            <attachment idref="CHEM-US-00300" attachment-type="mol" file="US20200368173A1-20201126-C00300.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>105 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">R<sup>106 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl or C8-C24 alkynyloxypropyl;</div>
<div class="claim-text">X<sup>103 </sup>and X<sup>104 </sup>are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene, or X<sup>103 </sup>forms C2-C8 alkylene together with L<sup>111</sup>;</div>
<div class="claim-text">L<sup>111 </sup>is a hydrogen atom, C1-C6 alkyl, C3-C6 alkenyl, amino, monoalkylamino, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl, dialkylcarbamoyl, or C1-C6 alkyl or C3-C6 alkenyl substituted with one to three same or different substituents selected from amino, monoalkylamino, hydroxy, alkoxy, carbamoyl, monoalkylcarbamoyl and dialkylcarbamoyl, or forms C2-C8 alkylene together with X<sup>103</sup>;</div>
<div class="claim-text">L<sup>109 </sup>is C1-C6 alkylene;</div>
<div class="claim-text">L<sup>110 </sup>is a single bond, or C1-C6 alkylene, provided that the sum of the numbers of carbon atoms of L<sup>109 </sup>and L<sup>110 </sup>is 7 or less; when L<sup>111 </sup>is a hydrogen atom, L<sup>110 </sup>is a single bond; and when L<sup>111 </sup>forms C2-C6 alkylene together with X<sup>103</sup>, L<sup>110 </sup>is a single bond, or methylene or ethylene,</div>
</div>
        <div class="claim-text">formula (CL-IV)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00301" num="00301">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/36/30/22/5fffdf80ed150c/US20200368173A1-20201126-C00301.png"><img id="EMI-C00301" he="11.26mm" wi="50.72mm" file="US20200368173A1-20201126-C00301.TIF" alt="Figure US20200368173A1-20201126-C00301" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="203" height="45" alt="Figure US20200368173A1-20201126-C00301" class="patent-full-image" src="https://patentimages.storage.googleapis.com/36/30/22/5fffdf80ed150c/US20200368173A1-20201126-C00301.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00301" attachment-type="cdx" file="US20200368173A1-20201126-C00301.CDX"> </attachment>
            <attachment idref="CHEM-US-00301" attachment-type="mol" file="US20200368173A1-20201126-C00301.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>107 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">R<sup>108 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyloxyethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl, C8-C24 alkynyloxypropyl, C8-C24 alkyl oxy ethoxy ethyl, C8-C24 alkenyloxyethoxyethyl or C8-C24 alkynyloxyethoxyethyl; and</div>
<div class="claim-text">X<sup>105 </sup>is a hydrogen atom or optionally substituted C1-C4 alkyl,</div>
</div>
        <div class="claim-text">formula (CL-V)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00302" num="00302">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/9a/bb/6c/f19ee550cc3f9d/US20200368173A1-20201126-C00302.png"><img id="EMI-C00302" he="11.51mm" wi="58.17mm" file="US20200368173A1-20201126-C00302.TIF" alt="Figure US20200368173A1-20201126-C00302" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="233" height="46" alt="Figure US20200368173A1-20201126-C00302" class="patent-full-image" src="https://patentimages.storage.googleapis.com/9a/bb/6c/f19ee550cc3f9d/US20200368173A1-20201126-C00302.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00302" attachment-type="cdx" file="US20200368173A1-20201126-C00302.CDX"> </attachment>
            <attachment idref="CHEM-US-00302" attachment-type="mol" file="US20200368173A1-20201126-C00302.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>109 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">R<sup>110 </sup>is linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkyloxyethyl, C8-C24 alkyloxypropyl, C8-C24 alkenyl oxy ethyl, C8-C24 alkenyloxypropyl, C8-C24 alkynyloxyethyl or C8-C24 alkynyloxypropyl;</div>
<div class="claim-text">L<sup>112 </sup>is C1-C3 alkylene; and</div>
<div class="claim-text">X<sup>105</sup> is a hydrogen atom or C1-C3 alkyl,</div>
</div>
        <div class="claim-text">formula (CL-VI)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00303" num="00303">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/d5/ce/c4/5b2ec8446f177c/US20200368173A1-20201126-C00303.png"><img id="EMI-C00303" he="20.57mm" wi="61.38mm" file="US20200368173A1-20201126-C00303.TIF" alt="Figure US20200368173A1-20201126-C00303" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="246" height="82" alt="Figure US20200368173A1-20201126-C00303" class="patent-full-image" src="https://patentimages.storage.googleapis.com/d5/ce/c4/5b2ec8446f177c/US20200368173A1-20201126-C00303.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00303" attachment-type="cdx" file="US20200368173A1-20201126-C00303.CDX"> </attachment>
            <attachment idref="CHEM-US-00303" attachment-type="mol" file="US20200368173A1-20201126-C00303.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>111 </sup>and R<sup>112 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">X<sup>106 </sup>and X<sup>107 </sup>are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene;</div>
<div class="claim-text">p<sup>103</sup>, p<sup>104 </sup>and p<sup>105 </sup>are the same or different and are each 0 or 1, provided that p<sup>103</sup>, p<sup>104 </sup>and p<sup>105 </sup>are not 0 at the same time; and</div>
<div class="claim-text">L<sup>113 </sup>and L<sup>114 </sup>are the same or different and are each O, S or NH,</div>
</div>
        <div class="claim-text">formula (CL-VII)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00304" num="00304">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/64/ed/8b/3d568c0cd2b27a/US20200368173A1-20201126-C00304.png"><img id="EMI-C00304" he="15.16mm" wi="60.45mm" file="US20200368173A1-20201126-C00304.TIF" alt="Figure US20200368173A1-20201126-C00304" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="242" height="61" alt="Figure US20200368173A1-20201126-C00304" class="patent-full-image" src="https://patentimages.storage.googleapis.com/64/ed/8b/3d568c0cd2b27a/US20200368173A1-20201126-C00304.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00304" attachment-type="cdx" file="US20200368173A1-20201126-C00304.CDX"> </attachment>
            <attachment idref="CHEM-US-00304" attachment-type="mol" file="US20200368173A1-20201126-C00304.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>113 </sup>and R<sup>114 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">R<sup>115 </sup>is a hydrogen atom, hydroxy, optionally substituted C1-C4 alkyl, C1-C4 alkoxy or C1-C4 acyloxy;</div>
<div class="claim-text">X<sup>109 </sup>and X<sup>110 </sup>are the same or different and are each C1-C3 alkyl, or together form C2-C8 alkylene;</div>
<div class="claim-text">L<sup>115 </sup>is COO, OCO, NHCO or CONH;</div>
<div class="claim-text">p<sup>106 </sup>is an integer from 0 to 3; and</div>
<div class="claim-text">p<sup>107 </sup>is an integer from 1 to 4,</div>
</div>
        <div class="claim-text">formula (CL-VIII)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00305" num="00305">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/e9/ee/1f/7395622372bc47/US20200368173A1-20201126-C00305.png"><img id="EMI-C00305" he="24.47mm" wi="54.69mm" file="US20200368173A1-20201126-C00305.TIF" alt="Figure US20200368173A1-20201126-C00305" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="219" height="98" alt="Figure US20200368173A1-20201126-C00305" class="patent-full-image" src="https://patentimages.storage.googleapis.com/e9/ee/1f/7395622372bc47/US20200368173A1-20201126-C00305.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00305" attachment-type="cdx" file="US20200368173A1-20201126-C00305.CDX"> </attachment>
            <attachment idref="CHEM-US-00305" attachment-type="mol" file="US20200368173A1-20201126-C00305.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>116 </sup>and R<sup>117 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C7-C20 alkyloxy C1-C3 alkyl, C7-C20 alkenyl oxy C1-C3 alkyl or C7-C20 alkynyloxy C1-C3 alkyl;</div>
<div class="claim-text">B<sup>100 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, C1-C3 dialkylamino C2-C4 alkyl, formula (A):</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00306" num="00306">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/c3/1c/62/cc7e3e368a91ad/US20200368173A1-20201126-C00306.png"><img id="EMI-C00306" he="18.80mm" wi="54.10mm" file="US20200368173A1-20201126-C00306.TIF" alt="Figure US20200368173A1-20201126-C00306" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="216" height="75" alt="Figure US20200368173A1-20201126-C00306" class="patent-full-image" src="https://patentimages.storage.googleapis.com/c3/1c/62/cc7e3e368a91ad/US20200368173A1-20201126-C00306.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00306" attachment-type="cdx" file="US20200368173A1-20201126-C00306.CDX"> </attachment>
            <attachment idref="CHEM-US-00306" attachment-type="mol" file="US20200368173A1-20201126-C00306.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>111 </sup>and X<sup>112 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>111 </sup>and X<sup>112 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>110 </sup>is an integer from 2 to 6,</div>
        <div class="claim-text">or formula (B):</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00307" num="00307">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/84/43/e3/35c9266c13e7a6/US20200368173A1-20201126-C00307.png"><img id="EMI-C00307" he="14.48mm" wi="51.65mm" file="US20200368173A1-20201126-C00307.TIF" alt="Figure US20200368173A1-20201126-C00307" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="58" alt="Figure US20200368173A1-20201126-C00307" class="patent-full-image" src="https://patentimages.storage.googleapis.com/84/43/e3/35c9266c13e7a6/US20200368173A1-20201126-C00307.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00307" attachment-type="cdx" file="US20200368173A1-20201126-C00307.CDX"> </attachment>
            <attachment idref="CHEM-US-00307" attachment-type="mol" file="US20200368173A1-20201126-C00307.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>113 </sup>and X<sup>114 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>113 </sup>and X<sup>114 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>111 </sup>is an integer from 1 to 6;
<div class="claim-text">P<sup>108 </sup>is an integer from 0 to 4; P<sup>109 </sup>is an integer from 1 to 4, provided that when P<sup>108 </sup>is 0, P<sup>109 </sup>is not 1;</div>
<div class="claim-text">L<sup>116 </sup>is the same or different on each carbon to which it is bonded and is a hydrogen atom or C1-C3 alkyl; and</div>
<div class="claim-text">L<sup>117 </sup>is the same or different on each carbon to which it is bonded and is a hydrogen atom or C1-C3 alkyl,</div>
</div>
        <div class="claim-text">formula (CL-IX)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00308" num="00308">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/b9/4a/4b/567d31407fe668/US20200368173A1-20201126-C00308.png"><img id="EMI-C00308" he="20.49mm" wi="64.26mm" file="US20200368173A1-20201126-C00308.TIF" alt="Figure US20200368173A1-20201126-C00308" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="257" height="82" alt="Figure US20200368173A1-20201126-C00308" class="patent-full-image" src="https://patentimages.storage.googleapis.com/b9/4a/4b/567d31407fe668/US20200368173A1-20201126-C00308.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00308" attachment-type="cdx" file="US20200368173A1-20201126-C00308.CDX"> </attachment>
            <attachment idref="CHEM-US-00308" attachment-type="mol" file="US20200368173A1-20201126-C00308.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">X<sup>115 </sup>and X<sup>116 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl;</div>
<div class="claim-text">L<sup>118 </sup>and L<sup>119 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkylene or C8-C24 alkenylene;</div>
<div class="claim-text">M<sup>101 </sup>and M<sup>102 </sup>are the same or different and are each selected from the group consisting of CC, OC(O), C(O)O, SC(O), C(O)S, OC(S), C(S)O, SS, C(R)N, NC(R), C(R)NO, ONC(R), N(R)C(O), C(O)N(R), N(R)C(S), C(S)N(R), N(R)C(O)N(R), N(R)C(O)O, OC(O)N(R) and OC(O)O;</div>
<div class="claim-text">R and R are the same or different and are each a hydrogen atom or C1-C3 alkyl; and</div>
<div class="claim-text">R<sup>118 </sup>and R<sup>119 </sup>are the same or different and are each optionally substituted linear or branched C1-C16 alkyl or C2-C16 alkenyl,</div>
</div>
        <div class="claim-text">formula (CL-X)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00309" num="00309">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/29/63/bb/1ec8ed6f6376f4/US20200368173A1-20201126-C00309.png"><img id="EMI-C00309" he="21.59mm" wi="56.90mm" file="US20200368173A1-20201126-C00309.TIF" alt="Figure US20200368173A1-20201126-C00309" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="228" height="86" alt="Figure US20200368173A1-20201126-C00309" class="patent-full-image" src="https://patentimages.storage.googleapis.com/29/63/bb/1ec8ed6f6376f4/US20200368173A1-20201126-C00309.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00309" attachment-type="cdx" file="US20200368173A1-20201126-C00309.CDX"> </attachment>
            <attachment idref="CHEM-US-00309" attachment-type="mol" file="US20200368173A1-20201126-C00309.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">X<sup>117 </sup>and X<sup>118 </sup>are the same or different and are each a hydrogen atom, optionally substituted C1-C6 alkyl, heterocyclyl or polyamine, or X<sup>117 </sup>and X<sup>118 </sup>optionally form, together with the nitrogen to which they are bonded, a 4- to 7-membered monocyclic hetero ring optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen; and</div>
<div class="claim-text">R<sup>120 </sup>and R<sup>121 </sup>are the same or different and are each optionally substituted linear or branched C4-C24 alkyl or C4-C24 alkenyl,</div>
</div>
        <div class="claim-text">formula (CL-XI)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00310" num="00310">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/7c/37/22/9063784ddd47a5/US20200368173A1-20201126-C00310.png"><img id="EMI-C00310" he="20.15mm" wi="69.17mm" file="US20200368173A1-20201126-C00310.TIF" alt="Figure US20200368173A1-20201126-C00310" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="277" height="81" alt="Figure US20200368173A1-20201126-C00310" class="patent-full-image" src="https://patentimages.storage.googleapis.com/7c/37/22/9063784ddd47a5/US20200368173A1-20201126-C00310.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00310" attachment-type="cdx" file="US20200368173A1-20201126-C00310.CDX"> </attachment>
            <attachment idref="CHEM-US-00310" attachment-type="mol" file="US20200368173A1-20201126-C00310.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">X<sup>119 </sup>and X<sup>120 </sup>are the same or different and are each a hydrogen atom, optionally substituted linear or branched C1-C20 alkyl, C1-C20 alkenyl, C1-C20 alkynyl or C6-C20 acyl;</div>
<div class="claim-text">R<sup>122 </sup>and R<sup>123 </sup>are the same or different and are each optionally substituted linear or branched C1-C30 alkyl, C2-C30 alkenyl or C2-C30 alkynyl; and</div>
<div class="claim-text">p<sup>112</sup>, p<sup>113 </sup>and p<sup>114 </sup>are the same or different and are each 0, or an arbitrary positive integer,</div>
</div>
        <div class="claim-text">formula (CL-XII)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00311" num="00311">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/0e/b1/21/6646fc3b95ca00/US20200368173A1-20201126-C00311.png"><img id="EMI-C00311" he="16.43mm" wi="60.20mm" file="US20200368173A1-20201126-C00311.TIF" alt="Figure US20200368173A1-20201126-C00311" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="241" height="66" alt="Figure US20200368173A1-20201126-C00311" class="patent-full-image" src="https://patentimages.storage.googleapis.com/0e/b1/21/6646fc3b95ca00/US20200368173A1-20201126-C00311.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00311" attachment-type="cdx" file="US20200368173A1-20201126-C00311.CDX"> </attachment>
            <attachment idref="CHEM-US-00311" attachment-type="mol" file="US20200368173A1-20201126-C00311.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">X<sup>121 </sup>and X<sup>122 </sup>are the same or different and are each a hydrogen atom, C1-C6 alkyl, cycloalkyl or cycloalkenyl, or X<sup>121 </sup>and X<sup>122 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded;</div>
<div class="claim-text">L<sup>120 </sup>and L<sup>121 </sup>are the same or different and are each O, OC(O) or (O)CO; and</div>
<div class="claim-text">R<sup>124 </sup>and R<sup>125 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl or C8-C24 alkenyl,</div>
</div>
        <div class="claim-text">formula (CL-XIII)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00312" num="00312">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/98/1d/6f/f71bc0ebed5d4b/US20200368173A1-20201126-C00312.png"><img id="EMI-C00312" he="14.82mm" wi="53.59mm" file="US20200368173A1-20201126-C00312.TIF" alt="Figure US20200368173A1-20201126-C00312" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="214" height="59" alt="Figure US20200368173A1-20201126-C00312" class="patent-full-image" src="https://patentimages.storage.googleapis.com/98/1d/6f/f71bc0ebed5d4b/US20200368173A1-20201126-C00312.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00312" attachment-type="cdx" file="US20200368173A1-20201126-C00312.CDX"> </attachment>
            <attachment idref="CHEM-US-00312" attachment-type="mol" file="US20200368173A1-20201126-C00312.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>126 </sup>and R<sup>127 </sup>are the same or different and are each optionally substituted linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 heteroalkyl, C8-C24 heteroalkenyl or C8-C24 heteroalkynyl;</div>
<div class="claim-text">X<sup>123 </sup>is a hydrogen atom or optionally substituted C1-C6 alkyl;</div>
<div class="claim-text">X<sup>124 </sup>is C1-C6 alkyl, substituted C1-C6 alkyl which is substituted with NR<sup>4a</sup>R<sup>4b</sup>, or optionally substituted C3-C7 heterocyclyl;</div>
<div class="claim-text">R<sup>4a </sup>and R<sup>4b </sup>are the same or different and are each a hydrogen atom, C(NH)NH<sub>2 </sub>or optionally substituted C1-C6 alkyl, or R<sup>4a </sup>and R<sup>4b </sup>optionally form optionally substituted C3-C7 heterocyclyl;</div>
<div class="claim-text">X<sup>123 </sup>and X<sup>124 </sup>optionally form optionally substituted C3-C7 heterocyclyl together with the nitrogen atom to which they are bonded,</div>
<div class="claim-text">provided that X<sup>123 </sup>and X<sup>124 </sup>do not form imidazolyl, benzimidazolyl, or succinimidyl, and only one primary amine is allowed to be present on any one of X<sup>123 </sup>and X<sup>124</sup>, or any primary amine is not present on any one of X<sup>123 </sup>and X<sup>124</sup>, and neither X<sup>123 </sup>nor X<sup>124 </sup>is substituted amide;</div>
<div class="claim-text">when each of R<sup>126 </sup>and R<sup>127 </sup>is C11 alkyl or C15 alkyl, X<sup>123 </sup>is not a hydrogen atom;</div>
<div class="claim-text">when each of R<sup>126 </sup>and R<sup>127 </sup>is C16 alkyl or C17 alkyl, R<sup>126 </sup>and R<sup>127 </sup>are not substituted with OH;</div>
<div class="claim-text">when each of R<sup>126 </sup>and R<sup>127 </sup>is C17 alkyl, X<sup>123 </sup>and X<sup>124 </sup>are not substituted with OH; and</div>
<div class="claim-text">when each of R<sup>126 </sup>and R<sup>127 </sup>is C18 alkyl, X<sup>124 </sup>is not substituted with optionally substituted imidazolyl,</div>
</div>
        <div class="claim-text">formula (CL-XIV)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00313" num="00313">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4b/b1/87/5fb3b0446b583e/US20200368173A1-20201126-C00313.png"><img id="EMI-C00313" he="21.84mm" wi="61.21mm" file="US20200368173A1-20201126-C00313.TIF" alt="Figure US20200368173A1-20201126-C00313" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="245" height="87" alt="Figure US20200368173A1-20201126-C00313" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4b/b1/87/5fb3b0446b583e/US20200368173A1-20201126-C00313.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00313" attachment-type="cdx" file="US20200368173A1-20201126-C00313.CDX"> </attachment>
            <attachment idref="CHEM-US-00313" attachment-type="mol" file="US20200368173A1-20201126-C00313.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">X<sup>125 </sup>and X<sup>126 </sup>are the same or different and are each a hydrogen atom, optionally substituted C1-C6 alkyl, heterocyclyl or polyamine, or X<sup>125 </sup>and X<sup>126 </sup>optionally form, together with the nitrogen to which they are bonded, a 4- to 7-membered monocyclic hetero ring optionally containing one or two additional heteroatoms selected from N, O and S in addition to the nitrogen;</div>
<div class="claim-text">R<sup>130 </sup>is a hydrogen atom or C1-C6 alkyl; and</div>
<div class="claim-text">R<sup>128 </sup>and R<sup>129 </sup>are the same or different and are each optionally substituted linear or branched C4-C24 alkyl or C4-C24 alkenyl,</div>
</div>
        <div class="claim-text">formula (CL-XV)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00314" num="00314">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ea/1c/6e/50bca7dcdf9c27/US20200368173A1-20201126-C00314.png"><img id="EMI-C00314" he="17.78mm" wi="60.28mm" file="US20200368173A1-20201126-C00314.TIF" alt="Figure US20200368173A1-20201126-C00314" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="241" height="71" alt="Figure US20200368173A1-20201126-C00314" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ea/1c/6e/50bca7dcdf9c27/US20200368173A1-20201126-C00314.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00314" attachment-type="cdx" file="US20200368173A1-20201126-C00314.CDX"> </attachment>
            <attachment idref="CHEM-US-00314" attachment-type="mol" file="US20200368173A1-20201126-C00314.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">X<sup>127 </sup>and X<sup>128 </sup>are each independently C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl, or</div>
<div class="claim-text">X<sup>127 </sup>and X<sup>128 </sup>form, together with the nitrogen atom to which they are bonded, a hetero ring having one or two nitrogen atoms;</div>
<div class="claim-text">L<sup>122 </sup>is C(O)O, OC(O), C(O)N(X<sup>130</sup>), N(X<sup>130</sup>)C(O), OC(O)O, OC(O)N(X<sup>130</sup>), N(X<sup>130</sup>)C(O)N(X<sup>130</sup>), or N(X<sup>130</sup>)C(O)O;</div>
<div class="claim-text">each X<sup>130 </sup>present is independently a hydrogen atom or C1-C3 alkyl;</div>
<div class="claim-text">a is 1, 2, 3, 4, 5, or 6;</div>
<div class="claim-text">b is 0, 1, 2, or 3;</div>
<div class="claim-text">X<sup>129 </sup>is absent, or hydrogen or C1-C3 alkyl;</div>
<div class="claim-text">R<sup>131 </sup>and R<sup>132 </sup>are each independently alkyl having 12 to 24 carbon atoms, alkenyl having 12 to 24 carbon atoms, or alkoxy having 12 to 24 carbon atoms, which has one or more biodegradable groups; each biodegradable group independently interrupts the alkyl group, the alkenyl group, or the alkoxy group having 12 to 24 carbon atoms, or substitutes a terminal of the alkyl group, the alkenyl group, or the alkoxy group having 12 to 24 carbon atoms (wherein the interrupting biodegradable group is C(O)O, OC(O), C(O)N(X<sup>130</sup>), or N(X<sup>130</sup>)C(O), and the group having the terminal biodegradable group is C(O)OC1-C4 alkyl, OC(O)C1-C4 alkyl, C(O)N(X<sup>130</sup>)C1-C4 alkyl, or N(X<sup>130</sup>)C(O)C1-C4 alkyl); and</div>
<div class="claim-text">R<sup>131 </sup>and R<sup>132 </sup>each have at least four carbon atoms between the biodegradable group and the asterisked (*) tertiary carbon atom,</div>
</div>
        <div class="claim-text">formula (CL-XVI)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00315" num="00315">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/fd/55/08/faf3cc13ea099a/US20200368173A1-20201126-C00315.png"><img id="EMI-C00315" he="32.26mm" wi="73.41mm" file="US20200368173A1-20201126-C00315.TIF" alt="Figure US20200368173A1-20201126-C00315" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="294" height="129" alt="Figure US20200368173A1-20201126-C00315" class="patent-full-image" src="https://patentimages.storage.googleapis.com/fd/55/08/faf3cc13ea099a/US20200368173A1-20201126-C00315.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00315" attachment-type="cdx" file="US20200368173A1-20201126-C00315.CDX"> </attachment>
            <attachment idref="CHEM-US-00315" attachment-type="mol" file="US20200368173A1-20201126-C00315.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>133 </sup>and R<sup>134 </sup>are the same or different and are each linear or branched C1-C9 alkyl, C2-C11 alkenyl or C2-C11 alkynyl;</div>
<div class="claim-text">L<sup>123 </sup>and L<sup>124 </sup>are the same or different and are each linear C5-C18 alkylene or linear C5-C18 alkenylene, or forms a hetero ring with N;</div>
<div class="claim-text">L<sup>125 </sup>is a single bond, or COO, thereby forming -L<sup>124</sup>-COOR<sup>134</sup>;</div>
<div class="claim-text">L<sup>127 </sup>is S or O;</div>
<div class="claim-text">L<sup>126 </sup>is a single bond or linear or branched C1-C6 alkylene, or forms a hetero ring with N;</div>
<div class="claim-text">L<sup>128 </sup>is linear or branched C1-C6 alkyl ene; and</div>
<div class="claim-text">X<sup>131 </sup>and X<sup>132 </sup>are the same or different and are each hydrogen or linear or branched C1-C6 alkyl,</div>
</div>
        <div class="claim-text">formula (CL-XVII)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00316" num="00316">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/cb/8d/b2/fb68379a21af8f/US20200368173A1-20201126-C00316.png"><img id="EMI-C00316" he="28.19mm" wi="67.56mm" file="US20200368173A1-20201126-C00316.TIF" alt="Figure US20200368173A1-20201126-C00316" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="270" height="113" alt="Figure US20200368173A1-20201126-C00316" class="patent-full-image" src="https://patentimages.storage.googleapis.com/cb/8d/b2/fb68379a21af8f/US20200368173A1-20201126-C00316.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00316" attachment-type="cdx" file="US20200368173A1-20201126-C00316.CDX"> </attachment>
            <attachment idref="CHEM-US-00316" attachment-type="mol" file="US20200368173A1-20201126-C00316.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">L<sup>131 </sup>is C2-C4 alkyl ene or CH<sub>2</sub>SCH<sub>2</sub>CH<sub>2</sub>;</div>
<div class="claim-text">L<sup>129 </sup>and L<sup>130 </sup>are the same or different and are each C1-C6 alkyl;</div>
<div class="claim-text">R<sup>135 </sup>and R<sup>136 </sup>are the same or different and are each C10-C30 alkyl or C10-C30 alkenyl; and</div>
<div class="claim-text">X<sup>133 </sup>and X<sup>134 </sup>are the same or different and are each hydrogen, C1-C6 alkyl or CH<sub>2</sub>CH<sub>2</sub>OH,</div>
</div>
        <div class="claim-text">formula (CL-XVIII)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00317" num="00317">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/23/1a/45/49049af68c1d8f/US20200368173A1-20201126-C00317.png"><img id="EMI-C00317" he="15.83mm" wi="58.59mm" file="US20200368173A1-20201126-C00317.TIF" alt="Figure US20200368173A1-20201126-C00317" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="234" height="63" alt="Figure US20200368173A1-20201126-C00317" class="patent-full-image" src="https://patentimages.storage.googleapis.com/23/1a/45/49049af68c1d8f/US20200368173A1-20201126-C00317.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00317" attachment-type="cdx" file="US20200368173A1-20201126-C00317.CDX"> </attachment>
            <attachment idref="CHEM-US-00317" attachment-type="mol" file="US20200368173A1-20201126-C00317.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>137 </sup>and R<sup>138 </sup>are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, C8-24 alkenylthioethyl, or C8-C24 alkynylthioethyl;</div>
<div class="claim-text">X<sup>135 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (C):</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00318" num="00318">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/5b/9b/b9/3918d509b27eb1/US20200368173A1-20201126-C00318.png"><img id="EMI-C00318" he="18.20mm" wi="54.69mm" file="US20200368173A1-20201126-C00318.TIF" alt="Figure US20200368173A1-20201126-C00318" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="219" height="73" alt="Figure US20200368173A1-20201126-C00318" class="patent-full-image" src="https://patentimages.storage.googleapis.com/5b/9b/b9/3918d509b27eb1/US20200368173A1-20201126-C00318.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00318" attachment-type="cdx" file="US20200368173A1-20201126-C00318.CDX"> </attachment>
            <attachment idref="CHEM-US-00318" attachment-type="mol" file="US20200368173A1-20201126-C00318.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>136 </sup>and X<sup>137 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>136 </sup>and X<sup>137 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; L<sup>132 </sup>is S or O; and p<sup>115 </sup>is an integer from 2 to 4,</div>
        <div class="claim-text">formula (D):</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00319" num="00319">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/a1/30/6b/48dcaf6f38beb2/US20200368173A1-20201126-C00319.png"><img id="EMI-C00319" he="14.48mm" wi="51.73mm" file="US20200368173A1-20201126-C00319.TIF" alt="Figure US20200368173A1-20201126-C00319" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="58" alt="Figure US20200368173A1-20201126-C00319" class="patent-full-image" src="https://patentimages.storage.googleapis.com/a1/30/6b/48dcaf6f38beb2/US20200368173A1-20201126-C00319.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00319" attachment-type="cdx" file="US20200368173A1-20201126-C00319.CDX"> </attachment>
            <attachment idref="CHEM-US-00319" attachment-type="mol" file="US20200368173A1-20201126-C00319.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>138 </sup>and X<sup>139 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>138 </sup>and X<sup>139 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>116 </sup>is an integer from 1 to 4,</div>
        <div class="claim-text">or formula (E):</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00320" num="00320">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/de/73/0b/780e73aa04e8eb/US20200368173A1-20201126-C00320.png"><img id="EMI-C00320" he="14.39mm" wi="51.56mm" file="US20200368173A1-20201126-C00320.TIF" alt="Figure US20200368173A1-20201126-C00320" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="206" height="58" alt="Figure US20200368173A1-20201126-C00320" class="patent-full-image" src="https://patentimages.storage.googleapis.com/de/73/0b/780e73aa04e8eb/US20200368173A1-20201126-C00320.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00320" attachment-type="cdx" file="US20200368173A1-20201126-C00320.CDX"> </attachment>
            <attachment idref="CHEM-US-00320" attachment-type="mol" file="US20200368173A1-20201126-C00320.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>140 </sup>and X<sup>141 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>140 </sup>and X<sup>141 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>117 </sup>is an integer from 1 to 4, and</div>
        <div class="claim-text">formula (CL-XIX)</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00321" num="00321">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ae/4a/e0/da2f8c71219037/US20200368173A1-20201126-C00321.png"><img id="EMI-C00321" he="17.19mm" wi="59.44mm" file="US20200368173A1-20201126-C00321.TIF" alt="Figure US20200368173A1-20201126-C00321" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="238" height="69" alt="Figure US20200368173A1-20201126-C00321" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ae/4a/e0/da2f8c71219037/US20200368173A1-20201126-C00321.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00321" attachment-type="cdx" file="US20200368173A1-20201126-C00321.CDX"> </attachment>
            <attachment idref="CHEM-US-00321" attachment-type="mol" file="US20200368173A1-20201126-C00321.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>139 </sup>and R<sup>140 </sup>are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">L<sup>133 </sup>is S or O; and</div>
<div class="claim-text">X<sup>142 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (F):</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00322" num="00322">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/38/71/7c/82a3cc6611b008/US20200368173A1-20201126-C00322.png"><img id="EMI-C00322" he="18.46mm" wi="54.86mm" file="US20200368173A1-20201126-C00322.TIF" alt="Figure US20200368173A1-20201126-C00322" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="219" height="74" alt="Figure US20200368173A1-20201126-C00322" class="patent-full-image" src="https://patentimages.storage.googleapis.com/38/71/7c/82a3cc6611b008/US20200368173A1-20201126-C00322.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00322" attachment-type="cdx" file="US20200368173A1-20201126-C00322.CDX"> </attachment>
            <attachment idref="CHEM-US-00322" attachment-type="mol" file="US20200368173A1-20201126-C00322.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>143 </sup>and X<sup>144 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>143 </sup>and X<sup>144 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; L<sup>134 </sup>is S or O; and p<sup>118 </sup>is an integer from 2 to 4,</div>
        <div class="claim-text">or formula (G):</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00323" num="00323">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/ab/42/25/1884f3b926061e/US20200368173A1-20201126-C00323.png"><img id="EMI-C00323" he="14.48mm" wi="51.73mm" file="US20200368173A1-20201126-C00323.TIF" alt="Figure US20200368173A1-20201126-C00323" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="58" alt="Figure US20200368173A1-20201126-C00323" class="patent-full-image" src="https://patentimages.storage.googleapis.com/ab/42/25/1884f3b926061e/US20200368173A1-20201126-C00323.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00323" attachment-type="cdx" file="US20200368173A1-20201126-C00323.CDX"> </attachment>
            <attachment idref="CHEM-US-00323" attachment-type="mol" file="US20200368173A1-20201126-C00323.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>145 </sup>and X<sup>146 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>145 </sup>and X<sup>146 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>119 </sup>is an integer from 1 to 4.</div>
      </div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00034" num="00034" class="claim">
      <div class="claim-text"> <b>34</b>. The nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00033">claim 33</claim-ref>, wherein the cationic lipid is the lipid B.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00035" num="00035" class="claim">
      <div class="claim-text"> <b>35</b>. The nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>, further comprising a lipid derivative or a fatty acid derivative of a water-soluble polymer.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00036" num="00036" class="claim">
      <div class="claim-text"> <b>36</b>. The nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>, further comprising a neutral lipid.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00037" num="00037" class="claim">
      <div class="claim-text"> <b>37</b>. The nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>, wherein the nucleic acid is a nucleic acid having a silencing effect on a target gene through the use of RNA interference (RNAi).</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00038" num="00038" class="claim">
      <div class="claim-text"> <b>38</b>. A method for stabilizing a nucleic acid-containing lipid nanoparticle using an analog of a fatty acid ester of glycerol, wherein the analog is not hydrolyzable by a lipase.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00039" num="00039" class="claim">
      <div class="claim-text"> <b>39</b>. A method for introducing a nucleic acid into a cell using the nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00040" num="00040" class="claim">
      <div class="claim-text"> <b>40</b>. The method according to <claim-ref idref="CLM-00039">claim 39</claim-ref>, wherein the cell is a cell residing at a mammalian tumor or inflammation site.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00041" num="00041" class="claim">
      <div class="claim-text"> <b>41</b>. The method according to <claim-ref idref="CLM-00039">claim 39</claim-ref>, wherein a method for the introduction into the cell is a method of introduction into the cell by intravenous administration or subcutaneous administration.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00042" num="00042" class="claim">
      <div class="claim-text"> <b>42</b>. A method for treating a cancer or an inflammatory disease, comprising administering the nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref> to a mammal.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00043" num="00043" class="claim">
      <div class="claim-text"> <b>43</b>. The method for treating according to <claim-ref idref="CLM-00042">claim 42</claim-ref>, wherein the administration is intravenous administration or subcutaneous administration.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00044" num="00044" class="claim">
      <div class="claim-text"> <b>44</b>. A medicament comprising the nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00045" num="00045" class="claim">
      <div class="claim-text"> <b>45</b>. The medicament according to <claim-ref idref="CLM-00044">claim 44</claim-ref>, wherein the medicament is intended for intravenous administration or subcutaneous administration.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00046" num="00046" class="claim">
      <div class="claim-text"> <b>46</b>. A therapeutic agent for a cancer or an inflammatory disease, comprising the nucleic acid-containing lipid nanoparticle according to <claim-ref idref="CLM-00028">claim 28</claim-ref>.</div>
    </div>
    </div> <div class="claim-dependent"> <div id="CLM-00047" num="00047" class="claim">
      <div class="claim-text"> <b>47</b>. The therapeutic agent according to <claim-ref idref="CLM-00046">claim 46</claim-ref>, wherein the therapeutic agent is intended for intravenous administration or subcutaneous administration.</div>
    </div>
    </div> <div class="claim"> <div id="CLM-00048" num="00048" class="claim">
      <div class="claim-text"> <b>48</b>. A compound represented by formula (CL-XVIII), or a pharmaceutically acceptable salt thereof:</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00324" num="00324">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/78/41/0c/14e3009f87b244/US20200368173A1-20201126-C00324.png"><img id="EMI-C00324" he="15.83mm" wi="58.59mm" file="US20200368173A1-20201126-C00324.TIF" alt="Figure US20200368173A1-20201126-C00324" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="234" height="63" alt="Figure US20200368173A1-20201126-C00324" class="patent-full-image" src="https://patentimages.storage.googleapis.com/78/41/0c/14e3009f87b244/US20200368173A1-20201126-C00324.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00324" attachment-type="cdx" file="US20200368173A1-20201126-C00324.CDX"> </attachment>
            <attachment idref="CHEM-US-00324" attachment-type="mol" file="US20200368173A1-20201126-C00324.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>137 </sup>and R<sup>138 </sup>are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl, C8-C24 alkynyl, C8-C24 alkylthioethyl, C8-24 alkenylthioethyl, or C8-C24 alkynylthioethyl; and</div>
<div class="claim-text">X<sup>135 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (C):</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00325" num="00325">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/68/a7/e1/3f79cfa39ff533/US20200368173A1-20201126-C00325.png"><img id="EMI-C00325" he="17.95mm" wi="55.03mm" file="US20200368173A1-20201126-C00325.TIF" alt="Figure US20200368173A1-20201126-C00325" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="220" height="72" alt="Figure US20200368173A1-20201126-C00325" class="patent-full-image" src="https://patentimages.storage.googleapis.com/68/a7/e1/3f79cfa39ff533/US20200368173A1-20201126-C00325.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00325" attachment-type="cdx" file="US20200368173A1-20201126-C00325.CDX"> </attachment>
            <attachment idref="CHEM-US-00325" attachment-type="mol" file="US20200368173A1-20201126-C00325.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>136 </sup>and X<sup>137 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>136 </sup>and X<sup>137 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; L<sup>132 </sup>is S or O; and p<sup>115 </sup>is an integer from 2 to 4,</div>
        <div class="claim-text">formula (D):</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00326" num="00326">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/97/13/4a/e3b01d0e07bca5/US20200368173A1-20201126-C00326.png"><img id="EMI-C00326" he="14.48mm" wi="51.73mm" file="US20200368173A1-20201126-C00326.TIF" alt="Figure US20200368173A1-20201126-C00326" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="58" alt="Figure US20200368173A1-20201126-C00326" class="patent-full-image" src="https://patentimages.storage.googleapis.com/97/13/4a/e3b01d0e07bca5/US20200368173A1-20201126-C00326.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00326" attachment-type="cdx" file="US20200368173A1-20201126-C00326.CDX"> </attachment>
            <attachment idref="CHEM-US-00326" attachment-type="mol" file="US20200368173A1-20201126-C00326.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>138 </sup>and X<sup>139 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>138 </sup>and X<sup>139 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>116 </sup>is an integer from 1 to 4,</div>
        <div class="claim-text">or formula (E):</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00327" num="00327">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/4c/53/22/594cb593761308/US20200368173A1-20201126-C00327.png"><img id="EMI-C00327" he="14.48mm" wi="51.56mm" file="US20200368173A1-20201126-C00327.TIF" alt="Figure US20200368173A1-20201126-C00327" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="206" height="58" alt="Figure US20200368173A1-20201126-C00327" class="patent-full-image" src="https://patentimages.storage.googleapis.com/4c/53/22/594cb593761308/US20200368173A1-20201126-C00327.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00327" attachment-type="cdx" file="US20200368173A1-20201126-C00327.CDX"> </attachment>
            <attachment idref="CHEM-US-00327" attachment-type="mol" file="US20200368173A1-20201126-C00327.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>140 </sup>and X<sup>141 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>140 </sup>and X<sup>141 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>117 </sup>is an integer from 1 to 4.</div>
      </div>
    </div>
    </div> <div class="claim"> <div id="CLM-00049" num="00049" class="claim">
      <div class="claim-text"> <b>49</b>. A compound represented by formula (CL-XIX), or a pharmaceutically acceptable salt thereof:</div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00328" num="00328">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/66/73/ae/0886c19640f40c/US20200368173A1-20201126-C00328.png"><img id="EMI-C00328" he="17.53mm" wi="59.61mm" file="US20200368173A1-20201126-C00328.TIF" alt="Figure US20200368173A1-20201126-C00328" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="238" height="70" alt="Figure US20200368173A1-20201126-C00328" class="patent-full-image" src="https://patentimages.storage.googleapis.com/66/73/ae/0886c19640f40c/US20200368173A1-20201126-C00328.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00328" attachment-type="cdx" file="US20200368173A1-20201126-C00328.CDX"> </attachment>
            <attachment idref="CHEM-US-00328" attachment-type="mol" file="US20200368173A1-20201126-C00328.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein
<div class="claim-text">R<sup>139 </sup>and R<sup>140 </sup>are the same or different and are each linear or branched C8-C24 alkyl, C8-C24 alkenyl or C8-C24 alkynyl;</div>
<div class="claim-text">L<sup>133 </sup>is S or O; and</div>
<div class="claim-text">X<sup>142 </sup>is a hydrogen atom, C1-C3 alkyl, hydroxy C2-C4 alkyl, formula (F):</div>
</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00329" num="00329">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/87/df/55/1a3968ea41b482/US20200368173A1-20201126-C00329.png"><img id="EMI-C00329" he="18.46mm" wi="54.86mm" file="US20200368173A1-20201126-C00329.TIF" alt="Figure US20200368173A1-20201126-C00329" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="219" height="74" alt="Figure US20200368173A1-20201126-C00329" class="patent-full-image" src="https://patentimages.storage.googleapis.com/87/df/55/1a3968ea41b482/US20200368173A1-20201126-C00329.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00329" attachment-type="cdx" file="US20200368173A1-20201126-C00329.CDX"> </attachment>
            <attachment idref="CHEM-US-00329" attachment-type="mol" file="US20200368173A1-20201126-C00329.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>143 </sup>and X<sup>144 </sup>are the same or different and are each a hydrogen atom or C1-C3 alkyl, or X<sup>143 </sup>and X<sup>144 </sup>optionally form a C2-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; L<sup>134 </sup>is S or O; and p<sup>118 </sup>is an integer from 2 to 4,</div>
        <div class="claim-text">or formula (G):</div>
      </div>
      <div class="claim-text">
        <chemistry id="CHEM-US-00330" num="00330">
          <div class="patent-image"><a href="https://patentimages.storage.googleapis.com/f6/ad/1b/7bb47c623a8566/US20200368173A1-20201126-C00330.png"><img id="EMI-C00330" he="14.56mm" wi="51.73mm" file="US20200368173A1-20201126-C00330.TIF" alt="Figure US20200368173A1-20201126-C00330" img-content="chem" img-format="tif" orientation="portrait" inline="no" width="207" height="58" alt="Figure US20200368173A1-20201126-C00330" class="patent-full-image" src="https://patentimages.storage.googleapis.com/f6/ad/1b/7bb47c623a8566/US20200368173A1-20201126-C00330.png"/></a></div>
          <attachments>
            <attachment idref="CHEM-US-00330" attachment-type="cdx" file="US20200368173A1-20201126-C00330.CDX"> </attachment>
            <attachment idref="CHEM-US-00330" attachment-type="mol" file="US20200368173A1-20201126-C00330.MOL"> </attachment>
          </attachments>
        </chemistry>
        <div class="claim-text">wherein X<sup>145 </sup>and X<sup>146 </sup>are the same or different and are each a hydrogen atom or C1 to C3 alkyl, or X<sup>145 </sup>and X<sup>146 </sup>optionally form a C3-C6 nitrogen-containing hetero ring together with the nitrogen atom to which they are bonded; and p<sup>119 </sup>is an integer from 1 to 4.</div>
      </div>
    </div>
  </div> </div>
  </div>
  </section>

  <section itemprop="application" itemscope>

    <section itemprop="metadata" itemscope>
      <span itemprop="applicationNumber">US16/636,177</span>
      <span itemprop="priorityDate">2017-08-04</span>
      <span itemprop="filingDate">2018-08-06</span>
      <span itemprop="title">Nucleic acid-containing lipid nanoparticle 
       </span>
      <span itemprop="ifiStatus">Active</span>
      <span itemprop="ifiExpiration">2039-10-08</span>
      <a href="/patent/US11633365B2/en">
        <span itemprop="representativePublication">US11633365B2</span>
        (<span itemprop="primaryLanguage">en</span>)
      </a>
    </section>

    

    <h2>Applications Claiming Priority (4)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">JPJP2017-151525</span>
            
          </td>
          <td itemprop="priorityDate"></td>
          <td itemprop="filingDate">2017-08-04</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">JP2017-151525</span>
            
          </td>
          <td itemprop="priorityDate"></td>
          <td itemprop="filingDate">2017-08-04</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">JP2017151525</span>
            
          </td>
          <td itemprop="priorityDate"></td>
          <td itemprop="filingDate">2017-08-04</td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="appsClaimingPriority" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">PCT/JP2018/029446</span>
            <a href="/patent/WO2019027055A1/en">
              <span itemprop="representativePublication">WO2019027055A1</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2017-08-04</td>
          <td itemprop="filingDate">2018-08-06</td>
          <td itemprop="title">
        Nucleic acid-containing lipid nanoparticles
       
       </td>
        </tr>
      </tbody>
    </table>

    

    

    <h2>Publications (2)</h2>
    <table>
      <thead>
        <tr>
          <th>Publication Number</th>
          <th>Publication Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">US20200368173A1</span>
            
            <span itemprop="thisPatent">true</span>
            <a href="/patent/US20200368173A1/en">
              US20200368173A1
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2020-11-26</td>
        </tr>
        <tr itemprop="pubs" itemscope repeat>
          <td>
            <span itemprop="publicationNumber">US11633365B2</span>
            
            <a href="/patent/US11633365B2/en">
              US11633365B2
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-04-25</td>
        </tr>
      </tbody>
    </table>

  </section>

  <section itemprop="family" itemscope>
    <h1>Family</h1>
    <h2>ID=65232899</h2>

    <h2>Family Applications (1)</h2>
    <table>
      <thead>
        <tr>
          <th>Application Number</th>
          <th>Title</th>
          <th>Priority Date</th>
          <th>Filing Date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="applications" itemscope repeat>
          <td>
            <span itemprop="applicationNumber">US16/636,177</span>
            <span itemprop="ifiStatus">Active</span>
            <span itemprop="ifiExpiration">2039-10-08</span>
            <a href="/patent/US11633365B2/en">
              <span itemprop="representativePublication">US11633365B2</span>
                (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="priorityDate">2017-08-04</td>
          <td itemprop="filingDate">2018-08-06</td>
          <td itemprop="title">Nucleic acid-containing lipid nanoparticle 
       </td>
        </tr>
      </tbody>
    </table>

    

    

    <h2>Country Status (5)</h2>
    <table>
      <thead>
        <tr>
          <th>Country</th>
          <th>Link</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">US</span>
            (<span itemprop="num">1</span>)
            <meta itemprop="thisCountry" content="true">
          </td>
          <td>
            <a href="/patent/US11633365B2/en">
              <span itemprop="representativePublication">US11633365B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">EP</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/EP3662913A4/en">
              <span itemprop="representativePublication">EP3662913A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">JP</span>
            (<span itemprop="num">2</span>)
            
          </td>
          <td>
            <a href="/patent/JP7429536B2/en">
              <span itemprop="representativePublication">JP7429536B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">CA</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/CA3071968A1/en">
              <span itemprop="representativePublication">CA3071968A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
        <tr itemprop="countryStatus" itemscope repeat>
          <td>
            <span itemprop="countryCode">WO</span>
            (<span itemprop="num">1</span>)
            
          </td>
          <td>
            <a href="/patent/WO2019027055A1/en">
              <span itemprop="representativePublication">WO2019027055A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
        </tr>
      </tbody>
    </table>

    <h2>Cited By (10)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023005971A1/en">
              <span itemprop="publicationNumber">WO2023005971A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-07-27</td>
          <td itemprop="publicationDate">2023-02-02</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Use of fa-type lipid compounds in preparation of nucleic acid delivery reagent and related product 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US20230149310A1/en">
              <span itemprop="publicationNumber">US20230149310A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2018-03-30</td>
          <td itemprop="publicationDate">2023-05-18</td>
          <td><span itemprop="assigneeOriginal">Arcturus Therapeutics, Inc.</span></td>
          <td itemprop="title">Lipid particles for nucleic acid delivery 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023136688A1/en">
              <span itemprop="publicationNumber">WO2023136688A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-01-17</td>
          <td itemprop="publicationDate">2023-07-20</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">Ionizable lipid containing biodegradable disulfide bond and lipid nanoparticles comprising same 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023143591A1/en">
              <span itemprop="publicationNumber">WO2023143591A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-01-30</td>
          <td itemprop="publicationDate">2023-08-03</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Novel ionizable lipid used for nucleic acid delivery and lnp composition thereof and vaccine 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2023143601A1/en">
              <span itemprop="publicationNumber">WO2023143601A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-01-30</td>
          <td itemprop="publicationDate">2023-08-03</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Novel ionizable lipid used for nucleic acid delivery as well as lnp composition and vaccine thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/CN116768697A/en">
              <span itemprop="publicationNumber">CN116768697A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-12-09</td>
          <td itemprop="publicationDate">2023-09-19</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Method for preparing dipropylmalonic acid by using chloropropane as alkylating agent and application of dipropylmalonic acid 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11773061B2/en">
              <span itemprop="publicationNumber">US11773061B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2021-09-14</td>
          <td itemprop="publicationDate">2023-10-03</td>
          <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
          <td itemprop="title">Cyclic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US11865190B2/en">
              <span itemprop="publicationNumber">US11865190B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2018-10-09</td>
          <td itemprop="publicationDate">2024-01-09</td>
          <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
          <td itemprop="title">Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2024187626A1/en">
              <span itemprop="publicationNumber">WO2024187626A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-03-10</td>
          <td itemprop="publicationDate">2024-09-19</td>
          <td><span itemprop="assigneeOriginal">()</span></td>
          <td itemprop="title">Nano delivery system formed from amino acid lipids and use thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/WO2025178465A1/en">
              <span itemprop="publicationNumber">WO2025178465A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2024-02-19</td>
          <td itemprop="publicationDate">2025-08-28</td>
          <td><span itemprop="assigneeOriginal"> </span></td>
          <td itemprop="title">Novel ionizable lipid and lipid nanoparticle composition using same 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Families Citing this family (12)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4168391A1/en">
              <span itemprop="publicationNumber">EP4168391A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2020-08-20</td>
          <td itemprop="publicationDate">2023-04-26</td>
          <td><span itemprop="assigneeOriginal">Suzhou Abogen Biosciences Co., Ltd.</span></td>
          <td itemprop="title">Lipid compounds and lipid nanoparticle compositions 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP4213882A4/en">
              <span itemprop="publicationNumber">EP4213882A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2020-09-15</td>
          <td itemprop="publicationDate">2025-02-26</td>
          <td><span itemprop="assigneeOriginal">Verve Therapeutics, Inc.</span></td>
          <td itemprop="title">
        TAL EFFECTOR NUCLEASES FOR GENE EDITING
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR20230162973A/en">
              <span itemprop="publicationNumber">KR20230162973A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-05-28</td>
          <td itemprop="publicationDate">2023-11-29</td>
          <td><span itemprop="assigneeOriginal">   </span></td>
          <td itemprop="title">
        Lipid compounds and their applications in nucleic acid delivery
       
     </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202328053A/en">
              <span itemprop="publicationNumber">TW202328053A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2021-12-16</td>
          <td itemprop="publicationDate">2023-07-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Purification methods of compositions, compositions, compounds and lipid nanoparticles
       
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JPWO2023176821A1/en">
              <span itemprop="publicationNumber">JPWO2023176821A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-03-15</td>
          <td itemprop="publicationDate">2023-09-21</td>
          <td></td>
          <td itemprop="title"></td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3262328A1/en">
              <span itemprop="publicationNumber">CA3262328A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-07-19</td>
          <td itemprop="publicationDate">2025-04-23</td>
          <td><span itemprop="assigneeOriginal">National University Corporation Hokkaido University</span></td>
          <td itemprop="title">Neutral lipid and lipid nanoparticle 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2024018762A1/en">
              <span itemprop="publicationNumber">WO2024018762A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2022-07-19</td>
          <td itemprop="publicationDate">2024-01-25</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Ph-sensitive cationic lipid and lipid nanoparticle 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025026545A1/en">
              <span itemprop="publicationNumber">WO2025026545A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-08-01</td>
          <td itemprop="publicationDate">2025-02-06</td>
          <td><span itemprop="assigneeOriginal">BioNTech SE</span></td>
          <td itemprop="title">Ionizable thioplipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW202519509A/en">
              <span itemprop="publicationNumber">TW202519509A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-08-01</td>
          <td itemprop="publicationDate">2025-05-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Ionizable thiolipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025076625A1/en">
              <span itemprop="publicationNumber">WO2025076625A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-10-11</td>
          <td itemprop="publicationDate">2025-04-17</td>
          <td><span itemprop="assigneeOriginal">Providence Therapeutics Holdings Inc.</span></td>
          <td itemprop="title">Glutamic acid-based lipids, lipid nanoparticle containing glutamic acid-based lipids, and formulations thereof 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025084317A1/en">
              <span itemprop="publicationNumber">WO2025084317A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2023-10-16</td>
          <td itemprop="publicationDate">2025-04-24</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Zwitterionic phospholipid compound and lipid nanoparticle containing the same 
       </td>
        </tr>
        <tr itemprop="forwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2025187760A1/en">
              <span itemprop="publicationNumber">WO2025187760A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2024-03-07</td>
          <td itemprop="publicationDate">2025-09-12</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid nanoparticle 
       </td>
        </tr>
      </tbody>
    </table>

    <h2>Citations (2)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US20170210698A1/en">
              <span itemprop="publicationNumber">US20170210698A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="publicationDate">2017-07-27</td>
          <td>
            <span itemprop="assigneeOriginal">Modernatx, Inc.</span>
          </td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
     </td>
        </tr>
        <tr itemprop="backwardReferencesOrig" itemscope repeat>
          <td>
            <a href="/patent/US20180353434A1/en">
              <span itemprop="publicationNumber">US20180353434A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2015-03-24</td>
          <td itemprop="publicationDate">2018-12-13</td>
          <td>
            <span itemprop="assigneeOriginal">Kyowa Hakko Kirin Co., Ltd.</span>
          </td>
          <td itemprop="title">Nucleic acid-containing lipid nanoparticles 
     </td>
        </tr>
      </tbody>
    </table>

    <h2>Family Cites Families (35)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1489184A1/en">
              <span itemprop="publicationNumber">EP1489184A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-06-07</td>
          <td itemprop="publicationDate">2004-12-22</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceutical Corp.</span></td>
          <td itemprop="title">Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US5981501A/en">
              <span itemprop="publicationNumber">US5981501A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1995-06-07</td>
          <td itemprop="publicationDate">1999-11-09</td>
          <td><span itemprop="assigneeOriginal">Inex Pharmaceuticals Corp.</span></td>
          <td itemprop="title">Methods for encapsulating plasmids in lipid bilayers 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE69841002D1/en">
              <span itemprop="publicationNumber">DE69841002D1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">1997-05-14</td>
          <td itemprop="publicationDate">2009-09-03</td>
          <td><span itemprop="assigneeOriginal">Univ British Columbia</span></td>
          <td itemprop="title">
        Highly effective encapsulation of nucleic acids in lipid vesicles
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1519714B1/en">
              <span itemprop="publicationNumber">EP1519714B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2002-06-28</td>
          <td itemprop="publicationDate">2010-10-20</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics Inc.</span></td>
          <td itemprop="title">Method and apparatus for producing liposomes 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CA2524634A1/en">
              <span itemprop="publicationNumber">CA2524634A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2003-05-09</td>
          <td itemprop="publicationDate">2004-11-25</td>
          <td><span itemprop="assigneeOriginal">Novosom Ag</span></td>
          <td itemprop="title">Injectable liposomal depots for delivering active ingredients 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2005089287A2/en">
              <span itemprop="publicationNumber">WO2005089287A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-03-15</td>
          <td itemprop="publicationDate">2005-09-29</td>
          <td><span itemprop="assigneeOriginal">City Of Hope</span></td>
          <td itemprop="title">Methods and compositions for the specific inhibition of gene expression by double-stranded rna 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/DE102004054730A1/en">
              <span itemprop="publicationNumber">DE102004054730A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2004-03-28</td>
          <td itemprop="publicationDate">2006-05-11</td>
          <td><span itemprop="assigneeOriginal">Novosom Ag</span></td>
          <td itemprop="title">
  Serum stable amphoteric liposomes
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP1871424A2/en">
              <span itemprop="publicationNumber">EP1871424A2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2005-04-22</td>
          <td itemprop="publicationDate">2008-01-02</td>
          <td><span itemprop="assigneeOriginal">Alza Corporation</span></td>
          <td itemprop="title">Immunoliposome composition for targeting to a her2 cell receptor 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2009002719A1/en">
              <span itemprop="publicationNumber">WO2009002719A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2007-06-22</td>
          <td itemprop="publicationDate">2008-12-31</td>
          <td><span itemprop="assigneeOriginal">The Board Of Regents Of The University Of Texas System</span></td>
          <td itemprop="title">Liposomal inhibitory nucleic acid against stat proteins 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2009129385A1/en">
              <span itemprop="publicationNumber">WO2009129385A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-04-16</td>
          <td itemprop="publicationDate">2009-10-22</td>
          <td><span itemprop="assigneeOriginal">Abbott Laboratories</span></td>
          <td itemprop="title">Cationic lipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2009129395A1/en">
              <span itemprop="publicationNumber">WO2009129395A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-04-16</td>
          <td itemprop="publicationDate">2009-10-22</td>
          <td><span itemprop="assigneeOriginal">Abbott Laboratories</span></td>
          <td itemprop="title">Cationic lipids and uses thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2011529912A/en">
              <span itemprop="publicationNumber">JP2011529912A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-07-31</td>
          <td itemprop="publicationDate">2011-12-15</td>
          <td><span itemprop="assigneeOriginal">  </span></td>
          <td itemprop="title">
  Nanoparticle compositions for nucleic acid delivery systems
 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2475065T3/en">
              <span itemprop="publicationNumber">ES2475065T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-10-09</td>
          <td itemprop="publicationDate">2014-07-10</td>
          <td><span itemprop="assigneeOriginal">Tekmira Pharmaceuticals Corporation</span></td>
          <td itemprop="title">
        Enhanced amino acids and methods for nucleic acid administration
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/JP5747282B2/en">
              <span itemprop="publicationNumber">JP5747282B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-11-10</td>
          <td itemprop="publicationDate">2015-07-15</td>
          <td><span itemprop="assigneeOriginal">    </span></td>
          <td itemprop="title">
        Novel lipids and compositions for delivering therapeutic agents
       
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2010056403A1/en">
              <span itemprop="publicationNumber">WO2010056403A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2008-11-17</td>
          <td itemprop="publicationDate">2010-05-20</td>
          <td><span itemprop="assigneeOriginal">Enzon Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">Branched cationic lipids for nucleic acids delivery system 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3403647A1/en">
              <span itemprop="publicationNumber">EP3403647A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2009-12-01</td>
          <td itemprop="publicationDate">2018-11-21</td>
          <td><span itemprop="assigneeOriginal">Translate Bio, Inc.</span></td>
          <td itemprop="title">Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2011136368A1/en">
              <span itemprop="publicationNumber">WO2011136368A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-04-28</td>
          <td itemprop="publicationDate">2011-11-03</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Cationic lipid 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/KR101198715B1/en">
              <span itemprop="publicationNumber">KR101198715B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-05-14</td>
          <td itemprop="publicationDate">2012-11-13</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Asymmetric liposomes with higher encapsulation efficiency of nucleic acids and hydrophilic anion chemicals 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8802863B2/en">
              <span itemprop="publicationNumber">US8802863B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-05-24</td>
          <td itemprop="publicationDate">2014-08-12</td>
          <td><span itemprop="assigneeOriginal">Sirna Therapeutics, Inc.</span></td>
          <td itemprop="title">Amino alcohol cationic lipids for oligonucleotide delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/ES2634087T3/en">
              <span itemprop="publicationNumber">ES2634087T3</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-06-03</td>
          <td itemprop="publicationDate">2017-09-26</td>
          <td><span itemprop="assigneeOriginal">Alnylam Pharmaceuticals, Inc.</span></td>
          <td itemprop="title">
  Biodegradable lipids for the administration of active agents
 
     </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US8466122B2/en">
              <span itemprop="publicationNumber">US8466122B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2010-09-17</td>
          <td itemprop="publicationDate">2013-06-18</td>
          <td><span itemprop="assigneeOriginal">Protiva Biotherapeutics, Inc.</span></td>
          <td itemprop="title">Trialkyl cationic lipids and methods of use thereof 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2012267467B8/en">
              <span itemprop="publicationNumber">AU2012267467B8</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-06-08</td>
          <td itemprop="publicationDate">2017-06-15</td>
          <td><span itemprop="assigneeOriginal">Nitto Denko Corporation</span></td>
          <td itemprop="title">Compounds for targeting drug delivery and enhancing siRNA activity 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN103987847B/en">
              <span itemprop="publicationNumber">CN103987847B</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-10-18</td>
          <td itemprop="publicationDate">2017-06-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">
        Amine cationic lipids and uses thereof
       
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/RS58562B1/en">
              <span itemprop="publicationNumber">RS58562B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-11-04</td>
          <td itemprop="publicationDate">2019-05-31</td>
          <td><span itemprop="assigneeOriginal">Nitto Denko Corp</span></td>
          <td itemprop="title">Method for sterilely producing lipid-nucleic acid particles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013089151A1/en">
              <span itemprop="publicationNumber">WO2013089151A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2011-12-12</td>
          <td itemprop="publicationDate">2013-06-20</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Lipid nanoparticles for drug delivery system containing cationic lipids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2013143555A1/en">
              <span itemprop="publicationNumber">WO2013143555A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2012-03-26</td>
          <td itemprop="publicationDate">2013-10-03</td>
          <td><span itemprop="assigneeOriginal">Biontech Ag</span></td>
          <td itemprop="title">Rna formulation for immunotherapy 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/US9546128B2/en">
              <span itemprop="publicationNumber">US9546128B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-03-29</td>
          <td itemprop="publicationDate">2017-01-17</td>
          <td><span itemprop="assigneeOriginal">Shire Human Genetic Therapies, Inc.</span></td>
          <td itemprop="title">Ionizable cationic lipids 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW201408625A/en">
              <span itemprop="publicationNumber">TW201408625A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2012-07-06</td>
          <td itemprop="publicationDate">2014-03-01</td>
          <td><span itemprop="assigneeOriginal">Kyowa Hakko Kirin Co Ltd</span></td>
          <td itemprop="title">Cationic lipid 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP2968147A4/en">
              <span itemprop="publicationNumber">EP2968147A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-03-15</td>
          <td itemprop="publicationDate">2017-02-22</td>
          <td><span itemprop="assigneeOriginal">The Penn State Research Foundation</span></td>
          <td itemprop="title">Acid stable liposomal compositions 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/AU2014348212C1/en">
              <span itemprop="publicationNumber">AU2014348212C1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2013-11-18</td>
          <td itemprop="publicationDate">2018-11-29</td>
          <td><span itemprop="assigneeOriginal">Arcturus Therapeutics, Inc.</span></td>
          <td itemprop="title">Ionizable cationic lipid for RNA delivery 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3162794B1/en">
              <span itemprop="publicationNumber">EP3162794B1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2014-06-30</td>
          <td itemprop="publicationDate">2020-09-16</td>
          <td><span itemprop="assigneeOriginal">Kyowa Kirin Co., Ltd.</span></td>
          <td itemprop="title">Alkyl substituted azetidines as cationic lipid 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2016180467A1/en">
              <span itemprop="publicationNumber">WO2016180467A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2015-05-11</td>
          <td itemprop="publicationDate">2016-11-17</td>
          <td><span itemprop="assigneeOriginal">Biontech Cell &amp; Gene Therapies Gmbh</span></td>
          <td itemprop="title">Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/TW201813632A/en">
              <span itemprop="publicationNumber">TW201813632A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-09-28</td>
          <td itemprop="publicationDate">2018-04-16</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">Nucleic-acid-containing lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3301928A1/en">
              <span itemprop="publicationNumber">EP3301928A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2016-09-30</td>
          <td itemprop="publicationDate">2018-04-04</td>
          <td><span itemprop="assigneeOriginal">Thomson Licensing</span></td>
          <td itemprop="title">Methods, devices and stream to encode global rotation motion compensated images 
       </td>
        </tr>
        <tr itemprop="backwardReferencesFamily" itemscope repeat>
          <td>
            <a href="/patent/CN106540271A/en">
              <span itemprop="publicationNumber">CN106540271A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            
            
          </td>
          <td itemprop="priorityDate">2016-10-27</td>
          <td itemprop="publicationDate">2017-03-29</td>
          <td><span itemprop="assigneeOriginal"></span></td>
          <td itemprop="title">A kind of cationic liposomal gene carrier and its preparation method and application 
       </td>
        </tr>
      </tbody>
    </table>

    <ul>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2018</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-08-06</span>
            <span itemprop="countryCode">EP</span>
            <span itemprop="applicationNumber">EP18840323.2A</span>
            <a href="/patent/EP3662913A4/en"><span itemprop="documentId">patent/EP3662913A4/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-08-06</span>
            <span itemprop="countryCode">US</span>
            <span itemprop="applicationNumber">US16/636,177</span>
            <a href="/patent/US11633365B2/en"><span itemprop="documentId">patent/US11633365B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            <span itemprop="thisApp" content="true" bool></span>
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-08-06</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2019534608A</span>
            <a href="/patent/JP7429536B2/en"><span itemprop="documentId">patent/JP7429536B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-08-06</span>
            <span itemprop="countryCode">WO</span>
            <span itemprop="applicationNumber">PCT/JP2018/029446</span>
            <a href="/patent/WO2019027055A1/en"><span itemprop="documentId">patent/WO2019027055A1/en</span></a>
            <span itemprop="legalStatusCat">not_active</span>
            <span itemprop="legalStatus">Ceased</span>
            
          </li>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2018-08-06</span>
            <span itemprop="countryCode">CA</span>
            <span itemprop="applicationNumber">CA3071968A</span>
            <a href="/patent/CA3071968A1/en"><span itemprop="documentId">patent/CA3071968A1/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Pending</span>
            
          </li>
        </ul>
      </li>
      <li itemprop="applicationsByYear" itemscope repeat>
        <span itemprop="year">2023</span>
        <ul>
          <li itemprop="application" itemscope repeat>
            <span itemprop="filingDate">2023-11-21</span>
            <span itemprop="countryCode">JP</span>
            <span itemprop="applicationNumber">JP2023197668A</span>
            <a href="/patent/JP7754908B2/en"><span itemprop="documentId">patent/JP7754908B2/en</span></a>
            <span itemprop="legalStatusCat">active</span>
            <span itemprop="legalStatus">Active</span>
            
          </li>
        </ul>
      </li>
    </ul>

    </section>

  <section>
    <h2>Patent Citations (2)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Priority date</th>
          <th>Publication date</th>
          <th>Assignee</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="backwardReferences" itemscope repeat>
          <td>
            <a href="/patent/US20180353434A1/en">
              <span itemprop="publicationNumber">US20180353434A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2015-03-24</td>
          <td itemprop="publicationDate">2018-12-13</td>
          <td><span itemprop="assigneeOriginal">Kyowa Hakko Kirin Co., Ltd.</span></td>
          <td itemprop="title">Nucleic acid-containing lipid nanoparticles 
     </td>
        </tr>
        <tr itemprop="backwardReferences" itemscope repeat>
          <td>
            <a href="/patent/US20170210698A1/en">
              <span itemprop="publicationNumber">US20170210698A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
            <span itemprop="examinerCited">*</span>
            
          </td>
          <td itemprop="priorityDate">2015-09-17</td>
          <td itemprop="publicationDate">2017-07-27</td>
          <td><span itemprop="assigneeOriginal">Modernatx, Inc.</span></td>
          <td itemprop="title">Compounds and compositions for intracellular delivery of therapeutic agents 
     </td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Non-Patent Citations (3)</h2>
    <table>
      <caption>* Cited by examiner,  Cited by third party</caption>
      <thead>
        <tr>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="detailedNonPatentLiterature" itemscope repeat>
          <td>
            <span itemprop="title">Damase et al (Frontiers in Bioengineering and Biotech., Vol. 9, article 628137, pages 1-24 (2021)) (Year: 2021)</span>
            <span itemprop="examinerCited">*</span>
            
          </td>
        </tr>
        <tr itemprop="detailedNonPatentLiterature" itemscope repeat>
          <td>
            <span itemprop="title">Roberts et al (Nature Reviews: Drug Discovery, Vol. 19, pages 673-694 (2020)) (Year: 2020)</span>
            <span itemprop="examinerCited">*</span>
            
          </td>
        </tr>
        <tr itemprop="detailedNonPatentLiterature" itemscope repeat>
          <td>
            <span itemprop="title">Structures provided. (Year: 2017)</span>
            <span itemprop="examinerCited">*</span>
            
          </td>
        </tr>
      </tbody>
    </table>
  </section>

  <h2>Cited By (13)</h2>
  <table>
    <caption>* Cited by examiner,  Cited by third party</caption>
    <thead>
      <tr>
        <th>Publication number</th>
        <th>Priority date</th>
        <th>Publication date</th>
        <th>Assignee</th>
        <th>Title</th>
      </tr>
    </thead>
    <tbody>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US20230149310A1/en">
            <span itemprop="publicationNumber">US20230149310A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2018-03-30</td>
        <td itemprop="publicationDate">2023-05-18</td>
        <td><span itemprop="assigneeOriginal">Arcturus Therapeutics, Inc.</span></td>
        <td itemprop="title">Lipid particles for nucleic acid delivery 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US12083224B2/en">
            <span itemprop="publicationNumber">US12083224B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2018-03-30</td>
        <td itemprop="publicationDate">2024-09-10</td>
        <td><span itemprop="assigneeOriginal">Arcturus Therapeutics, Inc.</span></td>
        <td itemprop="title">Lipid particles for nucleic acid delivery 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11980673B2/en">
            <span itemprop="publicationNumber">US11980673B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2018-10-09</td>
        <td itemprop="publicationDate">2024-05-14</td>
        <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
        <td itemprop="title">Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11865190B2/en">
            <span itemprop="publicationNumber">US11865190B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2018-10-09</td>
        <td itemprop="publicationDate">2024-01-09</td>
        <td><span itemprop="assigneeOriginal">The University Of British Columbia</span></td>
        <td itemprop="title">Compositions and systems comprising transfection-competent vesicles free of organic-solvents and detergents and methods related thereto 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023005971A1/en">
            <span itemprop="publicationNumber">WO2023005971A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2021-07-27</td>
        <td itemprop="publicationDate">2023-02-02</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">Use of fa-type lipid compounds in preparation of nucleic acid delivery reagent and related product 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/US11773061B2/en">
            <span itemprop="publicationNumber">US11773061B2</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          
          
        </td>
        <td itemprop="priorityDate">2021-09-14</td>
        <td itemprop="publicationDate">2023-10-03</td>
        <td><span itemprop="assigneeOriginal">Renagade Therapeutics Management Inc.</span></td>
        <td itemprop="title">Cyclic lipids and methods of use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023136688A1/en">
            <span itemprop="publicationNumber">WO2023136688A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-01-17</td>
        <td itemprop="publicationDate">2023-07-20</td>
        <td><span itemprop="assigneeOriginal"> </span></td>
        <td itemprop="title">Ionizable lipid containing biodegradable disulfide bond and lipid nanoparticles comprising same 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/JP2025504802A/en">
            <span itemprop="publicationNumber">JP2025504802A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-01-17</td>
        <td itemprop="publicationDate">2025-02-19</td>
        <td><span itemprop="assigneeOriginal">   </span></td>
        <td itemprop="title">
        Biodegradable disulfide bond-containing ionizable lipids and lipid nanoparticles containing the same
       
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023143601A1/en">
            <span itemprop="publicationNumber">WO2023143601A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-01-30</td>
        <td itemprop="publicationDate">2023-08-03</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">Novel ionizable lipid used for nucleic acid delivery as well as lnp composition and vaccine thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2023143591A1/en">
            <span itemprop="publicationNumber">WO2023143591A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-01-30</td>
        <td itemprop="publicationDate">2023-08-03</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">Novel ionizable lipid used for nucleic acid delivery and lnp composition thereof and vaccine 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/CN116768697A/en">
            <span itemprop="publicationNumber">CN116768697A</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2022-12-09</td>
        <td itemprop="publicationDate">2023-09-19</td>
        <td><span itemprop="assigneeOriginal"></span></td>
        <td itemprop="title">Method for preparing dipropylmalonic acid by using chloropropane as alkylating agent and application of dipropylmalonic acid 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2024187626A1/en">
            <span itemprop="publicationNumber">WO2024187626A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2023-03-10</td>
        <td itemprop="publicationDate">2024-09-19</td>
        <td><span itemprop="assigneeOriginal">()</span></td>
        <td itemprop="title">Nano delivery system formed from amino acid lipids and use thereof 
       </td>
      </tr>
      <tr itemprop="forwardReferences" itemscope repeat>
        <td>
          <a href="/patent/WO2025178465A1/en">
            <span itemprop="publicationNumber">WO2025178465A1</span>
            (<span itemprop="primaryLanguage">en</span>)
          </a>
          <span itemprop="examinerCited">*</span>
          
        </td>
        <td itemprop="priorityDate">2024-02-19</td>
        <td itemprop="publicationDate">2025-08-28</td>
        <td><span itemprop="assigneeOriginal"> </span></td>
        <td itemprop="title">Novel ionizable lipid and lipid nanoparticle composition using same 
       </td>
      </tr>
    </tbody>
  </table>

  <section>
    <h2>Also Published As</h2>
    <table>
      <thead>
        <tr>
          <th>Publication number</th>
          <th>Publication date</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7429536B2/en">
              <span itemprop="publicationNumber">JP7429536B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-02-08</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3662913A4/en">
              <span itemprop="publicationNumber">EP3662913A4</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2021-06-30</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/US11633365B2/en">
              <span itemprop="publicationNumber">US11633365B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2023-04-25</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/WO2019027055A1/en">
              <span itemprop="publicationNumber">WO2019027055A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-02-07</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/EP3662913A1/en">
              <span itemprop="publicationNumber">EP3662913A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2020-06-10</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/CA3071968A1/en">
              <span itemprop="publicationNumber">CA3071968A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2019-02-07</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP7754908B2/en">
              <span itemprop="publicationNumber">JP7754908B2</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2025-10-15</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JP2024026137A/en">
              <span itemprop="publicationNumber">JP2024026137A</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2024-02-28</td>
        </tr>
        <tr itemprop="docdbFamily" itemscope repeat>
          <td>
            <a href="/patent/JPWO2019027055A1/en">
              <span itemprop="publicationNumber">JPWO2019027055A1</span>
              (<span itemprop="primaryLanguage">en</span>)
            </a>
          </td>
          <td itemprop="publicationDate">2020-08-20</td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Similar Documents</h2>
    <table>
      <thead>
        <tr>
          <th>Publication</th>
          <th>Publication Date</th>
          <th>Title</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US11633365B2/en">
                <span itemprop="publicationNumber">US11633365B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2023-04-25">2023-04-25</time>
            
            
          </td>
          <td itemprop="title">Nucleic acid-containing lipid nanoparticle 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US11298326B2/en">
                <span itemprop="publicationNumber">US11298326B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2022-04-12">2022-04-12</time>
            
            
          </td>
          <td itemprop="title">Nucleic acid-containing lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US10342758B2/en">
                <span itemprop="publicationNumber">US10342758B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2019-07-09">2019-07-09</time>
            
            
          </td>
          <td itemprop="title">Cationic lipid 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/WO2018062413A1/en">
                <span itemprop="publicationNumber">WO2018062413A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2018-04-05">2018-04-05</time>
            
            
          </td>
          <td itemprop="title">Nucleic-acid-containing lipid nanoparticles 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US9920028B2/en">
                <span itemprop="publicationNumber">US9920028B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2018-03-20">2018-03-20</time>
            
            
          </td>
          <td itemprop="title">Cationic lipid 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/AU2012353463B2/en">
                <span itemprop="publicationNumber">AU2012353463B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2017-08-24">2017-08-24</time>
            
            
          </td>
          <td itemprop="title">Lipid nanoparticles containing combinations of cationic lipids 
       </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20170349532A1/en">
                <span itemprop="publicationNumber">US20170349532A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2017-12-07">2017-12-07</time>
            
            
          </td>
          <td itemprop="title">Cationic lipid 
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/JP6495408B2/en">
                <span itemprop="publicationNumber">JP6495408B2</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2019-04-03">2019-04-03</time>
            
            
          </td>
          <td itemprop="title">
        Cationic lipid
       
     </td>
        </tr>
        <tr itemprop="similarDocuments" itemscope repeat>
          <td>
            <meta itemprop="isPatent" content="true">
              <a href="/patent/US20140294978A1/en">
                <span itemprop="publicationNumber">US20140294978A1</span>
                (<span itemprop="primaryLanguage">en</span>)
              </a>
            
            
          </td>
          <td>
            <time itemprop="publicationDate" datetime="2014-10-02">2014-10-02</time>
            
            
          </td>
          <td itemprop="title">Cationic lipid 
       </td>
        </tr>
      </tbody>
    </table>
  </section>

  <section>
    <h2>Legal Events</h2>
    <table>
      <thead>
        <tr>
          <th>Date</th>
          <th>Code</th>
          <th>Title</th>
          <th>Description</th>
        </tr>
      </thead>
      <tbody>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2020-02-03">2020-02-03</time></td>
          <td itemprop="code">FEPP</td>
          <td itemprop="title">Fee payment procedure</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2020-03-16">2020-03-16</time></td>
          <td itemprop="code">AS</td>
          <td itemprop="title">Assignment</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Owner name</strong>:
              <span itemprop="value">KYOWA KIRIN CO., LTD., JAPAN</span>
            </p>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HATANAKA, KENTARO;MAEMOTO, MICHIHIRO;HOSOE, SHINTARO;SIGNING DATES FROM 20200225 TO 20200227;REEL/FRAME:052121/0904</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2020-09-11">2020-09-11</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2021-06-20">2021-06-20</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">DOCKETED NEW CASE - READY FOR EXAMINATION</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-03-16">2022-03-16</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">NON FINAL ACTION MAILED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-05-02">2022-05-02</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-06-30">2022-06-30</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">NON FINAL ACTION MAILED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2022-11-02">2022-11-02</time></td>
          <td itemprop="code">STPP</td>
          <td itemprop="title">Information on status: patent application and granting procedure in general</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">FINAL REJECTION MAILED</span>
            </p>
          </td>
        </tr>
        <tr itemprop="legalEvents" itemscope repeat>
          <td><time itemprop="date" datetime="2023-04-05">2023-04-05</time></td>
          <td itemprop="code">STCF</td>
          <td itemprop="title">Information on status: patent grant</td>
          <td>
            <p itemprop="attributes" itemscope repeat>
              <strong itemprop="label">Free format text</strong>:
              <span itemprop="value">PATENTED CASE</span>
            </p>
          </td>
        </tr>
      </tbody>
    </table>
  </section>

</article>

    </search-app>
    
    <script></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/api.js"></script>
    <script type="text/javascript" src="//www.gstatic.com/feedback/js/help/prod/service/lazy.min.js"></script>
    <script type="text/javascript">
      if (window.help && window.help.service) {
        helpApi = window.help.service.Lazy.create(0, {apiKey: 'AIzaSyDTEI_0tLX4varJ7bwK8aT-eOI5qr3BmyI', locale: 'en-US'});
        window.requestedSurveys = new Set();
        window.requestSurvey = function(triggerId) {
          if (window.requestedSurveys.has(triggerId)) {
            return;
          }
          window.requestedSurveys.add(triggerId);
          helpApi.requestSurvey({
            triggerId: triggerId,
            enableTestingMode: false,
            callback: (requestSurveyCallbackParam) => {
              if (!requestSurveyCallbackParam.surveyData) {
                return;
              }
              helpApi.presentSurvey({
                productData: {
                  productVersion: window.version,
                  customData: {
                    "experiments": "",
                  },
                },
                surveyData: requestSurveyCallbackParam.surveyData,
                colorScheme: 1,
                customZIndex: 10000,
              });
            }
          });
        };

        window.requestSurvey('YXTwAsvoW0kedxbuTdH0RArc9VhT');
      }
    </script>
    <script src="/sw/null_loader.js"></script>
  </body>
</html>
